<ALL>	O
Ventricular	B-Multi-tissue_structure
fibrillation	O
due	O
to	O
long	O
QT	O
syndrome	O
probably	O
caused	O
by	O
clindamycin	O
.	O
</ALL>	O

<ALL>	O
Prolongation	O
of	O
QT	O
time	O
interval	O
may	O
be	O
provoked	O
by	O
a	O
limited	O
number	O
of	O
drugs	O
,	O
especially	O
macrolide	O
antibiotics	O
.	O
</ALL>	O

<ALL>	O
We	O
describe	O
a	O
case	O
of	O
QT	O
time	O
interval	O
prolongation	O
induced	O
by	O
clindamycin	O
with	O
subsequent	O
repeated	O
ventricular	B-Multi-tissue_structure
fibrillation	O
and	O
resuscitation	O
;	O
there	O
is	O
no	O
previous	O
report	O
in	O
the	O
literature	O
of	O
QT	O
time	O
prolongation	O
caused	O
by	O
lincosamides	O
.	O
</ALL>	O

<ALL>	O
Decontamination	O
of	O
medical	O
equipment	O
-	O
-	O
manufacturer	O
'	O
s	O
problems	O
.	O
</ALL>	O

<ALL>	O
1	O
.	O
</ALL>	O

<ALL>	O
Small	O
items	O
sent	O
via	O
the	O
post	O
present	O
a	O
much	O
greater	O
hidden	O
hazard	O
and	O
a	O
higher	O
potential	O
for	O
catching	O
people	O
unawares	O
.	O
</ALL>	O

<ALL>	O
2	O
.	O
</ALL>	O

<ALL>	O
Large	O
items	O
accompanied	O
by	O
a	O
Decontamination	O
Certificate	O
need	O
to	O
be	O
treated	O
with	O
caution	O
because	O
only	O
those	O
surfaces	O
which	O
are	O
accessible	O
will	O
have	O
been	O
cleaned	O
;	O
as	O
soon	O
as	O
engineers	O
start	O
dismantling	O
equipment	O
,	O
areas	O
which	O
are	O
still	O
soiled	O
become	O
exposed	O
.	O
</ALL>	O

<ALL>	O
3	O
.	O
</ALL>	O

<ALL>	O
Total	O
co	O
-	O
operation	O
between	O
hospital	O
staff	O
and	O
service	O
engineers	O
is	O
necessary	O
to	O
resolve	O
these	O
problems	O
-	O
neither	O
can	O
work	O
safely	O
without	O
the	O
assistance	O
of	O
the	O
other	O
.	O
</ALL>	O

<ALL>	O
4	O
.	O
</ALL>	O

<ALL>	O
Many	O
products	O
in	O
use	O
in	O
hospitals	O
may	O
be	O
up	O
to	O
20	O
years	O
old	O
and	O
clearly	O
were	O
not	O
designed	O
to	O
facilitate	O
decontamination	O
and	O
therefore	O
present	O
far	O
greater	O
risk	O
to	O
all	O
concerned	O
.	O
</ALL>	O

<ALL>	O
5	O
.	O
</ALL>	O

<ALL>	O
For	O
the	O
future	O
there	O
a	O
clearly	O
a	O
responsibility	O
with	O
manufacturers	O
to	O
give	O
more	O
thought	O
to	O
the	O
design	O
of	O
their	O
equipment	O
so	O
that	O
decontamination	O
can	O
be	O
achieved	O
more	O
effectively	O
.	O
</ALL>	O

<ALL>	O
Enterococci	O
at	O
the	O
crossroads	O
of	O
food	O
safety	O
?	O
</ALL>	O

<ALL>	O
Enterococci	O
are	O
gram	O
-	O
positive	O
bacteria	O
and	O
fit	O
within	O
the	O
general	O
definition	O
of	O
lactic	O
acid	O
bacteria	O
.	O
</ALL>	O

<ALL>	O
Modern	O
classification	O
techniques	O
resulted	O
in	O
the	O
transfer	O
of	O
some	O
members	O
of	O
the	O
genus	O
Streptococcus	O
,	O
notably	O
some	O
of	O
the	O
Lancefield	O
'	O
s	O
group	O
D	O
streptococci	O
,	O
to	O
the	O
new	O
genus	O
Enterococcus	O
.	O
</ALL>	O

<ALL>	O
Enterococci	O
can	O
be	O
used	O
as	O
indicators	O
of	O
faecal	B-Organism_substance
contamination	O
.	O
</ALL>	O

<ALL>	O
They	O
have	O
been	O
implicated	O
in	O
outbreaks	O
of	O
foodborne	O
illness	O
,	O
and	O
they	O
have	O
been	O
ascribed	O
a	O
beneficial	O
or	O
detrimental	O
role	O
in	O
foods	O
.	O
</ALL>	O

<ALL>	O
In	O
processed	O
meats	B-Organism_subdivision
,	O
enterococci	O
may	O
survive	O
heat	O
processing	O
and	O
cause	O
spoilage	O
,	O
though	O
in	O
certain	O
cheeses	O
the	O
growth	O
of	O
enterococci	O
contributes	O
to	O
ripening	O
and	O
development	O
of	O
product	O
flavour	O
.	O
</ALL>	O

<ALL>	O
Some	O
enterococci	O
of	O
food	O
origin	O
produce	O
bacteriocins	O
that	O
exert	O
anti	O
-	O
Listeria	O
activity	O
.	O
</ALL>	O

<ALL>	O
Enterococci	O
are	O
used	O
as	O
probiotics	O
to	O
improve	O
the	O
microbial	O
balance	O
of	O
the	O
intestine	B-Organ
,	O
or	O
as	O
a	O
treatment	O
for	O
gastroenteritis	O
in	O
humans	O
and	O
animals	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
other	O
hand	O
,	O
enterococci	O
have	O
become	O
recognised	O
as	O
serious	O
nosocomial	O
pathogens	O
causing	O
bacteraemia	O
,	O
endocarditis	O
,	O
urinary	B-Multi-tissue_structure
tract	I-Multi-tissue_structure
and	O
other	O
infections	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
in	O
part	O
explained	O
by	O
the	O
resistance	O
of	O
some	O
of	O
these	O
bacteria	O
to	O
most	O
antibiotics	O
that	O
are	O
currently	O
in	O
use	O
.	O
</ALL>	O

<ALL>	O
Resistance	O
is	O
acquired	O
by	O
gene	O
transfer	O
systems	O
,	O
such	O
as	O
conjugative	B-Cellular_component
or	O
nonconjugative	B-Cellular_component
plasmids	I-Cellular_component
or	O
transposons	O
.	O
</ALL>	O

<ALL>	O
Virulence	O
of	O
enterococci	O
is	O
not	O
well	O
understood	O
but	O
adhesins	O
,	O
haemolysin	O
,	O
hyaluronidase	O
,	O
aggregation	O
substance	O
and	O
gelatinase	O
are	O
putative	O
virulence	O
factors	O
.	O
</ALL>	O

<ALL>	O
It	O
appears	O
that	O
foods	O
could	O
be	O
a	O
source	O
of	O
vancomycin	O
-	O
resistant	O
enterococci	O
.	O
</ALL>	O

<ALL>	O
This	O
review	O
addresses	O
the	O
issue	O
of	O
the	O
health	O
risk	O
of	O
foods	O
containing	O
enterococci	O
.	O
</ALL>	O

<ALL>	O
Obstructive	O
nephropathy	O
:	O
lessons	O
from	O
cystic	O
kidney	B-Organ
disease	O
.	O
</ALL>	O

<ALL>	O
Obstructive	O
nephropathy	O
is	O
one	O
of	O
the	O
most	O
important	O
causes	O
of	O
renal	B-Organ
failure	O
in	O
infants	O
and	O
children	O
,	O
while	O
polycystic	O
kidney	B-Organ
disease	O
(	O
PKD	O
)	O
is	O
a	O
major	O
cause	O
of	O
renal	B-Organ
failure	O
in	O
the	O
adult	O
population	O
.	O
</ALL>	O

<ALL>	O
This	O
review	O
summarizes	O
the	O
evidence	O
that	O
there	O
may	O
be	O
a	O
number	O
of	O
mechanisms	O
common	O
to	O
the	O
pathophysiology	O
of	O
both	O
conditions	O
.	O
</ALL>	O

<ALL>	O
In	O
animal	O
models	O
of	O
obstructive	O
nephropathy	O
and	O
PKD	O
,	O
the	O
renal	B-Multi-tissue_structure
tubular	I-Multi-tissue_structure
expression	O
of	O
epidermal	O
growth	O
factor	O
is	O
suppressed	O
,	O
and	O
expression	O
of	O
clusterin	O
is	O
increased	O
,	O
both	O
of	O
which	O
suggest	O
arrested	O
maturation	O
or	O
dedifferentiation	O
of	O
the	O
tubular	B-Cell
cell	I-Cell
.	O
</ALL>	O

<ALL>	O
There	O
is	O
a	O
marked	O
increase	O
in	O
apoptosis	O
of	O
epithelial	B-Cell
cells	I-Cell
in	O
dilated	O
tubules	B-Multi-tissue_structure
,	O
associated	O
with	O
an	O
increase	O
in	O
apoptotic	O
stimuli	O
.	O
</ALL>	O

<ALL>	O
The	O
renin	O
-	O
angiotensin	O
system	O
is	O
activated	O
in	O
both	O
obstructive	O
nephropathy	O
and	O
PKD	O
,	O
which	O
may	O
contribute	O
to	O
tubular	B-Multi-tissue_structure
atrophy	O
and	O
interstitial	B-Immaterial_anatomical_entity
fibrosis	O
,	O
which	O
characterize	O
the	O
progression	O
of	O
both	O
conditions	O
.	O
</ALL>	O

<ALL>	O
Focal	O
cystic	O
dilatation	O
of	O
the	O
tubule	B-Multi-tissue_structure
is	O
found	O
in	O
obstructive	O
nephropathy	O
,	O
while	O
tubular	B-Multi-tissue_structure
obstruction	O
is	O
present	O
in	O
cystic	O
kidney	B-Organ
disease	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
therefore	O
likely	O
that	O
elucidation	O
of	O
the	O
effects	O
of	O
mechanical	O
stretch	O
on	O
renal	B-Cell
tubular	I-Cell
epithelial	I-Cell
cells	I-Cell
will	O
contribute	O
to	O
our	O
understanding	O
of	O
both	O
conditions	O
.	O
</ALL>	O

<ALL>	O
Genuine	O
monovalent	O
ligands	O
of	O
TrkA	O
nerve	O
growth	O
factor	O
receptors	O
reveal	O
a	O
novel	O
pharmacological	O
mechanism	O
of	O
action	O
.	O
</ALL>	O

<ALL>	O
Developing	O
small	O
molecule	O
agonistic	O
ligands	O
for	O
tyrosine	O
kinase	O
receptors	O
has	O
been	O
difficult	O
,	O
and	O
it	O
is	O
generally	O
thought	O
that	O
such	O
ligands	O
require	O
bivalency	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
multisubunit	O
receptors	O
are	O
difficult	O
to	O
target	O
,	O
because	O
each	O
subunit	O
contributes	O
to	O
ligand	O
affinity	O
,	O
and	O
each	O
subunit	O
may	O
have	O
distinct	O
and	O
sometimes	O
opposing	O
functions	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
the	O
nerve	O
growth	O
factor	O
receptor	O
subunits	O
p75	O
and	O
the	O
tyrosine	O
kinase	O
TrkA	O
were	O
studied	O
using	O
artificial	O
ligands	O
that	O
bind	O
specifically	O
to	O
their	O
extracellular	B-Immaterial_anatomical_entity
domain	O
.	O
</ALL>	O

<ALL>	O
Bivalent	O
TrkA	O
ligands	O
afford	O
robust	O
signals	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
genuine	O
monomeric	O
and	O
monovalent	O
TrkA	O
ligands	O
afford	O
partial	O
agonism	O
,	O
activate	O
the	O
tyrosine	O
kinase	O
activity	O
,	O
cause	O
receptor	O
internalization	O
,	O
and	O
induce	O
survival	O
and	O
differentiation	O
in	O
cell	B-Cell
lines	I-Cell
and	O
primary	O
neurons	B-Cell
.	O
</ALL>	O

<ALL>	O
Monomeric	O
and	O
monovalent	O
TrkA	O
ligands	O
can	O
synergize	O
with	O
ligands	O
that	O
bind	O
the	O
p75	O
subunit	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
p75	O
ligands	O
used	O
in	O
this	O
study	O
must	O
be	O
bivalent	O
,	O
and	O
monovalent	O
p75	O
ligands	O
have	O
no	O
effect	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
will	O
be	O
useful	O
in	O
designing	O
and	O
developing	O
screens	O
of	O
small	O
molecules	O
selective	O
for	O
tyrosine	O
kinase	O
receptors	O
and	O
indicate	O
that	O
strategies	O
for	O
designing	O
agonists	O
of	O
multisubunit	O
receptors	O
require	O
consideration	O
of	O
the	O
role	O
of	O
each	O
subunit	O
.	O
</ALL>	O

<ALL>	O
Last	O
,	O
the	O
strategy	O
of	O
using	O
anti	O
-	O
receptor	O
mAbs	O
and	O
small	O
molecule	O
hormone	O
mimics	O
as	O
receptor	O
ligands	O
could	O
be	O
applied	O
to	O
the	O
study	O
of	O
many	O
other	O
heteromeric	O
cell	B-Cellular_component
surface	I-Cellular_component
receptors	O
.	O
</ALL>	O

<ALL>	O
Application	O
of	O
microsatellite	O
PCR	O
techniques	O
in	O
the	O
identification	O
of	O
mixed	O
up	O
tissue	B-Tissue
specimens	I-Tissue
in	O
surgical	O
pathology	O
.	O
</ALL>	O

<ALL>	O
A	O
fragment	B-Pathological_formation
of	O
tumour	B-Pathological_formation
was	O
erroneously	O
mixed	O
up	O
with	O
an	O
endometrial	B-Tissue
biopsy	I-Tissue
.	O
</ALL>	O

<ALL>	O
Micro	O
-	O
satellite	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
clearly	O
demonstrated	O
the	O
extraneous	O
nature	O
of	O
the	O
fragment	B-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Micro	O
-	O
satellite	O
PCR	O
may	O
be	O
useful	O
for	O
the	O
identification	O
of	O
mis	O
-	O
labelled	O
or	O
mismatched	O
tissue	B-Tissue
fragments	I-Tissue
in	O
surgical	O
pathology	O
specimens	B-Tissue
.	O
</ALL>	O

<ALL>	O
Specific	O
subgroup	O
B	O
adenovirus	O
diagnosis	O
by	O
PCR	O
of	O
the	O
fibre	O
gene	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
</ALL>	O

<ALL>	O
A	O
highly	O
sensitive	O
and	O
specific	O
PCR	O
assay	O
targeting	O
regions	O
of	O
the	O
fibre	O
gene	O
was	O
developed	O
for	O
the	O
identification	O
of	O
subgroup	O
B	O
adenovirus	O
strains	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
critical	O
,	O
since	O
these	O
adenovirus	O
strains	O
are	O
frequently	O
associated	O
with	O
severe	O
respiratory	B-Anatomical_system
infections	O
in	O
infants	O
and	O
new	O
-	O
borns	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
Clinical	O
samples	B-Organism_substance
from	O
nasopharyngeal	B-Organism_substance
aspirates	I-Organism_substance
were	O
analysed	O
by	O
PCR	O
using	O
several	O
sets	O
of	O
primers	O
corresponding	O
to	O
sequences	O
of	O
the	O
gene	O
coding	O
for	O
the	O
fibre	O
protein	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
The	O
assay	O
allowed	O
the	O
detection	O
and	O
identification	O
of	O
all	O
the	O
genotypes	O
of	O
adenovirus	O
subgroup	O
B	O
,	O
based	O
on	O
the	O
size	O
of	O
the	O
amplified	O
product	O
when	O
analysed	O
on	O
polyacrilamide	O
gel	O
electrophoresis	O
.	O
</ALL>	O

<ALL>	O
Specifically	O
,	O
one	O
set	O
of	O
primers	O
was	O
able	O
to	O
amplify	O
DNA	O
of	O
subgroup	O
B	O
but	O
not	O
subgroup	O
C	O
and	O
E	O
viruses	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
</ALL>	O

<ALL>	O
The	O
detection	O
of	O
adenovirus	O
and	O
the	O
genotyping	O
can	O
be	O
done	O
on	O
a	O
routine	O
basis	O
by	O
a	O
PCR	O
assay	O
using	O
the	O
fibre	O
gene	O
as	O
a	O
target	O
.	O
</ALL>	O

<ALL>	O
The	O
assay	O
allows	O
the	O
identification	O
of	O
ADV	O
subgroup	O
B	O
,	O
including	O
genotype	O
7h	O
,	O
which	O
is	O
the	O
single	O
most	O
important	O
viral	O
pathogen	O
associated	O
with	O
respiratory	B-Anatomical_system
diseases	O
in	O
infants	O
and	O
young	O
children	O
in	O
the	O
southern	O
part	O
of	O
South	O
America	O
.	O
</ALL>	O

<ALL>	O
[	O
Anesthetic	O
management	O
of	O
a	O
patient	O
with	O
Dyggve	O
-	O
Melchior	O
-	O
Clausen	O
syndrome	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
Dyggve	O
-	O
Melchior	O
-	O
Clausen	O
syndrome	O
(	O
DMCS	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
skeletal	B-Anatomical_system
dysplasia	O
characterized	O
by	O
short	O
-	O
trunk	B-Organism_subdivision
dwarfism	O
and	O
mental	O
retardation	O
.	O
</ALL>	O

<ALL>	O
A	O
49	O
-	O
year	O
-	O
old	O
male	O
with	O
DMCS	O
underwent	O
resection	O
arthroplasty	O
for	O
contracture	O
of	O
the	O
right	B-Multi-tissue_structure
hip	I-Multi-tissue_structure
joint	I-Multi-tissue_structure
under	O
general	O
anesthesia	O
using	O
thiamylal	O
,	O
nitrous	O
oxide	O
,	O
sevoflurane	O
,	O
and	O
vecuronium	O
.	O
</ALL>	O

<ALL>	O
Although	O
he	O
was	O
assumed	O
to	O
have	O
difficult	O
airway	B-Multi-tissue_structure
due	O
to	O
short	O
neck	B-Organism_subdivision
,	O
macroglossia	O
,	O
and	O
disturbance	O
of	O
neck	B-Organism_subdivision
flexion	O
,	O
tracheal	B-Multi-tissue_structure
intubation	O
was	O
not	O
difficult	O
.	O
</ALL>	O

<ALL>	O
No	O
complications	O
including	O
malignant	O
hyperthermia	O
were	O
observed	O
during	O
the	O
95	O
min	O
of	O
the	O
operation	O
.	O
</ALL>	O

<ALL>	O
Assembly	O
strategies	O
and	O
GTPase	O
regulation	O
of	O
the	O
eukaryotic	O
and	O
Escherichia	O
coil	O
translocons	B-Cellular_component
.	O
</ALL>	O

<ALL>	O
The	O
translocation	O
of	O
most	O
proteins	O
across	O
the	O
endoplasmic	B-Cellular_component
reticulum	I-Cellular_component
or	O
bacterial	O
inner	B-Cellular_component
membrane	I-Cellular_component
occurs	O
through	O
an	O
aqueous	B-Cellular_component
pore	I-Cellular_component
that	O
spans	O
the	O
membrane	B-Cellular_component
.	O
</ALL>	O

<ALL>	O
Substrates	O
that	O
are	O
translocated	O
co	O
-	O
translationally	O
across	O
the	O
membrane	B-Cellular_component
are	O
directed	O
to	O
the	O
translocation	B-Cellular_component
pore	I-Cellular_component
via	O
an	O
interaction	O
between	O
the	O
cytosolic	B-Organism_substance
signal	O
recognition	O
particle	O
and	O
its	O
membrane	B-Cellular_component
-	O
bound	O
receptor	O
.	O
</ALL>	O

<ALL>	O
Together	O
the	O
translocation	B-Cellular_component
pore	I-Cellular_component
and	O
the	O
receptor	O
are	O
referred	O
to	O
as	O
a	O
translocon	B-Cellular_component
.	O
</ALL>	O

<ALL>	O
By	O
studying	O
the	O
biogenesis	O
of	O
the	O
translocon	B-Cellular_component
a	O
number	O
of	O
alternate	O
targeting	O
and	O
membrane	B-Cellular_component
-	O
integration	O
pathways	O
have	O
been	O
discovered	O
that	O
operate	O
independently	O
of	O
the	O
signal	O
recognition	O
particle	O
(	O
SRP	O
)	O
pathway	O
.	O
</ALL>	O

<ALL>	O
The	O
novel	O
assembly	O
strategies	O
of	O
the	O
translocon	B-Cellular_component
and	O
the	O
ways	O
in	O
which	O
these	O
components	O
interact	O
to	O
ensure	O
the	O
fidelity	O
and	O
unidirectionality	O
of	O
the	O
targeting	O
and	O
translocation	O
process	O
are	O
reviewed	O
here	O
.	O
</ALL>	O

<ALL>	O
Phonology	O
:	O
a	O
review	O
and	O
proposals	O
from	O
a	O
connectionist	O
perspective	O
.	O
</ALL>	O

<ALL>	O
A	O
parallel	O
distributed	O
processing	O
(	O
PDP	O
)	O
model	O
of	O
phonological	O
processing	O
is	O
developed	O
,	O
including	O
components	O
to	O
support	O
repetition	O
,	O
auditory	O
processing	O
,	O
comprehension	O
,	O
and	O
language	O
production	O
.	O
</ALL>	O

<ALL>	O
From	O
the	O
performance	O
of	O
the	O
PDP	O
reading	O
model	O
of	O
Plaut	O
,	O
McClelland	O
,	O
Seidenberg	O
,	O
and	O
Patterson	O
(	O
1996	O
)	O
,	O
it	O
is	O
inferred	O
that	O
the	O
acoustic	O
-	O
articulatory	O
motor	O
pattern	O
associator	O
that	O
supports	O
repetition	O
provides	O
the	O
basis	O
for	O
phonological	O
sequence	O
knowledge	O
.	O
</ALL>	O

<ALL>	O
From	O
the	O
observation	O
that	O
many	O
patients	O
make	O
phonemic	O
paraphasic	O
errors	O
in	O
language	O
production	O
,	O
as	O
in	O
repetition	O
,	O
it	O
is	O
argued	O
that	O
there	O
must	O
be	O
a	O
direct	O
link	O
between	O
distributed	O
concept	O
representations	O
(	O
lexical	O
semantic	O
knowledge	O
)	O
and	O
this	O
network	O
representation	O
of	O
sequence	O
knowledge	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
way	O
,	O
both	O
lexical	O
semantic	O
and	O
phonotactic	O
constraints	O
are	O
brought	O
to	O
bear	O
on	O
language	O
production	O
.	O
</ALL>	O

<ALL>	O
The	O
literature	O
on	O
phonological	O
function	O
in	O
normal	O
subjects	O
(	O
slip	O
-	O
of	O
-	O
the	O
-	O
tongue	O
corpora	O
)	O
and	O
in	O
patients	O
with	O
aphasia	O
is	O
critically	O
reviewed	O
from	O
this	O
perspective	O
.	O
</ALL>	O

<ALL>	O
The	O
relationship	O
between	O
acoustic	O
and	O
articulatory	O
motor	O
representations	O
in	O
the	O
process	O
of	O
phonetic	O
perception	O
is	O
considered	O
.	O
</ALL>	O

<ALL>	O
Repetition	O
and	O
reproduction	O
conduction	O
aphasia	O
are	O
reviewed	O
in	O
detail	O
and	O
extended	O
consideration	O
is	O
given	O
to	O
the	O
representation	O
of	O
auditory	O
verbal	O
short	O
-	O
term	O
memory	O
in	O
the	O
model	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
the	O
PDP	O
model	O
is	O
reconciled	O
with	O
information	O
processing	O
models	O
of	O
phonological	O
processing	O
,	O
including	O
that	O
of	O
Lichtheim	O
,	O
and	O
with	O
current	O
knowledge	O
of	O
the	O
anatomic	O
localization	O
of	O
phonological	O
processing	O
.	O
</ALL>	O

<ALL>	O
Although	O
no	O
simulations	O
of	O
the	O
model	O
were	O
run	O
,	O
a	O
number	O
of	O
simulation	O
studies	O
are	O
proposed	O
.	O
</ALL>	O

<ALL>	O
Male	O
role	O
in	O
fertility	O
decisions	O
in	O
Robertsport	O
,	O
Liberia	O
:	O
an	O
experimental	O
exercise	O
for	O
policy	O
formulation	O
.	O
</ALL>	O

<ALL>	O
There	O
is	O
a	O
tendency	O
to	O
believe	O
that	O
in	O
African	O
societies	O
men	O
are	O
the	O
dominant	O
decision	O
makers	O
in	O
the	O
family	O
.	O
</ALL>	O

<ALL>	O
In	O
Robertsport	O
,	O
Liberia	O
,	O
there	O
are	O
indications	O
that	O
,	O
with	O
respect	O
to	O
fertility	O
regulation	O
,	O
the	O
dominance	O
of	O
the	O
husband	O
in	O
fertility	O
decisions	O
exists	O
,	O
but	O
it	O
is	O
also	O
apparent	O
that	O
many	O
of	O
these	O
decisions	O
are	O
made	O
jointly	O
by	O
both	O
husband	O
and	O
wife	O
.	O
</ALL>	O

<ALL>	O
Education	O
is	O
particularly	O
influential	O
in	O
the	O
joint	O
fertility	O
decision	O
-	O
making	O
process	O
.	O
</ALL>	O

<ALL>	O
The	O
100	O
husbands	O
sampled	O
in	O
1982	O
desired	O
a	O
large	O
number	O
of	O
children	O
and	O
had	O
experience	O
with	O
infant	O
and	O
child	O
mortality	O
.	O
</ALL>	O

<ALL>	O
If	O
family	O
planning	O
programs	O
should	O
attain	O
their	O
goals	O
,	O
men	O
should	O
be	O
more	O
involved	O
,	O
than	O
at	O
present	O
,	O
in	O
every	O
aspect	O
of	O
the	O
programs	O
.	O
</ALL>	O

<ALL>	O
Equally	O
important	O
is	O
the	O
urgency	O
for	O
studies	O
related	O
to	O
the	O
role	O
of	O
men	O
in	O
fertility	O
regulation	O
,	O
using	O
adequately	O
large	O
samples	O
.	O
</ALL>	O

<ALL>	O
Act	O
No	O
.	O
16	O
.	O
045	O
of	O
2	O
June	O
1989	O
prohibiting	O
all	O
discrimination	O
that	O
violates	O
the	O
principle	O
of	O
equality	O
of	O
treatment	O
and	O
opportunities	O
for	O
both	O
sexes	O
in	O
all	O
sectors	O
of	O
labor	O
activity	O
.	O
</ALL>	O

<ALL>	O
This	O
Uruguayan	O
Act	O
prohibits	O
discrimination	O
in	O
employment	O
with	O
respect	O
to	O
the	O
following	O
areas	O
,	O
among	O
others	O
:	O
1	O
)	O
advertising	O
for	O
the	O
provision	O
of	O
positions	O
;	O
2	O
)	O
selection	O
criteria	O
;	O
3	O
)	O
recruitment	O
and	O
hiring	O
;	O
4	O
)	O
evaluation	O
of	O
performance	O
criteria	O
;	O
5	O
)	O
the	O
right	O
to	O
advancement	O
and	O
promotion	O
;	O
6	O
)	O
labour	O
stability	O
;	O
7	O
)	O
social	O
benefits	O
;	O
8	O
)	O
suspension	O
and	O
dismissal	O
,	O
particularly	O
in	O
cases	O
involving	O
a	O
change	O
of	O
civil	O
status	O
,	O
pregnancy	O
,	O
or	O
nursing	O
;	O
9	O
)	O
possibilities	O
for	O
professional	O
and	O
technical	O
education	O
or	O
retraining	O
;	O
and	O
10	O
)	O
remuneration	O
criteria	O
.	O
</ALL>	O

<ALL>	O
Reserving	O
places	O
for	O
one	O
sex	O
because	O
of	O
the	O
presence	O
of	O
activities	O
in	O
which	O
the	O
sex	O
of	O
the	O
employee	O
is	O
essential	O
for	O
performance	O
or	O
to	O
comply	O
with	O
international	O
labor	O
treaties	O
does	O
not	O
constitute	O
discrimination	O
.	O
</ALL>	O

<ALL>	O
Nor	O
do	O
compensatory	O
acts	O
designed	O
to	O
promote	O
equality	O
of	O
opportunities	O
and	O
treatment	O
of	O
both	O
sexes	O
in	O
concrete	O
situations	O
.	O
</ALL>	O

<ALL>	O
In	O
cases	O
where	O
the	O
provisions	O
of	O
this	O
Act	O
have	O
been	O
violated	O
,	O
specially	O
designated	O
judges	O
will	O
call	O
the	O
parties	O
together	O
and	O
may	O
adopt	O
measures	O
designed	O
to	O
end	O
the	O
situation	O
complained	O
of	O
.	O
</ALL>	O

<ALL>	O
If	O
they	O
deem	O
it	O
necessary	O
,	O
the	O
judges	O
may	O
institute	O
more	O
formal	O
proceedings	O
.	O
</ALL>	O

<ALL>	O
If	O
the	O
measures	O
adopted	O
are	O
not	O
carried	O
out	O
,	O
the	O
person	O
violating	O
the	O
law	O
is	O
subject	O
to	O
a	O
daily	O
fine	O
,	O
as	O
well	O
as	O
administrative	O
penalties	O
set	O
out	O
in	O
Act	O
15	O
.	O
903	O
of	O
10	O
November	O
1987	O
.	O
</ALL>	O

<ALL>	O
Adverse	O
decisions	O
may	O
be	O
appealed	O
.	O
</ALL>	O

<ALL>	O
The	O
state	O
is	O
also	O
to	O
undertake	O
educative	O
campaigns	O
to	O
create	O
interest	O
in	O
and	O
understanding	O
of	O
the	O
problems	O
affecting	O
women	O
workers	O
,	O
thus	O
promoting	O
awareness	O
in	O
such	O
workers	O
and	O
their	O
employers	O
of	O
their	O
situation	O
.	O
</ALL>	O

<ALL>	O
CXC	O
chemokine	O
receptors	O
in	O
the	O
central	B-Anatomical_system
nervous	I-Anatomical_system
system	I-Anatomical_system
:	O
Role	O
in	O
cerebellar	B-Multi-tissue_structure
neuromodulation	O
and	O
development	O
.	O
</ALL>	O

<ALL>	O
Chemokines	O
and	O
their	O
receptors	O
are	O
constitutively	O
present	O
in	O
the	O
central	B-Anatomical_system
nervous	I-Anatomical_system
system	I-Anatomical_system
(	O
CNS	B-Anatomical_system
)	O
,	O
expressed	O
in	O
neurons	B-Cell
and	O
glial	B-Cell
cells	I-Cell
.	O
</ALL>	O

<ALL>	O
Much	O
evidence	O
suggests	O
that	O
,	O
beyond	O
their	O
involvement	O
in	O
neuroinflammation	O
,	O
these	O
proteins	O
play	O
a	O
role	O
in	O
neurodevelopment	O
and	O
neurophysiological	O
signaling	O
.	O
</ALL>	O

<ALL>	O
The	O
goal	O
of	O
this	O
review	O
is	O
to	O
summarize	O
recent	O
information	O
concerning	O
expression	O
,	O
signaling	O
,	O
and	O
function	O
of	O
CXC	O
chemokine	O
receptor	O
in	O
the	O
CNS	B-Anatomical_system
,	O
with	O
the	O
main	O
focus	O
on	O
the	O
developmental	O
and	O
neuromodulatory	O
actions	O
of	O
chemokines	O
in	O
the	O
cerebellum	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Combined	O
tracheal	B-Multi-tissue_structure
and	O
esophageal	B-Multi-tissue_structure
stenting	O
for	O
palliation	O
of	O
tracheoesophageal	B-Multi-tissue_structure
symptoms	O
from	O
mediastinal	B-Pathological_formation
lymphoma	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Mediastinal	B-Pathological_formation
lymphoma	I-Pathological_formation
as	O
a	O
cause	O
of	O
tracheobronchial	B-Multi-tissue_structure
obstruction	O
is	O
uncommon	O
,	O
and	O
a	O
malignant	O
tracheoesophageal	B-Immaterial_anatomical_entity
fistula	I-Immaterial_anatomical_entity
in	O
the	O
setting	O
of	O
mediastinal	B-Pathological_formation
lymphoma	I-Pathological_formation
is	O
rare	O
.	O
</ALL>	O

<ALL>	O
Malignant	O
tracheoesophageal	B-Immaterial_anatomical_entity
fistulas	I-Immaterial_anatomical_entity
are	O
associated	O
with	O
pronounced	O
morbidity	O
and	O
mortality	O
.	O
</ALL>	O

<ALL>	O
We	O
describe	O
a	O
patient	O
with	O
mediastinal	B-Pathological_formation
lymphomatous	I-Pathological_formation
infiltration	O
resulting	O
in	O
tracheal	B-Multi-tissue_structure
obstruction	O
,	O
esophageal	B-Multi-tissue_structure
obstruction	O
,	O
and	O
tracheoesophageal	B-Immaterial_anatomical_entity
fistula	I-Immaterial_anatomical_entity
that	O
were	O
successfully	O
palliated	O
with	O
combined	O
airway	B-Multi-tissue_structure
and	O
esophageal	B-Multi-tissue_structure
stent	O
placement	O
.	O
</ALL>	O

<ALL>	O
Rural	O
/	O
urban	O
differences	O
in	O
access	O
to	O
and	O
utilization	O
of	O
services	O
among	O
people	O
in	O
Alabama	O
with	O
sickle	B-Cell
cell	I-Cell
disease	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
</ALL>	O

<ALL>	O
This	O
study	O
examined	O
relationships	O
between	O
socioeconomic	O
factors	O
and	O
the	O
geographic	O
distribution	O
of	O
662	O
cases	O
of	O
sickle	B-Cell
cell	I-Cell
disease	O
in	O
Alabama	O
in	O
1999	O
-	O
2001	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
Measures	O
of	O
community	O
distress	O
,	O
physical	O
functioning	O
,	O
and	O
medical	O
problems	O
were	O
used	O
in	O
analyzing	O
utilization	O
differences	O
between	O
individuals	O
with	O
sickle	B-Cell
cell	I-Cell
disease	O
living	O
in	O
urban	O
and	O
rural	O
areas	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
Utilization	O
of	O
comprehensive	O
sickle	B-Cell
cells	I-Cell
disease	O
services	O
was	O
lower	O
for	O
individuals	O
with	O
sickle	B-Cell
cell	I-Cell
disease	O
living	O
in	O
rural	O
areas	O
than	O
for	O
those	O
living	O
in	O
urban	O
areas	O
.	O
</ALL>	O

<ALL>	O
Rural	O
clients	O
reported	O
significantly	O
more	O
limitations	O
than	O
urban	O
clients	O
on	O
several	O
measures	O
of	O
physical	O
functioning	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
also	O
suggest	O
that	O
utilization	O
of	O
services	O
was	O
higher	O
for	O
those	O
with	O
more	O
medical	O
problems	O
and	O
those	O
who	O
lived	O
in	O
high	O
distress	O
areas	O
,	O
although	O
these	O
findings	O
did	O
not	O
meet	O
the	O
criterion	O
for	O
statistical	O
significance	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
</ALL>	O

<ALL>	O
Conclusions	O
based	O
on	O
statistical	O
evidence	O
that	O
geographic	O
location	O
and	O
socioeconomic	O
factors	O
relate	O
to	O
significantly	O
different	O
health	O
care	O
service	O
experience	O
bear	O
important	O
implications	O
for	O
medical	O
and	O
health	O
care	O
support	O
systems	O
,	O
especially	O
on	O
the	O
community	O
level	O
.	O
</ALL>	O

<ALL>	O
Impact	O
of	O
technology	O
on	O
the	O
utilisation	O
of	O
positron	O
emission	O
tomography	O
in	O
lymphoma	B-Pathological_formation
:	O
current	O
and	O
future	O
perspectives	O
.	O
</ALL>	O

<ALL>	O
Positron	O
emission	O
tomography	O
(	O
PET	O
)	O
has	O
now	O
gained	O
a	O
place	O
in	O
the	O
management	O
of	O
patients	O
with	O
cancer	B-Pathological_formation
,	O
including	O
those	O
with	O
Hodgkin	O
'	O
s	O
disease	O
and	O
non	B-Pathological_formation
-	I-Pathological_formation
Hodgkin	I-Pathological_formation
'	I-Pathological_formation
s	I-Pathological_formation
lymphoma	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Restaging	O
studies	O
and	O
those	O
addressing	O
the	O
monitoring	O
of	O
response	O
to	O
treatment	O
are	O
especially	O
in	O
focus	O
.	O
</ALL>	O

<ALL>	O
Most	O
of	O
the	O
knowledge	O
gained	O
has	O
been	O
achieved	O
with	O
dedicated	O
BGO	O
-	O
based	O
PET	O
technology	O
,	O
but	O
there	O
are	O
a	O
number	O
of	O
developments	O
that	O
will	O
impact	O
on	O
the	O
use	O
of	O
this	O
metabolic	O
imaging	O
technique	O
in	O
the	O
investigation	O
of	O
patients	O
with	O
lymphoma	B-Pathological_formation
.	O
</ALL>	O

<ALL>	O
The	O
challenges	O
ahead	O
are	O
determined	O
by	O
the	O
need	O
for	O
high	O
-	O
quality	O
whole	O
-	O
body	O
imaging	O
associated	O
with	O
increased	O
patient	O
throughput	O
and	O
the	O
need	O
to	O
investigate	O
the	O
role	O
of	O
new	O
labelled	O
ligands	O
.	O
</ALL>	O

<ALL>	O
The	O
latter	O
are	O
likely	O
to	O
yield	O
new	O
insights	O
into	O
tumour	B-Cell
cell	I-Cell
characterisation	O
,	O
tumour	B-Pathological_formation
behaviour	O
and	O
tumour	B-Pathological_formation
outcome	O
assessment	O
.	O
</ALL>	O

<ALL>	O
The	O
study	O
of	O
new	O
radiolabelled	O
ligands	O
will	O
impose	O
further	O
demands	O
for	O
rapid	O
dynamic	O
data	O
acquisition	O
and	O
accurate	O
tracer	O
quantification	O
.	O
</ALL>	O

<ALL>	O
Current	O
and	O
future	O
developments	O
in	O
PET	O
technology	O
range	O
from	O
the	O
use	O
of	O
new	O
detector	O
materials	O
to	O
different	O
detector	O
geometries	O
and	O
data	O
acquisition	O
modes	O
.	O
</ALL>	O

<ALL>	O
The	O
search	O
for	O
alternatives	O
to	O
BGO	O
scintillation	O
materials	O
for	O
PET	O
has	O
led	O
to	O
the	O
development	O
of	O
PET	O
instruments	O
utilising	O
new	O
crystals	O
such	O
as	O
LSO	O
and	O
GSO	O
.	O
</ALL>	O

<ALL>	O
The	O
use	O
of	O
these	O
new	O
detectors	O
and	O
the	O
increased	O
sensitivity	O
achieved	O
with	O
3D	O
data	O
acquisitions	O
represent	O
the	O
most	O
significant	O
current	O
developments	O
in	O
the	O
field	O
.	O
</ALL>	O

<ALL>	O
With	O
the	O
increasing	O
demands	O
imposed	O
on	O
the	O
clinical	O
utilisation	O
of	O
PET	O
,	O
issues	O
such	O
as	O
study	O
cost	O
and	O
patient	O
throughput	O
will	O
emerge	O
as	O
significant	O
future	O
factors	O
.	O
</ALL>	O

<ALL>	O
As	O
a	O
consequence	O
,	O
low	O
-	O
cost	O
units	O
are	O
being	O
offered	O
by	O
the	O
manufacturers	O
through	O
the	O
utilisation	O
of	O
gamma	O
camera	O
-	O
based	O
SPET	O
systems	O
for	O
PET	O
coincidence	O
imaging	O
.	O
</ALL>	O

<ALL>	O
Unfortunately	O
,	O
clinical	O
studies	O
in	O
lymphoma	B-Pathological_formation
and	O
other	O
cancers	B-Pathological_formation
have	O
already	O
demonstrated	O
the	O
limitations	O
of	O
this	O
technology	O
,	O
with	O
20	O
%	O
of	O
lesions	B-Pathological_formation
<	O
15	O
mm	O
in	O
size	O
escaping	O
detection	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
other	O
hand	O
,	O
the	O
recent	O
development	O
of	O
combined	O
PET	O
/	O
CT	O
devices	O
attempts	O
to	O
address	O
the	O
lack	O
of	O
anatomical	O
information	O
inherent	O
with	O
PET	O
images	O
,	O
taking	O
advantage	O
of	O
further	O
improvement	O
in	O
patient	O
throughput	O
and	O
hence	O
cost	O
-	O
effectiveness	O
.	O
</ALL>	O

<ALL>	O
Preliminary	O
studies	O
using	O
this	O
multimodality	O
imaging	O
approach	O
have	O
already	O
demonstrated	O
the	O
potential	O
of	O
the	O
technique	O
.	O
</ALL>	O

<ALL>	O
Although	O
the	O
potential	O
exists	O
,	O
certain	O
technical	O
issues	O
with	O
PET	O
/	O
CT	O
require	O
refinement	O
of	O
the	O
methodology	O
.	O
</ALL>	O

<ALL>	O
Such	O
issues	O
include	O
organ	B-Organ
movement	O
(	O
such	O
as	O
respiratory	B-Anatomical_system
motion	O
)	O
,	O
which	O
strongly	O
influences	O
the	O
image	O
fusion	O
of	O
a	O
rapidly	O
acquired	O
CT	O
scan	O
with	O
the	O
slower	O
acquisition	O
of	O
a	O
PET	O
dataset	O
,	O
and	O
the	O
derivation	O
of	O
CT	O
-	O
based	O
attenuation	O
coefficients	O
in	O
the	O
presence	O
of	O
contrast	O
agents	O
or	O
metallic	O
implants	O
.	O
</ALL>	O

<ALL>	O
The	O
application	O
of	O
the	O
technology	O
for	O
radiotherapy	O
planning	O
also	O
poses	O
a	O
number	O
of	O
associated	O
challenges	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
the	O
development	O
of	O
dedicated	O
PET	O
systems	O
based	O
on	O
planar	O
detector	O
arrangements	O
with	O
new	O
detector	O
components	O
has	O
the	O
potential	O
to	O
improve	O
clinical	O
throughput	O
by	O
over	O
100	O
%	O
,	O
but	O
clinical	O
trials	O
using	O
such	O
systems	O
have	O
still	O
to	O
be	O
carried	O
out	O
in	O
order	O
to	O
establish	O
the	O
associated	O
whole	O
-	O
body	B-Organism_subdivision
image	O
quality	O
.	O
</ALL>	O

<ALL>	O
Stereoselective	O
synthesis	O
of	O
1	O
-	O
aminoalkanephosphonic	O
acids	O
with	O
two	O
chiral	O
centers	O
and	O
their	O
activity	O
towards	O
leucine	O
aminopeptidase	O
.	O
</ALL>	O

<ALL>	O
The	O
stereoselective	O
synthesis	O
of	O
1	O
-	O
amino	O
-	O
2	O
-	O
alkylalkanephosphonic	O
acids	O
,	O
namely	O
,	O
compounds	O
bearing	O
two	O
chiral	O
centers	O
,	O
was	O
achieved	O
by	O
the	O
condensation	O
of	O
hypophosphorous	O
acid	O
salts	O
of	O
(	O
R	O
)	O
(	O
+	O
)	O
or	O
(	O
S	O
)	O
(	O
-	O
)	O
-	O
N	O
-	O
alpha	O
-	O
methylbenzylamine	O
with	O
the	O
appropriate	O
aldehydes	O
in	O
isopropanol	O
.	O
</ALL>	O

<ALL>	O
Simultaneous	O
deprotection	O
and	O
oxidation	O
by	O
the	O
action	O
of	O
bromine	O
water	O
provided	O
equimolar	O
mixtures	O
of	O
the	O
RS	O
:	O
RR	O
and	O
SR	O
:	O
SS	O
diastereomers	O
of	O
desired	O
acids	O
.	O
</ALL>	O

<ALL>	O
They	O
appeared	O
to	O
act	O
as	O
moderate	O
inhibitors	O
of	O
kidney	B-Organ
leucine	O
aminopeptidase	O
with	O
potency	O
dependent	O
on	O
the	O
absolute	O
configuration	O
of	O
both	O
centers	O
of	O
chirality	O
.	O
</ALL>	O

<ALL>	O
[	O
Community	O
intervention	O
on	O
hypertension	O
and	O
stroke	O
]	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
</ALL>	O

<ALL>	O
To	O
evaluate	O
the	O
community	O
-	O
based	O
intervention	O
on	O
reduction	O
of	O
hypertension	O
and	O
stroke	O
in	O
different	O
age	O
groups	O
and	O
subtypes	O
hypertension	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
In	O
6	O
cities	O
,	O
2	O
geographically	O
separated	O
communities	O
with	O
a	O
registered	O
population	O
about	O
10	O
000	O
of	O
each	O
were	O
selected	O
as	O
either	O
intervention	O
or	O
control	O
communities	O
.	O
</ALL>	O

<ALL>	O
A	O
cohort	O
containing	O
2	O
700	O
subjects	O
,	O
35	O
years	O
or	O
older	O
,	O
and	O
free	O
of	O
stroke	O
were	O
sampled	O
from	O
each	O
community	O
.	O
</ALL>	O

<ALL>	O
The	O
baseline	O
survey	O
was	O
conducted	O
to	O
screen	O
the	O
subjects	O
for	O
intervention	O
.	O
</ALL>	O

<ALL>	O
In	O
each	O
city	O
,	O
a	O
program	O
for	O
control	O
of	O
hypertension	O
,	O
heart	B-Organ
diseases	O
and	O
diabetes	O
was	O
initiated	O
in	O
the	O
intervention	O
cohort	O
and	O
health	O
education	O
was	O
provided	O
to	O
the	O
whole	O
intervention	O
community	O
.	O
</ALL>	O

<ALL>	O
A	O
follow	O
-	O
up	O
survey	O
was	O
conducted	O
3	O
years	O
later	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
Within	O
3	O
years	O
,	O
the	O
prevalence	O
of	O
hypertension	O
increased	O
in	O
both	O
intervention	O
and	O
control	O
cohorts	O
,	O
as	O
well	O
as	O
in	O
the	O
middle	O
and	O
elderly	O
cohorts	O
,	O
especially	O
in	O
the	O
middle	O
aged	O
in	O
control	O
group	O
.	O
</ALL>	O

<ALL>	O
Among	O
hypertensives	O
in	O
the	O
intervention	O
cohort	O
,	O
the	O
rates	O
of	O
awareness	O
,	O
treatment	O
and	O
control	O
of	O
hypertension	O
got	O
improved	O
.	O
</ALL>	O

<ALL>	O
The	O
incidence	O
of	O
stroke	O
was	O
29	O
%	O
lower	O
(	O
HR	O
=	O
0	O
.	O
71	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
58	O
-	O
0	O
.	O
87	O
)	O
and	O
mortality	O
of	O
stroke	O
was	O
40	O
%	O
lower	O
(	O
HR	O
=	O
0	O
.	O
60	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
42	O
-	O
0	O
.	O
86	O
)	O
in	O
the	O
intervention	O
cohort	O
than	O
the	O
control	O
cohort	O
.	O
</ALL>	O

<ALL>	O
The	O
intervention	O
was	O
most	O
effective	O
in	O
reduction	O
of	O
stroke	O
for	O
those	O
with	O
isolated	O
systolic	O
hypertension	O
and	O
combined	O
systolic	O
and	O
diastolic	O
hypertension	O
(	O
All	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
</ALL>	O

<ALL>	O
Meanwhile	O
,	O
all	O
-	O
cause	O
mortality	O
was	O
11	O
%	O
lower	O
(	O
HR	O
=	O
0	O
.	O
89	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
78	O
-	O
0	O
.	O
99	O
)	O
in	O
the	O
intervention	O
cohort	O
than	O
in	O
the	O
control	O
cohort	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
</ALL>	O

<ALL>	O
The	O
community	O
-	O
based	O
intervention	O
was	O
effective	O
in	O
controlling	O
the	O
development	O
of	O
hypertension	O
and	O
stroke	O
,	O
while	O
the	O
elderly	O
people	O
benefit	O
more	O
than	O
the	O
middle	O
aged	O
people	O
from	O
the	O
intervention	O
.	O
</ALL>	O

<ALL>	O
[	O
Laboratory	O
diagnostics	O
of	O
Crimean	O
hemorrhagic	O
fever	O
by	O
polymerase	O
chain	O
reaction	O
]	O
.	O
</ALL>	O

<ALL>	O
Our	O
group	O
developed	O
,	O
within	O
the	O
present	O
case	O
study	O
,	O
two	O
techniques	O
'	O
variations	O
,	O
i	O
.	O
e	O
.	O
a	O
single	O
-	O
step	O
RT	O
-	O
PCR	O
and	O
nested	O
RT	O
-	O
PCR	O
assays	O
,	O
for	O
the	O
purpose	O
of	O
detecting	O
the	O
Crimean	O
-	O
Congo	O
hemorrhagic	O
fever	O
RNA	O
virus	O
in	O
human	O
samples	O
.	O
</ALL>	O

<ALL>	O
The	O
above	O
assays	O
as	O
well	O
as	O
those	O
previously	O
recommended	O
by	O
the	O
Ministry	O
of	O
Health	O
of	O
the	O
Russian	O
Federation	O
were	O
simultaneously	O
used	O
in	O
14	O
clinical	O
samples	O
obtained	O
from	O
patients	O
with	O
Crimean	O
hemorrhagic	O
fever	O
.	O
</ALL>	O

<ALL>	O
After	O
assessing	O
the	O
detection	O
accuracy	O
,	O
it	O
was	O
found	O
that	O
the	O
developed	O
-	O
by	O
-	O
us	O
test	O
system	O
displayed	O
the	O
same	O
or	O
even	O
better	O
diagnostic	O
values	O
versus	O
the	O
previously	O
recommended	O
nested	O
RT	O
-	O
PCR	O
and	O
a	O
1000	O
-	O
fold	O
advantage	O
over	O
the	O
previously	O
recommended	O
single	O
-	O
step	O
RT	O
-	O
PCA	O
.	O
</ALL>	O

<ALL>	O
The	O
single	O
-	O
step	O
RT	O
-	O
PCR	O
assay	O
variation	O
is	O
always	O
more	O
preferable	O
in	O
sense	O
of	O
technical	O
and	O
economic	O
motivations	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
the	O
test	O
system	O
developed	O
by	O
us	O
has	O
every	O
reason	O
to	O
become	O
the	O
method	O
of	O
choice	O
in	O
routine	O
PCR	O
diagnosis	O
of	O
Crimean	O
hemorrhagic	O
fever	O
after	O
all	O
official	O
trials	O
and	O
approvals	O
are	O
duly	O
complied	O
with	O
.	O
</ALL>	O

<ALL>	O
Prognostic	O
significance	O
and	O
correlation	O
with	O
survival	O
of	O
bcl	O
-	O
2	O
and	O
TGF	O
-	O
beta	O
RII	O
in	O
colon	B-Pathological_formation
cancer	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Bcl	O
-	O
2	O
and	O
TGF	O
-	O
beta	O
receptors	O
type	O
II	O
(	O
RII	O
)	O
in	O
colon	B-Pathological_formation
carcinomas	I-Pathological_formation
were	O
studied	O
in	O
a	O
series	O
of	O
113	O
patients	O
,	O
to	O
determine	O
their	O
prognostic	O
significance	O
and	O
to	O
correlate	O
their	O
expression	O
with	O
other	O
prognostic	O
indicators	O
.	O
</ALL>	O

<ALL>	O
Bcl	O
-	O
2	O
expression	O
in	O
the	O
tumor	B-Cell
cells	I-Cell
showed	O
a	O
reverse	O
relation	O
with	O
tumor	B-Pathological_formation
size	O
(	O
P	O
=	O
0	O
.	O
018	O
)	O
,	O
histological	O
grade	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
,	O
and	O
stage	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O
</ALL>	O

<ALL>	O
Univariate	O
survival	O
analysis	O
using	O
the	O
log	O
rank	O
test	O
showed	O
that	O
the	O
survival	O
of	O
patients	O
with	O
bcl	B-Pathological_formation
-	I-Pathological_formation
2	I-Pathological_formation
-	I-Pathological_formation
positive	I-Pathological_formation
tumors	I-Pathological_formation
was	O
significantly	O
better	O
than	O
the	O
survival	O
of	O
patients	O
with	O
bcl	B-Pathological_formation
-	I-Pathological_formation
2	I-Pathological_formation
-	I-Pathological_formation
negative	I-Pathological_formation
tumors	I-Pathological_formation
(	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
when	O
entered	O
into	O
a	O
multivariate	O
analysis	O
model	O
,	O
it	O
was	O
not	O
found	O
to	O
be	O
of	O
independent	O
prognostic	O
significance	O
.	O
</ALL>	O

<ALL>	O
TGF	O
-	O
beta	O
RII	O
expression	O
was	O
correlated	O
with	O
stage	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
,	O
while	O
no	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
TGF	O
-	O
beta	O
RII	O
expression	O
and	O
histological	O
grade	O
or	O
survival	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
these	O
results	O
provide	O
additional	O
evidence	O
for	O
the	O
role	O
of	O
bcl	O
-	O
2	O
and	O
TGF	O
-	O
beta	O
RII	O
in	O
carcinogenesis	O
of	O
the	O
colon	B-Organ
,	O
while	O
they	O
do	O
not	O
support	O
the	O
use	O
of	O
these	O
factors	O
as	O
prognostic	O
markers	O
in	O
patients	O
with	O
colon	B-Pathological_formation
cancer	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Antibiotic	O
-	O
induced	O
persistence	O
of	O
cytotoxic	O
Staphylococcus	O
aureus	O
in	O
non	B-Cell
-	I-Cell
phagocytic	I-Cell
cells	I-Cell
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
</ALL>	O

<ALL>	O
After	O
infection	O
of	O
non	B-Cell
-	I-Cell
phagocytic	I-Cell
cells	I-Cell
,	O
some	O
Staphylococcus	O
aureus	O
strains	O
are	O
able	O
to	O
survive	O
and	O
kill	O
their	O
host	O
cells	B-Cell
.	O
</ALL>	O

<ALL>	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
action	O
of	O
various	O
antibiotics	O
on	O
the	O
survival	O
of	O
host	O
cells	B-Cell
and	O
/	O
or	O
intracellular	B-Immaterial_anatomical_entity
S	O
.	O
aureus	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
Murine	O
keratinocyte	B-Cell
(	O
PAM212	B-Cell
)	O
and	O
fibroblast	B-Cell
(	O
mKSA	B-Cell
)	I-Cell
cell	I-Cell
lines	I-Cell
were	O
infected	O
with	O
cytotoxic	O
S	O
.	O
aureus	O
and	O
cultured	O
in	O
the	O
presence	O
of	O
various	O
antibiotics	O
at	O
graded	O
concentrations	O
.	O
</ALL>	O

<ALL>	O
The	O
viability	O
of	O
host	O
cells	B-Cell
was	O
measured	O
24	O
h	O
after	O
infection	O
.	O
</ALL>	O

<ALL>	O
To	O
determine	O
the	O
bacterial	O
viability	O
within	O
host	O
cells	B-Cell
,	O
cellular	B-Organism_substance
lysates	I-Organism_substance
were	O
prepared	O
and	O
colony	O
forming	O
units	O
were	O
quantified	O
using	O
a	O
spiral	O
plater	O
.	O
</ALL>	O

<ALL>	O
Host	O
cells	B-Cell
infected	O
with	O
fluorescein	O
isothiocyanate	O
(	O
FITC	O
)	O
-	O
labelled	O
S	O
.	O
aureus	O
were	O
analysed	O
by	O
flow	O
cytometry	O
and	O
microscopy	O
to	O
determine	O
the	O
subcellular	B-Cellular_component
localization	O
S	O
.	O
aureus	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
Oxacillin	O
,	O
vancomycin	O
,	O
gentamicin	O
,	O
ciprofloxacin	O
and	O
trimethoprim	O
/	O
sulfamethoxazole	O
did	O
not	O
rescue	O
host	O
cells	B-Cell
from	O
cell	B-Cell
death	O
induced	O
by	O
intracellular	B-Immaterial_anatomical_entity
S	O
.	O
aureus	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
linezolid	O
,	O
rifampicin	O
,	O
azithromycin	O
,	O
clindamycin	O
,	O
erythromycin	O
and	O
quinupristin	O
/	O
dalfopristin	O
suppressed	O
the	O
cytotoxic	O
action	O
of	O
S	O
.	O
aureus	O
.	O
</ALL>	O

<ALL>	O
After	O
withdrawal	O
of	O
antibiotics	O
,	O
intracellular	B-Immaterial_anatomical_entity
S	O
.	O
aureus	O
regained	O
cytotoxic	O
activity	O
and	O
killed	O
their	O
host	O
cells	B-Cell
.	O
</ALL>	O

<ALL>	O
Only	O
rifampicin	O
was	O
able	O
to	O
eliminate	O
intracellular	B-Immaterial_anatomical_entity
S	O
.	O
aureus	O
completely	O
within	O
72	O
h	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
clindamycin	O
,	O
azithromycin	O
and	O
linezolid	O
induced	O
a	O
state	O
of	O
intracellular	B-Immaterial_anatomical_entity
persistence	O
of	O
viable	O
S	O
.	O
aureus	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
</ALL>	O

<ALL>	O
Antibiotics	O
commonly	O
used	O
for	O
the	O
management	O
of	O
S	O
.	O
aureus	O
infections	O
appear	O
to	O
create	O
a	O
niche	O
for	O
invasive	O
intracellular	B-Immaterial_anatomical_entity
S	O
.	O
aureus	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
for	O
persistence	O
and	O
recurrence	O
of	O
infection	O
.	O
</ALL>	O

<ALL>	O
Because	O
of	O
its	O
unique	O
ability	O
to	O
eliminate	O
intracellular	B-Immaterial_anatomical_entity
S	O
.	O
aureus	O
,	O
rifampicin	O
appears	O
to	O
be	O
valuable	O
for	O
the	O
treatment	O
of	O
invasive	O
S	O
.	O
aureus	O
infections	O
.	O
</ALL>	O

<ALL>	O
Full	O
sequencing	O
analysis	O
of	O
estrogen	O
receptor	O
-	O
alpha	O
gene	O
polymorphism	O
and	O
its	O
association	O
with	O
breast	B-Pathological_formation
cancer	I-Pathological_formation
risk	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
</ALL>	O

<ALL>	O
The	O
estrogen	O
receptor	O
plays	O
a	O
critical	O
role	O
in	O
breast	B-Pathological_formation
cancer	I-Pathological_formation
development	O
and	O
progression	O
.	O
</ALL>	O

<ALL>	O
So	O
the	O
genetic	O
polymorphism	O
of	O
ER	O
-	O
alpha	O
gene	O
could	O
affect	O
cancer	B-Pathological_formation
risk	O
and	O
phenotype	O
.	O
</ALL>	O

<ALL>	O
MATERIALS	O
AND	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
We	O
fully	O
sequenced	O
the	O
ER	O
-	O
alpha	O
gene	O
to	O
investigate	O
its	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
100	O
breast	B-Pathological_formation
cancer	I-Pathological_formation
patients	O
and	O
100	O
controls	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
Six	O
novel	O
polymorphism	O
in	O
the	O
control	O
and	O
11	O
in	O
cancer	B-Pathological_formation
patients	O
were	O
found	O
.	O
</ALL>	O

<ALL>	O
The	O
G	O
/	O
G	O
genotype	O
at	O
C975	O
G	O
and	O
A	O
/	O
A	O
genotype	O
at	O
G1782	O
A	O
had	O
a	O
protective	O
effect	O
against	O
breast	B-Pathological_formation
cancer	I-Pathological_formation
when	O
compared	O
to	O
other	O
genotypes	O
(	O
OR	O
=	O
0	O
.	O
3	O
and	O
0	O
.	O
3	O
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
975G	O
allele	O
was	O
associated	O
inversely	O
with	O
the	O
p53	O
expression	O
and	O
positively	O
with	O
the	O
bcl	O
-	O
2	O
expression	O
in	O
cancer	B-Pathological_formation
with	O
borderline	O
significance	O
.	O
</ALL>	O

<ALL>	O
Combining	O
this	O
result	O
with	O
our	O
previous	O
study	O
,	O
these	O
associations	O
became	O
more	O
significant	O
(	O
p	O
=	O
0	O
.	O
005	O
and	O
0	O
.	O
019	O
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
</ALL>	O

<ALL>	O
Polymorphisms	O
in	O
ER	O
-	O
alpha	O
gene	O
can	O
affect	O
the	O
breast	B-Pathological_formation
cancer	I-Pathological_formation
susceptibility	O
and	O
may	O
be	O
related	O
to	O
other	O
protein	O
expression	O
,	O
such	O
as	O
p53	O
and	O
bcl	O
-	O
2	O
.	O
</ALL>	O

<ALL>	O
Covariance	O
structure	O
analysis	O
:	O
statistical	O
practice	O
,	O
theory	O
,	O
and	O
directions	O
.	O
</ALL>	O

<ALL>	O
Although	O
covariance	O
structure	O
analysis	O
is	O
used	O
increasingly	O
to	O
analyze	O
nonexperimental	O
data	O
,	O
important	O
statistical	O
requirements	O
for	O
its	O
proper	O
use	O
are	O
frequently	O
ignored	O
.	O
</ALL>	O

<ALL>	O
Valid	O
conclusions	O
about	O
the	O
adequacy	O
of	O
a	O
model	O
as	O
an	O
acceptable	O
representation	O
of	O
data	O
,	O
which	O
are	O
based	O
on	O
goodness	O
-	O
of	O
-	O
fit	O
test	O
statistics	O
and	O
standard	O
errors	O
of	O
parameter	O
estimates	O
,	O
rely	O
on	O
the	O
model	O
estimation	O
procedure	O
being	O
appropriate	O
for	O
the	O
data	O
.	O
</ALL>	O

<ALL>	O
Using	O
analogies	O
to	O
linear	O
regression	O
and	O
anova	O
,	O
this	O
review	O
examines	O
conditions	O
under	O
which	O
conclusions	O
drawn	O
from	O
various	O
estimation	O
methods	O
will	O
be	O
correct	O
and	O
the	O
consequences	O
of	O
ignoring	O
these	O
conditions	O
.	O
</ALL>	O

<ALL>	O
A	O
distinction	O
is	O
made	O
between	O
estimation	O
methods	O
that	O
are	O
either	O
correctly	O
or	O
incorrectly	O
specified	O
for	O
the	O
distribution	O
of	O
data	O
being	O
analyzed	O
,	O
and	O
it	O
is	O
shown	O
that	O
valid	O
conclusions	O
are	O
possible	O
even	O
under	O
misspecification	O
.	O
</ALL>	O

<ALL>	O
A	O
brief	O
example	O
illustrates	O
the	O
ideas	O
.	O
</ALL>	O

<ALL>	O
Internet	O
access	O
is	O
given	O
to	O
a	O
computer	O
code	O
for	O
several	O
methods	O
that	O
are	O
not	O
available	O
in	O
programs	O
such	O
as	O
EQS	O
or	O
LISREL	O
.	O
</ALL>	O

<ALL>	O
Potent	O
antibacterial	O
activity	O
of	O
Y	O
-	O
754	O
,	O
a	O
novel	O
benzimidazole	O
compound	O
with	O
selective	O
action	O
against	O
Helicobacter	O
pylori	O
.	O
</ALL>	O

<ALL>	O
Y	O
-	O
754	O
,	O
a	O
novel	O
benzimidazole	O
compound	O
,	O
was	O
investigated	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
antibacterial	O
activity	O
.	O
</ALL>	O

<ALL>	O
Unlike	O
amoxicillin	O
,	O
clarithromycin	O
,	O
and	O
metronidazole	O
,	O
the	O
compound	O
had	O
no	O
activity	O
against	O
common	O
aerobic	O
and	O
anaerobic	O
bacteria	O
other	O
than	O
Helicobacter	O
pylori	O
.	O
</ALL>	O

<ALL>	O
The	O
minimum	O
inhibitory	O
concentration	O
of	O
Y	O
-	O
754	O
against	O
H	O
.	O
pylori	O
,	O
at	O
0	O
.	O
025	O
microg	O
/	O
ml	O
,	O
was	O
nearly	O
equal	O
to	O
that	O
of	O
amoxicillin	O
and	O
clarithromycin	O
.	O
</ALL>	O

<ALL>	O
The	O
respective	O
concentrations	O
of	O
Y	O
-	O
754	O
,	O
amoxicillin	O
,	O
clarithromycin	O
,	O
and	O
metronidazole	O
required	O
to	O
inhibit	O
90	O
%	O
of	O
39	O
isolates	O
of	O
H	O
.	O
pylori	O
were	O
0	O
.	O
05	O
,	O
0	O
.	O
39	O
,	O
6	O
.	O
25	O
,	O
and	O
25	O
microg	O
/	O
ml	O
,	O
indicating	O
the	O
potent	O
activity	O
of	O
Y	O
-	O
754	O
,	O
including	O
activity	O
against	O
clarithromycin	O
-	O
and	O
metronidazole	O
-	O
resistant	O
strains	O
.	O
</ALL>	O

<ALL>	O
The	O
anti	O
-	O
H	O
.	O
pylori	O
activity	O
of	O
Y	O
-	O
754	O
was	O
potent	O
even	O
at	O
pH	O
5	O
.	O
5	O
and	O
was	O
bactericidal	O
at	O
concentrations	O
of	O
0	O
.	O
1	O
microg	O
/	O
ml	O
and	O
above	O
.	O
</ALL>	O

<ALL>	O
Exposure	O
of	O
H	O
.	O
pylori	O
to	O
Y	O
-	O
754	O
did	O
not	O
result	O
in	O
the	O
induction	O
of	O
drug	O
-	O
resistant	O
mutation	O
.	O
</ALL>	O

<ALL>	O
Oral	O
administration	O
(	O
10	O
mg	O
/	O
kg	O
twice	O
a	O
day	O
for	O
7	O
days	O
)	O
to	O
Mongolian	O
gerbils	O
infected	O
with	O
strain	O
ATCC	O
43504	O
demonstrated	O
that	O
Y	O
-	O
754	O
was	O
effective	O
in	O
H	O
.	O
pylori	O
eradication	O
and	O
that	O
its	O
eradication	O
efficacy	O
increased	O
in	O
line	O
with	O
the	O
progress	O
of	O
damage	O
to	O
the	O
gastric	B-Multi-tissue_structure
mucosa	I-Multi-tissue_structure
caused	O
by	O
H	O
.	O
pylori	O
infection	O
.	O
</ALL>	O

<ALL>	O
Y	O
-	O
754	O
was	O
also	O
efficacious	O
in	O
the	O
treatment	O
of	O
infection	O
by	O
the	O
clarithromycin	O
-	O
resistant	O
strain	O
OIT	O
-	O
36	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
obtained	O
lead	O
to	O
the	O
expectation	O
that	O
the	O
new	O
benzimidazole	O
Y	O
-	O
754	O
will	O
,	O
in	O
the	O
near	O
future	O
,	O
be	O
used	O
for	O
H	O
.	O
pylori	O
eradication	O
therapy	O
in	O
peptic	B-Pathological_formation
ulcer	I-Pathological_formation
patients	O
.	O
</ALL>	O

<ALL>	O
Active	O
respiratory	O
syncytial	O
virus	O
purified	O
by	O
ion	O
-	O
exchange	O
chromatography	O
:	O
characterization	O
of	O
binding	O
and	O
elution	O
requirements	O
.	O
</ALL>	O

<ALL>	O
Two	O
viruses	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
were	O
used	O
to	O
evaluate	O
viral	O
purification	O
by	O
an	O
affinity	O
resin	O
column	O
(	O
Matrex	O
Cellufine	O
Sulfate	O
(	O
MCS	O
)	O
;	O
Amicon	O
Division	O
,	O
WR	O
Grace	O
&	O
Co	O
.	O
)	O
.	O
</ALL>	O

<ALL>	O
Viable	O
RSV	O
was	O
purified	O
significantly	O
from	O
crude	O
cell	B-Organism_substance
lysate	I-Organism_substance
by	O
a	O
single	O
pass	O
through	O
a	O
column	O
containing	O
the	O
anionic	O
MCS	O
resin	O
.	O
</ALL>	O

<ALL>	O
Most	O
cell	B-Cell
protein	O
and	O
albumin	O
eluted	O
from	O
the	O
MCS	O
resin	O
with	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
)	O
but	O
RSV	O
eluted	O
at	O
high	O
ionic	O
strength	O
,	O
i	O
.	O
e	O
.	O
,	O
greater	O
than	O
or	O
equal	O
to	O
0	O
.	O
6	O
M	O
NaCl	O
.	O
</ALL>	O

<ALL>	O
Further	O
purification	O
was	O
possible	O
by	O
sucrose	O
step	O
gradient	O
centrifugation	O
.	O
</ALL>	O

<ALL>	O
The	O
RSV	O
prepared	O
by	O
column	O
purification	O
or	O
by	O
column	O
plus	O
sucrose	O
gradient	O
separation	O
was	O
both	O
intact	O
and	O
infective	O
.	O
</ALL>	O

<ALL>	O
RSV	O
and	O
pure	O
samples	O
of	O
VSV	O
were	O
used	O
to	O
optimize	O
ionic	O
strength	O
and	O
salts	O
for	O
elution	O
from	O
the	O
MCS	O
column	O
:	O
0	O
.	O
8	O
M	O
NaCl	O
removed	O
most	O
of	O
the	O
viral	O
protein	O
.	O
</ALL>	O

<ALL>	O
The	O
capacity	O
of	O
the	O
MCS	O
gel	O
for	O
RSV	O
or	O
VSV	O
was	O
found	O
to	O
be	O
about	O
0	O
.	O
6	O
-	O
0	O
.	O
8	O
mg	O
viral	O
protein	O
per	O
ml	O
of	O
hydrated	O
resin	O
.	O
</ALL>	O

<ALL>	O
Detergent	O
-	O
solubilized	O
viral	O
membrane	B-Cellular_component
proteins	O
bound	O
to	O
the	O
MCS	O
resin	O
in	O
0	O
.	O
145	O
M	O
NaCl	O
and	O
eluted	O
with	O
higher	O
salt	O
concentrations	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
this	O
resin	O
also	O
may	O
be	O
a	O
useful	O
aid	O
for	O
relatively	O
gentle	O
purification	O
of	O
these	O
proteins	O
.	O
</ALL>	O

<ALL>	O
Novel	O
insights	O
into	O
the	O
pathogenesis	O
of	O
uric	O
acid	O
nephrolithiasis	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
OF	O
REVIEW	O
:	O
</ALL>	O

<ALL>	O
The	O
factors	O
involved	O
in	O
the	O
pathogenesis	O
of	O
uric	O
acid	O
nephrolithiasis	O
are	O
well	O
known	O
.	O
</ALL>	O

<ALL>	O
A	O
low	O
urinary	B-Organism_substance
pH	O
is	O
the	O
most	O
significant	O
element	O
in	O
the	O
generation	O
of	O
stones	B-Organism_substance
,	O
with	O
hyperuricosuria	O
being	O
a	O
less	O
common	O
finding	O
.	O
</ALL>	O

<ALL>	O
The	O
underlying	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
these	O
disturbances	O
remain	O
poorly	O
characterized	O
.	O
</ALL>	O

<ALL>	O
This	O
review	O
summarizes	O
previous	O
knowledge	O
and	O
highlights	O
some	O
recent	O
developments	O
in	O
the	O
pathophysiology	O
of	O
low	O
urine	B-Organism_substance
pH	O
and	O
hyperuricosuria	O
.	O
</ALL>	O

<ALL>	O
RECENT	O
FINDINGS	O
:	O
</ALL>	O

<ALL>	O
Epidemiological	O
and	O
metabolic	O
studies	O
have	O
indicated	O
an	O
association	O
between	O
uric	O
acid	O
nephrolithiasis	O
and	O
insulin	O
resistance	O
.	O
</ALL>	O

<ALL>	O
Some	O
potential	O
mechanisms	O
include	O
impaired	O
ammoniagenesis	O
caused	O
by	O
resistance	O
to	O
insulin	O
action	O
in	O
the	O
renal	B-Multi-tissue_structure
proximal	I-Multi-tissue_structure
tubule	I-Multi-tissue_structure
,	O
or	O
substrate	O
competition	O
by	O
free	O
fatty	O
acids	O
.	O
</ALL>	O

<ALL>	O
The	O
evaluation	O
of	O
a	O
large	O
Sicilian	O
kindred	O
recently	O
revealed	O
a	O
putative	O
genetic	O
locus	O
linked	O
to	O
uric	B-Organism_substance
acid	I-Organism_substance
stone	I-Organism_substance
disease	O
.	O
</ALL>	O

<ALL>	O
The	O
identification	O
of	O
novel	O
complementary	O
DNA	O
has	O
provided	O
an	O
interesting	O
insight	O
into	O
the	O
renal	B-Organ
handling	O
of	O
uric	O
acid	O
,	O
including	O
one	O
genetic	O
cause	O
of	O
renal	B-Organ
uric	O
acid	O
wasting	O
.	O
</ALL>	O

<ALL>	O
SUMMARY	O
:	O
</ALL>	O

<ALL>	O
The	O
recognition	O
of	O
metabolic	O
,	O
molecular	O
,	O
and	O
genetic	O
factors	O
that	O
influence	O
urinary	B-Organism_substance
pH	O
,	O
and	O
uric	O
acid	O
metabolism	O
and	O
excretion	O
,	O
will	O
provide	O
novel	O
insights	O
into	O
the	O
pathogenesis	O
of	O
uric	B-Organism_substance
acid	I-Organism_substance
stones	I-Organism_substance
,	O
and	O
open	O
the	O
way	O
for	O
new	O
therapeutic	O
strategies	O
.	O
</ALL>	O

<ALL>	O
Flow	O
dynamics	O
of	O
the	O
internal	B-Multi-tissue_structure
thoracic	I-Multi-tissue_structure
and	O
radial	B-Multi-tissue_structure
artery	I-Multi-tissue_structure
T	O
-	O
graft	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
</ALL>	O

<ALL>	O
Complex	O
use	O
of	O
arterial	B-Multi-tissue_structure
conduits	I-Multi-tissue_structure
has	O
resurrected	O
concerns	O
about	O
the	O
adequacy	O
of	O
conduit	B-Multi-tissue_structure
flow	O
.	O
</ALL>	O

<ALL>	O
The	O
T	O
-	O
graft	O
is	O
the	O
extreme	O
example	O
of	O
this	O
trend	O
.	O
</ALL>	O

<ALL>	O
Our	O
purpose	O
was	O
to	O
identify	O
the	O
limitation	O
of	O
single	O
source	O
inflow	O
and	O
to	O
compare	O
flow	O
capacity	O
with	O
completion	O
coronary	B-Multi-tissue_structure
flow	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
Between	O
February	O
1999	O
and	O
November	O
2001	O
,	O
372	O
patients	O
underwent	O
total	O
arterial	B-Multi-tissue_structure
revascularization	O
with	O
the	O
T	O
-	O
graft	O
alone	O
.	O
</ALL>	O

<ALL>	O
Intraoperative	O
flows	O
were	O
recorded	O
for	O
each	O
limb	B-Multi-tissue_structure
of	O
the	O
T	O
-	O
graft	O
before	O
and	O
after	O
distal	O
anastomoses	O
in	O
204	O
patients	O
.	O
</ALL>	O

<ALL>	O
Independent	O
predictors	O
of	O
T	O
-	O
graft	O
flow	O
were	O
identified	O
by	O
multivariate	O
analysis	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
Free	O
flow	O
for	O
the	O
radial	B-Multi-tissue_structure
arterial	I-Multi-tissue_structure
(	I-Multi-tissue_structure
RA	I-Multi-tissue_structure
)	I-Multi-tissue_structure
limb	I-Multi-tissue_structure
was	O
161	O
+	O
/	O
-	O
81	O
mL	O
/	O
min	O
,	O
the	O
internal	B-Multi-tissue_structure
thoracic	I-Multi-tissue_structure
artery	I-Multi-tissue_structure
(	I-Multi-tissue_structure
ITA	I-Multi-tissue_structure
)	I-Multi-tissue_structure
limb	I-Multi-tissue_structure
137	O
+	O
/	O
-	O
57	O
mL	O
/	O
min	O
(	O
combined	O
298	O
+	O
/	O
-	O
101	O
mL	O
/	O
min	O
)	O
versus	O
simultaneous	O
limb	B-Multi-tissue_structure
flow	O
of	O
226	O
+	O
/	O
-	O
84	O
mL	O
/	O
min	O
giving	O
a	O
flow	O
restriction	O
of	O
24	O
%	O
+	O
/	O
-	O
14	O
%	O
.	O
</ALL>	O

<ALL>	O
Completion	O
coronary	B-Multi-tissue_structure
flow	O
was	O
88	O
+	O
/	O
-	O
49	O
mL	O
/	O
min	O
for	O
the	O
RA	B-Multi-tissue_structure
,	O
60	O
+	O
/	O
-	O
45	O
mL	O
/	O
min	O
for	O
the	O
ITA	B-Multi-tissue_structure
,	O
and	O
140	O
+	O
/	O
-	O
70	O
mL	O
/	O
min	O
for	O
both	O
limbs	B-Multi-tissue_structure
simultaneously	O
to	O
give	O
a	O
flow	O
reserve	O
(	O
vs	O
simultaneous	O
free	O
flow	O
)	O
of	O
160	O
%	O
or	O
1	O
.	O
6	O
.	O
</ALL>	O

<ALL>	O
Independent	O
predictors	O
of	O
completion	O
RA	B-Multi-tissue_structure
limb	I-Multi-tissue_structure
flow	O
are	O
RA	B-Multi-tissue_structure
proximal	O
diameter	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
,	O
number	O
of	O
anastomoses	O
(	O
p	O
=	O
0	O
.	O
018	O
)	O
,	O
and	O
target	O
stenosis	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
</ALL>	O

<ALL>	O
A	O
flow	O
reserve	O
of	O
1	O
.	O
6	O
compares	O
favorably	O
with	O
an	O
ITA	B-Multi-tissue_structure
flow	O
reserve	O
of	O
1	O
.	O
8	O
at	O
1	O
-	O
month	O
postoperatively	O
and	O
1	O
.	O
8	O
for	O
both	O
the	O
ITA	B-Multi-tissue_structure
T	O
-	O
graft	O
and	O
the	O
ITA	B-Multi-tissue_structure
/	I-Multi-tissue_structure
RA	I-Multi-tissue_structure
T	O
-	O
graft	O
at	O
1	O
-	O
week	O
postoperatively	O
as	O
reported	O
by	O
others	O
.	O
</ALL>	O

<ALL>	O
Proximal	O
RA	B-Multi-tissue_structure
diameter	O
and	O
competitive	O
coronary	B-Multi-tissue_structure
flow	O
influence	O
completion	O
T	O
-	O
graft	O
flow	O
.	O
</ALL>	O

<ALL>	O
These	O
data	O
quantitate	O
the	O
limitation	O
of	O
single	O
source	O
inflow	O
of	O
the	O
T	O
-	O
graft	O
configuration	O
and	O
support	O
its	O
continued	O
use	O
.	O
</ALL>	O

<ALL>	O
Thiazole	O
orange	O
positive	O
platelets	B-Cell
in	O
a	O
dog	O
with	O
Evans	O
'	O
syndrome	O
.	O
</ALL>	O

<ALL>	O
We	O
examined	O
transition	O
for	O
the	O
percentage	O
of	O
reticulated	B-Cell
platelets	I-Cell
(	O
RP	B-Cell
%	O
)	O
and	O
platelet	B-Cell
count	O
in	O
a	O
canine	O
case	O
of	O
Evans	O
'	O
syndrome	O
.	O
</ALL>	O

<ALL>	O
The	O
result	O
demonstrated	O
that	O
measurement	O
of	O
the	O
RP	B-Cell
%	O
can	O
be	O
useful	O
in	O
evaluating	O
platelet	B-Cell
production	O
in	O
the	O
bone	B-Multi-tissue_structure
marrow	I-Multi-tissue_structure
and	O
response	O
to	O
treatment	O
.	O
</ALL>	O

<ALL>	O
Human	O
cytomegalovirus	O
5	O
-	O
kilobase	O
immediate	O
-	O
early	O
RNA	O
is	O
a	O
stable	O
intron	O
.	O
</ALL>	O

<ALL>	O
Immediate	O
-	O
early	O
viral	O
gene	O
products	O
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
are	O
derived	O
from	O
several	O
genomic	O
loci	O
and	O
largely	O
serve	O
to	O
establish	O
a	O
cellular	B-Cell
environment	O
conducive	O
to	O
viral	O
replication	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
further	O
examined	O
an	O
unusual	O
immediate	O
-	O
early	O
transcript	O
known	O
as	O
the	O
5	O
-	O
kb	O
RNA	O
,	O
concluding	O
that	O
it	O
is	O
a	O
stable	O
intron	O
encoded	O
by	O
HCMV	O
.	O
</ALL>	O

<ALL>	O
The	O
5	O
-	O
kb	O
RNA	O
is	O
highly	O
AT	O
rich	O
in	O
sequence	O
and	O
lacks	O
open	O
reading	O
frames	O
likely	O
to	O
be	O
translated	O
into	O
protein	O
.	O
</ALL>	O

<ALL>	O
We	O
confirmed	O
the	O
absence	O
of	O
polyadenylation	O
of	O
the	O
transcript	O
and	O
showed	O
that	O
it	O
is	O
primarily	O
nuclear	B-Cellular_component
localized	O
during	O
viral	O
infection	O
.	O
</ALL>	O

<ALL>	O
We	O
mapped	O
the	O
5	O
'	O
end	O
of	O
the	O
5	O
-	O
kb	O
RNA	O
to	O
a	O
consensus	O
splice	O
donor	O
site	O
and	O
localized	O
the	O
3	O
'	O
end	O
in	O
the	O
vicinity	O
of	O
a	O
splice	O
acceptor	O
site	O
.	O
</ALL>	O

<ALL>	O
In	O
transfection	O
studies	O
,	O
we	O
showed	O
that	O
the	O
5	O
-	O
kb	O
RNA	O
can	O
be	O
spliced	O
from	O
a	O
heterologous	O
primary	O
transcript	O
.	O
</ALL>	O

<ALL>	O
Using	O
bacterial	O
artificial	O
chromosome	B-Cellular_component
technology	O
,	O
we	O
constructed	O
a	O
viral	O
recombinant	O
containing	O
a	O
mutation	O
in	O
the	O
5	O
'	O
splice	O
donor	O
site	O
that	O
defines	O
the	O
5	O
'	O
end	O
of	O
the	O
RNA	O
and	O
found	O
that	O
this	O
mutation	O
eliminates	O
expression	O
of	O
the	O
5	O
-	O
kb	O
RNA	O
during	O
viral	O
infection	O
.	O
</ALL>	O

<ALL>	O
This	O
mutant	O
grows	O
in	O
human	O
fibroblasts	B-Cell
without	O
complementation	O
.	O
</ALL>	O

<ALL>	O
Taken	O
together	O
,	O
these	O
data	O
support	O
the	O
conclusion	O
that	O
the	O
5	O
-	O
kb	O
RNA	O
is	O
a	O
stable	O
intron	O
expressed	O
by	O
HCMV	O
.	O
</ALL>	O

<ALL>	O
Reduced	O
prognostic	O
power	O
of	O
ventricular	B-Multi-tissue_structure
late	O
potentials	O
in	O
post	O
-	O
infarction	O
patients	O
of	O
the	O
reperfusion	O
era	O
.	O
</ALL>	O

<ALL>	O
AIMS	O
:	O
</ALL>	O

<ALL>	O
To	O
test	O
the	O
prognostic	O
value	O
of	O
ventricular	B-Multi-tissue_structure
late	O
potentials	O
(	O
LPs	O
)	O
in	O
a	O
large	O
cohort	O
of	O
post	O
-	O
infarction	O
patients	O
in	O
the	O
modern	O
reperfusion	O
era	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
AND	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
1800	O
consecutive	O
survivors	O
of	O
acute	O
myocardial	B-Multi-tissue_structure
infarction	O
in	O
sinus	B-Immaterial_anatomical_entity
rhythm	O
and	O
under	O
76	O
years	O
of	O
age	O
were	O
enrolled	O
.	O
</ALL>	O

<ALL>	O
Many	O
(	O
99	O
%	O
)	O
of	O
the	O
patients	O
received	O
reperfusion	O
/	O
revascularization	O
therapy	O
(	O
91	O
%	O
percutaneous	O
coronary	B-Multi-tissue_structure
intervention	O
)	O
and	O
up	O
-	O
to	O
-	O
date	O
pharmacological	O
treatment	O
(	O
99	O
%	O
aspirin	O
,	O
93	O
%	O
beta	O
-	O
blockers	O
,	O
90	O
%	O
ACE	O
-	O
inhibitors	O
,	O
and	O
85	O
%	O
statins	O
)	O
.	O
</ALL>	O

<ALL>	O
LPs	O
were	O
calculated	O
in	O
968	O
patients	O
and	O
found	O
to	O
be	O
present	O
in	O
90	O
(	O
9	O
.	O
3	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
primary	O
endpoint	O
was	O
the	O
composite	O
of	O
cardiac	B-Organ
death	O
and	O
serious	O
arrhythmic	O
events	O
.	O
</ALL>	O

<ALL>	O
The	O
secondary	O
endpoint	O
was	O
the	O
composite	O
of	O
sudden	O
cardiac	B-Organ
death	O
and	O
serious	O
arrhythmic	O
events	O
.	O
</ALL>	O

<ALL>	O
During	O
follow	O
-	O
up	O
(	O
median	O
34	O
months	O
)	O
,	O
26	O
patients	O
reached	O
the	O
primary	O
endpoint	O
.	O
</ALL>	O

<ALL>	O
The	O
presence	O
of	O
LPs	O
was	O
not	O
significantly	O
associated	O
with	O
the	O
primary	O
endpoint	O
in	O
univariable	O
or	O
multivariable	O
analysis	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
low	O
(	O
<	O
or	O
=	O
30	O
%	O
)	O
left	B-Multi-tissue_structure
ventricular	I-Multi-tissue_structure
ejection	O
fraction	O
(	O
hazard	O
ratio	O
9	O
.	O
6	O
,	O
95	O
%	O
confidence	O
interval	O
4	O
.	O
1	O
-	O
22	O
.	O
4	O
)	O
,	O
heart	B-Organ
rate	O
turbulence	O
category	O
2	O
(	O
7	O
.	O
5	O
,	O
2	O
.	O
4	O
-	O
23	O
.	O
9	O
)	O
and	O
category	O
1	O
(	O
5	O
.	O
3	O
,	O
1	O
.	O
9	O
-	O
14	O
.	O
9	O
)	O
were	O
significant	O
predictors	O
in	O
both	O
univariable	O
and	O
multivariable	O
analysis	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
</ALL>	O

<ALL>	O
Ventricular	B-Multi-tissue_structure
LPs	O
are	O
of	O
limited	O
use	O
for	O
risk	O
stratification	O
in	O
unselected	O
post	O
-	O
infarction	O
patients	O
in	O
the	O
modern	O
reperfusion	O
era	O
.	O
</ALL>	O

<ALL>	O
Bcl	O
-	O
2	O
decreases	O
cell	B-Cell
proliferation	O
and	O
promotes	O
accumulation	O
of	O
cells	B-Cell
in	O
S	O
phase	O
without	O
affecting	O
the	O
rate	O
of	O
apoptosis	O
in	O
human	O
ovarian	B-Cell
carcinoma	I-Cell
cells	I-Cell
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
</ALL>	O

<ALL>	O
The	O
Bcl	O
-	O
2	O
protein	O
is	O
an	O
important	O
regulator	O
of	O
the	O
apoptotic	O
cascade	O
and	O
promotes	O
cell	B-Cell
survival	O
.	O
</ALL>	O

<ALL>	O
Bcl	O
-	O
2	O
can	O
also	O
delay	O
entry	O
into	O
the	O
cell	B-Cell
cycle	O
from	O
quiescence	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
we	O
used	O
two	O
isogenic	O
human	O
ovarian	B-Cell
carcinoma	I-Cell
cell	I-Cell
lines	I-Cell
,	O
which	O
expressed	O
differential	O
levels	O
of	O
Bcl	O
-	O
2	O
proteins	O
,	O
to	O
demonstrate	O
that	O
Bcl	O
-	O
2	O
may	O
regulate	O
the	O
growth	O
rates	O
of	O
adenocarcinoma	B-Cell
cells	I-Cell
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
The	O
growth	O
rates	O
of	O
two	O
isogenic	O
ovarian	B-Cell
cancer	I-Cell
cell	I-Cell
lines	I-Cell
were	O
determined	O
by	O
XTT	O
assays	O
and	O
flow	O
cytometry	O
combined	O
with	O
PI	O
staining	O
.	O
</ALL>	O

<ALL>	O
Bcl	B-Cell
-	I-Cell
2	I-Cell
-	I-Cell
overexpressing	I-Cell
SKOV3	I-Cell
cells	I-Cell
were	O
modified	O
to	O
express	O
a	O
doxycycline	O
-	O
inducible	O
anti	O
-	O
Bcl	O
-	O
2	O
single	O
-	O
chain	O
antibody	O
and	O
the	O
effects	O
of	O
Bcl	O
-	O
2	O
protein	O
inhibition	O
on	O
cell	B-Cell
proliferation	O
and	O
apoptosis	O
were	O
assessed	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
We	O
demonstrate	O
that	O
Bcl	O
-	O
2	O
promotes	O
the	O
accumulation	O
of	O
proliferating	O
carcinoma	B-Cell
cells	I-Cell
in	O
S	O
phase	O
.	O
</ALL>	O

<ALL>	O
The	O
Bcl	B-Cell
-	I-Cell
2	I-Cell
-	I-Cell
overexpressing	I-Cell
SKOV3	I-Cell
cell	I-Cell
line	I-Cell
proliferates	O
markedly	O
faster	O
and	O
shows	O
delayed	O
progression	O
to	O
G2M	O
phase	O
compared	O
to	O
its	O
low	O
Bcl	B-Cell
-	I-Cell
2	I-Cell
-	I-Cell
expressing	I-Cell
counterpart	I-Cell
SKOV3	I-Cell
.	I-Cell
ip1	I-Cell
cell	I-Cell
line	I-Cell
.	O
</ALL>	O

<ALL>	O
Single	O
-	O
chain	O
antibody	O
-	O
mediated	O
inhibition	O
of	O
Bcl	O
-	O
2	O
in	O
SKOV3	B-Cell
cells	I-Cell
was	O
associated	O
with	O
increased	O
growth	O
rates	O
and	O
more	O
rapid	O
cell	B-Cell
cycle	O
progression	O
.	O
</ALL>	O

<ALL>	O
Treatment	O
with	O
cisplatin	O
resulted	O
in	O
more	O
cells	B-Cell
accumulating	O
in	O
S	O
phase	O
in	O
Bcl	B-Cell
-	I-Cell
2	I-Cell
-	I-Cell
overexpressing	I-Cell
SKOV3	I-Cell
cells	I-Cell
,	O
while	O
the	O
inhibition	O
of	O
Bcl	O
-	O
2	O
abolished	O
delayed	O
entry	O
into	O
G2M	O
phase	O
without	O
affecting	O
cisplatin	O
-	O
induced	O
apoptosis	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
</ALL>	O

<ALL>	O
Our	O
results	O
suggest	O
that	O
,	O
in	O
ovarian	B-Cell
cancer	I-Cell
cells	I-Cell
,	O
Bcl	O
-	O
2	O
delays	O
cell	B-Cell
cycle	O
progression	O
by	O
promoting	O
accumulation	O
of	O
cells	B-Cell
in	O
S	O
phase	O
without	O
affecting	O
the	O
rate	O
of	O
apoptosis	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
in	O
addition	O
to	O
its	O
known	O
role	O
at	O
the	O
G0	O
/	O
G1	O
checkpoint	O
,	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
Bcl	O
-	O
2	O
also	O
regulates	O
the	O
S	O
phase	O
.	O
</ALL>	O

<ALL>	O
A	O
novel	O
conotoxin	O
from	O
Conus	O
delessertii	O
with	O
posttranslationally	O
modified	O
lysine	O
residues	O
.	O
</ALL>	O

<ALL>	O
A	O
major	O
peptide	O
,	O
de13a	O
from	O
the	O
crude	O
venom	B-Organism_substance
of	O
Conus	O
delessertii	O
collected	O
in	O
the	O
Yucatan	O
Channel	O
,	O
Mexico	O
,	O
was	O
purified	O
.	O
</ALL>	O

<ALL>	O
The	O
peptide	O
had	O
a	O
high	O
content	O
of	O
posttranslationally	O
modified	O
amino	O
acids	O
,	O
including	O
6	O
-	O
bromotryptophan	O
and	O
a	O
nonstandard	O
amino	O
acid	O
that	O
proved	O
to	O
be	O
5	O
-	O
hydroxylysine	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
the	O
first	O
report	O
of	O
5	O
-	O
hydroxylysine	O
residues	O
in	O
conotoxins	O
.	O
</ALL>	O

<ALL>	O
The	O
sequence	O
analysis	O
,	O
together	O
with	O
cDNA	O
cloning	O
and	O
a	O
mass	O
determination	O
(	O
monoisotopic	O
mass	O
of	O
3486	O
.	O
76	O
Da	O
)	O
,	O
established	O
that	O
the	O
mature	O
toxin	O
has	O
the	O
sequence	O
DCOTSCOTTCANGWECCKGYOCVNKACSGCTH	O
,	O
where	O
O	O
is	O
4	O
-	O
hydroxyproline	O
,	O
W	O
6	O
-	O
bromotryptophan	O
,	O
and	O
K	O
5	O
-	O
hydroxylysine	O
,	O
the	O
asterisk	O
represents	O
the	O
amidated	O
C	O
-	O
terminus	O
,	O
and	O
the	O
calculated	O
monoisotopic	O
mass	O
is	O
3487	O
.	O
09	O
Da	O
.	O
</ALL>	O

<ALL>	O
The	O
eight	O
Cys	O
residues	O
are	O
arranged	O
in	O
a	O
pattern	O
(	O
C	O
-	O
C	O
-	O
C	O
-	O
CC	O
-	O
C	O
-	O
C	O
-	O
C	O
)	O
not	O
described	O
previously	O
in	O
conotoxins	O
.	O
</ALL>	O

<ALL>	O
This	O
arrangement	O
,	O
for	O
which	O
we	O
propose	O
the	O
designation	O
of	O
framework	O
#	O
13	O
or	O
XIII	O
,	O
differs	O
from	O
the	O
ones	O
(	O
C	O
-	O
C	O
-	O
CC	O
-	O
CC	O
-	O
C	O
-	O
C	O
and	O
C	O
-	O
C	O
-	O
C	O
-	O
C	O
-	O
CC	O
-	O
C	O
-	O
C	O
)	O
present	O
in	O
other	O
conotoxins	O
which	O
also	O
contain	O
eight	O
Cys	O
residues	O
.	O
</ALL>	O

<ALL>	O
This	O
peptide	O
thus	O
defines	O
a	O
novel	O
class	O
of	O
conotoxins	O
,	O
with	O
a	O
new	O
posttranslational	O
modification	O
not	O
previously	O
found	O
in	O
other	O
Conus	O
peptide	O
families	O
.	O
</ALL>	O

<ALL>	O
Enhancement	O
of	O
skin	B-Organ
permeation	O
of	O
ketotifen	O
by	O
supersaturation	O
generated	O
by	O
amorphous	O
form	O
of	O
the	O
drug	O
.	O
</ALL>	O

<ALL>	O
Pressure	O
sensitive	O
adhesive	O
(	O
PSA	O
)	O
matrices	O
containing	O
amorphous	O
ketotifen	O
were	O
prepared	O
and	O
evaluated	O
for	O
enhanced	O
skin	B-Organ
permeability	O
of	O
the	O
drug	O
.	O
</ALL>	O

<ALL>	O
A	O
solvent	O
casting	O
method	O
using	O
silicone	O
-	O
typed	O
PSA	O
was	O
employed	O
,	O
and	O
n	O
-	O
hexane	O
,	O
an	O
original	O
solvent	O
for	O
the	O
PSA	O
and	O
one	O
more	O
solvent	O
,	O
dichloromethane	O
,	O
tetrahydrofuran	O
,	O
acetone	O
,	O
ethyl	O
acetate	O
or	O
toluene	O
,	O
were	O
used	O
for	O
complete	O
dissolution	O
of	O
ketotifen	O
and	O
high	O
dispersion	O
in	O
an	O
amorphous	O
state	O
of	O
the	O
drug	O
.	O
</ALL>	O

<ALL>	O
Presence	O
of	O
the	O
amorphous	O
form	O
was	O
judged	O
based	O
on	O
the	O
in	O
vitro	O
drug	O
release	O
rate	O
from	O
the	O
matrix	O
.	O
</ALL>	O

<ALL>	O
As	O
a	O
result	O
,	O
dichloromethane	O
and	O
tetrahudrofuran	O
were	O
selected	O
as	O
appropriate	O
dilution	O
solvents	O
.	O
</ALL>	O

<ALL>	O
In	O
vitro	O
permeation	O
experiments	O
through	O
excised	O
hairless	O
mouse	O
skin	B-Organ
revealed	O
that	O
the	O
steady	O
-	O
state	O
flux	O
from	O
the	O
amorphous	O
ketotifen	O
-	O
dispersed	O
matrices	O
was	O
about	O
five	O
times	O
greater	O
than	O
that	O
of	O
the	O
crystalline	O
ketotifen	O
-	O
dispersed	O
matrices	O
,	O
and	O
that	O
the	O
enhancement	O
ratio	O
was	O
in	O
good	O
agreement	O
with	O
the	O
solubility	O
ratio	O
of	O
the	O
amorphous	O
to	O
crystalline	O
form	O
of	O
the	O
drug	O
.	O
</ALL>	O

<ALL>	O
Comparison	O
of	O
the	O
skin	B-Organ
permeation	O
profiles	O
of	O
amorphous	O
ketotifen	O
-	O
dispersed	O
matrices	O
between	O
two	O
different	O
drug	O
contents	O
suggested	O
that	O
the	O
steady	O
-	O
state	O
flux	O
was	O
not	O
influenced	O
by	O
the	O
drug	O
content	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
at	O
both	O
drug	O
contents	O
,	O
the	O
period	O
of	O
the	O
steady	O
-	O
state	O
permeation	O
coincided	O
with	O
the	O
time	O
until	O
the	O
amorphous	O
drug	O
was	O
depleted	O
from	O
the	O
matrix	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
suggest	O
that	O
the	O
increase	O
in	O
skin	B-Organ
permeation	O
of	O
ketotifen	O
from	O
PSA	O
matrix	O
was	O
due	O
to	O
the	O
supersaturation	O
generated	O
by	O
amorphous	O
form	O
,	O
and	O
that	O
the	O
amorphous	O
form	O
was	O
stable	O
during	O
the	O
application	O
period	O
.	O
</ALL>	O

<ALL>	O
Polybrominated	O
diphenyl	O
ethers	O
in	O
indoor	O
dust	O
in	O
Ottawa	O
,	O
Canada	O
:	O
implications	O
for	O
sources	O
and	O
exposure	O
.	O
</ALL>	O

<ALL>	O
Polybrominated	O
diphenyl	O
ethers	O
(	O
PBDEs	O
)	O
are	O
widely	O
used	O
as	O
additive	O
flame	O
retardants	O
in	O
plastics	O
,	O
soft	O
furnishings	O
,	O
electrical	O
and	O
electronic	O
equipment	O
,	O
and	O
insulation	O
in	O
the	O
indoor	O
environment	O
,	O
and	O
may	O
be	O
released	O
indoors	O
via	O
volatilization	O
or	O
as	O
dusts	O
.	O
</ALL>	O

<ALL>	O
The	O
penta	O
-	O
and	O
octa	O
-	O
brominated	O
mixes	O
are	O
now	O
banned	O
in	O
most	O
parts	O
of	O
Europe	O
,	O
and	O
phasing	O
out	O
of	O
their	O
use	O
has	O
recently	O
begun	O
in	O
North	O
America	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
follows	O
a	O
previous	O
investigation	O
into	O
indoor	O
air	O
levels	O
of	O
PBDEs	O
.	O
</ALL>	O

<ALL>	O
House	O
dust	O
was	O
analyzed	O
from	O
the	O
family	O
vacuum	O
cleaners	O
of	O
68	O
of	O
the	O
same	O
74	O
randomly	O
selected	O
homes	O
,	O
in	O
Ottawa	O
,	O
Canada	O
during	O
the	O
winter	O
of	O
2002	O
-	O
2003	O
.	O
</ALL>	O

<ALL>	O
PBDEs	O
,	O
comprising	O
on	O
average	O
42	O
%	O
BDE	O
-	O
209	O
,	O
were	O
found	O
in	O
all	O
samples	O
.	O
</ALL>	O

<ALL>	O
The	O
levels	O
were	O
log	O
-	O
normally	O
distributed	O
with	O
a	O
geometric	O
mean	O
sigmaPBDE	O
of	O
2000	O
ng	O
g	O
(	O
-	O
1	O
)	O
,	O
and	O
a	O
median	O
of	O
1800	O
ng	O
g	O
(	O
-	O
1	O
)	O
dust	O
.	O
</ALL>	O

<ALL>	O
The	O
levels	O
in	O
dust	O
did	O
not	O
correlate	O
with	O
questionnaire	O
information	O
on	O
house	O
characteristics	O
.	O
</ALL>	O

<ALL>	O
Correlations	O
were	O
found	O
between	O
pentamix	O
congener	O
levels	O
in	O
dust	O
and	O
in	O
air	O
from	O
the	O
same	O
homes	O
,	O
but	O
not	O
for	O
congeners	O
of	O
the	O
more	O
highly	O
brominated	O
mixes	O
.	O
</ALL>	O

<ALL>	O
Exposure	O
scenarios	O
are	O
presented	O
for	O
mean	O
and	O
high	O
dust	O
ingestion	O
rates	O
,	O
and	O
compared	O
against	O
exposures	O
from	O
other	O
pathways	O
,	O
for	O
both	O
adults	O
and	O
toddlers	O
(	O
6	O
months	O
-	O
2	O
years	O
)	O
.	O
</ALL>	O

<ALL>	O
Assuming	O
a	O
mean	O
dust	O
ingestion	O
rate	O
and	O
median	O
dust	O
and	O
air	O
concentrations	O
,	O
adults	O
would	O
be	O
exposed	O
to	O
ca	O
.	O
</ALL>	O

<ALL>	O
7	O
.	O
5	O
ng	O
sigmaPBDE	O
d	O
(	O
-	O
1	O
)	O
via	O
the	O
dust	O
ingestion	O
pathway	O
,	O
which	O
represents	O
approximately	O
14	O
%	O
of	O
total	O
daily	O
exposure	O
when	O
compared	O
to	O
diet	O
(	O
82	O
%	O
)	O
and	O
inhalation	O
(	O
4	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
for	O
toddlers	O
the	O
equivalent	O
intakes	O
would	O
be	O
99	O
ng	O
d	O
(	O
-	O
1	O
)	O
,	O
representing	O
80	O
%	O
of	O
their	O
daily	O
PBDE	O
exposure	O
.	O
</ALL>	O

<ALL>	O
At	O
high	O
dust	O
ingestion	O
rates	O
these	O
values	O
increase	O
to	O
180	O
ng	O
d	O
(	O
-	O
1	O
)	O
(	O
80	O
%	O
daily	O
intake	O
)	O
for	O
adults	O
and	O
360	O
ng	O
d	O
(	O
-	O
1	O
)	O
(	O
89	O
%	O
daily	O
intake	O
)	O
for	O
toddlers	O
.	O
</ALL>	O

<ALL>	O
The	O
data	O
give	O
a	O
clearer	O
picture	O
of	O
sources	O
of	O
PBDE	O
exposure	O
in	O
the	O
home	O
environment	O
and	O
suggest	O
that	O
dust	O
could	O
be	O
a	O
significant	O
exposure	O
pathway	O
for	O
some	O
individuals	O
,	O
particularly	O
children	O
.	O
</ALL>	O

<ALL>	O
Pathogenesis	O
of	O
thrombosis	O
in	O
essential	O
thrombocythemia	O
and	O
polycythemia	O
vera	O
:	O
the	O
role	O
of	O
neutrophils	B-Cell
.	O
</ALL>	O

<ALL>	O
Thrombotic	O
complications	O
are	O
frequently	O
observed	O
in	O
patients	O
with	O
polycythemia	O
vera	O
(	O
PV	O
)	O
and	O
essential	O
thrombocythemia	O
(	O
ET	O
)	O
.	O
</ALL>	O

<ALL>	O
Abnormalities	O
of	O
red	B-Cell
blood	I-Cell
cells	I-Cell
and	O
platelets	B-Cell
arising	O
from	O
the	O
clonal	O
rearrangement	O
of	O
hematopoietic	B-Cell
cells	I-Cell
have	O
been	O
considered	O
,	O
although	O
causal	O
relationships	O
between	O
any	O
of	O
these	O
specific	O
abnormalities	O
and	O
thrombosis	O
have	O
not	O
been	O
clearly	O
established	O
.	O
</ALL>	O

<ALL>	O
The	O
involvement	O
of	O
neutrophils	B-Cell
and	O
macrophages	B-Cell
,	O
which	O
participate	O
in	O
thrombosis	O
and	O
hemostasis	O
,	O
has	O
been	O
insufficiently	O
explored	O
in	O
PV	O
and	O
ET	O
.	O
</ALL>	O

<ALL>	O
Persistent	O
activation	O
of	O
circulating	O
neutrophils	B-Cell
was	O
recently	O
demonstrated	O
in	O
ET	O
and	O
PV	O
patients	O
,	O
in	O
parallel	O
with	O
an	O
increase	O
in	O
plasma	B-Organism_substance
concentrations	O
of	O
endothelial	B-Tissue
damage	O
-	O
derived	O
and	O
prothrombotic	O
substances	O
.	O
</ALL>	O

<ALL>	O
Other	O
studies	O
have	O
explored	O
whether	O
the	O
augmentation	O
of	O
adhesion	O
of	O
neutrophils	B-Cell
may	O
affect	O
neutrophil	B-Cell
/	O
platelet	B-Cell
interaction	O
since	O
a	O
significant	O
increase	O
in	O
circulating	O
neutrophil	B-Cell
/	O
platelet	B-Cell
aggregates	O
is	O
found	O
in	O
ET	O
and	O
PV	O
.	O
</ALL>	O

<ALL>	O
This	O
review	O
summarizes	O
the	O
current	O
knowledge	O
of	O
the	O
pathogenesis	O
of	O
thrombosis	O
in	O
PV	O
and	O
ET	O
,	O
with	O
emphasis	O
on	O
the	O
role	O
of	O
neutrophils	B-Cell
in	O
hemostasis	O
and	O
their	O
possible	O
involvement	O
in	O
the	O
mechanisms	O
of	O
the	O
acquired	O
thrombophilia	O
of	O
these	O
patients	O
.	O
</ALL>	O

<ALL>	O
Available	O
data	O
suggest	O
that	O
these	O
hemostatic	O
markers	O
deserve	O
to	O
be	O
included	O
in	O
prospective	O
clinical	O
studies	O
aimed	O
at	O
identifying	O
their	O
predictive	O
role	O
in	O
the	O
vascular	B-Multi-tissue_structure
complications	O
of	O
patients	O
with	O
ET	O
and	O
PV	O
.	O
</ALL>	O

<ALL>	O
Sensitivity	O
variation	O
in	O
two	O
-	O
center	O
holographic	O
recording	O
.	O
</ALL>	O

<ALL>	O
An	O
experimental	O
study	O
of	O
variation	O
of	O
sensitivity	O
with	O
recording	O
and	O
sensitizing	O
intensities	O
in	O
two	O
-	O
center	O
recording	O
is	O
presented	O
.	O
</ALL>	O

<ALL>	O
The	O
experimental	O
results	O
are	O
in	O
good	O
agreement	O
with	O
the	O
theoretical	O
predictions	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
shown	O
experimentally	O
,	O
for	O
what	O
is	O
to	O
our	O
knowledge	O
the	O
first	O
time	O
,	O
that	O
the	O
sensitivity	O
is	O
a	O
function	O
of	O
the	O
ratio	O
of	O
recording	O
to	O
sensitizing	O
intensities	O
and	O
not	O
the	O
absolute	O
intensities	O
.	O
</ALL>	O

<ALL>	O
Also	O
,	O
the	O
ratio	O
of	O
recording	O
to	O
sensitizing	O
intensities	O
should	O
be	O
small	O
to	O
obtain	O
high	O
sensitivity	O
values	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
report	O
the	O
highest	O
sensitivity	O
(	O
S	O
=	O
0	O
.	O
15	O
cm	O
/	O
J	O
)	O
that	O
has	O
been	O
achieved	O
to	O
date	O
for	O
a	O
LiNbO3	O
:	O
Fe	O
:	O
Mn	O
crystal	O
.	O
</ALL>	O

<ALL>	O
Recent	O
advances	O
in	O
minisatellite	O
biology	O
.	O
</ALL>	O

<ALL>	O
Highly	O
polymorphic	O
tandemly	O
repeated	O
'	O
minisatellite	O
'	O
loci	O
are	O
very	O
abundant	O
in	O
the	O
human	O
genome	O
,	O
and	O
of	O
considerable	O
utility	O
in	O
human	O
genetic	O
analysis	O
.	O
</ALL>	O

<ALL>	O
This	O
review	O
describes	O
the	O
use	O
of	O
an	O
ordered	O
-	O
array	O
Charomid	O
library	O
in	O
the	O
systematic	O
and	O
efficient	O
cloning	O
of	O
these	O
regions	O
,	O
and	O
in	O
the	O
analysis	O
of	O
the	O
relative	O
overlap	O
between	O
the	O
different	O
probes	O
used	O
to	O
screen	O
for	O
hypervariable	O
loci	O
.	O
</ALL>	O

<ALL>	O
Recent	O
work	O
on	O
the	O
process	O
of	O
mutation	O
leading	O
to	O
the	O
generation	O
of	O
new	O
-	O
length	O
alleles	O
is	O
also	O
discussed	O
,	O
including	O
the	O
observation	O
that	O
at	O
least	O
some	O
mutations	O
may	O
be	O
due	O
to	O
unequal	O
exchanges	O
.	O
</ALL>	O

<ALL>	O
The	O
ictal	O
bradycardia	O
syndrome	O
:	O
localization	O
and	O
lateralization	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
</ALL>	O

<ALL>	O
Previous	O
studies	O
have	O
established	O
the	O
importance	O
of	O
the	O
insular	B-Multi-tissue_structure
cortex	I-Multi-tissue_structure
and	O
temporal	B-Multi-tissue_structure
lobe	I-Multi-tissue_structure
in	O
cardiovascular	B-Anatomical_system
autonomic	O
modulation	O
.	O
</ALL>	O

<ALL>	O
Some	O
investigators	O
,	O
based	O
on	O
the	O
results	O
of	O
cortical	B-Multi-tissue_structure
stimulation	O
response	O
,	O
functional	O
imaging	O
,	O
EEG	O
recordings	O
of	O
seizures	O
,	O
and	O
lesional	O
studies	O
,	O
have	O
suggested	O
that	O
cardiac	B-Organ
sympathetic	O
and	O
parasympathetic	O
function	O
may	O
be	O
lateralized	O
,	O
with	O
sympathetic	O
representation	O
lateralized	O
to	O
the	O
right	B-Multi-tissue_structure
insula	I-Multi-tissue_structure
,	O
and	O
parasympathetic	O
,	O
to	O
the	O
left	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
These	O
studies	O
have	O
suggested	O
that	O
ictal	O
bradycardia	O
is	O
most	O
commonly	O
a	O
manifestation	O
of	O
activation	O
of	O
the	O
left	B-Multi-tissue_structure
temporal	I-Multi-tissue_structure
and	O
insular	B-Multi-tissue_structure
cortex	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
evidence	O
for	O
this	O
is	O
inconsistent	O
.	O
</ALL>	O

<ALL>	O
We	O
sought	O
to	O
assess	O
critically	O
the	O
predictable	O
value	O
of	O
ictal	O
bradycardia	O
for	O
seizure	O
localization	O
and	O
lateralization	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
reviewed	O
the	O
localization	O
of	O
seizure	O
activity	O
in	O
13	O
consecutive	O
patients	O
with	O
ictal	O
bradycardia	O
diagnosed	O
during	O
prolonged	O
video	O
-	O
EEG	O
monitoring	O
at	O
Mayo	O
Clinic	O
Rochester	O
.	O
</ALL>	O

<ALL>	O
The	O
localization	O
of	O
electrographic	O
seizure	O
activity	O
at	O
seizure	O
onset	O
and	O
bradycardia	O
onset	O
was	O
identified	O
in	O
all	O
patients	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
we	O
performed	O
a	O
comprehensive	O
review	O
of	O
the	O
ictal	O
bradycardia	O
literature	O
focusing	O
on	O
localization	O
of	O
seizure	O
activity	O
in	O
ictal	O
bradycardia	O
cases	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
All	O
occurrences	O
of	O
ictal	O
bradycardia	O
in	O
the	O
13	O
identified	O
patients	O
were	O
associated	O
with	O
temporal	O
lobe	O
-	O
onset	O
seizures	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
no	O
consistent	O
lateralization	O
of	O
seizure	O
activity	O
was	O
found	O
at	O
onset	O
of	O
seizure	O
activity	O
or	O
at	O
onset	O
of	O
bradycardia	O
in	O
this	O
population	O
.	O
</ALL>	O

<ALL>	O
Seizure	O
activity	O
was	O
bilateral	O
at	O
bradycardia	O
onset	O
in	O
nine	O
of	O
13	O
patients	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
from	O
the	O
literature	O
review	O
also	O
showed	O
that	O
a	O
predominance	O
of	O
patients	O
had	O
bilateral	O
activity	O
at	O
bradycardia	O
onset	O
;	O
however	O
,	O
more	O
of	O
the	O
ictal	O
bradycardia	O
cases	O
from	O
the	O
literature	O
had	O
left	B-Multi-tissue_structure
hemispheric	I-Multi-tissue_structure
localization	O
of	O
seizure	O
onset	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
</ALL>	O

<ALL>	O
Ictal	O
bradycardia	O
most	O
often	O
occurs	O
in	O
association	O
with	O
bilateral	O
hemispheric	O
seizure	O
activity	O
and	O
is	O
not	O
a	O
consistent	O
lateralizing	O
sign	O
in	O
localizing	O
seizure	O
onset	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
do	O
not	O
support	O
the	O
existence	O
of	O
a	O
strictly	O
unilateral	O
parasympathetic	O
cardiomotor	O
representation	O
in	O
the	O
left	O
hemisphere	O
,	O
as	O
has	O
been	O
suggested	O
.	O
</ALL>	O

<ALL>	O
Dendrimer	O
-	O
templated	O
Fe	O
nanoparticles	O
for	O
the	O
growth	O
of	O
single	O
-	O
wall	O
carbon	O
nanotubes	O
by	O
plasma	O
-	O
enhanced	O
CVD	O
.	O
</ALL>	O

<ALL>	O
A	O
fourth	O
-	O
generation	O
(	O
G4	O
)	O
poly	O
(	O
amidoamine	O
)	O
(	O
PAMAM	O
)	O
dendrimer	O
(	O
G4	O
-	O
NH2	O
)	O
has	O
been	O
used	O
as	O
a	O
template	O
to	O
deliver	O
nearly	O
monodispersed	O
catalyst	O
nanoparticles	O
to	O
SiO2	O
/	O
Si	O
,	O
Ti	O
/	O
Si	O
,	O
sapphire	O
,	O
and	O
porous	O
anodic	O
alumina	O
(	O
PAA	O
)	O
substrates	O
.	O
</ALL>	O

<ALL>	O
Fe2O3	O
nanoparticles	O
obtained	O
after	O
calcination	O
of	O
the	O
immobilized	O
Fe3	O
+	O
/	O
G4	O
-	O
NH2	O
composite	O
served	O
as	O
catalytic	O
"	O
seeds	O
"	O
for	O
the	O
growth	O
of	O
single	O
-	O
wall	O
carbon	O
nanotubes	O
(	O
SWNTs	O
)	O
by	O
microwave	O
plasma	O
-	O
enhanced	O
CVD	O
(	O
PECVD	O
)	O
.	O
</ALL>	O

<ALL>	O
To	O
surmount	O
the	O
difficulty	O
associated	O
with	O
SWNT	O
growth	O
via	O
PECVD	O
,	O
reaction	O
conditions	O
that	O
promote	O
the	O
stabilization	O
of	O
Fe	O
nanoparticles	O
,	O
resulting	O
in	O
enhanced	O
SWNT	O
selectivity	O
and	O
quality	O
,	O
have	O
been	O
identified	O
.	O
</ALL>	O

<ALL>	O
In	O
particular	O
,	O
in	O
situ	O
annealing	O
of	O
Fe	O
catalyst	O
in	O
an	O
N2	O
atmosphere	O
was	O
found	O
to	O
improve	O
SWNT	O
selectivity	O
and	O
quality	O
.	O
</ALL>	O

<ALL>	O
H2	O
prereduction	O
at	O
900	O
degrees	O
C	O
for	O
5	O
min	O
was	O
also	O
found	O
to	O
enhance	O
SWNT	O
selectivity	O
and	O
quality	O
for	O
SiO2	O
/	O
Si	O
supported	O
catalyst	O
,	O
albeit	O
of	O
lower	O
quality	O
for	O
sapphire	O
supported	O
catalyst	O
.	O
</ALL>	O

<ALL>	O
The	O
application	O
of	O
positive	O
dc	O
bias	O
voltage	O
(	O
+	O
200	O
V	O
)	O
during	O
SWNT	O
growth	O
was	O
shown	O
to	O
be	O
very	O
effective	O
in	O
removing	O
amorphous	O
carbon	O
impurities	O
while	O
enhancing	O
graphitization	O
,	O
SWNT	O
selectivity	O
,	O
and	O
vertical	O
alignment	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
of	O
this	O
study	O
should	O
promote	O
the	O
use	O
of	O
exposed	O
Fe	O
nanoparticles	O
supported	O
on	O
different	O
substrates	O
for	O
the	O
growth	O
of	O
high	O
-	O
quality	O
SWNTs	O
by	O
PECVD	O
.	O
</ALL>	O

<ALL>	O
Fluoro	O
-	O
Jade	O
B	O
staining	O
following	O
zymosan	O
microinjection	O
into	O
the	O
spinal	B-Multi-tissue_structure
cord	I-Multi-tissue_structure
white	I-Multi-tissue_structure
matter	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
1	O
.	O
</ALL>	O

<ALL>	O
The	O
fluorescein	O
derivate	O
Fluoro	O
-	O
Jade	O
B	O
(	O
FJB	O
)	O
,	O
which	O
primarily	O
labels	O
dead	O
or	O
dying	O
neurons	B-Cell
,	O
was	O
used	O
to	O
study	O
the	O
acute	O
focal	O
inflammation	O
in	O
the	O
spinal	B-Multi-tissue_structure
cord	I-Multi-tissue_structure
white	I-Multi-tissue_structure
matter	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Inflammation	O
was	O
induced	O
by	O
microinjection	O
of	O
the	O
yeast	O
particulate	O
zymosan	O
to	O
evaluate	O
the	O
biological	O
effects	O
of	O
intraspinal	B-Cell
macrophages	I-Cell
activation	O
without	O
the	O
confounding	O
effects	O
of	O
physical	O
trauma	O
.	O
</ALL>	O

<ALL>	O
2	O
.	O
</ALL>	O

<ALL>	O
A	O
single	O
bolus	O
of	O
zymosan	O
(	O
Sigma	O
,	O
75	O
nL	O
)	O
was	O
stereotaxically	O
injected	O
at	O
the	O
thoracic	B-Multi-tissue_structure
level	O
into	O
the	O
lateral	B-Multi-tissue_structure
white	I-Multi-tissue_structure
matter	I-Multi-tissue_structure
of	O
rat	O
spinal	B-Organ
cord	I-Organ
.	O
</ALL>	O

<ALL>	O
A	O
standard	O
Fluoro	O
-	O
Jade	O
B	O
staining	O
protocol	O
was	O
applied	O
to	O
spinal	B-Organ
cord	I-Organ
sections	O
at	O
6	O
,	O
12	O
,	O
24	O
h	O
and	O
2	O
,	O
4	O
days	O
postinjection	O
.	O
</ALL>	O

<ALL>	O
Neutral	O
Red	O
,	O
NADPH	O
-	O
diaphorase	O
,	O
Iba1	O
-	O
IR	O
,	O
and	O
DAPI	O
staining	O
protocols	O
accomplished	O
examination	O
of	O
the	O
cells	B-Cell
participating	O
in	O
the	O
acute	O
inflammatory	O
response	O
.	O
</ALL>	O

<ALL>	O
3	O
.	O
</ALL>	O

<ALL>	O
Zymosan	O
caused	O
formation	O
of	O
clearly	O
delineated	O
inflammation	B-Pathological_formation
lesions	I-Pathological_formation
localized	O
in	O
the	O
lateral	B-Multi-tissue_structure
white	I-Multi-tissue_structure
matter	I-Multi-tissue_structure
of	O
the	O
spinal	B-Organ
cord	I-Organ
.	O
</ALL>	O

<ALL>	O
Fluoro	O
-	O
Jade	O
B	O
stained	O
cells	B-Cell
in	O
the	O
area	O
of	O
inflammation	B-Pathological_formation
were	O
not	O
observed	O
at	O
12	O
h	O
postinjection	O
while	O
mild	O
FJB	O
staining	O
appeared	O
at	O
24	O
h	O
and	O
intense	O
staining	O
was	O
observed	O
at	O
2	O
and	O
4	O
days	O
postinjection	O
.	O
</ALL>	O

<ALL>	O
4	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
shows	O
that	O
the	O
acute	O
response	O
to	O
zymosan	O
-	O
induced	O
inflammation	O
in	O
the	O
rat	O
spinal	B-Multi-tissue_structure
cord	I-Multi-tissue_structure
white	I-Multi-tissue_structure
matter	I-Multi-tissue_structure
causes	O
a	O
gradual	O
appearance	O
of	O
phagocytic	B-Cell
microglia	I-Cell
/	O
macrophages	B-Cell
and	O
delayed	O
FJB	O
staining	O
of	O
the	O
inflammatory	B-Cell
cells	I-Cell
.	O
</ALL>	O

<ALL>	O
5	O
.	O
</ALL>	O

<ALL>	O
FJB	O
,	O
a	O
reliable	O
marker	O
of	O
dying	O
neurons	B-Cell
,	O
is	O
a	O
more	O
universal	O
agent	O
than	O
formerly	O
believed	O
.	O
</ALL>	O

<ALL>	O
One	O
possible	O
explanation	O
for	O
the	O
gradual	O
appearance	O
of	O
FJB	O
-	O
stained	O
cells	B-Cell
in	O
the	O
area	O
of	O
inflammation	B-Pathological_formation
is	O
that	O
specific	O
time	O
is	O
required	O
for	O
sufficient	O
levels	O
of	O
proteins	O
and	O
/	O
or	O
myelin	O
debris	O
of	O
axonal	O
origin	O
to	O
appear	O
in	O
the	O
cytoplasm	B-Organism_substance
of	O
phagocytic	B-Cell
microglia	I-Cell
/	O
macrophages	B-Cell
.	O
</ALL>	O

<ALL>	O
Changes	O
of	O
lymphocyte	B-Cell
subsets	O
in	O
leukemia	O
patients	O
who	O
received	O
allogenic	O
bone	B-Multi-tissue_structure
marrow	I-Multi-tissue_structure
transplantation	O
.	O
</ALL>	O

<ALL>	O
Proportional	O
changes	O
of	O
lymphocyte	B-Cell
subsets	O
in	O
the	O
peripheral	B-Organism_substance
blood	I-Organism_substance
were	O
monitored	O
by	O
two	O
-	O
color	O
flow	O
-	O
cytometry	O
in	O
seven	O
leukemia	O
patients	O
who	O
had	O
received	O
allogenic	O
bone	B-Multi-tissue_structure
marrow	I-Multi-tissue_structure
transplantation	O
(	O
BMT	O
)	O
.	O
</ALL>	O

<ALL>	O
Lymphocyte	B-Cell
counts	O
,	O
and	O
proportions	O
of	O
T	B-Cell
and	O
B	B-Cell
-	I-Cell
cells	I-Cell
returned	O
to	O
normal	O
ranges	O
between	O
the	O
2nd	O
and	O
12th	O
months	O
after	O
BMT	O
.	O
</ALL>	O

<ALL>	O
Activated	O
T	B-Cell
-	I-Cell
cells	I-Cell
prominently	O
increased	O
after	O
BMT	O
,	O
and	O
the	O
values	O
gradually	O
returned	O
toward	O
normal	O
.	O
</ALL>	O

<ALL>	O
As	O
to	O
lymphocyte	B-Cell
subsets	O
,	O
the	O
proportions	O
of	O
CD	B-Cell
4	I-Cell
+	I-Cell
cells	I-Cell
had	O
remained	O
low	O
,	O
while	O
those	O
of	O
CD	B-Cell
8	I-Cell
+	I-Cell
cells	I-Cell
high	O
for	O
a	O
whole	O
observation	O
period	O
after	O
BMT	O
.	O
</ALL>	O

<ALL>	O
The	O
changes	O
of	O
CD	B-Cell
4	I-Cell
+	I-Cell
cells	I-Cell
were	O
caused	O
by	O
the	O
decrease	O
of	O
suppressor	B-Cell
-	I-Cell
inducer	I-Cell
T	I-Cell
-	I-Cell
cells	I-Cell
(	O
CD	O
4	O
+	O
Leu	O
8	O
+	O
)	O
.	O
</ALL>	O

<ALL>	O
High	O
proportion	O
of	O
CD	B-Cell
8	I-Cell
+	I-Cell
cells	I-Cell
was	O
mainly	O
associated	O
with	O
increased	O
suppressor	B-Cell
T	I-Cell
-	I-Cell
cells	I-Cell
(	O
CD	O
8	O
+	O
CD	O
11	O
+	O
)	O
.	O
</ALL>	O

<ALL>	O
Among	O
natural	B-Cell
killer	I-Cell
(	I-Cell
NK	I-Cell
)	I-Cell
cells	I-Cell
,	O
highly	O
active	O
NK	B-Cell
cells	I-Cell
(	O
CD	O
16	O
+	O
CD	O
57	O
-	O
)	O
markedly	O
increased	O
shortly	O
after	O
BMT	O
,	O
and	O
gradually	O
returned	O
to	O
normal	O
.	O
</ALL>	O

<ALL>	O
CD	B-Cell
16	I-Cell
-	I-Cell
CD	I-Cell
57	I-Cell
+	I-Cell
NK	I-Cell
cells	I-Cell
increased	O
beyond	O
normal	O
ranges	O
after	O
the	O
2nd	O
month	O
.	O
</ALL>	O

<ALL>	O
The	O
incidence	O
or	O
degree	O
of	O
acute	O
and	O
chronic	O
graft	B-Multi-tissue_structure
-	O
versus	O
-	O
host	O
diseases	O
(	O
GVHD	O
)	O
did	O
not	O
correlate	O
with	O
the	O
changes	O
of	O
any	O
lymphocyte	B-Cell
subsets	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
results	O
suggest	O
that	O
the	O
increase	O
of	O
activated	O
T	B-Cell
-	I-Cell
cells	I-Cell
shortly	O
after	O
BMT	O
reflects	O
lymphocyte	B-Cell
reconstitution	O
.	O
</ALL>	O

<ALL>	O
The	O
prolonged	O
immune	O
deficiency	O
after	O
BMT	O
might	O
be	O
related	O
to	O
either	O
deficient	O
expression	O
of	O
homing	O
receptor	O
(	O
Leu	O
8	O
antigen	O
)	O
on	O
CD	B-Cell
4	I-Cell
+	I-Cell
cells	I-Cell
or	O
increased	O
suppressor	B-Cell
T	I-Cell
-	I-Cell
cells	I-Cell
(	O
CD	O
8	O
+	O
CD	O
11	O
+	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
early	O
increase	O
of	O
NK	B-Cell
cells	I-Cell
after	O
BMT	O
may	O
compensate	O
for	O
the	O
immune	O
deficiency	O
in	O
BMT	O
patients	O
.	O
</ALL>	O

<ALL>	O
Fluoroscopically	O
guided	O
cervical	B-Organism_subdivision
prolotherapy	O
for	O
instability	O
with	O
blinded	O
pre	O
and	O
post	O
radiographic	O
reading	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
</ALL>	O

<ALL>	O
Several	O
authors	O
have	O
postulated	O
that	O
cervical	B-Organism_subdivision
instability	O
is	O
a	O
major	O
cause	O
of	O
traumatic	O
spinal	B-Organism_subdivision
pain	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
</ALL>	O

<ALL>	O
The	O
purpose	O
of	O
this	O
prospective	O
case	O
series	O
study	O
(	O
n	O
=	O
6	O
)	O
was	O
to	O
determine	O
if	O
proliferant	O
injections	O
have	O
an	O
effect	O
on	O
cervical	B-Organism_subdivision
translation	O
as	O
measured	O
by	O
a	O
blinded	O
reader	O
.	O
</ALL>	O

<ALL>	O
DESIGN	O
:	O
</ALL>	O

<ALL>	O
This	O
study	O
was	O
a	O
prospective	O
case	O
series	O
.	O
</ALL>	O

<ALL>	O
Study	O
participants	O
were	O
selected	O
from	O
patients	O
seen	O
for	O
the	O
primary	O
complaint	O
of	O
Motor	O
Vehicle	O
Collision	O
related	O
neck	B-Organism_subdivision
pain	O
in	O
a	O
private	O
sub	O
-	O
specialty	O
pain	O
clinic	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
Flexion	O
and	O
extension	O
views	O
were	O
obtained	O
by	O
standard	O
radiographs	O
taken	O
with	O
a	O
C	O
-	O
Arm	O
fluoroscope	O
under	O
Valium	O
sedation	O
.	O
</ALL>	O

<ALL>	O
Patients	O
with	O
more	O
than	O
2	O
.	O
7	O
mm	O
of	O
absolute	O
cervical	B-Organism_subdivision
translation	O
and	O
at	O
least	O
50	O
%	O
reduction	O
of	O
cervical	B-Organism_subdivision
and	O
referred	O
pain	O
with	O
a	O
two	O
day	O
rigid	O
cervical	B-Organism_subdivision
immobilization	O
test	O
were	O
admitted	O
into	O
the	O
study	O
.	O
</ALL>	O

<ALL>	O
Participants	O
underwent	O
3	O
prolotherapy	O
injections	O
at	O
all	O
sites	O
that	O
demonstrated	O
translation	O
.	O
</ALL>	O

<ALL>	O
The	O
difference	O
in	O
means	O
between	O
pre	O
-	O
test	O
and	O
post	O
-	O
test	O
measurements	O
(	O
flexion	O
translation	O
,	O
extension	O
translation	O
,	O
and	O
pain	O
VAS	O
scores	O
)	O
were	O
assessed	O
by	O
a	O
Wilcoxon	O
signed	O
ranks	O
test	O
(	O
alpha	O
=	O
0	O
.	O
05	O
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
The	O
mean	O
post	O
-	O
test	O
VAS	O
score	O
(	O
M	O
=	O
3	O
.	O
83	O
,	O
SD	O
=	O
2	O
.	O
3	O
,	O
t	O
=	O
2	O
.	O
889	O
)	O
was	O
significantly	O
less	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
than	O
the	O
mean	O
pre	O
-	O
test	O
VAS	O
score	O
(	O
M	O
=	O
5	O
.	O
75	O
,	O
SD	O
=	O
1	O
.	O
94	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
correlation	O
between	O
difference	O
in	O
mean	O
extension	O
at	O
C2	O
-	O
3	O
and	O
C5	O
-	O
6	O
and	O
difference	O
in	O
mean	O
extension	O
was	O
significant	O
(	O
rho	O
=	O
0	O
.	O
89	O
,	O
p	O
=	O
0	O
.	O
02	O
and	O
rho	O
=	O
0	O
.	O
85	O
,	O
p	O
=	O
0	O
.	O
03	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
Difference	O
in	O
mean	O
flexion	O
at	O
C3	O
-	O
4	O
and	O
C4	O
-	O
5	O
was	O
significantly	O
correlated	O
with	O
difference	O
in	O
mean	O
flexion	O
(	O
rho	O
=	O
0	O
.	O
88	O
,	O
p	O
=	O
0	O
.	O
02	O
and	O
rho	O
=	O
0	O
.	O
941	O
,	O
p	O
<	O
0	O
.	O
01	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
</ALL>	O

<ALL>	O
The	O
results	O
of	O
this	O
study	O
demonstrate	O
statistically	O
significant	O
correlations	O
between	O
proliferant	O
injections	O
,	O
a	O
reduction	O
of	O
both	O
cervical	B-Organism_subdivision
flexion	O
and	O
extension	O
translation	O
,	O
as	O
well	O
as	O
a	O
reduction	O
in	O
pain	O
VAS	O
score	O
.	O
</ALL>	O

<ALL>	O
Since	O
patients	O
with	O
traumatic	O
cervical	B-Organism_subdivision
instability	O
have	O
few	O
viable	O
treatment	O
options	O
other	O
than	O
surgical	O
fusion	O
,	O
cervical	B-Organism_subdivision
proliferant	O
injections	O
under	O
C	O
-	O
Arm	O
fluoroscope	O
may	O
be	O
a	O
viable	O
treatment	O
option	O
.	O
</ALL>	O

<ALL>	O
[	O
The	O
prevalence	O
of	O
ADHD	O
and	O
attention	O
problems	O
in	O
preschool	O
-	O
aged	O
children	O
.	O
A	O
comparison	O
of	O
two	O
diagnostic	O
instruments	O
]	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
:	O
</ALL>	O

<ALL>	O
In	O
order	O
to	O
analyse	O
the	O
prevalence	O
of	O
ADHD	O
and	O
attention	O
problems	O
in	O
preschool	O
-	O
aged	O
children	O
,	O
mothers	O
were	O
asked	O
to	O
rate	O
their	O
children	O
using	O
two	O
measuring	O
instruments	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
The	O
analysis	O
is	O
part	O
of	O
a	O
prospective	O
,	O
randomised	O
control	O
study	O
of	O
N	O
=	O
280	O
children	O
aged	O
three	O
to	O
six	O
years	O
,	O
whose	O
mothers	O
rated	O
them	O
using	O
the	O
Child	O
Behaviour	O
Checklist	O
/	O
CBCL	O
1	O
1	O
/	O
2	O
-	O
5	O
and	O
the	O
Parent	O
Rating	O
Scale	O
for	O
Attention	O
-	O
Deficit	O
Hyperactivity	O
Disorder	O
(	O
ADHD	O
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
The	O
prevalence	O
rates	O
ranged	O
from	O
2	O
.	O
7	O
%	O
to	O
9	O
.	O
9	O
%	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
no	O
significant	O
gender	O
effect	O
in	O
this	O
age	O
group	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
</ALL>	O

<ALL>	O
The	O
study	O
delivers	O
initial	O
findings	O
and	O
provides	O
support	O
for	O
decisions	O
to	O
implement	O
in	O
Germany	O
new	O
assessment	O
methods	O
for	O
preschool	O
-	O
aged	O
children	O
with	O
ADHD	O
or	O
hyperkinetic	O
syndrome	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
the	O
different	O
rates	O
of	O
prevalence	O
and	O
the	O
implications	O
of	O
the	O
findings	O
for	O
epidemiology	O
and	O
the	O
prevention	O
of	O
ADHD	O
and	O
attention	O
problems	O
among	O
preschool	O
-	O
aged	O
children	O
are	O
discussed	O
.	O
</ALL>	O

<ALL>	O
Medical	O
adherence	O
and	O
childhood	O
chronic	O
illness	O
:	O
family	O
daily	O
management	O
skills	O
and	O
emotional	O
climate	O
as	O
emerging	O
contributors	O
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
OF	O
REVIEW	O
:	O
</ALL>	O

<ALL>	O
To	O
describe	O
recent	O
research	O
that	O
examines	O
family	O
factors	O
that	O
promote	O
or	O
derail	O
adherence	O
to	O
medical	O
regimens	O
for	O
children	O
with	O
chronic	O
health	O
conditions	O
,	O
primarily	O
asthma	O
,	O
diabetes	O
,	O
and	O
cystic	O
fibrosis	O
.	O
</ALL>	O

<ALL>	O
From	O
the	O
past	O
2	O
years	O
,	O
eight	O
correlational	O
studies	O
were	O
identified	O
which	O
specifically	O
examined	O
the	O
links	O
between	O
family	O
management	O
strategies	O
,	O
family	O
climate	O
and	O
medical	O
adherence	O
.	O
</ALL>	O

<ALL>	O
RECENT	O
FINDINGS	O
:	O
</ALL>	O

<ALL>	O
Findings	O
from	O
the	O
studies	O
suggest	O
that	O
team	O
-	O
based	O
management	O
strategies	O
and	O
cohesive	O
family	O
climate	O
promote	O
adherence	O
to	O
medical	O
treatments	O
over	O
time	O
.	O
</ALL>	O

<ALL>	O
Family	O
interactions	O
that	O
are	O
characterized	O
by	O
conflict	O
and	O
disengagement	O
tend	O
to	O
disrupt	O
adherence	O
and	O
inevitably	O
cause	O
a	O
decline	O
in	O
child	O
health	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
these	O
findings	O
seem	O
to	O
be	O
moderated	O
by	O
child	O
age	O
in	O
that	O
poorer	O
adherence	O
often	O
occurs	O
when	O
a	O
child	O
reaches	O
adolescence	O
and	O
is	O
searching	O
for	O
greater	O
autonomy	O
.	O
</ALL>	O

<ALL>	O
SUMMARY	O
:	O
</ALL>	O

<ALL>	O
Future	O
research	O
should	O
consider	O
the	O
challenges	O
in	O
measuring	O
medical	O
adherence	O
in	O
the	O
family	O
context	O
as	O
well	O
as	O
incorporating	O
more	O
naturalistic	O
studies	O
of	O
family	O
interactions	O
.	O
</ALL>	O

<ALL>	O
Randomized	O
controlled	O
trials	O
using	O
family	O
-	O
based	O
interventions	O
may	O
consider	O
focusing	O
on	O
medical	O
adherence	O
as	O
an	O
important	O
mediator	O
between	O
family	O
process	O
and	O
child	O
health	O
outcomes	O
.	O
</ALL>	O

<ALL>	O
The	O
relationship	O
between	O
brain	B-Organ
activity	O
and	O
peak	O
grip	O
force	O
is	O
modulated	O
by	O
corticospinal	B-Anatomical_system
system	I-Anatomical_system
integrity	O
after	O
subcortical	B-Multi-tissue_structure
stroke	O
.	O
</ALL>	O

<ALL>	O
In	O
healthy	O
human	O
subjects	O
,	O
the	O
relative	O
contribution	O
of	O
cortical	B-Multi-tissue_structure
regions	I-Multi-tissue_structure
to	O
motor	O
performance	O
varies	O
with	O
the	O
task	O
parameters	O
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
after	O
stroke	O
,	O
recruitment	O
of	O
cortical	B-Multi-tissue_structure
areas	I-Multi-tissue_structure
during	O
a	O
simple	O
motor	O
task	O
varies	O
with	O
corticospinal	B-Anatomical_system
system	I-Anatomical_system
integrity	O
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
whether	O
the	O
pattern	O
of	O
motor	O
system	O
recruitment	O
in	O
a	O
task	O
involving	O
increasingly	O
forceful	O
hand	B-Organism_subdivision
grips	O
is	O
influenced	O
by	O
the	O
degree	O
of	O
corticospinal	B-Anatomical_system
system	I-Anatomical_system
damage	O
.	O
</ALL>	O

<ALL>	O
Nine	O
chronic	O
subcortical	B-Multi-tissue_structure
stroke	O
patients	O
and	O
nine	O
age	O
-	O
matched	O
controls	O
underwent	O
functional	O
magnetic	O
brain	B-Organ
imaging	O
whilst	O
performing	O
repetitive	O
isometric	O
hand	B-Organism_subdivision
grips	O
.	O
</ALL>	O

<ALL>	O
Target	O
grip	O
forces	O
were	O
varied	O
between	O
15	O
%	O
and	O
45	O
%	O
of	O
individual	O
maximum	O
grip	O
force	O
.	O
</ALL>	O

<ALL>	O
Corticospinal	O
system	O
functional	O
integrity	O
was	O
assessed	O
with	O
transcranial	O
magnetic	O
stimulation	O
.	O
</ALL>	O

<ALL>	O
Averaged	O
across	O
all	O
forces	O
,	O
there	O
was	O
more	O
task	O
-	O
related	O
activation	O
compared	O
with	O
rest	O
in	O
the	O
secondary	O
motor	O
areas	O
of	O
patients	O
with	O
greater	O
corticospinal	B-Anatomical_system
system	I-Anatomical_system
damage	O
,	O
confirming	O
previous	O
reports	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
here	O
we	O
were	O
primarily	O
interested	O
in	O
regional	O
brain	B-Organ
activation	O
,	O
which	O
covaried	O
with	O
the	O
amount	O
of	O
force	O
generated	O
,	O
implying	O
a	O
prominent	O
executive	O
role	O
in	O
force	O
production	O
.	O
</ALL>	O

<ALL>	O
We	O
found	O
that	O
in	O
control	O
subjects	O
and	O
patients	O
with	O
lesser	O
corticospinal	B-Anatomical_system
system	I-Anatomical_system
damage	O
,	O
signal	O
change	O
increased	O
linearly	O
with	O
increasing	O
force	O
output	O
in	O
contralateral	O
primary	O
motor	B-Multi-tissue_structure
cortex	I-Multi-tissue_structure
,	O
supplementary	O
motor	O
area	O
and	O
ipsilateral	O
cerebellum	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
in	O
patients	O
with	O
greater	O
corticospinal	B-Anatomical_system
system	I-Anatomical_system
damage	O
,	O
force	O
-	O
related	O
signal	O
changes	O
were	O
seen	O
mainly	O
in	O
contralesional	B-Multi-tissue_structure
dorsolateral	I-Multi-tissue_structure
premotor	I-Multi-tissue_structure
cortex	I-Multi-tissue_structure
,	O
bilateral	B-Multi-tissue_structure
ventrolateral	I-Multi-tissue_structure
premotor	I-Multi-tissue_structure
cortices	I-Multi-tissue_structure
and	O
contralesional	B-Multi-tissue_structure
cerebellum	I-Multi-tissue_structure
,	O
but	O
not	O
ipsilesional	B-Multi-tissue_structure
primary	I-Multi-tissue_structure
motor	I-Multi-tissue_structure
cortex	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
suggest	O
that	O
the	O
premotor	B-Multi-tissue_structure
cortices	I-Multi-tissue_structure
might	O
play	O
a	O
new	O
and	O
functionally	O
relevant	O
role	O
in	O
controlling	O
force	O
production	O
in	O
patients	O
with	O
more	O
severe	O
corticospinal	B-Anatomical_system
system	I-Anatomical_system
disruption	O
.	O
</ALL>	O

<ALL>	O
Characterization	O
of	O
transferrin	O
glycoforms	O
in	O
human	O
serum	B-Organism_substance
by	O
CE	O
-	O
UV	O
and	O
CE	O
-	O
ESI	O
-	O
MS	O
.	O
</ALL>	O

<ALL>	O
Human	O
transferrin	O
(	O
Tf	O
)	O
is	O
a	O
model	O
glycoprotein	O
for	O
congenital	O
disorders	O
of	O
glycosylation	O
(	O
CDG	O
)	O
diagnosis	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
last	O
few	O
years	O
,	O
new	O
CE	O
-	O
UV	O
methods	O
for	O
intact	O
Tf	O
glycoforms	O
analysis	O
have	O
been	O
developed	O
using	O
nonvolatile	O
BGEs	O
and	O
organic	O
modifiers	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
use	O
of	O
these	O
BGEs	O
does	O
not	O
allow	O
the	O
coupling	O
of	O
these	O
procedures	O
with	O
electrospray	O
MS	O
(	O
ESI	O
-	O
MS	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
a	O
new	O
CE	O
-	O
UV	O
separation	O
method	O
of	O
Tf	O
glycoforms	O
is	O
developed	O
,	O
using	O
a	O
double	O
-	O
layer	O
stable	O
coating	O
and	O
a	O
volatile	O
BGE	O
based	O
on	O
ammonium	O
acetate	O
.	O
</ALL>	O

<ALL>	O
The	O
separation	O
method	O
is	O
optimized	O
using	O
standard	O
Tf	O
and	O
their	O
potential	O
is	O
demonstrated	O
applying	O
the	O
method	O
to	O
the	O
analysis	O
of	O
sera	B-Organism_substance
Tf	O
from	O
healthy	O
individuals	O
and	O
CDG	O
patients	O
.	O
</ALL>	O

<ALL>	O
The	O
CE	O
-	O
UV	O
separation	O
method	O
has	O
been	O
coupled	O
to	O
ESI	O
-	O
MS	O
detection	O
.	O
</ALL>	O

<ALL>	O
Main	O
parameters	O
such	O
as	O
sheath	O
liquid	O
composition	O
are	O
optimized	O
in	O
order	O
to	O
obtain	O
a	O
good	O
sensitivity	O
.	O
</ALL>	O

<ALL>	O
The	O
CE	O
-	O
ESI	O
-	O
MS	O
method	O
has	O
also	O
been	O
used	O
in	O
serum	B-Organism_substance
samples	I-Organism_substance
obtaining	O
the	O
separation	O
of	O
the	O
different	O
proteins	O
present	O
in	O
serum	B-Organism_substance
and	O
partial	O
separation	O
of	O
Tf	O
glycoforms	O
.	O
</ALL>	O

<ALL>	O
Different	O
mass	O
spectra	O
and	O
deconvoluted	O
molecular	O
masses	O
were	O
obtained	O
for	O
each	O
sialoform	O
,	O
allowing	O
unequivocal	O
glycoform	O
identification	O
.	O
</ALL>	O

<ALL>	O
Selective	O
activation	O
of	O
mast	B-Cell
cells	I-Cell
in	O
rheumatoid	B-Tissue
synovial	I-Tissue
tissue	I-Tissue
results	O
in	O
production	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
1Ra	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVES	O
AND	O
DESIGN	O
:	O
</ALL>	O

<ALL>	O
To	O
study	O
the	O
consequences	O
of	O
mast	B-Cell
cell	I-Cell
activation	O
in	O
human	O
synovial	B-Tissue
tissue	I-Tissue
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
Synovial	B-Tissue
tissue	I-Tissue
was	O
obtained	O
from	O
18	O
RA	O
patients	O
and	O
mast	B-Cell
cells	I-Cell
was	O
selectively	O
activated	O
in	O
synovial	B-Tissue
tissue	I-Tissue
explant	O
cultures	O
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
1Ra	O
were	O
determined	O
and	O
tissue	B-Tissue
distribution	O
of	O
IL	O
-	O
1beta	O
was	O
studied	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
Compared	O
to	O
untreated	O
synovia	B-Tissue
,	O
selective	O
activation	O
of	O
synovial	B-Cell
mast	I-Cell
cells	I-Cell
increased	O
significantly	O
the	O
production	O
of	O
TNF	O
-	O
alpha	O
(	O
0	O
.	O
49	O
+	O
/	O
-	O
0	O
.	O
88	O
vs	O
.	O
4	O
.	O
56	O
+	O
/	O
-	O
3	O
.	O
18	O
pg	O
/	O
mg	O
wet	O
tissue	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
IL	O
-	O
1beta	O
(	O
0	O
.	O
058	O
+	O
/	O
-	O
0	O
.	O
032	O
vs	O
.	O
2	O
.	O
55	O
+	O
/	O
-	O
1	O
.	O
98	O
pg	O
/	O
mg	O
wet	O
tissue	O
,	O
p	O
=	O
0	O
.	O
013	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
expression	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1beta	O
mRNA	O
increased	O
significantly	O
(	O
19	O
-	O
fold	O
(	O
p	O
=	O
0	O
.	O
009	O
)	O
and	O
13	O
-	O
fold	O
(	O
p	O
=	O
0	O
.	O
031	O
)	O
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
Mast	B-Cell
cell	I-Cell
activation	O
induced	O
IL	O
-	O
1beta	O
expression	O
in	O
particular	O
in	O
nearby	O
CD68	B-Cell
positive	I-Cell
synovial	I-Cell
macrophages	I-Cell
.	O
</ALL>	O

<ALL>	O
Secretion	O
of	O
IL	O
-	O
1Ra	O
was	O
also	O
increased	O
but	O
to	O
a	O
lesser	O
degree	O
than	O
that	O
of	O
IL	O
-	O
1beta	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
</ALL>	O

<ALL>	O
Synovial	B-Cell
mast	I-Cell
cells	I-Cell
produce	O
proinflammmatory	O
cytokines	O
and	O
may	O
thus	O
contribute	O
to	O
the	O
inflammation	O
in	O
RA	O
.	O
</ALL>	O

<ALL>	O
Rapid	O
mixing	O
between	O
old	O
and	O
new	O
C	O
pools	O
in	O
the	O
canopy	O
of	O
mature	O
forest	O
trees	O
.	O
</ALL>	O

<ALL>	O
Stable	O
C	O
isotope	O
signals	O
in	O
plant	O
tissues	B-Tissue
became	O
a	O
key	O
tool	O
in	O
explaining	O
growth	O
responses	O
to	O
the	O
environment	O
.	O
</ALL>	O

<ALL>	O
The	O
technique	O
is	O
based	O
on	O
the	O
fundamental	O
assumption	O
that	O
the	O
isotopic	O
composition	O
of	O
a	O
given	O
unit	O
of	O
tissue	B-Tissue
(	O
e	O
.	O
g	O
.	O
a	O
tree	B-Tissue
ring	I-Tissue
)	O
reflects	O
the	O
specific	O
C	O
uptake	O
conditions	O
in	O
the	O
leaf	B-Organ
at	O
a	O
given	O
time	O
.	O
</ALL>	O

<ALL>	O
Beyond	O
the	O
methodological	O
implications	O
of	O
any	O
deviation	O
from	O
this	O
assumption	O
,	O
it	O
is	O
of	O
physiological	O
interest	O
whether	O
new	O
C	O
is	O
transferred	O
directly	O
from	O
sources	O
(	O
a	O
photosynthesizing	O
leaf	B-Organ
)	O
to	O
structural	O
sinks	O
(	O
e	O
.	O
g	O
.	O
adjacent	O
stem	B-Tissue
tissue	I-Tissue
)	O
,	O
or	O
inherently	O
passes	O
through	O
existing	O
(	O
mobile	O
)	O
C	O
pools	O
,	O
which	O
may	O
be	O
of	O
variable	O
(	O
older	O
)	O
age	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
explore	O
the	O
fate	O
of	O
(	O
13	O
)	O
C	O
-	O
labelled	O
photosynthates	O
in	O
the	O
crowns	B-Organism_subdivision
of	O
a	O
30	O
-	O
35	O
m	O
tall	O
,	O
mixed	O
forest	O
using	O
a	O
canopy	O
crane	O
.	O
</ALL>	O

<ALL>	O
In	O
all	O
nine	O
study	O
species	O
labelled	O
C	O
reached	O
woody	B-Tissue
tissue	I-Tissue
within	O
2	O
-	O
9	O
h	O
after	O
labelling	O
.	O
</ALL>	O

<ALL>	O
Four	O
months	O
later	O
,	O
very	O
small	O
signals	O
were	O
left	O
in	O
branch	O
wood	O
of	O
Tilia	O
suggesting	O
that	O
low	O
mixing	O
of	O
new	O
,	O
labelled	O
C	O
with	O
old	O
C	O
had	O
taken	O
place	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
signals	O
in	O
Fagus	O
and	O
Quercus	O
had	O
increased	O
,	O
indicating	O
more	O
intense	O
mixing	O
.	O
</ALL>	O

<ALL>	O
This	O
species	O
-	O
specific	O
mixing	O
of	O
new	O
with	O
old	O
C	O
pools	O
is	O
likely	O
to	O
mask	O
year	O
-	O
or	O
season	O
-	O
specific	O
linkages	O
between	O
tree	B-Tissue
ring	I-Tissue
formation	O
and	O
climate	O
and	O
has	O
considerable	O
implications	O
for	O
climate	O
reconstruction	O
using	O
stable	O
isotopes	O
as	O
proxies	O
for	O
past	O
climatic	O
conditions	O
.	O
</ALL>	O

<ALL>	O
M	O
.	O
leprae	O
-	O
and	O
BCG	O
-	O
induced	O
chemiluminescence	O
response	O
of	O
monocytes	B-Cell
from	O
leprosy	O
patients	O
and	O
healthy	O
subjects	O
:	O
effects	O
of	O
gamma	O
-	O
interferon	O
and	O
GM	O
-	O
CSF	O
.	O
</ALL>	O

<ALL>	O
Mycobacterium	O
leprae	O
,	O
in	O
contrast	O
to	O
BCG	O
,	O
failed	O
to	O
trigger	O
any	O
chemiluminescence	O
(	O
CL	O
)	O
response	O
in	O
mononuclear	B-Cell
cells	I-Cell
from	O
either	O
leprosy	O
patients	O
or	O
healthy	O
subjects	O
,	O
a	O
deficit	O
not	O
reversed	O
by	O
either	O
interferon	O
-	O
gamma	O
or	O
GM	O
-	O
CSF	O
.	O
</ALL>	O

<ALL>	O
Chemiluminescence	O
responses	O
induced	O
without	O
mycobacteria	O
or	O
with	O
BCG	O
were	O
found	O
to	O
be	O
lower	O
in	O
leprosy	O
patients	O
than	O
in	O
controls	O
.	O
</ALL>	O

<ALL>	O
M	O
.	O
leprae	O
were	O
also	O
less	O
well	O
phagocytosed	O
than	O
BCG	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
phagocytosis	O
between	O
healthy	O
and	O
tuberculoid	O
leprosy	O
subjects	O
.	O
</ALL>	O

<ALL>	O
Phagocytosis	O
was	O
not	O
altered	O
by	O
the	O
addition	O
of	O
either	O
lymphokine	O
,	O
and	O
no	O
major	O
differences	O
between	O
healthy	O
subjects	O
and	O
patients	O
were	O
observed	O
.	O
</ALL>	O

<ALL>	O
Preincubating	O
mononuclear	B-Cell
cells	I-Cell
with	O
anti	O
-	O
mycobacteria	O
antibodies	O
(	O
lepromatous	O
patients	O
'	O
sera	B-Organism_substance
)	O
did	O
not	O
increase	O
the	O
CL	O
response	O
nor	O
the	O
phagocytosis	O
of	O
M	O
.	O
leprae	O
or	O
BCG	O
.	O
</ALL>	O

<ALL>	O
A	O
practical	O
interface	O
for	O
microfluidics	O
and	O
nanoelectrospray	O
mass	O
spectrometry	O
.	O
</ALL>	O

<ALL>	O
We	O
report	O
a	O
new	O
method	O
for	O
fabricating	O
nanospray	O
ionization	O
tips	O
for	O
MS	O
,	O
formed	O
from	O
glass	O
substrates	O
and	O
the	O
inert	O
polymer	O
,	O
parylene	O
-	O
C	O
.	O
</ALL>	O

<ALL>	O
Using	O
a	O
single	O
photolithography	O
step	O
,	O
the	O
emitters	O
are	O
formed	O
contiguously	O
with	O
microchannels	O
,	O
such	O
that	O
no	O
dead	O
volumes	O
are	O
observed	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
because	O
the	O
devices	O
are	O
very	O
thin	O
(	O
approximately	O
0	O
.	O
3	O
mm	O
)	O
and	O
the	O
tips	O
are	O
formed	O
at	O
rectangular	O
corners	O
,	O
the	O
Taylor	O
cone	O
volumes	O
are	O
small	O
,	O
which	O
makes	O
the	O
method	O
attractive	O
for	O
future	O
integration	O
with	O
microfluidic	O
separations	O
.	O
</ALL>	O

<ALL>	O
Device	O
performance	O
was	O
demonstrated	O
by	O
evaluating	O
diverse	O
analytes	O
,	O
ranging	O
from	O
synthetic	O
polymers	O
,	O
to	O
peptides	O
,	O
to	O
nucleic	O
acids	O
.	O
</ALL>	O

<ALL>	O
For	O
all	O
analytes	O
,	O
performance	O
was	O
similar	O
to	O
that	O
of	O
conventional	O
emitters	O
(	O
pulled	O
-	O
glass	O
capillaries	O
and	O
the	O
Agilent	O
HPLC	O
Chip	O
)	O
with	O
the	O
advantage	O
of	O
rapid	O
,	O
batch	O
fabrication	O
of	O
identical	O
devices	O
.	O
</ALL>	O

<ALL>	O
Intraoperative	O
handling	O
and	O
wound	B-Pathological_formation
healing	O
of	O
arthroscopic	O
portal	O
wounds	B-Pathological_formation
:	O
a	O
clinical	O
study	O
comparing	O
nylon	O
suture	O
with	O
wound	B-Pathological_formation
closure	O
strips	O
.	O
</ALL>	O

<ALL>	O
This	O
prospective	O
,	O
single	O
-	O
centre	O
study	O
compared	O
wound	B-Pathological_formation
closure	O
methods	O
in	O
patients	O
undergoing	O
arthroscopy	O
.	O
</ALL>	O

<ALL>	O
Closure	O
of	O
arthroscopic	O
portal	O
wounds	B-Pathological_formation
with	O
sterile	O
adhesive	O
strips	O
is	O
effective	O
and	O
convenient	O
for	O
wound	B-Pathological_formation
management	O
.	O
</ALL>	O

<ALL>	O
The	O
method	O
was	O
associated	O
with	O
a	O
reduced	O
potential	O
for	O
infection	O
,	O
faster	O
renewal	O
of	O
tensile	O
strength	O
,	O
greater	O
cost	O
effectiveness	O
,	O
and	O
better	O
cosmetic	O
effects	O
comparing	O
with	O
suture	O
closure	O
.	O
</ALL>	O

<ALL>	O
This	O
method	O
of	O
wound	B-Pathological_formation
closure	O
may	O
also	O
reduce	O
the	O
incidence	O
of	O
needle	O
stick	O
injury	O
in	O
the	O
theatre	O
environment	O
.	O
</ALL>	O

<ALL>	O
Thereby	O
the	O
incidence	O
of	O
percutaneous	O
exposure	O
following	O
a	O
surgical	O
procedure	O
may	O
not	O
facilitate	O
transmission	O
of	O
blood	B-Organism_substance
borne	O
pathogens	O
such	O
as	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
hepatitis	O
C	O
virus	O
and	O
hepatitis	O
B	O
virus	O
.	O
</ALL>	O

<ALL>	O
As	O
a	O
result	O
it	O
may	O
reduce	O
litigation	O
in	O
today	O
'	O
s	O
changing	O
healthcare	O
climate	O
.	O
</ALL>	O

<ALL>	O
Investigation	O
of	O
the	O
effect	O
of	O
kaolin	O
and	O
tissue	B-Tissue
-	O
factor	O
-	O
activated	O
citrated	O
whole	B-Organism_substance
blood	I-Organism_substance
,	O
on	O
clot	B-Organism_substance
-	O
forming	O
variables	O
,	O
as	O
evaluated	O
by	O
thromboelastography	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
</ALL>	O

<ALL>	O
The	O
Thrombelastograph	O
(	O
TEG	O
;	O
Haemoscope	O
Corp	O
.	O
)	O
analyzes	O
clot	B-Organism_substance
formation	O
in	O
whole	B-Organism_substance
blood	I-Organism_substance
(	O
WB	B-Organism_substance
)	O
and	O
treatment	O
based	O
on	O
this	O
analysis	O
has	O
been	O
shown	O
to	O
reduce	O
transfusion	O
requirements	O
in	O
liver	B-Organ
and	O
cardiac	B-Organ
surgery	O
when	O
compared	O
to	O
conventional	O
coagulation	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Implementing	O
TEG	O
as	O
a	O
routine	O
laboratory	O
-	O
based	O
analysis	O
,	O
however	O
,	O
requires	O
validation	O
of	O
the	O
activators	O
employed	O
and	O
the	O
effect	O
of	O
storage	O
of	O
the	O
WB	B-Organism_substance
sample	O
in	O
citrate	O
before	O
analysis	O
.	O
</ALL>	O

<ALL>	O
STUDY	O
DESIGN	O
AND	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
The	O
effect	O
of	O
kaolin	O
,	O
tissue	B-Tissue
factor	O
(	O
TF	O
)	O
1	O
:	O
17	O
,	O
000	O
,	O
or	O
TF	O
1	O
:	O
42	O
,	O
500	O
on	O
TEG	O
clotting	O
time	O
(	O
R	O
)	O
,	O
Angle	O
(	O
velocity	O
of	O
clot	B-Organism_substance
formation	O
)	O
,	O
and	O
maximum	O
clot	B-Organism_substance
strength	O
(	O
amplitude	O
[	O
MA	O
]	O
)	O
were	O
evaluated	O
,	O
together	O
with	O
day	O
-	O
to	O
-	O
day	O
variation	O
,	O
the	O
coefficient	O
of	O
variance	O
(	O
CV	O
%	O
)	O
,	O
and	O
the	O
effect	O
of	O
citrate	O
storage	O
time	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
Clot	B-Organism_substance
formation	O
variables	O
were	O
equally	O
affected	O
by	O
TF	O
1	O
:	O
17	O
,	O
000	O
and	O
kaolin	O
activation	O
,	O
whereas	O
R	O
was	O
significantly	O
longer	O
when	O
TF	O
1	O
:	O
42	O
,	O
500	O
was	O
used	O
.	O
</ALL>	O

<ALL>	O
The	O
CV	O
for	O
the	O
different	O
variables	O
varied	O
from	O
3	O
to	O
13	O
percent	O
with	O
no	O
significant	O
differences	O
between	O
assays	O
.	O
</ALL>	O

<ALL>	O
Storage	O
of	O
citrated	O
WB	B-Organism_substance
significantly	O
affected	O
the	O
TEG	O
variables	O
in	O
a	O
hypercoagulable	O
direction	O
.	O
</ALL>	O

<ALL>	O
Only	O
the	O
R	O
,	O
however	O
,	O
was	O
significantly	O
affected	O
(	O
12	O
%	O
)	O
when	O
samples	O
rested	O
for	O
0	O
and	O
30	O
minutes	O
were	O
evaluated	O
with	O
kaolin	O
as	O
the	O
activator	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
</ALL>	O

<ALL>	O
The	O
TEG	O
assays	O
evaluated	O
were	O
reproducible	O
and	O
present	O
with	O
an	O
acceptable	O
CV	O
%	O
for	O
routine	O
clinical	O
practice	O
.	O
</ALL>	O

<ALL>	O
Kaolin	O
and	O
TF	O
1	O
:	O
17	O
,	O
000	O
equally	O
affected	O
the	O
clot	B-Organism_substance
formation	O
variables	O
.	O
</ALL>	O

<ALL>	O
Storage	O
of	O
WB	B-Organism_substance
for	O
up	O
to	O
30	O
minutes	O
in	O
citrate	O
did	O
not	O
,	O
except	O
for	O
R	O
,	O
affect	O
clot	B-Organism_substance
formation	O
variables	O
when	O
kaolin	O
was	O
used	O
as	O
activator	O
allowing	O
for	O
immediate	O
analysis	O
when	O
the	O
sample	O
arrives	O
in	O
the	O
laboratory	O
.	O
</ALL>	O

<ALL>	O
[	O
TESE	O
and	O
mTESE	O
.	O
Therapeutic	O
options	O
in	O
male	O
infertility	O
due	O
to	O
testicular	B-Organ
azoospermia	O
]	O
.	O
</ALL>	O

<ALL>	O
Modern	O
techniques	O
of	O
testicular	B-Cell
sperm	I-Cell
extraction	O
(	O
TESE	O
)	O
make	O
it	O
possible	O
for	O
an	O
infertile	O
man	O
to	O
father	O
a	O
child	O
.	O
</ALL>	O

<ALL>	O
The	O
operations	O
are	O
standardized	O
to	O
a	O
large	O
extent	O
and	O
the	O
underlying	O
morphological	O
alterations	O
of	O
spermatogenesis	O
also	O
appear	O
to	O
be	O
sufficiently	O
known	O
.	O
</ALL>	O

<ALL>	O
Current	O
research	O
is	O
focused	O
on	O
prognostic	O
factors	O
for	O
the	O
testicular	B-Organ
material	O
that	O
determine	O
the	O
sperm	B-Cell
retrieval	O
rate	O
and	O
success	O
rates	O
after	O
in	O
vitro	O
fertilization	O
/	O
intracytoplasmic	O
sperm	B-Cell
injection	O
(	O
IVF	O
-	O
ICSI	O
)	O
.	O
TESE	O
and	O
microTESE	O
are	O
accepted	O
standard	O
operations	O
for	O
testicular	B-Cell
sperm	I-Cell
retrieval	O
for	O
IVF	O
/	O
ICSI	O
.	O
</ALL>	O

<ALL>	O
Predictions	O
for	O
effective	O
sperm	B-Cell
recovery	O
are	O
addressed	O
.	O
</ALL>	O

<ALL>	O
Quantitative	O
retention	O
-	O
biological	O
activity	O
relationship	O
study	O
by	O
micellar	O
liquid	O
chromatography	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
previous	O
paper	O
,	O
the	O
usefulness	O
of	O
micellar	O
liquid	O
chromatography	O
(	O
MLC	O
)	O
in	O
predicting	O
octanol	O
-	O
water	O
partition	O
coefficients	O
of	O
organic	O
compounds	O
was	O
reported	O
.	O
</ALL>	O

<ALL>	O
This	O
paper	O
is	O
the	O
first	O
successful	O
report	O
of	O
a	O
quantitative	O
retention	O
-	O
activity	O
relationship	O
study	O
using	O
the	O
retention	O
factor	O
in	O
MLC	O
for	O
predicting	O
the	O
biological	O
activity	O
of	O
a	O
group	O
of	O
phenolic	O
compounds	O
.	O
</ALL>	O

<ALL>	O
Excellent	O
correlation	O
was	O
obtained	O
between	O
the	O
capacity	O
factor	O
in	O
MLC	O
and	O
the	O
bioactivity	O
(	O
measured	O
as	O
log	O
1	O
/	O
C	O
,	O
where	O
C	O
is	O
the	O
50	O
%	O
inhibitory	O
growth	O
concentration	O
)	O
of	O
26	O
para	O
-	O
substituted	O
phenols	O
.	O
</ALL>	O

<ALL>	O
A	O
single	O
MLC	O
retention	O
parameter	O
is	O
capable	O
of	O
describing	O
the	O
bioactivity	O
of	O
phenols	O
,	O
while	O
three	O
conventional	O
molecular	O
descriptors	O
(	O
log	O
P	O
(	O
ow	O
)	O
,	O
pKa	O
,	O
and	O
R	O
)	O
are	O
needed	O
to	O
achieve	O
a	O
similar	O
correlation	O
.	O
</ALL>	O

<ALL>	O
This	O
indicates	O
that	O
both	O
hydrophobic	O
and	O
electronic	O
interactions	O
are	O
incorporated	O
in	O
a	O
single	O
MLC	O
retention	O
parameter	O
,	O
which	O
is	O
due	O
to	O
the	O
amphiphilic	O
nature	O
of	O
surfactants	O
in	O
the	O
system	O
.	O
</ALL>	O

<ALL>	O
In	O
situations	O
like	O
this	O
,	O
QRAR	O
is	O
a	O
suitable	O
alternative	O
to	O
QSAR	O
since	O
measuring	O
MLC	O
retention	O
is	O
much	O
easier	O
than	O
measuring	O
different	O
molecular	O
descriptors	O
needed	O
to	O
build	O
the	O
QSAR	O
model	O
.	O
</ALL>	O

<ALL>	O
Addition	O
of	O
10	O
%	O
2	O
-	O
propanol	O
to	O
a	O
micellar	O
system	O
(	O
hybrid	O
system	O
)	O
proved	O
to	O
be	O
the	O
best	O
chromatographic	O
system	O
for	O
the	O
best	O
estimation	O
of	O
the	O
phenols	O
bioactivity	O
.	O
</ALL>	O

<ALL>	O
Other	O
chromatographic	O
factors	O
such	O
as	O
pH	O
and	O
stationary	O
phase	O
also	O
showed	O
significant	O
effect	O
on	O
the	O
correlation	O
between	O
capacity	O
factor	O
k	O
'	O
and	O
log	O
1	O
/	O
C	O
.	O
</ALL>	O

<ALL>	O
Atypical	O
mycobacteriosis	O
of	O
the	O
larynx	B-Multi-tissue_structure
:	O
an	O
unusual	O
clinical	O
presentation	O
secondary	O
to	O
steroids	O
inhalation	O
.	O
</ALL>	O

<ALL>	O
Vocal	O
cords	O
stiffness	O
can	O
be	O
associated	O
with	O
a	O
variety	O
of	O
etiologic	O
agents	O
,	O
but	O
it	O
is	O
rarely	O
seen	O
with	O
atypical	O
mycobacteria	O
,	O
for	O
example	O
,	O
Mycobacterium	O
avium	O
complex	O
.	O
</ALL>	O

<ALL>	O
We	O
report	O
a	O
case	O
of	O
a	O
35	O
-	O
year	O
-	O
old	O
white	O
woman	O
who	O
is	O
and	O
was	O
maintained	O
on	O
inhaled	O
steroids	O
.	O
</ALL>	O

<ALL>	O
She	O
presented	O
with	O
hoarseness	O
and	O
low	O
-	O
grade	O
fever	O
,	O
but	O
her	O
medical	O
history	O
was	O
otherwise	O
unremarkable	O
.	O
</ALL>	O

<ALL>	O
Laryngoscopy	O
revealed	O
bilateral	O
scarring	O
of	O
the	O
vocal	B-Multi-tissue_structure
cords	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Vocal	B-Multi-tissue_structure
cord	I-Multi-tissue_structure
biopsies	O
were	O
performed	O
.	O
</ALL>	O

<ALL>	O
Histologic	O
examination	O
revealed	O
unremarkable	O
laryngeal	B-Multi-tissue_structure
mucosa	I-Multi-tissue_structure
,	O
except	O
for	O
abundant	O
subepithelial	B-Pathological_formation
non	I-Pathological_formation
-	I-Pathological_formation
necrotizing	I-Pathological_formation
granulomata	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
The	O
differential	O
diagnosis	O
included	O
sarcoid	B-Pathological_formation
,	O
Klebsiella	B-Pathological_formation
scleroma	I-Pathological_formation
,	O
and	O
tuberculosis	O
.	O
</ALL>	O

<ALL>	O
Special	O
stains	O
reviewed	O
abundant	O
acid	O
-	O
fast	O
bacilli	O
,	O
later	O
confirmed	O
by	O
a	O
DNA	O
assay	O
on	O
induced	O
deep	O
sputum	B-Organism_substance
,	O
consistent	O
with	O
M	O
avium	O
complex	O
.	O
</ALL>	O

<ALL>	O
Subsequently	O
,	O
steroids	O
were	O
withdrawn	O
,	O
and	O
the	O
patient	O
was	O
treated	O
with	O
a	O
multiple	O
-	O
drug	O
antituberculous	O
regimen	O
and	O
had	O
a	O
full	O
recovery	O
.	O
</ALL>	O

<ALL>	O
This	O
unusual	O
clinical	O
presentation	O
of	O
the	O
atypical	O
mycobacteriosis	O
may	O
be	O
encountered	O
by	O
otolaryngologists	O
and	O
pathologists	O
,	O
and	O
it	O
is	O
critical	O
to	O
recognize	O
it	O
in	O
patients	O
immunocompromised	O
because	O
of	O
steroids	O
.	O
</ALL>	O

<ALL>	O
Are	O
former	O
female	O
elite	O
athletes	O
more	O
likely	O
to	O
experience	O
urinary	B-Organism_substance
incontinence	O
later	O
in	O
life	O
than	O
non	O
-	O
athletes	O
?	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
whether	O
former	O
female	O
elite	O
athletes	O
are	O
more	O
likely	O
to	O
experience	O
urinary	B-Organism_substance
incontinence	O
(	O
UI	O
)	O
later	O
in	O
life	O
than	O
non	O
-	O
athletes	O
and	O
to	O
assess	O
possible	O
risk	O
factors	O
for	O
UI	O
in	O
athletes	O
.	O
</ALL>	O

<ALL>	O
Three	O
hundred	O
and	O
thirty	O
-	O
one	O
former	O
elite	O
athletes	O
(	O
response	O
rate	O
81	O
%	O
)	O
and	O
640	O
controls	O
replied	O
to	O
a	O
postal	O
questionnaire	O
including	O
validated	O
questions	O
on	O
UI	O
.	O
</ALL>	O

<ALL>	O
While	O
competing	O
in	O
sport	O
,	O
10	O
.	O
9	O
%	O
and	O
2	O
.	O
7	O
%	O
of	O
the	O
former	O
elite	O
athletes	O
reported	O
stress	O
urinary	B-Organism_substance
incontinence	O
(	O
SUI	O
)	O
and	O
urge	O
incontinence	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Presently	O
,	O
36	O
.	O
5	O
%	O
of	O
the	O
former	O
elite	O
athletes	O
and	O
36	O
.	O
9	O
%	O
of	O
the	O
controls	O
reported	O
SUI	O
.	O
</ALL>	O

<ALL>	O
9	O
.	O
1	O
%	O
and	O
9	O
.	O
4	O
%	O
reported	O
urge	O
incontinence	O
.	O
</ALL>	O

<ALL>	O
Among	O
former	O
elite	O
athletes	O
,	O
those	O
with	O
two	O
or	O
three	O
children	O
were	O
more	O
likely	O
than	O
nulliparous	O
women	O
to	O
have	O
UI	O
now	O
.	O
</ALL>	O

<ALL>	O
Also	O
,	O
among	O
former	O
athletes	O
,	O
UI	O
was	O
more	O
common	O
in	O
women	O
with	O
vs	O
those	O
without	O
UI	O
while	O
competing	O
(	O
odds	O
ratio	O
8	O
.	O
57	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
3	O
.	O
55	O
-	O
20	O
.	O
71	O
)	O
.	O
</ALL>	O

<ALL>	O
Age	O
,	O
menopause	O
and	O
being	O
regularly	O
physically	O
active	O
now	O
were	O
not	O
associated	O
with	O
UI	O
in	O
either	O
group	O
.	O
</ALL>	O

<ALL>	O
Based	O
on	O
this	O
study	O
,	O
the	O
prevalence	O
of	O
UI	O
does	O
not	O
seem	O
to	O
be	O
higher	O
in	O
former	O
athletes	O
than	O
in	O
controls	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
results	O
indicate	O
that	O
UI	O
early	O
in	O
life	O
,	O
as	O
reported	O
during	O
elite	O
sport	O
,	O
is	O
a	O
strong	O
predictor	O
of	O
UI	O
later	O
in	O
life	O
.	O
</ALL>	O

<ALL>	O
Handling	O
within	O
run	O
retention	O
time	O
shifts	O
in	O
two	O
-	O
dimensional	O
chromatography	O
data	O
using	O
shift	O
correction	O
and	O
modeling	O
.	O
</ALL>	O

<ALL>	O
The	O
use	O
of	O
PARAFAC	O
for	O
modeling	O
GC	O
x	O
GC	O
-	O
TOFMS	O
peaks	O
is	O
well	O
documented	O
.	O
</ALL>	O

<ALL>	O
This	O
success	O
is	O
due	O
to	O
the	O
trilinear	O
structure	O
of	O
these	O
data	O
under	O
ideal	O
,	O
or	O
sufficiently	O
close	O
to	O
ideal	O
,	O
chromatographic	O
conditions	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
using	O
temperature	O
programming	O
to	O
cope	O
with	O
the	O
general	O
elution	O
problem	O
,	O
deviations	O
from	O
trilinearity	O
within	O
a	O
run	O
are	O
more	O
likely	O
to	O
be	O
seen	O
for	O
the	O
following	O
three	O
cases	O
:	O
(	O
1	O
)	O
compounds	O
(	O
i	O
.	O
e	O
.	O
,	O
analytes	O
)	O
severely	O
broadened	O
on	O
the	O
first	O
column	O
hence	O
defined	O
by	O
many	O
modulation	O
periods	O
,	O
(	O
2	O
)	O
analytes	O
with	O
a	O
very	O
high	O
retention	O
factor	O
on	O
the	O
second	O
column	O
and	O
likely	O
wrapped	O
around	O
in	O
that	O
dimension	O
,	O
or	O
(	O
3	O
)	O
with	O
fast	O
temperature	O
program	O
rates	O
.	O
</ALL>	O

<ALL>	O
This	O
deviation	O
from	O
trilinearity	O
is	O
seen	O
as	O
retention	O
time	O
-	O
shifted	O
peak	O
profiles	O
in	O
subsequent	O
modulation	O
periods	O
(	O
first	O
column	O
fractions	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
report	O
,	O
a	O
relaxed	O
yet	O
powerful	O
version	O
of	O
PARAFAC	O
,	O
known	O
as	O
PARAFAC2	O
has	O
been	O
applied	O
to	O
handle	O
this	O
shift	O
within	O
the	O
model	O
step	O
by	O
allowing	O
generation	O
of	O
individual	O
peak	O
profiles	O
in	O
subsequent	O
first	O
column	O
fractions	O
.	O
</ALL>	O

<ALL>	O
An	O
alternative	O
approach	O
was	O
also	O
studied	O
,	O
utilizing	O
a	O
standard	O
retention	O
time	O
shift	O
correction	O
to	O
restore	O
the	O
data	O
trilinearity	O
structure	O
followed	O
by	O
PARAFAC	O
.	O
</ALL>	O

<ALL>	O
These	O
two	O
approaches	O
are	O
compared	O
when	O
identifying	O
and	O
quantifying	O
a	O
known	O
analyte	O
over	O
a	O
large	O
concentration	O
series	O
where	O
a	O
certain	O
shift	O
is	O
simulated	O
in	O
the	O
successive	O
first	O
column	O
fractions	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
the	O
methods	O
are	O
applied	O
to	O
real	O
chromatographic	O
data	O
showing	O
severely	O
shifted	O
peak	O
profiles	O
.	O
</ALL>	O

<ALL>	O
The	O
pros	O
and	O
cons	O
of	O
the	O
presented	O
approaches	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
model	O
parameters	O
,	O
the	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
and	O
the	O
degree	O
of	O
shift	O
.	O
</ALL>	O

<ALL>	O
[	O
Incidence	O
of	O
fungal	O
infection	O
in	O
surgical	O
diseases	O
of	O
the	O
pancreas	B-Organ
]	O
.	O
</ALL>	O

<ALL>	O
Recently	O
the	O
number	O
of	O
mycotic	O
infections	O
has	O
increased	O
significantly	O
.	O
</ALL>	O

<ALL>	O
Authors	O
have	O
observed	O
13	O
mycotic	O
infections	O
on	O
operated	O
patients	O
suffering	O
pancreatic	B-Organ
diseases	O
between	O
1984	O
and	O
1990	O
.	O
</ALL>	O

<ALL>	O
9	O
of	O
13	O
patients	O
had	O
pancreatic	B-Pathological_formation
abscesses	I-Pathological_formation
as	O
well	O
.	O
</ALL>	O

<ALL>	O
The	O
risk	O
factors	O
of	O
fungal	O
infections	O
are	O
analysed	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
important	O
to	O
take	O
differentiation	O
between	O
fungal	O
colonisation	O
and	O
septicaemia	O
caused	O
by	O
yeasts	O
.	O
</ALL>	O

<ALL>	O
Repeated	O
microbiological	O
examinations	O
can	O
promote	O
recognising	O
of	O
the	O
fungal	O
invasion	O
.	O
</ALL>	O

<ALL>	O
The	O
base	O
of	O
the	O
therapy	O
is	O
to	O
avoid	O
risk	O
factors	O
of	O
infections	O
and	O
to	O
use	O
antifungal	O
medication	O
in	O
time	O
.	O
</ALL>	O

<ALL>	O
[	O
Quantitative	O
analysis	O
of	O
regional	O
cerebral	B-Organ
blood	B-Organism_substance
flow	O
in	O
elderly	O
with	O
white	B-Pathological_formation
matter	I-Pathological_formation
lesions	I-Pathological_formation
]	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
</ALL>	O

<ALL>	O
To	O
observe	O
whether	O
the	O
severity	O
of	O
white	B-Pathological_formation
matter	I-Pathological_formation
lesions	I-Pathological_formation
(	O
WML	B-Pathological_formation
)	O
is	O
related	O
to	O
ischemia	O
in	O
elderly	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
WML	B-Pathological_formation
were	O
divided	O
into	O
2	O
categories	O
(	O
centrum	B-Multi-tissue_structure
semiovale	I-Multi-tissue_structure
and	O
periventricular	B-Multi-tissue_structure
regions	I-Multi-tissue_structure
)	O
and	O
four	O
grades	O
(	O
grade	O
0	O
,	O
grade	O
1	O
,	O
grade	O
2	O
and	O
grade	O
3	O
)	O
according	O
to	O
the	O
severity	O
of	O
WML	B-Pathological_formation
showing	O
on	O
the	O
FLAIR	O
sequence	O
of	O
MRI	O
using	O
modified	O
Fazekas	O
scale	O
.	O
</ALL>	O

<ALL>	O
The	O
values	O
of	O
regional	O
cerebral	B-Organ
blood	B-Organism_substance
flow	O
(	O
rCBF	O
)	O
within	O
WML	B-Pathological_formation
and	O
other	O
brain	B-Organ
regions	O
were	O
measured	O
using	O
Xenon	O
contrast	O
CT	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
Mean	O
rCBF	O
(	O
ml	O
x	O
100	O
g	O
(	O
-	O
1	O
)	O
x	O
min	O
(	O
-	O
1	O
)	O
)	O
within	O
lesions	B-Pathological_formation
around	O
periventricular	B-Multi-tissue_structure
areas	I-Multi-tissue_structure
,	O
in	O
right	O
and	O
left	O
centrum	B-Multi-tissue_structure
semiovale	I-Multi-tissue_structure
were	O
20	O
.	O
8	O
+	O
/	O
-	O
2	O
.	O
8	O
,	O
22	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
9	O
and	O
22	O
.	O
2	O
+	O
/	O
-	O
2	O
.	O
1	O
in	O
grade	O
0	O
;	O
20	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
5	O
,	O
21	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
0	O
and	O
21	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
8	O
in	O
grade1	O
;	O
16	O
.	O
3	O
+	O
/	O
-	O
2	O
.	O
0	O
,	O
15	O
.	O
6	O
+	O
/	O
-	O
1	O
.	O
7	O
and	O
15	O
.	O
9	O
+	O
/	O
-	O
0	O
.	O
9	O
in	O
grade	O
2	O
;	O
14	O
.	O
1	O
+	O
/	O
-	O
2	O
.	O
6	O
,	O
14	O
.	O
5	O
+	O
/	O
-	O
2	O
.	O
2	O
and	O
14	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
9	O
in	O
grade	O
3	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
severity	O
of	O
WML	B-Pathological_formation
is	O
associated	O
significantly	O
with	O
reduction	O
of	O
rCBF	O
within	O
lesions	B-Pathological_formation
both	O
in	O
centrum	B-Multi-tissue_structure
semiovale	I-Multi-tissue_structure
and	O
periventricular	B-Multi-tissue_structure
regions	I-Multi-tissue_structure
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
no	O
significant	O
difference	O
in	O
rCBF	O
values	O
between	O
grade	O
0	O
and	O
1	O
,	O
but	O
significant	O
differences	O
existed	O
between	O
grade	O
0	O
and	O
grades	O
2	O
and	O
3	O
,	O
between	O
grade	O
1	O
and	O
grades	O
2	O
and	O
3	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
</ALL>	O

<ALL>	O
Statistical	O
significance	O
also	O
existed	O
between	O
the	O
severity	O
of	O
white	B-Pathological_formation
matter	I-Pathological_formation
lesions	I-Pathological_formation
and	O
rCBF	O
in	O
bilateral	O
temporal	B-Multi-tissue_structure
lobes	I-Multi-tissue_structure
and	O
lentiform	O
nucleases	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
</ALL>	O

<ALL>	O
The	O
severity	O
of	O
WML	B-Pathological_formation
both	O
in	O
centrum	B-Multi-tissue_structure
semiovale	I-Multi-tissue_structure
and	O
periventricular	B-Pathological_formation
regions	I-Pathological_formation
is	O
associated	O
significantly	O
with	O
reduction	O
of	O
rCBF	O
within	O
lesions	B-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Aging	O
affects	O
the	O
cardiovascular	B-Anatomical_system
responses	O
to	O
cold	O
stress	O
in	O
humans	O
.	O
</ALL>	O

<ALL>	O
Cardiovascular	B-Anatomical_system
-	O
related	O
mortality	O
peaks	O
during	O
cold	O
winter	O
months	O
,	O
particularly	O
in	O
older	O
adults	O
.	O
</ALL>	O

<ALL>	O
Acute	O
physiological	O
responses	O
,	O
such	O
as	O
increases	O
in	O
blood	B-Organism_substance
pressure	O
,	O
in	O
response	O
to	O
cold	O
exposure	O
may	O
contribute	O
to	O
these	O
associations	O
.	O
</ALL>	O

<ALL>	O
To	O
determine	O
whether	O
the	O
blood	B-Organism_substance
pressure	O
-	O
raising	O
effect	O
(	O
pressor	O
response	O
)	O
of	O
non	O
-	O
internal	O
body	B-Organism_subdivision
temperature	O
-	O
reducing	O
cold	O
stress	O
is	O
greater	O
with	O
age	O
,	O
we	O
measured	O
physiological	O
responses	O
to	O
20	O
min	O
of	O
superficial	O
skin	B-Organ
cooling	O
,	O
via	O
water	O
-	O
perfused	O
suit	O
,	O
in	O
12	O
younger	O
[	O
25	O
+	O
/	O
-	O
1	O
(	O
SE	O
)	O
yr	O
old	O
]	O
and	O
12	O
older	O
(	O
65	O
+	O
/	O
-	O
2	O
yr	O
old	O
)	O
adults	O
.	O
</ALL>	O

<ALL>	O
We	O
found	O
that	O
superficial	O
skin	B-Organ
cooling	O
elicited	O
an	O
increase	O
in	O
blood	B-Organism_substance
pressure	O
from	O
resting	O
levels	O
(	O
pressor	O
response	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
younger	O
and	O
older	O
adults	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
magnitude	O
of	O
this	O
pressor	O
response	O
(	O
systolic	O
and	O
mean	O
blood	B-Organism_substance
pressure	O
)	O
was	O
more	O
than	O
twofold	O
higher	O
in	O
older	O
adults	O
(	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
younger	O
adults	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
magnitude	O
of	O
the	O
pressor	O
response	O
was	O
similar	O
at	O
peripheral	O
(	O
brachial	B-Organism_subdivision
)	O
and	O
central	O
(	O
estimated	O
in	O
the	O
aorta	B-Multi-tissue_structure
)	O
measurement	O
sites	O
.	O
</ALL>	O

<ALL>	O
Regression	O
analysis	O
revealed	O
that	O
aortic	B-Multi-tissue_structure
pulse	O
wave	O
velocity	O
,	O
a	O
measure	O
of	O
central	O
arterial	B-Multi-tissue_structure
stiffness	O
obtained	O
before	O
cooling	O
,	O
was	O
the	O
best	O
predictor	O
of	O
the	O
increased	O
pressor	O
response	O
to	O
superficial	O
skin	B-Organ
cooling	O
in	O
older	O
adults	O
,	O
explaining	O
approximately	O
63	O
%	O
of	O
its	O
variability	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
indicate	O
that	O
there	O
is	O
a	O
greater	O
pressor	O
response	O
to	O
non	O
-	O
internal	O
body	B-Organism_subdivision
temperature	O
-	O
reducing	O
cold	O
stress	O
with	O
age	O
in	O
humans	O
that	O
may	O
be	O
mediated	O
by	O
increased	O
levels	O
of	O
central	O
arterial	B-Multi-tissue_structure
stiffness	O
.	O
</ALL>	O

<ALL>	O
Magnesium	O
for	O
treatment	O
of	O
asthma	O
in	O
children	O
.	O
</ALL>	O

<ALL>	O
QUESTION	O
:	O
Magnesium	O
is	O
considered	O
adjuvant	O
therapy	O
for	O
moderate	O
to	O
severe	O
asthma	O
exacerbations	O
in	O
adults	O
,	O
but	O
can	O
it	O
be	O
used	O
to	O
treat	O
children	O
?	O
</ALL>	O

<ALL>	O
ANSWER	O
:	O
Magnesium	O
seems	O
to	O
be	O
beneficial	O
in	O
the	O
treatment	O
of	O
moderate	O
to	O
severe	O
asthma	O
in	O
children	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
a	O
safe	O
drug	O
to	O
administer	O
,	O
but	O
there	O
have	O
been	O
minor	O
side	O
effects	O
reported	O
,	O
such	O
as	O
epigastric	B-Organism_subdivision
or	O
facial	B-Organism_subdivision
warmth	O
,	O
flushing	O
,	O
pain	O
and	O
numbness	O
at	O
the	O
infusion	O
site	O
,	O
dry	O
mouth	B-Organism_subdivision
,	O
malaise	O
,	O
and	O
hypotension	O
.	O
</ALL>	O

<ALL>	O
Owing	O
to	O
its	O
bronchodilating	O
and	O
anti	O
-	O
inflammatory	O
effects	O
,	O
magnesium	O
is	O
an	O
encouraging	O
adjuvant	O
therapy	O
for	O
pediatric	O
patients	O
who	O
do	O
not	O
respond	O
to	O
conventional	O
treatment	O
in	O
acute	O
severe	O
exacerbations	O
.	O
</ALL>	O

<ALL>	O
Future	O
studies	O
should	O
focus	O
on	O
establishing	O
the	O
optimal	O
dosage	O
for	O
maximal	O
benefits	O
and	O
the	O
best	O
route	O
of	O
administration	O
.	O
</ALL>	O

<ALL>	O
Magnesium	O
should	O
also	O
be	O
considered	O
as	O
a	O
prophylactic	O
treatment	O
.	O
</ALL>	O

<ALL>	O
Effectiveness	O
of	O
different	O
approaches	O
for	O
establishing	O
cisplatin	O
-	O
induced	O
cochlear	B-Pathological_formation
lesions	I-Pathological_formation
in	O
mice	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
</ALL>	O

<ALL>	O
Mouse	O
cochleae	B-Multi-tissue_structure
are	O
highly	O
resistant	O
to	O
systemically	O
administered	O
cisplatin	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
cochlear	B-Pathological_formation
lesions	I-Pathological_formation
can	O
be	O
produced	O
effectively	O
in	O
mice	O
when	O
cisplatin	O
is	O
applied	O
locally	O
through	O
the	O
round	B-Immaterial_anatomical_entity
window	I-Immaterial_anatomical_entity
niche	I-Immaterial_anatomical_entity
or	O
tympanum	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
</ALL>	O

<ALL>	O
To	O
explore	O
the	O
optimal	O
approach	O
for	O
creating	O
cisplatin	O
-	O
induced	O
cochlear	B-Pathological_formation
lesions	I-Pathological_formation
in	O
mice	O
.	O
</ALL>	O

<ALL>	O
MATERIALS	O
AND	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
Cisplatin	O
was	O
administered	O
to	O
adult	O
C57BL	O
/	O
6J	O
mice	O
via	O
four	O
approaches	O
:	O
(	O
1	O
)	O
transtympanic	O
injection	O
,	O
(	O
2	O
)	O
round	B-Immaterial_anatomical_entity
window	I-Immaterial_anatomical_entity
niche	I-Immaterial_anatomical_entity
injection	O
,	O
(	O
3	O
)	O
intraperitoneal	O
injection	O
(	O
i	O
.	O
p	O
.	O
)	O
at	O
4	O
mg	O
/	O
kg	O
/	O
day	O
for	O
4	O
consecutive	O
days	O
,	O
and	O
(	O
4	O
)	O
one	O
15	O
mg	O
/	O
kg	O
dose	O
i	O
.	O
p	O
.	O
</ALL>	O

<ALL>	O
The	O
hearing	O
was	O
monitored	O
using	O
frequency	O
-	O
specific	O
auditory	O
brainstem	B-Multi-tissue_structure
responses	O
(	O
ABRs	O
)	O
and	O
distortion	O
-	O
product	O
otoacoustic	O
emissions	O
(	O
DPOAEs	O
)	O
.	O
</ALL>	O

<ALL>	O
Cochlear	B-Multi-tissue_structure
pathology	O
was	O
observed	O
in	O
cochleograms	O
with	O
Harris	O
'	O
hematoxylin	O
staining	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
Cisplatin	O
applied	O
systemically	O
did	O
not	O
cause	O
any	O
significant	O
ABR	O
threshold	O
elevation	O
across	O
the	O
frequencies	O
tested	O
(	O
2	O
-	O
32	O
kHz	O
)	O
,	O
whereas	O
local	O
application	O
of	O
cisplatin	O
through	O
the	O
round	B-Immaterial_anatomical_entity
window	I-Immaterial_anatomical_entity
niche	I-Immaterial_anatomical_entity
or	O
tympanum	B-Multi-tissue_structure
resulted	O
in	O
significant	O
ABR	O
threshold	O
elevations	O
from	O
high	O
to	O
medium	O
frequencies	O
.	O
</ALL>	O

<ALL>	O
The	O
functional	O
changes	O
were	O
consistent	O
with	O
the	O
cochlear	B-Multi-tissue_structure
pathology	O
across	O
groups	O
.	O
</ALL>	O

<ALL>	O
Further	O
Characterization	O
of	O
Activin	O
A	O
-	O
induced	O
IgA	O
Response	O
in	O
Murine	O
B	B-Cell
Lymphocytes	I-Cell
.	O
</ALL>	O

<ALL>	O
We	O
have	O
recently	O
shown	O
that	O
activin	O
A	O
,	O
a	O
member	O
of	O
TGF	O
-	O
beta	O
superfamily	O
,	O
stimulates	O
mouse	O
B	B-Cell
cells	I-Cell
to	O
express	O
IgA	O
isotype	O
but	O
other	O
isotypes	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
we	O
further	O
characterized	O
effects	O
of	O
activin	O
A	O
on	O
B	B-Cell
cell	I-Cell
growth	O
and	O
IgA	O
expression	O
.	O
</ALL>	O

<ALL>	O
We	O
found	O
that	O
activin	O
A	O
did	O
not	O
have	O
effect	O
on	O
LPS	O
-	O
stimulated	O
cell	B-Cell
viability	O
.	O
</ALL>	O

<ALL>	O
In	O
parallel	O
,	O
CFSE	O
staining	O
analysis	O
revealed	O
that	O
activin	O
A	O
did	O
not	O
alter	O
cell	B-Cell
division	O
.	O
</ALL>	O

<ALL>	O
An	O
increase	O
of	O
IgA	O
secretion	O
by	O
activin	O
A	O
was	O
completely	O
abrogated	O
by	O
anti	O
-	O
activin	O
A	O
Ab	O
but	O
not	O
by	O
anti	O
-	O
TGFbeta1	O
Ab	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
same	O
conditions	O
,	O
no	O
other	O
isotypes	O
are	O
significantly	O
affected	O
by	O
each	O
antibody	O
treatment	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
activin	O
A	O
,	O
as	O
similar	O
to	O
TGF	O
-	O
beta1	O
,	O
increased	O
IgA	O
secretion	O
by	O
mesenteric	O
lymph	B-Cell
node	I-Cell
cells	I-Cell
.	O
</ALL>	O

<ALL>	O
These	O
results	O
suggest	O
that	O
activin	O
A	O
can	O
specifically	O
stimulate	O
IgA	O
response	O
,	O
independent	O
of	O
TGF	O
-	O
beta	O
in	O
the	O
gut	B-Organism_subdivision
.	O
</ALL>	O

<ALL>	O
Posterior	O
stabilization	O
of	O
the	O
cervical	B-Organism_subdivision
spine	I-Organism_subdivision
with	O
hook	O
plates	O
.	O
</ALL>	O

<ALL>	O
Hook	O
-	O
plate	O
fixation	O
is	O
designed	O
for	O
posterior	O
cervical	B-Organism_subdivision
stabilization	O
from	O
C2	O
to	O
C7	O
.	O
</ALL>	O

<ALL>	O
Indications	O
remain	O
the	O
same	O
as	O
for	O
standard	O
posterior	O
fixations	O
.	O
</ALL>	O

<ALL>	O
The	O
prime	O
indications	O
are	O
discoligamentous	O
injuries	O
.	O
</ALL>	O

<ALL>	O
The	O
plates	O
are	O
hooked	O
under	O
the	O
lower	B-Multi-tissue_structure
laminas	I-Multi-tissue_structure
and	O
attached	O
to	O
the	O
articular	B-Multi-tissue_structure
masses	I-Multi-tissue_structure
of	O
the	O
upper	O
vertebra	B-Organ
by	O
oblique	O
screws	O
.	O
</ALL>	O

<ALL>	O
An	O
H	O
-	O
graft	O
is	O
placed	O
between	O
the	O
spinous	O
processes	O
.	O
</ALL>	O

<ALL>	O
The	O
vertebrae	B-Organ
are	O
compressed	O
together	O
by	O
the	O
plates	O
at	O
three	O
points	O
,	O
the	O
facet	O
joints	O
,	O
and	O
graft	O
.	O
</ALL>	O

<ALL>	O
The	O
resulting	O
pre	O
-	O
stressed	O
system	O
is	O
stable	O
in	O
all	O
directions	O
.	O
</ALL>	O

<ALL>	O
A	O
protocol	O
for	O
safe	O
reduction	O
of	O
cervical	B-Organism_subdivision
dislocations	O
is	O
observed	O
.	O
</ALL>	O

<ALL>	O
Of	O
70	O
patients	O
treated	O
from	O
1979	O
to	O
1986	O
,	O
51	O
were	O
examined	O
12	O
-	O
54	O
months	O
after	O
surgery	O
.	O
</ALL>	O

<ALL>	O
All	O
fusions	O
consolidated	O
.	O
</ALL>	O

<ALL>	O
Two	O
neurologic	B-Anatomical_system
complications	O
not	O
attributable	O
to	O
the	O
fixation	O
occurred	O
.	O
</ALL>	O

<ALL>	O
Other	O
major	O
complications	O
were	O
not	O
seen	O
.	O
</ALL>	O

<ALL>	O
Is	O
the	O
elimination	O
of	O
HIV	O
infection	O
within	O
reach	O
in	O
the	O
United	O
States	O
?	O
</ALL>	O

<ALL>	O
Lessons	O
from	O
an	O
epidemiologic	O
transmission	O
model	O
.	O
</ALL>	O

<ALL>	O
Recent	O
estimates	O
show	O
that	O
the	O
transmission	O
rate	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
in	O
the	O
U	O
.	O
S	O
.	O
has	O
substantially	O
decreased	O
.	O
</ALL>	O

<ALL>	O
This	O
raises	O
the	O
question	O
,	O
is	O
elimination	O
of	O
HIV	O
infection	O
in	O
the	O
nation	O
feasible	O
in	O
the	O
foreseeable	O
future	O
?	O
</ALL>	O

<ALL>	O
We	O
demonstrate	O
that	O
if	O
the	O
HIV	O
transmission	O
rate	O
were	O
reduced	O
by	O
50	O
%	O
,	O
then	O
the	O
reproductive	O
rate	O
of	O
HIV	O
infection	O
would	O
drop	O
below	O
unity	O
and	O
lead	O
to	O
eventual	O
elimination	O
of	O
infection	O
.	O
</ALL>	O

<ALL>	O
In	O
recent	O
congressional	O
testimony	O
,	O
the	O
director	O
of	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
and	O
others	O
asserted	O
that	O
the	O
HIV	O
transmission	O
rate	O
can	O
be	O
halved	O
by	O
2020	O
,	O
if	O
not	O
earlier	O
,	O
provided	O
sufficient	O
investment	O
is	O
made	O
toward	O
achieving	O
this	O
goal	O
.	O
</ALL>	O

<ALL>	O
We	O
assert	O
that	O
if	O
adequate	O
investment	O
is	O
made	O
and	O
the	O
transmission	O
rate	O
is	O
in	O
fact	O
lowered	O
by	O
50	O
%	O
,	O
then	O
the	O
HIV	O
reproductive	O
rate	O
would	O
fall	O
below	O
unity	O
,	O
setting	O
the	O
stage	O
for	O
eventual	O
elimination	O
of	O
HIV	O
infection	O
in	O
the	O
U	O
.	O
S	O
.	O
</ALL>	O

<ALL>	O
Pain	O
assessment	O
by	O
continuous	O
EEG	O
:	O
association	O
between	O
subjective	O
perception	O
of	O
tonic	O
pain	O
and	O
peak	O
frequency	O
of	O
alpha	O
oscillations	O
during	O
stimulation	O
and	O
at	O
rest	O
.	O
</ALL>	O

<ALL>	O
Recordings	O
of	O
neurophysiological	O
brain	B-Organ
responses	O
to	O
noxious	O
stimuli	O
have	O
been	O
traditionally	O
based	O
on	O
short	O
stimuli	O
,	O
in	O
the	O
order	O
of	O
milliseconds	O
,	O
which	O
induce	O
distinct	O
event	O
-	O
related	O
potentials	O
(	O
ERPs	O
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
using	O
such	O
stimuli	O
in	O
the	O
experimental	O
setting	O
is	O
disadvantageous	O
as	O
they	O
are	O
too	O
brief	O
to	O
faithfully	O
simulate	O
clinical	O
pain	O
.	O
</ALL>	O

<ALL>	O
We	O
aimed	O
at	O
utilizing	O
continuous	O
EEG	O
to	O
investigate	O
the	O
properties	O
of	O
peak	O
alpha	O
frequency	O
(	O
PAF	O
)	O
as	O
an	O
objective	O
cortical	B-Multi-tissue_structure
measure	O
associated	O
with	O
subjective	O
perception	O
of	O
tonic	O
pain	O
.	O
</ALL>	O

<ALL>	O
Five	O
minute	O
long	O
continuous	O
EEG	O
was	O
recorded	O
in	O
18	O
healthy	O
volunteers	O
under	O
:	O
(	O
i	O
)	O
resting	O
-	O
state	O
;	O
(	O
ii	O
)	O
innocuous	O
temperature	O
;	O
and	O
(	O
iii	O
)	O
psychophysically	O
-	O
anchored	O
noxious	O
temperature	O
.	O
</ALL>	O

<ALL>	O
Numerical	O
pain	O
scores	O
(	O
NPSs	O
)	O
collected	O
during	O
the	O
application	O
of	O
tonic	O
noxious	O
stimuli	O
were	O
tested	O
for	O
correlation	O
with	O
peak	O
frequencies	O
of	O
alpha	O
power	O
-	O
curves	O
derived	O
from	O
central	O
,	O
temporal	O
and	O
frontal	O
electrodes	O
.	O
</ALL>	O

<ALL>	O
NPSs	O
and	O
PAFs	O
remained	O
stable	O
throughout	O
the	O
recording	O
conditions	O
(	O
RM	O
-	O
ANOVAs	O
;	O
Ps	O
>	O
0	O
.	O
51	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
noxious	O
condition	O
,	O
PAFs	O
obtained	O
at	O
the	O
bilateral	O
temporal	B-Multi-tissue_structure
scalp	I-Multi-tissue_structure
were	O
correlated	O
with	O
NPSs	O
(	O
Ps	O
<	O
0	O
.	O
001	O
)	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
resting	O
-	O
state	O
PAFs	O
recorded	O
at	O
the	O
bilateral	O
temporal	B-Multi-tissue_structure
scalp	I-Multi-tissue_structure
were	O
correlated	O
with	O
NPSs	O
reported	O
during	O
the	O
noxious	O
condition	O
(	O
Ps	O
<	O
0	O
.	O
01	O
)	O
.	O
</ALL>	O

<ALL>	O
These	O
psychophysical	O
-	O
neurophysiological	O
relations	O
attest	O
to	O
the	O
properties	O
of	O
PAF	O
as	O
a	O
novel	O
cortical	B-Multi-tissue_structure
objective	O
measure	O
of	O
subjective	O
perception	O
of	O
tonic	O
pain	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
resting	O
-	O
state	O
PAFs	O
might	O
hold	O
inherent	O
pain	O
modulation	O
attributes	O
,	O
possibly	O
enabling	O
the	O
prediction	O
of	O
individual	O
responsiveness	O
to	O
prolonged	O
pain	O
.	O
</ALL>	O

<ALL>	O
The	O
relevance	O
of	O
PAF	O
to	O
the	O
neural	B-Cell
processing	O
of	O
tonic	O
pain	O
may	O
indicate	O
its	O
potential	O
to	O
advance	O
pain	O
research	O
as	O
well	O
as	O
clinical	O
pain	O
characterization	O
.	O
</ALL>	O

<ALL>	O
Acoustic	O
trauma	O
evokes	O
hyperactivity	O
and	O
changes	O
in	O
gene	O
expression	O
in	O
guinea	O
-	O
pig	O
auditory	O
brainstem	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Hearing	O
loss	O
from	O
acoustic	O
trauma	O
is	O
a	O
risk	O
factor	O
for	O
tinnitus	O
.	O
</ALL>	O

<ALL>	O
Animal	O
models	O
using	O
acoustic	O
trauma	O
have	O
demonstrated	O
hyperactivity	O
in	O
central	O
auditory	O
pathways	O
,	O
which	O
has	O
been	O
suggested	O
as	O
a	O
substrate	O
for	O
tinnitus	O
.	O
</ALL>	O

<ALL>	O
We	O
used	O
a	O
guinea	O
-	O
pig	O
model	O
of	O
unilateral	O
acoustic	O
trauma	O
.	O
</ALL>	O

<ALL>	O
Within	O
the	O
same	O
animals	O
,	O
measurements	O
of	O
peripheral	O
hearing	O
loss	O
,	O
spontaneous	O
activity	O
of	O
single	O
neurons	B-Cell
in	O
the	O
inferior	B-Multi-tissue_structure
colliculus	I-Multi-tissue_structure
and	O
gene	O
expression	O
in	O
cochlear	B-Multi-tissue_structure
nucleus	I-Multi-tissue_structure
and	O
inferior	B-Multi-tissue_structure
colliculus	I-Multi-tissue_structure
were	O
combined	O
,	O
acutely	O
and	O
after	O
recovery	O
from	O
acoustic	O
trauma	O
.	O
</ALL>	O

<ALL>	O
Genes	O
investigated	O
related	O
to	O
inhibitory	O
(	O
GABA	O
-	O
A	O
receptor	O
subunit	O
alpha	O
1	O
;	O
glycine	O
receptor	O
subunit	O
alpha	O
1	O
)	O
and	O
excitatory	O
neurotransmission	O
(	O
glutamate	O
decarboxylase	O
1	O
;	O
glutamate	O
receptor	O
AMPA	O
subunit	O
alpha	O
2	O
;	O
glutamate	O
receptor	O
NMDA	O
subunit	O
1	O
)	O
,	O
regulation	O
of	O
transmitter	O
release	O
(	O
member	O
of	O
RAB	O
family	O
of	O
small	O
GTPase	O
;	O
RAB3	O
GTPase	O
activating	O
protein	O
subunit	O
1	O
)	O
and	O
neuronal	B-Cell
excitability	O
(	O
potassium	O
channel	O
subfamily	O
K	O
member	O
15	O
)	O
.	O
</ALL>	O

<ALL>	O
Acoustic	O
trauma	O
resulted	O
in	O
unilateral	O
hearing	O
loss	O
and	O
hyperactivity	O
bilaterally	O
in	O
inferior	B-Multi-tissue_structure
colliculus	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Changes	O
in	O
expression	O
of	O
different	O
mRNAs	O
were	O
observed	O
in	O
ipsilateral	O
cochlear	B-Multi-tissue_structure
nucleus	I-Multi-tissue_structure
and	O
in	O
ipsi	O
-	O
and	O
contralateral	O
inferior	B-Multi-tissue_structure
colliculus	I-Multi-tissue_structure
,	O
immediately	O
after	O
acoustic	O
trauma	O
,	O
and	O
after	O
2	O
and	O
4	O
weeks	O
'	O
recovery	O
.	O
</ALL>	O

<ALL>	O
Gene	O
expression	O
was	O
generally	O
reduced	O
immediately	O
after	O
trauma	O
,	O
followed	O
by	O
a	O
return	O
to	O
near	O
normal	O
levels	O
or	O
over	O
-	O
expression	O
as	O
recovery	O
time	O
increased	O
.	O
</ALL>	O

<ALL>	O
Different	O
mechanisms	O
appear	O
to	O
underlie	O
the	O
spontaneous	O
hyperactivity	O
observed	O
.	O
</ALL>	O

<ALL>	O
There	O
is	O
evidence	O
of	O
down	O
-	O
regulation	O
of	O
genes	O
associated	O
with	O
neuronal	B-Cell
inhibition	O
in	O
the	O
contralateral	O
inferior	B-Multi-tissue_structure
colliculus	I-Multi-tissue_structure
,	O
whereas	O
in	O
ipsilateral	O
cochlear	B-Multi-tissue_structure
nucleus	I-Multi-tissue_structure
,	O
competing	O
actions	O
of	O
inhibitory	O
and	O
excitatory	O
systems	O
seem	O
to	O
play	O
a	O
major	O
role	O
in	O
determining	O
overall	O
excitability	O
.	O
</ALL>	O

<ALL>	O
Yellow	O
-	O
green	O
52	O
.	O
3W	O
laser	O
at	O
556nm	O
based	O
on	O
frequency	O
doubling	O
of	O
a	O
diode	O
side	O
-	O
pumped	O
Q	O
-	O
switched	O
Nd	O
:	O
YAG	O
laser	O
.	O
</ALL>	O

<ALL>	O
We	O
demonstrate	O
a	O
high	O
-	O
power	O
556nm	O
yellow	O
-	O
green	O
laser	O
generated	O
by	O
intracavity	O
frequency	O
doubling	O
of	O
a	O
diode	O
side	O
-	O
pumped	O
Nd	O
:	O
YAG	O
laser	O
at	O
1112nm	O
.	O
</ALL>	O

<ALL>	O
A	O
symmetrical	O
L	O
-	O
shaped	O
flat	O
-	O
flat	O
cavity	O
was	O
employed	O
to	O
implement	O
efficient	O
operation	O
of	O
the	O
low	O
-	O
gain	O
1112nm	O
transition	O
and	O
to	O
achieve	O
good	O
power	O
scalability	O
.	O
</ALL>	O

<ALL>	O
The	O
coatings	O
of	O
the	O
cavity	O
mirrors	O
were	O
carefully	O
designed	O
to	O
optimize	O
the	O
performance	O
of	O
the	O
laser	O
,	O
and	O
a	O
92W	O
continuous	O
wave	O
laser	O
output	O
at	O
1112nm	O
was	O
achieved	O
when	O
the	O
pumping	O
power	O
of	O
the	O
laser	O
diodes	O
reached	O
960W	O
.	O
</ALL>	O

<ALL>	O
By	O
intracavity	O
frequency	O
doubling	O
of	O
the	O
fundamental	O
laser	O
in	O
a	O
lithium	O
triborate	O
crystal	O
,	O
the	O
maximum	O
power	O
of	O
the	O
frequency	O
-	O
doubled	O
output	O
at	O
556nm	O
was	O
found	O
to	O
be	O
as	O
high	O
as	O
52	O
.	O
3W	O
with	O
a	O
pulse	O
repetition	O
frequency	O
of	O
10kHz	O
.	O
</ALL>	O

<ALL>	O
This	O
corresponds	O
to	O
an	O
optical	O
-	O
to	O
-	O
optical	O
conversion	O
efficiency	O
of	O
about	O
5	O
.	O
4	O
%	O
.	O
</ALL>	O

<ALL>	O
Ventral	B-Multi-tissue_structure
and	O
dorsal	B-Multi-tissue_structure
striatal	I-Multi-tissue_structure
dopamine	O
efflux	O
and	O
behavior	O
in	O
rats	O
with	O
simple	O
vs	O
.	O
co	O
-	O
morbid	O
histories	O
of	O
cocaine	O
sensitization	O
and	O
neonatal	B-Pathological_formation
ventral	I-Pathological_formation
hippocampal	I-Pathological_formation
lesions	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
UNLABELLED	O
:	O
</ALL>	O

<ALL>	O
RATIONAL	O
:	O
Exposing	O
animal	O
models	O
of	O
mental	O
illness	O
to	O
addictive	O
drugs	O
provides	O
an	O
approach	O
to	O
understanding	O
the	O
neural	B-Multi-tissue_structure
etiology	O
of	O
dual	O
diagnosis	O
disorders	O
.	O
</ALL>	O

<ALL>	O
Previous	O
studies	O
have	O
shown	O
that	O
neonatal	B-Pathological_formation
ventral	I-Pathological_formation
hippocampal	I-Pathological_formation
lesions	I-Pathological_formation
(	O
NVHL	B-Pathological_formation
)	O
in	O
rats	O
produce	O
features	O
of	O
both	O
schizophrenia	O
and	O
addiction	O
vulnerability	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
</ALL>	O

<ALL>	O
This	O
study	O
investigated	O
ventral	B-Multi-tissue_structure
and	O
dorsal	B-Multi-tissue_structure
striatal	I-Multi-tissue_structure
dopamine	O
(	O
DA	O
)	O
efflux	O
in	O
NVHL	B-Pathological_formation
rats	O
combined	O
with	O
behavioral	O
sensitization	O
to	O
cocaine	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
Adult	O
NVHL	B-Pathological_formation
vs	O
.	O
SHAM	O
-	O
operated	O
rats	O
underwent	O
a	O
5	O
-	O
day	O
injection	O
series	O
of	O
cocaine	O
(	O
15	O
mg	O
/	O
kg	O
/	O
day	O
)	O
vs	O
.	O
saline	O
.	O
</ALL>	O

<ALL>	O
One	O
week	O
later	O
,	O
rats	O
were	O
cannulated	O
in	O
nucleus	B-Multi-tissue_structure
accumbens	I-Multi-tissue_structure
SHELL	O
,	O
CORE	O
,	O
or	O
caudate	B-Multi-tissue_structure
-	I-Multi-tissue_structure
putamen	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Another	O
week	O
later	O
,	O
in	O
vivo	O
microdialysis	O
sampled	O
DA	O
during	O
locomotor	O
testing	O
in	O
which	O
a	O
single	O
cocaine	O
injection	O
(	O
15	O
mg	O
/	O
kg	O
)	O
was	O
delivered	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
NVHLs	B-Pathological_formation
and	O
cocaine	O
history	O
significantly	O
increased	O
behavioral	O
activation	O
approximately	O
2	O
-	O
fold	O
over	O
SHAM	O
-	O
saline	O
history	O
rats	O
.	O
</ALL>	O

<ALL>	O
DA	O
efflux	O
curves	O
corresponded	O
time	O
dependently	O
with	O
the	O
cocaine	O
injection	O
and	O
locomotor	O
curves	O
and	O
varied	O
significantly	O
by	O
striatal	B-Multi-tissue_structure
region	I-Multi-tissue_structure
:	O
Baseline	O
DA	O
levels	O
increased	O
5	O
-	O
fold	O
while	O
cocaine	O
-	O
stimulated	O
DA	O
efflux	O
decreased	O
by	O
half	O
across	O
a	O
ventral	B-Multi-tissue_structure
to	O
dorsal	B-Multi-tissue_structure
striatal	I-Multi-tissue_structure
gradient	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
NVHLs	B-Pathological_formation
,	O
prior	O
cocaine	O
history	O
,	O
and	O
individual	O
differences	O
in	O
behavior	O
were	O
not	O
underpinned	O
by	O
differential	O
DA	O
efflux	O
overall	O
or	O
within	O
any	O
striatal	B-Multi-tissue_structure
region	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
</ALL>	O

<ALL>	O
Differences	O
in	O
ventral	B-Multi-tissue_structure
/	O
dorsal	B-Multi-tissue_structure
striatal	I-Multi-tissue_structure
DA	O
efflux	O
are	O
not	O
present	O
in	O
and	O
are	O
not	O
required	O
for	O
producing	O
differential	O
levels	O
of	O
acute	O
cocaine	O
-	O
induced	O
behavioral	O
activation	O
in	O
NVHLs	B-Pathological_formation
with	O
and	O
without	O
a	O
behaviorally	O
sensitizing	O
cocaine	O
history	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
suggest	O
other	O
neurotransmitter	O
systems	O
,	O
and	O
alterations	O
in	O
striatal	B-Multi-tissue_structure
network	O
function	O
post	O
-	O
synaptic	O
to	O
DA	O
transmission	O
are	O
more	O
important	O
to	O
understanding	O
the	O
interactive	O
effects	O
of	O
addictive	O
drugs	O
and	O
mental	O
illness	O
.	O
</ALL>	O

<ALL>	O
Predictive	O
value	O
of	O
serum	B-Organism_substance
carbohydrate	O
antigen	O
19	O
-	O
9	O
in	O
malignant	O
intraductal	O
papillary	B-Pathological_formation
mucinous	I-Pathological_formation
neoplasms	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
</ALL>	O

<ALL>	O
The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
predictive	O
value	O
of	O
serum	B-Organism_substance
carbohydrate	O
antigen	O
19	O
-	O
9	O
(	O
CA	O
19	O
-	O
9	O
)	O
in	O
the	O
diagnosis	O
of	O
malignant	O
intraductal	B-Pathological_formation
papillary	I-Pathological_formation
mucinous	I-Pathological_formation
neoplasms	I-Pathological_formation
of	O
pancreas	B-Organ
(	O
IPMNs	B-Pathological_formation
)	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
Eighty	O
-	O
six	O
patients	O
with	O
pathological	O
diagnosis	O
of	O
IPMNs	B-Pathological_formation
in	O
Zhongshan	O
Hospital	O
between	O
March	O
1999	O
and	O
November	O
2008	O
were	O
retrospectively	O
reviewed	O
.	O
</ALL>	O

<ALL>	O
Data	O
reflecting	O
clinical	O
characteristics	O
,	O
tumor	B-Pathological_formation
marker	O
level	O
,	O
and	O
prognosis	O
were	O
collected	O
.	O
</ALL>	O

<ALL>	O
The	O
potential	O
predictive	O
value	O
of	O
CA	O
19	O
-	O
9	O
was	O
analyzed	O
by	O
receiver	O
operating	O
characteristic	O
(	O
ROC	O
)	O
curve	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
Eighty	O
-	O
six	O
consecutive	O
patients	O
with	O
IPMNs	B-Pathological_formation
all	O
underwent	O
surgical	O
intervention	O
.	O
</ALL>	O

<ALL>	O
A	O
high	O
level	O
of	O
CA	O
19	O
-	O
9	O
or	O
carcinoembryonic	O
antigen	O
(	O
CEA	O
)	O
was	O
associated	O
with	O
more	O
advanced	O
stage	O
of	O
malignant	O
IPMNs	B-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Carbohydrate	O
antigen	O
19	O
-	O
9	O
was	O
significant	O
for	O
judging	O
malignant	O
IPMNs	B-Pathological_formation
in	O
the	O
binary	O
logistic	O
regression	O
model	O
(	O
p	O
=	O
0	O
.	O
047	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
hazard	O
ratio	O
was	O
1	O
.	O
014	O
,	O
whose	O
95	O
.	O
0	O
%	O
confidence	O
interval	O
was	O
0	O
.	O
91	O
-	O
1	O
.	O
028	O
.	O
</ALL>	O

<ALL>	O
Receiver	O
operating	O
characteristic	O
analysis	O
showed	O
that	O
the	O
serum	B-Organism_substance
CA	O
19	O
-	O
9	O
level	O
had	O
good	O
predictive	O
value	O
for	O
malignant	O
or	O
invasive	O
IPMNs	B-Pathological_formation
,	O
postoperative	O
survival	O
,	O
and	O
disease	O
-	O
specific	O
recurrence	O
.	O
</ALL>	O

<ALL>	O
The	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
was	O
0	O
.	O
856	O
,	O
0	O
.	O
893	O
,	O
0	O
.	O
815	O
,	O
and	O
0	O
.	O
857	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
According	O
to	O
the	O
follow	O
-	O
up	O
,	O
mean	O
survival	O
time	O
for	O
groups	O
with	O
CA	O
19	O
-	O
9	O
>	O
63	O
.	O
60	O
U	O
/	O
ml	O
was	O
dramatically	O
shorter	O
than	O
that	O
for	O
groups	O
with	O
CA	O
19	O
-	O
9	O
<	O
=	O
63	O
.	O
60	O
U	O
/	O
ml	O
(	O
57	O
.	O
38	O
+	O
/	O
-	O
2	O
.	O
85	O
versus	O
29	O
.	O
24	O
+	O
/	O
-	O
5	O
.	O
82	O
[	O
months	O
]	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
</ALL>	O

<ALL>	O
Serum	B-Organism_substance
CA	O
19	O
-	O
9	O
level	O
has	O
good	O
predictive	O
value	O
for	O
malignant	O
or	O
invasive	O
IPMNs	B-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Patients	O
with	O
CA	O
19	O
-	O
9	O
>	O
63	O
.	O
60	O
U	O
/	O
ml	O
had	O
poor	O
postoperative	O
prognosis	O
in	O
IPMNs	B-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Preoperative	O
abnormal	O
serum	B-Organism_substance
CA	O
19	O
-	O
9	O
might	O
be	O
predictive	O
for	O
an	O
aggressive	O
surgical	O
intervention	O
in	O
IPMNs	B-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Saliva	O
proteins	O
of	O
vector	O
Culicoides	O
modify	O
structure	O
and	O
infectivity	O
of	O
bluetongue	O
virus	O
particles	O
.	O
</ALL>	O

<ALL>	O
Bluetongue	O
virus	O
(	O
BTV	O
)	O
and	O
epizootic	O
haemorrhagic	O
disease	O
virus	O
(	O
EHDV	O
)	O
are	O
related	O
orbiviruses	O
,	O
transmitted	O
between	O
their	O
ruminant	O
hosts	O
primarily	O
by	O
certain	O
haematophagous	O
midge	O
vectors	O
(	O
Culicoides	O
spp	O
.	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
larger	O
of	O
the	O
BTV	O
outer	O
-	O
capsid	O
proteins	O
,	O
'	O
VP2	O
'	O
,	O
can	O
be	O
cleaved	O
by	O
proteases	O
(	O
including	O
trypsin	O
or	O
chymotrypsin	O
)	O
,	O
forming	O
infectious	O
subviral	O
particles	O
(	O
ISVP	O
)	O
which	O
have	O
enhanced	O
infectivity	O
for	O
adult	O
Culicoides	O
,	O
or	O
KC	B-Cell
cells	I-Cell
(	O
a	O
cell	B-Cell
-	I-Cell
line	I-Cell
derived	O
from	O
C	O
.	O
sonorensis	O
)	O
.	O
</ALL>	O

<ALL>	O
We	O
demonstrate	O
that	O
VP2	O
present	O
on	O
purified	O
virus	O
particles	O
from	O
3	O
different	O
BTV	O
strains	O
can	O
also	O
be	O
cleaved	O
by	O
treatment	O
with	O
saliva	O
from	O
adult	O
Culicoides	O
.	O
</ALL>	O

<ALL>	O
The	O
saliva	O
proteins	O
from	O
C	O
.	O
sonorensis	O
(	O
a	O
competent	O
BTV	O
vector	O
)	O
,	O
cleaved	O
BTV	O
-	O
VP2	O
more	O
efficiently	O
than	O
those	O
from	O
C	O
.	O
nubeculosus	O
(	O
a	O
less	O
competent	O
/	O
non	O
-	O
vector	O
species	O
)	O
.	O
</ALL>	O

<ALL>	O
Electrophoresis	O
and	O
mass	O
spectrometry	O
identified	O
a	O
trypsin	O
-	O
like	O
protease	O
in	O
C	O
.	O
sonorensis	O
saliva	O
,	O
which	O
was	O
significantly	O
reduced	O
or	O
absent	O
from	O
C	O
.	O
nubeculosus	O
saliva	O
.	O
</ALL>	O

<ALL>	O
Incubating	O
purified	O
BTV	O
-	O
1	O
with	O
C	O
.	O
sonorensis	O
saliva	O
proteins	O
also	O
increased	O
their	O
infectivity	O
for	O
KC	B-Cell
cells	I-Cell
~	O
10	O
fold	O
,	O
while	O
infectivity	O
for	O
BHK	B-Cell
cells	I-Cell
was	O
reduced	O
by	O
2	O
-	O
6	O
fold	O
.	O
</ALL>	O

<ALL>	O
Treatment	O
of	O
an	O
'	O
eastern	O
'	O
strain	O
of	O
EHDV	O
-	O
2	O
with	O
saliva	O
proteins	O
of	O
either	O
C	O
.	O
sonorensis	O
or	O
C	O
.	O
nubeculosus	O
cleaved	O
VP2	O
,	O
but	O
a	O
'	O
western	O
'	O
strain	O
of	O
EHDV	O
-	O
2	O
remained	O
unmodified	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
indicate	O
that	O
temperature	O
,	O
strain	O
of	O
virus	O
and	O
protein	O
composition	O
of	O
Culicoides	O
saliva	O
(	O
particularly	O
its	O
protease	O
content	O
which	O
is	O
dependent	O
upon	O
vector	O
species	O
)	O
,	O
can	O
all	O
play	O
a	O
significant	O
role	O
in	O
the	O
efficiency	O
of	O
VP2	O
cleavage	O
,	O
influencing	O
virus	O
infectivity	O
.	O
</ALL>	O

<ALL>	O
Saliva	O
of	O
several	O
other	O
arthropod	O
species	O
has	O
previously	O
been	O
shown	O
to	O
increase	O
transmission	O
,	O
infectivity	O
and	O
virulence	O
of	O
certain	O
arboviruses	O
,	O
by	O
modulating	O
and	O
/	O
or	O
suppressing	O
the	O
mammalian	O
immune	O
response	O
.	O
</ALL>	O

<ALL>	O
The	O
findings	O
presented	O
here	O
,	O
however	O
,	O
demonstrate	O
a	O
novel	O
mechanism	O
by	O
which	O
proteases	O
in	O
Culicoides	O
saliva	O
can	O
also	O
directly	O
modify	O
the	O
orbivirus	O
particle	O
structure	O
,	O
leading	O
to	O
increased	O
infectivity	O
specifically	O
for	O
Culicoides	O
cells	B-Cell
and	O
,	O
in	O
turn	O
,	O
efficiency	O
of	O
transmission	O
to	O
the	O
insect	O
vector	O
.	O
</ALL>	O

<ALL>	O
mirAct	O
:	O
a	O
web	O
tool	O
for	O
evaluating	O
microRNA	O
activity	O
based	O
on	O
gene	O
expression	O
data	O
.	O
</ALL>	O

<ALL>	O
MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
critical	O
regulators	O
in	O
the	O
complex	O
cellular	B-Cell
networks	O
.	O
</ALL>	O

<ALL>	O
The	O
mirAct	O
web	O
server	O
(	O
http	O
:	O
/	O
/	O
sysbio	O
.	O
ustc	O
.	O
edu	O
.	O
cn	O
/	O
software	O
/	O
mirAct	O
)	O
is	O
a	O
tool	O
designed	O
to	O
investigate	O
miRNA	O
activity	O
based	O
on	O
gene	O
-	O
expression	O
data	O
by	O
using	O
the	O
negative	O
regulation	O
relationship	O
between	O
miRNAs	O
and	O
their	O
target	O
genes	O
.	O
</ALL>	O

<ALL>	O
mirAct	O
supports	O
multiple	O
-	O
class	O
data	O
and	O
enables	O
clustering	O
analysis	O
based	O
on	O
computationally	O
determined	O
miRNA	O
activity	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
we	O
describe	O
the	O
framework	O
of	O
mirAct	O
,	O
demonstrate	O
its	O
performance	O
by	O
comparing	O
with	O
other	O
similar	O
programs	O
and	O
exemplify	O
its	O
applications	O
using	O
case	O
studies	O
.	O
</ALL>	O

<ALL>	O
Non	O
-	O
heart	B-Organ
-	O
beating	O
organ	B-Organ
donation	O
in	O
Italy	O
.	O
</ALL>	O

<ALL>	O
In	O
2007	O
the	O
non	O
-	O
heart	B-Organ
-	O
beating	O
organ	B-Organ
donation	O
(	O
NHBD	O
)	O
"	O
Programma	O
Alba	O
"	O
(	O
Sunrise	O
Programme	O
)	O
started	O
in	O
Pavia	O
,	O
Italy	O
.	O
</ALL>	O

<ALL>	O
The	O
initial	O
plan	O
was	O
to	O
cut	O
down	O
waiting	O
list	O
for	O
kidney	B-Organ
transplantation	O
,	O
while	O
its	O
final	O
aim	O
is	O
to	O
shorten	O
organ	B-Organ
transplantation	O
waiting	O
lists	O
.	O
</ALL>	O

<ALL>	O
When	O
compared	O
to	O
European	O
countries	O
and	O
the	O
USA	O
,	O
the	O
Italian	O
NHBD	O
program	O
has	O
taken	O
longer	O
to	O
get	O
established	O
.	O
</ALL>	O

<ALL>	O
Initially	O
Italian	O
physicians	O
were	O
not	O
entirely	O
aware	O
of	O
the	O
NHBD	O
organ	B-Organ
viability	O
for	O
transplantation	O
,	O
furthermore	O
ethical	O
issues	O
and	O
the	O
need	O
to	O
regulate	O
medical	O
requirements	O
to	O
Italian	O
law	O
slowed	O
down	O
the	O
NHBD	O
program	O
.	O
</ALL>	O

<ALL>	O
In	O
particular	O
,	O
Italian	O
legislation	O
provides	O
for	O
death	O
ascertainment	O
after	O
irreversible	O
cardiac	B-Organ
arrest	O
,	O
20	O
-	O
minute	O
flat	O
electrocardiogram	O
.	O
</ALL>	O

<ALL>	O
This	O
no	O
-	O
touch	O
period	O
is	O
longer	O
when	O
compared	O
to	O
worldwide	O
legislation	O
,	O
and	O
organ	B-Organ
viability	O
has	O
been	O
a	O
main	O
concern	O
for	O
Italian	O
transplant	O
doctors	O
over	O
the	O
years	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
recent	O
data	O
let	O
up	O
to	O
40	O
-	O
minute	O
warm	O
ischemia	O
time	O
to	O
preserve	O
organ	B-Organ
viability	O
;	O
this	O
has	O
encouraged	O
Pavia	O
'	O
s	O
group	O
to	O
establish	O
the	O
NHBD	O
"	O
Programma	O
Alba	O
"	O
.	O
</ALL>	O

<ALL>	O
It	O
was	O
designed	O
according	O
to	O
Italian	O
legislation	O
from	O
death	O
diagnosis	O
to	O
graft	B-Organ
placement	O
,	O
from	O
this	O
perspective	O
must	O
the	O
significant	O
role	O
of	O
the	O
Transplant	O
coordinator	O
be	O
recognized	O
.	O
</ALL>	O

<ALL>	O
Since	O
2007	O
seven	O
kidneys	B-Organ
have	O
been	O
gathered	O
from	O
seven	O
NHBD	O
.	O
</ALL>	O

<ALL>	O
Of	O
these	O
,	O
six	O
NHBD	O
kidneys	B-Organ
have	O
been	O
transplanted	O
.	O
</ALL>	O

<ALL>	O
Currently	O
,	O
four	O
patients	O
are	O
out	O
of	O
dialysis	O
.	O
</ALL>	O

<ALL>	O
This	O
report	O
is	O
a	O
detailed	O
description	O
of	O
NHBD	O
"	O
Programma	O
Alba	O
"	O
and	O
its	O
preliminary	O
results	O
.	O
</ALL>	O

<ALL>	O
Massive	O
osteolysis	O
in	O
a	O
dog	O
resembling	O
Gorham	O
'	O
s	O
disease	O
in	O
humans	O
.	O
</ALL>	O

<ALL>	O
An	O
eight	O
-	O
month	O
-	O
old	O
mixed	O
-	O
breed	O
dog	O
was	O
presented	O
with	O
a	O
history	O
of	O
sudden	O
onset	O
pelvic	B-Organism_subdivision
limb	I-Organism_subdivision
lameness	O
.	O
</ALL>	O

<ALL>	O
Radiographic	O
and	O
computed	O
tomographic	O
examinations	O
demonstrated	O
an	O
osteolytic	O
process	O
involving	O
the	O
lumbar	B-Organ
spine	I-Organ
and	O
pelvis	B-Organ
.	O
</ALL>	O

<ALL>	O
A	O
comprehensive	O
work	O
-	O
up	O
including	O
serial	O
radiographic	O
skeletal	B-Anatomical_system
survey	O
,	O
biopsy	O
,	O
routine	O
laboratory	O
investigation	O
and	O
evaluation	O
of	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
and	O
25	O
-	O
hydroxy	O
-	O
vitamin	O
D	O
levels	O
failed	O
to	O
reveal	O
any	O
underlying	O
cause	O
for	O
the	O
osteolysis	O
.	O
</ALL>	O

<ALL>	O
Conservative	O
treatment	O
using	O
the	O
bisphosphonate	O
drug	O
alendronate	O
and	O
oral	O
analgesic	O
medications	O
resulted	O
in	O
a	O
return	O
to	O
nearly	O
normal	O
long	O
-	O
term	O
function	O
,	O
despite	O
massive	O
lumbar	O
and	O
pelvic	O
osteolysis	O
.	O
</ALL>	O

<ALL>	O
The	O
clinical	O
,	O
radiological	O
and	O
histopathological	O
features	O
in	O
this	O
dog	O
are	O
reported	O
,	O
and	O
similarities	O
with	O
the	O
human	O
condition	O
known	O
as	O
Gorham	O
'	O
s	O
disease	O
are	O
discussed	O
.	O
</ALL>	O

<ALL>	O
[	O
Rubella	O
in	O
Poland	O
in	O
2009	O
]	O
.	O
</ALL>	O

<ALL>	O
In	O
Poland	O
,	O
7	O
,	O
587	O
cases	O
of	O
rubella	O
were	O
registered	O
in	O
2009	O
(	O
incidence	O
19	O
.	O
9	O
per	O
100	O
,	O
000	O
population	O
)	O
.	O
</ALL>	O

<ALL>	O
According	O
to	O
a	O
new	O
rubella	O
case	O
definition	O
,	O
introduced	O
in	O
2009	O
,	O
7	O
(	O
0	O
.	O
1	O
%	O
)	O
cases	O
were	O
classified	O
as	O
confirmed	O
cases	O
,	O
30	O
(	O
0	O
.	O
4	O
%	O
)	O
as	O
probable	O
.	O
</ALL>	O

<ALL>	O
One	O
case	O
of	O
congenital	O
rubella	O
syndrome	O
was	O
reported	O
.	O
</ALL>	O

<ALL>	O
The	O
incidence	O
in	O
men	O
(	O
26	O
.	O
6	O
)	O
was	O
1	O
.	O
9	O
-	O
times	O
higher	O
than	O
in	O
women	O
(	O
13	O
.	O
6	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
highest	O
incidence	O
was	O
observed	O
in	O
children	O
aged	O
7	O
and	O
8	O
years	O
(	O
180	O
.	O
3	O
and	O
175	O
.	O
6	O
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
No	O
rubella	O
deaths	O
were	O
registered	O
.	O
</ALL>	O

<ALL>	O
An	O
improvement	O
of	O
laboratory	O
diagnosis	O
of	O
reported	O
cases	O
is	O
necessary	O
to	O
assess	O
the	O
impact	O
of	O
2	O
-	O
dose	O
immunization	O
implemented	O
in	O
2003	O
on	O
rubella	O
epidemiology	O
in	O
Poland	O
.	O
</ALL>	O

<ALL>	O
Burns	O
from	O
hot	O
wheat	O
bags	O
:	O
a	O
public	O
safety	O
issue	O
.	O
</ALL>	O

<ALL>	O
Introduction	O
:	O
Wheat	O
bags	O
are	O
therapeutic	O
devices	O
that	O
are	O
heated	O
in	O
microwaves	O
and	O
commonly	O
used	O
to	O
provide	O
relief	O
from	O
muscle	B-Organ
and	O
joint	B-Multi-tissue_structure
pain	O
.	O
</ALL>	O

<ALL>	O
The	O
Royal	O
Adelaide	O
Hospital	O
Burns	O
Unit	O
has	O
observed	O
a	O
number	O
of	O
patients	O
with	O
significant	O
burn	O
injuries	O
resulting	O
from	O
their	O
use	O
.	O
</ALL>	O

<ALL>	O
Despite	O
their	O
dangers	O
,	O
the	O
products	O
come	O
with	O
limited	O
safety	O
information	O
.	O
</ALL>	O

<ALL>	O
Methods	O
:	O
Data	O
were	O
collected	O
from	O
the	O
Burns	O
Unit	O
database	O
for	O
all	O
patients	O
admitted	O
with	O
burns	O
due	O
to	O
hot	O
wheat	O
bags	O
from	O
2004	O
to	O
2009	O
.	O
</ALL>	O

<ALL>	O
This	O
was	O
analyzed	O
to	O
determine	O
the	O
severity	O
of	O
the	O
burn	O
injury	O
and	O
identify	O
any	O
predisposing	O
factors	O
.	O
</ALL>	O

<ALL>	O
An	O
experimental	O
study	O
was	O
performed	O
to	O
measure	O
the	O
temperature	O
of	O
wheat	O
bags	O
when	O
heated	O
to	O
determine	O
their	O
potential	O
for	O
causing	O
thermal	O
injury	O
.	O
</ALL>	O

<ALL>	O
Results	O
:	O
11	O
patients	O
were	O
admitted	O
with	O
burns	O
due	O
to	O
hot	O
wheat	O
bags	O
.	O
</ALL>	O

<ALL>	O
The	O
median	O
age	O
was	O
52	O
years	O
and	O
the	O
mean	O
total	O
body	B-Organism_subdivision
surface	I-Organism_subdivision
area	I-Organism_subdivision
was	O
1	O
.	O
1	O
%	O
.	O
</ALL>	O

<ALL>	O
All	O
burns	O
were	O
either	O
deep	O
dermal	B-Multi-tissue_structure
(	O
45	O
.	O
5	O
%	O
)	O
or	O
full	O
thickness	O
(	O
54	O
.	O
5	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Ten	O
patients	O
required	O
operative	O
management	O
.	O
</ALL>	O

<ALL>	O
Predisposing	O
factors	O
(	O
eg	O
,	O
neuropathy	O
)	O
to	O
thermal	O
injury	O
were	O
identified	O
in	O
7	O
patients	O
.	O
</ALL>	O

<ALL>	O
The	O
experimental	O
study	O
showed	O
that	O
hot	O
wheat	O
bags	O
reached	O
temperatures	O
of	O
57	O
.	O
3degreesC	O
(	O
135	O
.	O
1degreesF	O
)	O
when	O
heated	O
according	O
to	O
instructions	O
,	O
63	O
.	O
3degreesC	O
(	O
145	O
.	O
9degreesF	O
)	O
in	O
a	O
1000	O
W	O
microwave	O
and	O
69	O
.	O
6degreesC	O
(	O
157	O
.	O
3degreesF	O
)	O
on	O
reheating	O
.	O
</ALL>	O

<ALL>	O
Conclusions	O
:	O
Hot	O
wheat	O
bags	O
cause	O
serious	O
burn	O
injury	O
.	O
</ALL>	O

<ALL>	O
When	O
heated	O
improperly	O
,	O
they	O
can	O
reach	O
temperatures	O
high	O
enough	O
to	O
cause	O
epidermal	B-Multi-tissue_structure
necrosis	O
in	O
a	O
short	O
period	O
of	O
time	O
.	O
</ALL>	O

<ALL>	O
Patients	O
with	O
impaired	O
temperature	O
sensation	O
are	O
particularly	O
at	O
risk	O
.	O
</ALL>	O

<ALL>	O
There	O
should	O
be	O
greater	O
public	O
awareness	O
of	O
the	O
dangers	O
of	O
wheat	O
bag	O
use	O
and	O
more	O
specific	O
safety	O
warnings	O
on	O
the	O
products	O
.	O
</ALL>	O

<ALL>	O
The	O
enlarging	O
clinical	O
spectrum	O
of	O
Lyme	O
disease	O
:	O
Lyme	O
cerebral	B-Organ
vasculitis	O
,	O
a	O
new	O
disease	O
entity	O
.	O
</ALL>	O

<ALL>	O
The	O
case	O
of	O
a	O
patient	O
with	O
cerebral	B-Organ
vasculitis	O
with	O
a	O
right	B-Multi-tissue_structure
thalamic	I-Multi-tissue_structure
infarct	O
associated	O
with	O
cerebral	B-Organism_substance
spinal	I-Organism_substance
fluid	I-Organism_substance
Lyme	O
disease	O
is	O
presented	O
.	O
</ALL>	O

<ALL>	O
This	O
entity	O
has	O
not	O
been	O
described	O
in	O
the	O
United	O
States	O
,	O
and	O
only	O
one	O
similar	O
case	O
in	O
the	O
world	O
literature	O
could	O
be	O
found	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	O
presented	O
with	O
a	O
progressive	O
headache	O
and	O
subsequent	O
development	O
of	O
grand	O
mal	O
seizure	O
activity	O
.	O
</ALL>	O

<ALL>	O
Lyme	O
disease	O
has	O
been	O
associated	O
with	O
cranial	B-Multi-tissue_structure
nerve	I-Multi-tissue_structure
palsies	O
,	O
peripheral	O
and	O
cranial	B-Organism_subdivision
radiculopathies	O
,	O
aseptic	O
meningitis	O
,	O
encephalitic	O
symptoms	O
,	O
chorea	O
,	O
and	O
demyelinating	O
polyneuropathy	O
presenting	O
like	O
Guillain	O
-	O
Barre	O
syndrome	O
.	O
</ALL>	O

<ALL>	O
These	O
syndromes	O
can	O
occur	O
separately	O
or	O
in	O
combination	O
.	O
</ALL>	O

<ALL>	O
Stroke	O
and	O
strokelike	O
syndromes	O
have	O
been	O
attributed	O
to	O
Lyme	O
disease	O
.	O
</ALL>	O

<ALL>	O
The	O
literature	O
concerning	O
the	O
neurologic	B-Anatomical_system
manifestations	O
of	O
Lyme	O
disease	O
is	O
reviewed	O
.	O
</ALL>	O

<ALL>	O
Gastric	B-Organ
microcirculatory	O
change	O
and	O
development	O
of	O
acute	O
gastric	B-Pathological_formation
mucosal	I-Pathological_formation
lesions	I-Pathological_formation
(	O
stress	B-Pathological_formation
ulcer	I-Pathological_formation
)	O
.	O
</ALL>	O

<ALL>	O
Concerning	O
the	O
pathogenesis	O
of	O
acute	O
gastric	B-Pathological_formation
mucosal	I-Pathological_formation
lesions	I-Pathological_formation
,	O
gastric	B-Organ
microcirculatory	O
change	O
has	O
drawn	O
attention	O
as	O
an	O
important	O
factor	O
.	O
</ALL>	O

<ALL>	O
In	O
view	O
of	O
this	O
fact	O
,	O
gastric	B-Multi-tissue_structure
mucosal	I-Multi-tissue_structure
blood	B-Organism_substance
flow	O
and	O
microvascular	B-Tissue
structure	O
were	O
investigated	O
in	O
normal	O
and	O
in	O
burn	O
stressed	O
rats	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
alterations	O
in	O
acid	O
and	O
pepsin	O
activities	O
in	O
by	O
morphological	O
and	O
biochemical	O
procedures	O
in	O
order	O
to	O
evaluate	O
the	O
relationship	O
between	O
defensive	O
and	O
aggressive	O
factors	O
of	O
the	O
gastric	B-Multi-tissue_structure
mucosa	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Gastric	B-Multi-tissue_structure
mucosal	I-Multi-tissue_structure
blood	B-Organism_substance
flow	O
decreased	O
significantly	O
in	O
early	O
period	O
after	O
induction	O
of	O
stress	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
incidence	O
of	O
ulceration	O
showed	O
a	O
correlative	O
relation	O
with	O
the	O
decrease	O
of	O
mucosal	B-Multi-tissue_structure
blood	B-Organism_substance
flow	O
.	O
</ALL>	O

<ALL>	O
Reduction	O
of	O
blood	B-Organism_substance
flow	O
in	O
burn	O
was	O
due	O
to	O
opening	O
of	O
arteriovenular	B-Multi-tissue_structure
shunt	O
and	O
it	O
appeared	O
that	O
this	O
was	O
responsible	O
for	O
mucosal	B-Multi-tissue_structure
ischemia	O
and	O
congestion	O
.	O
</ALL>	O

<ALL>	O
Following	O
the	O
decrease	O
of	O
blood	B-Organism_substance
flow	O
,	O
acid	O
output	O
was	O
lower	O
in	O
stress	O
than	O
that	O
in	O
control	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
the	O
results	O
of	O
these	O
studies	O
demonstrated	O
the	O
importance	O
of	O
defensive	O
factors	O
.	O
</ALL>	O

<ALL>	O
The	O
reduction	O
of	O
mucosal	B-Multi-tissue_structure
blood	B-Organism_substance
flow	O
resulted	O
in	O
the	O
sequence	O
of	O
events	O
that	O
led	O
to	O
formation	O
of	O
acute	O
gastric	B-Pathological_formation
mucosal	I-Pathological_formation
lesion	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Type	O
-	O
A	O
cholecystokinin	O
receptors	O
in	O
CHP212	B-Cell
neuroblastoma	I-Cell
cells	I-Cell
:	O
evidence	O
for	O
association	O
with	O
G	O
protein	O
and	O
activation	O
of	O
phosphoinositide	O
hydrolysis	O
.	O
</ALL>	O

<ALL>	O
125I	O
-	O
Bolton	O
Hunter	O
-	O
cholecystokinin	O
octapeptide	O
(	O
BH	O
-	O
CCK8	O
)	O
and	O
(	O
-	O
)	O
-	O
[	O
3H	O
]	O
L	O
-	O
364718	O
membrane	B-Cellular_component
binding	O
assays	O
were	O
used	O
to	O
identify	O
and	O
characterize	O
cholecystokinin	O
(	O
CCK	O
)	O
receptors	O
in	O
CHP212	B-Cell
human	O
neuroblastoma	B-Cell
cells	I-Cell
.	O
</ALL>	O

<ALL>	O
The	O
ligand	O
binding	O
properties	O
of	O
CCK	O
receptors	O
in	O
these	O
cells	B-Cell
are	O
similar	O
to	O
those	O
found	O
in	O
pancreas	B-Organ
(	O
CCK	O
-	O
A	O
sites	O
)	O
and	O
differ	O
from	O
the	O
predominant	O
type	O
of	O
CCK	O
binding	O
site	O
found	O
in	O
brain	B-Organ
(	O
CCK	O
-	O
B	O
sites	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
specific	O
binding	O
of	O
125I	O
-	O
BH	O
-	O
CCK8	O
but	O
not	O
(	O
-	O
)	O
-	O
[	O
3H	O
]	O
L	O
-	O
364718	O
was	O
reduced	O
by	O
the	O
metabolically	O
stable	O
GTP	O
analog	O
guanosine	O
5	O
'	O
-	O
(	O
beta	O
-	O
delta	O
-	O
imido	O
)	O
trisphosphate	O
.	O
</ALL>	O

<ALL>	O
A	O
substantial	O
difference	O
in	O
the	O
Bmax	O
for	O
the	O
radiolabeled	O
agonist	O
(	O
125I	O
-	O
BH	O
-	O
CCK8	O
)	O
and	O
antagonist	O
[	O
(	O
-	O
)	O
-	O
[	O
3H	O
]	O
L	O
-	O
364718	O
]	O
was	O
noted	O
.	O
</ALL>	O

<ALL>	O
These	O
observations	O
are	O
consistent	O
with	O
CCK	O
receptors	O
existing	O
in	O
guanine	O
nucleotide	O
-	O
binding	O
protein	O
-	O
coupled	O
and	O
-	O
uncoupled	O
states	O
.	O
</ALL>	O

<ALL>	O
Similar	O
to	O
its	O
action	O
in	O
pancreatic	B-Cell
acinar	I-Cell
cells	I-Cell
,	O
CCK8	O
(	O
S	O
)	O
stimulated	O
the	O
accumulation	O
of	O
[	O
3H	O
]	O
inositol	O
phosphates	O
in	O
cells	B-Cell
prelabeled	O
with	O
[	O
3H	O
]	O
myo	O
-	O
inositol	O
(	O
EC50	O
=	O
3	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
4	O
nM	O
;	O
maximum	O
response	O
=	O
4	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
4	O
x	O
basal	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
intrinsic	O
activity	O
of	O
CCK	O
analogues	O
in	O
stimulating	O
phosphoinositide	O
hydrolysis	O
was	O
substantially	O
less	O
than	O
their	O
reported	O
intrinsic	O
activity	O
in	O
stimulating	O
phosphoinositide	O
hydrolysis	O
in	O
pancreatic	B-Cell
acinar	I-Cell
cells	I-Cell
.	O
</ALL>	O

<ALL>	O
The	O
CHP212	B-Cell
neuroblastoma	I-Cell
cell	I-Cell
may	O
serve	O
as	O
a	O
useful	O
model	O
for	O
the	O
recently	O
reported	O
CCK	O
-	O
A	O
binding	O
site	O
found	O
in	O
the	O
central	B-Anatomical_system
nervous	I-Anatomical_system
system	I-Anatomical_system
.	O
</ALL>	O

<ALL>	O
Screening	O
method	O
for	O
insecticidal	O
activity	O
using	O
first	O
instars	O
of	O
black	O
blow	O
fly	O
(	O
Diptera	O
:	O
Calliphoridae	O
)	O
.	O
</ALL>	O

<ALL>	O
A	O
bioassay	O
method	O
suitable	O
for	O
rapid	O
mass	O
screening	O
of	O
fermentation	O
and	O
synthetic	O
organic	O
compounds	O
for	O
insecticidal	O
activity	O
is	O
described	O
.	O
</ALL>	O

<ALL>	O
The	O
test	O
,	O
which	O
uses	O
first	O
instars	O
of	O
susceptible	O
black	O
blow	O
fly	O
,	O
Phormia	O
regina	O
(	O
Meigen	O
)	O
,	O
in	O
a	O
bovine	O
serum	B-Organism_substance
medium	O
,	O
detects	O
insecticidal	O
activity	O
with	O
reproducible	O
results	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
capable	O
of	O
selecting	O
the	O
most	O
active	O
compound	O
in	O
structure	O
-	O
activity	O
relationships	O
by	O
minimum	O
effective	O
dose	O
concentration	O
studies	O
.	O
</ALL>	O

<ALL>	O
The	O
bioassay	O
system	O
is	O
easy	O
to	O
operate	O
and	O
requires	O
only	O
a	O
minute	O
quantity	O
of	O
chemical	O
compound	O
.	O
</ALL>	O

<ALL>	O
Early	O
post	O
-	O
mortem	O
metabolism	O
and	O
muscle	B-Organ
shortening	O
in	O
the	O
Pectoralis	O
major	O
muscle	B-Organ
of	O
broiler	O
chickens	O
.	O
</ALL>	O

<ALL>	O
Three	O
experiments	O
were	O
conducted	O
to	O
examine	O
the	O
effects	O
of	O
sodium	O
pentobarbital	O
(	O
SP	O
)	O
,	O
iodoacetate	O
(	O
IO	O
)	O
,	O
tubocurarine	O
(	O
TC	O
)	O
,	O
and	O
surgical	O
denervation	O
(	O
DN	O
)	O
on	O
early	O
rigor	O
development	O
in	O
broiler	O
breast	B-Organ
muscle	I-Organ
.	O
</ALL>	O

<ALL>	O
In	O
Experiment	O
1	O
,	O
birds	O
were	O
either	O
anesthetized	O
or	O
not	O
with	O
SP	O
before	O
receiving	O
an	O
injection	O
of	O
IO	O
or	O
TC	O
or	O
maintained	O
as	O
noninjected	O
controls	O
.	O
</ALL>	O

<ALL>	O
Experiment	O
2	O
was	O
identical	O
except	O
that	O
a	O
treatment	O
of	O
denervation	O
of	O
the	O
breast	B-Organ
muscle	I-Organ
was	O
added	O
.	O
</ALL>	O

<ALL>	O
Experiment	O
3	O
was	O
conducted	O
to	O
contrast	O
birds	O
at	O
1	O
day	O
(	O
DN1	O
)	O
and	O
3	O
days	O
(	O
DN3	O
)	O
denervation	O
prior	O
to	O
slaughter	O
to	O
nonoperated	O
controls	O
.	O
</ALL>	O

<ALL>	O
Measurements	O
of	O
muscle	B-Organ
lactate	O
,	O
ATP	O
,	O
R	O
value	O
(	O
ratio	O
of	O
inosine	O
to	O
adenine	O
nucleotides	O
)	O
,	O
pH	O
,	O
sarcomere	B-Tissue
lengths	O
,	O
and	O
shear	O
were	O
used	O
to	O
evaluate	O
treatment	O
effects	O
.	O
</ALL>	O

<ALL>	O
Results	O
for	O
Experiment	O
1	O
showed	O
no	O
significant	O
differences	O
among	O
treatment	O
and	O
control	O
groups	O
for	O
ATP	O
and	O
lactate	O
contents	O
,	O
R	O
values	O
,	O
or	O
sarcomere	B-Tissue
lengths	O
;	O
however	O
,	O
significantly	O
lower	O
pH	O
and	O
higher	O
shear	O
values	O
were	O
observed	O
for	O
control	O
birds	O
.	O
</ALL>	O

<ALL>	O
In	O
Experiment	O
2	O
,	O
no	O
significant	O
differences	O
were	O
observed	O
among	O
the	O
treatment	O
groups	O
for	O
ATP	O
,	O
R	O
values	O
,	O
or	O
sarcomere	B-Tissue
lengths	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
lactate	O
and	O
shear	O
values	O
were	O
significantly	O
lower	O
,	O
and	O
pH	O
higher	O
,	O
for	O
the	O
DN	O
and	O
SP	O
treated	O
birds	O
.	O
</ALL>	O

<ALL>	O
Experiment	O
3	O
resulted	O
in	O
lower	O
lactate	O
and	O
higher	O
pH	O
values	O
for	O
the	O
DN3	O
treatment	O
in	O
comparison	O
with	O
both	O
DN1	O
and	O
control	O
groups	O
.	O
</ALL>	O

<ALL>	O
Results	O
of	O
these	O
studies	O
indicate	O
that	O
the	O
use	O
of	O
SP	O
and	O
DN	O
can	O
be	O
used	O
to	O
alter	O
the	O
early	O
profiles	O
of	O
rigor	O
development	O
.	O
</ALL>	O

<ALL>	O
Anaplastic	B-Pathological_formation
and	I-Pathological_formation
sarcomatoid	I-Pathological_formation
carcinoma	I-Pathological_formation
of	O
the	O
small	B-Organ
intestine	I-Organ
:	O
a	O
clinicopathologic	O
study	O
.	O
</ALL>	O

<ALL>	O
Carcinomas	B-Pathological_formation
involving	O
the	O
jejunum	B-Multi-tissue_structure
and	O
ileum	B-Multi-tissue_structure
are	O
rare	O
tumors	B-Pathological_formation
.	O
</ALL>	O

<ALL>	O
During	O
a	O
review	O
of	O
small	B-Pathological_formation
intestinal	I-Pathological_formation
neoplasms	I-Pathological_formation
,	O
six	O
primary	O
carcinomas	B-Pathological_formation
of	O
jejunum	B-Multi-tissue_structure
or	O
ileum	B-Multi-tissue_structure
with	O
an	O
anaplastic	O
and	O
sarcomatoid	B-Pathological_formation
histology	O
were	O
identified	O
.	O
</ALL>	O

<ALL>	O
At	O
presentation	O
,	O
three	O
of	O
the	O
patients	O
had	O
symptoms	O
related	O
to	O
metastatic	O
disease	O
and	O
three	O
had	O
symptoms	O
referable	O
to	O
the	O
local	O
tumor	B-Pathological_formation
.	O
</ALL>	O

<ALL>	O
The	O
tumors	B-Pathological_formation
were	O
large	O
(	O
greater	O
than	O
4	O
.	O
5	O
cm	O
in	O
diameter	O
)	O
,	O
usually	O
endophytic	O
masses	O
composed	O
of	O
large	O
cells	B-Cell
with	O
eosinophilic	B-Organism_substance
cytoplasm	I-Organism_substance
,	O
anaplastic	O
nuclei	B-Cellular_component
,	O
and	O
prominent	O
nucleoli	B-Cellular_component
.	O
</ALL>	O

<ALL>	O
In	O
many	O
areas	O
,	O
the	O
cells	B-Cell
had	O
a	O
spindled	O
configuration	O
.	O
</ALL>	O

<ALL>	O
Mucin	O
positivity	O
was	O
identified	O
in	O
all	O
six	O
cases	O
.	O
</ALL>	O

<ALL>	O
Electron	O
microscopic	O
findings	O
in	O
two	O
cases	O
were	O
indicative	O
of	O
epithelial	B-Tissue
differentiation	O
.	O
</ALL>	O

<ALL>	O
The	O
tumors	B-Pathological_formation
behaved	O
aggressively	O
;	O
all	O
five	O
patients	O
for	O
whom	O
there	O
was	O
clinical	O
follow	O
-	O
up	O
died	O
of	O
metastases	B-Pathological_formation
within	O
40	O
months	O
.	O
</ALL>	O

<ALL>	O
The	O
six	O
anaplastic	B-Pathological_formation
and	I-Pathological_formation
sarcomatoid	I-Pathological_formation
carcinomas	I-Pathological_formation
were	O
compared	O
with	O
29	O
typical	O
adenocarcinomas	B-Pathological_formation
arising	O
in	O
the	O
jejunum	B-Multi-tissue_structure
or	O
ileum	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Only	O
two	O
of	O
the	O
latter	O
group	O
had	O
symptoms	O
referable	O
to	O
distant	O
metastases	B-Pathological_formation
at	O
presentation	O
.	O
</ALL>	O

<ALL>	O
These	O
tumors	B-Pathological_formation
also	O
tended	O
to	O
be	O
smaller	O
at	O
presentation	O
(	O
11	O
tumors	B-Pathological_formation
were	O
less	O
than	O
4	O
cm	O
in	O
greatest	O
dimension	O
)	O
.	O
</ALL>	O

<ALL>	O
Of	O
25	O
patients	O
with	O
typical	O
adenocarcinomas	B-Pathological_formation
who	O
had	O
acceptable	O
follow	O
-	O
up	O
,	O
18	O
(	O
72	O
%	O
)	O
died	O
of	O
disease	O
and	O
five	O
(	O
20	O
%	O
)	O
were	O
alive	O
with	O
no	O
evidence	O
of	O
disease	O
after	O
5	O
years	O
.	O
</ALL>	O

<ALL>	O
We	O
conclude	O
that	O
anaplastic	B-Pathological_formation
and	I-Pathological_formation
sarcomatoid	I-Pathological_formation
carcinoma	I-Pathological_formation
is	O
a	O
rare	O
variant	O
of	O
small	B-Pathological_formation
intestinal	I-Pathological_formation
carcinoma	I-Pathological_formation
with	O
an	O
aggressive	O
clinical	O
course	O
.	O
</ALL>	O

<ALL>	O
Time	O
course	O
of	O
transmitter	O
action	O
at	O
the	O
sympathetic	B-Tissue
neuroeffector	I-Tissue
junction	I-Tissue
in	O
rodent	O
vascular	B-Organ
and	O
non	B-Organ
-	I-Organ
vascular	I-Organ
smooth	I-Organ
muscle	I-Organ
.	O
</ALL>	O

<ALL>	O
1	O
.	O
</ALL>	O

<ALL>	O
Transmitter	O
release	O
from	O
sympathetic	B-Multi-tissue_structure
postganglionic	I-Multi-tissue_structure
nerve	I-Multi-tissue_structure
terminals	O
innervating	O
the	O
guinea	O
-	O
pig	O
and	O
mouse	O
vas	B-Multi-tissue_structure
deferens	I-Multi-tissue_structure
and	O
the	O
rat	O
tail	B-Multi-tissue_structure
artery	I-Multi-tissue_structure
has	O
been	O
studied	O
in	O
vitro	O
by	O
focal	O
extracellular	B-Immaterial_anatomical_entity
recording	O
with	O
particular	O
emphasis	O
on	O
the	O
time	O
course	O
of	O
transmitter	O
action	O
underlying	O
the	O
intracellular	B-Immaterial_anatomical_entity
potential	O
changes	O
.	O
</ALL>	O

<ALL>	O
2	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
absence	O
of	O
stimulation	O
,	O
spontaneous	O
excitatory	B-Tissue
junction	I-Tissue
currents	O
(	O
SEJCs	O
)	O
were	O
recorded	O
with	O
amplitudes	O
up	O
to	O
500	O
microV	O
and	O
durations	O
between	O
40	O
and	O
100	O
ms	O
.	O
</ALL>	O

<ALL>	O
SEJCs	O
were	O
unaffected	O
by	O
the	O
competitive	O
alpha	O
-	O
adrenoceptor	O
antagonist	O
prazosin	O
but	O
blocked	O
by	O
alpha	O
,	O
beta	O
-	O
methylene	O
ATP	O
which	O
desensitizes	O
P2	O
-	O
purinoceptors	O
.	O
</ALL>	O

<ALL>	O
3	O
.	O
</ALL>	O

<ALL>	O
During	O
trains	O
of	O
supramaximal	O
stimuli	O
at	O
0	O
.	O
1	O
-	O
4	O
Hz	O
stimulus	O
locked	O
excitatory	B-Tissue
junction	I-Tissue
currents	O
(	O
EJCs	O
)	O
were	O
evoked	O
intermittently	O
from	O
the	O
population	O
of	O
varicosities	O
located	O
under	O
the	O
suction	O
electrode	O
.	O
</ALL>	O

<ALL>	O
4	O
.	O
</ALL>	O

<ALL>	O
SEJCs	O
were	O
similar	O
in	O
amplitude	O
and	O
time	O
course	O
to	O
EJCs	O
evoked	O
by	O
low	O
-	O
frequency	O
stimulation	O
in	O
the	O
same	O
attachment	O
in	O
all	O
three	O
tissues	B-Tissue
.	O
</ALL>	O

<ALL>	O
5	O
.	O
</ALL>	O

<ALL>	O
SEJCs	O
recorded	O
using	O
either	O
a	O
conventional	O
AC	O
amplifier	O
or	O
a	O
patch	O
clamp	O
amplifier	O
had	O
the	O
same	O
time	O
course	O
.	O
</ALL>	O

<ALL>	O
6	O
.	O
</ALL>	O

<ALL>	O
These	O
studies	O
show	O
that	O
the	O
time	O
course	O
of	O
the	O
current	O
underlying	O
the	O
excitatory	B-Tissue
junction	I-Tissue
potential	O
is	O
brief	O
and	O
essentially	O
the	O
same	O
in	O
three	O
different	O
tissues	B-Tissue
.	O
</ALL>	O

<ALL>	O
The	O
prolonged	O
time	O
course	O
of	O
the	O
excitatory	B-Tissue
junction	I-Tissue
potential	O
in	O
different	O
tissues	B-Tissue
can	O
be	O
accounted	O
for	O
by	O
the	O
passive	O
membrane	B-Multi-tissue_structure
properties	O
.	O
</ALL>	O

<ALL>	O
Differential	O
secretion	O
of	O
proteins	O
and	O
glycoproteins	O
by	O
livers	B-Organ
of	O
immature	O
and	O
adult	O
rats	O
.	O
</ALL>	O

<ALL>	O
Effect	O
of	O
antimicrotubule	B-Cellular_component
drugs	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
was	O
initiated	O
to	O
re	O
-	O
examine	O
reported	O
differences	O
in	O
the	O
action	O
of	O
antimicrotubule	B-Cellular_component
agents	O
on	O
plasma	B-Organism_substance
protein	O
secretion	O
from	O
livers	B-Organ
of	O
immature	O
versus	O
adult	O
rats	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
was	O
(	O
1	O
)	O
to	O
determine	O
the	O
composition	O
and	O
to	O
monitor	O
the	O
secretion	O
of	O
various	O
plasma	B-Organism_substance
proteins	O
and	O
glycoproteins	O
from	O
liver	B-Multi-tissue_structure
slices	I-Multi-tissue_structure
labeled	O
in	O
vitro	O
with	O
specific	O
amino	O
acids	O
and	O
sugar	O
residues	O
,	O
and	O
(	O
2	O
)	O
to	O
correlate	O
observed	O
differences	O
in	O
secretion	O
of	O
these	O
proteins	O
with	O
structural	O
changes	O
in	O
the	O
hepatocytes	B-Cell
of	O
the	O
different	O
aged	O
animals	O
.	O
</ALL>	O

<ALL>	O
For	O
the	O
most	O
part	O
,	O
slices	B-Multi-tissue_structure
of	O
liver	B-Organ
from	O
fetal	B-Developing_anatomical_structure
(	O
term	O
)	O
,	O
neonatal	O
(	O
4	O
-	O
to	O
5	O
days	O
old	O
)	O
,	O
and	O
adult	O
rats	O
(	O
70	O
days	O
old	O
)	O
were	O
incubated	O
with	O
radioactive	O
amino	O
acids	O
or	O
various	O
tritiated	O
sugars	O
specific	O
for	O
N	O
-	O
linked	O
core	O
oligosaccharide	O
and	O
/	O
or	O
N	O
-	O
linked	O
terminal	O
oligosaccharide	O
chains	O
.	O
</ALL>	O

<ALL>	O
Our	O
findings	O
indicate	O
that	O
liver	B-Multi-tissue_structure
slices	I-Multi-tissue_structure
of	O
fetal	B-Developing_anatomical_structure
and	O
neonatal	O
rats	O
are	O
efficient	O
in	O
synthesizing	O
plasma	B-Organism_substance
proteins	O
including	O
fully	O
glycosylated	O
glycoproteins	O
.	O
</ALL>	O

<ALL>	O
The	O
secretion	O
of	O
glycosylated	O
and	O
nonglycosylated	O
proteins	O
believed	O
to	O
be	O
processed	O
through	O
Golgi	B-Cellular_component
complexes	I-Cellular_component
was	O
inhibited	O
to	O
the	O
same	O
extent	O
(	O
approximately	O
70	O
-	O
80	O
%	O
)	O
by	O
antimicrotubule	B-Cellular_component
agents	O
,	O
regardless	O
of	O
the	O
age	O
of	O
the	O
host	O
animal	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
other	O
proteins	O
and	O
glycoproteins	O
secreted	O
by	O
livers	B-Organ
of	O
immature	O
rats	O
were	O
found	O
to	O
be	O
relatively	O
insensitive	O
(	O
i	O
.	O
e	O
.	O
inhibited	O
to	O
only	O
30	O
-	O
40	O
%	O
)	O
to	O
the	O
action	O
of	O
various	O
antimicrotubule	B-Cellular_component
drugs	O
.	O
</ALL>	O

<ALL>	O
The	O
glycoproteins	O
were	O
found	O
to	O
lack	O
N	O
-	O
linked	O
terminal	O
sugars	O
(	O
although	O
the	O
glycoproteins	O
did	O
contain	O
N	O
-	O
linked	O
core	O
sugars	O
)	O
,	O
and	O
it	O
is	O
likely	O
that	O
the	O
drug	O
-	O
insensitive	O
proteins	O
bypassed	O
critical	O
glycosylating	O
sites	O
in	O
the	O
Golgi	B-Cellular_component
compartment	I-Cellular_component
prior	O
to	O
release	O
.	O
</ALL>	O

<ALL>	O
Overall	O
,	O
these	O
findings	O
support	O
earlier	O
data	O
showing	O
that	O
antimicrotubule	B-Cellular_component
drugs	O
have	O
a	O
special	O
impact	O
on	O
Golgi	B-Cellular_component
-	O
associated	O
events	O
in	O
liver	B-Cell
cells	I-Cell
.	O
</ALL>	O

<ALL>	O
To	O
what	O
extent	O
these	O
findings	O
are	O
related	O
to	O
the	O
action	O
of	O
microtubules	B-Cellular_component
remains	O
to	O
be	O
seen	O
.	O
</ALL>	O

<ALL>	O
Torsade	O
de	O
pointes	O
during	O
loading	O
with	O
amiodarone	O
.	O
</ALL>	O

<ALL>	O
Torsade	O
de	O
pointes	O
represents	O
a	O
potential	O
complication	O
of	O
chronic	O
amiodarone	O
therapy	O
.	O
</ALL>	O

<ALL>	O
Several	O
reports	O
have	O
emphasized	O
the	O
need	O
for	O
a	O
loading	O
dose	O
in	O
order	O
to	O
achieve	O
therapeutic	O
blood	B-Organism_substance
levels	O
rapidly	O
.	O
</ALL>	O

<ALL>	O
We	O
report	O
a	O
case	O
of	O
torsade	O
de	O
pointes	O
following	O
a	O
single	O
oral	O
dose	O
of	O
amiodarone	O
(	O
1400	O
mg	O
or	O
30	O
mg	O
kg	O
-	O
1	O
)	O
administered	O
after	O
short	O
intravenous	B-Multi-tissue_structure
loading	O
for	O
prevention	O
of	O
paroxysmal	O
atrial	B-Multi-tissue_structure
flutter	O
.	O
</ALL>	O

<ALL>	O
Torsades	O
de	O
pointes	O
were	O
preceded	O
and	O
associated	O
with	O
marked	O
QT	O
prolongation	O
and	O
bradycardia	O
.	O
</ALL>	O

<ALL>	O
This	O
report	O
suggests	O
that	O
careful	O
monitoring	O
of	O
patients	O
undergoing	O
oral	O
amiodarone	O
loading	O
is	O
necessary	O
.	O
</ALL>	O

<ALL>	O
Unsatisfactory	O
forehead	B-Pathological_formation
scar	I-Pathological_formation
following	O
face	B-Organism_subdivision
lift	O
.	O
</ALL>	O

<ALL>	O
The	O
W	O
-	O
plasty	O
scar	B-Pathological_formation
revision	O
technique	O
has	O
been	O
found	O
to	O
be	O
effective	O
in	O
the	O
repair	O
of	O
the	O
difficult	O
and	O
cosmetically	O
unsatisfactory	O
hairline	B-Pathological_formation
scar	I-Pathological_formation
following	O
the	O
ill	O
-	O
advised	O
face	B-Organism_subdivision
lift	O
technique	O
that	O
excises	O
forehead	B-Multi-tissue_structure
skin	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Clinical	O
evaluation	O
of	O
radiotherapy	O
for	O
Graves	O
'	O
ophthalmopathy	O
.	O
</ALL>	O

<ALL>	O
Seventeen	O
patients	O
with	O
moderately	O
severe	O
ophthalmopathy	O
due	O
to	O
Graves	O
'	O
disease	O
were	O
treated	O
by	O
cobalt	O
or	O
supervoltage	O
radiotherapy	O
.	O
</ALL>	O

<ALL>	O
All	O
patients	O
complained	O
of	O
diplopia	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
proptosis	O
value	O
was	O
21	O
.	O
4	O
mm	O
.	O
</ALL>	O

<ALL>	O
Three	O
patients	O
(	O
18	O
%	O
)	O
showed	O
good	O
response	O
,	O
7	O
(	O
41	O
%	O
)	O
moderate	O
and	O
7	O
minimal	O
or	O
no	O
response	O
.	O
</ALL>	O

<ALL>	O
Improvement	O
was	O
noted	O
mainly	O
in	O
soft	B-Tissue
tissue	I-Tissue
changes	O
and	O
diplopia	O
,	O
while	O
proptosis	O
decreased	O
in	O
only	O
5	O
patients	O
.	O
</ALL>	O

<ALL>	O
All	O
except	O
one	O
patient	O
who	O
had	O
marked	O
extraocular	B-Multi-tissue_structure
muscle	I-Multi-tissue_structure
involvement	O
revealed	O
by	O
computed	O
tomography	O
responded	O
to	O
treatment	O
.	O
</ALL>	O

<ALL>	O
These	O
data	O
indicate	O
that	O
radiotherapy	O
may	O
be	O
indicated	O
in	O
patients	O
with	O
progressive	O
ophthalmopathy	O
,	O
especially	O
in	O
those	O
who	O
are	O
associated	O
with	O
extraocular	B-Multi-tissue_structure
muscle	I-Multi-tissue_structure
enlargement	O
.	O
</ALL>	O

<ALL>	O
Management	O
of	O
the	O
tortuous	B-Multi-tissue_structure
internal	I-Multi-tissue_structure
carotid	I-Multi-tissue_structure
artery	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
The	O
tortuous	B-Multi-tissue_structure
internal	I-Multi-tissue_structure
carotid	I-Multi-tissue_structure
artery	I-Multi-tissue_structure
as	O
the	O
basis	O
of	O
cerebral	B-Multi-tissue_structure
vascular	I-Multi-tissue_structure
insufficiency	O
is	O
a	O
controversial	O
entity	O
,	O
as	O
such	O
lesions	B-Pathological_formation
frequently	O
occur	O
without	O
neurologic	B-Anatomical_system
symptoms	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
some	O
tortuous	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
are	O
associated	O
with	O
significant	O
carotid	B-Multi-tissue_structure
atherosclerotic	O
disease	O
requiring	O
a	O
specific	O
surgical	O
approach	O
.	O
</ALL>	O

<ALL>	O
This	O
formed	O
the	O
basis	O
of	O
our	O
report	O
.	O
</ALL>	O

<ALL>	O
Symptoms	O
of	O
cerebrovascular	B-Multi-tissue_structure
insufficiency	O
in	O
association	O
with	O
a	O
tortuous	B-Multi-tissue_structure
internal	I-Multi-tissue_structure
carotid	I-Multi-tissue_structure
artery	I-Multi-tissue_structure
was	O
encountered	O
in	O
27	O
of	O
853	O
carotid	B-Multi-tissue_structure
endarterectomies	O
over	O
a	O
22	O
year	O
period	O
.	O
</ALL>	O

<ALL>	O
Stenosis	O
of	O
hemodynamic	O
significance	O
was	O
noted	O
in	O
nine	O
patients	O
and	O
irregularities	O
or	O
ulceration	O
were	O
noted	O
in	O
the	O
rest	O
.	O
</ALL>	O

<ALL>	O
With	O
the	O
standard	O
technique	O
of	O
carotid	B-Multi-tissue_structure
endarterectomy	O
,	O
removal	O
of	O
plaque	B-Cell
from	O
a	O
tortuous	B-Multi-tissue_structure
vessel	I-Multi-tissue_structure
leads	O
to	O
loss	O
of	O
the	O
stenting	O
effect	O
provided	O
by	O
the	O
plaque	B-Cell
such	O
that	O
angulation	O
occlusion	O
is	O
likely	O
to	O
occur	O
.	O
</ALL>	O

<ALL>	O
The	O
optimal	O
reconstruction	O
in	O
our	O
experience	O
is	O
eversion	O
endarterectomy	O
by	O
transection	O
and	O
lower	O
reimplantation	O
of	O
the	O
internal	B-Multi-tissue_structure
carotid	I-Multi-tissue_structure
artery	I-Multi-tissue_structure
on	O
the	O
common	B-Multi-tissue_structure
carotid	I-Multi-tissue_structure
artery	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Our	O
experience	O
with	O
17	O
such	O
procedures	O
in	O
15	O
patients	O
has	O
been	O
presented	O
.	O
</ALL>	O

<ALL>	O
Rapid	O
enzyme	O
analysis	O
of	O
amniotic	B-Organism_substance
fluid	I-Organism_substance
phospholipids	O
containing	O
choline	O
:	O
a	O
comparison	O
with	O
the	O
lecithin	O
to	O
sphingomyelin	O
ratio	O
in	O
prenatal	O
assessment	O
of	O
fetal	B-Organ
lung	I-Organ
maturity	O
.	O
</ALL>	O

<ALL>	O
The	O
relation	O
between	O
the	O
choline	O
containing	O
surfactant	O
phospholipids	O
lecithin	O
and	O
sphingomyelin	O
in	O
amniotic	B-Organism_substance
fluid	I-Organism_substance
and	O
fetal	B-Organ
lung	I-Organ
maturity	O
is	O
well	O
established	O
.	O
</ALL>	O

<ALL>	O
An	O
enzymatic	O
method	O
that	O
had	O
been	O
automated	O
and	O
optimised	O
for	O
use	O
on	O
a	O
centrifugal	O
analyser	O
was	O
used	O
to	O
measure	O
the	O
total	O
choline	O
containing	O
phospholipids	O
in	O
amniotic	B-Organism_substance
fluid	I-Organism_substance
.	O
</ALL>	O

<ALL>	O
The	O
total	O
time	O
taken	O
for	O
this	O
assay	O
was	O
10	O
minutes	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
obtained	O
from	O
100	O
patient	O
samples	O
,	O
using	O
this	O
procedure	O
,	O
compared	O
favourably	O
with	O
the	O
results	O
obtained	O
by	O
the	O
thin	O
layer	O
chromatography	O
procedure	O
used	O
to	O
determine	O
the	O
lecithin	O
to	O
sphingomyelin	O
ratio	O
(	O
r	O
=	O
0	O
.	O
93	O
)	O
.	O
</ALL>	O

<ALL>	O
A	O
clinical	O
study	O
of	O
60	O
patients	O
showed	O
that	O
this	O
assay	O
predicted	O
prenatal	O
respiratory	B-Anatomical_system
distress	O
syndrome	O
as	O
well	O
as	O
the	O
lecithin	O
to	O
sphingomyelin	O
ratios	O
.	O
</ALL>	O

<ALL>	O
The	O
advantage	O
of	O
this	O
assay	O
over	O
existing	O
procedures	O
is	O
that	O
it	O
requires	O
minimum	O
preparation	O
of	O
the	O
specimen	B-Organism_substance
and	O
no	O
extraction	O
,	O
is	O
quick	O
,	O
and	O
shows	O
a	O
high	O
degree	O
of	O
precision	O
.	O
</ALL>	O

<ALL>	O
Differences	O
between	O
the	O
arterial	B-Multi-tissue_structure
and	O
the	O
venous	B-Multi-tissue_structure
pathomorphology	O
in	O
Buerger	O
'	O
s	O
disease	O
.	O
</ALL>	O

<ALL>	O
Morphological	O
lesions	B-Pathological_formation
were	O
found	O
to	O
be	O
different	O
in	O
arteries	B-Multi-tissue_structure
and	O
in	O
veins	B-Multi-tissue_structure
,	O
in	O
9	O
cases	O
of	O
Buerger	O
'	O
s	O
disease	O
.	O
</ALL>	O

<ALL>	O
The	O
arterial	B-Pathological_formation
lesions	I-Pathological_formation
were	O
not	O
characteristic	O
and	O
consisted	O
of	O
non	O
-	O
specific	O
inflammation	O
,	O
thrombosis	O
and	O
obliteration	O
which	O
also	O
occur	O
in	O
many	O
other	O
disease	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
in	O
addition	O
to	O
wall	B-Multi-tissue_structure
infiltration	O
and	O
thrombosis	O
,	O
the	O
veins	B-Multi-tissue_structure
showed	O
microabscesses	B-Pathological_formation
and	O
giant	B-Pathological_formation
cell	I-Pathological_formation
granulomas	I-Pathological_formation
,	O
which	O
we	O
believe	O
to	O
be	O
absent	O
in	O
all	O
other	O
known	O
diseases	O
.	O
</ALL>	O

<ALL>	O
The	O
affected	O
venous	B-Multi-tissue_structure
segment	O
exhibited	O
a	O
variety	O
of	O
lesions	B-Pathological_formation
.	O
</ALL>	O

<ALL>	O
In	O
the	O
earliest	O
period	O
,	O
the	O
morphological	O
aspect	O
of	O
inflammation	O
in	O
arteries	B-Multi-tissue_structure
and	O
veins	B-Multi-tissue_structure
was	O
fairly	O
similar	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
late	O
periods	O
,	O
that	O
is	O
those	O
of	O
vascular	B-Multi-tissue_structure
obliteration	O
,	O
the	O
arteries	B-Multi-tissue_structure
and	O
veins	B-Multi-tissue_structure
did	O
not	O
show	O
any	O
distinguishing	O
morphological	O
differences	O
.	O
</ALL>	O

<ALL>	O
Phosphorylation	O
-	O
induced	O
mobility	O
shift	O
in	O
phospholamban	O
in	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gels	O
.	O
</ALL>	O

<ALL>	O
Evidence	O
for	O
a	O
protein	O
structure	O
consisting	O
of	O
multiple	O
identical	O
phosphorylatable	O
subunits	O
.	O
</ALL>	O

<ALL>	O
Phosphorylation	O
of	O
purified	O
phospholamban	O
isolated	O
from	O
canine	O
cardiac	B-Cellular_component
sarcoplasmic	I-Cellular_component
reticulum	I-Cellular_component
vesicles	I-Cellular_component
decreased	O
the	O
electrophoretic	O
mobility	O
of	O
the	O
protein	O
in	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)	O
-	O
polyacrylamide	O
gels	O
.	O
</ALL>	O

<ALL>	O
Different	O
mobility	O
forms	O
of	O
phospholamban	O
in	O
SDS	O
gels	O
were	O
visualized	O
both	O
by	O
direct	O
protein	O
staining	O
and	O
by	O
autoradiography	O
.	O
</ALL>	O

<ALL>	O
Unphosphorylated	O
phospholamban	O
migrated	O
with	O
an	O
apparent	O
Mr	O
=	O
25	O
,	O
000	O
in	O
SDS	O
gels	O
;	O
maximal	O
phosphorylation	O
of	O
phospholamban	O
by	O
cAMP	O
-	O
or	O
Ca2	O
+	O
-	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
increased	O
the	O
apparent	O
Mr	O
to	O
27	O
,	O
000	O
.	O
</ALL>	O

<ALL>	O
Partial	O
phosphorylation	O
of	O
phospholamban	O
by	O
either	O
protein	O
kinase	O
gave	O
intermediate	O
mobility	O
forms	O
of	O
molecular	O
weights	O
between	O
25	O
,	O
000	O
and	O
27	O
,	O
000	O
,	O
suggesting	O
that	O
more	O
than	O
one	O
phosphorylation	O
site	O
was	O
present	O
on	O
the	O
holoprotein	O
for	O
each	O
activity	O
.	O
</ALL>	O

<ALL>	O
Boiling	O
of	O
phospholamban	O
in	O
SDS	O
dissociated	O
the	O
holoprotein	O
into	O
an	O
apparently	O
homogeneous	O
class	O
of	O
low	O
molecular	O
weight	O
"	O
monomers	O
.	O
"	O
Only	O
two	O
mobility	O
forms	O
of	O
monomeric	O
phospholamban	O
were	O
observed	O
in	O
SDS	O
gels	O
after	O
phosphorylation	O
by	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
,	O
corresponding	O
to	O
9	O
-	O
kDa	O
dephospho	O
-	O
and	O
11	O
-	O
kDa	O
phosphoproteins	O
.	O
</ALL>	O

<ALL>	O
All	O
of	O
the	O
9	O
-	O
kDa	O
protein	O
could	O
be	O
phosphorylated	O
and	O
converted	O
into	O
the	O
11	O
-	O
kDa	O
mobility	O
form	O
,	O
suggesting	O
the	O
presence	O
of	O
only	O
one	O
site	O
of	O
phosphorylation	O
on	O
a	O
single	O
type	O
of	O
monomer	O
for	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
.	O
</ALL>	O

<ALL>	O
Simultaneous	O
phosphorylation	O
of	O
monomeric	O
phospholamban	O
by	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
and	O
Ca2	O
+	O
-	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
gave	O
an	O
additional	O
mobility	O
form	O
of	O
the	O
protein	O
,	O
suggesting	O
that	O
different	O
sites	O
of	O
phosphorylation	O
were	O
present	O
for	O
each	O
activity	O
on	O
each	O
monomer	O
.	O
</ALL>	O

<ALL>	O
Incomplete	O
dissociation	O
of	O
the	O
holoprotein	O
by	O
boiling	O
it	O
in	O
a	O
relatively	O
low	O
concentration	O
of	O
SDS	O
facilitated	O
the	O
detection	O
of	O
five	O
major	O
mobility	O
forms	O
of	O
the	O
protein	O
in	O
SDS	O
gels	O
,	O
and	O
the	O
mobilities	O
of	O
all	O
of	O
these	O
forms	O
were	O
decreased	O
by	O
phosphorylation	O
.	O
</ALL>	O

<ALL>	O
We	O
propose	O
that	O
the	O
high	O
molecular	O
weight	O
form	O
of	O
phospholamban	O
is	O
a	O
multimer	O
of	O
electrophoretically	O
indistinguishable	O
monomers	O
,	O
each	O
of	O
which	O
contains	O
a	O
different	O
phosphorylation	O
site	O
for	O
cAMP	O
-	O
dependent	O
protein	O
kinase	O
activity	O
and	O
Ca2	O
+	O
-	O
calmodulin	O
-	O
dependent	O
protein	O
kinase	O
activity	O
.	O
</ALL>	O

<ALL>	O
Phosphorylation	O
of	O
phospholamban	O
at	O
multiple	O
sites	O
is	O
responsible	O
for	O
the	O
various	O
mobility	O
forms	O
of	O
the	O
holoprotein	O
detected	O
in	O
SDS	O
-	O
polyacrylamide	O
gels	O
.	O
</ALL>	O

<ALL>	O
Preliminary	O
evidence	O
for	O
a	O
pyridine	O
nucleotide	O
cycle	O
in	O
Bordetella	O
pertussis	O
.	O
</ALL>	O

<ALL>	O
Preliminary	O
evidence	O
that	O
Bordetella	O
pertussis	O
has	O
a	O
functional	O
pyridine	O
nucleotide	O
cycle	O
was	O
the	O
observation	O
that	O
[	O
14C	O
]	O
-	O
nicotinic	O
acid	O
was	O
rapidly	O
metabolized	O
during	O
its	O
uptake	O
by	O
the	O
bacteria	O
to	O
pyridine	O
nucleotides	O
and	O
nicotinamide	O
.	O
</ALL>	O

<ALL>	O
Nicotinamide	O
deamidase	O
activity	O
,	O
necessary	O
for	O
the	O
completion	O
of	O
the	O
cycle	O
by	O
conversion	O
of	O
nicotinamide	O
to	O
nicotinic	O
acid	O
,	O
was	O
found	O
in	O
a	O
soluble	O
extract	O
(	O
20	O
000	O
X	O
g	O
supernatant	O
)	O
of	O
B	O
.	O
pertussis	O
cell	B-Organism_substance
lysates	I-Organism_substance
.	O
</ALL>	O

<ALL>	O
Use	O
of	O
monoclonal	O
antibodies	O
to	O
investigate	O
a	O
possible	O
role	O
of	O
thyroglobulin	O
in	O
the	O
pathogenesis	O
of	O
Graves	O
'	O
ophthalmopathy	O
.	O
</ALL>	O

<ALL>	O
One	O
possible	O
mechanism	O
for	O
Graves	O
'	O
ophthalmopathy	O
is	O
that	O
the	O
progressive	O
orbital	B-Immaterial_anatomical_entity
inflammation	O
is	O
initiated	O
by	O
formation	O
of	O
thyroglobulin	O
(	O
Tg	O
)	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
at	O
sites	O
of	O
Tg	O
binding	O
to	O
extraocular	B-Tissue
muscle	I-Tissue
membranes	I-Tissue
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
monoclonal	O
antibodies	O
(	O
MCAB	O
)	O
against	O
human	O
Tg	O
were	O
used	O
as	O
probes	O
(	O
1	O
)	O
to	O
identify	O
Tg	O
in	O
eye	B-Tissue
muscle	I-Tissue
membranes	I-Tissue
prepared	O
from	O
normal	O
subjects	O
and	O
(	O
2	O
)	O
to	O
measure	O
binding	O
of	O
human	O
Tg	O
and	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
to	O
eye	B-Tissue
muscle	I-Tissue
membranes	I-Tissue
.	O
</ALL>	O

<ALL>	O
Reactivity	O
of	O
anti	O
-	O
Tg	O
MCAB	O
with	O
Tg	O
,	O
thyroid	B-Tissue
,	O
and	O
eye	B-Tissue
muscle	I-Tissue
membranes	I-Tissue
was	O
determined	O
by	O
binding	O
of	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
monoclonal	O
antibody	O
,	O
an	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
,	O
and	O
the	O
indirect	O
immunofluorescence	O
technique	O
.	O
</ALL>	O

<ALL>	O
Seven	O
membrane	B-Tissue
fractions	I-Tissue
,	O
prepared	O
by	O
differential	O
sucrose	O
gradient	O
centrifugation	O
,	O
were	O
used	O
.	O
</ALL>	O

<ALL>	O
Whereas	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
MCAB	O
bound	O
to	O
all	O
thyroid	B-Tissue
membrane	I-Tissue
fractions	I-Tissue
tested	O
,	O
no	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
bound	O
to	O
eye	B-Tissue
muscle	I-Tissue
membranes	I-Tissue
.	O
</ALL>	O

<ALL>	O
Similarly	O
,	O
reactivity	O
of	O
anti	O
-	O
Tg	O
MCAB	O
with	O
eye	B-Tissue
muscle	I-Tissue
membranes	I-Tissue
was	O
not	O
demonstrated	O
in	O
ELISA	O
or	O
immunofluorescence	O
tests	O
.	O
</ALL>	O

<ALL>	O
Although	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
bound	O
to	O
thyroid	B-Tissue
membranes	I-Tissue
,	O
such	O
complexes	O
did	O
not	O
bind	O
to	O
eye	B-Tissue
muscle	I-Tissue
membranes	I-Tissue
.	O
</ALL>	O

<ALL>	O
Significant	O
binding	O
of	O
[	O
125I	O
]	O
human	O
Tg	O
to	O
eye	B-Tissue
muscle	I-Tissue
or	O
thyroid	B-Tissue
membranes	I-Tissue
was	O
not	O
demonstrated	O
for	O
any	O
membrane	B-Tissue
preparation	I-Tissue
.	O
</ALL>	O

<ALL>	O
On	O
the	O
other	O
hand	O
moderate	O
,	O
but	O
significant	O
,	O
binding	O
to	O
skeletal	B-Organ
muscle	I-Organ
was	O
shown	O
.	O
</ALL>	O

<ALL>	O
Similar	O
results	O
were	O
found	O
using	O
an	O
ELISA	O
.	O
</ALL>	O

<ALL>	O
Binding	O
of	O
[	O
125I	O
]	O
anti	O
-	O
Tg	O
-	O
Tg	O
complexes	O
of	O
[	O
125I	O
]	O
Tg	O
to	O
thyroid	B-Tissue
and	O
eye	B-Tissue
muscle	I-Tissue
membranes	I-Tissue
was	O
not	O
affected	O
by	O
the	O
presence	O
of	O
normal	O
human	O
serum	B-Organism_substance
,	O
phosphate	O
ions	O
,	O
pH	O
,	O
or	O
incubation	O
temperature	O
,	O
conditions	O
claimed	O
by	O
others	O
to	O
be	O
critical	O
for	O
Tg	O
and	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complex	O
binding	O
.	O
</ALL>	O

<ALL>	O
Since	O
Tg	O
is	O
not	O
present	O
in	O
normal	O
human	O
eye	B-Tissue
muscle	I-Tissue
a	O
major	O
role	O
of	O
Tg	O
,	O
or	O
Tg	O
-	O
anti	O
-	O
Tg	O
immune	O
complexes	O
,	O
in	O
the	O
pathogenesis	O
of	O
Graves	O
'	O
ophthalmopathy	O
appears	O
to	O
have	O
been	O
excluded	O
by	O
these	O
findings	O
.	O
</ALL>	O

<ALL>	O
Purification	O
and	O
characterization	O
of	O
various	O
esterases	O
from	O
rat	O
liver	B-Organ
.	O
</ALL>	O

<ALL>	O
The	O
major	O
rat	O
liver	B-Cellular_component
microsomal	I-Cellular_component
esterases	O
acting	O
on	O
o	O
-	O
nitrophenylacetate	O
with	O
isoelectric	O
points	O
5	O
.	O
0	O
,	O
5	O
.	O
5	O
,	O
6	O
.	O
1	O
and	O
6	O
.	O
4	O
were	O
resolved	O
by	O
isoelectric	O
focusing	O
.	O
</ALL>	O

<ALL>	O
Molecular	O
weights	O
were	O
determined	O
by	O
sedimentation	O
analysis	O
in	O
isokinetic	O
gradients	O
of	O
sucrose	O
and	O
,	O
after	O
purification	O
,	O
in	O
sodium	O
dodecyl	O
sulphate	O
/	O
polyacrylamide	O
gel	O
electrophoresis	O
.	O
</ALL>	O

<ALL>	O
Their	O
subunit	O
molecular	O
weights	O
were	O
between	O
57	O
000	O
and	O
60	O
000	O
.	O
</ALL>	O

<ALL>	O
They	O
behaved	O
as	O
monomers	O
except	O
the	O
pI	O
-	O
6	O
.	O
1	O
enzyme	O
which	O
behaved	O
as	O
a	O
trimer	O
.	O
</ALL>	O

<ALL>	O
Esterases	O
of	O
pI	O
5	O
.	O
0	O
,	O
pI	O
6	O
.	O
1	O
and	O
pI	O
6	O
.	O
4	O
behaved	O
like	O
glycoproteins	O
of	O
the	O
polymannose	O
type	O
in	O
the	O
presence	O
of	O
125I	O
-	O
labelled	O
concanavalin	O
A	O
.	O
</ALL>	O

<ALL>	O
Preparations	O
of	O
the	O
pI	O
-	O
5	O
.	O
0	O
enzyme	O
contained	O
two	O
esterases	O
of	O
highly	O
homologous	O
structure	O
.	O
</ALL>	O

<ALL>	O
Antibodies	O
directed	O
against	O
this	O
preparation	O
did	O
not	O
inhibit	O
but	O
precipitated	O
pI	O
-	O
5	O
.	O
0	O
esterase	O
activity	O
quantitatively	O
.	O
</ALL>	O

<ALL>	O
They	O
did	O
not	O
react	O
with	O
the	O
pI	O
-	O
6	O
.	O
1	O
and	O
pI	O
-	O
6	O
.	O
4	O
esterases	O
but	O
precipitated	O
several	O
nonimmunologically	O
related	O
esterases	O
.	O
</ALL>	O

<ALL>	O
Two	O
of	O
these	O
enzymes	O
were	O
inducible	O
by	O
phenobarbital	O
.	O
</ALL>	O

<ALL>	O
Total	O
activity	O
was	O
very	O
low	O
in	O
3	O
-	O
day	O
-	O
old	O
animals	O
.	O
</ALL>	O

<ALL>	O
Individual	O
esterase	O
activities	O
rose	O
at	O
different	O
rates	O
during	O
development	O
;	O
the	O
enzyme	O
focusing	O
near	O
pI	O
5	O
.	O
0	O
was	O
about	O
three	O
times	O
more	O
active	O
in	O
adult	O
females	O
than	O
in	O
males	O
.	O
</ALL>	O

<ALL>	O
All	O
microsomal	O
esterases	O
are	O
located	O
on	O
the	O
luminal	O
side	O
of	O
the	O
endoplasmic	B-Cellular_component
reticulum	I-Cellular_component
.	O
</ALL>	O

<ALL>	O
Hippocampal	B-Multi-tissue_structure
afterdischarge	O
interferes	O
with	O
storage	O
of	O
spatial	O
information	O
in	O
a	O
working	O
memory	O
test	O
.	O
</ALL>	O

<ALL>	O
In	O
an	O
attempt	O
to	O
impair	O
spatial	O
working	O
memory	O
by	O
reversible	O
functional	O
blockade	O
rather	O
than	O
by	O
irreversible	O
lesion	B-Pathological_formation
of	O
the	O
hippocampus	B-Multi-tissue_structure
,	O
eight	O
male	O
hooded	O
rats	O
were	O
trained	O
to	O
asymptotic	O
performance	O
of	O
1	O
.	O
2	O
to	O
1	O
.	O
4	O
errors	O
per	O
trial	O
in	O
the	O
spatial	O
12	O
-	O
choice	O
apparatus	O
(	O
Bure	O
s	O
et	O
al	O
.	O
1982	O
)	O
,	O
formally	O
similar	O
to	O
the	O
radial	O
maze	O
.	O
</ALL>	O

<ALL>	O
The	O
rats	O
were	O
implanted	O
with	O
hippocampal	B-Multi-tissue_structure
stimulating	O
and	O
recording	O
electrodes	O
,	O
which	O
were	O
used	O
for	O
eliciting	O
and	O
monitoring	O
hippocampal	B-Multi-tissue_structure
afterdischarge	O
(	O
HAD	O
)	O
lasting	O
for	O
at	O
least	O
20	O
s	O
.	O
</ALL>	O

<ALL>	O
In	O
Experiment	O
1	O
,	O
HAD	O
elicited	O
1	O
or	O
10	O
min	O
before	O
testing	O
increased	O
the	O
incidence	O
of	O
errors	O
to	O
2	O
.	O
75	O
or	O
2	O
.	O
50	O
per	O
trial	O
,	O
respectively	O
,	O
but	O
the	O
performance	O
still	O
remained	O
above	O
chance	O
level	O
(	O
4	O
.	O
18	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
Experiment	O
2	O
,	O
interruption	O
of	O
the	O
trial	O
by	O
1	O
,	O
10	O
,	O
20	O
and	O
30	O
min	O
intervals	O
inserted	O
between	O
choices	O
6	O
and	O
7	O
increased	O
the	O
incidence	O
of	O
errors	O
in	O
choices	O
7	O
to	O
12	O
to	O
1	O
.	O
0	O
,	O
1	O
.	O
5	O
,	O
2	O
.	O
1	O
and	O
2	O
.	O
5	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
HAD	O
elicited	O
immediately	O
after	O
choice	O
6	O
increased	O
error	O
incidence	O
in	O
the	O
subsequent	O
6	O
choices	O
performed	O
after	O
1	O
-	O
min	O
or	O
10	O
-	O
min	O
intervals	O
to	O
3	O
.	O
1	O
or	O
2	O
.	O
75	O
,	O
respectively	O
,	O
i	O
.	O
e	O
.	O
to	O
the	O
chance	O
level	O
of	O
3	O
errors	O
in	O
6	O
choices	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
concluded	O
that	O
HAD	O
elicits	O
transient	O
shortening	O
of	O
the	O
memory	O
span	O
for	O
newly	O
acquired	O
spatial	O
information	O
(	O
anterograde	O
effect	O
)	O
and	O
erases	O
the	O
current	O
spatial	O
working	O
memory	O
record	O
(	O
retrograde	O
effect	O
)	O
.	O
</ALL>	O

<ALL>	O
[	O
In	O
vitro	O
studies	O
of	O
the	O
thyroid	B-Organ
gland	I-Organ
regulation	O
principles	O
and	O
their	O
evaluation	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
free	O
fractions	O
of	O
the	O
thyroid	O
hormone	O
further	O
the	O
metabolism	O
of	O
the	O
body	B-Cell
cells	I-Cell
and	O
regulate	O
the	O
synthesis	O
of	O
the	O
thyroid	O
hormone	O
.	O
</ALL>	O

<ALL>	O
Once	O
the	O
level	O
of	O
FT3	O
and	O
FT4	O
decreases	O
.	O
</ALL>	O

<ALL>	O
With	O
the	O
help	O
of	O
a	O
liberation	O
of	O
the	O
hormone	O
stimulating	O
the	O
thyroid	B-Organ
gland	I-Organ
from	O
the	O
anterior	B-Multi-tissue_structure
lobe	I-Multi-tissue_structure
of	O
the	O
pituitary	B-Organ
gland	I-Organ
the	O
lack	O
of	O
thyroid	O
hormone	O
is	O
corrected	O
.	O
</ALL>	O

<ALL>	O
The	O
synthesis	O
and	O
secretion	O
of	O
the	O
thyroid	B-Organ
gland	I-Organ
stimulating	O
hormone	O
is	O
induced	O
by	O
the	O
thyreotropin	O
releasing	O
hormone	O
which	O
is	O
given	O
by	O
the	O
hypothalamus	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
the	O
organism	O
is	O
able	O
as	O
needed	O
to	O
carry	O
out	O
the	O
monodiodation	O
of	O
LT4	O
to	O
biologically	O
active	O
LT3	O
or	O
biologically	O
inactive	O
so	O
-	O
called	O
revers	O
T3	O
(	O
RT3	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
estimation	O
of	O
thyroid	B-Organ
gland	I-Organ
stimulating	O
hormone	O
before	O
and	O
30	O
minutes	O
after	O
intravenous	B-Multi-tissue_structure
application	O
of	O
thyreotropin	O
releasing	O
hormone	O
has	O
its	O
main	O
importance	O
for	O
the	O
early	O
recognition	O
of	O
a	O
disturbance	O
of	O
the	O
regulating	O
circle	O
hypophysis	O
-	O
thyroid	B-Organ
gland	I-Organ
,	O
above	O
all	O
in	O
the	O
diagnosis	O
of	O
clinically	O
not	O
yet	O
manifest	O
clinical	O
pictures	O
,	O
such	O
as	O
the	O
latent	O
hypothyreosis	O
and	O
the	O
latent	O
hyperthyreosis	O
,	O
respectively	O
(	O
Basedow	O
hyperthyreosis	O
and	O
thyroidal	O
autonomy	O
)	O
.	O
</ALL>	O

<ALL>	O
According	O
to	O
the	O
questioning	O
the	O
estimations	O
of	O
the	O
levels	O
of	O
the	O
thyroid	O
hormones	O
and	O
of	O
the	O
thyroid	B-Organ
gland	I-Organ
stimulating	O
hormone	O
should	O
be	O
used	O
stepwise	O
.	O
</ALL>	O

<ALL>	O
Relationship	O
of	O
self	O
-	O
concept	O
during	O
late	O
pregnancy	O
to	O
neonatal	O
perception	O
and	O
parenting	O
profile	O
.	O
</ALL>	O

<ALL>	O
Thirty	O
-	O
one	O
gravidas	O
were	O
studied	O
to	O
examine	O
the	O
relationship	O
between	O
a	O
woman	O
'	O
s	O
feelings	O
about	O
herself	O
during	O
late	O
pregnancy	O
,	O
her	O
perception	O
of	O
her	O
newborn	O
,	O
and	O
her	O
profile	O
of	O
parenting	O
.	O
</ALL>	O

<ALL>	O
The	O
Tennessee	O
Self	O
-	O
Concept	O
Scale	O
was	O
completed	O
during	O
the	O
third	O
trimester	O
of	O
pregnancy	O
,	O
the	O
Neonatal	O
Perception	O
Inventory	O
I	O
at	O
one	O
-	O
to	O
-	O
two	O
days	O
postpartum	O
,	O
and	O
the	O
Neonatal	O
Perception	O
Inventory	O
II	O
and	O
the	O
Michigan	O
Screening	O
Profile	O
of	O
Parenting	O
at	O
four	O
-	O
to	O
-	O
six	O
weeks	O
postpartum	O
.	O
</ALL>	O

<ALL>	O
When	O
considered	O
separately	O
,	O
no	O
positive	O
significant	O
relationships	O
were	O
found	O
between	O
scores	O
on	O
these	O
variables	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
all	O
subjects	O
with	O
negative	O
scores	O
on	O
both	O
self	O
-	O
concept	O
and	O
neonatal	O
perception	O
had	O
negative	O
scores	O
on	O
at	O
least	O
two	O
subscales	O
of	O
the	O
parenting	O
profile	O
.	O
</ALL>	O

<ALL>	O
Verrucous	B-Pathological_formation
carcinoma	I-Pathological_formation
of	O
the	O
endometrium	B-Multi-tissue_structure
-	O
-	O
a	O
unique	O
neoplasm	B-Pathological_formation
with	O
long	O
survival	O
.	O
</ALL>	O

<ALL>	O
A	O
case	O
of	O
verrucous	B-Pathological_formation
carcinoma	I-Pathological_formation
of	O
the	O
endometrium	B-Multi-tissue_structure
with	O
long	O
survival	O
is	O
described	O
.	O
</ALL>	O

<ALL>	O
It	O
represents	O
the	O
first	O
of	O
its	O
type	O
to	O
be	O
recorded	O
in	O
this	O
site	O
.	O
</ALL>	O

<ALL>	O
The	O
literature	O
on	O
verrucous	B-Pathological_formation
carcinoma	I-Pathological_formation
and	O
on	O
other	O
cases	O
of	O
squamous	B-Pathological_formation
carcinoma	I-Pathological_formation
of	O
the	O
endometrium	B-Multi-tissue_structure
is	O
briefly	O
reviewed	O
.	O
</ALL>	O

<ALL>	O
[	O
Organization	O
of	O
pectoral	B-Cell
muscle	I-Cell
motor	I-Cell
neurons	I-Cell
in	O
the	O
rat	O
.	O
Contribution	O
to	O
the	O
study	O
of	O
the	O
axillary	B-Multi-tissue_structure
arch	I-Multi-tissue_structure
(	O
Achselbogen	O
)	O
]	O
.	O
</ALL>	O

<ALL>	O
In	O
spite	O
of	O
their	O
role	O
of	O
the	O
forelimb	B-Organism_subdivision
activity	O
,	O
the	O
organization	O
of	O
the	O
mammalian	O
pectoral	B-Organ
muscles	I-Organ
remains	O
unclear	O
.	O
</ALL>	O

<ALL>	O
In	O
order	O
to	O
get	O
more	O
information	O
,	O
we	O
have	O
studied	O
,	O
qualitatively	O
and	O
quantitatively	O
,	O
the	O
motor	O
pools	O
of	O
the	O
various	O
pectoral	B-Organ
muscles	I-Organ
in	O
the	O
rat	O
(	O
musculus	B-Organ
pectoralis	I-Organ
major	I-Organ
,	O
musculus	B-Organ
pectoralis	I-Organ
minor	I-Organ
and	O
musculus	B-Organ
panniculus	I-Organ
carnosus	I-Organ
)	O
.	O
</ALL>	O

<ALL>	O
The	O
method	O
applied	O
was	O
the	O
retrograde	O
transport	O
of	O
horseradish	O
peroxidase	O
by	O
the	O
peripheral	B-Multi-tissue_structure
nerves	I-Multi-tissue_structure
supplying	O
the	O
various	O
muscles	B-Organ
.	O
</ALL>	O

<ALL>	O
The	O
results	O
provided	O
the	O
precise	O
localization	O
within	O
the	O
ventral	B-Cellular_component
horn	I-Cellular_component
of	O
the	O
motor	B-Cell
neurons	I-Cell
from	O
the	O
pectoral	B-Organ
muscles	I-Organ
which	O
were	O
all	O
in	O
the	O
most	O
ventral	B-Multi-tissue_structure
part	I-Multi-tissue_structure
of	O
the	O
gray	B-Multi-tissue_structure
matter	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Three	O
distinct	O
motor	O
pools	O
were	O
observed	O
,	O
which	O
confirms	O
the	O
functional	O
identity	O
of	O
each	O
muscle	B-Organ
.	O
</ALL>	O

<ALL>	O
The	O
motor	B-Cell
neurons	I-Cell
of	O
m	O
.	O
panniculus	O
carnosus	O
exhibited	O
some	O
particularities	O
.	O
</ALL>	O

<ALL>	O
They	O
were	O
4	O
times	O
more	O
numerous	O
than	O
those	O
from	O
m	O
.	O
pectoralis	O
major	O
,	O
they	O
occupied	O
the	O
whole	O
ventral	B-Cellular_component
edge	I-Cellular_component
of	O
the	O
ventral	B-Cellular_component
horn	I-Cellular_component
,	O
from	O
its	O
medial	O
part	O
to	O
its	O
lateral	O
tip	O
.	O
</ALL>	O

<ALL>	O
The	O
cell	B-Cell
size	O
was	O
different	O
from	O
that	O
of	O
the	O
other	O
muscles	B-Organ
.	O
</ALL>	O

<ALL>	O
These	O
results	O
were	O
discussed	O
,	O
according	O
to	O
the	O
role	O
of	O
this	O
muscle	B-Organ
,	O
which	O
links	O
the	O
forelimb	B-Organism_subdivision
to	O
the	O
whole	O
trunk	B-Organism_subdivision
.	O
</ALL>	O

<ALL>	O
In	O
mammals	O
,	O
m	O
.	O
panniculus	O
carnosus	O
constitutes	O
,	O
with	O
musculus	B-Organ
latissimus	I-Organ
dorsi	I-Organ
,	O
the	O
axillary	B-Multi-tissue_structure
arch	I-Multi-tissue_structure
(	O
Achselbogen	O
)	O
.	O
</ALL>	O

<ALL>	O
A	O
small	O
area	O
of	O
overlapping	O
between	O
the	O
motor	O
pools	O
of	O
these	O
two	O
muscles	B-Organ
was	O
observed	O
.	O
</ALL>	O

<ALL>	O
It	O
was	O
suggested	O
that	O
the	O
muscular	B-Cell
fibers	I-Cell
from	O
the	O
axillary	B-Multi-tissue_structure
arch	I-Multi-tissue_structure
were	O
innervated	O
by	O
the	O
same	O
,	O
well	O
-	O
defined	O
spinal	B-Organism_subdivision
area	I-Organism_subdivision
,	O
independent	O
of	O
the	O
muscle	B-Organ
from	O
which	O
they	O
originate	O
.	O
</ALL>	O

<ALL>	O
Additional	O
tests	O
of	O
interest	O
to	O
the	O
dermatologist	O
.	O
</ALL>	O

<ALL>	O
The	O
carcinoid	O
syndrome	O
and	O
its	O
clinical	O
manifestations	O
have	O
been	O
discussed	O
.	O
</ALL>	O

<ALL>	O
The	O
standard	O
laboratory	O
test	O
for	O
making	O
that	O
diagnosis	O
is	O
urinary	B-Organism_substance
5	O
-	O
HIAA	O
levels	O
but	O
newer	O
,	O
more	O
sensitive	O
tests	O
may	O
also	O
be	O
available	O
.	O
</ALL>	O

<ALL>	O
Central	B-Anatomical_system
nervous	I-Anatomical_system
system	I-Anatomical_system
infection	O
with	O
Eikenella	O
corrodens	O
:	O
report	O
of	O
two	O
cases	O
.	O
</ALL>	O

<ALL>	O
Two	O
cases	O
of	O
central	B-Anatomical_system
nervous	I-Anatomical_system
system	I-Anatomical_system
infections	O
from	O
which	O
E	O
.	O
corrodens	O
has	O
been	O
isolated	O
are	O
reported	O
.	O
</ALL>	O

<ALL>	O
The	O
portals	O
of	O
entry	O
,	O
clinical	O
course	O
,	O
and	O
antimicrobial	O
responses	O
conform	O
to	O
other	O
reports	O
in	O
the	O
literature	O
.	O
</ALL>	O

<ALL>	O
The	O
importance	O
of	O
obtaining	O
careful	O
anaerobic	O
cultures	O
is	O
emphasized	O
.	O
</ALL>	O

<ALL>	O
Comparative	O
immunohistochemical	O
study	O
of	O
primary	B-Pathological_formation
and	O
metastatic	B-Pathological_formation
carcinomas	I-Pathological_formation
of	O
the	O
liver	B-Organ
.	O
</ALL>	O

<ALL>	O
Distinguishing	O
primary	B-Pathological_formation
hepatocellular	I-Pathological_formation
carcinoma	I-Pathological_formation
(	O
HCC	B-Pathological_formation
)	O
from	O
metastatic	B-Pathological_formation
carcinomas	I-Pathological_formation
to	O
the	O
liver	B-Organ
is	O
often	O
difficult	O
,	O
if	O
not	O
impossible	O
,	O
particularly	O
in	O
needle	B-Multi-tissue_structure
biopsy	I-Multi-tissue_structure
and	O
fine	B-Multi-tissue_structure
-	I-Multi-tissue_structure
needle	I-Multi-tissue_structure
aspiration	I-Multi-tissue_structure
specimens	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
In	O
an	O
attempt	O
to	O
identify	O
a	O
specific	O
immunohistochemical	O
profile	O
that	O
would	O
distinguish	O
HCC	B-Pathological_formation
from	O
metastatic	B-Pathological_formation
carcinomas	I-Pathological_formation
,	O
we	O
studied	O
56	O
HCCs	O
,	O
8	O
cholangiocarcinomas	B-Pathological_formation
,	O
and	O
24	O
metastatic	B-Pathological_formation
adenocarcinomas	I-Pathological_formation
with	O
monoclonal	O
antibodies	O
to	O
alpha	O
-	O
fetoprotein	O
(	O
AFP	O
)	O
,	O
keratin	O
(	O
AE1	O
,	O
AE3	O
,	O
and	O
CAM5	O
.	O
2	O
)	O
,	O
Leu	O
-	O
M1	O
,	O
human	O
milk	O
fat	O
globule	O
(	O
HMFG	O
-	O
2	O
)	O
,	O
tumor	B-Pathological_formation
-	O
associated	O
glycoprotein	O
-	O
72	O
(	O
B72	O
.	O
3	O
)	O
,	O
epithelial	B-Tissue
specific	O
membrane	B-Cellular_component
antigen	O
(	O
Ber	O
-	O
EP4	O
)	O
,	O
and	O
BCA	O
-	O
225	O
(	O
CU	O
-	O
18	O
)	O
.	O
</ALL>	O

<ALL>	O
Both	O
monoclonal	O
and	O
polyclonal	O
(	O
mCEA	O
and	O
pCEA	O
)	O
antibodies	O
to	O
carcinoembryonic	O
antigen	O
also	O
were	O
used	O
.	O
</ALL>	O

<ALL>	O
Metastatic	B-Pathological_formation
adenocarcinomas	I-Pathological_formation
were	O
often	O
positive	O
for	O
CU	O
-	O
18	O
(	O
71	O
%	O
)	O
,	O
Leu	O
-	O
M1	O
(	O
75	O
%	O
)	O
,	O
B72	O
.	O
3	O
(	O
50	O
%	O
)	O
,	O
HMFG	O
-	O
2	O
(	O
67	O
%	O
)	O
,	O
Ber	O
-	O
EP4	O
(	O
83	O
%	O
)	O
and	O
mCEA	O
(	O
71	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Using	O
these	O
antibodies	O
,	O
the	O
frequency	O
of	O
positivity	O
for	O
HCC	B-Pathological_formation
was	O
9	O
%	O
,	O
16	O
%	O
,	O
11	O
%	O
,	O
20	O
%	O
,	O
36	O
%	O
,	O
and	O
11	O
%	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
CU	O
-	O
18	O
was	O
the	O
only	O
monoclonal	O
antibody	O
in	O
which	O
there	O
was	O
a	O
significant	O
difference	O
in	O
positive	O
rates	O
between	O
HCC	B-Pathological_formation
and	O
metastatic	B-Pathological_formation
adenocarcinomas	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Most	O
HCCs	B-Pathological_formation
(	O
71	O
%	O
)	O
revealed	O
a	O
bile	B-Multi-tissue_structure
canalicular	I-Multi-tissue_structure
staining	O
pattern	O
with	O
pCEA	O
.	O
</ALL>	O

<ALL>	O
Because	O
this	O
staining	O
pattern	O
was	O
absent	O
in	O
metastatic	B-Pathological_formation
carcinomas	I-Pathological_formation
,	O
pCEA	O
appears	O
to	O
be	O
useful	O
in	O
confirming	O
a	O
diagnosis	O
of	O
HCC	O
.	O
</ALL>	O

<ALL>	O
AE1	O
,	O
AE3	O
and	O
CAM5	O
.	O
2	O
antibodies	O
were	O
not	O
useful	O
in	O
distinguishing	O
HCC	B-Pathological_formation
from	O
metastatic	B-Pathological_formation
carcinomas	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Each	O
cholangiocarcinoma	B-Pathological_formation
shared	O
a	O
staining	O
profile	O
similar	O
to	O
that	O
of	O
metastatic	B-Pathological_formation
carcinomas	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Differential	O
effects	O
of	O
carbachol	O
on	O
calcium	O
entry	O
and	O
release	O
in	O
CHO	B-Cell
cells	I-Cell
expressing	O
the	O
m3	O
muscarinic	O
receptor	O
.	O
</ALL>	O

<ALL>	O
Calcium	O
signalling	O
was	O
examined	O
in	O
CHO	B-Cell
-	I-Cell
k1	I-Cell
cells	I-Cell
that	O
stably	O
express	O
the	O
m3	O
subtype	O
of	O
the	O
muscarinic	O
receptor	O
.	O
</ALL>	O

<ALL>	O
The	O
calcium	O
indicator	O
Fura	O
-	O
2	O
was	O
retained	O
in	O
these	O
cells	B-Cell
only	O
in	O
the	O
presence	O
of	O
probenecid	O
(	O
1	O
mM	O
)	O
,	O
suggesting	O
that	O
Fura	O
-	O
2	O
efflux	O
was	O
mediated	O
by	O
an	O
organic	O
anion	O
transporter	O
.	O
</ALL>	O

<ALL>	O
The	O
addition	O
of	O
carbachol	O
(	O
CCh	O
)	O
to	O
Fura	O
-	O
2	O
loaded	O
cells	B-Cell
in	O
suspension	O
caused	O
a	O
rapid	O
transient	O
increase	O
in	O
intracellular	B-Immaterial_anatomical_entity
calcium	O
[	O
Ca	O
]	O
i	O
followed	O
by	O
a	O
smaller	O
sustained	O
plateau	O
phase	O
.	O
</ALL>	O

<ALL>	O
The	O
transient	O
rise	O
in	O
[	O
Ca	O
]	O
i	O
was	O
dose	O
-	O
dependent	O
with	O
a	O
threshold	O
response	O
of	O
89	O
+	O
/	O
-	O
18	O
nM	O
above	O
baseline	O
with	O
10	O
nM	O
CCh	O
and	O
a	O
maximum	O
stimulation	O
of	O
734	O
+	O
/	O
-	O
46	O
nM	O
with	O
10	O
microM	O
CCh	O
.	O
</ALL>	O

<ALL>	O
This	O
phase	O
was	O
accompanied	O
by	O
a	O
similar	O
dose	O
-	O
dependent	O
stimulation	O
of	O
total	O
inositol	O
phosphate	O
production	O
and	O
was	O
assumed	O
to	O
be	O
generated	O
by	O
release	O
from	O
intracellular	B-Immaterial_anatomical_entity
stores	O
of	O
the	O
endoplasmic	B-Cellular_component
reticulum	I-Cellular_component
(	O
ER	B-Cellular_component
)	O
.	O
</ALL>	O

<ALL>	O
The	O
sustained	O
increase	O
in	O
[	O
Ca	O
]	O
i	O
was	O
generated	O
by	O
entry	O
from	O
the	O
extracellular	B-Immaterial_anatomical_entity
bath	O
since	O
it	O
was	O
blocked	O
by	O
pretreatment	O
with	O
La3	O
+	O
(	O
1	O
microM	O
)	O
and	O
was	O
absent	O
when	O
bath	O
calcium	O
was	O
chelated	O
with	O
EGTA	O
.	O
</ALL>	O

<ALL>	O
This	O
phase	O
was	O
not	O
dependent	O
on	O
CCh	O
dose	O
,	O
and	O
a	O
stimulation	O
of	O
[	O
Ca	O
]	O
i	O
of	O
approximately	O
90	O
nM	O
above	O
baseline	O
was	O
observed	O
with	O
CCh	O
concentrations	O
between	O
50	O
nM	O
and	O
10	O
microM	O
.	O
</ALL>	O

<ALL>	O
With	O
this	O
dose	O
range	O
,	O
the	O
rate	O
of	O
Mn2	O
+	O
quenching	O
of	O
Fura	O
-	O
2	O
at	O
the	O
Ca	O
-	O
insensitive	O
excitation	O
wavelength	O
of	O
360	O
nm	O
was	O
likewise	O
maximally	O
stimulated	O
.	O
</ALL>	O

<ALL>	O
At	O
lower	O
CCh	O
concentrations	O
(	O
10	O
-	O
50	O
nM	O
)	O
,	O
it	O
was	O
clear	O
that	O
the	O
activation	O
of	O
Ca	O
entry	O
could	O
not	O
be	O
dissociated	O
from	O
a	O
threshold	O
release	O
of	O
Ca	O
from	O
intracellular	B-Immaterial_anatomical_entity
stores	O
.	O
</ALL>	O

<ALL>	O
The	O
phorbol	O
ester	O
PMA	O
,	O
which	O
uncouples	O
the	O
muscarinic	O
receptor	O
from	O
phospholipase	O
C	O
,	O
reduced	O
the	O
transient	O
rise	O
in	O
[	O
Ca	O
]	O
i	O
by	O
approximately	O
50	O
%	O
with	O
little	O
or	O
no	O
effect	O
on	O
Ca	O
entry	O
at	O
higher	O
CCh	O
levels	O
(	O
>	O
or	O
=	O
1	O
microM	O
)	O
.	O
</ALL>	O

<ALL>	O
At	O
lower	O
CCh	O
concentrations	O
(	O
<	O
or	O
=	O
100	O
nM	O
)	O
however	O
,	O
pretreatment	O
with	O
PMA	O
completely	O
blocked	O
all	O
Ca	O
mobilization	O
and	O
supports	O
the	O
contention	O
that	O
Ca	O
entry	O
is	O
coupled	O
to	O
Ca	O
release	O
from	O
stores	O
or	O
to	O
store	O
depletion	O
.	O
</ALL>	O

<ALL>	O
The	O
emptying	O
of	O
inositol	O
trisphosphate	O
-	O
sensitive	O
stores	O
with	O
thapsigargin	O
(	O
10	O
nM	O
)	O
stimulated	O
Ca	O
entry	O
and	O
also	O
the	O
rate	O
of	O
Mn2	O
+	O
quenching	O
.	O
</ALL>	O

<ALL>	O
Store	O
depletion	O
by	O
incubation	O
in	O
Ca	O
-	O
free	O
media	O
likewise	O
stimulated	O
Mn2	O
+	O
uptake	O
without	O
a	O
rise	O
in	O
[	O
Ca	O
]	O
i	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
are	O
therefore	O
consistent	O
with	O
a	O
'	O
capacitative	O
'	O
coupling	O
model	O
,	O
whereby	O
the	O
activation	O
of	O
the	O
plasma	B-Cellular_component
membrane	I-Cellular_component
receptor	O
leads	O
to	O
an	O
InsP3	O
-	O
induced	O
change	O
in	O
the	O
degree	O
of	O
filling	O
of	O
the	O
ER	B-Cellular_component
Ca	O
pool	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
</ALL>	O

<ALL>	O
Appetite	O
regulation	O
by	O
serotoninergic	O
mechanisms	O
and	O
effects	O
of	O
d	O
-	O
fenfluramine	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
literature	O
review	O
,	O
evidence	O
is	O
presented	O
for	O
the	O
theory	O
that	O
the	O
neurotransmitter	O
,	O
serotonin	O
(	O
5	O
-	O
hydroxytryptamine	O
,	O
5HT	O
)	O
,	O
in	O
medial	B-Multi-tissue_structure
hypothalamic	I-Multi-tissue_structure
centres	I-Multi-tissue_structure
is	O
an	O
important	O
regulator	O
for	O
appetite	O
and	O
for	O
the	O
selection	O
of	O
major	O
food	O
constituents	O
.	O
</ALL>	O

<ALL>	O
High	O
local	O
levels	O
of	O
5HT	O
cause	O
a	O
reduction	O
of	O
appetite	O
and	O
a	O
preference	O
for	O
protein	O
,	O
low	O
levels	O
the	O
opposite	O
.	O
</ALL>	O

<ALL>	O
The	O
main	O
antagonistic	O
system	O
is	O
noradrenergic	O
.	O
</ALL>	O

<ALL>	O
The	O
drug	O
d	O
-	O
fenfluramine	O
mimics	O
the	O
effects	O
of	O
5HT	O
by	O
releasing	O
5HT	O
from	O
serotoninergic	O
nerve	B-Multi-tissue_structure
endings	O
and	O
inhibiting	O
its	O
neuronal	B-Cell
re	O
-	O
uptake	O
.	O
</ALL>	O

<ALL>	O
Further	O
experimental	O
data	O
prove	O
that	O
a	O
high	O
-	O
carbohydrate	O
,	O
low	O
-	O
protein	O
diet	O
promotes	O
uptake	O
of	O
serum	B-Organism_substance
tryptophan	O
in	O
the	O
brain	B-Organ
and	O
its	O
conversion	O
into	O
5HT	O
.	O
</ALL>	O

<ALL>	O
Hence	O
,	O
this	O
serotoninergic	O
system	O
may	O
function	O
as	O
a	O
self	O
-	O
regulatory	O
mechanism	O
.	O
</ALL>	O

<ALL>	O
In	O
patients	O
with	O
decreased	O
peripheral	O
insulin	O
sensitivity	O
,	O
the	O
system	O
may	O
be	O
disturbed	O
,	O
causing	O
overconsumption	O
of	O
carbohydrates	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
sometimes	O
compulsive	O
(	O
"	O
carbohydrate	O
craving	O
"	O
)	O
.	O
</ALL>	O

<ALL>	O
It	O
may	O
be	O
presumed	O
that	O
in	O
the	O
treatment	O
of	O
obesity	O
,	O
in	O
addition	O
to	O
the	O
use	O
of	O
serotoninergic	O
drugs	O
,	O
successes	O
with	O
reducing	O
diets	O
may	O
be	O
enhanced	O
by	O
including	O
periods	O
of	O
high	O
-	O
carbohydrate	O
,	O
low	O
-	O
protein	O
intake	O
.	O
</ALL>	O

<ALL>	O
It	O
would	O
be	O
worthwhile	O
to	O
explore	O
whether	O
similar	O
alimentary	O
self	O
-	O
regulatory	O
mechanisms	O
of	O
neurotransmitter	O
function	O
exist	O
in	O
other	O
regulatory	O
systems	O
.	O
</ALL>	O

<ALL>	O
[	O
Preliminary	O
results	O
of	O
observing	O
18	O
cases	O
of	O
retinoblastoma	B-Pathological_formation
carried	O
within	O
the	O
international	O
research	O
program	O
RICS	O
]	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
years	O
1988	O
-	O
1989	O
,	O
the	O
Ophthalmological	O
Clinic	O
in	O
Cracow	O
took	O
part	O
in	O
the	O
International	O
Research	O
Programme	O
on	O
Retinoblastoma	B-Pathological_formation
as	O
one	O
of	O
28	O
clinical	O
centres	O
in	O
14	O
countries	O
.	O
</ALL>	O

<ALL>	O
The	O
study	O
included	O
18	O
children	O
with	O
retinoblastoma	B-Pathological_formation
,	O
in	O
most	O
cases	O
in	O
the	O
advanced	O
stadium	O
of	O
the	O
disease	O
.	O
</ALL>	O

<ALL>	O
As	O
a	O
rule	O
,	O
the	O
eyes	B-Organ
filled	O
with	O
tumours	B-Pathological_formation
were	O
enucleated	O
,	O
and	O
the	O
less	O
advanced	O
cases	O
were	O
treated	O
with	O
combined	O
methods	O
applying	O
radiation	O
with	O
60Co	O
plaques	O
with	O
xenon	O
arc	O
photocoagulation	O
,	O
cryopexy	O
,	O
and	O
chemotherapy	O
.	O
</ALL>	O

<ALL>	O
In	O
18	O
treated	O
children	O
23	O
eyes	B-Organ
were	O
enucleated	O
(	O
in	O
5	O
children	O
both	O
eyes	B-Organ
,	O
in	O
6	O
children	O
with	O
bilateral	O
retinoblastoma	B-Pathological_formation
1	O
eye	B-Organ
,	O
and	O
7	O
eyes	B-Organ
in	O
all	O
unilateral	O
cases	O
)	O
.	O
</ALL>	O

<ALL>	O
Six	O
eyes	B-Organ
with	O
less	O
advanced	O
lesions	B-Pathological_formation
were	O
treated	O
with	O
combined	O
methods	O
.	O
</ALL>	O

<ALL>	O
One	O
child	O
died	O
because	O
of	O
metastases	B-Pathological_formation
to	O
the	O
brain	B-Organ
.	O
</ALL>	O

<ALL>	O
The	O
obtained	O
data	O
reveal	O
that	O
retinoblastoma	B-Pathological_formation
is	O
diagnosed	O
too	O
late	O
,	O
which	O
decreases	O
the	O
chance	O
of	O
cure	O
and	O
causes	O
great	O
danger	O
for	O
the	O
life	O
of	O
the	O
child	O
.	O
</ALL>	O

<ALL>	O
Epilepsy	O
in	O
Down	O
syndrome	O
:	O
clinical	O
aspects	O
and	O
possible	O
mechanisms	O
.	O
</ALL>	O

<ALL>	O
Although	O
epilepsy	O
is	O
more	O
common	O
in	O
persons	O
with	O
trisomy	O
21	O
(	O
Down	O
syndrome	O
)	O
than	O
in	O
the	O
general	O
population	O
,	O
the	O
mechanisms	O
by	O
which	O
seizures	O
are	O
generated	O
in	O
this	O
population	O
have	O
received	O
little	O
attention	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
likely	O
that	O
this	O
increased	O
seizure	O
susceptibility	O
is	O
due	O
to	O
a	O
combination	O
of	O
medical	O
risk	O
factors	O
and	O
inherent	O
neurologic	B-Anatomical_system
abnormalities	O
characteristic	O
of	O
Down	O
syndrome	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
review	O
clinical	O
aspects	O
of	O
seizures	O
among	O
individuals	O
with	O
Down	O
syndrome	O
were	O
described	O
and	O
possible	O
mechanisms	O
by	O
which	O
the	O
trisomy	O
21	O
brain	B-Organ
may	O
generate	O
seizures	O
were	O
explored	O
.	O
</ALL>	O

<ALL>	O
Chelation	O
treatment	O
of	O
neurological	B-Anatomical_system
Wilson	O
'	O
s	O
disease	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
of	O
chelation	O
treatment	O
of	O
137	O
patients	O
presenting	O
with	O
neurological	B-Anatomical_system
Wilson	O
'	O
s	O
disease	O
are	O
described	O
,	O
together	O
with	O
the	O
more	O
commonly	O
observed	O
toxic	O
reactions	O
to	O
the	O
various	O
drugs	O
employed	O
.	O
</ALL>	O

<ALL>	O
Fifty	O
-	O
seven	O
patients	O
made	O
an	O
excellent	O
response	O
to	O
treatment	O
and	O
became	O
symptom	O
free	O
.	O
</ALL>	O

<ALL>	O
Thirty	O
-	O
six	O
patients	O
made	O
a	O
good	O
recovery	O
,	O
but	O
were	O
left	O
with	O
some	O
minor	O
neurological	B-Anatomical_system
deficit	O
.	O
</ALL>	O

<ALL>	O
Twenty	O
-	O
four	O
patients	O
had	O
a	O
poor	O
response	O
:	O
although	O
the	O
disease	O
process	O
was	O
arrested	O
they	O
were	O
left	O
more	O
or	O
less	O
disabled	O
.	O
</ALL>	O

<ALL>	O
Twenty	O
patients	O
died	O
:	O
nine	O
had	O
little	O
or	O
no	O
treatment	O
,	O
but	O
11	O
died	O
despite	O
apparently	O
adequate	O
chelation	O
therapy	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
no	O
obvious	O
reason	O
for	O
this	O
failure	O
.	O
</ALL>	O

<ALL>	O
The	O
liver	B-Organ
copper	O
level	O
was	O
estimated	O
in	O
six	O
of	O
these	O
patients	O
:	O
it	O
was	O
still	O
significantly	O
elevated	O
in	O
only	O
one	O
,	O
but	O
in	O
all	O
four	O
in	O
whom	O
it	O
was	O
possible	O
to	O
make	O
the	O
determination	O
,	O
the	O
concentration	O
of	O
copper	O
in	O
the	O
basal	B-Multi-tissue_structure
ganglia	I-Multi-tissue_structure
was	O
in	O
excess	O
of	O
45	O
micrograms	O
/	O
g	O
wet	O
weight	O
.	O
</ALL>	O

<ALL>	O
It	O
was	O
not	O
apparent	O
why	O
adequate	O
therapy	O
failed	O
to	O
remove	O
copper	O
from	O
the	O
brains	B-Organ
of	O
these	O
patients	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
no	O
obvious	O
clinical	O
,	O
histological	O
or	O
biochemical	O
indicator	O
of	O
failure	O
to	O
respond	O
to	O
treatment	O
.	O
</ALL>	O

<ALL>	O
Initial	O
deterioration	O
before	O
improvement	O
was	O
seen	O
in	O
30	O
patients	O
:	O
the	O
prognosis	O
for	O
a	O
useful	O
recovery	O
was	O
not	O
necessarily	O
worse	O
than	O
that	O
in	O
patients	O
who	O
did	O
not	O
show	O
this	O
phenomenon	O
.	O
</ALL>	O

<ALL>	O
[	O
Prehospital	O
service	O
in	O
Denmark	O
]	O
.	O
</ALL>	O

<ALL>	O
In	O
Denmark	O
,	O
emergency	O
ambulances	O
are	O
dispatched	O
by	O
41	O
centres	O
manned	O
either	O
by	O
trained	O
firemen	O
(	O
in	O
Copenhagen	O
)	O
or	O
policemen	O
(	O
outside	O
Copenhagen	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
1990	O
,	O
emergency	O
ambulance	O
calls	O
totalled	O
284	O
,	O
000	O
.	O
</ALL>	O

<ALL>	O
Utilisation	O
of	O
emergency	O
ambulance	O
services	O
increases	O
with	O
urbanisation	O
.	O
</ALL>	O

<ALL>	O
A	O
doctor	O
-	O
manned	O
ambulance	O
is	O
in	O
operation	O
in	O
Copenhagen	O
,	O
and	O
in	O
some	O
other	O
large	O
towns	O
anaesthesiology	O
and	O
intensive	O
care	O
teams	O
can	O
be	O
dispatched	O
from	O
hospital	O
to	O
give	O
on	O
-	O
the	O
-	O
spot	O
care	O
.	O
</ALL>	O

<ALL>	O
In	O
less	O
populated	O
areas	O
,	O
some	O
general	O
practitioners	O
give	O
advanced	O
life	O
-	O
support	O
.	O
</ALL>	O

<ALL>	O
Although	O
many	O
areas	O
are	O
serviced	O
by	O
ambulances	O
equipped	O
with	O
defibrillators	O
,	O
the	O
majority	O
of	O
patients	O
receive	O
only	O
basic	O
life	O
-	O
support	O
from	O
ambulance	O
personnel	O
.	O
</ALL>	O

<ALL>	O
New	O
initiatives	O
resulting	O
from	O
a	O
recent	O
report	O
by	O
a	O
commission	O
appointed	O
by	O
central	O
authorities	O
,	O
and	O
focused	O
on	O
prehospital	O
treatment	O
,	O
are	O
expected	O
to	O
improve	O
the	O
service	O
by	O
raising	O
the	O
level	O
of	O
training	O
given	O
to	O
ambulance	O
personnel	O
.	O
</ALL>	O

<ALL>	O
Cell	B-Cellular_component
surface	I-Cellular_component
binding	O
characteristics	O
correlate	O
with	O
consensus	O
type	O
I	O
interferon	O
enhanced	O
activity	O
.	O
</ALL>	O

<ALL>	O
The	O
binding	O
characteristics	O
of	O
a	O
genetically	O
engineered	O
consensus	O
interferon	O
with	O
unusually	O
high	O
biologic	O
activity	O
were	O
compared	O
to	O
the	O
characteristics	O
of	O
recombinant	O
interferon	O
-	O
alpha	O
2	O
.	O
</ALL>	O

<ALL>	O
Both	O
interferon	O
-	O
alpha	O
2	O
and	O
the	O
consensus	O
interferon	O
produced	O
typical	O
biphasic	O
Scatchard	O
plots	O
,	O
indicating	O
multiple	O
independent	O
binding	O
sites	O
.	O
</ALL>	O

<ALL>	O
The	O
consensus	O
interferon	O
,	O
which	O
exhibited	O
a	O
biologic	O
potency	O
more	O
than	O
10	O
-	O
fold	O
greater	O
than	O
all	O
other	O
type	O
I	O
interferons	O
,	O
also	O
exhibited	O
binding	O
site	O
affinities	O
greater	O
than	O
those	O
for	O
IFN	O
-	O
alpha	O
2b	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
a	O
larger	O
number	O
of	O
high	O
,	O
and	O
low	O
-	O
affinity	O
cell	B-Cellular_component
surface	I-Cellular_component
sites	O
were	O
recognized	O
by	O
the	O
consensus	O
interferon	O
,	O
resulting	O
in	O
equivalent	O
numbers	O
of	O
sites	O
at	O
reduced	O
molar	O
concentrations	O
compared	O
to	O
IFN	O
-	O
a2b	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
at	O
any	O
given	O
biologic	O
activity	O
,	O
similar	O
numbers	O
of	O
sites	O
were	O
bound	O
by	O
the	O
consensus	O
interferon	O
and	O
IFN	O
-	O
alpha	O
2	O
,	O
despite	O
differences	O
in	O
their	O
molar	O
concentrations	O
.	O
</ALL>	O

<ALL>	O
No	O
differences	O
in	O
internalization	O
kinetics	O
were	O
identified	O
between	O
the	O
two	O
interferons	O
,	O
indicating	O
that	O
the	O
differences	O
in	O
cell	B-Cellular_component
surface	I-Cellular_component
binding	O
may	O
be	O
sufficient	O
to	O
produce	O
the	O
differences	O
in	O
biologic	O
activity	O
.	O
</ALL>	O

<ALL>	O
Human	O
immunodeficiency	O
virus	O
type	O
1	O
viral	O
background	O
plays	O
a	O
major	O
role	O
in	O
development	O
of	O
resistance	O
to	O
protease	O
inhibitors	O
.	O
</ALL>	O

<ALL>	O
The	O
observed	O
in	O
vitro	O
and	O
in	O
vivo	O
benefit	O
of	O
combination	O
treatment	O
with	O
anti	O
-	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
agents	O
prompted	O
us	O
to	O
examine	O
the	O
potential	O
of	O
resistance	O
development	O
when	O
two	O
protease	O
inhibitors	O
are	O
used	O
concurrently	O
.	O
</ALL>	O

<ALL>	O
Recombinant	O
HIV	O
-	O
1	O
(	O
NL4	O
-	O
3	O
)	O
proteases	O
containing	O
combined	O
resistance	O
mutations	O
associated	O
with	O
BMS	O
-	O
186318	O
and	O
A	O
-	O
77003	O
(	O
or	O
saquinavir	O
)	O
were	O
either	O
inactive	O
or	O
had	O
impaired	O
enzyme	O
activity	O
.	O
</ALL>	O

<ALL>	O
Subsequent	O
construction	O
of	O
HIV	O
-	O
1	O
(	O
NL4	O
-	O
3	O
)	O
proviral	O
clones	O
containing	O
the	O
same	O
mutations	O
yielded	O
viruses	O
that	O
were	O
severely	O
impaired	O
in	O
growth	O
or	O
nonviable	O
,	O
confirming	O
that	O
combination	O
therapy	O
may	O
be	O
advantageous	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
passage	O
of	O
BMS	O
-	O
186318	O
-	O
resistant	O
HIV	O
-	O
1	O
(	O
RF	O
)	O
in	O
the	O
presence	O
of	O
either	O
saquinavir	O
or	O
SC52151	O
,	O
which	O
represented	O
sequential	O
drug	O
treatment	O
,	O
produced	O
viable	O
viruses	O
resistant	O
to	O
both	O
BMS	O
-	O
186318	O
and	O
the	O
second	O
compound	O
.	O
</ALL>	O

<ALL>	O
The	O
predominant	O
breakthrough	O
virus	O
contained	O
the	O
G48V	O
/	O
A71T	O
/	O
V82A	O
protease	O
mutations	O
.	O
</ALL>	O

<ALL>	O
The	O
clone	O
-	O
purified	O
RF	O
(	O
G48V	O
/	O
A71T	O
/	O
V82A	O
)	O
virus	O
,	O
unlike	O
the	O
corresponding	O
defective	O
NL4	O
-	O
3	O
triple	O
mutant	O
,	O
grew	O
well	O
and	O
displayed	O
cross	O
-	O
resistance	O
to	O
four	O
distinct	O
protease	O
inhibitors	O
.	O
</ALL>	O

<ALL>	O
Chimeric	O
virus	O
and	O
in	O
vitro	O
mutagenesis	O
studies	O
indicated	O
that	O
the	O
RF	O
-	O
specific	O
protease	O
sequence	O
,	O
specifically	O
the	O
Ile	O
at	O
residue	O
10	O
,	O
enabled	O
the	O
NL4	O
-	O
3	O
strain	O
with	O
the	O
triple	O
mutant	O
to	O
grow	O
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
clearly	O
indicate	O
that	O
viral	O
genetic	O
background	O
will	O
play	O
a	O
key	O
role	O
in	O
determining	O
whether	O
cross	O
-	O
resistance	O
variants	O
will	O
arise	O
.	O
</ALL>	O

<ALL>	O
Referral	O
bias	O
among	O
health	O
workers	O
in	O
studies	O
using	O
hospitalization	O
as	O
a	O
proxy	O
measure	O
of	O
the	O
underlying	O
incidence	O
rate	O
.	O
</ALL>	O

<ALL>	O
Contacts	O
with	O
health	O
services	O
like	O
hospitals	O
or	O
general	O
practitioners	O
are	O
usually	O
the	O
only	O
available	O
proxy	O
measure	O
of	O
incidence	O
of	O
disease	O
in	O
studies	O
based	O
on	O
secondary	O
data	O
and	O
differential	O
referrals	O
or	O
care	O
-	O
seeking	O
behavior	O
often	O
bias	O
such	O
proxy	O
measures	O
.	O
</ALL>	O

<ALL>	O
In	O
former	O
analyses	O
based	O
on	O
the	O
Occupational	O
Hospitalization	O
Register	O
in	O
Denmark	O
assisting	O
nurses	O
had	O
high	O
Standardized	O
Hospitalization	O
Ratios	O
for	O
many	O
diseases	O
.	O
</ALL>	O

<ALL>	O
It	O
was	O
,	O
however	O
,	O
suspected	O
that	O
it	O
fully	O
or	O
partly	O
was	O
due	O
to	O
a	O
referral	O
bias	O
or	O
self	O
-	O
selection	O
to	O
hospital	O
treatment	O
rather	O
than	O
exposures	O
to	O
occupational	O
hazards	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
evaluate	O
the	O
referral	O
bias	O
hypothesis	O
by	O
comparing	O
hospitalization	O
and	O
mortality	O
data	O
for	O
health	O
workers	O
for	O
a	O
disease	O
category	O
with	O
a	O
high	O
mortality	O
.	O
</ALL>	O

<ALL>	O
Cohorts	O
of	O
all	O
gainfully	O
employed	O
20	O
-	O
to	O
59	O
-	O
year	O
-	O
old	O
Danes	O
were	O
formed	O
in	O
order	O
to	O
compare	O
Standardized	O
Mortality	O
Ratios	O
and	O
Standardized	O
Hospitalization	O
Ratios	O
of	O
ischemic	O
heart	B-Organ
disease	O
(	O
IHD	O
)	O
in	O
occupational	O
groups	O
.	O
</ALL>	O

<ALL>	O
The	O
follow	O
-	O
up	O
period	O
was	O
10	O
years	O
.	O
</ALL>	O

<ALL>	O
For	O
most	O
of	O
the	O
investigated	O
occupational	O
groups	O
a	O
similar	O
disease	O
pattern	O
was	O
found	O
whether	O
hospitalization	O
or	O
death	O
was	O
used	O
as	O
the	O
outcome	O
measure	O
.	O
</ALL>	O

<ALL>	O
In	O
"	O
nurse	O
assistants	O
"	O
a	O
statistically	O
significant	O
higher	O
risk	O
was	O
,	O
however	O
,	O
found	O
using	O
hospitalization	O
due	O
to	O
IHD	O
as	O
the	O
end	O
point	O
rather	O
than	O
mortality	O
.	O
</ALL>	O

<ALL>	O
Additional	O
analysis	O
did	O
not	O
support	O
the	O
hypothesis	O
that	O
the	O
finding	O
could	O
be	O
explained	O
by	O
differentiated	O
hospitalization	O
due	O
to	O
social	O
factors	O
.	O
</ALL>	O

<ALL>	O
The	O
true	O
incidence	O
rates	O
of	O
the	O
disease	O
need	O
not	O
be	O
equally	O
well	O
described	O
by	O
proxy	O
measures	O
such	O
as	O
hospitalization	O
diagnosis	O
or	O
death	O
diagnosis	O
in	O
all	O
occupational	O
groups	O
.	O
</ALL>	O

<ALL>	O
Differential	O
access	O
to	O
medical	O
treatment	O
in	O
some	O
groups	O
may	O
lead	O
to	O
bias	O
when	O
hospital	O
data	O
are	O
used	O
as	O
proxy	O
measures	O
for	O
the	O
underlying	O
incidence	O
rates	O
.	O
</ALL>	O

<ALL>	O
Induction	O
of	O
p18INK4c	O
and	O
its	O
predominant	O
association	O
with	O
CDK4	O
and	O
CDK6	O
during	O
myogenic	O
differentiation	O
.	O
</ALL>	O

<ALL>	O
Terminal	O
cell	B-Cell
differentiation	O
involves	O
permanent	O
withdrawal	O
from	O
the	O
cell	B-Cell
division	O
cycle	O
.	O
</ALL>	O

<ALL>	O
The	O
inhibitors	O
of	O
cyclin	O
-	O
dependent	O
kinases	O
(	O
CDKs	O
)	O
are	O
potential	O
molecules	O
functioning	O
to	O
couple	O
cell	B-Cell
cycle	O
arrest	O
and	O
cell	B-Cell
differentiation	O
.	O
</ALL>	O

<ALL>	O
In	O
murine	O
C2C12	B-Cell
myoblast	I-Cell
cells	I-Cell
,	O
G1	O
CDK	O
enzymes	O
(	O
CDK2	O
,	O
CDK4	O
,	O
and	O
CDK6	O
)	O
associate	O
with	O
four	O
CDK	O
inhibitors	O
:	O
p18INK4c	O
,	O
p19INK4d	O
,	O
p21	O
,	O
and	O
p27Kip1	O
.	O
</ALL>	O

<ALL>	O
During	O
induced	O
myogenesis	O
,	O
p21	O
and	O
its	O
associated	O
CDK	O
proteins	O
underwent	O
an	O
initial	O
increase	O
followed	O
by	O
a	O
decrease	O
as	O
cells	B-Cell
became	O
terminally	O
differentiated	O
.	O
</ALL>	O

<ALL>	O
The	O
level	O
of	O
p27	O
protein	O
gradually	O
increased	O
,	O
but	O
the	O
amount	O
of	O
total	O
associated	O
CDK	O
proteins	O
remained	O
unchanged	O
.	O
</ALL>	O

<ALL>	O
p19	O
protein	O
decreased	O
gradually	O
during	O
differentiation	O
,	O
as	O
did	O
its	O
associated	O
CDK4	O
protein	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
p18	O
protein	O
increased	O
50	O
-	O
fold	O
,	O
from	O
negligible	O
levels	O
in	O
proliferating	O
myoblasts	B-Cell
to	O
clearly	O
detectable	O
levels	O
within	O
8	O
-	O
12	O
h	O
of	O
myogenic	O
induction	O
.	O
</ALL>	O

<ALL>	O
This	O
initial	O
rise	O
was	O
followed	O
by	O
a	O
precipitous	O
increase	O
between	O
12	O
and	O
24	O
h	O
postinduction	O
,	O
with	O
p18	O
protein	O
finally	O
accumulating	O
to	O
its	O
highest	O
level	O
in	O
terminally	O
differentiated	O
cells	B-Cell
.	O
</ALL>	O

<ALL>	O
Induction	O
of	O
p18	O
correlated	O
with	O
increased	O
and	O
sequential	O
complex	O
formation	O
-	O
-	O
first	O
increasing	O
association	O
with	O
CDK6	O
and	O
then	O
with	O
CDK4	O
over	O
the	O
course	O
of	O
myogenic	O
differentiation	O
.	O
</ALL>	O

<ALL>	O
All	O
of	O
the	O
CDK6	O
and	O
half	O
of	O
the	O
CDK4	O
were	O
complexed	O
with	O
p18	O
in	O
terminally	O
differentiated	O
C2C12	B-Cell
cells	I-Cell
as	O
well	O
as	O
in	O
adult	O
mouse	O
muscle	B-Tissue
tissue	I-Tissue
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
kinase	O
activity	O
of	O
CDK2	O
and	O
CDK4	O
decreases	O
as	O
C2C12	B-Cell
cells	I-Cell
differentiate	O
,	O
whereas	O
the	O
CDK6	O
kinase	O
activity	O
is	O
low	O
in	O
both	O
proliferating	O
myoblasts	B-Cell
and	O
differentiated	O
myotubes	B-Tissue
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
indicate	O
that	O
p18	O
may	O
play	O
a	O
critical	O
role	O
in	O
causing	O
and	O
/	O
or	O
maintaining	O
permanent	O
cell	B-Cell
cycle	O
arrest	O
associated	O
with	O
mature	O
muscle	B-Tissue
formation	O
.	O
</ALL>	O

<ALL>	O
Functional	O
model	O
of	O
benign	O
paroxysmal	O
positional	O
vertigo	O
using	O
an	O
isolated	O
frog	O
semicircular	B-Multi-tissue_structure
canal	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Bull	O
frogs	O
posterior	B-Multi-tissue_structure
semicircular	I-Multi-tissue_structure
canals	I-Multi-tissue_structure
(	O
psc	B-Multi-tissue_structure
)	O
wee	O
used	O
to	O
simulate	O
the	O
condition	O
of	O
benign	O
paroxysmal	O
positional	O
vertigo	O
(	O
BPPV	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
psc	B-Multi-tissue_structure
was	O
isolated	O
in	O
frog	O
Ringer	O
'	O
s	O
solution	O
,	O
and	O
the	O
saccular	B-Organism_substance
otoconia	I-Organism_substance
were	O
used	O
as	O
a	O
responsible	O
material	O
to	O
stimulate	O
the	O
cupula	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
When	O
the	O
otoconia	B-Organism_substance
were	O
placed	O
on	O
the	O
cupular	B-Multi-tissue_structure
surface	I-Multi-tissue_structure
to	O
mimic	O
the	O
condition	O
of	O
cupulolithiasis	O
,	O
the	O
psc	B-Multi-tissue_structure
ampullary	I-Multi-tissue_structure
nerve	I-Multi-tissue_structure
action	O
potentials	O
instantaneously	O
changed	O
according	O
to	O
the	O
direction	O
of	O
the	O
gravity	O
produced	O
by	O
otoconia	B-Organism_substance
.	O
</ALL>	O

<ALL>	O
When	O
the	O
otoconia	B-Organism_substance
were	O
dropped	O
into	O
the	O
canal	B-Multi-tissue_structure
to	O
mimic	O
the	O
condition	O
of	O
moving	O
otoconia	B-Organism_substance
in	O
the	O
canal	B-Multi-tissue_structure
,	O
the	O
action	O
potentials	O
changed	O
together	O
with	O
the	O
otoconial	B-Organism_substance
flow	O
after	O
a	O
latent	O
period	O
.	O
</ALL>	O

<ALL>	O
Both	O
cupulolithiasis	O
and	O
moving	O
otoconia	B-Organism_substance
are	O
possibly	O
valid	O
mechanisms	O
of	O
BPPV	O
,	O
since	O
they	O
effectively	O
stimulate	O
the	O
cupula	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
However	O
,	O
moving	O
otoconia	B-Organism_substance
with	O
a	O
latent	O
period	O
would	O
better	O
explain	O
clinical	O
features	O
of	O
BPPV	O
.	O
</ALL>	O

<ALL>	O
[	O
Considerations	O
regarding	O
two	O
cases	O
of	O
macromastia	O
(	O
author	O
'	O
s	O
transl	O
)	O
]	O
.	O
</ALL>	O

<ALL>	O
Two	O
cases	O
of	O
macromastia	O
have	O
been	O
shown	O
;	O
one	O
which	O
appeared	O
during	O
puberty	O
,	O
the	O
other	O
during	O
menopause	O
.	O
</ALL>	O

<ALL>	O
Histopathological	O
examination	O
has	O
demonstrated	O
for	O
the	O
both	O
cases	O
a	O
cystic	O
degeneracy	O
of	O
the	O
glandular	B-Tissue
tissue	I-Tissue
with	O
a	O
hyperplazia	O
and	O
hypertrophy	O
of	O
the	O
conjunctive	B-Tissue
tissue	I-Tissue
.	O
</ALL>	O

<ALL>	O
The	O
pathogeny	O
of	O
macromastia	O
is	O
being	O
discussed	O
and	O
it	O
is	O
demonstrated	O
both	O
the	O
role	O
of	O
hypophysis	O
hormones	O
(	O
prolactine	O
and	O
growth	O
hormone	O
)	O
and	O
of	O
ovarian	B-Organ
hormones	O
(	O
estrogens	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
treatment	O
was	O
surgical	O
for	O
the	O
both	O
cases	O
.	O
</ALL>	O

<ALL>	O
Procedural	O
memory	O
stimulation	O
in	O
Alzheimer	O
'	O
s	O
disease	O
:	O
impact	O
of	O
a	O
training	O
programme	O
.	O
</ALL>	O

<ALL>	O
The	O
study	O
evaluates	O
the	O
efficacy	O
of	O
a	O
procedural	O
memory	O
stimulation	O
programme	O
in	O
mild	O
and	O
mild	O
-	O
moderate	O
Alzheimer	O
'	O
s	O
disease	O
(	O
AD	O
)	O
.	O
</ALL>	O

<ALL>	O
Twenty	O
basic	O
and	O
instrumental	O
activities	O
of	O
daily	O
living	O
have	O
been	O
selected	O
,	O
and	O
divided	O
into	O
two	O
groups	O
,	O
comparable	O
for	O
difficulty	O
.	O
</ALL>	O

<ALL>	O
Ten	O
normal	O
elderly	O
subjects	O
(	O
age	O
68	O
.	O
0	O
+	O
/	O
-	O
4	O
.	O
8	O
years	O
;	O
MMSE	O
score	O
:	O
28	O
.	O
7	O
+	O
/	O
-	O
0	O
.	O
9	O
;	O
education	O
:	O
7	O
.	O
6	O
+	O
/	O
-	O
3	O
.	O
5	O
years	O
)	O
were	O
asked	O
to	O
perform	O
the	O
two	O
groups	O
of	O
daily	O
activities	O
and	O
the	O
time	O
required	O
to	O
perform	O
the	O
tasks	O
of	O
each	O
group	O
was	O
recorded	O
and	O
used	O
as	O
a	O
reference	O
.	O
</ALL>	O

<ALL>	O
Ten	O
mild	O
and	O
mild	O
-	O
moderate	O
AD	O
patients	O
(	O
age	O
77	O
.	O
2	O
+	O
/	O
-	O
5	O
.	O
3	O
years	O
;	O
MMSE	O
score	O
:	O
19	O
.	O
8	O
+	O
/	O
-	O
3	O
.	O
5	O
;	O
education	O
:	O
7	O
.	O
3	O
+	O
/	O
-	O
4	O
.	O
7	O
years	O
)	O
without	O
major	O
behavioural	O
disturbances	O
constituted	O
the	O
experimental	O
group	O
.	O
</ALL>	O

<ALL>	O
Patients	O
were	O
evaluated	O
in	O
all	O
20	O
daily	O
activities	O
and	O
the	O
time	O
employed	O
was	O
recorded	O
at	O
baseline	O
and	O
after	O
a	O
3	O
-	O
week	O
training	O
(	O
1	O
h	O
/	O
d	O
,	O
5	O
d	O
/	O
week	O
)	O
period	O
.	O
</ALL>	O

<ALL>	O
Five	O
patients	O
were	O
trained	O
during	O
the	O
3	O
weeks	O
on	O
half	O
of	O
the	O
20	O
daily	O
activities	O
and	O
the	O
other	O
five	O
patients	O
were	O
trained	O
on	O
the	O
remainder	O
.	O
</ALL>	O

<ALL>	O
This	O
procedure	O
was	O
adopted	O
in	O
order	O
to	O
detect	O
separately	O
the	O
improvement	O
in	O
"	O
trained	O
"	O
and	O
"	O
not	O
trained	O
"	O
activities	O
,	O
allowing	O
to	O
control	O
better	O
the	O
effects	O
of	O
the	O
intervention	O
.	O
</ALL>	O

<ALL>	O
The	O
assessment	O
of	O
the	O
functional	O
impact	O
of	O
the	O
training	O
was	O
directly	O
measured	O
,	O
through	O
the	O
variation	O
of	O
time	O
employed	O
to	O
perform	O
tasks	O
before	O
and	O
after	O
training	O
.	O
</ALL>	O

<ALL>	O
After	O
3	O
weeks	O
of	O
training	O
a	O
significant	O
improvement	O
was	O
observed	O
for	O
the	O
trained	O
activities	O
,	O
from	O
3	O
.	O
6	O
to	O
1	O
.	O
9	O
standard	O
deviations	O
below	O
the	O
performance	O
of	O
the	O
normal	O
elderly	O
controls	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
</ALL>	O

<ALL>	O
AD	O
patients	O
improved	O
also	O
in	O
not	O
-	O
trained	O
activities	O
from	O
3	O
.	O
5	O
to	O
2	O
.	O
7	O
standard	O
deviations	O
below	O
the	O
controls	O
'	O
performance	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
rehabilitation	O
of	O
activities	O
of	O
daily	O
living	O
through	O
developing	O
procedural	O
memory	O
strategies	O
may	O
be	O
effective	O
in	O
mild	O
and	O
mild	O
-	O
moderate	O
AD	O
patients	O
.	O
</ALL>	O

<ALL>	O
Some	O
findings	O
concerning	O
beliefs	O
about	O
alcoholism	O
.	O
</ALL>	O

<ALL>	O
The	O
beliefs	O
that	O
alcoholics	O
hold	O
about	O
alcoholism	O
and	O
themselves	O
,	O
and	O
the	O
beliefs	O
that	O
hospital	O
staff	O
and	O
other	O
personnel	O
hold	O
about	O
alcoholism	O
,	O
were	O
investigated	O
using	O
methods	O
derived	O
from	O
the	O
repertory	O
grid	O
,	O
with	O
anonymous	O
facial	B-Organism_subdivision
photographs	O
as	O
elements	O
.	O
</ALL>	O

<ALL>	O
Data	O
are	O
presented	O
as	O
to	O
the	O
degree	O
of	O
association	O
of	O
various	O
characteristics	O
with	O
alcoholism	O
for	O
the	O
various	O
groups	O
.	O
</ALL>	O

<ALL>	O
Differences	O
between	O
groups	O
,	O
and	O
overall	O
changes	O
during	O
group	O
psychotherapy	O
for	O
patients	O
were	O
small	O
.	O
</ALL>	O

<ALL>	O
The	O
relative	O
contribution	O
of	O
personal	O
and	O
shared	O
aspects	O
of	O
belief	O
was	O
measured	O
.	O
</ALL>	O

<ALL>	O
It	O
was	O
found	O
that	O
the	O
agreement	O
between	O
groups	O
was	O
high	O
and	O
closely	O
similar	O
to	O
that	O
predictable	O
from	O
consistencies	O
within	O
groups	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
concluded	O
that	O
there	O
may	O
be	O
a	O
very	O
general	O
stereotype	O
of	O
alcoholism	O
,	O
consistent	O
with	O
a	O
personality	O
disorder	O
concept	O
which	O
is	O
implicitly	O
held	O
even	O
in	O
the	O
face	O
of	O
nominal	O
acceptance	O
of	O
other	O
concepts	O
.	O
</ALL>	O

<ALL>	O
The	O
self	O
constructs	O
of	O
alcoholics	O
were	O
found	O
to	O
be	O
complex	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
small	O
follow	O
-	O
up	O
study	O
of	O
patients	O
,	O
there	O
was	O
found	O
to	O
be	O
a	O
relationship	O
of	O
poor	O
outcome	O
with	O
tightness	O
of	O
construing	O
for	O
key	O
constructs	O
after	O
psychotherapy	O
.	O
</ALL>	O

<ALL>	O
The	O
implications	O
of	O
the	O
findings	O
are	O
discussed	O
briefly	O
.	O
</ALL>	O

<ALL>	O
Monitoring	O
the	O
efficiency	O
of	O
interferon	O
-	O
alpha	O
therapy	O
in	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
patients	O
by	O
competitive	O
polymerase	O
chain	O
reaction	O
.	O
</ALL>	O

<ALL>	O
Interferon	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
induces	O
cytogenetic	O
responses	O
of	O
variable	O
degree	O
in	O
patients	O
with	O
CML	O
.	O
</ALL>	O

<ALL>	O
We	O
sought	O
to	O
establish	O
the	O
relationship	O
between	O
BCR	O
-	O
ABL	O
transcript	O
numbers	O
measured	O
by	O
competitive	O
two	O
-	O
step	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
cytogenetic	O
status	O
in	O
CML	O
patients	O
treated	O
with	O
IFN	O
-	O
alpha	O
.	O
</ALL>	O

<ALL>	O
All	O
398	O
samples	O
from	O
163	O
patients	O
investigated	O
by	O
RT	O
-	O
PCR	O
were	O
positive	O
for	O
BCR	O
-	O
ABL	O
transcripts	O
.	O
</ALL>	O

<ALL>	O
In	O
order	O
to	O
standardize	O
results	O
for	O
variability	O
in	O
RNA	O
and	O
cDNA	O
quality	O
,	O
we	O
quantified	O
total	O
ABL	O
transcripts	O
in	O
each	O
sample	O
as	O
internal	O
control	O
.	O
</ALL>	O

<ALL>	O
The	O
BCR	O
-	O
ABL	O
/	O
ABL	O
ratios	O
correlated	O
with	O
the	O
cytogenetic	O
results	O
.	O
</ALL>	O

<ALL>	O
Quantitative	O
nested	O
PCR	O
allowed	O
the	O
detection	O
of	O
residual	O
BCR	O
-	O
ABL	O
transcripts	O
in	O
all	O
complete	O
cytogenetic	O
responders	O
on	O
IFN	O
-	O
alpha	O
.	O
</ALL>	O

<ALL>	O
We	O
conclude	O
that	O
competitive	O
PCR	O
with	O
internal	O
controls	O
is	O
a	O
reliable	O
method	O
for	O
monitoring	O
patients	O
on	O
IFN	O
-	O
alpha	O
and	O
reduces	O
the	O
need	O
for	O
repeated	O
marrow	B-Multi-tissue_structure
investigations	O
.	O
</ALL>	O

<ALL>	O
[	O
Treatment	O
of	O
acute	O
liver	B-Organ
failure	O
in	O
children	O
]	O
.	O
</ALL>	O

<ALL>	O
Among	O
the	O
main	O
causes	O
of	O
acute	O
liver	B-Organ
failure	O
(	O
ALF	O
)	O
in	O
children	O
,	O
metabolic	O
diseases	O
(	O
especially	O
in	O
infants	O
)	O
,	O
viral	O
and	O
toxin	O
or	O
drug	O
induced	O
hepatitis	O
are	O
the	O
most	O
frequent	O
.	O
</ALL>	O

<ALL>	O
The	O
cause	O
remains	O
,	O
however	O
,	O
undetermined	O
in	O
about	O
30	O
%	O
of	O
the	O
cases	O
.	O
</ALL>	O

<ALL>	O
Management	O
must	O
be	O
conducted	O
in	O
a	O
pediatric	O
hepatology	O
unit	O
or	O
intensive	O
care	O
unit	O
in	O
relation	O
with	O
a	O
pediatric	O
transplant	O
team	O
in	O
order	O
:	O
1	O
)	O
to	O
perform	O
urgent	O
etiological	O
diagnosis	O
;	O
2	O
)	O
to	O
initiate	O
specific	O
therapy	O
and	O
symptomatic	O
treatment	O
;	O
3	O
)	O
to	O
evaluate	O
the	O
severity	O
and	O
prognosis	O
of	O
liver	B-Organ
disease	O
for	O
selection	O
of	O
children	O
for	O
emergency	O
liver	B-Organ
transplantation	O
;	O
4	O
)	O
to	O
evaluate	O
contraindications	O
to	O
liver	B-Organ
transplantation	O
.	O
</ALL>	O

<ALL>	O
The	O
overall	O
survival	O
of	O
post	O
-	O
emergency	O
liver	B-Organ
transplantation	O
for	O
ALF	O
in	O
children	O
averages	O
65	O
%	O
.	O
</ALL>	O

<ALL>	O
Blind	O
separation	O
of	O
auditory	O
event	O
-	O
related	O
brain	B-Organ
responses	O
into	O
independent	O
components	O
.	O
</ALL>	O

<ALL>	O
Averaged	O
event	O
-	O
related	O
potential	O
(	O
ERP	O
)	O
data	O
recorded	O
from	O
the	O
human	O
scalp	B-Multi-tissue_structure
reveal	O
electroencephalographic	O
(	O
EEG	O
)	O
activity	O
that	O
is	O
reliably	O
time	O
-	O
locked	O
and	O
phase	O
-	O
locked	O
to	O
experimental	O
events	O
.	O
</ALL>	O

<ALL>	O
We	O
report	O
here	O
the	O
application	O
of	O
a	O
method	O
based	O
on	O
information	O
theory	O
that	O
decomposes	O
one	O
or	O
more	O
ERPs	O
recorded	O
at	O
multiple	O
scalp	B-Multi-tissue_structure
sensors	O
into	O
a	O
sum	O
of	O
components	O
with	O
fixed	O
scalp	B-Multi-tissue_structure
distributions	O
and	O
sparsely	O
activated	O
,	O
maximally	O
independent	O
time	O
courses	O
.	O
</ALL>	O

<ALL>	O
Independent	O
component	O
analysis	O
(	O
ICA	O
)	O
decomposes	O
ERP	O
data	O
into	O
a	O
number	O
of	O
components	O
equal	O
to	O
the	O
number	O
of	O
sensors	O
.	O
</ALL>	O

<ALL>	O
The	O
derived	O
components	O
have	O
distinct	O
but	O
not	O
necessarily	O
orthogonal	O
scalp	B-Multi-tissue_structure
projections	O
.	O
</ALL>	O

<ALL>	O
Unlike	O
dipole	O
-	O
fitting	O
methods	O
,	O
the	O
algorithm	O
does	O
not	O
model	O
the	O
locations	O
of	O
their	O
generators	O
in	O
the	O
head	B-Organism_subdivision
.	O
</ALL>	O

<ALL>	O
Unlike	O
methods	O
that	O
remove	O
second	O
-	O
order	O
correlations	O
,	O
such	O
as	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
,	O
ICA	O
also	O
minimizes	O
higher	O
-	O
order	O
dependencies	O
.	O
</ALL>	O

<ALL>	O
Applied	O
to	O
detected	O
-	O
and	O
undetected	O
-	O
target	O
ERPs	O
from	O
an	O
auditory	O
vigilance	O
experiment	O
,	O
the	O
algorithm	O
derived	O
ten	O
components	O
that	O
decomposed	O
each	O
of	O
the	O
major	O
response	O
peaks	O
into	O
one	O
or	O
more	O
ICA	O
components	O
with	O
relatively	O
simple	O
scalp	B-Multi-tissue_structure
distributions	O
.	O
</ALL>	O

<ALL>	O
Three	O
of	O
these	O
components	O
were	O
active	O
only	O
when	O
the	O
subject	O
detected	O
the	O
targets	O
,	O
three	O
other	O
components	O
only	O
when	O
the	O
target	O
went	O
undetected	O
,	O
and	O
one	O
in	O
both	O
cases	O
.	O
</ALL>	O

<ALL>	O
Three	O
additional	O
components	O
accounted	O
for	O
the	O
steady	O
-	O
state	O
brain	B-Organ
response	O
to	O
a	O
39	O
-	O
Hz	O
background	O
click	O
train	O
.	O
</ALL>	O

<ALL>	O
Major	O
features	O
of	O
the	O
decomposition	O
proved	O
robust	O
across	O
sessions	O
and	O
changes	O
in	O
sensor	O
number	O
and	O
placement	O
.	O
</ALL>	O

<ALL>	O
This	O
method	O
of	O
ERP	O
analysis	O
can	O
be	O
used	O
to	O
compare	O
responses	O
from	O
multiple	O
stimuli	O
,	O
task	O
conditions	O
,	O
and	O
subject	O
states	O
.	O
</ALL>	O

<ALL>	O
[	O
Extra	O
-	O
anatomic	O
bypass	O
from	O
the	O
ascending	B-Multi-tissue_structure
aorta	I-Multi-tissue_structure
to	O
the	O
supraceliac	O
abdominal	B-Multi-tissue_structure
aorta	I-Multi-tissue_structure
-	O
-	O
surgical	O
option	O
applied	O
to	O
reoperation	O
for	O
aortic	B-Multi-tissue_structure
coarctation	O
or	O
interruption	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
optimal	O
approach	O
for	O
reoperation	O
following	O
repair	O
of	O
aortic	B-Multi-tissue_structure
coarctation	O
(	O
CoA	O
)	O
or	O
interruption	O
(	O
IAA	O
)	O
remains	O
controversial	O
.	O
</ALL>	O

<ALL>	O
Four	O
patients	O
underwent	O
extra	O
-	O
anatomic	O
bypass	O
for	O
restenosis	O
after	O
repair	O
of	O
CoA	O
or	O
IAA	O
.	O
</ALL>	O

<ALL>	O
The	O
age	O
ranged	O
from	O
4	O
to	O
12	O
years	O
.	O
</ALL>	O

<ALL>	O
The	O
initial	O
repairs	O
for	O
two	O
CoA	O
,	O
one	O
type	O
A	O
-	O
IAA	O
,	O
and	O
one	O
type	O
B	O
-	O
IAA	O
consisted	O
of	O
two	O
grafting	O
,	O
one	O
subclavian	O
arterial	B-Multi-tissue_structure
turning	O
-	O
down	O
aortoplasty	O
,	O
and	O
one	O
subclavian	O
flap	B-Multi-tissue_structure
aortoplasty	O
.	O
</ALL>	O

<ALL>	O
All	O
of	O
them	O
underwent	O
during	O
infancy	O
.	O
</ALL>	O

<ALL>	O
Preoperative	O
right	B-Organism_subdivision
arm	I-Organism_subdivision
systolic	O
pressure	O
ranged	O
from	O
140	O
to	O
190	O
mmHg	O
ar	O
rest	O
.	O
</ALL>	O

<ALL>	O
Through	O
a	O
midline	O
sternotomy	O
and	O
an	O
upper	O
laparotmy	O
incision	O
,	O
an	O
extra	O
-	O
anatomic	O
bypass	O
from	O
the	O
ascending	B-Multi-tissue_structure
aorta	I-Multi-tissue_structure
to	O
the	O
supraceliac	O
abdominal	B-Multi-tissue_structure
aorta	I-Multi-tissue_structure
was	O
employed	O
using	O
a	O
12	O
to	O
18	O
mm	O
tube	O
graft	O
.	O
</ALL>	O

<ALL>	O
All	O
patients	O
survived	O
surgeries	O
,	O
and	O
their	O
hypertension	O
markedly	O
improved	O
.	O
</ALL>	O

<ALL>	O
Our	O
experience	O
confirms	O
safety	O
and	O
effectiveness	O
of	O
this	O
option	O
in	O
selected	O
young	O
patients	O
with	O
re	O
-	O
stenosis	O
of	O
following	O
repair	O
of	O
CoA	O
or	O
IAA	O
.	O
</ALL>	O

<ALL>	O
Effect	O
of	O
a	O
mutation	O
in	O
the	O
anticodon	O
of	O
human	O
mitochondrial	B-Cellular_component
tRNAPro	O
on	O
its	O
post	O
-	O
transcriptional	O
modification	O
pattern	O
.	O
</ALL>	O

<ALL>	O
Although	O
the	O
gene	O
sequences	O
of	O
all	O
22	O
tRNAs	O
encoded	O
in	O
the	O
human	O
mitochondrial	B-Cellular_component
genome	I-Cellular_component
are	O
known	O
,	O
little	O
information	O
exists	O
about	O
their	O
sequences	O
at	O
the	O
RNA	O
level	O
.	O
</ALL>	O

<ALL>	O
This	O
becomes	O
a	O
crucial	O
limitation	O
when	O
searching	O
for	O
a	O
molecular	O
understanding	O
of	O
the	O
growing	O
number	O
of	O
maternally	O
inherited	O
human	O
diseases	O
correlated	O
with	O
point	O
mutations	O
in	O
tRNA	O
genes	O
.	O
</ALL>	O

<ALL>	O
Here	O
we	O
describe	O
the	O
sequence	O
of	O
human	O
mt	O
-	O
tRNAPropurified	O
from	O
placenta	B-Organ
.	O
</ALL>	O

<ALL>	O
It	O
shows	O
absence	O
of	O
editing	O
events	O
in	O
this	O
tRNA	O
and	O
highlights	O
the	O
presence	O
of	O
eight	O
post	O
-	O
transcriptional	O
modifications	O
.	O
</ALL>	O

<ALL>	O
These	O
include	O
T54	O
,	O
never	O
found	O
so	O
far	O
in	O
an	O
animal	O
mt	O
-	O
tRNA	O
,	O
and	O
m1G37	O
,	O
a	O
modification	O
known	O
to	O
have	O
fundamental	O
functional	O
properties	O
in	O
a	O
number	O
of	O
canonical	O
tRNAs	O
.	O
</ALL>	O

<ALL>	O
Occurrence	O
of	O
m1G37	O
was	O
further	O
investigated	O
in	O
an	O
analysis	O
of	O
the	O
substrate	O
properties	O
of	O
in	O
vitro	O
transcripts	O
of	O
human	O
mt	O
-	O
tRNAProtowards	O
pure	O
Escherichia	O
coli	O
methylguanosine	O
transferase	O
.	O
</ALL>	O

<ALL>	O
This	O
enzyme	O
properly	O
methylates	O
G37	O
in	O
mt	O
-	O
tRNA	O
and	O
is	O
sensitive	O
to	O
the	O
presence	O
of	O
a	O
second	O
G	O
at	O
position	O
36	O
,	O
neighboring	O
the	O
target	O
nucleotide	O
for	O
methylation	O
.	O
</ALL>	O

<ALL>	O
Since	O
mutation	O
of	O
nt	O
36	O
was	O
shown	O
to	O
be	O
correlated	O
with	O
myopathy	O
,	O
the	O
potential	O
consequences	O
of	O
non	O
-	O
modification	O
or	O
under	O
-	O
modification	O
of	O
mt	O
-	O
tRNA	O
nucleotides	O
in	O
expression	O
of	O
the	O
particular	O
myopathy	O
and	O
of	O
mitochondrial	B-Cellular_component
diseases	O
in	O
general	O
are	O
discussed	O
.	O
</ALL>	O

<ALL>	O
Clozapine	O
-	O
induced	O
agranulocytosis	O
and	O
thrombopenia	O
in	O
a	O
patient	O
with	O
dopaminergic	O
psychosis	O
.	O
</ALL>	O

<ALL>	O
In	O
patients	O
with	O
Parkinson	O
'	O
disease	O
and	O
dopaminergic	O
psychosis	O
,	O
clozapine	O
treatment	O
is	O
recommended	O
as	O
the	O
drug	O
is	O
free	O
from	O
extrapyramidal	O
side	O
effects	O
and	O
does	O
not	O
worsen	O
motor	O
symptoms	O
of	O
the	O
underlying	O
disease	O
.	O
</ALL>	O

<ALL>	O
The	O
use	O
of	O
clozapine	O
,	O
however	O
,	O
is	O
limited	O
due	O
to	O
its	O
hematotoxic	O
side	O
effects	O
.	O
</ALL>	O

<ALL>	O
For	O
treatment	O
of	O
clozapine	O
-	O
induced	O
agranulocytosis	O
,	O
granulocyte	O
colony	O
-	O
stimulating	O
factors	O
(	O
G	O
-	O
CSF	O
)	O
are	O
recommended	O
.	O
</ALL>	O

<ALL>	O
We	O
report	O
the	O
case	O
of	O
a	O
72	O
-	O
years	O
-	O
old	O
male	O
patient	O
with	O
clozapine	O
-	O
induced	O
agranulocytosis	O
and	O
thrombopenia	O
.	O
</ALL>	O

<ALL>	O
Neutropenia	O
was	O
successfully	O
treated	O
with	O
G	O
-	O
CSF	O
,	O
but	O
thrombopenia	O
persisted	O
and	O
resolved	O
spontaneously	O
after	O
14	O
days	O
.	O
</ALL>	O

<ALL>	O
Bone	B-Multi-tissue_structure
marrow	I-Multi-tissue_structure
toxicity	O
of	O
clozapine	O
is	O
not	O
restricted	O
to	O
white	B-Cell
cell	I-Cell
maturation	O
,	O
but	O
may	O
also	O
impair	O
thrombocytopoesis	O
.	O
</ALL>	O

<ALL>	O
Acylase	O
I	O
-	O
catalyzed	O
deacetylation	O
of	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
and	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
.	O
</ALL>	O

<ALL>	O
The	O
aminoacylase	O
that	O
catalyzes	O
the	O
hydrolysis	O
of	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
(	O
NAC	O
)	O
was	O
identified	O
as	O
acylase	O
I	O
after	O
purification	O
by	O
column	O
chromatography	O
and	O
electrophoretic	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Rat	O
kidney	B-Organism_substance
cytosol	I-Organism_substance
was	O
fractionated	O
by	O
ammonium	O
sulfate	O
precipitation	O
,	O
and	O
the	O
proteins	O
were	O
separated	O
by	O
ion	O
-	O
exchange	O
column	O
chromatography	O
,	O
gel	O
-	O
filtration	O
column	O
chromatography	O
,	O
and	O
hydrophobic	O
interaction	O
column	O
chromatography	O
.	O
</ALL>	O

<ALL>	O
Acylase	O
activity	O
with	O
NAC	O
and	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
methionine	O
(	O
NAM	O
)	O
,	O
a	O
known	O
substrate	O
for	O
acylase	O
I	O
,	O
as	O
substrates	O
coeluted	O
during	O
all	O
chromatographic	O
steps	O
.	O
</ALL>	O

<ALL>	O
Sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
showed	O
that	O
the	O
protein	O
was	O
purified	O
to	O
near	O
homogeneity	O
and	O
had	O
a	O
subunit	O
Mr	O
of	O
43	O
000	O
,	O
which	O
is	O
identical	O
with	O
the	O
Mr	O
of	O
acylase	O
I	O
from	O
porcine	O
kidney	B-Organ
and	O
bovine	O
liver	B-Organ
.	O
</ALL>	O

<ALL>	O
n	O
-	O
Butylmalonic	O
acid	O
was	O
a	O
slow	O
-	O
binding	O
inhibitor	O
of	O
acylase	O
I	O
and	O
inhibited	O
the	O
deacetylation	O
of	O
NAC	O
with	O
a	O
Ki	O
of	O
192	O
+	O
/	O
-	O
27	O
microM	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
show	O
that	O
acylase	O
I	O
catalyzes	O
the	O
deacetylation	O
of	O
NAC	O
.	O
</ALL>	O

<ALL>	O
The	O
acylase	O
I	O
-	O
catalyzed	O
deacetylation	O
of	O
a	O
range	O
of	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
,	O
their	O
carbon	O
and	O
oxygen	O
analogues	O
,	O
and	O
the	O
selenium	O
analogue	O
of	O
NAM	O
was	O
also	O
studied	O
with	O
porcine	O
kidney	B-Organ
acylase	O
I	O
.	O
</ALL>	O

<ALL>	O
The	O
specific	O
activity	O
of	O
the	O
acylase	O
I	O
-	O
catalyzed	O
deacetylation	O
of	O
these	O
substrates	O
was	O
related	O
to	O
their	O
calculated	O
molar	O
volumes	O
and	O
log	O
P	O
values	O
.	O
</ALL>	O

<ALL>	O
The	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
with	O
short	O
(	O
C0	O
-	O
C3	O
)	O
and	O
unbranched	O
S	O
-	O
alkyl	O
substituents	O
were	O
good	O
acylase	O
I	O
substrates	O
,	O
whereas	O
the	O
S	O
-	O
alkyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteines	O
with	O
long	O
(	O
>	O
C3	O
)	O
and	O
branched	O
S	O
-	O
alkyl	O
substituents	O
were	O
poLr	O
acylase	O
I	O
substrates	O
.	O
</ALL>	O

<ALL>	O
The	O
carbon	O
and	O
oxygen	O
analogues	O
of	O
S	O
-	O
methyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
and	O
the	O
carbon	O
analogue	O
of	O
S	O
-	O
ethyl	O
-	O
N	O
-	O
acetyl	O
-	O
L	O
-	O
cysteine	O
were	O
poor	O
acylase	O
I	O
substrates	O
,	O
whereas	O
the	O
selenium	O
analogue	O
of	O
NAM	O
was	O
a	O
good	O
acylase	O
I	O
substrate	O
.	O
</ALL>	O

<ALL>	O
Hemispheric	O
control	O
of	O
motor	O
function	O
:	O
a	O
whole	O
brain	B-Organ
echo	O
planar	O
fMRI	O
study	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
whether	O
recruitment	O
of	O
the	O
ipsilateral	B-Multi-tissue_structure
motor	I-Multi-tissue_structure
cortex	I-Multi-tissue_structure
during	O
non	O
-	O
dominant	O
motor	O
movement	O
reflects	O
left	B-Multi-tissue_structure
hemispheric	I-Multi-tissue_structure
control	O
of	O
motor	O
function	O
or	O
simply	O
the	O
greater	O
complexity	O
or	O
unfamiliarity	O
of	O
the	O
motor	O
task	O
.	O
</ALL>	O

<ALL>	O
BOLD	O
fMRI	O
was	O
performed	O
in	O
normal	O
right	O
-	O
handers	O
during	O
two	O
motor	O
tasks	O
:	O
(	O
1	O
)	O
sequential	O
finger	B-Organism_subdivision
movements	O
(	O
SM	O
task	O
)	O
with	O
the	O
right	O
or	O
left	O
hand	B-Organism_subdivision
;	O
and	O
(	O
2	O
)	O
random	O
finger	B-Organism_subdivision
movements	O
(	O
RM	O
task	O
)	O
with	O
the	O
right	O
hand	B-Organism_subdivision
.	O
</ALL>	O

<ALL>	O
In	O
all	O
subjects	O
,	O
activation	O
was	O
predominantly	O
in	O
the	O
contralateral	O
motor	O
areas	O
(	O
primary	O
sensorimotor	O
,	O
lateral	O
premotor	O
,	O
parietal	O
and	O
supplementary	O
motor	O
regions	O
)	O
and	O
ipsilateral	B-Multi-tissue_structure
cerebellum	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
While	O
the	O
ipsilateral	B-Multi-tissue_structure
motor	I-Multi-tissue_structure
areas	I-Multi-tissue_structure
were	O
also	O
activated	O
,	O
single	O
subject	O
analysis	O
revealed	O
these	O
areas	O
to	O
be	O
more	O
extensive	O
and	O
to	O
be	O
seen	O
in	O
more	O
subjects	O
during	O
the	O
non	O
-	O
dominant	O
hand	B-Organism_subdivision
SM	O
task	O
and	O
dominant	O
hand	B-Organism_subdivision
RM	O
task	O
than	O
during	O
the	O
more	O
familiar	O
dominant	O
hand	B-Organism_subdivision
SM	O
task	O
.	O
</ALL>	O

<ALL>	O
Similarly	O
,	O
group	O
analysis	O
also	O
revealed	O
ipsilateral	O
activation	O
in	O
the	O
primary	O
sensorimotor	O
and	O
lateral	B-Multi-tissue_structure
premotor	I-Multi-tissue_structure
areas	I-Multi-tissue_structure
,	O
but	O
only	O
during	O
the	O
non	O
-	O
dominant	O
SM	O
task	O
and	O
the	O
dominant	O
hand	B-Organism_subdivision
RM	O
task	O
.	O
</ALL>	O

<ALL>	O
Non	O
-	O
dominant	O
hand	B-Organism_subdivision
movements	O
,	O
perhaps	O
because	O
they	O
are	O
less	O
'	O
automatic	O
'	O
,	O
appear	O
to	O
require	O
more	O
cortical	B-Multi-tissue_structure
activity	O
similar	O
to	O
complex	O
tasks	O
with	O
the	O
dominant	O
hand	B-Organism_subdivision
,	O
and	O
result	O
in	O
greater	O
recruitment	O
of	O
ipsilateral	B-Multi-tissue_structure
cortical	I-Multi-tissue_structure
motor	I-Multi-tissue_structure
areas	I-Multi-tissue_structure
and	O
striatum	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
The	O
study	O
also	O
illustrates	O
how	O
potentially	O
meaningful	O
subtleties	O
seen	O
on	O
individual	O
maps	O
may	O
be	O
obscured	O
with	O
group	O
averaging	O
approaches	O
.	O
</ALL>	O

<ALL>	O
Selective	O
inhibition	O
of	O
the	O
renal	B-Organ
dopamine	O
subtype	O
D1A	O
receptor	O
induces	O
antinatriuresis	O
in	O
conscious	O
rats	O
.	O
</ALL>	O

<ALL>	O
Both	O
dopamine	O
D1	O
-	O
like	O
(	O
D1A	O
and	O
D1B	O
)	O
and	O
D2	O
-	O
like	O
(	O
D2	O
,	O
D3	O
,	O
and	O
D4	O
)	O
receptor	O
subfamilies	O
are	O
present	O
in	O
the	O
kidney	B-Organ
.	O
</ALL>	O

<ALL>	O
Blockade	O
of	O
the	O
intrarenal	O
D1	O
-	O
like	O
receptor	O
family	O
is	O
associated	O
with	O
natriuresis	O
and	O
diuresis	O
.	O
</ALL>	O

<ALL>	O
Because	O
the	O
D1A	O
and	O
D1B	O
receptor	O
subtypes	O
are	O
not	O
distinguishable	O
by	O
currently	O
available	O
dopaminergic	O
agents	O
,	O
their	O
functional	O
role	O
remains	O
undefined	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
selective	O
inhibition	O
of	O
the	O
renal	B-Organ
D1A	O
receptor	O
with	O
phosphorothioated	O
antisense	O
oligodeoxynucleotide	O
(	O
AS	O
-	O
ODN	O
)	O
was	O
investigated	O
in	O
conscious	O
uninephrectomized	O
rats	O
.	O
</ALL>	O

<ALL>	O
After	O
renal	B-Immaterial_anatomical_entity
interstitial	I-Immaterial_anatomical_entity
administration	O
of	O
Texas	O
red	O
-	O
labeled	O
D1A	O
receptor	O
AS	O
-	O
ODN	O
,	O
intense	O
fluorescent	O
signal	O
was	O
localized	O
in	O
the	O
renal	B-Tissue
tubular	I-Tissue
epithelium	I-Tissue
and	O
vasculature	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
In	O
rats	O
on	O
normal	O
salt	O
intake	O
,	O
AS	O
-	O
ODN	O
injected	O
interstitially	O
into	O
the	O
kidney	B-Organ
reduced	O
daily	O
urinary	B-Organism_substance
sodium	O
excretion	O
(	O
1	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
04	O
versus	O
0	O
.	O
8	O
+	O
/	O
-	O
0	O
.	O
2	O
mEq	O
/	O
d	O
,	O
n	O
=	O
5	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
urine	B-Organism_substance
output	O
(	O
16	O
.	O
9	O
+	O
/	O
-	O
3	O
.	O
8	O
versus	O
12	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
6	O
mL	O
/	O
d	O
,	O
n	O
=	O
5	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
rats	O
on	O
high	O
sodium	O
intake	O
,	O
continuous	O
renal	B-Immaterial_anatomical_entity
interstitial	I-Immaterial_anatomical_entity
administration	O
of	O
D1A	O
receptor	O
AS	O
-	O
ODN	O
transiently	O
decreased	O
daily	O
urinary	B-Organism_substance
sodium	O
excretion	O
(	O
5	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
5	O
versus	O
4	O
.	O
2	O
+	O
/	O
-	O
0	O
.	O
3	O
mEq	O
/	O
d	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
urine	B-Organism_substance
output	O
(	O
27	O
.	O
6	O
+	O
/	O
-	O
4	O
.	O
5	O
versus	O
18	O
.	O
1	O
+	O
/	O
-	O
1	O
.	O
8	O
mL	O
/	O
d	O
,	O
n	O
=	O
7	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
</ALL>	O

<ALL>	O
Neither	O
vehicle	O
nor	O
sense	O
oligodeoxynucleotide	O
had	O
significant	O
effects	O
.	O
</ALL>	O

<ALL>	O
Systolic	O
blood	B-Organism_substance
pressure	O
remained	O
unchanged	O
.	O
</ALL>	O

<ALL>	O
The	O
renal	B-Organ
D1A	O
receptor	O
protein	O
was	O
significantly	O
decreased	O
by	O
35	O
%	O
and	O
46	O
%	O
at	O
the	O
end	O
of	O
the	O
study	O
in	O
AS	O
-	O
ODN	O
-	O
treated	O
rats	O
on	O
normal	O
and	O
high	O
salt	O
intake	O
,	O
respectively	O
,	O
whereas	O
the	O
D1B	O
receptor	O
and	O
beta	O
-	O
actin	O
were	O
not	O
affected	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
the	O
renal	B-Organ
D1A	O
receptor	O
subtype	O
plays	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
sodium	O
excretion	O
.	O
</ALL>	O

<ALL>	O
[	O
Epidemiology	O
of	O
respiratory	B-Anatomical_system
allergy	O
in	O
children	O
]	O
.	O
</ALL>	O

<ALL>	O
Epidemiology	O
of	O
paediatric	O
respiratory	B-Anatomical_system
allergic	O
disorders	O
allows	O
the	O
approach	O
to	O
causal	O
and	O
preventive	O
risk	O
factors	O
by	O
studying	O
groups	O
or	O
sub	O
groups	O
of	O
children	O
in	O
different	O
locations	O
and	O
under	O
different	O
conditions	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
,	O
however	O
,	O
complicated	O
by	O
the	O
lack	O
of	O
consensus	O
on	O
disease	O
definitions	O
,	O
which	O
renders	O
comparisons	O
between	O
studies	O
difficult	O
.	O
</ALL>	O

<ALL>	O
Atopy	O
is	O
usually	O
defined	O
by	O
the	O
presence	O
of	O
positive	O
skin	B-Organ
tests	O
(	O
wheal	O
size	O
of	O
at	O
least	O
a	O
mean	O
diameter	O
>	O
or	O
=	O
3	O
mm	O
)	O
,	O
by	O
the	O
presence	O
of	O
specific	O
IgE	O
,	O
or	O
by	O
the	O
presence	O
of	O
increased	O
total	O
IgE	O
(	O
>	O
or	O
=	O
100	O
UI	O
/	O
mL	O
)	O
.	O
</ALL>	O

<ALL>	O
Infantile	O
asthma	O
is	O
not	O
well	O
defined	O
,	O
complicated	O
by	O
the	O
high	O
prevalence	O
of	O
bronchiolitis	O
;	O
one	O
thus	O
questions	O
between	O
wheezing	O
or	O
wheezy	O
bronchitis	O
.	O
</ALL>	O

<ALL>	O
Prevalence	O
is	O
high	O
:	O
among	O
early	O
wheezers	O
,	O
two	O
populations	O
will	O
be	O
defined	O
by	O
the	O
medium	O
term	O
evolution	O
:	O
transient	O
wheezers	O
and	O
persistent	O
wheezers	O
.	O
</ALL>	O

<ALL>	O
Risk	O
factors	O
for	O
these	O
two	O
conditions	O
are	O
different	O
.	O
</ALL>	O

<ALL>	O
Childhood	O
asthma	O
may	O
be	O
defined	O
by	O
the	O
diagnosis	O
of	O
asthma	O
(	O
specific	O
but	O
fairly	O
non	O
-	O
sensitive	O
)	O
,	O
by	O
asthmatic	O
symptoms	O
(	O
wheezing	O
,	O
waking	O
by	O
an	O
attack	O
of	O
shortness	O
of	O
breath	O
)	O
(	O
sensitive	O
but	O
not	O
very	O
specific	O
)	O
,	O
or	O
by	O
the	O
combination	O
of	O
symptoms	O
and	O
airway	B-Multi-tissue_structure
hyperresponsiveness	O
.	O
</ALL>	O

<ALL>	O
The	O
ISAAC	O
study	O
has	O
standardised	O
a	O
questionnaire	O
to	O
assess	O
the	O
prevalence	O
of	O
asthma	O
.	O
</ALL>	O

<ALL>	O
The	O
preliminary	O
results	O
show	O
that	O
there	O
are	O
wide	O
variations	O
across	O
the	O
world	O
.	O
</ALL>	O

<ALL>	O
The	O
prevalence	O
is	O
low	O
in	O
Africa	O
and	O
Asia	O
,	O
intermediate	O
in	O
Europe	O
,	O
and	O
high	O
in	O
Anglo	O
-	O
Saxon	O
countries	O
.	O
</ALL>	O

<ALL>	O
The	O
prevalence	O
of	O
asthma	O
has	O
gradually	O
increased	O
over	O
the	O
past	O
20	O
years	O
in	O
developed	O
countries	O
.	O
</ALL>	O

<ALL>	O
Asthma	O
and	O
atopy	O
are	O
closely	O
associated	O
in	O
children	O
.	O
</ALL>	O

<ALL>	O
Risk	O
factors	O
are	O
genetic	O
,	O
associated	O
with	O
sex	O
and	O
environmental	O
factors	O
.	O
</ALL>	O

<ALL>	O
Among	O
these	O
,	O
allergic	O
sensitisation	O
is	O
associated	O
with	O
the	O
degree	O
of	O
exposure	O
to	O
allergens	O
.	O
</ALL>	O

<ALL>	O
Westernization	O
of	O
way	O
of	O
life	O
is	O
associated	O
with	O
increased	O
prevalence	O
of	O
atopy	O
,	O
allergic	O
rhinitis	O
and	O
asthma	O
.	O
</ALL>	O

<ALL>	O
Atopy	O
seems	O
inversely	O
correlated	O
to	O
certain	O
infections	O
.	O
</ALL>	O

<ALL>	O
Passive	O
smoking	O
is	O
clearly	O
associated	O
with	O
early	O
wheezing	O
.	O
</ALL>	O

<ALL>	O
This	O
and	O
atmospheric	O
pollution	O
aggravate	O
childhood	O
asthma	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
inducing	O
role	O
of	O
pollution	O
on	O
asthma	O
is	O
still	O
controversial	O
.	O
</ALL>	O

<ALL>	O
Novel	O
mechanism	O
for	O
the	O
impairment	O
of	O
cell	B-Cell
proliferation	O
in	O
HIV	O
-	O
1	O
infection	O
.	O
</ALL>	O

<ALL>	O
The	O
synthesis	O
of	O
ribonucleotides	O
is	O
essential	O
to	O
cell	B-Cell
proliferation	O
.	O
</ALL>	O

<ALL>	O
Defects	O
in	O
the	O
relevant	O
metabolic	O
pathways	O
have	O
been	O
demonstrated	O
in	O
stimulated	O
T	B-Cell
cells	I-Cell
from	O
AIDS	O
patients	O
and	O
are	O
associated	O
with	O
lymphocyte	B-Cell
necrotic	O
death	O
.	O
</ALL>	O

<ALL>	O
Here	O
,	O
Margarita	O
Bofill	O
and	O
colleagues	O
discuss	O
the	O
possibility	O
that	O
an	O
impaired	O
ribonucleotide	O
metabolism	O
might	O
be	O
common	O
to	O
all	O
rapidly	O
dividing	O
cells	B-Cell
and	O
thus	O
contribute	O
to	O
other	O
recognized	O
symptoms	O
of	O
HIV	O
-	O
1	O
infection	O
.	O
</ALL>	O

<ALL>	O
A	O
pancreatic	B-Cell
beta	I-Cell
-	I-Cell
cell	I-Cell
-	O
specific	O
enhancer	O
in	O
the	O
human	O
PDX	O
-	O
1	O
gene	O
is	O
regulated	O
by	O
hepatocyte	O
nuclear	O
factor	O
3beta	O
(	O
HNF	O
-	O
3beta	O
)	O
,	O
HNF	O
-	O
1alpha	O
,	O
and	O
SPs	O
transcription	O
factors	O
.	O
</ALL>	O

<ALL>	O
The	O
PDX	O
-	O
1	O
transcription	O
factor	O
plays	O
a	O
key	O
role	O
in	O
pancreas	B-Organ
development	O
.	O
</ALL>	O

<ALL>	O
Although	O
expressed	O
in	O
all	O
cells	B-Cell
at	O
the	O
early	O
stages	O
,	O
in	O
the	O
adult	O
it	O
is	O
mainly	O
restricted	O
to	O
the	O
beta	B-Cell
-	I-Cell
cell	I-Cell
.	O
</ALL>	O

<ALL>	O
To	O
characterize	O
the	O
regulatory	O
elements	O
and	O
potential	O
transcription	O
factors	O
necessary	O
for	O
human	O
PDX	O
-	O
1	O
gene	O
expression	O
in	O
beta	B-Cell
-	I-Cell
cells	I-Cell
,	O
we	O
constructed	O
a	O
series	O
of	O
5	O
'	O
and	O
3	O
'	O
deletion	O
fragments	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
gene	O
,	O
fused	O
to	O
the	O
luciferase	O
reporter	O
gene	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
report	O
,	O
we	O
identify	O
by	O
transient	O
transfections	O
in	O
beta	B-Cell
-	I-Cell
and	O
non	B-Cell
-	I-Cell
beta	I-Cell
-	I-Cell
cells	I-Cell
a	O
novel	O
beta	B-Cell
-	I-Cell
cell	I-Cell
-	O
specific	O
distal	O
enhancer	O
element	O
located	O
between	O
-	O
3	O
.	O
7	O
and	O
-	O
3	O
.	O
45	O
kilobases	O
.	O
</ALL>	O

<ALL>	O
DNase	O
I	O
footprinting	O
analysis	O
revealed	O
two	O
protected	O
regions	O
,	O
one	O
binding	O
the	O
transcription	O
factors	O
SP1	O
and	O
SP3	O
and	O
the	O
other	O
hepatocyte	O
nuclear	O
factor	O
3beta	O
(	O
HNF	O
-	O
3beta	O
)	O
and	O
HNF	O
-	O
1alpha	O
.	O
</ALL>	O

<ALL>	O
Cotransfection	O
experiments	O
suggest	O
that	O
HNF	O
-	O
3beta	O
,	O
HNF	O
-	O
1alpha	O
,	O
and	O
SP1	O
are	O
positive	O
regulators	O
of	O
the	O
herein	O
-	O
described	O
human	O
PDX	O
-	O
1	O
enhancer	O
element	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
mutations	O
within	O
each	O
motif	O
abolished	O
the	O
binding	O
of	O
the	O
corresponding	O
factor	O
(	O
s	O
)	O
and	O
dramatically	O
impaired	O
the	O
enhancer	O
activity	O
,	O
therefore	O
suggesting	O
cooperativity	O
between	O
these	O
factors	O
.	O
</ALL>	O

<ALL>	O
[	O
A	O
decline	O
in	O
the	O
French	O
demographic	O
situation	O
in	O
the	O
context	O
of	O
a	O
Europe	O
also	O
in	O
demographic	O
decline	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
author	O
analyzes	O
the	O
decline	O
in	O
French	O
fertility	O
which	O
has	O
occurred	O
over	O
the	O
past	O
two	O
years	O
using	O
data	O
from	O
official	O
sources	O
.	O
</ALL>	O

<ALL>	O
Some	O
comparisons	O
are	O
made	O
with	O
fertility	O
trends	O
in	O
other	O
European	O
countries	O
.	O
</ALL>	O

<ALL>	O
The	O
patterns	O
of	O
internal	O
migration	O
in	O
Maharashtra	O
:	O
an	O
analysis	O
of	O
1971	O
census	O
data	O
.	O
</ALL>	O

<ALL>	O
Patterns	O
of	O
internal	O
migration	O
in	O
the	O
state	O
of	O
Maharashtra	O
,	O
India	O
,	O
for	O
the	O
period	O
1961	O
-	O
1971	O
are	O
analyzed	O
using	O
1971	O
census	O
data	O
.	O
</ALL>	O

<ALL>	O
The	O
nature	O
,	O
volume	O
,	O
and	O
direction	O
of	O
migration	O
are	O
examined	O
.	O
</ALL>	O

<ALL>	O
Migrants	O
are	O
characterized	O
according	O
to	O
factors	O
including	O
age	O
,	O
sex	O
,	O
marital	O
status	O
,	O
occupation	O
,	O
and	O
areas	O
of	O
origin	O
and	O
destination	O
.	O
</ALL>	O

<ALL>	O
Deletion	O
of	O
guanine	O
nucleotide	O
binding	O
protein	O
alpha	O
z	O
subunit	O
in	O
mice	O
induces	O
a	O
gene	O
dose	O
dependent	O
tolerance	O
to	O
morphine	O
.	O
</ALL>	O

<ALL>	O
The	O
mechanism	O
underlying	O
the	O
development	O
of	O
tolerance	O
to	O
morphine	O
is	O
still	O
incompletely	O
understood	O
.	O
</ALL>	O

<ALL>	O
Morphine	O
binds	O
to	O
opioid	O
receptors	O
,	O
which	O
in	O
turn	O
activates	O
downstream	O
second	O
messenger	O
cascades	O
through	O
heterotrimeric	O
guanine	O
nucleotide	O
binding	O
proteins	O
(	O
G	O
proteins	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
paper	O
,	O
we	O
show	O
that	O
G	O
(	O
z	O
)	O
,	O
a	O
member	O
of	O
the	O
inhibitory	O
G	O
protein	O
family	O
,	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
the	O
analgesic	O
and	O
lethality	O
effects	O
of	O
morphine	O
after	O
tolerance	O
development	O
.	O
</ALL>	O

<ALL>	O
We	O
blocked	O
signaling	O
through	O
the	O
G	O
(	O
z	O
)	O
second	O
messenger	O
cascade	O
by	O
genetic	O
ablation	O
of	O
the	O
alpha	O
subunit	O
of	O
the	O
G	O
protein	O
in	O
mice	O
.	O
</ALL>	O

<ALL>	O
The	O
Galpha	O
(	O
z	O
)	O
knockout	O
mouse	O
develops	O
significantly	O
increased	O
tolerance	O
to	O
morphine	O
,	O
which	O
depends	O
on	O
Galpha	O
(	O
z	O
)	O
gene	O
dosage	O
.	O
</ALL>	O

<ALL>	O
Further	O
experiments	O
demonstrate	O
that	O
the	O
enhanced	O
morphine	O
tolerance	O
is	O
not	O
caused	O
by	O
pharmacokinetic	O
and	O
behavioural	O
learning	O
mechanisms	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
suggest	O
that	O
G	O
(	O
z	O
)	O
signaling	O
pathways	O
are	O
involved	O
in	O
transducing	O
the	O
analgesic	O
and	O
lethality	O
effects	O
of	O
morphine	O
following	O
chronic	O
morphine	O
treatment	O
.	O
</ALL>	O

<ALL>	O
Effects	O
of	O
buffer	O
properties	O
on	O
cyclodextrin	O
glucanotransferase	O
reactions	O
and	O
cyclodextrin	O
production	O
from	O
raw	O
sago	O
(	O
Cycas	O
revoluta	O
)	O
starch	B-Organism_substance
.	O
</ALL>	O

<ALL>	O
Results	O
from	O
the	O
present	O
study	O
have	O
shown	O
that	O
the	O
ionic	O
species	O
of	O
buffers	O
,	O
pH	O
values	O
and	O
reaction	O
temperature	O
can	O
affect	O
the	O
enzyme	O
unit	O
activities	O
and	O
product	O
specificity	O
of	O
Toruzyme	O
(	O
Novo	O
Nordisk	O
A	O
/	O
S	O
Bagsvaerd	O
,	O
Denmark	O
)	O
CGTase	O
(	O
cyclodextrin	O
glucanotransferase	O
)	O
.	O
</ALL>	O

<ALL>	O
Applying	O
a	O
similar	O
reaction	O
environment	O
(	O
acetate	O
buffer	O
,	O
pH	O
6	O
.	O
0	O
;	O
temperature	O
,	O
60	O
degrees	O
C	O
)	O
,	O
the	O
CGTase	O
was	O
found	O
to	O
be	O
capable	O
of	O
producing	O
pre	O
dominantly	O
beta	O
-	O
cyclodextrin	O
from	O
either	O
raw	O
or	O
gelatinized	O
sago	O
(	O
Cycas	O
revoluta	O
)	O
starch	B-Organism_substance
.	O
</ALL>	O

<ALL>	O
Changing	O
the	O
buffer	O
from	O
acetate	O
to	O
phosphate	O
reduced	O
the	O
yield	O
of	O
beta	O
-	O
cyclodextrin	O
from	O
2	O
.	O
48	O
to	O
1	O
.	O
42	O
mg	O
/	O
ml	O
and	O
also	O
affected	O
the	O
product	O
specificity	O
,	O
where	O
production	O
of	O
both	O
alpha	O
-	O
and	O
beta	O
-	O
cyclodextrins	O
were	O
more	O
pronounced	O
.	O
</ALL>	O

<ALL>	O
The	O
decrease	O
in	O
the	O
production	O
of	O
cyclodextrins	O
in	O
phosphate	O
buffer	O
was	O
significant	O
at	O
both	O
pH	O
6	O
.	O
0	O
and	O
7	O
.	O
0	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
changing	O
the	O
buffer	O
to	O
Tris	O
/	O
HCl	O
(	O
pH	O
7	O
.	O
0	O
)	O
showed	O
a	O
significant	O
increase	O
in	O
beta	O
-	O
cyclodextrin	O
production	O
.	O
</ALL>	O

<ALL>	O
Increasing	O
the	O
ionic	O
strength	O
of	O
sodium	O
acetate	O
and	O
Tris	O
/	O
HCl	O
buffers	O
at	O
pH	O
6	O
.	O
0	O
and	O
7	O
.	O
0	O
to	O
equivalent	O
ionic	O
strength	O
of	O
phosphate	O
buffers	O
showed	O
no	O
significant	O
effects	O
on	O
cyclodextrin	O
production	O
.	O
</ALL>	O

<ALL>	O
Higher	O
yield	O
of	O
cyclodextrins	O
at	O
pH	O
7	O
.	O
0	O
when	O
Tris	O
/	O
HCl	O
was	O
used	O
might	O
be	O
due	O
to	O
the	O
binding	O
of	O
chloride	O
ions	O
at	O
the	O
calcium	O
-	O
binding	O
sites	O
of	O
the	O
CGTase	O
,	O
resulting	O
in	O
the	O
shift	O
of	O
the	O
optimum	O
pH	O
close	O
to	O
physiological	O
environment	O
,	O
leading	O
to	O
an	O
increase	O
in	O
the	O
activities	O
and	O
specificity	O
.	O
</ALL>	O

<ALL>	O
Rational	O
synthesis	O
of	O
multicyclic	O
bis	O
[	O
2	O
]	O
catenanes	O
.	O
</ALL>	O

<ALL>	O
Bis	O
-	O
loop	O
tetraurea	O
calix	O
[	O
4	O
]	O
arene	O
6	O
has	O
been	O
prepared	O
by	O
acylation	O
of	O
the	O
wide	O
-	O
rim	O
calix	O
[	O
4	O
]	O
arene	O
tetraamine	O
1	O
with	O
the	O
activated	O
bis	O
(	O
urethane	O
)	O
8	O
under	O
dilution	O
conditions	O
.	O
</ALL>	O

<ALL>	O
Similarly	O
the	O
bis	O
(	O
Boc	O
-	O
protected	O
)	O
tetraamine	O
2	O
is	O
converted	O
into	O
the	O
mono	O
-	O
loop	O
derivative	O
3	O
which	O
after	O
deprotection	O
and	O
acylation	O
gives	O
the	O
bisalkenyl	O
derivative	O
5	O
.	O
</ALL>	O

<ALL>	O
In	O
apolar	O
solvents	O
this	O
tetraurea	O
calix	O
[	O
4	O
]	O
arene	O
5	O
forms	O
regioselectively	O
a	O
single	O
hydrogen	O
-	O
bonded	O
homodimer	O
,	O
from	O
which	O
the	O
bis	O
[	O
2	O
]	O
catenane	O
10a	O
is	O
formed	O
in	O
49	O
%	O
by	O
a	O
metathesis	O
reaction	O
followed	O
by	O
hydrogenation	O
.	O
</ALL>	O

<ALL>	O
Bis	O
-	O
loop	O
derivative	O
6	O
forms	O
no	O
homodimers	O
for	O
steric	O
reasons	O
,	O
but	O
a	O
stoichiometric	O
mixture	O
with	O
the	O
open	O
-	O
chain	O
tetraalkenyl	O
derivative	O
7a	O
contains	O
exclusively	O
the	O
heterodimer	O
.	O
</ALL>	O

<ALL>	O
Metathesis	O
and	O
subsequent	O
hydrogenation	O
now	O
yields	O
65	O
%	O
of	O
the	O
pure	O
bis	O
[	O
2	O
]	O
catenane	O
10a	O
which	O
could	O
not	O
be	O
isolated	O
from	O
the	O
complex	O
reaction	O
mixture	O
obtained	O
from	O
the	O
homodimer	O
7a	O
.	O
7a	O
.	O
</ALL>	O

<ALL>	O
The	O
chirality	O
of	O
10a	O
(	O
D	O
(	O
2	O
)	O
symmetry	O
)	O
has	O
been	O
verified	O
by	O
optical	O
resolution	O
using	O
HPLC	O
on	O
a	O
chiral	O
stationary	O
phase	O
.	O
</ALL>	O

<ALL>	O
Sciatic	B-Multi-tissue_structure
nerve	I-Multi-tissue_structure
repair	O
by	O
microgrooved	O
nerve	B-Multi-tissue_structure
conduits	O
made	O
of	O
chitosan	O
-	O
gold	O
nanocomposites	O
.	O
</ALL>	O

<ALL>	O
BACKGROUND	O
:	O
</ALL>	O

<ALL>	O
To	O
better	O
direct	O
the	O
repair	O
of	O
peripheral	B-Multi-tissue_structure
nerve	I-Multi-tissue_structure
after	O
injury	O
,	O
an	O
implant	O
consisting	O
of	O
a	O
multicomponent	O
micropatterned	O
conduit	B-Multi-tissue_structure
seeded	O
with	O
NSC	B-Cell
was	O
designed	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
The	O
mechanical	O
properties	O
of	O
the	O
chi	O
-	O
Au	O
nanocomposites	O
were	O
tested	O
.	O
</ALL>	O

<ALL>	O
In	O
vitro	O
,	O
the	O
effect	O
of	O
chi	O
-	O
Au	O
on	O
cell	B-Cell
behavior	O
(	O
NSC	B-Cell
and	O
glial	B-Cell
cell	I-Cell
line	I-Cell
C6	I-Cell
)	O
and	O
the	O
influence	O
of	O
micropattern	O
on	O
cell	B-Cell
alignment	O
were	O
evaluated	O
.	O
</ALL>	O

<ALL>	O
In	O
vivo	O
,	O
the	O
micropatterned	O
conduits	O
with	O
/	O
without	O
the	O
preseeded	O
NSC	B-Cell
were	O
implanted	O
to	O
bridge	O
a	O
10	O
-	O
mm	O
-	O
long	O
defect	O
of	O
the	O
sciatic	B-Multi-tissue_structure
nerve	I-Multi-tissue_structure
in	O
9	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
.	O
</ALL>	O

<ALL>	O
The	O
repair	O
outcome	O
was	O
investigated	O
6	O
weeks	O
after	O
the	O
surgery	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
Based	O
on	O
the	O
dynamic	O
modulus	O
,	O
chitosan	O
with	O
50	O
ppm	O
or	O
more	O
gold	O
was	O
a	O
stronger	O
material	O
than	O
others	O
.	O
</ALL>	O

<ALL>	O
In	O
vitro	O
,	O
gold	O
at	O
25	O
or	O
50	O
ppm	O
led	O
to	O
better	O
cell	B-Cell
performance	O
for	O
NSC	B-Cell
;	O
and	O
gold	O
at	O
50	O
ppm	O
gave	O
better	O
cell	B-Cell
performance	O
for	O
C6	B-Cell
.	O
</ALL>	O

<ALL>	O
On	O
the	O
microgrooved	O
substrate	O
,	O
the	O
NSC	B-Cell
had	O
elongated	O
processes	O
oriented	O
parallel	O
to	O
the	O
grooves	O
,	O
whereas	O
the	O
NSC	B-Cell
on	O
the	O
nonpatterned	O
surfaces	O
did	O
not	O
exhibit	O
a	O
particular	O
bias	O
in	O
alignment	O
.	O
</ALL>	O

<ALL>	O
In	O
vivo	O
,	O
the	O
number	O
of	O
regenerated	O
axons	O
,	O
the	O
regenerated	O
area	O
,	O
and	O
the	O
number	O
of	O
blood	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
were	O
significantly	O
higher	O
in	O
the	O
NSC	B-Cell
-	O
preseeded	O
conduit	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
</ALL>	O

<ALL>	O
Modification	O
of	O
the	O
chitosan	O
matrix	O
by	O
gold	O
nanoparticles	O
not	O
only	O
provides	O
the	O
mechanical	O
strength	O
but	O
also	O
affects	O
the	O
cellular	B-Cell
response	O
.	O
</ALL>	O

<ALL>	O
The	O
preliminary	O
in	O
vivo	O
data	O
demonstrated	O
that	O
the	O
biodegradable	O
micropatterned	O
conduits	O
preseeded	O
with	O
NSC	B-Cell
provided	O
a	O
combination	O
of	O
physical	O
and	O
biological	O
guidance	O
cues	O
for	O
regenerating	O
axons	B-Cellular_component
at	O
the	O
cellular	B-Cell
level	O
and	O
offered	O
a	O
better	O
alternative	O
for	O
repairing	O
sciatic	B-Multi-tissue_structure
nerve	I-Multi-tissue_structure
transactions	O
.	O
</ALL>	O

<ALL>	O
[	O
The	O
clinical	O
and	O
laboratory	O
features	O
of	O
acute	O
promyelocytic	O
leukemia	O
:	O
an	O
analysis	O
of	O
513	O
cases	O
]	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
</ALL>	O

<ALL>	O
To	O
investigate	O
the	O
clinical	O
and	O
laboratory	O
features	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
513	O
APL	O
patients	O
in	O
the	O
last	O
two	O
decades	O
were	O
retrospectively	O
analyzed	O
in	O
this	O
research	O
.	O
</ALL>	O

<ALL>	O
We	O
investigated	O
the	O
clinical	O
features	O
including	O
age	O
,	O
sex	O
,	O
abnormality	O
of	O
peripheral	O
hemogram	O
before	O
treatment	O
,	O
therapeutic	O
effect	O
and	O
follow	O
-	O
up	O
and	O
laboratory	O
data	O
such	O
as	O
morphology	O
,	O
immunology	O
,	O
cytogenetics	O
and	O
molecular	O
biology	O
(	O
MICM	O
)	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
The	O
median	O
age	O
of	O
the	O
APL	O
patients	O
was	O
33	O
years	O
old	O
and	O
the	O
ratio	O
of	O
male	O
and	O
female	O
was	O
1	O
.	O
21	O
:	O
1	O
.	O
</ALL>	O

<ALL>	O
Before	O
treatment	O
,	O
the	O
median	O
level	O
of	O
WBC	B-Cell
was	O
4	O
.	O
3	O
x	O
10	O
(	O
9	O
)	O
/	O
L	O
and	O
the	O
detection	O
rate	O
of	O
abnormal	O
promyelocyte	B-Cell
on	O
blood	B-Organism_substance
film	O
was	O
85	O
.	O
8	O
%	O
;	O
with	O
immunophenotypic	O
detection	O
,	O
the	O
expression	O
levels	O
of	O
CD117	O
,	O
CD34	O
,	O
HLA	O
-	O
DR	O
,	O
CD7	O
,	O
CD14	O
and	O
CD19	O
in	O
APL	O
were	O
found	O
to	O
be	O
lower	O
and	O
the	O
expression	O
levels	O
of	O
CD2	O
,	O
CD33	O
and	O
MPO	O
higher	O
than	O
those	O
in	O
other	O
subtypes	O
of	O
acute	O
myelocytic	O
leukemia	O
(	O
AML	O
)	O
(	O
both	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
</ALL>	O

<ALL>	O
Specific	O
abnormal	O
chromosome	B-Cellular_component
t	O
(	O
15	O
;	O
17	O
)	O
was	O
detected	O
in	O
91	O
.	O
7	O
%	O
of	O
the	O
patients	O
,	O
of	O
whom	O
75	O
.	O
9	O
%	O
had	O
standard	O
translocation	O
of	O
t	O
(	O
15	O
;	O
17	O
)	O
,	O
being	O
the	O
most	O
common	O
one	O
and	O
15	O
.	O
8	O
%	O
of	O
the	O
patients	O
had	O
t	O
(	O
15	O
;	O
17	O
)	O
with	O
additional	O
abnormal	O
chromosome	B-Cellular_component
.	O
</ALL>	O

<ALL>	O
There	O
was	O
only	O
7	O
.	O
5	O
%	O
of	O
the	O
patients	O
with	O
normal	O
karyotype	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
presence	O
of	O
both	O
simple	O
translocation	O
and	O
complex	O
translocation	O
was	O
seldom	O
seen	O
.	O
</ALL>	O

<ALL>	O
With	O
molecular	O
biological	O
detection	O
,	O
PML	O
/	O
RARalpha	O
fusion	O
gene	O
positive	O
rate	O
was	O
99	O
.	O
6	O
%	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
relatively	O
long	O
clinical	O
follow	O
-	O
up	O
,	O
we	O
found	O
that	O
the	O
complete	O
remission	O
(	O
CR	O
)	O
rate	O
in	O
APL	O
patients	O
was	O
84	O
.	O
7	O
%	O
,	O
incidence	O
of	O
DIC	O
was	O
13	O
.	O
4	O
%	O
and	O
five	O
-	O
year	O
survival	O
rate	O
was	O
30	O
.	O
7	O
%	O
.	O
</ALL>	O

<ALL>	O
The	O
median	O
count	O
of	O
WBC	B-Cell
in	O
CR	O
group	O
was	O
lower	O
than	O
that	O
non	O
-	O
remission	O
group	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
</ALL>	O

<ALL>	O
There	O
were	O
no	O
significant	O
differences	O
on	O
expressions	O
of	O
CD34	O
and	O
CD2	O
and	O
changes	O
of	O
cytogenetics	O
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
</ALL>	O

<ALL>	O
Comprehensive	O
evaluation	O
of	O
MICM	O
could	O
be	O
of	O
important	O
significance	O
in	O
the	O
diagnosis	O
and	O
prognosis	O
judgment	O
for	O
APL	O
patients	O
.	O
</ALL>	O

<ALL>	O
The	O
CR	O
rate	O
in	O
these	O
patients	O
with	O
high	O
WBC	B-Cell
count	O
was	O
considerable	O
low	O
.	O
</ALL>	O

<ALL>	O
Cognitive	O
function	O
and	O
number	O
of	O
teeth	B-Organ
in	O
a	O
community	O
-	O
dwelling	O
elderly	O
population	O
without	O
dementia	O
.	O
</ALL>	O

<ALL>	O
Although	O
the	O
number	O
of	O
sound	O
or	O
decayed	O
teeth	B-Organ
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
cognitive	O
function	O
in	O
elderly	O
populations	O
with	O
dementia	O
,	O
little	O
is	O
known	O
about	O
this	O
association	O
in	O
elderly	O
populations	O
without	O
dementia	O
.	O
</ALL>	O

<ALL>	O
We	O
evaluated	O
this	O
relationship	O
,	O
with	O
adjustment	O
for	O
confounding	O
factors	O
,	O
in	O
Japanese	O
populations	O
of	O
60	O
-	O
year	O
-	O
old	O
(	O
n	O
=	O
270	O
;	O
120	O
males	O
and	O
150	O
females	O
)	O
and	O
65	O
-	O
year	O
-	O
old	O
(	O
n	O
=	O
123	O
;	O
57	O
males	O
and	O
66	O
females	O
)	O
individuals	O
residing	O
in	O
Fukuoka	O
Prefecture	O
of	O
Japan	O
.	O
</ALL>	O

<ALL>	O
Dental	O
examinations	O
were	O
performed	O
in	O
all	O
subjects	O
,	O
along	O
with	O
the	O
Mini	O
-	O
mental	O
state	O
examination	O
(	O
MMSE	O
)	O
for	O
assessing	O
cognitive	O
function	O
.	O
</ALL>	O

<ALL>	O
Among	O
the	O
total	O
of	O
393	O
subjects	O
,	O
the	O
mean	O
MMSE	O
score	O
was	O
27	O
.	O
9	O
+	O
/	O
-	O
1	O
.	O
9	O
,	O
and	O
391	O
subjects	O
scored	O
24	O
or	O
higher	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
numbers	O
of	O
sound	O
and	O
decayed	O
teeth	B-Organ
were	O
12	O
.	O
0	O
+	O
/	O
-	O
6	O
.	O
3	O
and	O
0	O
.	O
5	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
Associations	O
were	O
found	O
between	O
the	O
numbers	O
of	O
sound	O
and	O
decayed	O
teeth	B-Organ
and	O
MMSE	O
in	O
total	O
subjects	O
and	O
males	O
,	O
but	O
not	O
in	O
females	O
,	O
by	O
multiple	O
regression	O
analysis	O
adjusted	O
for	O
gender	O
,	O
age	O
,	O
level	O
of	O
education	O
,	O
marital	O
status	O
,	O
smoking	O
,	O
alcohol	O
drinking	O
,	O
working	O
status	O
,	O
systolic	O
blood	B-Organism_substance
pressure	O
and	O
blood	B-Organism_substance
glucose	O
.	O
</ALL>	O

<ALL>	O
An	O
association	O
was	O
also	O
found	O
between	O
MMSE	O
and	O
the	O
number	O
of	O
sound	O
teeth	B-Organ
in	O
a	O
logistic	O
regression	O
analysis	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
associations	O
were	O
found	O
between	O
normal	O
-	O
range	O
cognitive	O
function	O
and	O
the	O
numbers	O
of	O
sound	O
and	O
decayed	O
teeth	B-Organ
,	O
after	O
adjustment	O
for	O
various	O
confounding	O
factors	O
,	O
in	O
an	O
elderly	O
Japanese	O
population	O
.	O
</ALL>	O

<ALL>	O
Comment	O
on	O
"	O
Why	O
reduced	O
-	O
form	O
regression	O
models	O
of	O
health	O
effects	O
versus	O
exposures	O
should	O
not	O
replace	O
QRA	O
:	O
livestock	O
production	O
and	O
infant	O
mortality	O
as	O
an	O
example	O
,	O
"	O
by	O
Louis	O
Anthony	O
(	O
Tony	O
)	O
Cox	O
,	O
Jr	O
.	O
,	O
Risk	O
Analysis	O
2009	O
,	O
Vol	O
.	O
</ALL>	O

<ALL>	O
29	O
,	O
No	O
.	O
12	O
.	O
</ALL>	O

<ALL>	O
While	O
a	O
recent	O
paper	O
by	O
Cox	O
in	O
this	O
journal	O
uses	O
as	O
its	O
motivating	O
factor	O
the	O
benefits	O
of	O
quantitative	O
risk	O
assessment	O
,	O
its	O
content	O
is	O
entirely	O
devoted	O
to	O
critiquing	O
Sneeringer	O
'	O
s	O
article	O
in	O
the	O
American	O
Journal	O
of	O
Agricultural	O
Economics	O
.	O
</ALL>	O

<ALL>	O
Cox	O
'	O
s	O
two	O
main	O
critiques	O
of	O
Sneeringer	O
are	O
fundamentally	O
flawed	O
and	O
misrepresent	O
the	O
original	O
article	O
.	O
</ALL>	O

<ALL>	O
Cox	O
posits	O
that	O
Sneeringer	O
did	O
A	O
and	O
B	O
,	O
and	O
then	O
argues	O
why	O
A	O
and	O
B	O
are	O
incorrect	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
Sneeringer	O
in	O
fact	O
did	O
C	O
and	O
D	O
;	O
thus	O
critiques	O
of	O
A	O
and	O
B	O
are	O
not	O
applicable	O
to	O
Sneeringer	O
'	O
s	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Prognostic	O
significance	O
of	O
TRAIL	O
signaling	O
molecules	O
in	O
stage	B-Pathological_formation
II	I-Pathological_formation
and	I-Pathological_formation
III	I-Pathological_formation
colorectal	I-Pathological_formation
cancer	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
PURPOSE	O
:	O
</ALL>	O

<ALL>	O
We	O
previously	O
found	O
that	O
cellular	O
FLICE	O
-	O
inhibitory	O
protein	O
(	O
c	O
-	O
FLIP	O
)	O
,	O
caspase	O
8	O
,	O
and	O
tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
receptor	O
2	O
(	O
DR5	O
)	O
are	O
major	O
regulators	O
of	O
cell	B-Cell
viability	O
and	O
chemotherapy	O
-	O
induced	O
apoptosis	O
in	O
colorectal	B-Pathological_formation
cancer	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
determined	O
the	O
prognostic	O
significance	O
of	O
c	O
-	O
FLIP	O
,	O
caspase	O
8	O
,	O
TRAIL	O
and	O
DR5	O
expression	O
in	O
tissues	B-Tissue
from	O
patients	O
with	O
stage	B-Pathological_formation
II	I-Pathological_formation
and	I-Pathological_formation
III	I-Pathological_formation
colorectal	I-Pathological_formation
cancer	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
EXPERIMENTAL	O
DESIGN	O
:	O
</ALL>	O

<ALL>	O
Tissue	B-Tissue
microarrays	O
were	O
constructed	O
from	O
matched	O
normal	B-Tissue
and	O
tumor	B-Tissue
tissue	I-Tissue
derived	O
from	O
patients	O
(	O
n	O
=	O
253	O
)	O
enrolled	O
in	O
a	O
phase	O
III	O
trial	O
of	O
adjuvant	O
5	O
-	O
fluorouracil	O
-	O
based	O
chemotherapy	O
versus	O
postoperative	O
observation	O
alone	O
.	O
</ALL>	O

<ALL>	O
TRAIL	O
,	O
DR5	O
,	O
caspase	O
8	O
,	O
and	O
c	O
-	O
FLIP	O
expression	O
levels	O
were	O
determined	O
by	O
immunohistochemistry	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
Colorectal	B-Pathological_formation
tumors	I-Pathological_formation
displayed	O
significantly	O
higher	O
expression	O
levels	O
of	O
c	O
-	O
FLIP	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
caspase	O
8	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
and	O
DR5	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
lower	O
levels	O
of	O
TRAIL	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
compared	O
with	O
matched	O
normal	B-Tissue
tissue	I-Tissue
.	O
</ALL>	O

<ALL>	O
In	O
univariate	O
analysis	O
,	O
higher	O
TRAIL	O
expression	O
in	O
the	O
tumor	B-Pathological_formation
was	O
associated	O
with	O
worse	O
overall	O
survival	O
(	O
P	O
=	O
0	O
.	O
026	O
)	O
,	O
with	O
a	O
trend	O
to	O
decreased	O
relapse	O
-	O
free	O
survival	O
(	O
RFS	O
;	O
P	O
=	O
0	O
.	O
06	O
)	O
,	O
and	O
higher	O
tumor	B-Pathological_formation
c	O
-	O
FLIP	O
expression	O
was	O
associated	O
with	O
a	O
significantly	O
decreased	O
RFS	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O
</ALL>	O

<ALL>	O
Using	O
multivariate	O
predictive	O
modeling	O
for	O
RFS	O
in	O
all	O
patients	O
and	O
including	O
all	O
biomarkers	O
,	O
age	O
,	O
treatment	O
,	O
and	O
stage	O
,	O
we	O
found	O
that	O
the	O
model	O
was	O
significant	O
when	O
the	O
mean	O
tumor	B-Pathological_formation
c	O
-	O
FLIP	O
expression	O
score	O
and	O
disease	O
stage	O
were	O
included	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
</ALL>	O

<ALL>	O
As	O
regards	O
overall	O
survival	O
,	O
the	O
overall	O
model	O
was	O
predictive	O
when	O
both	O
TRAIL	O
expression	O
and	O
disease	O
stage	O
were	O
included	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
:	O
</ALL>	O

<ALL>	O
High	O
c	O
-	O
FLIP	O
and	O
TRAIL	O
expression	O
may	O
be	O
independent	O
adverse	O
prognostic	O
markers	O
in	O
stage	B-Pathological_formation
II	I-Pathological_formation
and	I-Pathological_formation
III	I-Pathological_formation
colorectal	I-Pathological_formation
cancer	I-Pathological_formation
and	O
might	O
identify	O
patients	O
most	O
at	O
risk	O
of	O
relapse	O
.	O
</ALL>	O

<ALL>	O
Influences	O
on	O
the	O
pharmacokinetics	O
of	O
oxycodone	O
:	O
a	O
multicentre	O
cross	O
-	O
sectional	O
study	O
in	O
439	O
adult	O
cancer	B-Pathological_formation
patients	O
.	O
</ALL>	O

<ALL>	O
OBJECTIVE	O
:	O
</ALL>	O

<ALL>	O
Oxycodone	O
is	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
cancer	B-Pathological_formation
pain	O
,	O
but	O
little	O
is	O
known	O
of	O
its	O
pharmacokinetics	O
in	O
cancer	B-Pathological_formation
pain	O
patients	O
.	O
</ALL>	O

<ALL>	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
relationships	O
between	O
ordinary	O
patient	O
characteristics	O
and	O
serum	B-Organism_substance
concentrations	O
of	O
oxycodone	O
and	O
the	O
ratios	O
noroxycodone	O
or	O
oxymorphone	O
/	O
oxycodone	O
in	O
cancer	B-Pathological_formation
patients	O
.	O
</ALL>	O

<ALL>	O
METHODS	O
:	O
</ALL>	O

<ALL>	O
Four	O
hundred	O
and	O
thirty	O
-	O
nine	O
patients	O
using	O
oral	O
oxycodone	O
for	O
cancer	B-Pathological_formation
pain	O
were	O
included	O
.	O
</ALL>	O

<ALL>	O
The	O
patients	O
'	O
characteristics	O
(	O
sex	O
,	O
age	O
,	O
body	B-Organism_subdivision
mass	O
index	O
[	O
BMI	O
]	O
,	O
Karnofsky	O
performance	O
status	O
,	O
"	O
time	O
since	O
starting	O
opioids	O
"	O
,	O
"	O
oxycodone	O
total	O
daily	O
dose	O
"	O
,	O
"	O
time	O
from	O
last	O
oxycodone	O
dose	O
"	O
,	O
use	O
of	O
CYP3A4	O
inducer	O
/	O
inhibitor	O
,	O
"	O
use	O
of	O
systemic	O
steroids	O
"	O
,	O
"	O
number	O
of	O
medications	O
taken	O
in	O
the	O
last	O
24	O
h	O
"	O
,	O
glomerular	B-Multi-tissue_structure
filtration	O
rate	O
(	O
GFR	O
)	O
and	O
albumin	O
serum	B-Organism_substance
concentrations	O
)	O
influence	O
on	O
oxycodone	O
serum	B-Organism_substance
concentrations	O
or	O
metabolite	O
/	O
oxycodone	O
ratios	O
were	O
explored	O
by	O
multiple	O
regression	O
analyses	O
.	O
</ALL>	O

<ALL>	O
RESULTS	O
:	O
</ALL>	O

<ALL>	O
Sex	O
,	O
CYP3A4	O
inducers	O
/	O
inhibitors	O
,	O
total	O
daily	O
dose	O
,	O
and	O
"	O
time	O
from	O
last	O
oxycodone	O
dose	O
"	O
predicted	O
oxycodone	O
concentrations	O
.	O
</ALL>	O

<ALL>	O
CYP3A4	O
inducers	O
,	O
total	O
daily	O
dose	O
,	O
and	O
"	O
number	O
of	O
medications	O
taken	O
in	O
the	O
last	O
24	O
h	O
"	O
predicted	O
the	O
oxymorphone	O
/	O
oxycodone	O
ratio	O
.	O
</ALL>	O

<ALL>	O
Total	O
daily	O
dose	O
,	O
"	O
time	O
from	O
last	O
dose	O
to	O
blood	B-Organism_substance
sample	I-Organism_substance
"	O
,	O
albumin	O
,	O
sex	O
,	O
CYP3A4	O
inducers	O
/	O
inhibitors	O
,	O
steroids	O
,	O
BMI	O
and	O
GFR	O
predicted	O
the	O
noroxycodone	O
/	O
oxycodone	O
ratio	O
.	O
</ALL>	O

<ALL>	O
CONCLUSION	O
:	O
</ALL>	O

<ALL>	O
Women	O
had	O
lower	O
oxycodone	O
serum	B-Organism_substance
concentrations	O
than	O
men	O
.	O
</ALL>	O

<ALL>	O
CYP3A4	O
inducers	O
/	O
inhibitors	O
should	O
be	O
used	O
with	O
caution	O
as	O
these	O
are	O
predicted	O
to	O
have	O
a	O
significant	O
impact	O
on	O
oxycodone	O
pharmacokinetics	O
.	O
</ALL>	O

<ALL>	O
Other	O
characteristics	O
explained	O
only	O
minor	O
parts	O
of	O
the	O
variability	O
of	O
the	O
outcomes	O
.	O
</ALL>	O

<ALL>	O
Phase	O
II	O
trial	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
in	O
prostatic	B-Pathological_formation
carcinoma	I-Pathological_formation
:	O
comparison	O
with	O
other	O
hormonal	O
agents	O
.	O
</ALL>	O

<ALL>	O
Various	O
approaches	O
to	O
hormonal	O
treatment	O
of	O
prostate	B-Pathological_formation
carcinoma	I-Pathological_formation
are	O
discussed	O
.	O
</ALL>	O

<ALL>	O
Eighty	O
-	O
one	O
patients	O
with	O
prostatic	B-Pathological_formation
carcinoma	I-Pathological_formation
,	O
eight	O
with	O
stage	O
B	O
,	O
nine	O
with	O
stage	O
C	O
,	O
and	O
64	O
with	O
stage	O
D	O
disease	O
,	O
were	O
treated	O
subcutaneously	O
daily	O
for	O
3	O
months	O
with	O
the	O
LH	O
-	O
RH	O
agonist	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
(	O
Decapeptyl	O
)	O
in	O
order	O
to	O
evaluate	O
the	O
incidence	O
of	O
remissions	O
according	O
to	O
WHO	O
recommendations	O
for	O
oncologic	O
trials	O
.	O
</ALL>	O

<ALL>	O
The	O
findings	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
other	O
hormonal	O
therapies	O
of	O
prostatic	B-Pathological_formation
carcinoma	I-Pathological_formation
according	O
to	O
the	O
statistical	O
method	O
of	O
"	O
expected	O
response	O
rate	O
"	O
as	O
adapted	O
by	O
Lee	O
and	O
Wesley	O
for	O
phase	O
II	O
trials	O
.	O
</ALL>	O

<ALL>	O
Treatment	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
greatly	O
reduced	O
serum	B-Organism_substance
LH	O
and	O
testosterone	O
levels	O
without	O
raising	O
serum	B-Organism_substance
prolactin	O
.	O
</ALL>	O

<ALL>	O
After	O
1	O
-	O
2	O
weeks	O
of	O
therapy	O
,	O
there	O
was	O
relief	O
of	O
subjective	O
symptoms	O
and	O
a	O
reversal	O
of	O
the	O
signs	O
of	O
prostatism	O
as	O
well	O
as	O
a	O
marked	O
decrease	O
in	O
bone	B-Organ
pain	O
.	O
</ALL>	O

<ALL>	O
At	O
90	O
days	O
52	O
patients	O
had	O
complete	O
relief	O
of	O
prostatism	O
and	O
21	O
had	O
only	O
mild	O
signs	O
and	O
symptoms	O
.	O
</ALL>	O

<ALL>	O
Seventy	O
patients	O
were	O
experiencing	O
no	O
bone	B-Organ
pain	O
and	O
an	O
additional	O
six	O
had	O
only	O
mild	O
pain	O
.	O
</ALL>	O

<ALL>	O
Prostatic	B-Organ
size	O
,	O
evaluated	O
by	O
rectal	O
examination	O
and	O
transabdominal	B-Organism_subdivision
ultrasonography	O
,	O
reverted	O
to	O
normal	O
in	O
26	O
.	O
4	O
%	O
of	O
patients	O
(	O
complete	O
remission	O
)	O
and	O
was	O
reduced	O
by	O
more	O
than	O
50	O
%	O
in	O
an	O
additional	O
17	O
.	O
6	O
%	O
(	O
partial	O
remission	O
)	O
,	O
the	O
overall	O
rate	O
of	O
complete	O
plus	O
partial	O
regression	O
of	O
prostatic	B-Organ
enlargement	O
being	O
44	O
%	O
.	O
</ALL>	O

<ALL>	O
Scans	O
showed	O
a	O
major	O
improvement	O
of	O
bone	B-Pathological_formation
lesions	I-Pathological_formation
in	O
14	O
.	O
8	O
%	O
of	O
cases	O
.	O
</ALL>	O

<ALL>	O
This	O
response	O
increased	O
to	O
37	O
%	O
after	O
more	O
than	O
6	O
months	O
of	O
follow	O
-	O
up	O
.	O
</ALL>	O

<ALL>	O
Prostatic	B-Organ
acid	O
phosphatase	O
levels	O
were	O
decreased	O
by	O
more	O
than	O
50	O
%	O
in	O
61	O
%	O
of	O
the	O
patients	O
,	O
but	O
this	O
test	O
appears	O
to	O
be	O
a	O
less	O
valid	O
marker	O
than	O
the	O
lipid	O
-	O
associated	O
sialic	O
acid	O
(	O
LASA	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
increase	O
in	O
LASA	O
before	O
treatment	O
and	O
a	O
reduction	O
after	O
treatment	O
can	O
frequently	O
be	O
correlated	O
with	O
the	O
objective	O
volume	O
of	O
the	O
neoplasms	B-Pathological_formation
.	O
</ALL>	O

<ALL>	O
No	O
flare	O
-	O
up	O
of	O
the	O
disease	O
was	O
encountered	O
,	O
and	O
there	O
were	O
no	O
side	O
effects	O
except	O
for	O
impotence	O
.	O
</ALL>	O

<ALL>	O
Statistical	O
analyses	O
of	O
results	O
by	O
the	O
method	O
of	O
Lee	O
and	O
Wesley	O
indicated	O
that	O
the	O
incidence	O
of	O
complete	O
and	O
partial	O
regression	O
(	O
CR	O
and	O
PR	O
)	O
observed	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
was	O
not	O
significantly	O
different	O
from	O
that	O
recorded	O
in	O
previous	O
studies	O
for	O
another	O
LH	O
-	O
RH	O
analog	O
,	O
Buserelin	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
CR	O
and	O
PR	O
obtained	O
with	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
(	O
44	O
%	O
)	O
were	O
significantly	O
higher	O
than	O
with	O
subcapsular	O
orchiectomy	O
(	O
22	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Hormonal	O
effects	O
and	O
some	O
other	O
actions	O
of	O
D	O
-	O
Trp	O
-	O
6	O
-	O
LH	O
-	O
RH	O
were	O
compared	O
and	O
contrasted	O
with	O
those	O
produced	O
by	O
castration	O
,	O
estrogens	O
,	O
antiandrogens	O
,	O
and	O
progestogens	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
</ALL>	O

<ALL>	O
[	O
Histophysiology	O
and	O
histopathology	O
of	O
the	O
adrenals	B-Organ
in	O
experimental	O
hypokinesia	O
]	O
.	O
</ALL>	O

<ALL>	O
In	O
experiments	O
on	O
male	O
rats	O
in	O
the	O
course	O
of	O
3	O
-	O
month	O
hypokinesia	O
phasic	O
changes	O
were	O
observed	O
in	O
the	O
relative	O
adrenal	B-Organ
gland	I-Organ
weight	O
,	O
in	O
the	O
volume	O
of	O
the	O
cell	B-Cellular_component
nuclei	I-Cellular_component
of	O
the	O
glomerular	B-Multi-tissue_structure
,	O
fasicular	B-Multi-tissue_structure
zones	I-Multi-tissue_structure
and	O
the	O
medulla	B-Multi-tissue_structure
,	O
in	O
the	O
activity	O
of	O
the	O
succinic	O
dehydrogenase	O
,	O
alkaline	O
and	O
acid	O
phosphatases	O
,	O
in	O
the	O
RNA	O
and	O
catecholamine	O
content	O
.	O
</ALL>	O

<ALL>	O
These	O
changes	O
are	O
associated	O
with	O
variations	O
in	O
the	O
secretion	O
and	O
biosynthesis	O
of	O
the	O
hormones	O
of	O
the	O
cortical	B-Multi-tissue_structure
and	O
the	O
medullary	B-Multi-tissue_structure
layer	I-Multi-tissue_structure
of	O
the	O
adrenal	B-Organ
glands	I-Organ
during	O
the	O
hypokinetic	O
stress	O
development	O
.	O
</ALL>	O

<ALL>	O
Dynorphin	O
is	O
contained	O
within	O
hippocampal	B-Tissue
mossy	I-Tissue
fibers	I-Tissue
:	O
immunochemical	O
alterations	O
after	O
kainic	O
acid	O
administration	O
and	O
colchicine	O
-	O
induced	O
neurotoxicity	O
.	O
</ALL>	O

<ALL>	O
Antisera	B-Organism_substance
raised	O
against	O
synthetic	O
dynorphin	O
or	O
[	O
Leu5	O
]	O
enkephalin	O
demonstrate	O
immunostaining	O
in	O
hippocampal	B-Tissue
mossy	I-Tissue
fibers	I-Tissue
and	O
in	O
dentate	B-Cell
granule	I-Cell
cells	I-Cell
.	O
</ALL>	O

<ALL>	O
However	O
,	O
dynorphin	O
immunoreactivity	O
(	O
ir	O
)	O
appears	O
to	O
be	O
denser	O
in	O
immunocytochemical	O
preparations	O
and	O
is	O
quantitatively	O
greater	O
by	O
radioimmunoassay	O
than	O
enkephalin	O
-	O
ir	O
.	O
</ALL>	O

<ALL>	O
Immunostaining	O
with	O
dynorphin	O
antisera	O
is	O
eliminated	O
by	O
adsorption	O
with	O
1	O
-	O
100	O
microM	O
dynorphin	O
-	O
17	O
whereas	O
immunostaining	O
with	O
enkephalin	O
antisera	O
is	O
eliminated	O
by	O
adsorption	O
with	O
1	O
-	O
100	O
microM	O
[	O
Leu5	O
]	O
enkephalin	O
,	O
dynorphin	O
-	O
17	O
,	O
dynorphin	O
-	O
(	O
1	O
-	O
13	O
)	O
,	O
or	O
alpha	O
-	O
neo	O
-	O
endorphin	O
.	O
</ALL>	O

<ALL>	O
Intrahippocampal	B-Multi-tissue_structure
colchicine	O
injections	O
,	O
which	O
selectively	O
destroy	O
dentate	O
granule	O
cells	O
,	O
significantly	O
decrease	O
the	O
dynorphin	O
-	O
ir	O
and	O
enkephalin	O
-	O
ir	O
levels	O
in	O
rat	O
hippocampus	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Intraventricularly	B-Multi-tissue_structure
administered	O
kainic	O
acid	O
,	O
which	O
selectively	O
destroys	O
CA3	B-Cell
-	I-Cell
4	I-Cell
pyramidal	I-Cell
cells	I-Cell
,	O
results	O
in	O
an	O
increase	O
of	O
enkephalin	O
immunostaining	O
in	O
mossy	B-Tissue
fibers	I-Tissue
and	O
a	O
significant	O
increase	O
in	O
enkephalin	O
-	O
ir	O
by	O
radioimmunoassay	O
in	O
whole	O
hippocampus	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
The	O
enkephalin	B-Cell
-	I-Cell
ir	I-Cell
cells	I-Cell
and	O
fibers	B-Tissue
in	O
entorhinal	B-Multi-tissue_structure
/	O
perirhinal	B-Multi-tissue_structure
cortex	I-Multi-tissue_structure
,	O
which	O
innervate	O
rat	O
hippocampus	B-Multi-tissue_structure
and	O
dentate	B-Multi-tissue_structure
gyrus	I-Multi-tissue_structure
,	O
do	O
not	O
contain	O
dynorphin	O
-	O
ir	O
.	O
</ALL>	O

<ALL>	O
Differential	O
reactivity	O
of	O
the	O
functional	O
sulfhydryl	O
groups	O
of	O
cysteine	O
-	O
32	O
and	O
cysteine	O
-	O
35	O
present	O
in	O
the	O
reduced	O
form	O
of	O
thioredoxin	O
from	O
Escherichia	O
coli	O
.	O
</ALL>	O

<ALL>	O
Only	O
one	O
of	O
the	O
sulfhydryl	O
groups	O
from	O
Cys	O
-	O
32	O
and	O
Cys	O
-	O
35	O
in	O
the	O
active	O
center	O
of	O
native	O
Escherichia	O
coli	O
thioredoxin	O
-	O
(	O
SH	O
)	O
2	O
was	O
alkylated	O
by	O
excess	O
iodoacetic	O
acid	O
at	O
pH	O
values	O
below	O
8	O
.	O
0	O
.	O
</ALL>	O

<ALL>	O
Both	O
groups	O
reacted	O
in	O
the	O
protein	O
denatured	O
with	O
4	O
.	O
5	O
M	O
guanidine	O
hydrochloride	O
.	O
</ALL>	O

<ALL>	O
The	O
second	O
order	O
rate	O
of	O
alkylation	O
of	O
thioredoxin	O
-	O
(	O
SH	O
)	O
2	O
with	O
1	O
eq	O
of	O
iodoacetic	O
acid	O
was	O
pH	O
-	O
dependent	O
and	O
showed	O
independent	O
initial	O
reactions	O
of	O
one	O
thiolate	O
ion	O
with	O
a	O
pK	O
value	O
of	O
6	O
.	O
7	O
and	O
a	O
second	O
with	O
a	O
pK	O
value	O
close	O
to	O
9	O
.	O
0	O
.	O
</ALL>	O

<ALL>	O
The	O
same	O
pH	O
dependence	O
was	O
observed	O
for	O
alkylation	O
with	O
iodoacetamide	O
but	O
the	O
apparent	O
rate	O
constant	O
,	O
107	O
M	O
-	O
1	O
S	O
-	O
1	O
at	O
pH	O
7	O
.	O
2	O
,	O
was	O
about	O
20	O
-	O
fold	O
higher	O
than	O
the	O
corresponding	O
rate	O
with	O
iodoacetate	O
.	O
</ALL>	O

<ALL>	O
The	O
sulfhydryl	O
group	O
with	O
a	O
pK	O
value	O
of	O
6	O
.	O
7	O
was	O
shown	O
to	O
belong	O
to	O
Cys	O
-	O
32	O
by	O
labeling	O
thioredoxin	O
with	O
[	O
14C	O
]	O
iodoacetic	O
acid	O
followed	O
by	O
complete	O
alkylation	O
with	O
[	O
3H	O
]	O
iodoacetate	O
and	O
amino	O
acid	O
sequence	O
analysis	O
of	O
peptides	O
from	O
the	O
active	O
center	O
.	O
</ALL>	O

<ALL>	O
The	O
abnormally	O
low	O
pK	O
value	O
of	O
Cys	O
-	O
32	O
is	O
suggested	O
to	O
arise	O
by	O
electrostatic	O
influence	O
from	O
a	O
positive	O
charge	O
on	O
the	O
amino	O
group	O
of	O
Lys	O
-	O
36	O
.	O
</ALL>	O

<ALL>	O
A	O
mechanism	O
of	O
action	O
for	O
thioredoxin	O
-	O
(	O
SH	O
)	O
2	O
as	O
a	O
protein	O
disulfide	O
reductase	O
has	O
been	O
formulated	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
based	O
on	O
an	O
initial	O
nucleophilic	O
attack	O
by	O
the	O
thiolate	O
of	O
Cys	O
-	O
32	O
with	O
the	O
formation	O
of	O
an	O
unstable	O
transient	O
mixed	O
disulfide	O
involving	O
Cys	O
-	O
32	O
and	O
one	O
of	O
the	O
sulfurs	O
in	O
the	O
substrate	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
followed	O
by	O
a	O
conformational	O
change	O
and	O
a	O
nucleophilic	O
attack	O
of	O
Cys	O
-	O
35	O
to	O
give	O
the	O
14	O
-	O
membered	O
disulfide	O
ring	O
in	O
thioredoxin	O
-	O
S2	O
and	O
the	O
dithiol	O
of	O
the	O
substrate	O
.	O
</ALL>	O

<ALL>	O
Identification	O
of	O
NAB1	O
,	O
a	O
repressor	O
of	O
NGFI	O
-	O
A	O
-	O
and	O
Krox20	O
-	O
mediated	O
transcription	O
.	O
</ALL>	O

<ALL>	O
NGFI	O
-	O
A	O
(	O
also	O
called	O
Egr1	O
,	O
Zif268	O
,	O
or	O
Krox24	O
)	O
and	O
the	O
closely	O
related	O
proteins	O
Krox20	O
,	O
NGFI	O
-	O
C	O
,	O
and	O
Egr3	O
are	O
zinc	O
-	O
finger	O
transcription	O
factors	O
encoded	O
by	O
immediate	O
-	O
early	O
genes	O
which	O
are	O
induced	O
by	O
a	O
wide	O
variety	O
of	O
extracellular	B-Immaterial_anatomical_entity
stimuli	O
.	O
</ALL>	O

<ALL>	O
NGFI	O
-	O
A	O
has	O
been	O
implicated	O
in	O
cell	B-Cell
proliferation	O
,	O
macrophage	B-Cell
differentiation	O
,	O
synaptic	B-Cellular_component
activation	O
,	O
and	O
long	O
-	O
term	O
potentiation	O
,	O
whereas	O
Krox20	O
is	O
critical	O
for	O
proper	O
hindbrain	O
segmentation	O
and	O
peripheral	B-Multi-tissue_structure
nerve	I-Multi-tissue_structure
myelination	O
.	O
</ALL>	O

<ALL>	O
In	O
previous	O
work	O
,	O
a	O
structure	O
/	O
function	O
analysis	O
of	O
NGFI	O
-	O
A	O
revealed	O
a	O
34	O
-	O
aa	O
inhibitory	O
domain	O
that	O
was	O
hypothesized	O
to	O
be	O
the	O
target	O
of	O
a	O
cellular	B-Cell
factor	O
that	O
represses	O
NGFI	O
-	O
A	O
transcriptional	O
activity	O
.	O
</ALL>	O

<ALL>	O
Using	O
the	O
yeast	O
two	O
-	O
hybrid	O
system	O
,	O
we	O
have	O
isolated	O
a	O
cDNA	O
clone	O
which	O
encodes	O
a	O
protein	O
that	O
interacts	O
with	O
this	O
inhibitory	O
domain	O
and	O
inhibits	O
the	O
ability	O
of	O
NGFI	O
-	O
A	O
to	O
activate	O
transcription	O
.	O
</ALL>	O

<ALL>	O
This	O
NGFI	O
-	O
A	O
-	O
binding	O
protein	O
,	O
NAB1	O
,	O
is	O
a	O
570	O
-	O
aa	O
nuclear	B-Cellular_component
protein	O
that	O
bears	O
no	O
obvious	O
sequence	O
homology	O
to	O
known	O
proteins	O
.	O
</ALL>	O

<ALL>	O
NAB1	O
also	O
represses	O
Krox20	O
activity	O
,	O
but	O
it	O
does	O
not	O
influence	O
Egr3	O
or	O
NGFI	O
-	O
G	O
,	O
thus	O
providing	O
a	O
mechanism	O
for	O
the	O
differential	O
regulation	O
of	O
this	O
family	O
of	O
immediate	O
-	O
early	O
transcription	O
factors	O
.	O
</ALL>	O

<ALL>	O
Comparison	O
of	O
image	O
(	O
CAS	O
200	O
)	O
and	O
flow	O
cytometry	O
determined	O
DNA	O
content	O
of	O
paraffin	O
-	O
embedded	O
Hodgkin	B-Tissue
'	I-Tissue
s	I-Tissue
disease	I-Tissue
tissue	I-Tissue
.	O
</ALL>	O

<ALL>	O
To	O
assess	O
the	O
reliability	O
of	O
DNA	O
estimation	O
using	O
image	O
cytometry	O
,	O
deparaffinized	O
lymph	B-Multi-tissue_structure
nodes	I-Multi-tissue_structure
from	O
70	O
patients	O
with	O
Hodgkin	O
'	O
s	O
disease	O
were	O
examined	O
and	O
the	O
results	O
obtained	O
were	O
compared	O
with	O
those	O
from	O
flow	O
cytometry	O
.	O
</ALL>	O

<ALL>	O
Image	O
analysis	O
without	O
discriminating	O
between	O
the	O
various	O
cell	B-Cell
types	O
,	O
as	O
found	O
in	O
Hodgkin	O
'	O
s	O
disease	O
,	O
revealed	O
no	O
separate	O
aneuploid	O
peak	O
.	O
</ALL>	O

<ALL>	O
Selecting	O
on	O
morphologically	O
defined	O
nuclear	B-Cellular_component
types	O
DNA	O
aneuploidy	O
was	O
detected	O
in	O
20	O
%	O
of	O
the	O
cases	O
(	O
14	O
/	O
70	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
aneuploid	O
populations	O
were	O
limited	O
to	O
the	O
population	O
of	O
nuclei	B-Cellular_component
defined	O
as	O
Reed	O
-	O
Sternberg	O
(	O
RS	O
)	O
-	O
like	O
or	O
medium	O
-	O
sized	O
lymphocytes	B-Cell
.	O
</ALL>	O

<ALL>	O
Benign	B-Pathological_formation
lymph	I-Pathological_formation
nodes	I-Pathological_formation
DNA	O
aneuploidy	O
was	O
not	O
found	O
in	O
any	O
of	O
the	O
controls	O
.	O
</ALL>	O

<ALL>	O
Comparison	O
of	O
DNA	O
histograms	O
obtained	O
by	O
image	O
and	O
flow	O
cytometry	O
showed	O
aneuploid	O
peaks	O
using	O
image	O
cytometry	O
in	O
4	O
of	O
30	O
diploid	O
and	O
10	O
of	O
40	O
aneuploid	O
flow	O
histograms	O
.	O
</ALL>	O

<ALL>	O
In	O
conclusion	O
,	O
image	O
analysis	O
using	O
the	O
CAS	O
200	O
system	O
as	O
compared	O
to	O
flow	O
cytometry	O
is	O
more	O
time	O
-	O
consuming	O
and	O
less	O
sensitive	O
to	O
assess	O
ploidy	O
status	O
,	O
although	O
it	O
may	O
provide	O
extra	O
information	O
in	O
some	O
selected	O
cases	O
.	O
</ALL>	O

<ALL>	O
Evidence	O
is	O
obtained	O
that	O
DNA	O
aneuploidy	O
in	O
Hodgkin	O
'	O
s	O
disease	O
is	O
preferentially	O
expressed	O
by	O
cells	B-Cell
with	O
the	O
RS	O
/	O
H	O
-	O
like	O
and	O
medium	O
-	O
sized	O
lymphocyte	B-Cell
morphology	O
.	O
</ALL>	O

<ALL>	O
Imaging	O
techniques	O
for	O
the	O
assessment	O
of	O
body	B-Organism_subdivision
composition	O
.	O
</ALL>	O

<ALL>	O
Three	O
imaging	O
methods	O
,	O
ultrasound	O
imaging	O
(	O
UI	O
)	O
,	O
computer	O
-	O
assisted	O
axial	O
tomography	O
(	O
CAT	O
)	O
and	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
,	O
are	O
widely	O
used	O
in	O
medicine	O
.	O
</ALL>	O

<ALL>	O
Their	O
application	O
to	O
the	O
assessment	O
of	O
body	B-Organism_subdivision
composition	O
in	O
nutrition	O
research	O
is	O
still	O
being	O
explored	O
and	O
developed	O
.	O
</ALL>	O

<ALL>	O
Ultrasound	O
imaging	O
yields	O
poor	O
image	O
quality	O
but	O
,	O
because	O
it	O
is	O
cheap	O
and	O
safe	O
,	O
deserves	O
further	O
exploration	O
.	O
</ALL>	O

<ALL>	O
Both	O
CAT	O
and	O
MRI	O
can	O
produce	O
images	O
with	O
good	O
discrimination	O
among	O
bone	B-Organ
,	O
muscle	B-Organ
and	O
adipose	B-Tissue
tissue	I-Tissue
.	O
</ALL>	O

<ALL>	O
Movement	O
artifacts	O
tend	O
to	O
be	O
more	O
serious	O
in	O
MRI	O
than	O
in	O
CAT	O
due	O
to	O
the	O
longer	O
imaging	O
time	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
other	O
hand	O
,	O
the	O
X	O
-	O
ray	O
exposure	O
in	O
CAT	O
is	O
likely	O
to	O
limit	O
its	O
use	O
in	O
human	O
nutrition	O
research	O
.	O
</ALL>	O

<ALL>	O
Repeated	O
measurements	O
of	O
tissue	B-Tissue
volumes	O
by	O
CAT	O
and	O
MRI	O
give	O
similar	O
CV	O
.	O
</ALL>	O

<ALL>	O
In	O
both	O
CAT	O
and	O
MRI	O
,	O
intra	O
-	O
abdominal	B-Tissue
adipose	I-Tissue
tissue	I-Tissue
presents	O
greater	O
problems	O
of	O
measurement	O
than	O
subcutaneous	B-Tissue
adipose	I-Tissue
tissue	I-Tissue
.	O
</ALL>	O

<ALL>	O
Validation	O
studies	O
with	O
77	O
-	O
kg	O
pigs	O
of	O
MRI	O
,	O
using	O
13	O
slices	O
,	O
predicted	O
total	O
body	B-Organism_subdivision
lipid	O
with	O
residual	O
standard	O
deviation	O
of	O
1	O
.	O
9	O
%	O
.	O
</ALL>	O

<ALL>	O
In	O
validating	O
any	O
of	O
these	O
methods	O
,	O
account	O
should	O
be	O
take	O
of	O
the	O
extent	O
to	O
which	O
the	O
information	O
they	O
give	O
can	O
augment	O
that	O
given	O
by	O
more	O
simple	O
measures	O
like	O
age	O
and	O
weight	O
.	O
</ALL>	O

<ALL>	O
Defective	O
biliary	O
copper	O
excretion	O
in	O
Wilson	O
'	O
s	O
disease	O
:	O
the	O
role	O
of	O
caeruloplasmin	O
.	O
</ALL>	O

<ALL>	O
Previous	O
studies	O
have	O
failed	O
to	O
explain	O
the	O
link	O
between	O
copper	O
accumulation	O
and	O
abnormal	O
caeruloplasmin	O
expression	O
in	O
Wilson	O
'	O
s	O
disease	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
despite	O
the	O
isolation	O
of	O
a	O
candidate	O
gene	O
for	O
Wilson	O
'	O
s	O
disease	O
,	O
which	O
predicts	O
a	O
defective	O
copper	O
transport	O
protein	O
,	O
the	O
localization	O
of	O
this	O
putative	O
protein	O
and	O
its	O
relationship	O
to	O
the	O
pathway	O
involved	O
in	O
copper	O
excretion	O
and	O
to	O
caeruloplasmin	O
remain	O
unknown	O
.	O
</ALL>	O

<ALL>	O
We	O
now	O
present	O
evidence	O
that	O
caeruloplasmin	O
,	O
the	O
major	O
plasma	B-Organism_substance
copper	O
-	O
carrying	O
protein	O
,	O
is	O
present	O
in	O
the	O
liver	B-Organ
in	O
Wilson	O
'	O
s	O
disease	O
,	O
and	O
thus	O
that	O
reduced	O
circulating	O
levels	O
of	O
the	O
protein	O
result	O
from	O
a	O
post	O
-	O
translational	O
defect	O
in	O
the	O
secretory	O
pathway	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
also	O
identified	O
a	O
novel	O
form	O
of	O
caeruloplasmin	O
,	O
molecular	O
weight	O
125	O
kD	O
,	O
which	O
we	O
propose	O
may	O
act	O
as	O
the	O
carrier	O
for	O
excretory	O
copper	O
into	O
bile	B-Organism_substance
,	O
since	O
it	O
is	O
normally	O
present	O
in	O
both	O
liver	B-Organ
and	O
bile	B-Organism_substance
,	O
although	O
largely	O
absent	O
from	O
serum	B-Organism_substance
,	O
and	O
undetectable	O
in	O
bile	B-Organism_substance
from	O
Wilson	O
'	O
s	O
disease	O
patients	O
.	O
</ALL>	O

<ALL>	O
The	O
presence	O
of	O
this	O
form	O
of	O
caeruloplasmin	O
in	O
Wilson	O
'	O
s	O
disease	O
liver	B-Organ
suggests	O
that	O
a	O
related	O
post	O
-	O
translational	O
defect	O
may	O
also	O
be	O
responsible	O
for	O
its	O
absence	O
from	O
bile	B-Organism_substance
in	O
Wilson	O
'	O
s	O
disease	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
thus	O
provides	O
the	O
first	O
plausible	O
explanation	O
of	O
a	O
link	O
between	O
the	O
defective	O
copper	O
excretion	O
and	O
the	O
reduced	O
plasma	B-Organism_substance
caeruloplasmin	O
,	O
which	O
characterize	O
Wilson	O
'	O
s	O
disease	O
.	O
</ALL>	O

<ALL>	O
Conservative	O
treatment	O
of	O
endometriosis	O
:	O
the	O
effects	O
of	O
limited	O
surgery	O
and	O
hormonal	O
pseudopregnancy	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
compares	O
the	O
effects	O
of	O
limited	O
surgery	O
or	O
hormonal	O
pseudopregnancy	O
,	O
or	O
a	O
combination	O
of	O
these	O
two	O
,	O
upon	O
fertility	O
and	O
the	O
need	O
for	O
subsequent	O
surgery	O
with	O
respect	O
to	O
the	O
extent	O
of	O
the	O
disease	O
at	O
the	O
time	O
of	O
initial	O
diagnosis	O
in	O
patients	O
with	O
endometriosis	O
externa	O
.	O
</ALL>	O

<ALL>	O
Of	O
the	O
61	O
patients	O
who	O
desired	O
to	O
enhance	O
or	O
preserve	O
reproductive	O
capacity	O
,	O
20	O
patients	O
became	O
pregnant	O
,	O
for	O
a	O
pregnancy	O
rate	O
of	O
33	O
%	O
.	O
</ALL>	O

<ALL>	O
The	O
pregnancy	O
rate	O
in	O
all	O
categories	O
,	O
that	O
is	O
,	O
those	O
patients	O
treated	O
with	O
pseudopregnancy	O
,	O
conservative	O
surgery	O
,	O
and	O
combined	O
pseudopregnancy	O
and	O
surgery	O
,	O
was	O
found	O
to	O
be	O
in	O
direct	O
relationship	O
to	O
the	O
initial	O
extent	O
of	O
disease	O
.	O
</ALL>	O

<ALL>	O
In	O
such	O
patients	O
,	O
conservative	O
surgery	O
alone	O
seemed	O
to	O
give	O
the	O
best	O
results	O
in	O
the	O
achievement	O
of	O
pregnancy	O
.	O
</ALL>	O

<ALL>	O
There	O
seemed	O
to	O
be	O
little	O
difference	O
between	O
pseudopregnancy	O
alone	O
and	O
conservative	O
surgery	O
in	O
regard	O
to	O
the	O
need	O
for	O
subsequent	O
surgery	O
after	O
initial	O
therapy	O
,	O
although	O
there	O
seemed	O
to	O
be	O
a	O
significantly	O
greater	O
chance	O
for	O
the	O
need	O
for	O
subsequent	O
surgery	O
in	O
patients	O
receiving	O
a	O
combination	O
of	O
the	O
two	O
forms	O
of	O
therapy	O
.	O
</ALL>	O

<ALL>	O
The	O
need	O
for	O
subsequent	O
surgery	O
after	O
initial	O
therapy	O
in	O
80	O
patients	O
increased	O
in	O
direct	O
relationship	O
to	O
the	O
initial	O
extent	O
of	O
disease	O
present	O
,	O
despite	O
the	O
form	O
of	O
therapy	O
used	O
.	O
</ALL>	O

<ALL>	O
Fifty	O
-	O
nine	O
other	O
patients	O
with	O
endometriosis	O
,	O
who	O
did	O
not	O
desire	O
to	O
preserve	O
fertility	O
and	O
presented	O
for	O
relief	O
of	O
other	O
symptoms	O
,	O
underwent	O
initial	O
"	O
radical	O
"	O
therapy	O
.	O
</ALL>	O

<ALL>	O
Forty	O
-	O
six	O
patients	O
underwent	O
complete	O
operation	O
,	O
including	O
removal	O
of	O
uterus	B-Organ
,	O
tubes	B-Multi-tissue_structure
and	O
ovaries	B-Organ
,	O
and	O
none	O
required	O
subsequent	O
reoperation	O
.	O
</ALL>	O

<ALL>	O
Of	O
the	O
13	O
remaining	O
patients	O
,	O
who	O
underwent	O
incomplete	O
surgical	O
removal	O
,	O
leaving	O
one	O
or	O
both	O
ovaries	B-Organ
in	O
situ	O
,	O
11	O
required	O
subsequent	O
reoperation	O
for	O
recurrent	O
pelvic	O
endometriosis	O
.	O
</ALL>	O

<ALL>	O
Lack	O
of	O
developmental	O
and	O
reproductive	O
toxicity	O
of	O
2	O
,	O
3	O
,	O
3	O
'	O
,	O
4	O
,	O
4	O
'	O
-	O
pentachlorobiphenyl	O
(	O
PCB	O
105	O
)	O
in	O
ring	O
-	O
necked	O
pheasants	O
.	O
</ALL>	O

<ALL>	O
Mono	O
-	O
ortho	O
PCBs	O
are	O
global	O
contaminants	O
of	O
wildlife	O
with	O
the	O
potential	O
to	O
produce	O
toxicity	O
by	O
an	O
aryl	O
hydrocarbon	O
receptor	O
(	O
AhR	O
)	O
-	O
mediated	O
mechanism	O
.	O
</ALL>	O

<ALL>	O
To	O
determine	O
the	O
potency	O
of	O
2	O
,	O
3	O
,	O
3	O
'	O
,	O
4	O
,	O
4	O
'	O
-	O
pentachlorobiphenyl	O
(	O
PCB	O
105	O
)	O
for	O
producing	O
reproductive	O
and	O
developmental	O
toxicity	O
,	O
adult	O
ring	O
-	O
necked	O
pheasant	O
hens	O
(	O
Phasianus	O
colchicus	O
)	O
were	O
orally	O
dosed	O
with	O
0	O
,	O
0	O
.	O
06	O
,	O
0	O
.	O
6	O
,	O
or	O
6	O
mg	O
PCB	O
105	O
/	O
kg	O
hen	O
/	O
week	O
for	O
10	O
weeks	O
to	O
achieve	O
cumulative	O
doses	O
of	O
0	O
,	O
0	O
.	O
6	O
,	O
6	O
,	O
or	O
60	O
mg	O
PCB	O
105	O
/	O
kg	O
hen	O
after	O
which	O
hens	O
were	O
bred	O
with	O
untreated	O
roosters	O
once	O
per	O
week	O
for	O
8	O
weeks	O
.	O
</ALL>	O

<ALL>	O
Except	O
at	O
week	O
6	O
of	O
the	O
egg	B-Developing_anatomical_structure
-	O
laying	O
period	O
when	O
cumulative	O
egg	B-Developing_anatomical_structure
production	O
in	O
the	O
6	O
mg	O
PCB	O
105	O
/	O
kg	O
hen	O
group	O
was	O
greater	O
than	O
controls	O
,	O
fertilized	O
egg	B-Developing_anatomical_structure
production	O
was	O
not	O
significantly	O
different	O
between	O
treatment	O
groups	O
.	O
</ALL>	O

<ALL>	O
Embryo	B-Developing_anatomical_structure
mortality	O
and	O
chick	O
mortality	O
were	O
not	O
significantly	O
different	O
between	O
treatment	O
groups	O
.	O
</ALL>	O

<ALL>	O
Total	O
body	B-Organism_subdivision
and	O
heart	B-Organ
weights	O
of	O
all	O
chicks	O
1	O
day	O
posthatch	O
(	O
dph	O
)	O
were	O
not	O
different	O
between	O
groups	O
,	O
however	O
,	O
liver	B-Organ
weights	O
of	O
chicks	O
from	O
the	O
60	O
mg	O
/	O
kg	O
treatment	O
group	O
were	O
greater	O
than	O
controls	O
at	O
1	O
dph	O
.	O
</ALL>	O

<ALL>	O
The	O
first	O
chick	O
to	O
hatch	O
from	O
each	O
hen	O
was	O
reared	O
to	O
21	O
dph	O
and	O
among	O
these	O
birds	O
,	O
the	O
total	O
body	B-Organism_subdivision
,	O
liver	B-Organ
,	O
and	O
heart	B-Organ
weights	O
were	O
not	O
different	O
between	O
groups	O
.	O
</ALL>	O

<ALL>	O
There	O
were	O
no	O
dose	O
-	O
related	O
malformations	O
of	O
the	O
beak	B-Organism_subdivision
or	O
limbs	B-Organism_subdivision
,	O
and	O
no	O
signs	O
of	O
subcutaneous	B-Pathological_formation
edema	I-Pathological_formation
,	O
ascites	B-Organism_substance
,	O
or	O
pericardial	B-Pathological_formation
edema	I-Pathological_formation
in	O
chicks	O
at	O
1	O
or	O
21	O
dph	O
.	O
</ALL>	O

<ALL>	O
Hepatic	O
microsomal	O
monooxygenase	O
activities	O
[	O
ethoxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
EROD	O
)	O
,	O
benzyloxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
BROD	O
)	O
,	O
and	O
methyloxyresorufin	O
-	O
O	O
-	O
dealkylase	O
(	O
MROD	O
)	O
]	O
were	O
significantly	O
elevated	O
in	O
chicks	O
at	O
1	O
dph	O
from	O
hens	O
given	O
a	O
cumulative	O
PCB	O
105	O
dose	O
of	O
6	O
mg	O
/	O
kg	O
and	O
in	O
chicks	O
at	O
21	O
dph	O
from	O
hens	O
given	O
a	O
cumulative	O
PCB	O
dose	O
of	O
60	O
mg	O
/	O
kg	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
indicate	O
that	O
a	O
cumulative	O
PCB	O
105	O
dose	O
up	O
to	O
60	O
mg	O
/	O
kg	O
hen	O
does	O
not	O
decrease	O
the	O
production	O
of	O
fertilized	O
eggs	B-Developing_anatomical_structure
or	O
increase	O
embryo	B-Developing_anatomical_structure
or	O
chick	O
mortality	O
in	O
ring	O
-	O
necked	O
pheasants	O
,	O
but	O
does	O
increase	O
chick	O
hepatic	B-Organ
monooxygenase	O
activity	O
.	O
</ALL>	O

<ALL>	O
Detection	O
of	O
total	O
assist	O
and	O
sucking	O
points	O
based	O
on	O
the	O
pulsatility	O
of	O
a	O
continuous	O
flow	O
artificial	O
heart	O
:	O
in	O
vivo	O
evaluation	O
.	O
</ALL>	O

<ALL>	O
Our	O
novel	O
control	O
strategy	O
for	O
a	O
continuous	O
flow	O
artificial	O
heart	O
by	O
detecting	O
the	O
total	O
assist	O
and	O
sucking	O
points	O
based	O
on	O
pump	O
pulsatility	O
was	O
evaluated	O
in	O
acute	O
animal	O
experiments	O
using	O
beagle	O
dogs	O
and	O
our	O
mixed	O
flow	O
pump	O
.	O
</ALL>	O

<ALL>	O
The	O
pump	O
was	O
installed	O
as	O
a	O
left	B-Multi-tissue_structure
ventricular	I-Multi-tissue_structure
(	O
LV	B-Multi-tissue_structure
)	O
bypass	O
through	O
a	O
left	O
thoracotomy	O
.	O
</ALL>	O

<ALL>	O
To	O
change	O
LV	B-Multi-tissue_structure
contractility	O
,	O
the	O
left	O
coronary	B-Multi-tissue_structure
arteries	I-Multi-tissue_structure
were	O
occluded	O
for	O
30	O
min	O
,	O
followed	O
by	O
a	O
120	O
min	O
reperfusion	O
.	O
</ALL>	O

<ALL>	O
To	O
change	O
LV	B-Multi-tissue_structure
end	O
diastolic	O
pressure	O
(	O
LVEDP	O
)	O
,	O
dextran	O
solution	O
was	O
rapidly	O
infused	O
.	O
</ALL>	O

<ALL>	O
To	O
estimate	O
the	O
pump	O
pulsatility	O
without	O
any	O
specific	O
sensor	O
,	O
we	O
calculated	O
the	O
index	O
of	O
current	O
amplitude	O
(	O
ICA	O
)	O
,	O
which	O
was	O
obtained	O
from	O
the	O
amplitude	O
of	O
the	O
motor	O
current	O
waveform	O
divided	O
by	O
the	O
simultaneous	O
mean	O
value	O
.	O
</ALL>	O

<ALL>	O
To	O
investigate	O
the	O
basic	O
characteristics	O
of	O
the	O
ICA	O
,	O
the	O
pump	O
speed	O
was	O
changed	O
temporarily	O
from	O
2	O
,	O
300	O
rpm	O
to	O
5	O
,	O
000	O
rpm	O
.	O
</ALL>	O

<ALL>	O
In	O
92	O
%	O
of	O
all	O
measurements	O
,	O
the	O
ICA	O
plotted	O
against	O
the	O
pump	O
speed	O
had	O
a	O
peak	O
point	O
(	O
t	O
-	O
point	O
)	O
that	O
corresponded	O
highly	O
with	O
the	O
turning	O
point	O
from	O
partial	O
to	O
total	O
assistance	O
.	O
</ALL>	O

<ALL>	O
The	O
ICA	O
also	O
had	O
a	O
trough	O
(	O
s	O
-	O
point	O
)	O
that	O
corresponded	O
with	O
the	O
beginning	O
of	O
severe	O
sucking	O
in	O
most	O
cases	O
.	O
</ALL>	O

<ALL>	O
Only	O
preload	O
significantly	O
influenced	O
pump	O
flow	O
rate	O
at	O
the	O
t	O
-	O
point	O
from	O
among	O
preload	O
(	O
LVEDP	O
)	O
,	O
afterload	O
(	O
SAoP	O
)	O
,	O
and	O
contractility	O
(	O
max	O
LV	B-Multi-tissue_structure
dP	O
/	O
dt	O
)	O
,	O
by	O
which	O
we	O
can	O
simulate	O
Starling	O
'	O
s	O
law	O
of	O
the	O
natural	O
heart	B-Organ
.	O
</ALL>	O

<ALL>	O
We	O
concluded	O
that	O
a	O
continuous	O
flow	O
artificial	O
heart	O
could	O
be	O
well	O
controlled	O
by	O
detecting	O
the	O
t	O
-	O
point	O
and	O
s	O
-	O
point	O
.	O
</ALL>	O

<ALL>	O
Immunostaining	O
and	O
confocal	O
analysis	O
</ALL>	O

<ALL>	O
DNA	O
labelling	O
and	O
staining	O
with	O
5	O
-	O
bromo	O
-	O
2	O
'	O
-	O
deoxyuridine	O
(	O
BrdU	O
labelling	O
and	O
detection	O
kit	O
I	O
;	O
Boehringer	O
Mannheim	O
,	O
Germany	O
)	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O
</ALL>	O

<ALL>	O
The	O
nucleoli	B-Cellular_component
were	O
detected	O
with	O
an	O
anti	O
-	O
nucleolin	O
antibody	O
(	O
clone	O
3G4B2	O
;	O
Upstate	O
biotechnology	O
,	O
Lake	O
Placid	O
,	O
NY	O
)	O
on	O
cells	B-Cell
fixed	O
in	O
2	O
%	O
formalin	O
for	O
10	O
min	O
followed	O
by	O
permeabilization	O
with	O
ice	O
-	O
cold	O
methanol	O
for	O
30	O
min	O
.	O
</ALL>	O

<ALL>	O
The	O
secondary	O
antibody	O
used	O
for	O
both	O
BrdU	O
and	O
nucleoli	B-Cellular_component
staining	O
was	O
a	O
rhodamine	O
(	O
tetra	O
-	O
methyl	O
)	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
antibody	O
(	O
T	O
-	O
2762	O
)	O
from	O
Molecular	O
Probe	O
(	O
Eugene	O
,	O
OR	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
cells	B-Cell
were	O
examined	O
in	O
a	O
Zeiss	O
LSM	O
510	O
laser	O
scanning	O
microscope	O
equipped	O
with	O
a	O
Plan	O
-	O
Apochromate	O
63x	O
/	O
1	O
.	O
4	O
oil	O
immersion	O
objective	O
.	O
</ALL>	O

<ALL>	O
We	O
used	O
the	O
488	O
nm	O
laser	O
line	O
for	O
excitation	O
of	O
EGFP	O
(	O
detected	O
at	O
505	O
nm	O
<	O
lambdaEGFP	O
<	O
530	O
nm	O
)	O
and	O
the	O
543	O
nm	O
laser	O
line	O
for	O
rhodamine	O
(	O
tetra	O
-	O
methyl	O
)	O
(	O
detected	O
at	O
lambdaRhodamine	O
>	O
560	O
nm	O
)	O
.	O
</ALL>	O

<ALL>	O
ECFP	O
fusion	O
protein	O
was	O
excited	O
with	O
a	O
458	O
nm	O
laser	O
line	O
(	O
detected	O
at	O
480	O
nm	O
<	O
lambdaECFP	O
<	O
520	O
nm	O
)	O
,	O
EYFP	O
fusion	O
protein	O
was	O
excited	O
with	O
a	O
514	O
nm	O
laser	O
line	O
(	O
lambdaEGFP	O
>	O
560	O
nm	O
)	O
and	O
HcRed	O
fusion	O
protein	O
was	O
excited	O
with	O
a	O
543	O
nm	O
laser	O
line	O
and	O
detected	O
at	O
>	O
585	O
or	O
650	O
nm	O
.	O
</ALL>	O

<ALL>	O
The	O
images	O
were	O
from	O
1	O
mum	O
thick	O
slices	B-Cell
of	O
the	O
cells	B-Cell
.	O
</ALL>	O

<ALL>	O
The	O
images	O
were	O
exported	O
into	O
Adobe	O
Photoshop	O
(	O
Adobe	O
Systems	O
Inc	O
.	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
.	O
</ALL>	O

<ALL>	O
Conclusions	O
</ALL>	O

<ALL>	O
Only	O
after	O
careful	O
consideration	O
of	O
the	O
biological	O
underpinnings	O
of	O
a	O
truly	O
beneficial	O
response	O
can	O
an	O
exposure	O
be	O
considered	O
for	O
the	O
general	O
population	O
,	O
such	O
as	O
the	O
addition	O
of	O
folic	O
acid	O
to	O
cereals	O
.	O
</ALL>	O

<ALL>	O
If	O
a	O
toxic	O
or	O
hazardous	O
pollutant	O
were	O
found	O
to	O
have	O
truly	O
beneficial	O
effects	O
at	O
low	O
dose	O
,	O
then	O
that	O
agent	O
should	O
be	O
tested	O
clinically	O
,	O
go	O
through	O
the	O
U	O
.	O
S	O
.	O
</ALL>	O

<ALL>	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
approval	O
process	O
,	O
and	O
be	O
regulated	O
as	O
a	O
pharmaceutical	O
for	O
those	O
who	O
might	O
benefit	O
from	O
its	O
use	O
.	O
</ALL>	O

<ALL>	O
Certainly	O
,	O
the	O
general	O
population	O
should	O
not	O
be	O
exposed	O
to	O
chemotherapeutic	O
agents	O
that	O
benefit	O
cancer	B-Pathological_formation
patients	O
.	O
</ALL>	O

<ALL>	O
For	O
pharmaceuticals	O
,	O
it	O
is	O
understood	O
that	O
there	O
are	O
trade	O
offs	O
between	O
benefits	O
and	O
risks	O
.	O
</ALL>	O

<ALL>	O
For	O
example	O
,	O
although	O
aspirin	O
is	O
a	O
generally	O
well	O
-	O
tolerated	O
pain	O
reliever	O
and	O
is	O
increasingly	O
advocated	O
as	O
a	O
preventative	O
tool	O
for	O
heart	B-Organ
attacks	O
and	O
colorectal	B-Pathological_formation
cancer	I-Pathological_formation
(	O
Vainio	O
and	O
Miller	O
2003	O
;	O
Werner	O
et	O
al	O
.	O
2004	O
)	O
,	O
it	O
is	O
also	O
linked	O
to	O
increased	O
risk	O
of	O
gastrointestinal	B-Organism_subdivision
bleeding	O
,	O
cerebral	B-Organ
hemorrhage	O
(	O
Werner	O
et	O
al	O
.	O
2004	O
)	O
,	O
and	O
asthma	O
attacks	O
(	O
Jenkins	O
et	O
al	O
.	O
2004	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
aspirin	O
is	O
not	O
recommended	O
for	O
children	O
or	O
teenagers	O
who	O
have	O
or	O
are	O
recovering	O
from	O
chicken	O
pox	O
or	O
flulike	O
symptoms	O
because	O
it	O
can	O
cause	O
debilitating	O
and	O
sometimes	O
lethal	O
Reyes	O
syndrome	O
(	O
U	O
.	O
S	O
.	O
FDA	O
2003	O
)	O
.	O
</ALL>	O

<ALL>	O
Individual	O
risks	O
to	O
pharmaceutical	O
agents	O
can	O
be	O
controlled	O
with	O
proper	O
usage	O
;	O
however	O
,	O
increased	O
exposure	O
to	O
environmental	O
toxins	O
presents	O
additional	O
involuntary	O
risks	O
for	O
the	O
general	O
population	O
.	O
</ALL>	O

<ALL>	O
Under	O
the	O
latter	O
condition	O
,	O
exposure	O
is	O
inadequately	O
controlled	O
,	O
and	O
there	O
is	O
no	O
mechanism	O
to	O
correct	O
for	O
individual	O
circumstances	O
(	O
e	O
.	O
g	O
.	O
,	O
medical	O
condition	O
or	O
age	O
)	O
that	O
may	O
result	O
in	O
harm	O
.	O
</ALL>	O

<ALL>	O
Although	O
hormetic	O
effects	O
may	O
occur	O
in	O
some	O
instances	O
,	O
it	O
is	O
indeed	O
rare	O
that	O
exposures	O
to	O
toxic	O
,	O
mutagenic	O
,	O
teratogenic	O
,	O
and	O
carcinogenic	O
chemicals	O
,	O
even	O
at	O
low	O
exposure	O
levels	O
,	O
would	O
be	O
risk	O
free	O
and	O
provide	O
health	O
benefits	O
for	O
the	O
general	O
public	O
.	O
</ALL>	O

<ALL>	O
Portraying	O
chemicals	O
with	O
numerous	O
adverse	O
effects	O
as	O
having	O
benefits	O
while	O
ignoring	O
their	O
hazards	O
is	O
irresponsible	O
and	O
does	O
not	O
provide	O
full	O
and	O
objective	O
disclosure	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
1950s	O
doctors	O
prescribed	O
DES	O
to	O
pregnant	O
women	O
to	O
prevent	O
miscarriage	O
and	O
premature	O
births	O
and	O
to	O
produce	O
"	O
bigger	O
and	O
stronger	O
babies	O
"	O
even	O
though	O
DES	O
had	O
been	O
shown	O
to	O
cause	O
damage	O
to	O
reproductive	O
tissues	B-Tissue
in	O
animals	O
(	O
Dinusson	O
et	O
al	O
.	O
1948	O
;	O
Dunn	O
and	O
Green	O
1963	O
;	O
Takasugi	O
and	O
Bern	O
1964	O
)	O
.	O
</ALL>	O

<ALL>	O
Human	O
use	O
of	O
DES	O
was	O
banned	O
in	O
the	O
United	O
States	O
in	O
1971	O
after	O
the	O
discovery	O
of	O
high	O
rates	O
of	O
rare	O
,	O
clear	O
-	O
cell	O
adenocarcinomas	B-Pathological_formation
of	O
the	O
vagina	B-Multi-tissue_structure
and	O
cervix	B-Multi-tissue_structure
in	O
DES	O
-	O
exposed	O
daughters	O
(	O
Herbst	O
1981	O
)	O
,	O
and	O
later	O
studies	O
showed	O
elevated	O
breast	B-Pathological_formation
cancer	I-Pathological_formation
risk	O
in	O
women	O
who	O
took	O
DES	O
during	O
pregnancy	O
(	O
Titus	O
-	O
Ernstoff	O
et	O
al	O
.	O
2001	O
)	O
.	O
</ALL>	O

<ALL>	O
Certainly	O
,	O
health	O
policy	O
decisions	O
should	O
be	O
based	O
on	O
scientific	O
evidence	O
and	O
not	O
on	O
speculation	O
of	O
health	O
benefits	O
in	O
order	O
for	O
the	O
general	O
population	O
to	O
avoid	O
repeating	O
the	O
mistakes	O
of	O
the	O
past	O
similar	O
to	O
that	O
of	O
the	O
DES	O
tragedy	O
.	O
</ALL>	O

<ALL>	O
The	O
claims	O
and	O
projections	O
of	O
health	O
benefits	O
from	O
exposures	O
to	O
environmental	O
toxicants	O
and	O
carcinogens	O
are	O
based	O
on	O
untested	O
assumptions	O
and	O
disregard	O
numerous	O
well	O
-	O
established	O
scientific	O
principles	O
that	O
underpin	O
a	O
public	O
health	O
-	O
protective	O
approach	O
to	O
regulating	O
exposure	O
to	O
toxic	O
substances	O
.	O
</ALL>	O

<ALL>	O
If	O
hormesis	O
were	O
used	O
in	O
the	O
decision	O
-	O
making	O
process	O
to	O
allow	O
higher	O
exposures	O
to	O
toxic	O
and	O
carcinogenic	O
agents	O
,	O
this	O
would	O
substantially	O
increase	O
health	O
risks	O
for	O
many	O
,	O
if	O
not	O
most	O
,	O
segments	O
of	O
the	O
general	O
population	O
.	O
</ALL>	O

<ALL>	O
Measured	O
analytes	O
in	O
five	O
biologic	O
sample	O
matrices	O
.	O
a	O
</ALL>	O

<ALL>	O
Competing	O
interests	O
</ALL>	O

<ALL>	O
None	O
declared	O
.	O
</ALL>	O

<ALL>	O
This	O
article	O
is	O
the	O
third	O
in	O
an	O
ongoing	O
,	O
educational	O
review	O
series	O
on	O
medical	O
statistics	O
in	O
critical	O
care	O
.	O
</ALL>	O

<ALL>	O
Previous	O
articles	O
have	O
covered	O
'	O
presenting	O
and	O
summarising	O
data	O
'	O
[	O
3	O
]	O
and	O
'	O
samples	O
and	O
populations	O
'	O
[	O
4	O
]	O
.	O
</ALL>	O

<ALL>	O
Future	O
topics	O
to	O
be	O
covered	O
include	O
power	O
calculations	O
,	O
comparison	O
of	O
means	O
,	O
comparison	O
of	O
proportions	O
,	O
and	O
analysis	O
of	O
survival	O
data	O
to	O
name	O
but	O
a	O
few	O
.	O
</ALL>	O

<ALL>	O
If	O
there	O
is	O
a	O
medical	O
statistics	O
topic	O
you	O
would	O
like	O
explained	O
contact	O
us	O
on	O
editorial	O
@	O
ccforum	O
.	O
com	O
.	O
</ALL>	O

<ALL>	O
Results	O
</ALL>	O

<ALL>	O
The	O
set	O
of	O
E	O
.	O
coli	O
expression	O
vectors	O
,	O
encode	O
for	O
either	O
a	O
hexa	O
-	O
histidine	O
tag	O
or	O
the	O
three	O
most	O
commonly	O
used	O
solubility	O
tags	O
(	O
GST	O
,	O
MBP	O
,	O
NusA	O
)	O
and	O
all	O
with	O
an	O
N	O
-	O
terminal	O
hexa	O
-	O
histidine	O
sequence	O
.	O
</ALL>	O

<ALL>	O
The	O
result	O
is	O
two	O
-	O
fold	O
:	O
the	O
His	O
-	O
tag	O
facilitates	O
purification	O
by	O
immobilised	O
metal	O
affinity	O
chromatography	O
,	O
whilst	O
the	O
fusion	O
domains	O
act	O
primarily	O
as	O
solubility	O
aids	O
during	O
expression	O
,	O
in	O
addition	O
to	O
providing	O
an	O
optional	O
purification	O
step	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
also	O
incorporated	O
a	O
TEV	O
recognition	O
sequence	O
following	O
the	O
solubility	O
tag	O
domain	O
,	O
which	O
allows	O
for	O
highly	O
specific	O
cleavage	O
(	O
using	O
TEV	O
protease	O
)	O
of	O
the	O
fusion	O
protein	O
to	O
yield	O
native	O
protein	O
.	O
</ALL>	O

<ALL>	O
These	O
vectors	O
are	O
also	O
designed	O
for	O
ligation	O
-	O
independent	O
cloning	O
and	O
they	O
possess	O
a	O
high	O
-	O
level	O
expressing	O
T7	O
promoter	O
,	O
which	O
is	O
suitable	O
for	O
auto	O
-	O
induction	O
.	O
</ALL>	O

<ALL>	O
To	O
validate	O
our	O
vector	O
system	O
,	O
we	O
have	O
cloned	O
four	O
different	O
genes	O
and	O
also	O
one	O
gene	O
into	O
all	O
four	O
vectors	O
and	O
used	O
small	O
-	O
scale	O
expression	O
and	O
purification	O
techniques	O
.	O
</ALL>	O

<ALL>	O
We	O
demonstrate	O
that	O
the	O
vectors	O
are	O
capable	O
of	O
high	O
levels	O
of	O
expression	O
and	O
that	O
efficient	O
screening	O
of	O
new	O
proteins	O
can	O
be	O
readily	O
achieved	O
at	O
the	O
laboratory	O
level	O
.	O
</ALL>	O

<ALL>	O
Inflammation	O
-	O
modulating	O
effect	O
of	O
antithrombin	O
on	O
the	O
endothelium	B-Tissue
.	O
</ALL>	O

<ALL>	O
Ligation	O
of	O
heparan	O
sulfate	O
proteoglycans	O
(	O
HSPGs	O
)	O
of	O
endothelium	B-Tissue
with	O
antithrombin	O
(	O
AT	O
)	O
induces	O
cellular	B-Cell
signalling	O
events	O
that	O
alter	O
the	O
cell	B-Cell
'	O
s	O
biochemical	O
and	O
functional	O
responses	O
to	O
inflammatory	O
stimuli	O
(	O
e	O
.	O
g	O
.	O
bacterial	O
lipopolysaccharide	O
[	O
LPS	O
]	O
)	O
.	O
</ALL>	O

<ALL>	O
Changes	O
include	O
reduced	O
release	O
of	O
inflammatory	O
and	O
procoagulatory	O
mediators	O
(	O
e	O
.	O
g	O
.	O
interleukin	O
[	O
IL	O
]	O
-	O
1	O
,	O
IL	O
-	O
6	O
,	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
[	O
TNF	O
]	O
)	O
,	O
tissue	O
factor	O
(	O
TF	O
)	O
,	O
adenosine	O
diphosphate	O
(	O
ADP	O
)	O
and	O
cellular	B-Cell
adhesion	O
molecules	O
(	O
not	O
shown	O
)	O
,	O
as	O
well	O
as	O
increased	O
release	O
of	O
anticoagulatory	O
prostacyclin	O
(	O
prostaglandin	O
[	O
PG	O
]	O
I	O
)	O
or	O
CD39	O
/	O
ATPDase	O
.	O
</ALL>	O

<ALL>	O
In	O
neuronal	B-Tissue
tissue	I-Tissue
,	O
protective	O
mechanisms	O
may	O
by	O
mediated	O
via	O
the	O
release	O
of	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
and	O
nitric	O
oxide	O
with	O
the	O
potential	O
to	O
affect	O
prostacyclin	O
release	O
[	O
55	O
]	O
.	O
</ALL>	O

<ALL>	O
Background	O
</ALL>	O

<ALL>	O
Hallucinations	O
may	O
occur	O
in	O
any	O
sensory	O
modalities	O
.	O
</ALL>	O

<ALL>	O
Formed	O
musical	O
hallucinations	O
(	O
i	O
.	O
e	O
.	O
Perception	O
of	O
either	O
vocal	O
or	O
instrumental	O
melodies	O
)	O
reported	O
in	O
English	O
literature	O
to	O
date	O
have	O
typically	O
been	O
associated	O
with	O
marked	O
hearing	O
loss	O
,	O
advanced	O
age	O
,	O
female	O
sex	O
(	O
71	O
%	O
)	O
,	O
lack	O
of	O
response	O
to	O
treatment	O
and	O
associated	O
psychopathology	O
[	O
1	O
]	O
but	O
has	O
been	O
concluded	O
that	O
hearing	O
loss	O
is	O
neither	O
a	O
necessary	O
nor	O
sufficient	O
condition	O
for	O
the	O
occurrence	O
of	O
musical	O
hallucinations	O
[	O
1	O
]	O
.	O
</ALL>	O

<ALL>	O
Tumor	B-Pathological_formation
like	O
Astrocytoma	B-Pathological_formation
,	O
Temporal	B-Multi-tissue_structure
lobe	I-Multi-tissue_structure
epilepsy	O
,	O
raised	O
intra	O
cranial	B-Organism_subdivision
tension	O
,	O
drug	O
induced	O
(	O
tricyclics	O
,	O
Propronolol	O
etc	O
;	O
)	O
,	O
meningitis	O
and	O
psychotic	O
illness	O
were	O
shown	O
to	O
cause	O
palinacousis	O
and	O
musical	O
hallucinations	O
[	O
2	O
,	O
3	O
]	O
.	O
</ALL>	O

<ALL>	O
Musical	O
hallucinations	O
are	O
pseudo	O
hallucinations	O
that	O
originate	O
in	O
memory	O
representations	O
and	O
they	O
may	O
undergo	O
a	O
transition	O
to	O
true	O
hallucination	O
.	O
</ALL>	O

<ALL>	O
In	O
musical	O
hallucination	O
spatial	O
projection	O
is	O
less	O
definite	O
.	O
</ALL>	O

<ALL>	O
Sometimes	O
they	O
are	O
perceived	O
like	O
the	O
tinnitus	O
in	O
patient	O
'	O
s	O
own	O
head	B-Organism_subdivision
.	O
</ALL>	O

<ALL>	O
The	O
quality	O
is	O
usually	O
very	O
intense	O
and	O
distinct	O
often	O
very	O
loud	O
.	O
</ALL>	O

<ALL>	O
They	O
vary	O
from	O
elementary	O
sounds	O
to	O
instrumental	O
music	O
,	O
vocal	O
music	O
,	O
bird	O
songs	O
,	O
bells	O
,	O
pieces	O
of	O
melodies	O
or	O
sentences	O
,	O
religious	O
music	O
etc	O
:	O
-	O
We	O
report	O
an	O
unusual	O
presentation	O
of	O
an	O
elderly	O
lady	O
who	O
had	O
experienced	O
musical	O
hallucinations	O
whilst	O
being	O
treated	O
with	O
Electro	O
Convulsive	O
Therapy	O
.	O
</ALL>	O

<ALL>	O
Though	O
this	O
has	O
never	O
been	O
reported	O
earlier	O
,	O
there	O
seemed	O
to	O
have	O
a	O
good	O
association	O
between	O
the	O
initiation	O
of	O
Electro	O
convulsive	O
therapy	O
and	O
musical	O
hallucination	O
in	O
our	O
patient	O
.	O
</ALL>	O

<ALL>	O
Correlation	O
between	O
sperm	B-Cell
morphology	O
and	O
seminal	B-Organism_substance
plasma	I-Organism_substance
NO	O
(	O
a	O
)	O
and	O
TBARS	O
(	O
b	O
)	O
levels	O
in	O
both	O
groups	O
.	O
</ALL>	O

<ALL>	O
Conclusion	O
</ALL>	O

<ALL>	O
The	O
survey	O
indicated	O
that	O
,	O
the	O
study	O
area	O
has	O
plenty	O
of	O
medicinal	O
plants	O
to	O
treat	O
a	O
wide	O
spectrum	O
of	O
human	O
ailments	O
.	O
</ALL>	O

<ALL>	O
Earlier	O
studies	O
on	O
traditional	O
medicinal	O
plants	O
also	O
revealed	O
that	O
the	O
economically	O
backward	O
local	O
and	O
tribal	O
people	O
of	O
Tamil	O
Nadu	O
prefer	O
folk	O
medicine	O
due	O
to	O
low	O
cost	O
and	O
sometimes	O
it	O
is	O
a	O
part	O
of	O
their	O
social	O
life	O
and	O
culture	O
[	O
40	O
-	O
45	O
]	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
evident	O
from	O
the	O
interviews	O
conducted	O
in	O
different	O
villages	O
,	O
knowledge	O
of	O
medicinal	O
plants	O
is	O
limited	O
to	O
traditional	O
healers	O
,	O
herbalists	O
and	O
elderly	O
persons	O
who	O
are	O
living	O
in	O
rural	O
areas	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
also	O
points	O
out	O
that	O
certain	O
species	O
of	O
medicinal	O
plants	O
are	O
being	O
exploited	O
by	O
the	O
local	O
residents	O
who	O
are	O
unaware	O
of	O
the	O
importance	O
of	O
medicinal	O
plants	O
in	O
the	O
ecosystem	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
concluded	O
that	O
even	O
though	O
the	O
accessibility	O
of	O
Western	O
medicine	O
for	O
simple	O
and	O
complicated	O
diseases	O
is	O
available	O
,	O
many	O
people	O
in	O
the	O
studied	O
parts	O
of	O
Kancheepuram	O
district	O
is	O
still	O
continue	O
to	O
depend	O
on	O
medicinal	O
plants	O
,	O
at	O
least	O
for	O
the	O
treatment	O
of	O
some	O
simple	O
diseases	O
such	O
as	O
,	O
cold	O
,	O
cough	O
,	O
fever	O
,	O
headache	O
,	O
poison	O
bites	O
,	O
skin	B-Organ
diseases	O
and	O
tooth	B-Organ
infections	O
.	O
</ALL>	O

<ALL>	O
Well	O
-	O
knowledged	O
healers	O
have	O
good	O
interactions	O
with	O
patients	O
and	O
this	O
would	O
improve	O
the	O
quality	O
of	O
healthcare	O
delivery	O
.	O
</ALL>	O

<ALL>	O
The	O
present	O
-	O
day	O
traditional	O
healers	O
are	O
very	O
old	O
.	O
</ALL>	O

<ALL>	O
Due	O
to	O
lack	O
of	O
interest	O
among	O
the	O
younger	O
generation	O
as	O
well	O
as	O
their	O
tendency	O
to	O
migrate	O
to	O
cities	O
for	O
lucrative	O
jobs	O
,	O
there	O
is	O
a	O
possibility	O
of	O
losing	O
this	O
wealth	O
of	O
knowledge	O
in	O
the	O
near	O
future	O
.	O
</ALL>	O

<ALL>	O
It	O
thus	O
becomes	O
necessary	O
to	O
acquire	O
and	O
preserve	O
this	O
traditional	O
system	O
of	O
medicine	O
by	O
proper	O
documentation	O
and	O
identification	O
of	O
specimens	O
.	O
</ALL>	O

<ALL>	O
Figures	O
and	O
Tables	O
</ALL>	O

<ALL>	O
Figure	O
1	O
</ALL>	O

<ALL>	O
Modular	O
crosstalking	O
in	O
synthetic	O
gene	O
networks	O
.	O
</ALL>	O

<ALL>	O
A	O
promoter	O
with	O
binding	O
sites	O
for	O
lambda	O
cI	O
dimers	O
(	O
OR1	O
and	O
OR2	O
)	O
and	O
for	O
the	O
lac	O
repressor	O
(	O
Olac	O
)	O
controls	O
the	O
production	O
of	O
the	O
lac	O
repressor	O
(	O
encoded	O
by	O
lacI	O
)	O
in	O
module	O
1	O
and	O
lambda	O
cI	O
(	O
encoded	O
by	O
cI	O
)	O
in	O
module	O
2	O
.	O
</ALL>	O

<ALL>	O
The	O
lac	O
repressor	O
and	O
lambda	O
cI	O
dimers	O
are	O
represented	O
by	O
blue	O
ellipsoids	O
and	O
red	O
circles	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
When	O
the	O
two	O
modules	O
are	O
put	O
together	O
,	O
two	O
pairs	O
of	O
lambda	O
cI	O
dimers	O
bound	O
at	O
different	O
operators	O
can	O
loop	O
DNA	O
and	O
octamerize	O
,	O
forming	O
a	O
tetramer	O
of	O
dimers	O
.	O
</ALL>	O

<ALL>	O
Comparison	O
of	O
the	O
Predicted	O
Irr	O
Regulon	O
and	O
ICE	O
Motifs	O
with	O
the	O
Published	O
Expression	O
Microarray	O
Data	O
for	O
Iron	O
-	O
and	O
Irr	O
-	O
Affected	O
Genes	O
in	O
Bradyrhizobium	O
japonicum	O
</ALL>	O

<ALL>	O
Mass	O
casualty	O
estimation	O
on	O
a	O
geographic	O
basis	O
</ALL>	O

<ALL>	O
The	O
Defense	O
Threat	O
Reduction	O
Agency	O
(	O
DTRA	O
)	O
has	O
expended	O
considerable	O
effort	O
to	O
develop	O
models	O
for	O
calculating	O
mass	O
casualties	O
from	O
a	O
nuclear	O
detonation	O
.	O
</ALL>	O

<ALL>	O
In	O
order	O
to	O
specifically	O
evaluate	O
urban	O
medical	O
systems	O
vulnerability	O
we	O
are	O
employing	O
the	O
PC	O
based	O
Consequence	O
Assessment	O
Tool	O
Set	O
(	O
CATS	O
)	O
v6	O
,	O
with	O
ESRI	O
'	O
s	O
ArcGIS9	O
[	O
14	O
]	O
,	O
CATS	O
/	O
JACE	O
(	O
Joint	O
Assessment	O
of	O
Catastrophic	O
Events	O
)	O
v5	O
with	O
ESRI	O
'	O
s	O
ArcView	O
3	O
.	O
3	O
,	O
Hazard	O
Prediction	O
and	O
Assessment	O
Capability	O
(	O
HPAC	O
)	O
V4	O
.	O
04SP3	O
[	O
15	O
]	O
,	O
as	O
well	O
as	O
custom	O
GIS	O
and	O
database	O
software	O
applications	O
.	O
</ALL>	O

<ALL>	O
HPAC	O
does	O
excellent	O
Chemical	O
Biological	O
and	O
Nuclear	O
(	O
CBN	O
)	O
modeling	O
,	O
although	O
output	O
could	O
provide	O
more	O
flexibility	O
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
results	O
can	O
be	O
exported	O
to	O
CATS	O
for	O
further	O
analysis	O
and	O
display	O
.	O
</ALL>	O

<ALL>	O
All	O
three	O
programs	O
can	O
access	O
the	O
current	O
weather	O
data	O
from	O
both	O
classified	O
and	O
unclassified	O
weather	O
servers	O
.	O
</ALL>	O

<ALL>	O
Examples	O
of	O
uses	O
of	O
CATS	O
/	O
HPAC	O
are	O
hurricane	O
,	O
tidal	O
surge	O
and	O
earthquake	O
damage	O
,	O
prediction	O
of	O
the	O
results	O
from	O
nuclear	O
,	O
biological	O
and	O
chemical	O
releases	O
,	O
assessment	O
of	O
persons	O
and	O
infrastructure	O
affected	O
and	O
at	O
risk	O
(	O
e	O
.	O
g	O
.	O
which	O
hospitals	O
and	O
pharmacies	O
are	O
under	O
a	O
CBN	O
plume	O
and	O
are	O
thus	O
out	O
of	O
commission	O
)	O
,	O
and	O
mobilization	O
of	O
surviving	O
and	O
nearby	O
infrastructure	O
outside	O
the	O
plume	O
that	O
would	O
be	O
needed	O
to	O
address	O
healthcare	O
and	O
other	O
emergency	O
response	O
needs	O
of	O
the	O
community	O
.	O
</ALL>	O

<ALL>	O
These	O
models	O
have	O
been	O
,	O
and	O
continue	O
to	O
be	O
,	O
developed	O
with	O
a	O
view	O
to	O
better	O
estimating	O
the	O
impact	O
of	O
WMD	O
weapons	O
in	O
an	O
offensive	O
setting	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
recent	O
DTRA	O
enhancements	O
and	O
our	O
modifications	O
have	O
facilitated	O
their	O
use	O
in	O
helping	O
estimate	O
potential	O
casualties	O
from	O
a	O
WMD	O
terrorist	O
incident	O
.	O
</ALL>	O

<ALL>	O
One	O
area	O
of	O
intense	O
interest	O
,	O
and	O
somewhat	O
of	O
a	O
vacuum	O
in	O
public	O
health	O
planning	O
,	O
has	O
been	O
the	O
utility	O
of	O
this	O
approach	O
in	O
estimating	O
medical	O
care	O
vulnerabilities	O
in	O
such	O
an	O
attack	O
,	O
and	O
for	O
the	O
calculation	O
of	O
the	O
distribution	O
of	O
surviving	O
medical	O
care	O
resources	O
.	O
</ALL>	O

<ALL>	O
While	O
much	O
work	O
has	O
already	O
occurred	O
in	O
estimating	O
the	O
impact	O
of	O
chemical	O
weapons	O
(	O
due	O
to	O
the	O
dual	O
use	O
in	O
chemical	O
spill	O
management	O
from	O
transportation	O
and	O
industrial	O
accidents	O
)	O
,	O
or	O
in	O
nuclear	O
power	O
plant	O
accident	O
management	O
,	O
much	O
less	O
research	O
and	O
development	O
has	O
gone	O
into	O
estimating	O
the	O
impact	O
on	O
our	O
civilian	O
population	O
of	O
a	O
nuclear	O
weapon	O
detonation	O
from	O
a	O
terrorist	O
incident	O
in	O
a	O
large	O
urban	O
area	O
.	O
</ALL>	O

<ALL>	O
The	O
models	O
already	O
calculate	O
such	O
factors	O
as	O
the	O
impact	O
of	O
blast	O
,	O
thermal	O
effects	O
and	O
fallout	O
,	O
but	O
results	O
are	O
often	O
not	O
available	O
at	O
the	O
detail	O
level	O
needed	O
for	O
civil	O
defense	O
purposes	O
,	O
casualty	O
management	O
,	O
and	O
planning	O
the	O
use	O
of	O
scarce	O
health	O
resources	O
in	O
response	O
to	O
a	O
nuclear	O
weapon	O
detonation	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
the	O
models	O
do	O
not	O
readily	O
facilitate	O
the	O
calculation	O
of	O
injuries	O
from	O
multiple	O
effects	O
such	O
as	O
burns	O
and	O
blast	O
with	O
fallout	O
or	O
prompt	O
radiation	O
.	O
</ALL>	O

<ALL>	O
The	O
complexity	O
of	O
the	O
urban	O
three	O
-	O
dimensional	O
landscape	O
and	O
its	O
local	O
impact	O
on	O
thermal	O
,	O
blast	O
and	O
radiation	O
is	O
also	O
poorly	O
understood	O
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
given	O
their	O
traditional	O
world	O
-	O
wide	O
focus	O
,	O
and	O
the	O
increased	O
sensitivity	O
to	O
providing	O
information	O
on	O
the	O
U	O
.	O
S	O
.	O
A	O
.	O
of	O
use	O
to	O
terrorists	O
,	O
the	O
models	O
do	O
not	O
provide	O
detailed	O
or	O
current	O
data	O
that	O
exists	O
for	O
the	O
United	O
States	O
that	O
would	O
help	O
provide	O
better	O
casualty	O
estimates	O
and	O
response	O
.	O
</ALL>	O

<ALL>	O
The	O
models	O
can	O
be	O
customized	O
locally	O
and	O
data	O
updated	O
if	O
the	O
user	O
has	O
sufficient	O
expertise	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
there	O
is	O
often	O
a	O
significant	O
duplication	O
of	O
effort	O
due	O
to	O
overlapping	O
jurisdictions	O
and	O
the	O
lack	O
of	O
data	O
sharing	O
due	O
to	O
security	O
and	O
other	O
considerations	O
.	O
</ALL>	O

<ALL>	O
CATS	O
and	O
HPAC	O
are	O
also	O
useful	O
for	O
creating	O
realistic	O
scenarios	O
for	O
training	O
and	O
planning	O
before	O
a	O
disaster	O
strikes	O
,	O
thus	O
enabling	O
responders	O
to	O
drill	O
and	O
exercise	O
so	O
they	O
know	O
roughly	O
what	O
to	O
expect	O
and	O
how	O
to	O
react	O
.	O
</ALL>	O

<ALL>	O
Contingency	O
plans	O
can	O
be	O
created	O
using	O
comprehensive	O
national	O
and	O
more	O
detailed	O
population	O
and	O
infrastructure	O
data	O
.	O
</ALL>	O

<ALL>	O
Should	O
disaster	O
strike	O
,	O
the	O
affected	O
population	O
and	O
the	O
impact	O
on	O
critical	O
facilities	O
can	O
be	O
quickly	O
assessed	O
,	O
although	O
efforts	O
frequently	O
need	O
to	O
be	O
expended	O
to	O
ensure	O
regional	O
and	O
local	O
databases	O
are	O
current	O
and	O
useful	O
.	O
</ALL>	O

<ALL>	O
Case	O
Presentation	O
</ALL>	O

<ALL>	O
The	O
patient	O
is	O
an	O
80	O
year	O
old	O
male	O
with	O
diabetes	O
mellitus	O
and	O
hypertension	O
,	O
who	O
at	O
age	O
74	O
(	O
March	O
2001	O
)	O
had	O
received	O
a	O
living	O
non	O
-	O
related	O
donor	O
kidney	B-Organ
transplant	O
.	O
</ALL>	O

<ALL>	O
At	O
that	O
time	O
he	O
was	O
discharged	O
with	O
a	O
double	O
immunosuppressive	O
therapy	O
consisting	O
of	O
prednisone	O
20	O
mg	O
/	O
day	O
and	O
mophetil	O
mycophenolate	O
1	O
.	O
5	O
gr	O
/	O
day	O
.	O
</ALL>	O

<ALL>	O
No	O
calcineurin	O
inhibitor	O
was	O
administered	O
.	O
</ALL>	O

<ALL>	O
His	O
prednisone	O
dose	O
was	O
further	O
decreased	O
to	O
5	O
mg	O
/	O
day	O
and	O
mophetil	O
mycophenolate	O
doses	O
sustained	O
.	O
</ALL>	O

<ALL>	O
In	O
November	O
2001	O
he	O
developed	O
cutaneous	O
purple	O
elevated	O
lesions	B-Pathological_formation
in	O
his	O
lower	B-Organism_subdivision
limbs	I-Organism_subdivision
that	O
were	O
diagnosed	O
as	O
KS	B-Pathological_formation
by	O
skin	B-Organ
biopsy	O
.	O
</ALL>	O

<ALL>	O
He	O
received	O
19	O
administrations	O
of	O
vincristine	O
(	O
1	O
mg	O
)	O
and	O
bleomycin	O
(	O
15	O
mg	O
)	O
weekly	O
that	O
resulted	O
in	O
flattening	O
and	O
fading	O
of	O
the	O
lesions	B-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Treatment	O
was	O
discontinued	O
for	O
two	O
months	O
,	O
and	O
KS	B-Pathological_formation
recurred	O
,	O
with	O
pain	O
and	O
edema	B-Pathological_formation
in	O
both	O
legs	B-Organism_subdivision
.	O
</ALL>	O

<ALL>	O
On	O
July	O
2002	O
,	O
with	O
an	O
almost	O
100	O
%	O
involvement	O
of	O
his	O
lower	B-Organ
limbs	I-Organ
skin	I-Organ
with	O
KS	B-Pathological_formation
but	O
no	O
visceral	O
involvement	O
he	O
received	O
50	O
mg	O
of	O
liposomal	O
-	O
adriamycin	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
he	O
was	O
then	O
prescribed	O
valganciclovir	O
450	O
mg	O
BID	O
(	O
corrected	O
for	O
creatinine	O
clearance	O
)	O
[	O
7	O
]	O
and	O
three	O
additional	O
administrations	O
of	O
liposomal	O
-	O
adriamycin	O
,	O
up	O
to	O
December	O
2002	O
.	O
</ALL>	O

<ALL>	O
He	O
showed	O
40	O
%	O
response	O
again	O
with	O
early	O
relapse	O
.	O
</ALL>	O

<ALL>	O
On	O
January	O
2003	O
the	O
patient	O
developed	O
disseminated	O
herpes	O
zoster	O
,	O
which	O
was	O
treated	O
with	O
IV	O
acyclovir	O
.	O
</ALL>	O

<ALL>	O
In	O
May	O
2003	O
KS	B-Pathological_formation
progression	O
was	O
observed	O
and	O
received	O
radiotherapy	O
with	O
no	O
benefit	O
Figure	O
1	O
.	O
</ALL>	O

<ALL>	O
In	O
August	O
2003	O
he	O
started	O
oral	O
etoposide	O
at	O
50	O
mg	O
QD	O
for	O
two	O
weeks	O
followed	O
by	O
two	O
weeks	O
off	O
until	O
May	O
2004	O
achieving	O
a	O
very	O
slow	O
50	O
%	O
response	O
.	O
</ALL>	O

<ALL>	O
Tolerance	O
was	O
good	O
and	O
serum	B-Organism_substance
creatinine	O
remain	O
stable	O
at	O
around	O
1	O
,	O
4	O
mg	O
/	O
dl	O
.	O
</ALL>	O

<ALL>	O
Mophetil	O
mycophenolate	O
dose	O
was	O
reduced	O
to	O
1	O
g	O
/	O
day	O
and	O
prednisone	O
to	O
2	O
.	O
5	O
mg	O
/	O
day	O
.	O
</ALL>	O

<ALL>	O
Figure	O
1	O
</ALL>	O

<ALL>	O
Kaposi	B-Pathological_formation
'	I-Pathological_formation
s	I-Pathological_formation
sarcoma	I-Pathological_formation
progressions	O
after	O
chemotherapy	O
withdrawal	O
,	O
both	O
lower	B-Organism_subdivision
limbs	I-Organism_subdivision
were	O
completely	O
covered	O
with	O
Kaposi	B-Pathological_formation
'	I-Pathological_formation
s	I-Pathological_formation
Sarcoma	I-Pathological_formation
(	O
June	O
2003	O
)	O
.	O
</ALL>	O

<ALL>	O
On	O
May	O
2004	O
the	O
patient	O
requested	O
a	O
second	O
opinion	O
and	O
was	O
prescribed	O
Imatinib	O
200	O
mg	O
qd	O
for	O
two	O
weeks	O
followed	O
by	O
400	O
mg	O
qd	O
.	O
</ALL>	O

<ALL>	O
After	O
four	O
weeks	O
of	O
Imatinib	O
,	O
his	O
health	O
deteriorated	O
rapidly	O
,	O
he	O
developed	O
anasarca	B-Pathological_formation
,	O
worsening	O
of	O
KS	O
,	O
his	O
serum	B-Organism_substance
creatinine	O
increased	O
from	O
1	O
.	O
4	O
mg	O
/	O
dl	O
to	O
2	O
.	O
3	O
mg	O
/	O
dl	O
and	O
he	O
developed	O
grade	O
4	O
granulocytopenia	O
(	O
Figure	O
2	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
patient	O
was	O
hospitalized	O
with	O
fever	O
and	O
was	O
started	O
on	O
IV	O
antibiotics	O
and	O
daily	O
G	O
-	O
CSF	O
for	O
four	O
days	O
after	O
which	O
his	O
WBC	B-Cell
count	O
normalized	O
.	O
</ALL>	O

<ALL>	O
Two	O
weeks	O
later	O
the	O
creatinine	O
level	O
returned	O
to	O
1	O
.	O
5	O
mg	O
/	O
dl	O
.	O
</ALL>	O

<ALL>	O
On	O
February	O
2005	O
he	O
was	O
started	O
on	O
30	O
mg	O
of	O
paclitaxel	O
IV	O
every	O
three	O
weeks	O
.	O
</ALL>	O

<ALL>	O
After	O
three	O
courses	O
with	O
no	O
clinical	O
benefit	O
he	O
developed	O
a	O
skin	B-Organ
rash	O
that	O
prompted	O
discontinuation	O
.	O
</ALL>	O

<ALL>	O
Figure	O
2	O
</ALL>	O

<ALL>	O
Patient	O
developed	O
anasarca	B-Pathological_formation
with	O
rapid	O
progression	O
of	O
Kaposi	B-Pathological_formation
'	I-Pathological_formation
s	I-Pathological_formation
Sarcoma	I-Pathological_formation
after	O
four	O
weeks	O
of	O
taking	O
Imatinib	O
(	O
June	O
2004	O
)	O
.	O
</ALL>	O

<ALL>	O
On	O
April	O
2005	O
,	O
he	O
was	O
started	O
on	O
Sirolimus	O
2	O
mg	O
a	O
day	O
,	O
and	O
after	O
8	O
weeks	O
escalated	O
to	O
4	O
mg	O
a	O
day	O
.	O
</ALL>	O

<ALL>	O
Three	O
weeks	O
later	O
mophetil	O
mycophenolate	O
and	O
prednisone	O
were	O
discontinued	O
.	O
</ALL>	O

<ALL>	O
Sustained	O
and	O
significant	O
KS	B-Pathological_formation
regression	O
was	O
evident	O
after	O
16	O
weeks	O
,	O
but	O
he	O
developed	O
a	O
basal	B-Pathological_formation
cell	I-Pathological_formation
carcinoma	I-Pathological_formation
and	O
pneumonia	O
that	O
required	O
hospital	O
admission	O
;	O
Sirolimus	O
dose	O
was	O
lowered	O
to	O
2	O
mg	O
a	O
day	O
.	O
</ALL>	O

<ALL>	O
Thereafter	O
his	O
clinical	O
course	O
has	O
been	O
satisfactory	O
with	O
continuous	O
and	O
progressive	O
regression	O
of	O
KS	B-Pathological_formation
lesions	I-Pathological_formation
(	O
Figure	O
3	O
)	O
.	O
</ALL>	O

<ALL>	O
His	O
serum	B-Organism_substance
creatinine	O
has	O
remained	O
under	O
1	O
.	O
6	O
mg	O
/	O
dl	O
and	O
he	O
has	O
not	O
developed	O
new	O
infectious	O
episodes	O
.	O
</ALL>	O

<ALL>	O
Figure	O
3	O
</ALL>	O

<ALL>	O
Extensive	O
regression	O
of	O
Kaposi	B-Pathological_formation
Sarcoma	I-Pathological_formation
after	O
immune	O
-	O
suppression	O
was	O
changed	O
to	O
Sirolimus	O
,	O
(	O
14	O
months	O
later	O
)	O
,	O
he	O
only	O
has	O
hyperpigmented	O
areas	O
at	O
knee	B-Organism_subdivision
levels	O
,	O
skin	B-Organ
looks	O
thin	O
and	O
delicate	O
and	O
easily	O
bruised	O
(	O
July	O
2006	O
)	O
.	O
</ALL>	O

<ALL>	O
Hypothetical	O
distribution	O
patterns	O
of	O
the	O
meadow	O
brown	O
Maniola	O
jurtina	O
in	O
Europe	O
during	O
the	O
last	O
glacial	O
maximum	O
(	O
dark	O
hatched	O
areas	O
)	O
.	O
</ALL>	O

<ALL>	O
Postglacial	O
expansions	O
are	O
indicated	O
by	O
solid	O
arrows	O
.	O
</ALL>	O

<ALL>	O
The	O
postulated	O
actual	O
hybrid	O
zone	O
is	O
shown	O
by	O
the	O
hatched	O
area	O
.	O
</ALL>	O

<ALL>	O
Question	O
marks	O
indicate	O
lack	O
of	O
information	O
concerning	O
ancient	O
distribution	O
patterns	O
in	O
the	O
South	O
and	O
present	O
distribution	O
of	O
hybrid	O
populations	O
in	O
the	O
North	O
.	O
</ALL>	O

<ALL>	O
Redrawn	O
from	O
Schmitt	O
et	O
.	O
</ALL>	O

<ALL>	O
al	O
.	O
</ALL>	O

<ALL>	O
[	O
36	O
]	O
;	O
based	O
on	O
Thomson	O
[	O
37	O
]	O
and	O
Schmitt	O
et	O
al	O
.	O
</ALL>	O

<ALL>	O
[	O
36	O
]	O
.	O
</ALL>	O

<ALL>	O
Supporting	O
Information	O
</ALL>	O

<ALL>	O
Alternate	O
Language	O
Article	O
S1	O
</ALL>	O

<ALL>	O
Translation	O
of	O
the	O
manuscript	O
into	O
French	O
by	O
EL	O
</ALL>	O

<ALL>	O
(	O
201	O
KB	O
DOC	O
)	O
.	O
</ALL>	O

<ALL>	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
</ALL>	O

<ALL>	O
Extrapyramidal	O
symptoms	O
based	O
on	O
Extrapyramidal	O
Symptoms	O
Rating	O
Scale	O
</ALL>	O

<ALL>	O
Etiology	O
</ALL>	O

<ALL>	O
Anorectal	B-Organism_subdivision
malformations	O
(	O
ARM	O
)	O
represent	O
a	O
spectrum	O
of	O
abnormalities	O
ranging	O
from	O
mild	O
anal	B-Immaterial_anatomical_entity
anomalies	O
to	O
complex	O
cloacal	O
malformations	O
.	O
</ALL>	O

<ALL>	O
The	O
etiology	O
of	O
such	O
malformations	O
remains	O
unclear	O
and	O
is	O
likely	O
multifactorial	O
.	O
</ALL>	O

<ALL>	O
There	O
are	O
however	O
reasons	O
to	O
believe	O
there	O
is	O
a	O
genetic	O
componenet	O
.	O
</ALL>	O

<ALL>	O
As	O
early	O
as	O
the	O
1950s	O
,	O
it	O
was	O
recognized	O
that	O
there	O
was	O
an	O
increased	O
risk	O
for	O
a	O
sibling	O
of	O
a	O
patient	O
with	O
ARM	O
to	O
be	O
born	O
with	O
a	O
malformation	O
,	O
as	O
much	O
as	O
1	O
in	O
100	O
,	O
compared	O
with	O
the	O
incidence	O
of	O
about	O
1	O
in	O
5000	O
in	O
the	O
general	O
population	O
.	O
</ALL>	O

<ALL>	O
Since	O
that	O
time	O
there	O
have	O
been	O
reports	O
of	O
families	O
with	O
2	O
or	O
more	O
affected	O
members	O
and	O
associations	O
of	O
ARMs	O
with	O
multisystem	O
syndromes	O
.	O
</ALL>	O

<ALL>	O
In	O
particular	O
,	O
mutations	O
in	O
specific	O
genes	O
encoding	O
transcription	O
factors	O
have	O
been	O
described	O
in	O
patients	O
having	O
Townes	O
-	O
Broks	O
syndrome	O
,	O
Currarino	O
'	O
s	O
syndrome	O
,	O
and	O
Pallister	O
-	O
Hall	O
syndrome	O
,	O
each	O
of	O
which	O
have	O
autosomal	O
dominant	O
modes	O
of	O
inheritance	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
it	O
has	O
been	O
found	O
that	O
there	O
is	O
not	O
only	O
an	O
increased	O
incidence	O
of	O
ARM	O
in	O
patient	O
with	O
trisomy	O
21	O
(	O
Down	O
'	O
s	O
syndrome	O
)	O
,	O
but	O
that	O
95	O
%	O
of	O
patients	O
with	O
trisomy	O
21	O
and	O
ARM	O
have	O
imperforate	O
anus	B-Immaterial_anatomical_entity
without	O
fistula	B-Pathological_formation
,	O
compared	O
with	O
only	O
5	O
%	O
of	O
all	O
patients	O
with	O
ARM	O
.	O
</ALL>	O

<ALL>	O
Based	O
on	O
this	O
evidence	O
,	O
it	O
is	O
likely	O
that	O
the	O
mutation	O
of	O
a	O
variety	O
of	O
different	O
genes	O
can	O
result	O
in	O
ARM	O
,	O
or	O
that	O
the	O
etiology	O
of	O
ARM	O
is	O
multigenic	O
[	O
13	O
]	O
.	O
</ALL>	O

<ALL>	O
Images	O
</ALL>	O

<ALL>	O
Fig	O
.	O
</ALL>	O

<ALL>	O
1	O
</ALL>	O

<ALL>	O
Fig	O
.	O
</ALL>	O

<ALL>	O
2	O
</ALL>	O

<ALL>	O
Fig	O
.	O
</ALL>	O

<ALL>	O
3	O
</ALL>	O

<ALL>	O
Images	O
</ALL>	O

<ALL>	O
Figure	O
1	O
</ALL>	O

<ALL>	O
Results	O
</ALL>	O

<ALL>	O
The	O
observation	O
that	O
AP	O
-	O
3	O
is	O
found	O
in	O
both	O
cytosolic	B-Organism_substance
and	O
membrane	B-Organism_substance
subcellular	I-Organism_substance
fractions	I-Organism_substance
,	O
and	O
that	O
membrane	B-Cellular_component
-	O
associated	O
AP	O
-	O
3	O
can	O
be	O
extracted	O
with	O
salts	O
(	O
Dell	O
'	O
Angelica	O
et	O
al	O
.	O
,	O
1997a	O
)	O
is	O
consistent	O
with	O
its	O
role	O
as	O
a	O
membrane	B-Cellular_component
coat	O
that	O
can	O
be	O
recruited	O
from	O
a	O
cytosolic	B-Organism_substance
pool	I-Organism_substance
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
punctate	O
staining	O
of	O
AP	O
-	O
3	O
by	O
immunofluorescence	O
microscopy	O
,	O
its	O
redistribution	O
to	O
the	O
cytosol	B-Organism_substance
by	O
BFA	O
,	O
and	O
the	O
reversibility	O
of	O
the	O
BFA	O
effect	O
(	O
Dell	O
'	O
Angelica	O
et	O
al	O
.	O
,	O
1997a	O
;	O
Simpson	O
et	O
al	O
.	O
,	O
1997	O
)	O
also	O
indicate	O
that	O
AP	O
-	O
3	O
can	O
cycle	O
between	O
the	O
cytosol	B-Organism_substance
and	O
membranes	B-Cellular_component
.	O
</ALL>	O

<ALL>	O
The	O
sensitivity	O
of	O
AP	O
-	O
3	O
to	O
BFA	O
in	O
cells	B-Cell
suggests	O
that	O
its	O
membrane	B-Cellular_component
association	O
may	O
be	O
regulated	O
by	O
ARF1	O
,	O
since	O
BFA	O
inhibits	O
ARF1	O
guanine	O
nucleotide	O
exchange	O
,	O
and	O
has	O
been	O
shown	O
to	O
prevent	O
ARF1	O
membrane	B-Cellular_component
binding	O
in	O
vitro	O
(	O
Donaldson	O
et	O
al	O
.	O
,	O
1992	O
;	O
Helms	O
and	O
Rothman	O
,	O
1992	O
;	O
Randazzo	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O
</ALL>	O

<ALL>	O
Immunocytochemistry	O
</ALL>	O

<ALL>	O
C2C12	B-Cell
cells	I-Cell
grown	O
in	O
8	O
-	O
chamber	O
slides	O
(	O
Nunc	O
)	O
were	O
fixed	O
in	O
4	O
%	O
PFA	O
/	O
PBS	O
for	O
10	O
min	O
and	O
permeabilized	O
in	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
for	O
20	O
min	O
.	O
</ALL>	O

<ALL>	O
In	O
some	O
cases	O
,	O
they	O
were	O
fixed	O
and	O
permeabilized	O
in	O
methanol	O
at	O
-	O
20degreesC	O
for	O
2	O
min	O
.	O
</ALL>	O

<ALL>	O
The	O
fixed	O
and	O
permeabilized	O
cells	B-Cell
were	O
blocked	O
in	O
PBS	O
containing	O
3	O
%	O
BSA	O
(	O
Jackson	O
ImmunoResearch	O
Laboratories	O
)	O
and	O
incubated	O
overnight	O
at	O
4degreesC	O
with	O
primary	O
antibodies	O
in	O
blocking	O
solution	O
.	O
</ALL>	O

<ALL>	O
Immunoreactivity	O
was	O
detected	O
with	O
either	O
Alexa	O
-	O
conjugated	O
secondary	O
antibody	O
(	O
Molecular	O
Probes	O
)	O
or	O
a	O
combination	O
of	O
biotin	O
-	O
conjugated	O
secondary	O
antibody	O
(	O
Vector	O
Laboratories	O
)	O
and	O
Alexa	O
-	O
conjugated	O
streptavidin	O
(	O
Molecular	O
Probes	O
)	O
.	O
</ALL>	O

<ALL>	O
Cytology	O
and	O
Histology	O
</ALL>	O

<ALL>	O
For	O
semithin	O
sections	O
,	O
embryoid	B-Developing_anatomical_structure
bodies	I-Developing_anatomical_structure
were	O
washed	O
twice	O
in	O
PBS	O
,	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
at	O
4degreesC	O
overnight	O
,	O
and	O
after	O
dehydration	O
in	O
ethanol	O
were	O
embedded	O
in	O
JB	O
-	O
4	O
resin	O
(	O
Polysciences	O
,	O
Inc	O
.	O
)	O
.	O
</ALL>	O

<ALL>	O
1	O
-	O
4	O
-	O
mum	O
sections	O
were	O
cut	O
with	O
a	O
glass	O
knife	O
.	O
</ALL>	O

<ALL>	O
For	O
cytology	O
,	O
the	O
sections	O
were	O
stained	O
with	O
toluidine	O
blue	O
.	O
</ALL>	O

<ALL>	O
In	O
cell	B-Cell
mixing	O
experiments	O
,	O
the	O
embryoid	B-Developing_anatomical_structure
bodies	I-Developing_anatomical_structure
were	O
prefixed	O
and	O
stained	O
for	O
beta	O
-	O
galactosidase	O
and	O
the	O
sections	O
were	O
counterstained	O
with	O
neutral	O
red	O
.	O
</ALL>	O

<ALL>	O
Teratocarcinomas	O
were	O
fixed	O
in	O
Bouin	O
fixative	O
,	O
embedded	O
in	O
Paraplast	O
,	O
and	O
the	O
sections	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
.	O
</ALL>	O

<ALL>	O
Microphotography	O
was	O
with	O
a	O
ZEISS	O
Axiomat	O
microscope	O
.	O
</ALL>	O

<ALL>	O
Films	O
were	O
scanned	O
and	O
figures	O
were	O
prepared	O
with	O
Photoshop	O
5	O
.	O
5	O
software	O
.	O
</ALL>	O

<ALL>	O
Stimulation	O
/	O
Inhibition	O
of	O
iDC	B-Cell
Functions	O
by	O
Activated	O
NK	B-Cell
Cells	I-Cell
.	O
</ALL>	O

<ALL>	O
Two	O
previous	O
studies	O
have	O
shown	O
that	O
both	O
resting	O
and	O
activated	O
NK	B-Cell
cells	I-Cell
partially	O
kill	O
autologous	O
DCs	B-Cell
,	O
as	O
measured	O
by	O
3	O
-	O
4	O
-	O
h	O
chromium	O
release	O
assays	O
using	O
high	O
NK	B-Cell
/	O
DC	B-Cell
ratios	O
(	O
11	O
,	O
12	O
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
in	O
our	O
long	O
-	O
term	O
cultures	O
(	O
24	O
-	O
48	O
h	O
)	O
the	O
NK	B-Cell
cells	I-Cell
stimulated	O
the	O
iDCs	B-Cell
rather	O
than	O
lysing	O
them	O
.	O
</ALL>	O

<ALL>	O
Based	O
on	O
these	O
conflicting	O
results	O
,	O
we	O
examined	O
in	O
more	O
detail	O
the	O
apparent	O
stimulation	O
of	O
iDCs	B-Cell
after	O
contact	O
with	O
NK	B-Cell
cells	I-Cell
.	O
</ALL>	O

<ALL>	O
We	O
reasoned	O
that	O
activated	O
NK	B-Cell
cells	I-Cell
would	O
be	O
more	O
useful	O
for	O
these	O
experiments	O
because	O
(	O
i	O
)	O
an	O
encounter	O
in	O
vivo	O
between	O
NK	B-Cell
cells	I-Cell
that	O
normally	O
traffic	O
in	O
the	O
blood	B-Organism_substance
(	O
4	O
)	O
and	O
iDCs	B-Cell
which	O
reside	O
in	O
the	O
tissues	B-Tissue
(	O
1	O
,	O
3	O
)	O
,	O
should	O
only	O
occur	O
when	O
both	O
cells	B-Cell
are	O
activated	O
;	O
(	O
ii	O
)	O
activated	O
NK	B-Cell
cells	I-Cell
mediate	O
more	O
potent	O
lysis	O
of	O
iDCs	B-Cell
(	O
11	O
-	O
13	O
)	O
,	O
thereby	O
allowing	O
for	O
a	O
more	O
rigorous	O
examination	O
of	O
a	O
potential	O
cytotoxic	O
effect	O
;	O
and	O
(	O
iii	O
)	O
the	O
number	O
of	O
NK	B-Cell
cells	I-Cell
obtained	O
after	O
short	O
-	O
term	O
in	O
vitro	O
culture	O
would	O
be	O
far	O
greater	O
providing	O
more	O
cells	B-Cell
for	O
analysis	O
(	O
9	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
DC	B-Cell
maturation	O
induced	O
by	O
resting	O
NK	B-Cell
cells	I-Cell
we	O
observed	O
was	O
dependent	O
on	O
endogenous	O
TNF	O
-	O
alpha	O
production	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
TNF	O
-	O
alpha	O
and	O
other	O
proinflammatory	O
cytokines	O
are	O
important	O
amplifiers	O
of	O
immune	O
responses	O
(	O
14	O
)	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
we	O
used	O
TNF	O
-	O
alpha	O
production	O
as	O
a	O
readout	O
for	O
DC	B-Cell
stimulation	O
in	O
our	O
culture	O
system	O
.	O
</ALL>	O

<ALL>	O
Culturing	O
activated	O
NK	B-Cell
cells	I-Cell
with	O
DCs	B-Cell
at	O
low	O
NK	B-Cell
/	O
DC	B-Cell
ratios	O
(	O
1	O
:	O
5	O
)	O
led	O
to	O
increases	O
in	O
TNF	O
-	O
alpha	O
production	O
,	O
which	O
were	O
augmented	O
dramatically	O
by	O
the	O
addition	O
of	O
suboptimal	O
doses	O
(	O
10	O
ng	O
/	O
ml	O
)	O
of	O
LPS	O
(	O
Fig	O
.	O
2	O
A	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
increased	O
TNF	O
-	O
alpha	O
production	O
was	O
dependent	O
on	O
cell	B-Cell
-	O
to	O
-	O
cell	B-Cell
contact	O
because	O
when	O
the	O
two	O
cell	B-Cell
types	O
were	O
separated	O
in	O
trans	O
-	O
wells	O
,	O
no	O
stimulation	O
was	O
observed	O
(	O
Fig	O
.	O
2	O
B	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
separate	O
experiments	O
we	O
observed	O
this	O
NK	B-Cell
-	O
stimulatory	O
effect	O
on	O
TNF	O
-	O
alpha	O
production	O
at	O
NK	B-Cell
/	O
DC	B-Cell
ratios	O
as	O
low	O
as	O
1	O
:	O
20	O
and	O
1	O
:	O
40	O
(	O
data	O
not	O
shown	O
)	O
.	O
</ALL>	O

<ALL>	O
Raising	O
the	O
NK	B-Cell
/	O
DC	B-Cell
ratio	O
to	O
5	O
:	O
1	O
changes	O
the	O
interaction	O
from	O
one	O
of	O
potent	O
DC	B-Cell
stimulation	O
to	O
that	O
of	O
complete	O
inhibition	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
(	O
Fig	O
.	O
2	O
C	O
)	O
.	O
</ALL>	O

<ALL>	O
An	O
identical	O
pattern	O
is	O
seen	O
for	O
IL	O
-	O
12	O
p40	O
production	O
(	O
Fig	O
.	O
2	O
D	O
)	O
.	O
</ALL>	O

<ALL>	O
No	O
IL	O
-	O
10	O
production	O
in	O
the	O
cultures	O
was	O
detected	O
under	O
any	O
of	O
the	O
conditions	O
tested	O
(	O
data	O
not	O
shown	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
massive	O
production	O
of	O
TNF	O
-	O
alpha	O
in	O
the	O
cultures	O
at	O
the	O
lowest	O
ratios	O
was	O
mediated	O
primarily	O
by	O
DCs	B-Cell
in	O
the	O
culture	O
due	O
to	O
the	O
low	O
number	O
of	O
NK	B-Cell
cells	I-Cell
(	O
2	O
x	O
104	O
cells	B-Cell
per	O
well	O
)	O
used	O
in	O
these	O
experiments	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
efforts	O
to	O
stimulate	O
NK	B-Cell
cells	I-Cell
directly	O
with	O
optimal	O
doses	O
of	O
anti	O
-	O
CD16	O
,	O
rIL	O
-	O
2	O
,	O
rIL	O
-	O
12	O
,	O
and	O
PMA	O
/	O
ionomycin	O
alone	O
or	O
in	O
combination	O
induced	O
only	O
moderate	O
(	O
<	O
500	O
pg	O
/	O
ml	O
)	O
TNF	O
-	O
alpha	O
production	O
by	O
the	O
NK	B-Cell
cells	I-Cell
alone	O
which	O
were	O
present	O
at	O
2	O
x	O
105	O
cells	B-Cell
per	O
well	O
(	O
data	O
not	O
shown	O
)	O
.	O
</ALL>	O

<ALL>	O
Figure	O
2	O
.	O
</ALL>	O

<ALL>	O
Activated	O
/	O
cultured	O
NK	B-Cell
cell	I-Cell
-	O
mediated	O
amplification	O
/	O
inhibition	O
of	O
DC	B-Cell
cytokine	O
production	O
.	O
</ALL>	O

<ALL>	O
Results	O
are	O
presented	O
on	O
log	O
scales	O
.	O
</ALL>	O

<ALL>	O
Cultured	O
iDCs	B-Cell
were	O
incubated	O
alone	O
or	O
with	O
cultured	O
/	O
purified	O
NK	B-Cell
cells	I-Cell
for	O
24	O
h	O
(	O
A	O
and	O
B	O
)	O
or	O
48	O
h	O
(	O
C	O
-	O
E	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
indicated	O
concentrations	O
of	O
LPS	O
.	O
</ALL>	O

<ALL>	O
After	O
culture	O
the	O
supernatants	O
were	O
removed	O
and	O
analyzed	O
by	O
ELISA	O
for	O
TNF	O
-	O
alpha	O
or	O
IL	O
-	O
12	O
p40	O
.	O
</ALL>	O

<ALL>	O
(	O
A	O
)	O
TNF	O
-	O
alpha	O
production	O
was	O
measured	O
in	O
the	O
supernatants	O
from	O
cultures	O
of	O
:	O
DCs	B-Cell
alone	O
(	O
gray	O
bars	O
)	O
;	O
NK	B-Cell
+	O
DC	B-Cell
(	O
1	O
:	O
5	O
)	O
(	O
black	O
bars	O
)	O
.	O
</ALL>	O

<ALL>	O
LPS	O
concentrations	O
used	O
were	O
:	O
0	O
,	O
10	O
,	O
and	O
1	O
,	O
000	O
ng	O
/	O
ml	O
(	O
DCs	B-Cell
alone	O
only	O
)	O
.	O
</ALL>	O

<ALL>	O
(	O
B	O
)	O
Contact	O
-	O
dependent	O
stimulation	O
of	O
iDC	B-Cell
TNF	O
-	O
alpha	O
production	O
by	O
NK	B-Cell
cells	I-Cell
was	O
tested	O
under	O
the	O
following	O
conditions	O
:	O
DCs	B-Cell
alone	O
(	O
gray	O
bars	O
)	O
;	O
NK	B-Cell
+	O
DC	B-Cell
(	O
1	O
:	O
5	O
)	O
(	O
black	O
bars	O
)	O
;	O
NK	B-Cell
/	O
DC	B-Cell
(	O
1	O
:	O
5	O
)	O
trans	O
-	O
wells	O
(	O
striped	O
bars	O
)	O
.	O
</ALL>	O

<ALL>	O
LPS	O
concentrations	O
used	O
were	O
:	O
10	O
ng	O
/	O
ml	O
(	O
donor	O
1	O
)	O
and	O
20	O
ng	O
/	O
ml	O
(	O
donor	O
2	O
)	O
.	O
</ALL>	O

<ALL>	O
(	O
C	O
and	O
D	O
)	O
Effect	O
of	O
increasing	O
the	O
NK	B-Cell
/	O
DC	B-Cell
ratio	O
(	O
DCs	B-Cell
alone	O
;	O
NK	B-Cell
:	O
DC	B-Cell
-	O
1	O
:	O
5	O
;	O
1	O
:	O
1	O
;	O
5	O
:	O
1	O
)	O
on	O
(	O
C	O
)	O
TNF	O
-	O
alpha	O
and	O
(	O
D	O
)	O
IL	O
-	O
12	O
p40	O
production	O
.	O
</ALL>	O

<ALL>	O
LPS	O
concentrations	O
used	O
were	O
:	O
0	O
ng	O
/	O
ml	O
(	O
*	O
)	O
;	O
20	O
ng	O
/	O
ml	O
(	O
*	O
)	O
;	O
50	O
ng	O
/	O
ml	O
(	O
^	O
)	O
;	O
and	O
1	O
,	O
000	O
ng	O
/	O
ml	O
-	O
LPS	O
(	O
*	O
)	O
(	O
DCs	B-Cell
alone	O
only	O
)	O
.	O
</ALL>	O

<ALL>	O
(	O
E	O
)	O
The	O
effect	O
of	O
neutralizing	O
IFN	O
-	O
gamma	O
production	O
was	O
tested	O
under	O
the	O
following	O
conditions	O
:	O
DCs	B-Cell
alone	O
(	O
gray	O
bars	O
)	O
;	O
NK	B-Cell
+	O
DC	B-Cell
(	O
1	O
:	O
5	O
)	O
(	O
black	O
bars	O
)	O
;	O
NK	B-Cell
+	O
DC	B-Cell
(	O
1	O
:	O
5	O
)	O
and	O
10	O
mug	O
/	O
ml	O
of	O
blocking	O
anti	O
-	O
IFN	O
-	O
gamma	O
mAb	O
(	O
stippled	O
bars	O
)	O
.	O
</ALL>	O

<ALL>	O
LPS	O
concentrations	O
used	O
were	O
:	O
0	O
ng	O
/	O
ml	O
(	O
NO	O
LPS	O
)	O
and	O
20	O
ng	O
/	O
ml	O
(	O
LPS	O
20	O
)	O
.	O
</ALL>	O

<ALL>	O
Blocking	O
reagents	O
for	O
CD80	O
,	O
CD86	O
,	O
CD154	O
,	O
CD95	O
,	O
CD11a	O
,	O
CD50	O
,	O
or	O
IL	O
-	O
12	O
,	O
had	O
no	O
effect	O
on	O
the	O
NK	B-Cell
cell	I-Cell
-	O
induced	O
TNF	O
-	O
alpha	O
or	O
IL	O
-	O
12	O
p40	O
production	O
,	O
whereas	O
a	O
neutralizing	O
antibody	O
for	O
IFN	O
-	O
gamma	O
while	O
not	O
affecting	O
TNF	O
-	O
alpha	O
production	O
partially	O
blocked	O
(	O
<	O
20	O
%	O
)	O
IL	O
-	O
12	O
p40	O
production	O
induced	O
by	O
the	O
NK	B-Cell
cells	I-Cell
(	O
Fig	O
.	O
2	O
E	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
partial	O
inhibition	O
is	O
consistent	O
with	O
numerous	O
previous	O
reports	O
demonstrating	O
a	O
central	O
role	O
for	O
an	O
IL	O
-	O
12	O
/	O
IFN	O
-	O
gamma	O
positive	O
feedback	O
loop	O
active	O
between	O
NK	B-Cell
cells	I-Cell
and	O
IL	B-Cell
-	I-Cell
12	I-Cell
-	I-Cell
producing	I-Cell
cells	I-Cell
(	O
15	O
-	O
17	O
)	O
.	O
</ALL>	O

<ALL>	O
Clearly	O
,	O
however	O
,	O
this	O
well	O
-	O
described	O
cytokine	O
cross	O
-	O
talk	O
mechanism	O
is	O
secondary	O
to	O
the	O
contact	O
-	O
dependent	O
activation	O
of	O
DCs	B-Cell
by	O
NK	B-Cell
cells	I-Cell
described	O
here	O
.	O
</ALL>	O

<ALL>	O
Taken	O
together	O
these	O
results	O
indicate	O
that	O
novel	O
mechanisms	O
control	O
cognate	O
interactions	O
between	O
NK	B-Cell
cells	I-Cell
and	O
DCs	B-Cell
and	O
that	O
NK	B-Cell
-	O
DC	B-Cell
contact	O
has	O
the	O
potential	O
to	O
serve	O
as	O
an	O
important	O
control	O
switch	O
for	O
both	O
amplifying	O
and	O
attenuating	O
innate	O
immune	O
responses	O
in	O
vivo	O
.	O
</ALL>	O

<ALL>	O
We	O
next	O
tested	O
directly	O
whether	O
NK	B-Cell
cell	I-Cell
killing	O
was	O
active	O
in	O
our	O
system	O
using	O
both	O
short	O
-	O
term	O
(	O
4	O
-	O
h	O
)	O
chromium	O
release	O
assays	O
(	O
data	O
not	O
shown	O
)	O
and	O
a	O
flow	O
cytometric	O
assay	O
which	O
allowed	O
us	O
to	O
follow	O
the	O
survival	O
of	O
the	O
autologous	O
iDCs	B-Cell
in	O
the	O
presence	O
of	O
NK	B-Cell
cells	I-Cell
over	O
longer	O
periods	O
(	O
Fig	O
.	O
3	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
demonstrate	O
that	O
NK	B-Cell
cells	I-Cell
kill	O
autologous	O
iDCs	B-Cell
(	O
Fig	O
.	O
3	O
A	O
)	O
at	O
all	O
NK	B-Cell
/	O
DC	B-Cell
ratios	O
tested	O
after	O
4	O
h	O
and	O
the	O
level	O
of	O
killing	O
is	O
similar	O
to	O
the	O
lysis	O
of	O
K562	B-Cell
cells	I-Cell
over	O
the	O
same	O
time	O
(	O
Fig	O
.	O
3	O
B	O
)	O
.	O
</ALL>	O

<ALL>	O
After	O
24	O
h	O
,	O
however	O
,	O
the	O
presence	O
of	O
NK	B-Cell
cells	I-Cell
led	O
to	O
completely	O
divergent	O
effects	O
on	O
the	O
DCs	B-Cell
.	O
</ALL>	O

<ALL>	O
At	O
the	O
5	O
:	O
1	O
(	O
NK	B-Cell
/	O
DC	B-Cell
)	O
ratio	O
,	O
NK	B-Cell
cell	I-Cell
-	O
mediated	O
destruction	O
of	O
the	O
iDCs	B-Cell
was	O
the	O
dominant	O
feature	O
,	O
whereas	O
at	O
the	O
low	O
ratio	O
(	O
1	O
:	O
5	O
)	O
the	O
same	O
NK	B-Cell
cells	I-Cell
promoted	O
iDCs	B-Cell
survival	O
compared	O
with	O
iDCs	B-Cell
alone	O
over	O
the	O
same	O
period	O
(	O
Fig	O
.	O
3	O
A	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
equal	O
ratio	O
of	O
NK	B-Cell
/	O
DC	B-Cell
(	O
1	O
:	O
1	O
)	O
fell	O
between	O
these	O
two	O
extremes	O
.	O
</ALL>	O

<ALL>	O
The	O
NK	B-Cell
cell	I-Cell
-	O
mediated	O
lysis	O
of	O
the	O
K562	B-Cell
targets	O
increased	O
at	O
all	O
ratios	O
tested	O
after	O
the	O
24	O
-	O
h	O
incubation	O
.	O
</ALL>	O

<ALL>	O
These	O
striking	O
differences	O
between	O
death	O
and	O
survival	O
of	O
DCs	B-Cell
upon	O
encountering	O
NK	B-Cell
cells	I-Cell
correlate	O
precisely	O
with	O
our	O
previous	O
results	O
on	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
12	O
p40	O
production	O
where	O
increasing	O
numbers	O
of	O
NK	B-Cell
cells	I-Cell
in	O
the	O
culture	O
shifts	O
the	O
NK	B-Cell
effect	O
from	O
potent	O
stimulation	O
to	O
complete	O
inhibition	O
(	O
Fig	O
.	O
2	O
)	O
.	O
</ALL>	O

<ALL>	O
Figure	O
3	O
.	O
</ALL>	O

<ALL>	O
Activated	O
/	O
cultured	O
NK	B-Cell
cell	I-Cell
-	O
mediated	O
death	O
/	O
survival	O
of	O
DCs	B-Cell
and	O
NK	B-Cell
-	O
DC	B-Cell
conjugate	O
formation	O
.	O
</ALL>	O

<ALL>	O
NK	B-Cell
cell	I-Cell
mediated	O
killing	O
/	O
survival	O
of	O
CFDA	O
.	O
SE	O
-	O
loaded	O
iDCs	B-Cell
(	O
A	O
)	O
and	O
K562	B-Cell
cells	I-Cell
(	O
B	O
)	O
was	O
measured	O
by	O
flow	O
cytometry	O
over	O
4	O
h	O
(	O
*	O
)	O
or	O
24	O
h	O
(	O
*	O
)	O
at	O
the	O
indicated	O
NK	B-Cell
/	O
DC	B-Cell
ratios	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O
</ALL>	O

<ALL>	O
Results	O
are	O
presented	O
as	O
percentage	O
of	O
specific	O
lysis	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
3	O
independent	O
experiments	O
)	O
.	O
</ALL>	O

<ALL>	O
NK	B-Cell
-	O
DC	B-Cell
(	O
C	O
-	O
E	O
)	O
or	O
NK	B-Cell
-	O
K562	B-Cell
(	O
F	O
-	O
H	O
)	O
conjugate	O
formation	O
was	O
measured	O
by	O
flow	O
cytometry	O
,	O
at	O
the	O
following	O
ratios	O
(	O
NK	B-Cell
/	O
DC	B-Cell
or	O
NK	B-Cell
/	O
K562	B-Cell
)	O
:	O
1	O
:	O
5	O
(	O
C	O
and	O
F	O
)	O
;	O
1	O
:	O
1	O
(	O
D	O
and	O
G	O
)	O
;	O
and	O
5	O
:	O
1	O
(	O
E	O
and	O
H	O
)	O
.	O
</ALL>	O

<ALL>	O
Snarf	O
-	O
1	O
(	O
FL3	O
)	O
-	O
labeled	O
iDCs	B-Cell
or	O
K562	B-Cell
cells	I-Cell
were	O
incubated	O
(	O
30	O
min	O
)	O
with	O
CFDA	O
.	O
SE	O
(	O
FL1	O
)	O
-	O
labeled	O
NK	B-Cell
cells	I-Cell
at	O
the	O
different	O
ratios	O
.	O
</ALL>	O

<ALL>	O
The	O
percentage	O
of	O
conjugates	O
formed	O
(	O
top	O
right	O
quadrant	O
)	O
was	O
calculated	O
by	O
determining	O
the	O
percentage	O
of	O
FL3	O
+	O
(	O
Snarf	O
-	O
1	O
)	O
events	O
which	O
were	O
also	O
positive	O
for	O
FL1	O
(	O
CFDA	O
.	O
SE	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
are	O
representative	O
of	O
four	O
experiments	O
performed	O
with	O
activated	O
NK	B-Cell
cells	I-Cell
.	O
</ALL>	O

<ALL>	O
Resting	O
NK	B-Cell
cells	I-Cell
also	O
readily	O
formed	O
conjugates	O
with	O
autologous	O
iDCs	B-Cell
(	O
data	O
not	O
shown	O
)	O
.	O
</ALL>	O

<ALL>	O
NK	B-Cell
cells	I-Cell
can	O
both	O
efficiently	O
kill	O
and	O
potently	O
stimulate	O
DCs	B-Cell
in	O
our	O
model	O
system	O
and	O
each	O
of	O
these	O
opposing	O
effects	O
appear	O
dependent	O
on	O
cell	B-Cell
-	O
to	O
-	O
cell	B-Cell
contact	O
.	O
</ALL>	O

<ALL>	O
To	O
quantify	O
these	O
apparent	O
cognate	O
interactions	O
we	O
measured	O
the	O
formation	O
of	O
NK	B-Cell
-	O
DC	B-Cell
conjugates	O
and	O
compared	O
them	O
to	O
conjugates	O
formed	O
by	O
NK	B-Cell
cells	I-Cell
and	O
tumor	B-Pathological_formation
targets	O
.	O
</ALL>	O

<ALL>	O
Our	O
analysis	O
revealed	O
that	O
NK	B-Cell
cells	I-Cell
bound	O
DC	B-Cell
(	O
Fig	O
.	O
3	O
C	O
-	O
E	O
)	O
with	O
an	O
efficiency	O
almost	O
equal	O
to	O
that	O
of	O
NK	B-Cell
cell	I-Cell
binding	O
to	O
the	O
classical	O
NK	B-Cell
-	O
target	O
,	O
K562	B-Cell
(	O
Fig	O
.	O
3	O
F	O
-	O
H	O
)	O
.	O
</ALL>	O

<ALL>	O
Binding	O
was	O
detectable	O
even	O
at	O
the	O
lowest	O
NK	B-Cell
/	O
DC	B-Cell
ratio	O
tested	O
(	O
1	O
:	O
5	O
)	O
indicating	O
that	O
NK	B-Cell
-	O
DC	B-Cell
conjugates	O
are	O
formed	O
in	O
our	O
other	O
experiments	O
measuring	O
cytokine	O
production	O
and	O
cell	B-Cell
killing	O
.	O
</ALL>	O

<ALL>	O
Our	O
initial	O
experiments	O
using	O
resting	O
NK	B-Cell
cells	I-Cell
(	O
Fig	O
.	O
1	O
)	O
demonstrated	O
a	O
contact	O
-	O
dependent	O
NK	B-Cell
effect	O
driving	O
iDCs	B-Cell
to	O
mature	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
we	O
tested	O
what	O
effects	O
activated	O
NK	B-Cell
cells	I-Cell
mediated	O
on	O
DC	B-Cell
maturation	O
(	O
Fig	O
.	O
4	O
)	O
.	O
</ALL>	O

<ALL>	O
Similar	O
to	O
our	O
previous	O
results	O
with	O
activated	O
NK	B-Cell
cells	I-Cell
(	O
Figs	O
.	O
2	O
and	O
3	O
)	O
,	O
addition	O
of	O
NK	B-Cell
cells	I-Cell
to	O
the	O
culture	O
leads	O
to	O
opposing	O
effects	O
on	O
the	O
iDC	B-Cell
population	O
depending	O
on	O
the	O
NK	B-Cell
/	O
DC	B-Cell
ratio	O
.	O
</ALL>	O

<ALL>	O
Compared	O
with	O
the	O
untreated	O
DCs	B-Cell
(	O
Fig	O
.	O
4	O
A	O
-	O
C	O
)	O
,	O
low	O
NK	B-Cell
/	O
DC	B-Cell
ratios	O
(	O
1	O
:	O
5	O
or	O
1	O
:	O
1	O
)	O
consistently	O
augmented	O
expression	O
of	O
the	O
maturation	O
markers	O
:	O
CD86	O
(	O
Fig	O
.	O
4	O
D	O
-	O
I	O
)	O
,	O
CD83	O
,	O
and	O
HLA	O
-	O
DR	O
(	O
data	O
not	O
shown	O
)	O
.	O
</ALL>	O

<ALL>	O
At	O
a	O
5	O
:	O
1	O
ratio	O
(	O
NK	B-Cell
/	O
DC	B-Cell
)	O
most	O
of	O
the	O
DCs	B-Cell
are	O
nonviable	O
(	O
Fig	O
.	O
4	O
J	O
-	O
L	O
)	O
.	O
</ALL>	O

<ALL>	O
Addition	O
of	O
suboptimal	O
doses	O
of	O
LPS	O
(	O
Fig	O
.	O
4	O
C	O
,	O
F	O
,	O
I	O
,	O
and	O
L	O
)	O
augmented	O
the	O
NK	B-Cell
-	O
induced	O
maturation	O
at	O
NK	B-Cell
/	O
DC	B-Cell
ratios	O
of	O
1	O
:	O
5	O
and	O
1	O
:	O
1	O
,	O
but	O
had	O
no	O
effect	O
at	O
the	O
5	O
:	O
1	O
ratio	O
.	O
</ALL>	O

<ALL>	O
Again	O
,	O
DC	B-Cell
maturation	O
was	O
dependent	O
on	O
NK	B-Cell
cell	I-Cell
contact	O
and	O
endogenously	O
produced	O
TNF	O
-	O
alpha	O
,	O
because	O
it	O
did	O
not	O
occur	O
when	O
the	O
two	O
cell	B-Cell
types	O
were	O
separated	O
in	O
trans	O
-	O
wells	O
or	O
upon	O
the	O
addition	O
of	O
a	O
neutralizing	O
antibody	O
for	O
TNF	O
-	O
alpha	O
(	O
Fig	O
.	O
5	O
)	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
addition	O
of	O
blocking	O
reagents	O
for	O
CD80	O
,	O
CD86	O
,	O
CD154	O
,	O
CD95	O
,	O
CD11a	O
,	O
CD50	O
,	O
IL	O
-	O
12	O
,	O
IFN	O
-	O
gamma	O
,	O
IFN	O
-	O
alpha	O
,	O
or	O
IFN	O
-	O
beta	O
had	O
no	O
effect	O
on	O
the	O
NK	B-Cell
-	O
induced	O
maturation	O
(	O
data	O
not	O
shown	O
)	O
.	O
</ALL>	O

<ALL>	O
Figure	O
4	O
.	O
</ALL>	O

<ALL>	O
Activated	O
/	O
cultured	O
NK	B-Cell
cell	I-Cell
-	O
mediated	O
maturation	O
/	O
death	O
of	O
DCs	B-Cell
.	O
</ALL>	O

<ALL>	O
Cultured	O
iDCs	B-Cell
were	O
incubated	O
for	O
48	O
h	O
,	O
alone	O
(	O
A	O
-	O
C	O
)	O
,	O
or	O
with	O
NK	B-Cell
cells	I-Cell
at	O
the	O
following	O
ratios	O
(	O
NK	B-Cell
/	O
DC	B-Cell
)	O
,	O
1	O
:	O
5	O
(	O
D	O
-	O
F	O
)	O
,	O
1	O
:	O
1	O
(	O
G	O
-	O
I	O
)	O
,	O
and	O
5	O
:	O
1	O
(	O
J	O
-	O
L	O
)	O
.	O
</ALL>	O

<ALL>	O
Forward	O
versus	O
side	O
scatter	O
plots	O
(	O
A	O
,	O
D	O
,	O
G	O
,	O
and	O
J	O
)	O
show	O
the	O
gating	O
on	O
the	O
DC	B-Cell
subset	O
and	O
demonstrate	O
its	O
disappearance	O
at	O
the	O
5	O
:	O
1	O
(	O
NK	B-Cell
/	O
DC	B-Cell
)	O
ratio	O
(	O
J	O
)	O
.	O
</ALL>	O

<ALL>	O
Propidium	O
iodide	O
staining	O
of	O
the	O
NK	B-Cell
/	O
DC	B-Cell
(	O
5	O
:	O
1	O
)	O
cultures	O
confirmed	O
the	O
almost	O
complete	O
absence	O
of	O
viable	O
DCs	B-Cell
(	O
data	O
not	O
shown	O
)	O
.	O
</ALL>	O

<ALL>	O
Staining	O
for	O
CD86	O
expression	O
was	O
performed	O
as	O
described	O
in	O
Fig	O
.	O
</ALL>	O

<ALL>	O
1	O
and	O
the	O
histograms	O
are	O
shown	O
for	O
DCs	B-Cell
cultured	O
in	O
the	O
presence	O
(	O
C	O
,	O
F	O
,	O
I	O
,	O
and	O
L	O
)	O
or	O
absence	O
(	O
B	O
,	O
E	O
,	O
H	O
,	O
and	O
K	O
)	O
of	O
1	O
ng	O
/	O
ml	O
of	O
LPS	O
.	O
</ALL>	O

<ALL>	O
Results	O
are	O
representative	O
of	O
six	O
experiments	O
performed	O
.	O
</ALL>	O

<ALL>	O
Figure	O
5	O
.	O
</ALL>	O

<ALL>	O
Activated	O
/	O
cultured	O
NK	B-Cell
cell	I-Cell
-	O
induced	O
DC	B-Cell
maturation	O
is	O
dependent	O
on	O
cell	B-Cell
-	O
to	O
-	O
cell	B-Cell
contact	O
and	O
endogenous	O
TNF	O
-	O
alpha	O
production	O
.	O
</ALL>	O

<ALL>	O
Cultured	O
iDCs	B-Cell
were	O
incubated	O
alone	O
(	O
A	O
,	O
D	O
,	O
and	O
G	O
)	O
;	O
with	O
activated	O
NK	B-Cell
cells	I-Cell
at	O
an	O
NK	B-Cell
/	O
DC	B-Cell
ratio	O
of	O
1	O
:	O
5	O
(	O
B	O
,	O
E	O
,	O
and	O
H	O
)	O
;	O
with	O
activated	O
NK	B-Cell
cells	I-Cell
(	O
NK	B-Cell
/	O
DC	B-Cell
;	O
1	O
:	O
5	O
)	O
separated	O
in	O
trans	O
-	O
wells	O
(	O
C	O
and	O
F	O
)	O
;	O
or	O
with	O
activated	O
NK	B-Cell
cells	I-Cell
and	O
10	O
mug	O
/	O
ml	O
of	O
a	O
neutralizing	O
antibody	O
for	O
TNF	O
-	O
alpha	O
(	O
I	O
)	O
.	O
</ALL>	O

<ALL>	O
LPS	O
concentrations	O
used	O
were	O
:	O
0	O
ng	O
/	O
ml	O
(	O
A	O
-	O
C	O
)	O
;	O
10	O
ng	O
/	O
ml	O
(	O
D	O
-	O
F	O
)	O
and	O
50	O
ng	O
/	O
ml	O
(	O
G	O
-	O
I	O
)	O
.	O
</ALL>	O

<ALL>	O
CD86	O
staining	O
of	O
the	O
DC	B-Cell
subset	O
was	O
performed	O
as	O
in	O
Figs	O
.	O
</ALL>	O

<ALL>	O
1	O
and	O
4	O
.	O
</ALL>	O

<ALL>	O
Results	O
are	O
representative	O
of	O
four	O
experiments	O
performed	O
.	O
</ALL>	O

<ALL>	O
Acknowledgements	O
</ALL>	O

<ALL>	O
We	O
would	O
like	O
to	O
thank	O
our	O
colleague	O
Dr	O
.	O
Nikolaos	O
Papathanasiou	O
for	O
his	O
assistance	O
in	O
performing	O
the	O
statistical	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Anion	O
to	O
cation	O
selectivity	O
ratio	O
determined	O
from	O
the	O
relative	O
rates	O
of	O
reaction	O
of	O
MTSES	O
-	O
and	O
MTSET	O
+	O
with	O
the	O
water	O
exposed	O
residues	O
in	O
the	O
M6	O
segment	O
.	O
</ALL>	O

<ALL>	O
The	O
anion	O
selectivity	O
ratio	O
is	O
calculated	O
as	O
described	O
in	O
Table	O
II	O
,	O
column	O
5	O
.	O
</ALL>	O

<ALL>	O
Note	O
the	O
marked	O
increase	O
in	O
anion	O
selectivity	O
at	O
the	O
residues	O
T351C	O
and	O
Q353C	O
.	O
</ALL>	O

<ALL>	O
A	O
ratio	O
of	O
1	O
indicates	O
no	O
selectivity	O
between	O
anions	O
and	O
cations	O
.	O
</ALL>	O

<ALL>	O
The	O
larger	O
the	O
ratio	O
the	O
greater	O
the	O
anion	O
selectivity	O
.	O
</ALL>	O

<ALL>	O
Authors	O
'	O
contributions	O
</ALL>	O

<ALL>	O
All	O
authors	O
contributed	O
to	O
the	O
development	O
of	O
the	O
methodology	O
.	O
</ALL>	O

<ALL>	O
CY	O
and	O
NZ	O
led	O
method	O
conceptualization	O
and	O
prepared	O
the	O
original	O
draft	O
,	O
which	O
was	O
revised	O
by	O
JR	O
.	O
</ALL>	O

<ALL>	O
CY	O
and	O
VD	O
performed	O
most	O
implementations	O
.	O
</ALL>	O

<ALL>	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
</ALL>	O

<ALL>	O
Background	O
</ALL>	O

<ALL>	O
Potato	O
late	O
blight	O
,	O
a	O
disease	O
caused	O
by	O
the	O
oomycete	O
pathogen	O
Phytophthora	O
infestans	O
,	O
is	O
one	O
of	O
the	O
world	O
'	O
s	O
most	O
devastating	O
crop	O
diseases	O
.	O
</ALL>	O

<ALL>	O
World	O
-	O
wide	O
losses	O
due	O
to	O
late	O
blight	O
exceed	O
several	O
billion	O
dollars	O
annually	O
[	O
1	O
]	O
.	O
</ALL>	O

<ALL>	O
Most	O
of	O
the	O
potato	O
cultivars	O
currently	O
grown	O
in	O
the	O
United	O
States	O
are	O
highly	O
susceptible	O
to	O
late	O
blight	O
and	O
control	O
of	O
this	O
disease	O
relies	O
almost	O
exclusively	O
on	O
fungicide	O
applications	O
.	O
</ALL>	O

<ALL>	O
The	O
most	O
effective	O
and	O
environmentally	O
sound	O
way	O
for	O
controlling	O
late	O
blight	O
is	O
to	O
incorporate	O
natural	O
resistance	O
into	O
potato	O
cultivars	O
.	O
</ALL>	O

<ALL>	O
The	O
pedigrees	O
of	O
many	O
potato	O
cultivars	O
currently	O
used	O
in	O
different	O
countries	O
include	O
late	O
blight	O
resistant	O
germplasm	O
derived	O
from	O
Solanum	O
demissum	O
,	O
Solanum	O
andigena	O
,	O
and	O
other	O
wild	O
species	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
most	O
of	O
the	O
resistance	O
derived	O
from	O
these	O
wild	O
species	O
is	O
controlled	O
by	O
single	O
dominant	O
resistance	O
genes	O
(	O
R	O
genes	O
)	O
.	O
</ALL>	O

<ALL>	O
These	O
R	O
genes	O
are	O
only	O
effective	O
in	O
preventing	O
the	O
development	O
of	O
late	O
blight	O
if	O
the	O
invading	O
P	O
.	O
infestans	O
race	O
contains	O
the	O
corresponding	O
avirulence	O
genes	O
.	O
</ALL>	O

<ALL>	O
This	O
R	O
gene	O
-	O
mediated	O
resistance	O
is	O
often	O
short	O
-	O
lived	O
and	O
is	O
rapidly	O
overcome	O
by	O
new	O
races	O
of	O
the	O
late	O
blight	O
pathogen	O
.	O
</ALL>	O

<ALL>	O
Solanum	O
bulbocastanum	O
(	O
2n	O
=	O
2x	O
=	O
24	O
)	O
is	O
a	O
diploid	O
species	O
that	O
has	O
adapted	O
in	O
the	O
same	O
environment	O
as	O
the	O
late	O
blight	O
pathogen	O
.	O
</ALL>	O

<ALL>	O
This	O
wild	O
species	O
was	O
characterized	O
as	O
possessing	O
durable	O
resistance	O
against	O
P	O
.	O
infestans	O
,	O
even	O
under	O
high	O
disease	O
pressure	O
[	O
2	O
,	O
3	O
]	O
.	O
</ALL>	O

<ALL>	O
Two	O
resistance	O
genes	O
,	O
RB	O
(	O
Rpi	O
-	O
blb1	O
)	O
and	O
Rpi	O
-	O
blb2	O
,	O
have	O
been	O
cloned	O
from	O
S	O
.	O
bulbocastanum	O
[	O
4	O
-	O
6	O
]	O
.	O
</ALL>	O

<ALL>	O
Both	O
genes	O
confer	O
broad	O
-	O
spectrum	O
resistance	O
against	O
a	O
wide	O
range	O
of	O
known	O
P	O
.	O
infestans	O
races	O
.	O
</ALL>	O

<ALL>	O
Transgenic	O
potato	O
lines	O
containing	O
a	O
single	O
RB	O
gene	O
showed	O
a	O
high	O
-	O
level	O
resistance	O
in	O
the	O
Toluca	O
Valley	O
,	O
Mexico	O
,	O
where	O
the	O
potato	O
fields	O
are	O
naturally	O
intensively	O
infested	O
with	O
the	O
most	O
diversified	O
P	O
.	O
infestans	O
populations	O
[	O
7	O
]	O
.	O
</ALL>	O

<ALL>	O
Most	O
interestingly	O
,	O
transgenic	O
RB	O
plants	O
did	O
not	O
show	O
total	O
immunity	O
to	O
late	O
blight	O
,	O
but	O
instead	O
showed	O
a	O
marked	O
delay	O
in	O
both	O
onset	O
of	O
symptoms	O
and	O
development	O
of	O
lesions	B-Pathological_formation
.	O
</ALL>	O

<ALL>	O
Such	O
rate	O
-	O
limiting	O
resistance	O
may	O
put	O
less	O
selection	O
pressure	O
on	O
the	O
P	O
.	O
infestans	O
populations	O
and	O
protect	O
the	O
durability	O
of	O
this	O
resistance	O
gene	O
.	O
</ALL>	O

<ALL>	O
The	O
RB	O
gene	O
therefore	O
provides	O
an	O
excellent	O
model	O
to	O
study	O
the	O
mechanism	O
of	O
broad	O
-	O
spectrum	O
and	O
rate	O
-	O
limiting	O
disease	O
resistances	O
.	O
</ALL>	O

<ALL>	O
An	O
understanding	O
of	O
the	O
underlying	O
mechanism	O
of	O
this	O
type	O
of	O
resistance	O
is	O
important	O
for	O
developing	O
strategies	O
to	O
breed	O
durable	O
and	O
sustainable	O
disease	O
resistance	O
.	O
</ALL>	O

<ALL>	O
Several	O
genes	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
R	O
gene	O
function	O
.	O
</ALL>	O

<ALL>	O
Of	O
these	O
genes	O
,	O
Rar1	O
and	O
Sgt1	O
are	O
among	O
the	O
most	O
extensively	O
studied	O
genes	O
.	O
</ALL>	O

<ALL>	O
The	O
Rar1	O
(	O
required	O
for	O
Mla12	O
resistance	O
)	O
gene	O
was	O
first	O
identified	O
for	O
its	O
essential	O
role	O
in	O
the	O
function	O
of	O
a	O
subset	O
of	O
Mla	O
genes	O
that	O
confer	O
resistance	O
to	O
barley	O
powdery	O
mildew	O
[	O
8	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
RAR1	O
protein	O
contains	O
two	O
highly	O
similar	O
but	O
distinct	O
cysteine	O
-	O
and	O
histidine	O
-	O
rich	O
(	O
CHORD	O
)	O
Zn2	O
+	O
-	O
binding	O
domains	O
and	O
was	O
proposed	O
to	O
play	O
a	O
role	O
in	O
stabilizing	O
R	O
proteins	O
in	O
a	O
confirmation	O
that	O
is	O
implicated	O
in	O
receiving	O
pathogen	O
signals	O
[	O
9	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
Sgt1	O
gene	O
(	O
suppressor	O
of	O
the	O
G2	O
allele	O
of	O
skp1	O
)	O
is	O
an	O
essential	O
gene	O
with	O
multiple	O
functions	O
in	O
yeast	O
.	O
</ALL>	O

<ALL>	O
SGT1	O
protein	O
was	O
initially	O
identified	O
as	O
a	O
RAR1	O
-	O
interacting	O
partner	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
[	O
10	O
]	O
.	O
</ALL>	O

<ALL>	O
SGT1	O
may	O
play	O
a	O
role	O
in	O
R	O
protein	O
accumulation	O
[	O
11	O
]	O
.	O
</ALL>	O

<ALL>	O
Rar1	O
and	O
Sgt1	O
genes	O
are	O
required	O
in	O
various	O
R	O
-	O
gene	O
mediated	O
resistance	O
against	O
viral	O
,	O
bacterial	O
,	O
oomycete	O
or	O
fungal	O
pathogens	O
[	O
12	O
]	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
none	O
of	O
the	O
previously	O
studied	O
R	O
genes	O
showed	O
a	O
race	O
-	O
non	O
-	O
specific	O
and	O
rate	O
-	O
limiting	O
resistance	O
phenotype	O
as	O
the	O
RB	O
gene	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
role	O
the	O
Rar1	O
and	O
Sgt1	O
genes	O
are	O
not	O
universal	O
and	O
these	O
genes	O
are	O
not	O
essential	O
for	O
resistance	O
involving	O
some	O
R	O
genes	O
[	O
12	O
,	O
13	O
]	O
.	O
</ALL>	O

<ALL>	O
Besides	O
the	O
two	O
broad	O
-	O
spectrum	O
resistance	O
genes	O
RB	O
and	O
Rpi	O
-	O
blb2	O
,	O
several	O
race	O
-	O
specific	O
late	O
blight	O
resistance	O
genes	O
have	O
also	O
been	O
cloned	O
[	O
14	O
-	O
16	O
]	O
.	O
</ALL>	O

<ALL>	O
Numerous	O
late	O
blight	O
resistance	O
genes	O
have	O
recently	O
been	O
mapped	O
in	O
various	O
potato	O
species	O
or	O
populations	O
[	O
17	O
-	O
25	O
]	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
there	O
is	O
almost	O
no	O
information	O
available	O
about	O
the	O
resistance	O
pathways	O
mediated	O
by	O
any	O
of	O
these	O
genes	O
.	O
</ALL>	O

<ALL>	O
As	O
an	O
initial	O
effort	O
to	O
understand	O
the	O
RB	O
-	O
mediated	O
late	O
blight	O
resistance	O
pathway	O
,	O
we	O
silenced	O
the	O
Rar1	O
and	O
Sgt1	O
genes	O
using	O
an	O
RNAi	O
-	O
based	O
approach	O
in	O
a	O
potato	O
line	O
containing	O
the	O
RB	O
gene	O
.	O
</ALL>	O

<ALL>	O
We	O
demonstrated	O
that	O
SGT1	O
,	O
but	O
not	O
RAR1	O
,	O
is	O
essential	O
for	O
the	O
RB	O
-	O
mediated	O
broad	O
-	O
spectrum	O
resistance	O
to	O
potato	O
late	O
blight	O
.	O
</ALL>	O

<ALL>	O
Ovariectomy	O
</ALL>	O

<ALL>	O
Based	O
on	O
the	O
uterine	B-Organ
weight	O
,	O
we	O
determined	O
seven	O
unsuccessful	O
OVXs	O
.	O
</ALL>	O

<ALL>	O
The	O
rats	O
concerned	O
were	O
removed	O
from	O
further	O
analyses	O
,	O
which	O
left	O
nine	O
rats	O
in	O
the	O
control	O
group	O
,	O
five	O
in	O
the	O
OVX	O
group	O
,	O
seven	O
in	O
the	O
OVX	O
and	O
late	O
ZOL	O
group	O
,	O
and	O
eight	O
in	O
the	O
OVX	O
and	O
early	O
ZOL	O
group	O
.	O
</ALL>	O

<ALL>	O
For	O
each	O
animal	O
,	O
we	O
determined	O
the	O
percentage	O
change	O
in	O
structural	O
parameters	O
compared	O
to	O
the	O
values	O
at	O
week	O
0	O
.	O
</ALL>	O

<ALL>	O
Figure	O
1	O
shows	O
the	O
average	O
percentage	O
change	O
and	O
upper	O
standard	O
deviation	O
for	O
all	O
groups	O
for	O
BV	O
/	O
TV	O
,	O
Conn	O
.	O
D	O
,	O
SMI	O
,	O
Tb	O
.	O
N	O
,	O
Tb	O
.	O
Th	O
,	O
and	O
Tb	O
.	O
Sp	O
.	O
</ALL>	O

<ALL>	O
The	O
OVX	O
group	O
without	O
treatment	O
showed	O
large	O
changes	O
in	O
structural	O
parameters	O
,	O
indicating	O
the	O
development	O
of	O
OVX	O
-	O
induced	O
bone	B-Tissue
loss	O
(	O
Figs	O
.	O
1	O
and	O
2	O
)	O
.	O
</ALL>	O

<ALL>	O
Paired	O
Student	O
'	O
s	O
t	O
-	O
test	O
indicated	O
significant	O
changes	O
within	O
2	O
weeks	O
after	O
OVX	O
for	O
all	O
structural	O
parameters	O
.	O
</ALL>	O

<ALL>	O
BV	O
/	O
TV	O
,	O
Conn	O
.	O
D	O
,	O
and	O
Tb	O
.	O
N	O
decreased	O
during	O
the	O
experiment	O
and	O
SMI	O
and	O
Tb	O
.	O
Sp	O
increased	O
.	O
</ALL>	O

<ALL>	O
Both	O
Tb	O
.	O
Th	O
and	O
Tb	O
.	O
N	O
decreased	O
within	O
2	O
weeks	O
,	O
indicating	O
that	O
both	O
thinning	O
and	O
complete	O
resorption	O
of	O
trabeculae	O
started	O
directly	O
after	O
OVX	O
.	O
</ALL>	O

<ALL>	O
The	O
initial	O
rapid	O
loss	O
of	O
bone	B-Tissue
and	O
connectivity	O
was	O
largely	O
accompanied	O
by	O
trabecular	B-Organ
thinning	O
,	O
while	O
secondary	O
,	O
slower	O
loss	O
of	O
bone	B-Tissue
was	O
concomitant	O
with	O
a	O
decrease	O
in	O
Tb	O
.	O
N	O
.	O
</ALL>	O

<ALL>	O
While	O
BV	O
/	O
TV	O
,	O
Conn	O
.	O
D	O
,	O
SMI	O
,	O
Tb	O
.	O
N	O
,	O
and	O
Tb	O
.	O
Sp	O
showed	O
continuous	O
changes	O
in	O
the	O
same	O
direction	O
throughout	O
the	O
experiment	O
,	O
Tb	O
.	O
Th	O
initially	O
decreased	O
significantly	O
until	O
4	O
weeks	O
after	O
OVX	O
and	O
then	O
increased	O
again	O
until	O
after	O
16	O
weeks	O
Tb	O
.	O
Th	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
control	O
group	O
.	O
</ALL>	O

<ALL>	O
Fig	O
.	O
</ALL>	O

<ALL>	O
1	O
</ALL>	O

<ALL>	O
Average	O
percentage	O
change	O
in	O
structural	O
parameters	O
in	O
the	O
metaphyseal	O
proximal	O
tibia	B-Organ
and	O
upper	O
standard	O
deviation	O
for	O
all	O
groups	O
at	O
all	O
time	O
points	O
.	O
</ALL>	O

<ALL>	O
Brackets	O
indicate	O
P	O
<	O
0	O
.	O
05	O
at	O
week	O
16	O
</ALL>	O

<ALL>	O
Fig	O
.	O
</ALL>	O

<ALL>	O
2	O
</ALL>	O

<ALL>	O
Same	O
slice	O
of	O
an	O
unprocessed	O
CT	O
scan	O
of	O
the	O
same	O
rat	O
in	O
the	O
OVX	O
group	O
taken	O
at	O
weeks	O
0	O
(	O
a	O
)	O
,	O
2	O
(	O
b	O
)	O
,	O
4	O
(	O
c	O
)	O
,	O
8	O
(	O
d	O
)	O
,	O
12	O
(	O
e	O
)	O
,	O
and	O
16	O
(	O
f	O
)	O
.	O
</ALL>	O

<ALL>	O
Images	O
show	O
typical	O
trabecular	B-Tissue
bone	I-Tissue
loss	O
due	O
to	O
OVX	O
in	O
the	O
metaphysis	O
.	O
</ALL>	O

<ALL>	O
Green	O
line	O
shows	O
the	O
analyzed	O
metaphyseal	O
bone	B-Tissue
</ALL>	O

<ALL>	O
The	O
absolute	O
average	O
values	O
and	O
standard	O
deviations	O
for	O
all	O
structural	O
parameters	O
of	O
all	O
measurements	O
are	O
shown	O
in	O
Table	O
1	O
.	O
</ALL>	O

<ALL>	O
At	O
the	O
starting	O
point	O
,	O
some	O
differences	O
in	O
the	O
values	O
between	O
the	O
groups	O
were	O
present	O
.	O
</ALL>	O

<ALL>	O
This	O
was	O
due	O
to	O
the	O
fact	O
that	O
some	O
animals	O
,	O
which	O
mostly	O
had	O
a	O
relatively	O
low	O
BV	O
/	O
TV	O
,	O
were	O
removed	O
from	O
the	O
study	O
because	O
they	O
did	O
not	O
respond	O
to	O
the	O
OVX	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
since	O
we	O
compared	O
the	O
relative	O
changes	O
in	O
each	O
animal	O
,	O
the	O
results	O
were	O
most	O
likely	O
not	O
affected	O
by	O
the	O
difference	O
in	O
absolute	O
values	O
.	O
</ALL>	O

<ALL>	O
Table	O
1	O
</ALL>	O

<ALL>	O
Mean	O
values	O
and	O
standard	O
deviation	O
of	O
all	O
structural	O
parameters	O
of	O
all	O
groups	O
at	O
the	O
start	O
of	O
the	O
experiment	O
</ALL>	O

<ALL>	O
Group	O
BV	O
/	O
TV	O
(	O
1	O
)	O
Conn	O
.	O
D	O
(	O
1	O
/	O
mm	O
)	O
SMI	O
(	O
1	O
)	O
Tb	O
.	O
N	O
(	O
1	O
/	O
mm	O
)	O
Tb	O
.	O
Th	O
(	O
mum	O
)	O
Tb	O
.	O
Sp	O
(	O
mum	O
)	O
</ALL>	O

<ALL>	O
Control	O
0	O
.	O
17	O
(	O
0	O
.	O
056	O
)	O
41	O
(	O
47	O
)	O
1	O
.	O
52	O
(	O
0	O
.	O
53	O
)	O
1	O
.	O
89	O
(	O
1	O
.	O
38	O
)	O
105	O
(	O
49	O
)	O
613	O
(	O
368	O
)	O
</ALL>	O

<ALL>	O
OVX	O
0	O
.	O
26	O
(	O
0	O
.	O
055	O
)	O
141	O
(	O
76	O
)	O
1	O
.	O
22	O
(	O
0	O
.	O
39	O
)	O
3	O
.	O
77	O
(	O
1	O
.	O
66	O
)	O
84	O
(	O
10	O
)	O
335	O
(	O
174	O
)	O
</ALL>	O

<ALL>	O
OVX	O
+	O
late	O
ZOL	O
0	O
.	O
23	O
(	O
0	O
.	O
062	O
)	O
86	O
(	O
66	O
)	O
1	O
.	O
23	O
(	O
0	O
.	O
34	O
)	O
2	O
.	O
77	O
(	O
1	O
.	O
55	O
)	O
89	O
(	O
13	O
)	O
482	O
(	O
227	O
)	O
</ALL>	O

<ALL>	O
OVX	O
+	O
early	O
ZOL	O
0	O
.	O
17	O
(	O
0	O
.	O
056	O
)	O
38	O
(	O
21	O
)	O
1	O
.	O
70	O
(	O
0	O
.	O
39	O
)	O
1	O
.	O
86	O
(	O
0	O
.	O
80	O
)	O
95	O
(	O
7	O
)	O
647	O
(	O
207	O
)	O
</ALL>	O

<ALL>	O
Click	O
here	O
for	O
file	O
</ALL>	O

<ALL>	O
Aim	O
</ALL>	O

<ALL>	O
This	O
study	O
reports	O
the	O
results	O
of	O
a	O
large	O
prospective	O
single	O
-	O
blinded	O
clinical	O
trial	O
of	O
3	O
SSRI	O
(	O
paroxetine	O
,	O
fluoxetine	O
and	O
escitalopram	O
)	O
in	O
PE	O
using	O
a	O
validated	O
questionnaire	O
.	O
</ALL>	O

<ALL>	O
Summary	O
of	O
studies	O
reporting	O
comorbidities	O
with	O
diabetes	O
.	O
</ALL>	O

<ALL>	O
Click	O
here	O
for	O
additional	O
data	O
file	O
.	O
</ALL>	O

<ALL>	O
Images	O
</ALL>	O

<ALL>	O
Figure	O
1	O
</ALL>	O

<ALL>	O
Figure	O
5	O
</ALL>	O

<ALL>	O
Figure	O
6	O
</ALL>	O

<ALL>	O
Characteristics	O
of	O
cases	O
with	O
childhood	O
leukaemia	O
(	O
n	O
=	O
162	O
)	O
and	O
matched	O
controls	O
(	O
n	O
=	O
2125	O
)	O
,	O
all	O
registered	O
within	O
3	O
months	O
of	O
birth	O
</ALL>	O

<ALL>	O
Appendix	O
Table	O
</ALL>	O

<ALL>	O
Detection	O
of	O
Nipah	O
virus	O
antibody	O
among	O
bat	O
serum	B-Organism_substance
samples	I-Organism_substance
collected	O
from	O
10	O
provinces	O
in	O
China	O
,	O
2004	O
-	O
2007	O
*	O
</ALL>	O

<ALL>	O
Whole	O
-	O
Body	O
gamma	O
-	O
Irradiation	O
</ALL>	O

<ALL>	O
To	O
evaluate	O
differential	O
sensitivity	O
to	O
irradiation	O
,	O
mice	O
were	O
exposed	O
to	O
gamma	O
-	O
irradiation	O
(	O
4	O
-	O
10	O
Gy	O
,	O
single	O
dose	O
)	O
and	O
closely	O
monitored	O
throughout	O
the	O
experimentation	O
period	O
.	O
</ALL>	O

<ALL>	O
Animals	O
were	O
killed	O
at	O
the	O
first	O
appearance	O
of	O
signs	O
of	O
poor	O
health	O
.	O
</ALL>	O

<ALL>	O
Recipients	O
of	O
bone	B-Multi-tissue_structure
marrow	I-Multi-tissue_structure
transplants	O
were	O
pre	O
-	O
irradiated	O
with	O
a	O
total	O
dose	O
of	O
10	O
.	O
2	O
Gy	O
(	O
two	O
doses	O
of	O
5	O
.	O
1	O
Gy	O
,	O
3	O
h	O
apart	O
)	O
.	O
</ALL>	O

<ALL>	O
For	O
in	O
vivo	O
DNA	O
damage	O
experiments	O
,	O
mice	O
were	O
irradiated	O
with	O
a	O
single	O
dose	O
of	O
5Gy	O
and	O
killed	O
after	O
1	O
,	O
3	O
or	O
6	O
hours	O
.	O
</ALL>	O

<ALL>	O
All	O
irradiations	O
were	O
carried	O
out	O
in	O
a	O
Cesium	O
Mark1	O
irradiator	O
(	O
Shepherd	O
Associates	O
)	O
.	O
</ALL>	O

<ALL>	O
Background	O
</ALL>	O

<ALL>	O
Sealant	O
application	O
criteria	O
for	O
molar	B-Organ
fissures	O
</ALL>	O

<ALL>	O
Power	O
(	O
Y	O
-	O
axis	O
)	O
as	O
a	O
function	O
of	O
main	O
effects	O
(	O
x	O
-	O
axis	O
)	O
.	O
</ALL>	O

<ALL>	O
For	O
a	O
pure	O
main	O
-	O
effects	O
model	O
(	O
x	O
-	O
axis	O
=	O
a1	O
>	O
0	O
;	O
interaction	O
effects	O
a2	O
=	O
a3	O
=	O
0	O
are	O
all	O
zero	O
)	O
,	O
Figure	O
1	O
shows	O
that	O
pattern	O
(	O
solid	O
red	O
line	O
)	O
and	O
single	O
-	O
locus	O
(	O
broken	O
blue	O
line	O
)	O
approaches	O
have	O
virtually	O
the	O
same	O
power	O
.	O
</ALL>	O

<ALL>	O
Peptide	O
-	O
BSA	O
conjugates	O
as	O
diagnostic	O
antigens	O
</ALL>	O

<ALL>	O
To	O
analyse	O
the	O
potential	O
of	O
the	O
peptides	O
to	O
behave	O
as	O
antigen	O
mimics	O
,	O
their	O
ability	O
to	O
react	O
with	O
IgM	O
antibodies	O
from	O
individuals	O
infected	O
with	O
EBV	O
was	O
assessed	O
.	O
</ALL>	O

<ALL>	O
In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
sensitivity	O
of	O
detection	O
was	O
greatly	O
improved	O
when	O
the	O
peptides	O
were	O
coupled	O
to	O
a	O
carrier	O
molecule	O
such	O
as	O
BSA	O
prior	O
to	O
immobilisation	O
onto	O
a	O
solid	O
surface	O
(	O
Casey	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
strategy	O
was	O
adopted	O
to	O
test	O
peptides	O
Eb1	O
-	O
4	O
and	O
H1	O
.	O
</ALL>	O

<ALL>	O
A	O
set	O
of	O
40	O
clinical	O
samples	O
that	O
were	O
classified	O
as	O
EBV	O
seropositive	O
(	O
n	O
=	O
16	O
)	O
,	O
seronegative	O
(	O
n	O
=	O
16	O
)	O
or	O
potentially	O
cross	O
-	O
reactive	O
sera	B-Organism_substance
(	O
n	O
=	O
8	O
)	O
were	O
assessed	O
for	O
reactivity	O
with	O
Eb1	O
-	O
4	O
and	O
H1	O
peptides	O
individually	O
.	O
</ALL>	O

<ALL>	O
The	O
cut	O
-	O
off	O
level	O
was	O
defined	O
as	O
the	O
mean	O
optical	O
density	O
of	O
the	O
seronegative	O
samples	O
plus	O
3	O
standard	O
deviations	O
shown	O
as	O
a	O
line	O
on	O
the	O
graphs	O
in	O
Fig	O
.	O
</ALL>	O

<ALL>	O
5	O
.	O
</ALL>	O

<ALL>	O
Readings	O
above	O
this	O
level	O
were	O
defined	O
as	O
positive	O
and	O
below	O
this	O
level	O
negative	O
.	O
</ALL>	O

<ALL>	O
The	O
same	O
set	O
of	O
samples	O
were	O
analysed	O
on	O
BSA	O
alone	O
and	O
these	O
values	O
were	O
subtracted	O
from	O
the	O
peptide	O
-	O
BSA	O
conjugate	O
readings	O
and	O
the	O
corrected	O
absorbance	O
readings	O
were	O
plotted	O
individually	O
for	O
our	O
new	O
peptides	O
Eb1	O
-	O
4	O
and	O
H1	O
in	O
Fig	O
.	O
</ALL>	O

<ALL>	O
5	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
a	O
clear	O
difference	O
in	O
the	O
detection	O
of	O
seropositive	O
antibodies	O
by	O
all	O
the	O
peptides	O
(	O
Fig	O
.	O
5A	O
-	O
E	O
)	O
compared	O
with	O
the	O
analysis	O
of	O
BSA	O
alone	O
(	O
Fig	O
.	O
5F	O
)	O
,	O
with	O
the	O
majority	O
of	O
absorbance	O
readings	O
above	O
the	O
cut	O
-	O
off	O
level	O
.	O
</ALL>	O

<ALL>	O
We	O
compared	O
the	O
ability	O
of	O
our	O
panel	O
of	O
peptide	O
mimotopes	O
to	O
be	O
recognised	O
by	O
antibodies	O
in	O
the	O
same	O
set	O
of	O
seropositive	O
samples	O
in	O
Fig	O
.	O
</ALL>	O

<ALL>	O
6A	O
and	O
the	O
sensitivity	O
of	O
detection	O
is	O
shown	O
in	O
Fig	O
.	O
</ALL>	O

<ALL>	O
6B	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
included	O
F1	O
and	O
Gp125	O
mimotopes	O
specific	O
for	O
two	O
mAbs	O
in	O
our	O
previous	O
study	O
(	O
Casey	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
</ALL>	O

<ALL>	O
Of	O
the	O
peptides	O
identified	O
from	O
polyclonal	O
sera	B-Organism_substance
Eb1	O
,	O
Gp125	O
and	O
F1	O
had	O
the	O
highest	O
sensitivity	O
(	O
94	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Slightly	O
lower	O
sensitivity	O
was	O
observed	O
for	O
Eb2	O
,	O
3	O
and	O
4	O
(	O
88	O
%	O
)	O
and	O
H1	O
peptide	O
had	O
the	O
lowest	O
sensitivity	O
(	O
81	O
%	O
)	O
as	O
summarised	O
in	O
Fig	O
.	O
</ALL>	O

<ALL>	O
6B	O
.	O
</ALL>	O

<ALL>	O
The	O
sensitivity	O
of	O
F1	O
and	O
Gp125	O
was	O
similar	O
to	O
that	O
produced	O
by	O
the	O
mimotopes	O
selected	O
in	O
our	O
previous	O
study	O
,	O
95	O
%	O
for	O
F1	O
and	O
92	O
%	O
for	O
Gp125	O
.	O
</ALL>	O

<ALL>	O
Fig	O
.	O
</ALL>	O

<ALL>	O
5	O
</ALL>	O

<ALL>	O
Evaluation	O
of	O
peptides	O
Eb1	O
-	O
4	O
and	O
H1	O
coupled	O
to	O
BSA	O
as	O
EBV	O
diagnostic	O
reagents	O
.	O
</ALL>	O

<ALL>	O
Human	O
serum	B-Organism_substance
(	O
n	O
=	O
40	O
)	O
previously	O
analysed	O
using	O
a	O
diagnostic	O
test	O
for	O
VCA	O
IgM	O
was	O
allowed	O
to	O
react	O
with	O
the	O
peptides	O
and	O
the	O
bound	O
IgM	O
antibodies	O
were	O
detected	O
using	O
anti	O
-	O
human	O
IgM	O
HRP	O
.	O
</ALL>	O

<ALL>	O
The	O
absorbance	O
readings	O
for	O
1	O
(	O
positive	O
)	O
,	O
2	O
(	O
negative	O
)	O
and	O
putative	O
cross	O
-	O
reactive	O
sera	B-Organism_substance
for	O
3	O
(	O
Parvo	O
)	O
,	O
4	O
(	O
HSV	O
)	O
,	O
5	O
(	O
CMV	O
)	O
and	O
6	O
(	O
RF	O
)	O
are	O
plotted	O
for	O
(	O
A	O
)	O
Eb1	O
,	O
(	O
B	O
)	O
Eb2	O
,	O
(	O
C	O
)	O
Eb3	O
,	O
(	O
D	O
)	O
Eb4	O
,	O
(	O
E	O
)	O
H1	O
and	O
(	O
F	O
)	O
BSA	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
cut	O
-	O
off	O
value	O
is	O
defined	O
as	O
the	O
mean	O
of	O
the	O
negative	O
population	O
+	O
3SD	O
indicated	O
by	O
a	O
solid	O
horizontal	O
line	O
;	O
since	O
there	O
were	O
no	O
false	O
positives	O
,	O
the	O
specificity	O
for	O
each	O
mimotope	O
was	O
100	O
%	O
.	O
</ALL>	O

<ALL>	O
Fig	O
.	O
</ALL>	O

<ALL>	O
6	O
</ALL>	O

<ALL>	O
Comparison	O
of	O
the	O
reactivities	O
of	O
our	O
panel	O
of	O
mimotopes	O
Eb1	O
-	O
4	O
,	O
H1	O
,	O
F1	O
and	O
Gp125	O
conjugated	O
to	O
BSA	O
with	O
EBV	O
IgM	O
-	O
positive	O
sera	B-Organism_substance
(	O
n	O
=	O
16	O
)	O
absorbance	O
values	O
are	O
plotted	O
and	O
the	O
cut	O
-	O
off	O
levels	O
are	O
depicted	O
by	O
a	O
horizontal	O
line	O
in	O
(	O
A	O
)	O
.	O
</ALL>	O

<ALL>	O
(	O
B	O
)	O
Summary	O
of	O
the	O
false	O
-	O
negative	O
results	O
from	O
the	O
5	O
/	O
16	O
serum	B-Organism_substance
samples	I-Organism_substance
seropositive	O
for	O
IgM	O
EBV	O
and	O
the	O
overall	O
sensitivity	O
for	O
each	O
mimotope	O
for	O
diagnosis	O
of	O
EBV	O
IgM	O
antibodies	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
considered	O
which	O
seropositive	O
EBV	O
samples	B-Organism_substance
contained	O
antibodies	O
that	O
did	O
not	O
recognise	O
the	O
panel	O
of	O
peptides	O
,	O
i	O
.	O
e	O
.	O
false	O
-	O
negative	O
readings	O
,	O
listed	O
in	O
Fig	O
.	O
</ALL>	O

<ALL>	O
6B	O
.	O
</ALL>	O

<ALL>	O
The	O
antibodies	O
in	O
serum	B-Organism_substance
1	O
(	O
s1	O
)	O
were	O
unreactive	O
with	O
all	O
of	O
the	O
peptides	O
identified	O
in	O
this	O
study	O
,	O
s2	O
was	O
not	O
reactive	O
with	O
Eb3	O
,	O
Eb4	O
and	O
H1	O
and	O
s3	O
was	O
unreactive	O
with	O
H1	O
.	O
</ALL>	O

<ALL>	O
Gp125	O
and	O
F1	O
that	O
were	O
selected	O
in	O
our	O
previous	O
study	O
were	O
recognised	O
by	O
s1	O
,	O
2	O
and	O
3	O
;	O
however	O
,	O
two	O
different	O
serum	B-Organism_substance
samples	I-Organism_substance
(	O
s4	O
and	O
5	O
)	O
did	O
not	O
recognise	O
F1	O
or	O
Gp125	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
This	O
demonstrates	O
that	O
individual	O
peptides	O
are	O
not	O
recognised	O
by	O
all	O
EBV	O
antibodies	O
and	O
confirms	O
that	O
different	O
peptides	O
are	O
required	O
to	O
represent	O
different	O
epitopes	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
a	O
combination	O
of	O
Eb1	O
peptide	O
F1	O
and	O
Gp125	O
peptides	O
could	O
be	O
recognised	O
by	O
antibodies	O
present	O
in	O
all	O
this	O
set	O
of	O
EBV	O
clinical	O
samples	O
resulting	O
in	O
100	O
%	O
sensitivity	O
.	O
</ALL>	O

<ALL>	O
For	O
the	O
samples	O
defined	O
as	O
EBV	O
-	O
seronegative	O
,	O
there	O
were	O
no	O
readings	O
above	O
the	O
cut	O
-	O
off	O
level	O
and	O
therefore	O
no	O
false	O
positives	O
,	O
resulting	O
in	O
100	O
%	O
specificity	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
there	O
were	O
no	O
absorbance	O
readings	O
above	O
the	O
cut	O
-	O
off	O
levels	O
for	O
the	O
potentially	O
cross	O
-	O
reactive	O
serum	B-Organism_substance
samples	I-Organism_substance
,	O
inferring	O
that	O
the	O
peptides	O
identified	O
in	O
this	O
study	O
have	O
high	O
specificity	O
for	O
EBV	O
antibodies	O
.	O
</ALL>	O

<ALL>	O
Additional	O
File	O
2	O
</ALL>	O

<ALL>	O
Full	O
Model	O
Code	O
.	O
</ALL>	O

<ALL>	O
Full	O
model	O
code	O
plus	O
instructions	O
for	O
running	O
in	O
Berkeley	O
Madonna	O
(	O
TM	O
)	O
.	O
</ALL>	O

<ALL>	O
Secchi	O
depth	O
in	O
the	O
Baltic	O
Proper	O
,	O
June	O
-	O
August	O
,	O
1957	O
-	O
1998	O
.	O
</ALL>	O

<ALL>	O
Number	O
of	O
data	O
:	O
3	O
,	O
452	O
.	O
</ALL>	O

<ALL>	O
Nucleotide	O
features	O
of	O
free	O
-	O
standing	O
homing	O
-	O
endonucleases	O
</ALL>	O

<ALL>	O
Gene	O
control	O
elements	O
were	O
identified	O
for	O
several	O
members	O
of	O
each	O
type	O
of	O
intervening	O
homing	O
endonuclease	O
genes	O
described	O
in	O
this	O
study	O
.	O
</ALL>	O

<ALL>	O
In	O
15	O
out	O
of	O
16	O
,	O
5	O
'	O
untranslated	O
regions	O
of	O
the	O
endonucleases	O
we	O
identified	O
RNA	O
hairpin	O
structures	O
upstream	O
of	O
initiation	O
codons	O
(	O
Figures	O
1	O
and	O
4A	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
may	O
be	O
a	O
translational	O
regulatory	O
hairpin	O
structure	O
known	O
from	O
various	O
phage	O
genes	O
,	O
including	O
homing	O
endonucleases	O
(	O
22	O
,	O
47	O
-	O
49	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
hairpins	O
we	O
found	O
are	O
in	O
fractured	O
gene	O
loci	O
with	O
different	O
protein	O
host	O
types	O
,	O
including	O
gp41	O
,	O
IMPDH	O
,	O
DnaE	O
,	O
NrdJ	O
and	O
NrdA	O
.	O
</ALL>	O

<ALL>	O
Ten	O
of	O
these	O
hairpins	O
also	O
include	O
a	O
conserved	O
sequence	O
of	O
Aeh1	O
phage	O
late	O
promoter	O
element	O
(	O
TATAAATA	O
)	O
,	O
which	O
was	O
recently	O
shown	O
to	O
inhibit	O
the	O
translation	O
of	O
a	O
gene	O
-	O
fracturing	O
endonuclease	O
gene	O
,	O
by	O
sequestering	O
its	O
ribosome	B-Cellular_component
binding	O
site	O
(	O
22	O
,	O
23	O
)	O
.	O
</ALL>	O

<ALL>	O
Analysis	O
of	O
the	O
endonuclease	O
5	O
'	O
untranslated	O
regions	O
revealed	O
two	O
conserved	O
motifs	O
(	O
Figures	O
4A	O
and	O
Supplementary	O
Figure	O
S4	O
)	O
,	O
which	O
usually	O
complement	O
each	O
other	O
on	O
the	O
stem	O
of	O
the	O
conserved	O
hairpin	O
structures	O
.	O
</ALL>	O

<ALL>	O
Figure	O
4	O
.	O
</ALL>	O

<ALL>	O
Nucleotide	O
features	O
of	O
endonuclease	O
genes	O
.	O
</ALL>	O

<ALL>	O
(	O
A	O
)	O
RNA	O
hairpin	O
structures	O
at	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
endonuclease	O
ORFs	O
in	O
the	O
gp41	O
-	O
1	O
(	O
representing	O
the	O
very	O
similar	O
sequences	O
of	O
gp41	O
-	O
1	O
-	O
7	O
)	O
,	O
nrdA	O
-	O
5	O
and	O
DnaE	O
-	O
1	O
gene	O
loci	O
.	O
</ALL>	O

<ALL>	O
Initiator	O
codons	O
are	O
marked	O
by	O
arrows	O
,	O
conserved	O
putative	O
T4	O
late	O
promoter	O
elements	O
are	O
boxed	O
,	O
and	O
conserved	O
sequence	O
motifs	O
(	O
Supplementary	O
Figure	O
S4	O
)	O
are	O
highlighted	O
in	O
grey	O
.	O
</ALL>	O

<ALL>	O
The	O
expected	O
values	O
for	O
motifs	O
1	O
and	O
2	O
are	O
1	O
.	O
7	O
-	O
10	O
and	O
9	O
.	O
9	O
-	O
3	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
RNA	O
structures	O
were	O
calculated	O
using	O
the	O
Vienna	O
package	O
(	O
http	O
:	O
/	O
/	O
rna	O
.	O
tbi	O
.	O
univie	O
.	O
ac	O
.	O
at	O
/	O
cgi	O
-	O
bin	O
/	O
RNAfold	O
.	O
cgi	O
)	O
,	O
and	O
sequence	O
motifs	O
were	O
identified	O
using	O
the	O
MEME	O
program	O
.	O
</ALL>	O

<ALL>	O
(	O
B	O
)	O
Overlapping	O
#	O
protein	O
coding	O
regions	O
of	O
endonuclease	O
3	O
'	O
termini	O
and	O
the	O
5	O
'	O
termini	O
of	O
their	O
downstream	O
genes	O
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
15	O
loci	O
included	O
an	O
overlapping	O
region	O
of	O
6	O
-	O
69	O
bp	O
between	O
the	O
coding	O
regions	O
of	O
the	O
probable	O
endonuclease	O
C	O
-	O
termini	O
and	O
the	O
downstream	O
N	O
-	O
termini	O
of	O
the	O
split	O
-	O
intein	O
part	O
(	O
Figures	O
1	O
and	O
4B	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
overlap	O
is	O
present	O
in	O
both	O
types	O
of	O
endonucleases	O
,	O
and	O
is	O
independent	O
on	O
the	O
presence	O
of	O
a	O
split	O
-	O
intein	O
part	O
in	O
the	O
fractured	O
gene	O
,	O
also	O
occurring	O
in	O
the	O
putative	O
sbcD	O
DNA	O
-	O
repair	O
gene	O
that	O
we	O
found	O
,	O
as	O
well	O
as	O
in	O
the	O
Aeh1	O
fractured	O
nrdA	O
found	O
by	O
Gibb	O
and	O
Edgell	O
(	O
22	O
)	O
.	O
</ALL>	O

<ALL>	O
Efficacy	O
of	O
MMF	O
in	O
current	O
immunosuppressive	O
regimens	O
after	O
kidney	B-Organ
transplantation	O
</ALL>	O

<ALL>	O
Current	O
established	O
immunosuppressive	O
strategies	O
in	O
kidney	B-Organ
transplantation	O
often	O
include	O
an	O
induction	O
agent	O
(	O
monoclonal	O
or	O
polyclonal	O
anti	O
-	O
T	B-Cell
-	I-Cell
cell	I-Cell
antibodies	O
)	O
based	O
on	O
the	O
immunologic	O
risk	O
of	O
the	O
recipient	O
,	O
followed	O
by	O
a	O
maintenance	O
regimen	O
combining	O
a	O
CNI	O
and	O
an	O
anti	O
-	O
proliferative	O
agent	O
,	O
with	O
or	O
without	O
corticosteroids	O
.	O
2	O
-	O
4	O
As	O
MMF	O
was	O
the	O
first	O
MPA	O
formulation	O
approved	O
in	O
clinical	O
kidney	B-Organ
transplantation	O
,	O
more	O
extensive	O
clinical	O
data	O
are	O
available	O
with	O
this	O
drug	O
in	O
comparison	O
to	O
EC	O
-	O
MPS	O
.	O
</ALL>	O

<ALL>	O
Sex	O
and	O
age	O
distributions	O
of	O
confirmed	O
cases	O
</ALL>	O

<ALL>	O
Of	O
480	O
confirmed	O
cases	O
,	O
56	O
%	O
(	O
269	O
/	O
480	O
)	O
were	O
male	O
patients	O
and	O
44	O
%	O
(	O
211	O
/	O
480	O
)	O
were	O
female	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
percentage	O
of	O
male	O
cases	O
was	O
higher	O
than	O
that	O
of	O
females	O
in	O
all	O
groups	O
except	O
for	O
the	O
group	O
aged	O
31	O
-	O
40	O
(	O
chi2	O
=	O
42	O
.	O
4	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
</ALL>	O

<ALL>	O
278	O
(	O
57	O
.	O
9	O
%	O
)	O
cases	O
were	O
in	O
the	O
group	O
aged	O
21	O
-	O
50	O
,	O
followed	O
by	O
102	O
(	O
21	O
.	O
3	O
%	O
)	O
,	O
79	O
(	O
16	O
.	O
5	O
%	O
)	O
and	O
21	O
(	O
4	O
.	O
4	O
%	O
)	O
cases	O
in	O
the	O
group	O
aged	O
51	O
-	O
70	O
,	O
0	O
-	O
20	O
,	O
and	O
>	O
=	O
71	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
youngest	O
and	O
oldest	O
cases	O
were	O
1	O
.	O
5	O
and	O
81	O
years	O
old	O
,	O
respectively	O
(	O
Table	O
2	O
)	O
.	O
</ALL>	O

<ALL>	O
Table	O
2	O
</ALL>	O

<ALL>	O
Age	O
and	O
occupational	O
distributions	O
and	O
activities	O
(	O
1	O
-	O
3	O
weeks	O
prior	O
to	O
symptom	O
appearance	O
)	O
of	O
confirmed	O
cases	O
</ALL>	O

<ALL>	O
Cases	O
(	O
%	O
)	O
(	O
Male	O
:	O
Female	O
,	O
%	O
)	O
</ALL>	O

<ALL>	O
Age	O
(	O
Years	O
)	O
</ALL>	O

<ALL>	O
0	O
-	O
10	O
46	O
(	O
9	O
.	O
6	O
)	O
(	O
76	O
:	O
24	O
)	O
</ALL>	O

<ALL>	O
11	O
-	O
20	O
33	O
(	O
6	O
.	O
9	O
)	O
(	O
79	O
:	O
21	O
)	O
</ALL>	O

<ALL>	O
21	O
-	O
30	O
78	O
(	O
16	O
.	O
3	O
)	O
(	O
51	O
:	O
49	O
)	O
</ALL>	O

<ALL>	O
31	O
-	O
40	O
99	O
(	O
20	O
.	O
6	O
)	O
(	O
46	O
:	O
54	O
)	O
</ALL>	O

<ALL>	O
41	O
-	O
50	O
101	O
(	O
21	O
.	O
0	O
)	O
(	O
56	O
:	O
44	O
)	O
</ALL>	O

<ALL>	O
51	O
-	O
60	O
47	O
(	O
9	O
.	O
8	O
)	O
(	O
55	O
:	O
45	O
)	O
</ALL>	O

<ALL>	O
61	O
-	O
70	O
55	O
(	O
11	O
.	O
5	O
)	O
(	O
53	O
:	O
47	O
)	O
</ALL>	O

<ALL>	O
>	O
=	O
71	O
21	O
(	O
4	O
.	O
4	O
)	O
(	O
52	O
:	O
48	O
)	O
</ALL>	O

<ALL>	O
Occupation	O
</ALL>	O

<ALL>	O
Children	O
at	O
preschool	O
age	O
20	O
(	O
4	O
.	O
2	O
)	O
(	O
75	O
:	O
25	O
)	O
</ALL>	O

<ALL>	O
Pupils	O
50	O
(	O
10	O
.	O
4	O
)	O
(	O
78	O
:	O
22	O
)	O
</ALL>	O

<ALL>	O
Farmers	O
408	O
(	O
85	O
.	O
0	O
)	O
(	O
52	O
:	O
48	O
)	O
</ALL>	O

<ALL>	O
Others	O
2	O
(	O
0	O
.	O
4	O
)	O
(	O
50	O
:	O
50	O
)	O
</ALL>	O

<ALL>	O
Activities	O
</ALL>	O

<ALL>	O
Farm	O
work	O
325	O
(	O
67	O
.	O
7	O
)	O
(	O
53	O
:	O
47	O
)	O
</ALL>	O

<ALL>	O
Play	O
on	O
grassland	O
65	O
(	O
13	O
.	O
5	O
)	O
(	O
75	O
:	O
25	O
)	O
</ALL>	O

<ALL>	O
Recreation	O
20	O
(	O
4	O
.	O
2	O
)	O
(	O
65	O
:	O
35	O
)	O
</ALL>	O

<ALL>	O
Housework	O
25	O
(	O
5	O
.	O
2	O
)	O
(	O
8	O
:	O
92	O
)	O
</ALL>	O

<ALL>	O
Unknown	O
45	O
(	O
9	O
.	O
4	O
)	O
(	O
71	O
:	O
29	O
)	O
</ALL>	O

<ALL>	O
Discussion	O
</ALL>	O

<ALL>	O
Because	O
Netherton	O
syndrome	O
exhibits	O
allergic	O
phenotype	O
,	O
it	O
is	O
reasonable	O
to	O
speculate	O
that	O
SPINK5	O
,	O
which	O
is	O
mutated	O
in	O
Netherton	O
syndrome	O
,	O
may	O
act	O
as	O
a	O
candidate	O
gene	O
for	O
asthma	O
and	O
other	O
allergic	O
diseases	O
[	O
9	O
]	O
.	O
</ALL>	O

<ALL>	O
An	O
extensive	O
search	O
for	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
SPINK5	O
led	O
to	O
the	O
identification	O
of	O
a	O
number	O
of	O
SNPs	O
,	O
including	O
six	O
nonsynonymous	O
SNPs	O
in	O
coding	O
region	O
that	O
might	O
perturb	O
its	O
immune	O
function	O
.	O
</ALL>	O

<ALL>	O
Subsequent	O
genotyping	O
of	O
three	O
nonsynonymous	O
SNPs	O
,	O
A1103G	O
,	O
G1156A	O
and	O
G1258A	O
in	O
two	O
independent	O
panels	O
of	O
British	O
families	O
showed	O
a	O
significant	O
association	O
between	O
SNP	O
G1258A	O
(	O
Glu420Lys	O
)	O
and	O
atopy	O
,	O
atopic	O
dermatitis	O
,	O
elevated	O
serum	B-Organism_substance
IgE	O
levels	O
and	O
asthma	O
[	O
10	O
]	O
.	O
</ALL>	O

<ALL>	O
This	O
association	O
was	O
confirmed	O
in	O
a	O
large	O
German	O
population	O
and	O
two	O
Japanese	O
populations	O
[	O
16	O
-	O
18	O
]	O
.	O
</ALL>	O

<ALL>	O
Kato	O
et	O
al	O
analyzed	O
eight	O
SNPs	O
in	O
exon	O
13	O
and	O
14	O
of	O
the	O
SPINK5	O
including	O
G1258A	O
(	O
Glu420Lys	O
)	O
,	O
and	O
found	O
a	O
positive	O
association	O
of	O
seven	O
SNPs	O
with	O
atopic	O
dermatitis	O
in	O
a	O
Japanese	O
study	O
sample	O
using	O
a	O
case	O
-	O
control	O
study	O
design	O
[	O
16	O
]	O
.	O
</ALL>	O

<ALL>	O
Nishio	O
et	O
al	O
surveyed	O
five	O
of	O
six	O
previously	O
reported	O
nonsynonymous	O
SPINK5	O
SNPs	O
in	O
Japanese	O
atopic	O
families	O
identified	O
through	O
asthmatic	O
children	O
or	O
subjects	O
with	O
atopic	O
dermatitis	O
and	O
found	O
that	O
SPINK5	O
was	O
associated	O
with	O
development	O
of	O
atopic	O
dermatitis	O
but	O
not	O
asthma	O
[	O
17	O
]	O
.	O
</ALL>	O

<ALL>	O
Kabesch	O
M	O
et	O
al	O
.	O
analyzed	O
G1258A	O
(	O
Glu420Lys	O
)	O
in	O
a	O
German	O
population	O
of	O
school	O
children	O
,	O
and	O
found	O
its	O
association	O
with	O
asthma	O
as	O
well	O
as	O
a	O
concomitant	O
occurrence	O
of	O
asthma	O
and	O
atopic	O
dermatitis	O
[	O
18	O
]	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
two	O
subsequent	O
studies	O
failed	O
to	O
replicate	O
the	O
original	O
SPINK5	O
findings	O
for	O
allergic	O
diseases	O
[	O
19	O
,	O
20	O
]	O
.	O
</ALL>	O

<ALL>	O
Folster	O
-	O
Holst	O
et	O
al	O
genotyped	O
four	O
nonsynonymous	O
SNPs	O
(	O
Asp106Asn	O
,	O
Asn368Ser	O
,	O
Asp386Asn	O
,	O
and	O
Glu420Lys	O
)	O
,	O
and	O
detected	O
no	O
association	O
between	O
SPINK5	O
and	O
atopic	O
dermatitis	O
in	O
populations	O
of	O
Northern	O
German	O
origin	O
[	O
20	O
]	O
.	O
</ALL>	O

<ALL>	O
Jongepier	O
H	O
et	O
al	O
.	O
failed	O
to	O
detect	O
any	O
association	O
between	O
SPINK5	O
and	O
asthma	O
,	O
atopic	O
phenotypes	O
and	O
atopic	O
dermatitis	O
in	O
a	O
Dutch	O
population	O
[	O
19	O
]	O
.	O
</ALL>	O

<ALL>	O
These	O
discordant	O
findings	O
probably	O
reflect	O
different	O
genetic	O
and	O
environmental	O
backgrounds	O
in	O
various	O
populations	O
.	O
</ALL>	O

<ALL>	O
To	O
determine	O
whether	O
nonsynonymous	O
SNPs	O
of	O
the	O
SPINK5	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
in	O
the	O
Chinese	O
Han	O
population	O
,	O
we	O
performed	O
a	O
case	O
-	O
control	O
study	O
by	O
genotyping	O
four	O
nonsynonymous	O
SNPs	O
in	O
the	O
SPINK5	O
.	O
</ALL>	O

<ALL>	O
We	O
did	O
not	O
detect	O
any	O
significant	O
association	O
between	O
these	O
nonsynonymous	O
SNPs	O
and	O
asthma	O
in	O
our	O
Chinese	O
samples	O
.	O
</ALL>	O

<ALL>	O
With	O
our	O
sample	O
size	O
,	O
we	O
expected	O
a	O
power	O
of	O
at	O
least	O
80	O
%	O
in	O
detecting	O
an	O
effect	O
of	O
OR	O
>	O
=	O
1	O
.	O
3	O
for	O
each	O
of	O
these	O
SNPs	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
our	O
failure	O
to	O
detect	O
an	O
association	O
for	O
these	O
4	O
SNPs	O
was	O
not	O
due	O
to	O
the	O
sample	O
size	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
suggest	O
that	O
the	O
polymorphisms	O
in	O
the	O
coding	O
region	O
of	O
the	O
SPINK5	O
are	O
unlikely	O
to	O
contribute	O
to	O
asthma	O
risk	O
in	O
the	O
Chinese	O
Han	O
population	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
because	O
our	O
patients	O
were	O
ascertained	O
for	O
asthma	O
,	O
we	O
could	O
not	O
exclude	O
a	O
role	O
of	O
the	O
coding	O
SNPs	O
of	O
the	O
SPINK5	O
in	O
atopic	O
dermatitis	O
in	O
our	O
population	O
.	O
</ALL>	O

<ALL>	O
The	O
variations	O
in	O
the	O
regulatory	O
sequences	O
of	O
genes	O
may	O
determine	O
risks	O
to	O
common	O
diseases	O
by	O
causing	O
different	O
levels	O
of	O
expression	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
the	O
identification	O
and	O
functional	O
evaluation	O
of	O
polymorphisms	O
in	O
promoter	O
region	O
are	O
of	O
great	O
value	O
in	O
understanding	O
the	O
genetic	O
susceptibility	O
to	O
asthma	O
.	O
</ALL>	O

<ALL>	O
In	O
order	O
to	O
determine	O
the	O
role	O
of	O
the	O
SPINK5	O
promoter	O
polymorphism	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
,	O
we	O
genotyped	O
a	O
promoter	O
polymorphism	O
,	O
-	O
206G	O
>	O
A	O
,	O
in	O
422	O
asthma	O
patients	O
and	O
410	O
controls	O
,	O
and	O
found	O
a	O
marginal	O
association	O
.	O
</ALL>	O

<ALL>	O
The	O
frequency	O
of	O
allele	O
G	O
was	O
significantly	O
higher	O
in	O
asthmatic	O
patients	O
than	O
that	O
in	O
controls	O
(	O
p	O
=	O
0	O
.	O
022	O
)	O
.	O
</ALL>	O

<ALL>	O
To	O
confirm	O
the	O
association	O
,	O
additional	O
267	O
asthma	O
patients	O
and	O
301	O
controls	O
newly	O
recruited	O
from	O
the	O
same	O
hospital	O
were	O
genotyped	O
,	O
and	O
the	O
-	O
206G	O
>	O
A	O
polymorphism	O
remained	O
significantly	O
associated	O
with	O
asthma	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
,	O
even	O
after	O
Bonferroni	O
correction	O
(	O
adjusted	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O
</ALL>	O

<ALL>	O
To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
association	O
of	O
-	O
206G	O
>	O
A	O
polymorphism	O
with	O
asthma	O
.	O
</ALL>	O

<ALL>	O
We	O
further	O
examined	O
the	O
potential	O
functional	O
role	O
of	O
this	O
promoter	O
polymorphism	O
,	O
and	O
found	O
that	O
the	O
G	O
to	O
A	O
substitution	O
at	O
-	O
206	O
generated	O
a	O
GATA	O
-	O
3	O
transcription	O
factor	O
binding	O
site	O
.	O
</ALL>	O

<ALL>	O
Major	O
transcription	O
factors	O
controlling	O
Th1	O
and	O
Th2	O
development	O
,	O
such	O
as	O
T	O
-	O
box	O
transcription	O
factor	O
and	O
GATA3	O
,	O
are	O
possibly	O
involved	O
in	O
asthma	O
and	O
atopic	O
diseases	O
.	O
</ALL>	O

<ALL>	O
GATA	O
-	O
3	O
,	O
a	O
transcription	O
factor	O
specifically	O
expressed	O
in	O
T	B-Cell
helper	I-Cell
2	I-Cell
(	I-Cell
Th2	I-Cell
)	I-Cell
cells	I-Cell
,	O
plays	O
a	O
critical	O
role	O
in	O
the	O
differentiation	O
of	O
Th2	B-Cell
cells	I-Cell
from	O
uncommitted	O
CD4	B-Cell
+	I-Cell
lymphocytes	I-Cell
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
GATA	O
-	O
3	O
is	O
essential	O
for	O
the	O
expression	O
of	O
the	O
cytokines	O
IL	O
-	O
4	O
,	O
IL	O
-	O
5	O
and	O
IL	O
-	O
13	O
that	O
mediate	O
allergic	O
inflammation	O
[	O
23	O
]	O
.	O
</ALL>	O

<ALL>	O
Our	O
luciferase	O
reporter	O
assay	O
confirmed	O
that	O
SNP	O
-	O
206G	O
>	O
A	O
is	O
associated	O
with	O
the	O
transcriptional	O
activity	O
of	O
SPINK5	O
.	O
</ALL>	O

<ALL>	O
The	O
G	O
allele	O
was	O
associated	O
with	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
SPINK5	O
.	O
</ALL>	O

<ALL>	O
The	O
mechanism	O
by	O
which	O
the	O
-	O
206G	O
>	O
A	O
SNP	O
affects	O
SPINK5	O
expression	O
may	O
be	O
explained	O
by	O
the	O
potential	O
differential	O
transcription	O
factor	O
binding	O
of	O
GATA	O
binding	O
factor	O
,	O
since	O
-	O
206G	O
>	O
A	O
is	O
located	O
at	O
the	O
core	O
sequence	O
of	O
GATA	O
binding	O
factor	O
binding	O
site	O
.	O
</ALL>	O

<ALL>	O
Electrophoretic	O
mobility	O
shift	O
assay	O
confirmed	O
that	O
the	O
A	O
to	O
G	O
substitution	O
at	O
-	O
206	O
significantly	O
reduced	O
the	O
binding	O
efficiency	O
of	O
nuclear	B-Cellular_component
proteins	O
to	O
this	O
element	O
.	O
</ALL>	O

<ALL>	O
Our	O
data	O
suggest	O
that	O
loss	O
of	O
GATA	O
transcription	O
factor	O
regulation	O
with	O
the	O
-	O
206G	O
may	O
decrease	O
the	O
SPINK5	O
expression	O
and	O
thereby	O
potentially	O
perturb	O
the	O
immunosuppressive	O
function	O
of	O
LEKTI	O
.	O
</ALL>	O

<ALL>	O
Statistical	O
Analysis	O
</ALL>	O

<ALL>	O
Mitochondrial	B-Cellular_component
DNA	O
haplogroup	O
frequencies	O
were	O
calculated	O
by	O
counting	O
from	O
the	O
observed	O
genotypes	O
.	O
</ALL>	O

<ALL>	O
The	O
Pearson	O
chi	O
-	O
square	O
test	O
and	O
the	O
chi	O
-	O
square	O
test	O
for	O
linear	O
-	O
by	O
-	O
linear	O
association	O
were	O
used	O
to	O
analyze	O
the	O
significances	O
between	O
the	O
prevalence	O
of	O
haplogroups	O
and	O
different	O
age	O
groups	O
.	O
</ALL>	O

<ALL>	O
SPSS	O
software	O
(	O
version	O
10	O
.	O
0	O
)	O
was	O
used	O
.	O
</ALL>	O

<ALL>	O
Duplicated	O
HGT	O
candidates	O
in	O
K	O
.	O
thermotolerans	O
.	O
</ALL>	O

<ALL>	O
(	O
A	O
)	O
Part	O
of	O
the	O
conserved	O
synteny	O
block	O
surrounding	O
KLTH0C07700g	O
and	O
KLTH0C07722g	O
tandem	O
genes	O
.	O
</ALL>	O

<ALL>	O
Same	O
legend	O
as	O
Figure	O
3A	O
.	O
</ALL>	O

<ALL>	O
(	O
B	O
)	O
Part	O
of	O
the	O
conserved	O
synteny	O
block	O
surrounding	O
KLTH0F12276g	O
gene	O
.	O
</ALL>	O

<ALL>	O
Same	O
legend	O
as	O
Figure	O
3A	O
.	O
</ALL>	O

<ALL>	O
(	O
C	O
)	O
Sequence	O
alignment	O
of	O
proteins	O
from	O
K	O
.	O
thermotolerans	O
and	O
K	O
.	O
waltii	O
.	O
</ALL>	O

<ALL>	O
(	O
D	O
)	O
Phylogenetic	O
tree	O
reconstructed	O
from	O
sequence	O
alignment	O
of	O
100	O
sites	O
of	O
K	O
.	O
thermotolerans	O
protein	O
family	O
members	O
,	O
K	O
.	O
waltii	O
gene	O
,	O
bacterial	O
(	O
green	O
)	O
and	O
amoebal	O
(	O
blue	O
)	O
proteins	O
.	O
</ALL>	O

<ALL>	O
Bootstrap	O
values	O
are	O
indicated	O
next	O
to	O
the	O
nodes	O
and	O
branch	O
length	O
scale	O
is	O
shown	O
at	O
bottom	O
left	O
.	O
</ALL>	O

<ALL>	O
Quantitative	O
reverse	O
transcription	O
PCR	O
</ALL>	O

<ALL>	O
Reverse	O
transcription	O
was	O
performed	O
using	O
0	O
.	O
2	O
mug	O
of	O
total	O
RNA	O
from	O
muscle	B-Tissue
of	O
10	O
week	O
-	O
old	O
and	O
19	O
month	O
-	O
old	O
C57Bl6	O
mice	O
(	O
five	O
animals	O
per	O
group	O
)	O
,	O
a	O
Core	O
kit	O
(	O
RT	O
-	O
RTCK	O
-	O
03	O
,	O
Eurogentec	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
instruction	O
and	O
a	O
mix	O
of	O
random	O
primers	O
(	O
9	O
mers	O
)	O
and	O
oligodT	O
.	O
</ALL>	O

<ALL>	O
qPCR	O
was	O
performed	O
on	O
SDS7900HT	O
(	O
Applied	O
Biosystem	O
)	O
using	O
Mesagreen	O
qPCR	O
kit	O
for	O
SYBR	O
(	O
Eurogentec	O
)	O
and	O
the	O
following	O
primers	O
:	O
</ALL>	O

<ALL>	O
PPARbeta	O
:	O
5	O
'	O
-	O
AGATGGTGGCAGAGCTATGACC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
TCCTCCTGTGGCTGTTCC	O
-	O
3	O
'	O
.	O
</ALL>	O

<ALL>	O
Catalase	O
:	O
5	O
'	O
-	O
GGATCCTGACATGGTCTGGG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
TGGAGAGACTCGGGACGAAG	O
-	O
3	O
'	O
.	O
</ALL>	O

<ALL>	O
PDK4	O
:	O
5	O
'	O
-	O
GCATTTCTACTCGGATGCTCAATG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CCAATGTGGCTTGGGTTTCC	O
-	O
3	O
'	O
.	O
</ALL>	O

<ALL>	O
36B4	O
:	O
5	O
'	O
-	O
TCCAGGCTTTGGGCATCA	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CTTTATCAGCTGCACATCACTCAGA	O
-	O
3	O
'	O
.	O
</ALL>	O

<ALL>	O
Data	O
were	O
all	O
normalised	O
using	O
36B4	O
as	O
housekeeping	O
gene	O
.	O
</ALL>	O

<ALL>	O
Chicken	O
CCN3	O
expression	O
in	O
embryonic	B-Tissue
and	O
extraembryonic	B-Tissue
tissues	I-Tissue
</ALL>	O

<ALL>	O
Expression	O
of	O
CCN3	O
in	O
axial	O
structure	O
becomes	O
visible	O
in	O
the	O
presegmentation	O
stage	O
and	O
reaches	O
to	O
the	O
highest	O
level	O
at	O
the	O
beginning	O
of	O
somitogenesis	O
(	O
HH	O
stage	O
7	O
,	O
Fig	O
.	O
1a	O
)	O
.	O
</ALL>	O

<ALL>	O
Strong	O
similarity	O
between	O
CCN3	O
and	O
Sonic	O
Hedgehog	O
was	O
observed	O
for	O
the	O
expression	O
pattern	O
in	O
axial	O
structure	O
(	O
notochord	O
and	O
floor	O
plate	O
)	O
,	O
in	O
which	O
the	O
left	O
-	O
right	O
asymmetrical	O
pattern	O
in	O
the	O
node	O
area	O
is	O
also	O
conserved	O
(	O
Fig	O
.	O
1b	O
)	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
Sonic	O
Hedgehog	O
expression	O
is	O
slightly	O
broader	O
than	O
that	O
of	O
CCN3	O
.	O
</ALL>	O

<ALL>	O
Since	O
CCN3	O
stimulates	O
Notch	O
signaling	O
(	O
Sakamoto	O
et	O
al	O
.	O
2002	O
)	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
Notch	O
signal	O
genes	O
.	O
</ALL>	O

<ALL>	O
Among	O
them	O
,	O
Serrate1	O
,	O
a	O
ligand	O
of	O
Notch	O
is	O
unique	O
because	O
its	O
expression	O
is	O
apparently	O
a	O
right	O
deviated	O
pattern	O
in	O
the	O
node	O
area	O
(	O
Fig	O
.	O
1c	O
)	O
.	O
</ALL>	O

<ALL>	O
Another	O
Notch	O
ligand	O
,	O
Delta1	O
shows	O
a	O
right	O
deviated	O
pattern	O
,	O
but	O
is	O
more	O
caudal	O
area	O
of	O
the	O
node	O
extending	O
to	O
the	O
primitive	O
streak	O
(	O
data	O
not	O
shown	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
expression	O
of	O
CCN3	O
in	O
axial	O
structure	O
was	O
followed	O
by	O
the	O
presomitic	O
mesoderm	O
although	O
it	O
is	O
diminished	O
(	O
Sakamoto	O
et	O
al	O
.	O
2002	O
)	O
.	O
</ALL>	O

<ALL>	O
Fig	O
.	O
</ALL>	O

<ALL>	O
1	O
</ALL>	O

<ALL>	O
Expression	O
of	O
mRNA	O
in	O
early	O
stage	O
chicken	O
embryo	B-Developing_anatomical_structure
;	O
CCN3	O
(	O
a	O
)	O
,	O
Sonic	O
Hedgehog	O
(	O
b	O
)	O
and	O
Serrate1	O
(	O
c	O
)	O
at	O
the	O
beginning	O
stage	O
of	O
somitogenesis	O
(	O
Hamburger	O
and	O
Hamilton	O
(	O
HH	O
)	O
Stage	O
7	O
)	O
.	O
</ALL>	O

<ALL>	O
Arrowheads	O
indicate	O
Hensen	O
'	O
s	O
node	O
.	O
</ALL>	O

<ALL>	O
Demonstrates	O
the	O
schematic	O
view	O
of	O
tissue	B-Tissue
organization	O
at	O
this	O
stage	O
(	O
d	O
)	O
.	O
</ALL>	O

<ALL>	O
Expression	O
of	O
CCN3	O
mRNA	O
in	O
blood	B-Organism_substance
islands	I-Organism_substance
of	O
chicken	O
extraembryonic	B-Tissue
tissue	I-Tissue
(	O
HH	O
stage	O
10	O
)	O
(	O
e	O
)	O
.	O
</ALL>	O

<ALL>	O
Ventral	B-Multi-tissue_structure
part	O
of	O
the	O
endothelial	B-Cell
precursor	I-Cell
cells	I-Cell
in	O
blood	B-Organism_substance
islands	I-Organism_substance
is	O
positive	O
for	O
CCN3	O
expression	O
.	O
</ALL>	O

<ALL>	O
Coloration	O
was	O
stopped	O
before	O
the	O
background	O
staining	O
started	O
in	O
sense	O
probes	O
(	O
negative	O
control	O
)	O
</ALL>	O

<ALL>	O
There	O
is	O
accumulating	O
evidence	O
of	O
CCN3	O
commitment	O
to	O
hematopoiesis	O
and	O
therefore	O
we	O
investigated	O
the	O
CCN3	O
expression	O
in	O
extraembryonic	B-Tissue
tissues	I-Tissue
.	O
</ALL>	O

<ALL>	O
Blood	B-Organism_substance
islands	I-Organism_substance
are	O
formed	O
in	O
the	O
yolk	B-Tissue
sac	I-Tissue
mesodermal	I-Tissue
area	O
just	O
between	O
the	O
visceral	B-Tissue
endodermal	I-Tissue
and	O
ectodermal	B-Tissue
layers	I-Tissue
,	O
which	O
supply	O
the	O
red	B-Cell
blood	I-Cell
cells	I-Cell
at	O
the	O
primary	O
stage	O
.	O
</ALL>	O

<ALL>	O
The	O
cells	B-Cell
in	O
blood	B-Organism_substance
islands	I-Organism_substance
are	O
called	O
hemangioblasts	B-Cell
since	O
they	O
also	O
differentiate	O
into	O
the	O
endothelial	B-Cell
cells	I-Cell
of	O
extraembryonic	B-Developing_anatomical_structure
blood	I-Developing_anatomical_structure
vessel	I-Developing_anatomical_structure
structure	I-Developing_anatomical_structure
.	O
</ALL>	O

<ALL>	O
In	O
chicken	O
embryo	B-Developing_anatomical_structure
,	O
differentiating	O
endothelial	B-Cell
cells	I-Cell
in	O
the	O
ventral	B-Multi-tissue_structure
part	O
of	O
blood	B-Organism_substance
islands	I-Organism_substance
express	O
CCN3	O
from	O
the	O
initial	O
stage	O
(	O
Fig	O
.	O
1e	O
)	O
.	O
</ALL>	O

<ALL>	O
Erythroblasts	B-Cell
in	O
the	O
center	O
of	O
blood	B-Organism_substance
islands	I-Organism_substance
(	O
spherical	O
cells	B-Cell
in	O
Fig	O
.	O
1e	O
)	O
weakly	O
express	O
CCN3	O
and	O
their	O
expression	O
is	O
mildly	O
enhanced	O
in	O
later	O
stage	O
(	O
data	O
not	O
shown	O
)	O
.	O
</ALL>	O

<ALL>	O
Assessment	O
of	O
various	O
forms	O
of	O
bevavioural	O
addictions	O
</ALL>	O

<ALL>	O
A	O
first	O
approach	O
for	O
the	O
comprehensive	O
and	O
standardized	O
assessment	O
of	O
different	O
forms	O
of	O
behavioural	O
addictions	O
(	O
e	O
.	O
g	O
.	O
,	O
pathological	O
gambling	O
,	O
workaholism	O
,	O
compulsive	O
buying	O
)	O
is	O
the	O
German	O
self	O
-	O
assessment	O
questionnaire	O
"	O
Fragebogen	O
zur	O
Differenzierten	O
Anamnese	O
exzessiver	O
Verhaltensweisen	O
"	O
(	O
FDAV	O
,	O
Questionnaire	O
on	O
Differentiated	O
Assessment	O
of	O
Excessive	O
Behaviours	O
)	O
[	O
96	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
FDAV	O
is	O
based	O
on	O
the	O
criteria	O
of	O
substance	O
-	O
related	O
addictions	O
,	O
pathological	O
gambling	O
and	O
impulse	O
control	O
disorders	O
of	O
the	O
ICD	O
-	O
10	O
[	O
3	O
]	O
and	O
the	O
DSM	O
-	O
IV	O
-	O
TR	O
[	O
2	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
FDAV	O
is	O
a	O
modified	O
version	O
of	O
the	O
"	O
Fragebogen	O
zur	O
Differenzierten	O
Drogenanamnese	O
"	O
(	O
FDDA	O
;	O
Questionnaire	O
on	O
Differentiated	O
Assessment	O
of	O
Addiction	O
,	O
QDAA	O
)	O
[	O
97	O
]	O
.	O
</ALL>	O

<ALL>	O
Its	O
seven	O
modules	O
obtain	O
"	O
sociodemographic	O
information	O
"	O
(	O
e	O
.	O
g	O
.	O
,	O
age	O
,	O
profession	O
,	O
marital	O
status	O
)	O
,	O
"	O
history	O
of	O
excessive	O
behaviour	O
"	O
(	O
e	O
.	O
g	O
.	O
,	O
diagnostic	O
criteria	O
for	O
addictions	O
and	O
impulse	O
control	O
disorder	O
,	O
individual	O
patterns	O
of	O
behaviour	O
,	O
craving	O
symptoms	O
)	O
,	O
"	O
critical	O
life	O
events	O
"	O
(	O
stress	O
caused	O
by	O
traumatic	O
events	O
)	O
,	O
"	O
legal	O
situation	O
"	O
,	O
"	O
medical	O
history	O
"	O
,	O
"	O
physical	O
and	O
psychological	O
complaints	O
"	O
,	O
and	O
"	O
emotional	O
state	O
"	O
(	O
triggering	O
psychological	O
conditions	O
,	O
or	O
consequences	O
of	O
the	O
addictive	O
behaviour	O
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
Every	O
module	O
can	O
be	O
administered	O
separately	O
according	O
to	O
the	O
suspected	O
behavioural	O
addiction	O
,	O
thereby	O
making	O
the	O
FDAV	O
an	O
economical	O
tool	O
in	O
assessing	O
behavioural	O
addictions	O
.	O
</ALL>	O

<ALL>	O
The	O
FDAV	O
is	O
suitable	O
for	O
diagnostics	O
,	O
evaluation	O
of	O
therapy	O
and	O
follow	O
-	O
up	O
in	O
clinical	O
practice	O
and	O
research	O
.	O
</ALL>	O

<ALL>	O
Currently	O
,	O
the	O
FDAV	O
is	O
being	O
validated	O
in	O
clinical	O
and	O
non	O
-	O
clinical	O
samples	O
.	O
</ALL>	O

<ALL>	O
Click	O
here	O
for	O
file	O
</ALL>	O

<ALL>	O
Method	O
</ALL>	O

<ALL>	O
Results	O
:	O
</ALL>	O

<ALL>	O
All	O
fractures	O
united	O
.	O
</ALL>	O

<ALL>	O
Individual	O
movement	O
of	O
dorsiflexion	O
,	O
palmar	B-Organism_subdivision
flexion	O
,	O
supination	O
,	O
pronation	O
and	O
radial	B-Organ
-	O
ulnar	B-Organ
deviation	O
were	O
all	O
significantly	O
better	O
in	O
the	O
dorsiflexed	O
-	O
immobilized	O
group	O
as	O
compared	O
with	O
the	O
palmar	B-Organism_subdivision
flexed	O
immobilized	O
group	O
.	O
</ALL>	O

<ALL>	O
Grip	O
strength	O
recovery	O
with	O
subjective	O
assessment	O
was	O
better	O
in	O
the	O
dorsiflexed	O
group	O
(	O
77	O
%	O
)	O
as	O
compared	O
to	O
the	O
palmar	B-Organism_subdivision
flexed	O
group	O
(	O
23	O
%	O
)	O
.	O
</ALL>	O

<ALL>	O
Radiological	O
parameters	O
were	O
markedly	O
better	O
in	O
the	O
dorsiflexed	O
group	O
.	O
</ALL>	O

<ALL>	O
Ninety	O
-	O
one	O
per	O
cent	O
of	O
patients	O
in	O
the	O
dorsiflexed	O
group	O
had	O
excellent	O
to	O
good	O
results	O
as	O
compared	O
to	O
66	O
%	O
in	O
the	O
palmar	B-Organism_subdivision
flexed	O
group	O
.	O
</ALL>	O

<ALL>	O
3	O
.	O
2	O
.	O
</ALL>	O

<ALL>	O
Cell	B-Cell
line	I-Cell
and	O
culture	O
</ALL>	O

<ALL>	O
DU145	B-Cell
(	I-Cell
prostate	I-Cell
cancer	I-Cell
)	I-Cell
cell	I-Cell
line	I-Cell
was	O
used	O
in	O
this	O
assay	O
.	O
</ALL>	O

<ALL>	O
DU145	B-Cell
was	O
grown	O
in	O
DMEM	O
/	O
F	O
-	O
12	O
medium	O
(	O
Gibco	O
BRL	O
Life	O
Technologies	O
,	O
San	O
Diego	O
,	O
CA	O
.	O
,	O
USA	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	B-Developing_anatomical_structure
calf	O
serum	B-Organism_substance
and	O
kept	O
in	O
a	O
humidified	O
37	O
degreesC	O
,	O
5	O
%	O
CO2	O
incubator	O
.	O
</ALL>	O

<ALL>	O
Target	O
volumes	O
'	O
coverage	O
</ALL>	O

<ALL>	O
The	O
mean	O
PTV1	O
and	O
PTV2	O
volumes	O
were	O
452	O
cm3	O
(	O
range	O
276	O
-	O
1074	O
cm3	O
)	O
and	O
300	O
cm3	O
(	O
range	O
137	O
-	O
567	O
cm3	O
)	O
respectively	O
.	O
</ALL>	O

<ALL>	O
A	O
mean	O
of	O
>	O
98	O
%	O
(	O
range	O
92	O
-	O
100	O
%	O
)	O
of	O
the	O
PTV1	O
received	O
100	O
%	O
of	O
the	O
prescribed	O
dose	O
in	O
all	O
planning	O
methods	O
.	O
</ALL>	O

<ALL>	O
A	O
mean	O
of	O
95	O
.	O
5	O
%	O
and	O
95	O
.	O
7	O
%	O
of	O
the	O
PTV2	O
received	O
100	O
%	O
of	O
the	O
prescribed	O
dose	O
with	O
TOMO	O
and	O
IMRT	O
plans	O
respectively	O
.	O
</ALL>	O

<ALL>	O
A	O
mean	O
of	O
94	O
%	O
and	O
92	O
%	O
of	O
the	O
PTV2	O
received	O
100	O
%	O
of	O
the	O
prescribed	O
dose	O
with	O
IB	O
and	O
3D	O
treatment	O
plans	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
IB	O
and	O
3D	O
plans	O
PTV2	O
coverage	O
was	O
significantly	O
inferior	O
then	O
the	O
IMRT	O
and	O
TOMO	O
plans	O
(	O
p	O
<	O
0	O
.	O
02	O
,	O
for	O
all	O
comparisons	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
Inhomogeneity	O
Coefficient	O
(	O
IC	O
)	O
was	O
significantly	O
lower	O
(	O
better	O
)	O
with	O
the	O
TOMO	O
plans	O
,	O
compared	O
to	O
all	O
other	O
plans	O
for	O
both	O
PTV1	O
and	O
PTV2	O
(	O
p	O
<	O
0	O
.	O
0003	O
for	O
all	O
comparisons	O
)	O
(	O
figure	O
3	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
IC	O
of	O
the	O
IMRT	O
plans	O
was	O
significantly	O
higher	O
(	O
worse	O
)	O
than	O
the	O
mean	O
IC	O
of	O
the	O
3D	O
plans	O
regarding	O
PTV	O
1	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
and	O
higher	O
(	O
worse	O
)	O
then	O
the	O
mean	O
IC	O
of	O
the	O
IB	O
plans	O
regarding	O
PTV2	O
(	O
p	O
<	O
0	O
.	O
03	O
)	O
(	O
figure	O
3	O
)	O
.	O
</ALL>	O

<ALL>	O
No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
means	O
of	O
the	O
IC	O
of	O
the	O
3D	O
and	O
IB	O
plans	O
.	O
</ALL>	O

<ALL>	O
Figure	O
3	O
</ALL>	O

<ALL>	O
The	O
mean	O
Inhomogeneity	O
Coefficient	O
(	O
IC	O
)	O
achieved	O
by	O
the	O
different	O
planning	O
methods	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
of	O
the	O
Inhomogeneity	O
Coefficient	O
is	O
a	O
measure	O
of	O
dose	O
inhomogeneity	O
in	O
the	O
target	O
volumes	O
.	O
</ALL>	O

<ALL>	O
The	O
closer	O
the	O
IC	O
to	O
zero	O
,	O
the	O
more	O
homogenous	O
the	O
dose	O
is	O
.	O
</ALL>	O

<ALL>	O
RESEARCH	O
DESIGN	O
AND	O
METHODS	O
</ALL>	O

<ALL>	O
For	O
this	O
study	O
,	O
20	O
individuals	O
(	O
mean	O
age	O
39	O
.	O
5	O
+	O
/	O
-	O
11	O
.	O
1	O
years	O
)	O
with	O
long	O
-	O
standing	O
type	O
1	O
diabetes	O
(	O
21	O
.	O
3	O
+	O
/	O
-	O
10	O
.	O
7	O
years	O
)	O
were	O
enrolled	O
in	O
this	O
prospective	O
open	O
-	O
label	O
crossover	O
trial	O
.	O
</ALL>	O

<ALL>	O
After	O
achieving	O
optimal	O
blood	B-Organism_substance
glucose	O
control	O
,	O
16	O
subjects	O
were	O
randomized	O
to	O
exenatide	O
with	O
or	O
without	O
daclizumab	O
.	O
</ALL>	O

<ALL>	O
Endogenous	O
insulin	O
production	O
was	O
determined	O
by	O
repeatedly	O
measuring	O
serum	B-Organism_substance
C	O
-	O
peptide	O
.	O
</ALL>	O

<ALL>	O
Subjects	O
and	O
Methods	O
</ALL>	O

<ALL>	O
ABPM	O
was	O
conducted	O
for	O
60	O
selected	O
patients	O
who	O
had	O
visited	O
Sunlin	O
Hospital	O
between	O
January	O
2008	O
and	O
August	O
2008	O
.	O
</ALL>	O

<ALL>	O
Patients	O
were	O
classified	O
into	O
3	O
groups	O
;	O
an	O
obese	O
group	O
whose	O
body	B-Organism_subdivision
mass	O
index	O
(	O
BMI	O
)	O
was	O
>	O
the	O
95th	O
percentile	O
,	O
an	O
overweight	O
group	O
whose	O
BMI	O
was	O
>	O
the	O
85th	O
percentile	O
but	O
less	O
than	O
the	O
95th	O
percentile	O
,	O
and	O
a	O
normal	O
group	O
whose	O
BMI	O
was	O
below	O
the	O
85th	O
percentile	O
.	O
</ALL>	O

<ALL>	O
Overall	O
mean	O
BP	O
,	O
day	O
and	O
night	O
BP	O
and	O
BP	O
load	O
were	O
measured	O
by	O
ABPM	O
.	O
</ALL>	O

<ALL>	O
Surgery	O
</ALL>	O

<ALL>	O
Trabeculectomy	O
should	O
be	O
considered	O
in	O
all	O
patients	O
,	O
when	O
the	O
'	O
target	O
IOP	O
'	O
is	O
not	O
achieved	O
with	O
glaucoma	O
medications	O
and	O
if	O
the	O
expected	O
rate	O
of	O
visual	O
loss	O
could	O
affect	O
the	O
patient	O
during	O
their	O
lifetime	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
procedure	O
,	O
an	O
opening	O
is	O
made	O
in	O
the	O
trabecular	B-Organ
meshwork	O
,	O
so	O
that	O
aqueous	O
humor	B-Organism_substance
can	O
drain	O
into	O
the	O
sclera	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Many	O
patients	O
can	O
discontinue	O
glaucoma	O
medications	O
after	O
surgery	O
.	O
</ALL>	O

<ALL>	O
Approximately	O
one	O
-	O
third	O
of	O
the	O
trabeculectomy	O
patients	O
develop	O
cataract	O
within	O
five	O
years	O
.	O
</ALL>	O

<ALL>	O
If	O
trabeculectomy	O
fails	O
,	O
another	O
type	O
of	O
surgery	O
places	O
a	O
drainage	O
tube	O
(	O
Molteno	O
tube	O
)	O
in	O
the	O
eye	B-Organ
,	O
between	O
the	O
cornea	B-Multi-tissue_structure
and	O
iris	B-Multi-tissue_structure
,	O
which	O
exits	O
at	O
the	O
junction	O
of	O
the	O
cornea	B-Multi-tissue_structure
and	O
sclera	B-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Cyclodestructive	O
procedures	O
,	O
which	O
lower	O
IOP	O
by	O
destroying	O
the	O
ciliary	B-Multi-tissue_structure
body	I-Multi-tissue_structure
,	O
are	O
typically	O
reserved	O
for	O
eyes	B-Organ
,	O
which	O
are	O
refractory	O
to	O
all	O
other	O
forms	O
of	O
therapy	O
.	O
</ALL>	O

<ALL>	O
These	O
procedures	O
include	O
cyclocryotherapy	O
,	O
cylcodiathermy	O
and	O
laser	O
cyclophotocoagulation	O
.	O
[	O
91	O
-	O
93	O
]	O
</ALL>	O

<ALL>	O
Follow	O
-	O
up	O
</ALL>	O

<ALL>	O
Patients	O
were	O
followed	O
up	O
at	O
the	O
outpatient	O
clinic	O
at	O
1	O
,	O
4	O
,	O
and	O
7	O
months	O
after	O
the	O
ablation	O
procedure	O
and	O
every	O
6	O
months	O
thereafter	O
.	O
</ALL>	O

<ALL>	O
Routine	O
24	O
or	O
48	O
h	O
Holter	O
monitoring	O
was	O
performed	O
before	O
each	O
appointment	O
,	O
and	O
a	O
12	O
-	O
lead	O
electrocardiogram	O
was	O
obtained	O
at	O
each	O
visit	O
.	O
</ALL>	O

<ALL>	O
Patients	O
were	O
asked	O
to	O
report	O
to	O
the	O
emergency	O
room	O
or	O
our	O
arrhythmia	O
unit	O
for	O
an	O
ECG	O
if	O
any	O
symptom	O
suggestive	O
of	O
recurrence	O
occurred	O
between	O
scheduled	O
visits	O
.	O
</ALL>	O

<ALL>	O
After	O
the	O
ablation	O
procedure	O
,	O
all	O
patients	O
received	O
anti	O
-	O
arrhythmic	O
treatment	O
for	O
at	O
least	O
1	O
month	O
to	O
protect	O
against	O
early	O
recurrences	O
and	O
continued	O
oral	O
anticoagulation	O
for	O
a	O
minimum	O
of	O
2	O
months	O
to	O
maintain	O
an	O
international	O
normalized	O
ratio	O
between	O
2	O
.	O
0	O
and	O
3	O
.	O
0	O
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
magnetic	O
resonance	O
angiography	O
was	O
repeated	O
at	O
3	O
-	O
6	O
months	O
after	O
the	O
procedure	O
to	O
evaluate	O
the	O
presence	O
of	O
PV	O
stenosis	O
.	O
</ALL>	O

<ALL>	O
Arrhythmia	O
recurrence	O
was	O
defined	O
as	O
a	O
documented	O
AF	O
or	O
atrial	B-Multi-tissue_structure
flutter	O
episode	O
of	O
>	O
30	O
s	O
.	O
</ALL>	O

<ALL>	O
Arrhythmic	O
episodes	O
within	O
the	O
first	O
3	O
months	O
after	O
the	O
CPVA	O
(	O
healing	O
period	O
)	O
were	O
not	O
considered	O
in	O
the	O
evaluation	O
of	O
final	O
success	O
rates	O
because	O
they	O
are	O
often	O
described	O
as	O
transient	O
recurrences	O
related	O
to	O
atrial	B-Multi-tissue_structure
inflammatory	O
processes	O
following	O
RF	O
lesions	O
.	O
26	O
</ALL>	O

<ALL>	O
The	O
endpoint	O
of	O
the	O
study	O
was	O
freedom	O
from	O
arrhythmia	O
recurrence	O
after	O
a	O
single	O
CPVA	O
procedure	O
,	O
without	O
anti	O
-	O
arrhythmic	O
medication	O
.	O
</ALL>	O

<ALL>	O
A	O
minimum	O
follow	O
-	O
up	O
of	O
3	O
months	O
was	O
required	O
.	O
</ALL>	O

<ALL>	O
Electrostatic	O
interaction	O
energies	O
between	O
the	O
SNARE	O
complex	O
and	O
fusing	O
membranes	B-Cellular_component
.	O
</ALL>	O

<ALL>	O
(	O
A	O
)	O
Schematic	O
diagram	O
and	O
definitions	O
of	O
intermolecular	O
interaction	O
energies	O
presented	O
in	O
(	O
B	O
)	O
and	O
(	O
C	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
(	O
A	O
)	O
through	O
(	O
C	O
)	O
,	O
only	O
the	O
SNARE	O
core	O
complex	O
is	O
considered	O
.	O
</ALL>	O

<ALL>	O
Interaction	O
free	O
energies	O
are	O
calculated	O
for	O
(	O
B	O
)	O
a	O
series	O
of	O
SNARE	O
/	O
membrane	B-Cellular_component
distances	O
and	O
(	O
C	O
)	O
different	O
membrane	B-Cellular_component
lipid	O
compositions	O
.	O
</ALL>	O

<ALL>	O
Arrow	O
in	O
(	O
B	O
)	O
indicates	O
the	O
most	O
physiologically	O
relevant	O
distance	O
when	O
the	O
closest	O
points	O
between	O
SNARE	O
and	O
membranes	B-Cellular_component
are	O
3	O
A	O
,	O
the	O
thickness	O
of	O
a	O
layer	O
of	O
water	O
.	O
[	O
19	O
]	O
In	O
(	O
D	O
)	O
through	O
(	O
F	O
)	O
,	O
TMDs	O
of	O
VAMP	O
and	O
syntaxin	O
are	O
present	O
and	O
embedded	O
in	O
membranes	B-Cellular_component
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
the	O
C	O
-	O
terminus	O
of	O
the	O
SNARE	O
motif	O
is	O
partially	O
unraveled	O
into	O
individual	O
alpha	O
-	O
helices	O
by	O
molecular	O
dynamics	O
simulations	O
to	O
represent	O
trans	O
-	O
SNARE	O
complex	O
.	O
</ALL>	O

<ALL>	O
Interaction	O
free	O
energies	O
are	O
then	O
calculated	O
for	O
(	O
E	O
)	O
a	O
series	O
of	O
SNARE	O
motif	O
C	O
-	O
terminus	O
separation	O
distances	O
and	O
(	O
F	O
)	O
different	O
lipid	O
compositions	O
of	O
the	O
membranes	B-Cellular_component
.	O
</ALL>	O

<ALL>	O
Conclusions	O
drawn	O
from	O
both	O
groups	O
of	O
studies	O
are	O
essentially	O
the	O
same	O
.	O
</ALL>	O

<ALL>	O
V	O
(	O
circles	O
)	O
:	O
Interaction	O
energies	O
between	O
the	O
SNARE	O
complex	O
and	O
the	O
v	B-Cellular_component
-	I-Cellular_component
membrane	I-Cellular_component
.	O
</ALL>	O

<ALL>	O
T	O
(	O
squares	O
)	O
:	O
Interaction	O
energies	O
between	O
SNARE	O
and	O
the	O
t	B-Cellular_component
-	I-Cellular_component
membrane	I-Cellular_component
.	O
</ALL>	O

<ALL>	O
VT	O
(	O
triangles	O
)	O
:	O
Interaction	O
energies	O
between	O
the	O
v	B-Cellular_component
-	I-Cellular_component
and	O
the	O
t	B-Cellular_component
-	I-Cellular_component
membranes	I-Cellular_component
if	O
the	O
SNARE	O
complex	O
were	O
extracted	O
.	O
</ALL>	O

<ALL>	O
Demographic	O
data	O
of	O
subjects	O
</ALL>	O

<ALL>	O
1	O
.	O
</ALL>	O

<ALL>	O
Background	O
</ALL>	O

<ALL>	O
The	O
United	O
Republic	O
of	O
Tanzania	O
,	O
is	O
among	O
the	O
many	O
countries	O
in	O
sub	O
-	O
Saharan	O
Africa	O
facing	O
a	O
human	O
resources	O
crisis	O
in	O
its	O
health	O
sector	O
,	O
with	O
a	O
small	O
and	O
inequitably	O
distributed	O
health	O
workforce	O
[	O
1	O
]	O
that	O
shoulders	O
a	O
disproportionately	O
high	O
burden	O
of	O
disease	O
[	O
2	O
]	O
.	O
</ALL>	O

<ALL>	O
Although	O
all	O
poor	O
countries	O
in	O
the	O
world	O
face	O
a	O
severe	O
human	O
resource	O
crisis	O
in	O
their	O
health	O
sectors	O
[	O
3	O
,	O
4	O
]	O
,	O
the	O
problem	O
is	O
most	O
acute	O
in	O
Sub	O
-	O
Saharan	O
Africa	O
,	O
in	O
which	O
an	O
estimated	O
workforce	O
of	O
750	O
000	O
health	O
workers	O
in	O
the	O
region	O
serves	O
682	O
million	O
people	O
[	O
2	O
]	O
.	O
</ALL>	O

<ALL>	O
By	O
comparison	O
,	O
the	O
ratio	O
is	O
10	O
to	O
15	O
times	O
higher	O
in	O
developed	O
countries	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
this	O
estimated	O
workforce	O
of	O
doctors	O
,	O
nurses	O
and	O
allied	O
health	O
workers	O
in	O
Sub	O
-	O
Saharan	O
Africa	O
constitutes	O
1	O
.	O
3	O
%	O
of	O
the	O
world	O
'	O
s	O
health	O
workforce	O
,	O
while	O
Africa	O
suffers	O
from	O
25	O
%	O
of	O
the	O
world	O
'	O
s	O
burden	O
of	O
disease	O
[	O
2	O
]	O
.	O
</ALL>	O

<ALL>	O
A	O
minimum	O
level	O
of	O
a	O
health	O
workforce	O
of	O
2	O
.	O
5	O
health	O
workers	O
per	O
1000	O
people	O
is	O
required	O
to	O
achieve	O
the	O
Millennium	O
Development	O
Goals	O
[	O
5	O
]	O
.	O
</ALL>	O

<ALL>	O
Africa	O
is	O
far	O
from	O
this	O
level	O
with	O
a	O
health	O
workforce	O
density	O
that	O
only	O
averages	O
0	O
.	O
8	O
worker	O
per	O
1000	O
people	O
,	O
while	O
the	O
world	O
median	O
density	O
of	O
health	O
personnel	O
is	O
5	O
per	O
1000	O
people	O
[	O
5	O
]	O
.	O
</ALL>	O

<ALL>	O
There	O
is	O
a	O
positive	O
correlation	O
between	O
health	O
worker	O
density	O
and	O
various	O
health	O
indices	O
,	O
most	O
notably	O
infant	O
mortality	O
rate	O
,	O
maternal	O
mortality	O
rates	O
,	O
and	O
various	O
disease	O
specific	O
mortality	O
and	O
morbidity	O
rates	O
[	O
6	O
,	O
7	O
]	O
.	O
</ALL>	O

<ALL>	O
An	O
increase	O
in	O
the	O
number	O
of	O
health	O
workers	O
per	O
capita	O
is	O
associated	O
with	O
a	O
notable	O
decline	O
in	O
the	O
rates	O
mentioned	O
above	O
.	O
</ALL>	O

<ALL>	O
As	O
a	O
consequence	O
,	O
it	O
has	O
been	O
argued	O
that	O
health	O
worker	O
shortages	O
have	O
impeded	O
the	O
implementation	O
of	O
development	O
goals	O
in	O
many	O
poor	O
countries	O
[	O
8	O
]	O
.	O
</ALL>	O

<ALL>	O
CASE	O
:	O
</ALL>	O

<ALL>	O
Here	O
for	O
the	O
first	O
time	O
a	O
case	O
of	O
CDLS	O
from	O
Iran	O
,	O
a	O
15	O
-	O
week	O
-	O
old	O
male	O
infant	O
who	O
was	O
refereed	O
as	O
a	O
case	O
of	O
multiple	O
congenital	O
anomalies	O
.	O
</ALL>	O

<ALL>	O
Clinical	O
investigation	O
showed	O
that	O
the	O
child	O
was	O
a	O
case	O
of	O
CDLS	O
.	O
</ALL>	O

<ALL>	O
Applying	O
A1C	O
cut	O
offs	O
to	O
the	O
AusDiab	O
population	O
(	O
4	O
.	O
6	O
%	O
undiagnosed	O
diabetes	O
)	O
</ALL>	O

<ALL>	O
Applying	O
the	O
same	O
cut	O
offs	O
,	O
a	O
total	O
75	O
.	O
9	O
%	O
of	O
the	O
AusDiab	O
population	O
had	O
diabetes	O
ruled	O
in	O
or	O
ruled	O
out	O
(	O
Fig	O
.	O
1B	O
)	O
,	O
while	O
the	O
remaining	O
24	O
.	O
1	O
%	O
had	O
impaired	O
A1C	O
.	O
</ALL>	O

<ALL>	O
From	O
those	O
with	O
impaired	O
A1C	O
,	O
69	O
.	O
3	O
%	O
had	O
abnormal	O
glucose	O
status	O
.	O
</ALL>	O

<ALL>	O
For	O
diabetes	O
,	O
A1C	O
at	O
5	O
.	O
5	O
%	O
provided	O
moderate	O
sensitivity	O
(	O
83	O
.	O
5	O
%	O
)	O
but	O
high	O
NPV	O
(	O
99	O
.	O
0	O
%	O
)	O
,	O
since	O
diabetes	O
prevalence	O
was	O
lower	O
in	O
the	O
AusDiab	O
than	O
in	O
the	O
MP	O
population	O
.	O
</ALL>	O

<ALL>	O
A1C	O
at	O
7	O
.	O
0	O
%	O
gave	O
100	O
%	O
specificity	O
and	O
100	O
%	O
PPV	O
.	O
</ALL>	O

<ALL>	O
By	O
dropping	O
the	O
cut	O
off	O
to	O
6	O
.	O
5	O
%	O
,	O
specificity	O
remained	O
99	O
.	O
9	O
%	O
,	O
with	O
PPV	O
near	O
100	O
%	O
.	O
</ALL>	O

<ALL>	O
Calcium	O
intake	O
and	O
effects	O
on	O
QUS	O
T	O
-	O
score	O
</ALL>	O

<ALL>	O
Figure	O
5	O
shows	O
the	O
amounts	O
of	O
dietary	O
calcium	O
intake	O
according	O
to	O
menopausal	O
status	O
.	O
</ALL>	O

<ALL>	O
Calcium	O
consumption	O
in	O
most	O
groups	O
,	O
like	O
that	O
in	O
the	O
study	O
population	O
as	O
a	O
whole	O
,	O
was	O
inadequate	O
.	O
</ALL>	O

<ALL>	O
Fewer	O
than	O
one	O
third	O
of	O
premenopausal	O
and	O
postmenopausal	O
women	O
received	O
more	O
than	O
800	O
mg	O
calcium	O
daily	O
,	O
and	O
fewer	O
than	O
16	O
%	O
of	O
premenopausal	O
women	O
in	O
the	O
50	O
-	O
59	O
age	O
decade	O
(	O
n	O
=	O
38	O
)	O
consumed	O
more	O
than	O
800	O
mg	O
calcium	O
daily	O
.	O
</ALL>	O

<ALL>	O
Figure	O
5	O
</ALL>	O

<ALL>	O
Daily	O
calcium	O
intake	O
in	O
premenopausal	O
and	O
postmenopausal	O
women	O
.	O
</ALL>	O

<ALL>	O
This	O
figure	O
depicts	O
the	O
daily	O
amounts	O
of	O
dietary	O
calcium	O
intake	O
(	O
and	O
percent	O
)	O
according	O
to	O
menopausal	O
status	O
using	O
800	O
mg	O
daily	O
as	O
cut	O
off	O
point	O
.	O
</ALL>	O

<ALL>	O
QUS	O
T	O
-	O
score	O
were	O
then	O
calculated	O
according	O
to	O
daily	O
calcium	O
intake	O
in	O
all	O
premenopausal	O
and	O
postmenopausal	O
activity	O
groups	O
using	O
800	O
mg	O
daily	O
calcium	O
as	O
cutoff	O
point	O
.	O
</ALL>	O

<ALL>	O
As	O
shown	O
in	O
Tables	O
3	O
and	O
4	O
and	O
Figure	O
6	O
,	O
premenopausal	O
women	O
who	O
were	O
systematically	O
active	O
and	O
consumed	O
more	O
than	O
800	O
mg	O
calcium	O
daily	O
had	O
significantly	O
higher	O
QUS	O
T	O
-	O
scores	O
compared	O
with	O
all	O
other	O
activity	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
</ALL>	O

<ALL>	O
Among	O
systematically	O
active	O
premenopausal	O
women	O
who	O
received	O
more	O
than	O
800	O
mg	O
calcium	O
per	O
day	O
,	O
this	O
difference	O
was	O
separately	O
significant	O
verses	O
sedentary	O
(	O
p	O
=	O
0	O
.	O
028	O
)	O
and	O
moderately	O
active	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
women	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
postmenopausal	O
women	O
showed	O
no	O
difference	O
in	O
QUS	O
T	O
-	O
scores	O
regardless	O
of	O
the	O
amount	O
of	O
daily	O
calcium	O
intake	O
.	O
</ALL>	O

<ALL>	O
Figure	O
6	O
</ALL>	O

<ALL>	O
Synergy	O
between	O
physical	O
activity	O
and	O
dietary	O
calcium	O
intake	O
in	O
women	O
consuming	O
calcium	O
amounts	O
greater	O
than	O
800	O
mg	O
/	O
day	O
.	O
</ALL>	O

<ALL>	O
This	O
graphic	O
depicts	O
mean	O
QUS	O
T	O
-	O
score	O
values	O
calculated	O
according	O
to	O
daily	O
calcium	O
intake	O
in	O
all	O
premenopausal	O
and	O
postmenopausal	O
activity	O
groups	O
using	O
800	O
mg	O
daily	O
as	O
cut	O
off	O
point	O
(	O
for	O
statistical	O
significant	O
values	O
see	O
text	O
)	O
.	O
</ALL>	O

<ALL>	O
CONCLUSIONS	O
</ALL>	O

<ALL>	O
The	O
lack	O
of	O
association	O
between	O
depression	O
and	O
glycemic	O
control	O
is	O
not	O
due	O
to	O
the	O
use	O
of	O
a	O
binary	O
measure	O
of	O
depression	O
.	O
</ALL>	O

<ALL>	O
Findings	O
further	O
clarify	O
the	O
significant	O
association	O
between	O
distress	O
and	O
A1C	O
.	O
</ALL>	O

<ALL>	O
Discussion	O
</ALL>	O

<ALL>	O
This	O
is	O
the	O
first	O
study	O
to	O
employ	O
such	O
a	O
large	O
number	O
of	O
replicated	O
samples	O
in	O
order	O
to	O
assess	O
the	O
bacterial	O
communities	O
of	O
healthy	O
and	O
diseased	O
corals	O
,	O
and	O
the	O
first	O
culture	O
-	O
independent	O
assessment	O
of	O
bacterial	O
communities	O
on	O
Acroporid	O
WS	O
corals	O
on	O
the	O
GBR	O
.	O
</ALL>	O

<ALL>	O
Despite	O
the	O
potential	O
of	O
not	O
capturing	O
rare	O
or	O
very	O
low	O
abundance	O
bacterial	O
ribotypes	O
,	O
the	O
DGGE	O
analysis	O
used	O
in	O
this	O
study	O
indicated	O
similar	O
results	O
of	O
captured	O
bacterial	O
ribotypes	O
and	O
tentative	O
bacterial	O
species	O
replacement	O
in	O
unhealthy	O
corals	O
to	O
that	O
of	O
less	O
replicated	O
studies	O
using	O
other	O
non	O
-	O
culture	O
based	O
techniques	O
(	O
e	O
.	O
g	O
.	O
[	O
3	O
]	O
,	O
[	O
54	O
]	O
,	O
[	O
69	O
]	O
;	O
Figure	O
4	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
from	O
this	O
research	O
reinforce	O
,	O
with	O
statistically	O
relevant	O
data	O
,	O
that	O
corals	O
harbour	O
bacterial	O
communities	O
different	O
to	O
the	O
water	O
column	O
[	O
7	O
]	O
,	O
[	O
9	O
]	O
,	O
[	O
42	O
]	O
,	O
corroborate	O
findings	O
that	O
corals	O
associate	O
only	O
with	O
certain	O
specific	O
bacterial	O
groups	O
,	O
and	O
that	O
these	O
coral	O
-	O
associated	O
bacterial	O
communities	O
are	O
'	O
host	O
'	O
species	O
-	O
specific	O
[	O
2	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
data	O
presented	O
here	O
highlight	O
a	O
cluster	O
of	O
bacterial	O
ribotypes	O
frequently	O
associated	O
with	O
corals	O
,	O
and	O
the	O
distribution	O
of	O
these	O
bacterial	O
ribotypes	O
on	O
healthy	O
and	O
diseased	O
corals	O
,	O
which	O
allows	O
for	O
further	O
targeted	O
research	O
into	O
a	O
tentative	O
link	O
between	O
these	O
common	O
coral	O
associates	O
and	O
coral	O
health	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
indicates	O
that	O
coral	O
bacterial	O
community	O
assessments	O
require	O
a	O
number	O
of	O
replicates	O
per	O
coral	O
species	O
and	O
site	O
to	O
accurately	O
describe	O
the	O
diversity	O
present	O
across	O
the	O
population	O
and	O
in	O
order	O
to	O
draw	O
inferences	O
on	O
health	O
-	O
related	O
changes	O
in	O
the	O
community	O
composition	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
comparisons	O
of	O
healthy	O
and	O
diseased	O
Acropora	O
hyacinthus	O
samples	O
showed	O
that	O
bacterial	O
communities	O
can	O
change	O
dramatically	O
in	O
diseased	O
individuals	O
.	O
</ALL>	O

<ALL>	O
The	O
DGGE	O
profiles	O
observed	O
for	O
corals	O
displaying	O
signs	O
of	O
White	O
Syndrome	O
comprised	O
a	O
range	O
of	O
bacterial	O
ribotypes	O
not	O
generally	O
found	O
on	O
healthy	O
corals	O
,	O
including	O
close	O
relatives	O
of	O
bacteria	O
previously	O
found	O
on	O
Black	O
Band	O
Diseased	O
corals	O
.	O
</ALL>	O

<ALL>	O
However	O
the	O
community	O
profiles	O
across	O
the	O
samples	O
taken	O
from	O
diseased	O
coral	O
colonies	O
were	O
inconsistent	O
and	O
not	O
indicative	O
of	O
a	O
single	O
bacterial	O
causative	O
agent	O
.	O
</ALL>	O

<ALL>	O
The	O
eukaryotic	O
parasite	O
Trypanosoma	O
brucei	O
is	O
able	O
to	O
import	O
inositol	O
from	O
the	O
environment	O
or	O
synthesize	O
it	O
de	O
novo	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
according	O
to	O
the	O
current	O
model	O
,	O
inositol	O
imported	O
from	O
the	O
environment	O
is	O
utilized	O
primarily	O
in	O
bulk	O
phosphatidylinositol	O
(	O
red	O
and	O
yellow	O
phospholipid	O
)	O
production	O
via	O
a	O
phosphatidylinositol	O
synthase	O
(	O
PIS	O
)	O
localized	O
to	O
the	O
Golgi	B-Cellular_component
complex	I-Cellular_component
.	O
</ALL>	O

<ALL>	O
Inositol	O
synthesized	O
de	O
novo	O
is	O
primarily	O
used	O
to	O
generate	O
phosphatidylinositol	O
that	O
is	O
used	O
for	O
production	O
of	O
glycosylphosphatidylinositols	O
(	O
GPIs	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
de	O
novo	O
-	O
synthesized	O
inositol	O
is	O
believed	O
to	O
be	O
utilized	O
mostly	O
for	O
GPI	O
production	O
because	O
the	O
IMPase	O
that	O
dephosphorylates	O
inositol	O
3	O
-	O
phosphate	O
to	O
inositol	O
is	O
localized	O
to	O
the	O
ER	O
,	O
where	O
GPI	O
synthesis	O
occurs	O
.	O
</ALL>	O

<ALL>	O
Mutants	O
lacking	O
TbINO1	O
are	O
inviable	O
because	O
of	O
diminished	O
GPI	O
production	O
.	O
</ALL>	O

<ALL>	O
Large	O
nodular	B-Pathological_formation
hepatic	I-Pathological_formation
flexure	I-Pathological_formation
lesions	I-Pathological_formation
as	O
seen	O
on	O
Colonoscopy	O
.	O
</ALL>	O

<ALL>	O
Water	O
emerging	O
from	O
the	O
yoke	O
adapter	O
of	O
the	O
nitrous	O
oxide	O
hose	O
</ALL>	O

<ALL>	O
The	O
pedigree	O
of	O
a	O
Korean	O
family	O
with	O
macular	B-Tissue
dystrophy	O
demonstrating	O
the	O
characteristics	O
of	O
an	O
autosomal	O
dominant	O
inheritance	O
trait	O
.	O
</ALL>	O

<ALL>	O
Histological	O
analysis	O
</ALL>	O

<ALL>	O
A	O
cross	O
-	O
section	O
of	O
the	O
distal	B-Multi-tissue_structure
colon	I-Multi-tissue_structure
(	O
2	O
cm	O
)	O
was	O
fixed	O
in	O
10	O
%	O
paraformaldehyde	O
solution	O
.	O
</ALL>	O

<ALL>	O
Afterwards	O
,	O
it	O
was	O
cut	O
into	O
small	O
fragments	O
,	O
dehydrated	O
through	O
an	O
ethanol	O
series	O
(	O
70	O
%	O
-	O
100	O
%	O
)	O
,	O
cleared	O
in	O
xylol	O
and	O
embedded	O
in	O
paraffin	O
.	O
</ALL>	O

<ALL>	O
The	O
fragments	B-Multi-tissue_structure
were	O
sliced	O
into	O
5	O
mum	O
thick	O
sections	O
and	O
stained	O
with	O
hematoxylin	O
-	O
eosin	O
.	O
</ALL>	O

<ALL>	O
Histological	O
evaluation	O
was	O
done	O
by	O
a	O
pathologist	O
who	O
was	O
blinded	O
to	O
the	O
experimental	O
groups	O
,	O
and	O
it	O
was	O
based	O
on	O
the	O
intensity	O
of	O
mononuclear	O
and	O
polymorphonuclear	O
infiltrates	O
in	O
the	O
lamina	B-Tissue
propria	I-Tissue
,	O
crypt	B-Immaterial_anatomical_entity
dilation	O
,	O
cellular	B-Cell
destruction	O
and	O
mucosal	B-Multi-tissue_structure
ulceration	O
.	O
</ALL>	O

<ALL>	O
Histopathological	O
changes	O
were	O
graded	O
according	O
to	O
the	O
degree	O
of	O
inflammation	O
using	O
the	O
following	O
scale	O
:	O
absent	O
(	O
0	O
)	O
,	O
light	O
(	O
1	O
)	O
,	O
moderate	O
(	O
2	O
)	O
and	O
intense	O
(	O
3	O
)	O
,	O
and	O
the	O
numbers	O
represented	O
the	O
inflammation	O
score	O
(	O
IS	O
)	O
.	O
</ALL>	O

<ALL>	O
Results	O
were	O
expressed	O
as	O
mean	O
values	O
of	O
IS	O
+	O
/	O
-	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
for	O
each	O
experimental	O
group	O
.	O
</ALL>	O

<ALL>	O
Pteris	O
vittata	O
</ALL>	O

<ALL>	O
Intervention	O
</ALL>	O

<ALL>	O
Patients	O
'	O
initial	O
introduction	O
to	O
the	O
Wrist	B-Organism_subdivision
Extension	O
Dynasplint	O
(	O
WED	O
)	O
system	O
,	O
[	O
Dynasplint	O
Systems	O
,	O
Inc	O
.	O
,	O
Severna	O
Park	O
,	O
MD	O
,	O
USA	O
]	O
included	O
customized	O
fitting	O
(	O
wrist	B-Organism_subdivision
length	O
,	O
width	O
,	O
and	O
girth	O
so	O
that	O
the	O
force	O
and	O
counter	O
force	O
straps	O
could	O
be	O
properly	O
aligned	O
)	O
and	O
training	O
on	O
donning	O
and	O
doffing	O
of	O
the	O
device	O
.	O
</ALL>	O

<ALL>	O
(	O
See	O
figure	O
1	O
.	O
)	O
Verbal	O
and	O
written	O
instructions	O
were	O
provided	O
throughout	O
the	O
duration	O
of	O
treatment	O
for	O
safety	O
,	O
general	O
wear	O
and	O
care	O
,	O
and	O
tension	O
setting	O
goals	O
based	O
on	O
patient	O
tolerance	O
.	O
</ALL>	O

<ALL>	O
Figure	O
1	O
</ALL>	O

<ALL>	O
Wrist	B-Organism_subdivision
Extension	O
Dynasplint	O
.	O
</ALL>	O

<ALL>	O
Each	O
patient	O
initially	O
wore	O
the	O
WED	O
for	O
4	O
-	O
6	O
continuous	O
hours	O
at	O
an	O
initial	O
tension	O
setting	O
of	O
#	O
2	O
(	O
0	O
.	O
1	O
foot	O
pounds	O
of	O
torque	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
duration	O
was	O
for	O
acclimatization	O
to	O
the	O
system	O
;	O
then	O
patients	O
were	O
instructed	O
to	O
wear	O
the	O
WED	O
system	O
at	O
night	O
while	O
sleeping	O
for	O
6	O
-	O
8	O
hours	O
of	O
continuous	O
wear	O
.	O
</ALL>	O

<ALL>	O
After	O
each	O
patient	O
was	O
comfortable	O
wearing	O
the	O
unit	O
for	O
one	O
week	O
at	O
tension	O
level	O
#	O
2	O
,	O
they	O
were	O
instructed	O
to	O
increase	O
the	O
tension	O
level	O
to	O
#	O
3	O
(	O
0	O
.	O
3	O
ft	O
lbs	O
.	O
)	O
and	O
make	O
continual	O
increases	O
every	O
two	O
weeks	O
.	O
</ALL>	O

<ALL>	O
If	O
prolonged	O
soreness	O
followed	O
a	O
session	O
(	O
soreness	O
for	O
more	O
than	O
15	O
minutes	O
)	O
the	O
patient	O
was	O
instructed	O
to	O
decrease	O
the	O
tension	O
one	O
half	O
a	O
setting	O
for	O
two	O
days	O
until	O
they	O
were	O
comfortable	O
wearing	O
it	O
for	O
6	O
-	O
8	O
hours	O
at	O
the	O
new	O
tension	O
setting	O
.	O
</ALL>	O

<ALL>	O
The	O
majority	O
of	O
all	O
patients	O
reached	O
level	O
#	O
5	O
(	O
0	O
.	O
8	O
foot	O
pounds	O
of	O
torque	O
)	O
by	O
the	O
end	O
of	O
two	O
months	O
.	O
</ALL>	O

<ALL>	O
All	O
range	O
of	O
motion	O
measurements	O
were	O
recorded	O
by	O
the	O
prescribing	O
clinician	O
.	O
</ALL>	O

<ALL>	O
Animals	O
</ALL>	O

<ALL>	O
STOP	O
null	O
mice	O
and	O
their	O
WT	O
littermates	O
were	O
generated	O
on	O
a	O
mixed	O
BALBc	O
/	O
129	O
SvPas	O
and	O
on	O
a	O
pure	O
129	O
SvPas	O
background	O
as	O
previously	O
reported	O
by	O
Andrieux	O
et	O
al	O
.	O
</ALL>	O

<ALL>	O
[	O
4	O
]	O
.	O
</ALL>	O

<ALL>	O
All	O
animals	O
used	O
in	O
the	O
study	O
underwent	O
immunohistochemistry	O
for	O
the	O
detection	O
of	O
STOP	O
protein	O
,	O
resulting	O
in	O
no	O
staining	O
in	O
STOP	O
null	O
mice	O
,	O
and	O
genotyping	O
by	O
PCR	O
as	O
described	O
by	O
Andrieux	O
et	O
al	O
.	O
</ALL>	O

<ALL>	O
[	O
4	O
]	O
.	O
</ALL>	O

<ALL>	O
All	O
mice	O
were	O
kept	O
under	O
standard	O
housing	O
conditions	O
with	O
a	O
12	O
-	O
hour	O
/	O
12	O
-	O
hour	O
dark	O
-	O
light	O
cycle	O
.	O
</ALL>	O

<ALL>	O
The	O
experiments	O
were	O
carried	O
out	O
in	O
accordance	O
with	O
the	O
European	O
Communities	O
Council	O
Directive	O
of	O
24	O
November	O
1986	O
(	O
86	O
/	O
609	O
/	O
EEC	O
)	O
,	O
and	O
the	O
French	O
Department	O
of	O
Agriculture	O
(	O
License	O
Ndegrees	O
67	O
-	O
95	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
protocol	O
was	O
approved	O
by	O
the	O
ethical	O
Animal	O
Research	O
Committee	O
of	O
Louis	O
Pasteur	O
University	O
(	O
CREMEAS	O
#	O
AL	O
/	O
01	O
/	O
19	O
/	O
10	O
/	O
07	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
first	O
experiment	O
,	O
we	O
searched	O
for	O
differences	O
in	O
glomerular	B-Multi-tissue_structure
ultrastructure	O
and	O
peripheral	O
neurogenesis	O
between	O
WT	O
and	O
STOP	O
null	O
mice	O
:	O
a	O
first	O
group	O
of	O
24	O
mice	O
,	O
3	O
-	O
to	O
6	O
-	O
month	O
-	O
old	O
,	O
was	O
used	O
for	O
ultrastructural	O
study	O
of	O
the	O
OBs	O
;	O
a	O
second	O
group	O
of	O
13	O
animals	O
was	O
used	O
to	O
analyse	O
proliferation	O
and	O
apoptosis	O
in	O
the	O
OE	B-Tissue
and	O
VNE	B-Tissue
on	O
paraffin	B-Tissue
sections	I-Tissue
in	O
3	O
-	O
month	O
-	O
old	O
mice	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
second	O
experiment	O
we	O
analysed	O
,	O
in	O
WT	O
and	O
STOP	O
null	O
mice	O
,	O
the	O
effect	O
of	O
OE	B-Tissue
regeneration	O
on	O
glomeruli	B-Multi-tissue_structure
structure	O
and	O
ultrastructure	O
and	O
on	O
peripheral	O
neurogenesis	O
at	O
two	O
age	O
times	O
(	O
3	O
and	O
10	O
months	O
)	O
.	O
</ALL>	O

<ALL>	O
Effect	O
of	O
the	O
deletion	O
of	O
IRE1alpha	O
on	O
the	O
liver	B-Organ
.	O
</ALL>	O

<ALL>	O
(	O
A	O
)	O
HE	O
-	O
stained	O
sections	B-Tissue
of	O
the	O
liver	B-Tissue
tissue	I-Tissue
(	O
scale	O
bar	O
:	O
50	O
mum	O
)	O
.	O
</ALL>	O

<ALL>	O
(	O
B	O
)	O
Comparison	O
of	O
the	O
serum	B-Organism_substance
AST	O
and	O
ALT	O
levels	O
between	O
the	O
IRE1alpha	O
CKO	O
mice	O
and	O
the	O
control	O
mice	O
.	O
</ALL>	O

<ALL>	O
Data	O
are	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
(	O
n	O
=	O
5	O
)	O
.	O
</ALL>	O

<ALL>	O
(	O
C	O
)	O
Quantitative	O
PCR	O
analysis	O
of	O
lipid	O
synthesis	O
genes	O
in	O
the	O
liver	B-Organ
of	O
mice	O
fed	O
normal	O
or	O
high	O
-	O
fructose	O
feed	O
.	O
</ALL>	O

<ALL>	O
Columns	O
indicate	O
mean	O
and	O
error	O
bars	O
denote	O
S	O
.	O
E	O
.	O
M	O
(	O
n	O
=	O
3	O
)	O
.	O
</ALL>	O

<ALL>	O
All	O
the	O
data	O
were	O
obtained	O
from	O
20	O
weeks	O
old	O
male	O
mice	O
.	O
</ALL>	O

<ALL>	O
2	O
.	O
</ALL>	O

<ALL>	O
Methods	O
</ALL>	O

<ALL>	O
Summary	O
of	O
instrument	O
characteristics	O
</ALL>	O

<ALL>	O
Histology	O
of	O
the	O
lung	B-Organ
</ALL>	O

<ALL>	O
The	O
left	O
lung	B-Organ
was	O
fixed	O
by	O
gentle	O
infusion	O
of	O
fixative	O
(	O
4	O
%	O
paraformaldehyde	O
)	O
through	O
the	O
tracheal	B-Multi-tissue_structure
cannula	O
[	O
24	O
]	O
.	O
</ALL>	O

<ALL>	O
After	O
excision	O
,	O
the	O
lung	B-Organ
was	O
immersed	O
in	O
a	O
fresh	O
fixative	O
for	O
2	O
h	O
.	O
</ALL>	O

<ALL>	O
The	O
lung	B-Multi-tissue_structure
lobe	I-Multi-tissue_structure
was	O
embedded	O
in	O
paraffin	O
and	O
cut	O
into	O
3	O
mum	O
transverse	O
sections	O
,	O
followed	O
by	O
immunohistochemical	O
and	O
chemical	O
staining	O
.	O
</ALL>	O

<ALL>	O
Photomicrographs	O
were	O
captured	O
using	O
KS400	O
image	O
analyze	O
platform	O
(	O
Zeiss	O
,	O
Oberkochen	O
,	O
Germany	O
)	O
and	O
analyzed	O
quantitatively	O
.	O
</ALL>	O

<ALL>	O
Data	O
collection	O
:	O
CrystalClear	O
(	O
Rigaku	O
/	O
MSC	O
,	O
2005	O
>	O
)	O
;	O
cell	B-Cell
refinement	O
:	O
CrystalClear	O
;	O
data	O
reduction	O
:	O
CrystalClear	O
;	O
program	O
(	O
s	O
)	O
used	O
to	O
solve	O
structure	O
:	O
SHELXS97	O
(	O
Sheldrick	O
,	O
2008	O
>	O
)	O
;	O
program	O
(	O
s	O
)	O
used	O
to	O
refine	O
structure	O
:	O
SHELXL97	O
(	O
Sheldrick	O
,	O
2008	O
>	O
)	O
;	O
molecular	O
graphics	O
:	O
ORTEPII	O
(	O
Johnson	O
,	O
1976	O
>	O
)	O
;	O
software	O
used	O
to	O
prepare	O
material	O
for	O
publication	O
:	O
SHELXL97	O
.	O
</ALL>	O

<ALL>	O
Experimental	O
</ALL>	O

<ALL>	O
The	O
molecular	O
structure	O
of	O
(	O
I	O
)	O
,	O
showing	O
displacement	O
ellipsoids	O
at	O
the	O
30	O
%	O
probability	O
level	O
for	O
non	O
-	O
H	O
atoms	O
.	O
</ALL>	O

<ALL>	O
Discussion	O
</ALL>	O

<ALL>	O
Our	O
results	O
indicate	O
beneficial	O
effects	O
of	O
motivational	O
incentives	O
on	O
cognitive	O
performance	O
and	O
alleviating	O
effects	O
on	O
cognitive	O
decline	O
.	O
</ALL>	O

<ALL>	O
These	O
beneficial	O
effects	O
were	O
evident	O
in	O
healthy	O
young	O
and	O
older	O
adults	O
and	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
.	O
</ALL>	O

<ALL>	O
Young	O
adults	O
showed	O
improved	O
antisaccade	O
preparation	O
when	O
a	O
reward	O
was	O
at	O
stake	O
;	O
older	O
adults	O
and	O
PD	O
patients	O
could	O
utilize	O
reward	O
prospect	O
to	O
improve	O
their	O
impaired	O
antisaccade	O
preparation	O
.	O
</ALL>	O

<ALL>	O
Elderly	O
participants	O
and	O
PD	O
patients	O
were	O
not	O
only	O
better	O
prepared	O
by	O
means	O
of	O
commonly	O
used	O
preparatory	O
aids	O
(	O
i	O
.	O
e	O
.	O
,	O
more	O
preparation	O
time	O
and	O
advance	O
information	O
on	O
the	O
upcoming	O
response	O
)	O
but	O
also	O
by	O
means	O
of	O
motivational	O
incentives	O
.	O
</ALL>	O

<ALL>	O
These	O
beneficial	O
effects	O
of	O
motivational	O
incentives	O
on	O
cognitive	O
action	O
preparation	O
in	O
healthy	O
and	O
pathological	O
aging	O
further	O
support	O
views	O
that	O
question	O
the	O
notion	O
of	O
monotonic	O
deterioration	O
of	O
cognitive	O
function	O
with	O
age	O
(	O
Allen	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O
</ALL>	O

<ALL>	O
They	O
indicate	O
that	O
age	O
-	O
related	O
declines	O
can	O
be	O
modulated	O
by	O
emotion	O
-	O
cognition	O
interactions	O
.	O
</ALL>	O

<ALL>	O
In	O
line	O
with	O
the	O
predominant	O
view	O
that	O
cognitive	O
control	O
deteriorates	O
in	O
aging	O
and	O
Parkinson	O
'	O
s	O
disease	O
,	O
and	O
in	O
line	O
with	O
previous	O
findings	O
on	O
age	O
-	O
related	O
changes	O
in	O
antisaccade	O
control	O
specifically	O
(	O
Eenshuistra	O
et	O
al	O
.	O
,	O
2004	O
;	O
Chan	O
et	O
al	O
.	O
,	O
2005	O
;	O
Amador	O
et	O
al	O
.	O
,	O
2006	O
;	O
Abel	O
and	O
Douglas	O
,	O
2007	O
)	O
,	O
the	O
current	O
results	O
showed	O
decline	O
in	O
antisaccade	O
preparation	O
in	O
PD	O
patients	O
with	O
severe	O
motor	O
symptoms	O
as	O
compared	O
to	O
healthy	O
seniors	O
.	O
</ALL>	O

<ALL>	O
Mild	O
-	O
symptom	O
patients	O
and	O
healthy	O
elderly	O
did	O
not	O
differ	O
in	O
antisaccade	O
preparation	O
.	O
</ALL>	O

<ALL>	O
Healthy	O
seniors	O
showed	O
declining	O
antisaccade	O
preparation	O
as	O
compared	O
to	O
young	O
adults	O
.	O
</ALL>	O

<ALL>	O
Decline	O
was	O
evident	O
on	O
several	O
oculomotor	B-Multi-tissue_structure
parameters	O
and	O
most	O
pronounced	O
on	O
antisaccade	O
onset	O
latencies	O
.	O
</ALL>	O

<ALL>	O
In	O
line	O
with	O
the	O
notion	O
that	O
in	O
general	O
,	O
elderly	O
tend	O
to	O
prefer	O
accuracy	O
over	O
speed	O
,	O
elderly	O
showed	O
no	O
decreased	O
antisaccade	O
accuracy	O
as	O
compared	O
to	O
young	O
adults	O
.	O
</ALL>	O

<ALL>	O
As	O
compared	O
to	O
the	O
young	O
group	O
,	O
elderly	O
and	O
PD	O
patients	O
exhibited	O
slightly	O
,	O
but	O
not	O
significantly	O
more	O
premature	O
eye	B-Organ
movements	O
.	O
</ALL>	O

<ALL>	O
Premature	O
eye	B-Organ
movements	O
,	O
however	O
significantly	O
increased	O
in	O
elderly	O
and	O
PD	O
patients	O
but	O
only	O
slightly	O
in	O
the	O
young	O
,	O
when	O
more	O
specific	O
information	O
on	O
the	O
upcoming	O
movement	O
was	O
available	O
in	O
advance	O
.	O
</ALL>	O

<ALL>	O
Presumably	O
,	O
this	O
increase	O
in	O
premature	O
eye	B-Organ
movements	O
reflects	O
difficulties	O
with	O
the	O
inhibition	O
of	O
externally	O
guided	O
movement	O
and	O
/	O
or	O
the	O
suppression	O
of	O
strongly	O
activated	O
prepotent	O
action	O
plans	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
one	O
hand	O
,	O
the	O
choice	O
for	O
medicated	O
PD	O
patients	O
represents	O
a	O
limitation	O
of	O
the	O
current	O
study	O
as	O
we	O
cannot	O
exclude	O
differential	O
effects	O
of	O
medication	O
on	O
behavior	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
other	O
hand	O
,	O
PD	O
patients	O
generally	O
take	O
medication	O
in	O
their	O
daily	O
routine	O
,	O
such	O
that	O
the	O
results	O
can	O
be	O
generalized	O
to	O
clinical	O
practice	O
.	O
</ALL>	O

<ALL>	O
Exploratory	O
analysis	O
within	O
the	O
PD	O
patient	O
group	O
revealed	O
that	O
patients	O
with	O
more	O
severe	O
motoric	O
symptoms	O
(	O
as	O
indexed	O
by	O
their	O
motoric	O
subscore	O
on	O
the	O
UPDRS	O
)	O
displayed	O
more	O
signs	O
of	O
antisaccade	O
decline	O
,	O
such	O
as	O
longer	O
antisaccade	O
latencies	O
and	O
lower	O
accuracy	O
compared	O
to	O
mildly	O
affected	O
patients	O
,	O
who	O
initiated	O
saccades	O
equally	O
fast	O
as	O
healthy	O
adults	O
.	O
</ALL>	O

<ALL>	O
This	O
suggests	O
that	O
dopaminergic	O
medication	O
was	O
not	O
sufficient	O
to	O
raise	O
the	O
patient	O
'	O
s	O
antisaccadic	O
preparation	O
up	O
to	O
the	O
level	O
of	O
the	O
healthy	O
older	O
adults	O
.	O
</ALL>	O

<ALL>	O
One	O
intriguing	O
observation	O
was	O
that	O
despite	O
the	O
different	O
extents	O
of	O
observed	O
antisaccade	O
performance	O
decline	O
in	O
elderly	O
and	O
PD	O
patients	O
,	O
reward	O
prospect	O
led	O
to	O
beneficial	O
effects	O
on	O
antisaccade	O
latency	O
and	O
accuracy	O
in	O
young	O
,	O
elderly	O
,	O
and	O
PD	O
patients	O
alike	O
.	O
</ALL>	O

<ALL>	O
Young	O
,	O
elderly	O
and	O
PD	O
patients	O
benefited	O
from	O
reward	O
prospect	O
to	O
the	O
same	O
extent	O
,	O
confirming	O
that	O
the	O
expectancy	O
of	O
reward	O
is	O
a	O
powerful	O
mediator	O
of	O
cognitive	O
control	O
,	O
even	O
if	O
cognitive	O
control	O
suffers	O
from	O
decline	O
.	O
</ALL>	O

<ALL>	O
The	O
expectation	O
of	O
rewarding	O
incentives	O
thus	O
seems	O
to	O
support	O
older	O
adults	O
'	O
and	O
PD	O
patients	O
'	O
ability	O
to	O
anticipate	O
,	O
prepare	O
and	O
initiate	O
goal	O
-	O
directed	O
behavior	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
imply	O
that	O
despite	O
a	O
general	O
decline	O
in	O
the	O
action	O
preparation	O
system	O
as	O
indexed	O
by	O
increased	O
antisaccade	O
latency	O
,	O
action	O
preparation	O
processes	O
remain	O
susceptible	O
to	O
the	O
prospect	O
of	O
future	O
reward	O
.	O
</ALL>	O

<ALL>	O
It	O
could	O
thus	O
be	O
argued	O
that	O
the	O
neural	B-Multi-tissue_structure
representations	O
of	O
upcoming	O
rewards	O
influence	O
neural	B-Anatomical_system
systems	I-Anatomical_system
concerned	O
with	O
action	O
preparation	O
and	O
oculomotor	B-Multi-tissue_structure
control	O
.	O
</ALL>	O

<ALL>	O
Although	O
the	O
current	O
behavioral	O
results	O
cannot	O
exclude	O
or	O
confirm	O
neural	B-Multi-tissue_structure
links	O
between	O
reward	O
anticipation	O
and	O
action	O
preparation	O
systems	O
in	O
the	O
brain	B-Organ
,	O
they	O
suggest	O
intact	O
cross	O
-	O
talk	O
among	O
subcortical	B-Multi-tissue_structure
circuits	O
that	O
allow	O
goal	O
-	O
directed	O
action	O
to	O
be	O
modified	O
by	O
motivational	O
factors	O
.	O
</ALL>	O

<ALL>	O
The	O
motivational	O
neural	B-Multi-tissue_structure
reward	O
anticipation	O
signal	O
presumably	O
activates	O
the	O
reward	O
network	O
including	O
the	O
amygdala	O
,	O
orbitofrontal	B-Multi-tissue_structure
cortex	I-Multi-tissue_structure
,	O
the	O
more	O
ventral	B-Multi-tissue_structure
and	O
dorsal	B-Multi-tissue_structure
striatum	I-Multi-tissue_structure
(	O
nucleus	B-Multi-tissue_structure
accumbens	I-Multi-tissue_structure
,	O
putamen	B-Multi-tissue_structure
,	O
and	O
caudate	B-Multi-tissue_structure
)	O
,	O
leading	O
to	O
an	O
release	O
of	O
caudate	O
/	O
SNr	O
inhibition	O
on	O
the	O
executive	O
oculomotor	B-Multi-tissue_structure
structure	I-Multi-tissue_structure
superior	I-Multi-tissue_structure
colliculus	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
This	O
transiently	O
decreased	O
inhibitory	O
force	O
on	O
superior	B-Multi-tissue_structure
colliculus	I-Multi-tissue_structure
may	O
improve	O
goal	O
-	O
directed	O
oculomotor	B-Multi-tissue_structure
control	O
.	O
</ALL>	O

<ALL>	O
Thus	O
reward	O
anticipation	O
might	O
compensate	O
for	O
the	O
age	O
-	O
and	O
disease	O
-	O
related	O
dopaminergic	O
loss	O
in	O
the	O
SNc	O
projections	O
to	O
the	O
caudate	O
/	O
SNr	O
and	O
may	O
thus	O
play	O
a	O
compensatory	O
role	O
in	O
"	O
boosting	O
"	O
the	O
efficiency	O
of	O
interactions	O
between	O
motivational	O
and	O
impaired	O
cognitive	O
control	O
processes	O
.	O
</ALL>	O

<ALL>	O
However	O
the	O
reward	O
-	O
related	O
modulation	O
of	O
the	O
oculomotor	B-Multi-tissue_structure
control	I-Multi-tissue_structure
system	I-Multi-tissue_structure
may	O
not	O
only	O
apply	O
to	O
the	O
basal	B-Multi-tissue_structure
ganglia	I-Multi-tissue_structure
part	O
of	O
the	O
oculomotor	B-Multi-tissue_structure
network	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Although	O
speculative	O
,	O
it	O
could	O
extend	O
to	O
the	O
cortical	B-Multi-tissue_structure
eyefields	I-Multi-tissue_structure
(	O
frontal	B-Multi-tissue_structure
,	O
supplementary	B-Multi-tissue_structure
,	O
and	O
parietal	B-Multi-tissue_structure
eyefields	I-Multi-tissue_structure
)	O
and	O
to	O
parts	O
of	O
the	O
visual	B-Multi-tissue_structure
cortex	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Human	O
research	O
shows	O
that	O
more	O
preparatory	O
activation	O
in	O
the	O
frontal	B-Multi-tissue_structure
eyefields	I-Multi-tissue_structure
leads	O
to	O
a	O
faster	O
antisaccade	O
latency	O
(	O
Connolly	O
et	O
al	O
.	O
,	O
2002	O
,	O
2005	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
compensatory	O
effect	O
on	O
the	O
antisaccade	O
latency	O
,	O
therefore	O
,	O
could	O
theoretically	O
stem	O
from	O
a	O
propagation	O
of	O
reward	O
anticipation	O
signal	O
in	O
the	O
caudate	B-Multi-tissue_structure
to	O
the	O
frontal	B-Multi-tissue_structure
eyefields	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Complex	O
structural	O
connections	O
enable	O
the	O
striatum	B-Multi-tissue_structure
to	O
exert	O
a	O
controlling	O
influence	O
over	O
the	O
cerebral	B-Multi-tissue_structure
cortex	I-Multi-tissue_structure
via	O
a	O
series	O
of	O
reentrant	B-Multi-tissue_structure
corticobasal	I-Multi-tissue_structure
ganglia	I-Multi-tissue_structure
circuits	O
.	O
</ALL>	O

<ALL>	O
Thus	O
reward	O
anticipation	O
may	O
increase	O
the	O
level	O
of	O
preparation	O
in	O
the	O
intact	O
cortical	B-Multi-tissue_structure
eyefields	I-Multi-tissue_structure
and	O
thereby	O
compensate	O
for	O
age	O
-	O
and	O
disease	O
-	O
related	O
subcortical	B-Multi-tissue_structure
decrements	O
in	O
the	O
oculomotor	B-Multi-tissue_structure
network	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Taken	O
together	O
,	O
it	O
seems	O
plausible	O
that	O
motivational	O
reward	O
processes	O
in	O
the	O
caudate	B-Multi-tissue_structure
enhance	O
preparatory	O
activation	O
in	O
subcortical	B-Multi-tissue_structure
as	O
well	O
as	O
in	O
cortical	B-Multi-tissue_structure
nodes	I-Multi-tissue_structure
of	O
the	O
oculomotor	B-Multi-tissue_structure
network	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
Several	O
neurotransmission	O
mechanisms	O
may	O
underlie	O
the	O
remedial	O
effect	O
of	O
positive	O
incentives	O
on	O
declining	O
antisaccadic	O
control	O
.	O
</ALL>	O

<ALL>	O
Given	O
the	O
convergence	O
of	O
dopamine	O
and	O
glutamate	O
inputs	O
at	O
the	O
spiny	B-Cell
projection	I-Cell
neurons	I-Cell
in	O
the	O
striatum	B-Multi-tissue_structure
(	O
Burns	O
et	O
al	O
.	O
,	O
1994	O
)	O
,	O
an	O
interaction	O
between	O
dopamine	O
and	O
glutamate	O
might	O
underlie	O
striatal	B-Multi-tissue_structure
processes	O
of	O
reward	O
anticipation	O
and	O
action	O
preparation	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
it	O
cannot	O
be	O
fully	O
excluded	O
that	O
alterations	O
in	O
other	O
neurotransmitter	O
systems	O
may	O
also	O
have	O
an	O
effect	O
on	O
declining	O
oculomotor	B-Multi-tissue_structure
control	O
and	O
on	O
remediating	O
incentive	O
effects	O
.	O
</ALL>	O

<ALL>	O
Non	O
-	O
dopaminergic	O
changes	O
such	O
as	O
noradrenergic	O
,	O
serotonergic	O
,	O
and	O
cholinergic	O
deafferentation	O
of	O
the	O
cortex	B-Multi-tissue_structure
also	O
occur	O
in	O
PD	O
and	O
can	O
inflict	O
cognitive	O
deficits	O
(	O
Agid	O
et	O
al	O
.	O
,	O
1987	O
)	O
.	O
</ALL>	O

<ALL>	O
Evidence	O
from	O
non	O
-	O
human	O
primates	O
suggests	O
that	O
basal	B-Multi-tissue_structure
ganglia	I-Multi-tissue_structure
dopamine	O
acts	O
to	O
speed	B-Multi-tissue_structure
motor	I-Multi-tissue_structure
responding	O
in	O
response	O
to	O
rewarding	O
cues	O
(	O
Niv	O
,	O
2007	O
;	O
Niv	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O
</ALL>	O

<ALL>	O
Among	O
at	O
least	O
five	O
types	O
of	O
DA	O
receptors	O
,	O
mainly	O
D1	O
and	O
D2	O
receptors	O
are	O
expressed	O
in	O
caudate	B-Cell
projection	I-Cell
neurons	I-Cell
(	O
Nakamura	O
and	O
Hikosaka	O
,	O
2006	O
)	O
.	O
</ALL>	O

<ALL>	O
Tendencies	O
to	O
speed	O
responses	O
to	O
obtain	O
large	O
rewards	O
have	O
been	O
found	O
to	O
be	O
dependent	O
on	O
striatal	B-Multi-tissue_structure
D1	O
receptors	O
(	O
Dalley	O
et	O
al	O
.	O
,	O
2005	O
;	O
Berridge	O
,	O
2007	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
to	O
this	O
D1	O
modulated	O
speeding	O
in	O
reward	O
-	O
motor	O
tasks	O
,	O
evidence	O
from	O
saccade	O
tasks	O
in	O
non	O
-	O
human	O
primates	O
suggests	O
D2	O
receptor	O
modulation	O
of	O
reward	O
dependent	O
improvements	O
of	O
performance	O
(	O
Nakamura	O
and	O
Hikosaka	O
,	O
2006	O
)	O
.	O
</ALL>	O

<ALL>	O
Injections	O
of	O
a	O
D1	O
antagonist	O
and	O
a	O
D2	O
antagonist	O
into	O
the	O
region	O
of	O
the	O
caudate	B-Multi-tissue_structure
where	O
saccade	O
-	O
related	O
neurons	B-Cell
are	O
clustered	O
while	O
the	O
monkey	O
performed	O
a	O
reward	O
-	O
biased	O
saccade	O
task	O
showed	O
that	O
D1	O
antagonists	O
attenuate	O
the	O
reward	O
modulation	O
of	O
saccade	O
behavior	O
whereas	O
D2	O
antagonists	O
into	O
the	O
same	O
region	O
enhanced	O
the	O
reward	O
-	O
dependent	O
changes	O
.	O
</ALL>	O

<ALL>	O
Future	O
studies	O
of	O
Parkinson	O
patients	O
on	O
versus	O
off	O
medication	O
,	O
could	O
provide	O
some	O
information	O
on	O
the	O
role	O
of	O
dopaminergic	O
mechanisms	O
in	O
the	O
remedial	O
effects	O
on	O
antisaccadic	O
performance	O
.	O
</ALL>	O

<ALL>	O
A	O
recent	O
study	O
of	O
reward	O
learning	O
in	O
Parkinson	O
patients	O
on	O
/	O
off	O
dopaminergic	O
medication	O
showed	O
that	O
patients	O
adapted	O
their	O
behavior	O
to	O
maximize	O
expected	O
reward	O
value	O
dependent	O
on	O
their	O
medication	O
status	O
(	O
Moustafa	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O
</ALL>	O

<ALL>	O
Whilst	O
off	O
dopaminergic	O
medication	O
,	O
patients	O
slowed	O
their	O
responses	O
to	O
avoid	O
low	O
expected	O
values	O
,	O
but	O
succeeded	O
less	O
well	O
in	O
speeding	O
responses	O
when	O
a	O
reward	O
was	O
at	O
stake	O
.	O
</ALL>	O

<ALL>	O
The	O
opposite	O
pattern	O
emerged	O
when	O
the	O
same	O
patients	O
were	O
on	O
medication	O
;	O
patients	O
showed	O
better	O
response	O
speeding	O
,	O
and	O
worse	O
response	O
slowing	O
,	O
to	O
maximize	O
expected	O
value	O
.	O
</ALL>	O

<ALL>	O
The	O
current	O
behavioral	O
findings	O
are	O
in	O
line	O
with	O
neuroimaging	O
research	O
showing	O
intact	O
neural	B-Multi-tissue_structure
representations	O
of	O
future	O
reward	O
in	O
the	O
aging	O
striatum	B-Multi-tissue_structure
(	O
Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
observation	O
however	O
that	O
older	O
adults	O
and	O
PD	O
patients	O
can	O
use	O
this	O
intact	O
neural	B-Multi-tissue_structure
representation	O
of	O
reward	O
anticipation	O
(	O
a	O
positive	O
motivational	O
incentive	O
)	O
to	O
optimize	O
their	O
preparatory	O
processes	O
,	O
cannot	O
necessarily	O
be	O
generalized	O
to	O
cognitive	O
contexts	O
with	O
negative	O
motivational	O
incentives	O
.	O
</ALL>	O

<ALL>	O
Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
(	O
2010	O
)	O
recently	O
showed	O
that	O
older	O
adults	O
were	O
not	O
able	O
to	O
optimally	O
use	O
their	O
intact	O
neural	B-Multi-tissue_structure
reward	O
anticipation	O
system	O
in	O
risky	O
financial	O
decision	O
making	O
.	O
</ALL>	O

<ALL>	O
Elderly	O
made	O
more	O
suboptimal	O
choices	O
when	O
they	O
were	O
to	O
choose	O
risky	O
assets	O
.	O
</ALL>	O

<ALL>	O
The	O
authors	O
deemed	O
it	O
likely	O
that	O
these	O
decrements	O
in	O
value	O
-	O
based	O
decision	O
making	O
are	O
explained	O
by	O
the	O
fact	O
that	O
value	O
-	O
based	O
decision	O
making	O
requires	O
the	O
weighting	O
of	O
behavioral	O
alternatives	O
,	O
that	O
may	O
lead	O
to	O
either	O
gain	O
or	O
loss	O
.	O
</ALL>	O

<ALL>	O
During	O
anticipation	O
of	O
rewards	O
older	O
adults	O
show	O
similar	O
neural	B-Multi-tissue_structure
responses	O
as	O
young	O
adults	O
but	O
they	O
show	O
reduced	O
neural	B-Multi-tissue_structure
activation	O
during	O
the	O
anticipation	O
of	O
losses	O
(	O
Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
latter	O
,	O
together	O
with	O
the	O
observation	O
that	O
older	O
adults	O
tend	O
to	O
shift	O
their	O
attention	O
away	O
from	O
negative	O
stimuli	O
and	O
attend	O
to	O
positive	O
information	O
instead	O
(	O
Mather	O
and	O
Carstensen	O
,	O
2003	O
,	O
2005	O
)	O
,	O
may	O
have	O
led	O
to	O
the	O
underestimation	O
of	O
loss	O
and	O
therefore	O
to	O
more	O
risky	O
and	O
suboptimal	O
decisions	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
respect	O
,	O
one	O
limitation	O
of	O
the	O
current	O
task	O
is	O
that	O
it	O
built	O
solely	O
on	O
reward	O
prospect	O
and	O
not	O
on	O
the	O
prospect	O
of	O
loss	O
,	O
such	O
that	O
the	O
question	O
of	O
how	O
the	O
anticipation	O
of	O
loss	O
influences	O
action	O
preparation	O
was	O
not	O
tested	O
.	O
</ALL>	O

<ALL>	O
The	O
impact	O
of	O
negative	O
incentives	O
might	O
be	O
an	O
intriguing	O
question	O
for	O
future	O
research	O
,	O
as	O
due	O
to	O
the	O
decreased	O
activation	O
of	O
the	O
neural	B-Multi-tissue_structure
loss	O
anticipation	O
system	O
(	O
Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
,	O
2007	O
)	O
together	O
with	O
the	O
observed	O
differential	O
attentional	O
bias	O
for	O
negative	O
and	O
positive	O
information	O
(	O
Mather	O
and	O
Carstensen	O
,	O
2003	O
)	O
,	O
it	O
seems	O
likely	O
that	O
negative	O
motivational	O
incentives	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
prospect	O
of	O
loss	O
,	O
might	O
have	O
a	O
different	O
impact	O
on	O
action	O
preparation	O
in	O
older	O
adults	O
than	O
in	O
the	O
young	O
.	O
</ALL>	O

<ALL>	O
Future	O
approaches	O
to	O
the	O
effect	O
of	O
loss	O
anticipation	O
on	O
declining	O
antisaccade	O
control	O
may	O
ideally	O
contain	O
a	O
sequence	O
of	O
experiments	O
,	O
starting	O
with	O
a	O
separate	O
(	O
punishment	O
only	O
)	O
approach	O
before	O
moving	O
to	O
combined	O
reward	O
-	O
punishment	O
designs	O
.	O
</ALL>	O

<ALL>	O
This	O
might	O
be	O
necessary	O
as	O
previous	O
evidence	O
(	O
from	O
healthy	O
young	O
adults	O
)	O
suggests	O
that	O
the	O
reward	O
effect	O
on	O
oculomotor	B-Multi-tissue_structure
control	O
disappears	O
in	O
the	O
presence	O
of	O
punishment	O
trials	O
.	O
</ALL>	O

<ALL>	O
The	O
authors	O
deemed	O
it	O
likely	O
that	O
the	O
participants	O
increased	O
caution	O
to	O
all	O
incentive	O
(	O
reward	O
and	O
punishment	O
)	O
trials	O
(	O
Blaukopf	O
and	O
DiGirolamo	O
,	O
2006	O
)	O
.	O
</ALL>	O

<ALL>	O
As	O
of	O
yet	O
,	O
age	O
-	O
related	O
changes	O
in	O
neural	B-Multi-tissue_structure
reward	O
anticipation	O
have	O
mainly	O
been	O
studied	O
in	O
isolation	O
.	O
</ALL>	O

<ALL>	O
Recently	O
however	O
,	O
the	O
interaction	O
of	O
neural	B-Multi-tissue_structure
reward	O
processing	O
with	O
other	O
cognitive	O
functions	O
and	O
their	O
underlying	O
neural	B-Anatomical_system
systems	I-Anatomical_system
,	O
such	O
as	O
the	O
action	B-Anatomical_system
control	I-Anatomical_system
system	I-Anatomical_system
,	O
has	O
gained	O
increasing	O
interest	O
(	O
Haber	O
and	O
Knutson	O
,	O
2010	O
)	O
.	O
</ALL>	O

<ALL>	O
Initial	O
evidence	O
suggests	O
coordinated	O
activity	O
between	O
distant	O
brain	B-Organ
regions	O
responsible	O
for	O
reward	O
processing	O
(	O
Cohen	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
current	O
results	O
encourage	O
further	O
neural	B-Multi-tissue_structure
network	I-Multi-tissue_structure
investigations	O
on	O
the	O
role	O
of	O
coordinated	O
brain	B-Organ
network	O
activity	O
in	O
motivated	O
behavior	O
.	O
</ALL>	O

<ALL>	O
Behavioral	O
benefits	O
from	O
motivation	O
might	O
be	O
associated	O
with	O
changes	O
in	O
functional	O
brain	B-Organ
connectivity	O
on	O
a	O
larger	O
scale	O
,	O
e	O
.	O
g	O
.	O
,	O
between	O
frontostriatal	B-Multi-tissue_structure
reward	O
and	O
action	O
preparation	O
structures	O
.	O
</ALL>	O

<ALL>	O
Another	O
important	O
factor	O
that	O
emerges	O
from	O
the	O
present	O
and	O
previous	O
results	O
,	O
is	O
the	O
importance	O
of	O
the	O
training	O
of	O
the	O
motivational	O
aspects	O
of	O
the	O
instructions	O
that	O
need	O
to	O
be	O
kept	O
in	O
working	O
memory	O
when	O
performing	O
a	O
cognitive	O
task	O
.	O
</ALL>	O

<ALL>	O
Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
</ALL>	O

<ALL>	O
(	O
2007	O
)	O
found	O
intact	O
neural	B-Multi-tissue_structure
reward	O
anticipation	O
processes	O
specifically	O
in	O
the	O
absence	O
of	O
learning	O
(	O
after	O
the	O
learning	O
process	O
of	O
reward	O
cue	O
-	O
reward	O
associations	O
was	O
completed	O
)	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
it	O
might	O
be	O
important	O
for	O
researchers	O
doing	O
experiments	O
with	O
motivation	O
based	O
instructions	O
to	O
keep	O
in	O
mind	O
that	O
,	O
compared	O
to	O
young	O
adults	O
,	O
elderly	O
and	O
PD	O
patients	O
are	O
generally	O
hampered	O
on	O
stimulus	O
-	O
response	O
learning	O
(	O
Shohamy	O
et	O
al	O
.	O
,	O
2004	O
;	O
Marschner	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
</ALL>	O

<ALL>	O
Reward	O
instruction	O
cues	O
,	O
as	O
they	O
were	O
used	O
in	O
the	O
current	O
study	O
require	O
participants	O
to	O
form	O
reward	O
cue	O
-	O
reward	O
associations	O
.	O
</ALL>	O

<ALL>	O
Impairments	O
in	O
the	O
learning	O
of	O
associations	O
between	O
the	O
cue	O
signaling	O
reward	O
and	O
the	O
actual	O
reward	O
might	O
conceal	O
intact	O
reward	O
anticipation	O
processes	O
.	O
</ALL>	O

<ALL>	O
When	O
the	O
formation	O
of	O
associations	O
is	O
weakened	O
,	O
it	O
could	O
appear	O
as	O
a	O
failure	O
to	O
capitalize	O
on	O
the	O
neural	B-Multi-tissue_structure
reward	O
anticipation	O
system	O
,	O
whereas	O
it	O
represents	O
an	O
indirect	O
effect	O
of	O
non	O
-	O
available	O
reward	O
associations	O
in	O
working	O
memory	O
when	O
preparing	O
the	O
response	O
.	O
</ALL>	O

<ALL>	O
Hence	O
,	O
one	O
might	O
circumvent	O
the	O
effect	O
of	O
potential	O
learning	O
impairments	O
on	O
reward	O
anticipation	O
processes	O
by	O
the	O
training	O
of	O
abstract	O
reward	O
cues	O
(	O
as	O
in	O
the	O
current	O
and	O
in	O
Samanez	O
-	O
Larkin	O
'	O
s	O
study	O
)	O
or	O
by	O
using	O
explicit	O
and	O
concrete	O
rewards	O
.	O
</ALL>	O

<ALL>	O
Once	O
the	O
learning	O
of	O
reward	O
cues	O
is	O
accomplished	O
the	O
intact	O
reward	O
anticipation	O
processes	O
might	O
become	O
evident	O
.	O
</ALL>	O

<ALL>	O
In	O
sum	O
,	O
the	O
results	O
confirmed	O
that	O
the	O
preparation	O
of	O
goal	O
-	O
directed	O
actions	O
declined	O
in	O
PD	O
patients	O
compared	O
to	O
healthy	O
seniors	O
,	O
and	O
in	O
healthy	O
seniors	O
compared	O
to	O
young	O
adults	O
.	O
</ALL>	O

<ALL>	O
Due	O
perhaps	O
to	O
deterioration	O
in	O
dopaminergic	O
striatal	B-Multi-tissue_structure
circuitry	O
,	O
antisaccade	O
performance	O
is	O
subject	O
to	O
decline	O
in	O
healthy	O
seniors	O
,	O
and	O
even	O
more	O
in	O
individuals	O
with	O
Parkinson	O
'	O
s	O
disease	O
.	O
</ALL>	O

<ALL>	O
The	O
prospect	O
of	O
future	O
reward	O
however	O
provided	O
a	O
motivational	O
incentive	O
for	O
optimizing	O
oculomotor	B-Multi-tissue_structure
preparation	O
in	O
all	O
groups	O
alike	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
suggest	O
that	O
reward	O
-	O
processing	O
networks	O
and	O
oculomotor	B-Multi-tissue_structure
-	I-Multi-tissue_structure
control	I-Multi-tissue_structure
networks	I-Multi-tissue_structure
in	O
the	O
brain	B-Organ
are	O
connected	O
in	O
such	O
a	O
way	O
(	O
presumably	O
with	O
the	O
dorsal	B-Multi-tissue_structure
striatum	I-Multi-tissue_structure
as	O
a	O
common	O
nexus	O
)	O
that	O
reward	O
anticipation	O
can	O
facilitate	O
oculomotor	B-Multi-tissue_structure
control	O
and	O
alleviate	O
the	O
deficiencies	O
experienced	O
by	O
healthy	O
seniors	O
and	O
PD	O
patients	O
.	O
</ALL>	O

<ALL>	O
Future	O
investigations	O
should	O
examine	O
whether	O
the	O
observed	O
effects	O
are	O
specific	O
for	O
the	O
current	O
task	O
or	O
generalize	O
to	O
other	O
tasks	O
that	O
show	O
age	O
-	O
and	O
PD	O
-	O
related	O
cognitive	O
decrements	O
(	O
e	O
.	O
g	O
.	O
,	O
in	O
task	O
switching	O
)	O
and	O
have	O
been	O
related	O
to	O
dopaminergic	O
denervation	O
in	O
the	O
caudate	B-Multi-tissue_structure
(	O
e	O
.	O
g	O
.	O
,	O
impaired	O
verbal	O
episodic	O
memory	O
,	O
attention	O
,	O
and	O
response	O
inhibition	O
;	O
Rinne	O
et	O
al	O
.	O
,	O
2000	O
;	O
Bruck	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
</ALL>	O

<ALL>	O
Future	O
studies	O
on	O
network	O
processes	O
may	O
help	O
to	O
localize	O
the	O
neural	B-Multi-tissue_structure
link	O
between	O
reward	O
prospect	O
and	O
action	O
preparation	O
that	O
enables	O
alleviating	O
effects	O
of	O
motivational	O
incentives	O
on	O
cognitive	O
decline	O
.	O
</ALL>	O

<ALL>	O
Crystal	O
data	O
</ALL>	O

<ALL>	O
C24H21ClN4O2S	O
</ALL>	O

<ALL>	O
M	O
r	O
=	O
464	O
.	O
96	O
</ALL>	O

<ALL>	O
Triclinic	O
,	O
</ALL>	O

<ALL>	O
a	O
=	O
8	O
.	O
6798	O
(	O
18	O
)	O
A	O
</ALL>	O

<ALL>	O
b	O
=	O
11	O
.	O
078	O
(	O
2	O
)	O
A	O
</ALL>	O

<ALL>	O
c	O
=	O
11	O
.	O
372	O
(	O
2	O
)	O
A	O
</ALL>	O

<ALL>	O
alpha	O
=	O
78	O
.	O
984	O
(	O
7	O
)	O
degrees	O
</ALL>	O

<ALL>	O
beta	O
=	O
81	O
.	O
867	O
(	O
10	O
)	O
degrees	O
</ALL>	O

<ALL>	O
gamma	O
=	O
81	O
.	O
718	O
(	O
11	O
)	O
degrees	O
</ALL>	O

<ALL>	O
V	O
=	O
1054	O
.	O
8	O
(	O
4	O
)	O
A3	O
</ALL>	O

<ALL>	O
Z	O
=	O
2	O
</ALL>	O

<ALL>	O
Cu	O
Kalpha	O
radiation	O
</ALL>	O

<ALL>	O
mu	O
=	O
2	O
.	O
78	O
mm	O
-	O
1	O
</ALL>	O

<ALL>	O
T	O
=	O
113	O
K	O
</ALL>	O

<ALL>	O
0	O
.	O
28	O
x	O
0	O
.	O
24	O
x	O
0	O
.	O
20	O
mm	O
</ALL>	O

<ALL>	O
Characteristics	O
of	O
fistula	B-Pathological_formation
lesions	I-Pathological_formation
</ALL>	O

<ALL>	O
Selective	O
SMA	O
angiography	O
was	O
performed	O
5	O
h	O
from	O
onset	O
.	O
</ALL>	O

<ALL>	O
Before	O
therapy	O
,	O
the	O
SMA	O
was	O
completely	O
occluded	O
by	O
an	O
embolus	B-Organism_substance
at	O
the	O
proximal	O
portion	O
(	O
a	O
)	O
,	O
and	O
after	O
the	O
bolus	B-Organism_substance
infusion	O
of	O
urokinase	O
(	O
600	O
,	O
000	O
IU	O
)	O
into	O
the	O
SMA	O
,	O
peripheral	B-Organism_substance
blood	I-Organism_substance
flow	O
was	O
improved	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
thrombus	B-Organism_substance
decreased	O
in	O
size	O
,	O
but	O
remained	O
(	O
b	O
)	O
.	O
</ALL>	O

<ALL>	O
Asterisks	O
indicate	O
thrombus	B-Organism_substance
.	O
</ALL>	O

<ALL>	O
Measurement	O
of	O
IgA1	O
content	O
</ALL>	O

<ALL>	O
IgA1	O
content	O
in	O
the	O
supernatant	B-Organism_substance
from	O
each	O
culture	O
well	O
was	O
measured	O
in	O
duplicate	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O
</ALL>	O

<ALL>	O
All	O
incubations	O
were	O
performed	O
at	O
room	O
temperature	O
except	O
for	O
capture	O
antibody	O
coating	O
.	O
</ALL>	O

<ALL>	O
Briefly	O
,	O
96	O
-	O
well	O
immunoplates	O
(	O
Thermo	O
Fisher	O
Scientific	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
were	O
coated	O
with	O
5	O
microg	O
/	O
mL	O
of	O
F	O
(	O
ab	O
'	O
)	O
2	O
fragment	O
goat	O
anti	O
-	O
human	O
IgA	O
antibody	O
(	O
Jackson	O
ImmunoResearch	O
Laboratories	O
,	O
West	O
Grove	O
,	O
PA	O
,	O
USA	O
)	O
,	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
at	O
4degreesC	O
overnight	O
.	O
</ALL>	O

<ALL>	O
After	O
three	O
washes	O
with	O
PBS	O
containing	O
0	O
.	O
05	O
%	O
Tween	O
-	O
20	O
(	O
PBST	O
)	O
,	O
plates	O
were	O
blocked	O
by	O
adding	O
PBS	O
containing	O
1	O
%	O
bovine	O
serum	B-Organism_substance
albumin	O
(	O
BSA	O
)	O
to	O
the	O
wells	O
for	O
90	O
min	O
.	O
</ALL>	O

<ALL>	O
Next	O
,	O
50	O
microL	O
of	O
supernatant	B-Organism_substance
sample	I-Organism_substance
or	O
standard	O
human	O
IgA1	O
(	O
CALBIOCHEM	O
,	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
was	O
added	O
to	O
the	O
reaction	O
wells	O
and	O
then	O
incubated	O
for	O
90	O
min	O
.	O
</ALL>	O

<ALL>	O
After	O
three	O
washes	O
,	O
0	O
.	O
75	O
microg	O
/	O
mL	O
alkaline	O
phosphatase	O
conjugated	O
goat	O
anti	O
-	O
human	O
IgA	O
(	O
Southern	O
Biotechnology	O
Associates	O
,	O
Birmingham	O
,	O
AL	O
,	O
USA	O
)	O
in	O
1	O
%	O
BSA	O
/	O
PBS	O
was	O
added	O
to	O
the	O
reaction	O
wells	O
and	O
then	O
incubated	O
for	O
90	O
min	O
.	O
</ALL>	O

<ALL>	O
Plates	O
were	O
washed	O
three	O
times	O
and	O
developed	O
with	O
a	O
substrate	O
solution	O
of	O
1	O
mg	O
/	O
mL	O
p	O
-	O
nitrophenyl	O
phosphate	O
disodium	O
salt	O
(	O
SIGMA	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
in	O
0	O
.	O
1	O
M	O
glycine	O
buffer	O
containing	O
1	O
mM	O
MgCl2	O
,	O
1	O
mM	O
ZnCl2	O
,	O
pH	O
10	O
.	O
4	O
.	O
</ALL>	O

<ALL>	O
The	O
optical	O
density	O
at	O
405	O
nm	O
was	O
determined	O
in	O
a	O
microplate	O
reader	O
(	O
Benchmark	O
PlusTM	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O
</ALL>	O

<ALL>	O
IgA1	O
concentration	O
in	O
unknown	O
duplicate	O
samples	O
was	O
determined	O
by	O
interpolation	O
of	O
the	O
respective	O
optical	O
density	O
into	O
the	O
appropriate	O
standard	O
curve	O
.	O
</ALL>	O

<ALL>	O
IgG	O
and	O
IgM	O
contents	O
in	O
the	O
supernatant	B-Organism_substance
were	O
measured	O
using	O
sandwich	O
ELISA	O
(	O
IMMUNOtek	O
(	O
R	O
)	O
,	O
ZeptoMetrix	O
Corporation	O
,	O
Buffalo	O
,	O
NY	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O
</ALL>	O

<ALL>	O
The	O
thickness	O
of	O
the	O
inner	B-Multi-tissue_structure
retina	I-Multi-tissue_structure
was	O
established	O
as	O
the	O
distance	O
between	O
retinal	B-Tissue
nerve	I-Tissue
fiber	I-Tissue
layer	I-Tissue
and	O
inner	B-Tissue
nuclear	I-Tissue
layer	I-Tissue
and	O
was	O
measured	O
using	O
the	O
1	O
,	O
000	O
mum	O
caliper	O
available	O
in	O
the	O
OCT	O
-	O
SLO	O
Spectralis	O
.	O
</ALL>	O

<ALL>	O
Ten	O
age	O
-	O
matched	O
normal	O
eyes	B-Organ
were	O
used	O
as	O
controls	O
.	O
</ALL>	O

<ALL>	O
Observe	O
the	O
decrease	O
in	O
the	O
nasal	B-Organism_subdivision
and	O
temporal	O
inner	B-Multi-tissue_structure
retinal	I-Multi-tissue_structure
thickness	O
in	O
the	O
right	O
eye	B-Organ
in	O
comparison	O
to	O
the	O
left	O
and	O
normal	O
control	O
eyes	B-Organ
.	O
</ALL>	O

<ALL>	O
Real	O
time	O
RT	O
-	O
PCR	O
</ALL>	O

<ALL>	O
RNA	O
extraction	O
and	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
were	O
performed	O
as	O
we	O
described	O
previously	O
[	O
22	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
sequences	O
of	O
ABCG2	O
primers	O
are	O
5	O
'	O
-	O
GGCTTTCTACCTGCACGAAAACCAGTTGAG	O
-	O
3	O
'	O
(	O
forward	O
)	O
and	O
5	O
'	O
-	O
ATGGCGTTGAGACCAG	O
-	O
3	O
'	O
(	O
reverse	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
sequences	O
of	O
GAPDH	O
primers	O
are	O
5	O
'	O
-	O
AAGGACTCATGACCACAGTCCAT	O
-	O
3	O
'	O
(	O
forward	O
)	O
and	O
5	O
'	O
-	O
CCATCACGCCACAGTTTCC	O
-	O
3	O
'	O
(	O
reverse	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
relative	O
ABCG2	O
RNA	O
level	O
(	O
2DeltaCT	O
)	O
treated	O
with	O
inhibitors	O
was	O
expressed	O
as	O
percentage	O
of	O
the	O
control	O
(	O
in	O
the	O
presence	O
of	O
0	O
.	O
1	O
%	O
DMSO	O
)	O
where	O
DeltaCT	O
(	O
threshold	O
cycle	O
)	O
=	O
(	O
CTABCG2	O
-	O
CTGAPDH	O
)	O
.	O
</ALL>	O

<ALL>	O
Introduction	O
</ALL>	O

<ALL>	O
Adipose	B-Tissue
tissue	I-Tissue
,	O
once	O
viewed	O
as	O
simply	O
a	O
storage	O
and	O
release	O
depot	O
for	O
lipids	O
,	O
is	O
now	O
considered	O
an	O
endocrine	B-Tissue
tissue	I-Tissue
[	O
1	O
,	O
2	O
]	O
that	O
secretes	O
various	O
substances	O
(	O
adipokines	O
)	O
,	O
including	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
,	O
interleukin	O
(	O
IL	O
)	O
-	O
6	O
,	O
leptin	O
,	O
adiponectin	O
,	O
resistin	O
,	O
visfatin	O
,	O
and	O
omenetin	O
[	O
3	O
,	O
4	O
]	O
.	O
</ALL>	O

<ALL>	O
Among	O
these	O
adipokines	O
,	O
much	O
attention	O
has	O
been	O
paid	O
to	O
adiponectin	O
'	O
s	O
relationship	O
with	O
insulin	O
sensitivity	O
and	O
glucose	O
and	O
lipid	O
metabolism	O
in	O
the	O
past	O
10	O
years	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
adiponectin	O
is	O
known	O
to	O
exhibit	O
potent	O
anti	O
-	O
inflammatory	O
[	O
5	O
]	O
,	O
atheroprotective	O
[	O
6	O
]	O
,	O
and	O
antidiabetic	O
[	O
7	O
]	O
effects	O
.	O
</ALL>	O

<ALL>	O
Recent	O
findings	O
suggest	O
that	O
adiponectin	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O
</ALL>	O

<ALL>	O
Levels	O
of	O
adiponectin	O
in	O
synovial	B-Organism_substance
fluid	I-Organism_substance
and	O
sera	B-Organism_substance
were	O
elevated	O
in	O
patients	O
with	O
RA	O
[	O
8	O
,	O
9	O
]	O
.	O
</ALL>	O

<ALL>	O
Adiponectin	O
also	O
induces	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
IL	O
-	O
6	O
,	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-	O
1	O
,	O
and	O
IL	O
-	O
8	O
from	O
RA	O
synovial	B-Cell
fibroblasts	I-Cell
in	O
vitro	O
[	O
10	O
,	O
11	O
]	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
it	O
was	O
suggested	O
that	O
adiponectin	O
can	O
also	O
exert	O
significant	O
proinflammatory	O
and	O
matrix	O
-	O
degrading	O
effects	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
the	O
role	O
of	O
adiponectin	O
in	O
the	O
pathogenesis	O
of	O
RA	O
is	O
still	O
controversial	O
because	O
of	O
conflicting	O
reports	O
about	O
its	O
function	O
[	O
10	O
,	O
12	O
-	O
15	O
]	O
.	O
</ALL>	O

<ALL>	O
In	O
particular	O
,	O
adiponectin	O
seems	O
to	O
play	O
an	O
anti	O
-	O
inflammatory	O
role	O
because	O
it	O
significantly	O
inhibited	O
IL	O
-	O
1beta	O
-	O
stimulated	O
synovial	B-Cell
cell	I-Cell
proliferation	O
in	O
collagen	O
-	O
induced	O
arthritic	O
mice	O
,	O
despite	O
increased	O
IL	O
-	O
6	O
expression	O
[	O
16	O
]	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
high	O
-	O
grade	O
inflammation	O
in	O
RA	O
patients	O
was	O
negatively	O
correlated	O
with	O
circulating	O
adiponectin	O
concentrations	O
[	O
17	O
]	O
.	O
</ALL>	O

<ALL>	O
Rather	O
,	O
it	O
was	O
suggested	O
that	O
circulating	O
adiponectin	O
may	O
be	O
involved	O
in	O
cardiovascular	B-Multi-tissue_structure
disease	O
in	O
RA	O
patients	O
.	O
</ALL>	O

<ALL>	O
Although	O
this	O
contradiction	O
was	O
partly	O
explained	O
by	O
the	O
induction	O
of	O
tolerance	O
to	O
inflammatory	O
stimuli	O
by	O
adiponectin	O
[	O
18	O
]	O
,	O
the	O
pro	O
-	O
or	O
anti	O
-	O
inflammatory	O
effects	O
of	O
adiponectin	O
on	O
the	O
pathogenesis	O
of	O
RA	O
remain	O
unknown	O
.	O
</ALL>	O

<ALL>	O
With	O
regard	O
to	O
adiponectin	O
'	O
s	O
proinflammatory	O
effects	O
,	O
we	O
wondered	O
whether	O
adiponectin	O
might	O
stimulate	O
the	O
production	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
MMPs	O
as	O
well	O
as	O
proinflammatory	O
mediators	O
like	O
IL	O
-	O
1beta	O
and	O
TNF	O
-	O
alpha	O
do	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
stimulatory	O
effect	O
of	O
adiponectin	O
on	O
the	O
production	O
of	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
VEGF	O
,	O
and	O
MMPs	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
the	O
correlation	O
between	O
adiponectin	O
and	O
VEGF	O
or	O
MMPs	O
was	O
investigated	O
by	O
measuring	O
the	O
levels	O
of	O
these	O
three	O
proteins	O
in	O
the	O
joint	B-Organism_substance
fluid	I-Organism_substance
of	O
patients	O
with	O
RA	O
or	O
osteoarthritis	O
(	O
OA	O
)	O
.	O
</ALL>	O

<ALL>	O
Refinement	O
</ALL>	O

<ALL>	O
The	O
H	O
-	O
atoms	O
were	O
positioned	O
geometrically	O
(	O
O	O
-	O
H	O
=	O
0	O
.	O
82	O
,	O
C	O
-	O
H	O
=	O
0	O
.	O
93	O
A	O
)	O
and	O
were	O
included	O
in	O
the	O
refinement	O
in	O
the	O
riding	O
model	O
approximation	O
,	O
with	O
Uiso	O
(	O
H	O
)	O
=	O
xUeq	O
(	O
C	O
,	O
O	O
)	O
,	O
where	O
x	O
=	O
1	O
.	O
2	O
for	O
all	O
H	O
-	O
atoms	O
.	O
</ALL>	O

<ALL>	O
Reagents	O
and	O
antibodies	O
</ALL>	O

<ALL>	O
Maxisorp	O
strips	O
(	O
NunC	O
,	O
Roskilde	O
,	O
Denmark	O
)	O
,	O
GST	O
-	O
PNMA2	O
recombinant	O
protein	O
(	O
Abnova	O
,	O
Taipei	O
,	O
Taiwan	O
)	O
;	O
3	O
,	O
3	O
'	O
,	O
5	O
,	O
5	O
-	O
tetramethylbenzidine	O
(	O
TMB	O
)	O
+	O
substrate	O
(	O
Dako	O
,	O
Glostrup	O
,	O
Denmark	O
)	O
,	O
Peroxidase	O
with	O
dakocytomation	O
peroxidase	O
block	O
(	O
Dako	O
)	O
,	O
Dakocytomation	O
envision	O
(	O
R	O
)	O
system	O
labeled	O
polymer	O
-	O
HRP	O
anti	O
-	O
rabbit	O
kit	O
and	O
3	O
-	O
3	O
'	O
-	O
diaminobenzidine	O
(	O
Dako	O
)	O
,	O
Mayer	O
'	O
s	O
hematoxylin	O
(	O
Histolab	O
Product	O
AB	O
,	O
Gothenburg	O
,	O
Sweden	O
)	O
,	O
Graded	O
alcohol	O
(	O
Kemetyl	O
,	O
Vestby	O
,	O
Norway	O
)	O
,	O
Xylen	O
(	O
Solveco	O
,	O
Rosersberg	O
,	O
Sweden	O
)	O
,	O
Pertex	O
(	O
R	O
)	O
(	O
Histolab	O
,	O
Gothenburg	O
,	O
Sweden	O
)	O
,	O
Tris	O
-	O
Glycine	O
blotting	O
buffer	O
(	O
Amresco	O
,	O
Solon	O
,	O
OH	O
)	O
,	O
Western	O
blotting	O
(	O
WB	O
)	O
reagent	O
and	O
Lumi	O
-	O
Light	O
WB	O
substrate	O
(	O
Roche	O
,	O
Basel	O
,	O
Switzerland	O
)	O
,	O
EasyTag	O
Methionine	O
-	O
L	O
-	O
35S	O
,	O
NEG709A005MC	O
(	O
PerkinElmer	O
,	O
Waltham	O
,	O
MA	O
)	O
,	O
Full	O
-	O
length	O
cDNA	O
clone	O
for	O
human	O
PNMA2	O
,	O
ID6580976	O
(	O
BioScience	O
Geneservice	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
TnT	O
(	O
R	O
)	O
SP6	O
Quick	O
Coupled	O
Transcription	O
/	O
Translation	O
System	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
,	O
Protein	O
G	O
-	O
Sepharose	O
beads	O
(	O
GE	O
Healthcare	O
,	O
Little	O
Chalfont	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
,	O
Peroxidase	O
(	O
HRP	O
)	O
-	O
conjugated	O
rabbit	O
anti	O
human	O
IgG	O
(	O
anti	O
-	O
IgG	O
)	O
(	O
Dako	O
)	O
,	O
rabbit	O
polyclonal	O
antibody	O
anti	O
-	O
PNMA2	O
(	O
Atlas	O
Antibodies	O
,	O
Stockholm	O
,	O
Sweden	O
)	O
,	O
monoclonal	O
mouse	O
anti	O
-	O
GST	O
,	O
sc	O
-	O
138	O
,	O
polyclonal	O
goat	O
anti	O
-	O
human	O
Ma2	O
,	O
sc	O
-	O
68099	O
,	O
HRP	O
-	O
donkey	O
anti	O
-	O
goat	O
,	O
sc	O
-	O
2020	O
,	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
,	O
HRP	O
-	O
goat	O
anti	O
-	O
rabbit	O
,	O
P0448	O
,	O
(	O
Dako	O
)	O
and	O
Ravo	O
PNS	O
-	O
Blot	O
,	O
(	O
Ravo	O
Diagnostika	O
GmbH	O
,	O
Freiburg	O
,	O
Germany	O
)	O
.	O
</ALL>	O

<ALL>	O
Statistical	O
analysis	O
</ALL>	O

<ALL>	O
All	O
statistical	O
analyses	O
were	O
performed	O
using	O
SPSS13	O
.	O
0	O
software	O
.	O
</ALL>	O

<ALL>	O
The	O
differences	O
between	O
groups	O
were	O
compared	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
,	O
and	O
data	O
were	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
SD	O
.	O
</ALL>	O

<ALL>	O
Statistical	O
difference	O
was	O
accepted	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O
</ALL>	O

<ALL>	O
The	O
importance	O
in	O
identifying	O
genes	O
involved	O
in	O
spinal	B-Organism_subdivision
curvature	O
</ALL>	O

<ALL>	O
Spinal	B-Organism_subdivision
curvature	O
is	O
a	O
prevalent	O
and	O
costly	O
deformity	O
among	O
humans	O
and	O
teleosts	O
.	O
</ALL>	O

<ALL>	O
The	O
estimated	O
annual	O
cost	O
of	O
treating	O
children	O
hospitalized	O
with	O
idiopathic	O
scoliosis	O
(	O
IS	O
)	O
in	O
the	O
United	O
States	O
alone	O
is	O
over	O
$	O
3	O
billion	O
.	O
</ALL>	O

<ALL>	O
This	O
cost	O
estimate	O
does	O
not	O
consider	O
Scheuermann	O
kyphosis	O
,	O
or	O
adults	O
with	O
idiopathic	O
-	O
type	O
spinal	B-Organism_subdivision
curvature	O
who	O
suffer	O
from	O
chronic	O
back	B-Organism_subdivision
pain	O
,	O
contributing	O
to	O
the	O
estimated	O
$	O
849	O
billion	O
cost	O
of	O
treatment	O
and	O
lost	O
wages	O
associated	O
with	O
musculoskeletal	B-Anatomical_system
disease	O
[	O
24	O
]	O
.	O
</ALL>	O

<ALL>	O
Among	O
teleosts	O
,	O
spinal	B-Organism_subdivision
column	I-Organism_subdivision
deformities	O
reduce	O
total	O
production	O
in	O
the	O
aquaculture	O
industry	O
substantially	O
[	O
12	O
]	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
to	O
humans	O
,	O
teleost	O
curve	O
phenotypes	O
are	O
less	O
well	O
characterized	O
;	O
although	O
heritable	O
curves	O
are	O
acknowledged	O
to	O
account	O
for	O
many	O
cases	O
among	O
cultured	O
stocks	O
,	O
whether	O
these	O
cases	O
are	O
from	O
congenital	O
defects	O
or	O
are	O
idiopathic	O
-	O
type	O
is	O
often	O
not	O
known	O
.	O
</ALL>	O

<ALL>	O
Despite	O
the	O
prevalence	O
and	O
impact	O
of	O
this	O
type	O
of	O
deformity	O
,	O
the	O
genetic	O
architecture	O
and	O
specific	O
genes	O
involved	O
are	O
unknown	O
.	O
</ALL>	O

<ALL>	O
The	O
current	O
view	O
is	O
that	O
human	O
idiopathic	O
-	O
type	O
scoliosis	O
is	O
a	O
complex	O
genetic	O
disorder	O
with	O
multiple	O
genes	O
segregating	O
in	O
the	O
population	O
exhibiting	O
complex	O
genotype	O
by	O
environment	O
interactions	O
[	O
25	O
-	O
30	O
]	O
.	O
</ALL>	O

<ALL>	O
In	O
aquaculture	O
stocks	O
,	O
inheritance	O
for	O
spinal	B-Organism_subdivision
curvature	O
has	O
been	O
described	O
as	O
Mendelian	O
recessive	O
or	O
dominant	O
,	O
as	O
well	O
as	O
polygenic	O
,	O
depending	O
on	O
how	O
well	O
the	O
phenotype	O
is	O
characterized	O
and	O
what	O
stock	O
is	O
considered	O
(	O
reviewed	O
in	O
[	O
13	O
]	O
,	O
[	O
16	O
]	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
guppy	O
curveback	O
phenotype	O
has	O
been	O
extensively	O
characterized	O
so	O
that	O
the	O
lineage	O
can	O
be	O
applied	O
as	O
a	O
model	O
for	O
understanding	O
the	O
biological	O
context	O
of	O
heritable	O
spinal	B-Organism_subdivision
curvature	O
[	O
1	O
,	O
7	O
-	O
9	O
]	O
.	O
</ALL>	O

<ALL>	O
Future	O
studies	O
can	O
use	O
approaches	O
to	O
map	O
QTL	O
affecting	O
shape	O
based	O
on	O
digital	O
photos	O
[	O
31	O
,	O
32	O
]	O
,	O
rather	O
than	O
the	O
qualitative	O
scale	O
used	O
in	O
the	O
present	O
study	O
.	O
</ALL>	O

<ALL>	O
The	O
identification	O
of	O
QTL	O
in	O
this	O
study	O
is	O
a	O
first	O
step	O
in	O
understanding	O
the	O
genetics	O
of	O
this	O
type	O
of	O
deformity	O
and	O
will	O
lead	O
to	O
the	O
identification	O
of	O
biological	O
pathways	O
associated	O
with	O
spinal	B-Organism_subdivision
integrity	O
.	O
</ALL>	O

<ALL>	O
Intact	O
mass	O
analysis	O
of	O
a	O
mixed	O
population	O
of	O
proteins	O
.	O
</ALL>	O

<ALL>	O
A	O
mixture	O
of	O
the	O
membrane	B-Cellular_component
protein	O
KCNJ12	O
,	O
the	O
soluble	O
TEV	O
protease	O
used	O
to	O
cleave	O
the	O
fusion	O
tag	O
,	O
and	O
the	O
membrane	B-Cellular_component
protein	O
HVCN1	O
,	O
which	O
occurred	O
as	O
a	O
contaminant	O
from	O
an	O
earlier	O
analysis	O
on	O
the	O
same	O
LC	O
column	O
.	O
</ALL>	O

<ALL>	O
The	O
asymmetric	O
unit	O
of	O
the	O
title	O
compound	O
with	O
the	O
atomic	O
labelling	O
scheme	O
.	O
Displacement	O
are	O
drawn	O
at	O
the	O
50	O
%	O
probability	O
level	O
.	O
</ALL>	O

<ALL>	O
H	O
atoms	O
are	O
represented	O
as	O
small	O
spheres	O
of	O
arbitrary	O
radii	O
.	O
</ALL>	O

<ALL>	O
Hydrogen	O
bonds	O
are	O
shown	O
as	O
dashed	O
lines	O
.	O
</ALL>	O

<ALL>	O
Modified	O
radiology	O
-	O
guided	O
percutaneous	O
gastrostomy	O
technique	O
.	O
</ALL>	O

<ALL>	O
A	O
.	O
</ALL>	O

<ALL>	O
21G	O
fine	O
needle	O
punctured	O
localized	O
collection	O
of	O
air	O
,	O
which	O
was	O
visible	O
in	O
collapsed	O
stomach	B-Organ
under	O
fluoroscopy	O
-	O
guided	O
gastrostomy	O
.	O
</ALL>	O

<ALL>	O
Needle	O
tip	O
is	O
then	O
gradually	O
withdrawn	O
while	O
injecting	O
small	O
amounts	O
of	O
water	O
-	O
soluble	O
contrast	O
medium	O
.	O
</ALL>	O

<ALL>	O
Location	O
of	O
stomach	B-Organ
is	O
confirmed	O
by	O
visualization	O
of	O
opacified	O
gastric	B-Organ
rugae	O
.	O
</ALL>	O

<ALL>	O
B	O
.	O
</ALL>	O

<ALL>	O
Stomach	B-Organ
was	O
inflated	O
with	O
approximately	O
600	O
-	O
800	O
mL	O
of	O
room	O
air	O
through	O
21G	O
fine	O
needle	O
.	O
</ALL>	O

<ALL>	O
C	O
.	O
</ALL>	O

<ALL>	O
100	O
-	O
cm	O
stainless	O
steel	O
guide	O
wire	O
is	O
inserted	O
through	O
needle	O
,	O
and	O
gastro	B-Organ
-	O
percutaneous	O
tract	O
is	O
gradually	O
dilated	O
.	O
</ALL>	O

<ALL>	O
D	O
.	O
</ALL>	O

<ALL>	O
Insertion	O
of	O
14	O
-	O
Fr	O
pigtail	O
gastrostomy	O
catheter	O
and	O
injection	O
of	O
small	O
amount	O
of	O
water	O
-	O
soluble	O
contrast	O
medium	O
via	O
pigtail	O
catheter	O
confirmed	O
that	O
gastrostomy	O
catheter	O
is	O
correctly	O
placed	O
within	O
stomach	B-Organ
.	O
</ALL>	O

<ALL>	O
Loss	O
of	O
body	B-Organism_subdivision
weight	O
after	O
challenge	O
-	O
infection	O
with	O
WNV	O
.	O
</ALL>	O

<ALL>	O
Mice	O
(	O
n	O
=	O
8	O
)	O
were	O
vaccinated	O
intranasally	B-Immaterial_anatomical_entity
with	O
Flu	O
-	O
NA	O
-	O
DIII	O
(	O
*	O
)	O
or	O
Flu	O
-	O
NA	O
-	O
GFP	O
(	O
o	O
)	O
or	O
by	O
the	O
subcutaneous	O
route	O
(	O
^	O
and	O
^	O
,	O
respectively	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
daily	O
weights	O
of	O
each	O
animal	O
were	O
calculated	O
compared	O
to	O
their	O
respective	O
weight	O
on	O
the	O
day	O
of	O
challenge	O
,	O
and	O
data	O
are	O
shown	O
as	O
the	O
average	O
percentage	O
of	O
initial	O
weight	O
for	O
each	O
group	O
.	O
</ALL>	O

<ALL>	O
Error	O
bars	O
represent	O
the	O
standard	O
error	O
for	O
all	O
samples	O
available	O
at	O
that	O
time	O
point	O
.	O
</ALL>	O

<ALL>	O
Subsequently	O
,	O
the	O
mice	O
were	O
challenged	O
subcutaneously	O
with	O
106	O
TCID50	O
WNV	O
-	O
NY99	O
and	O
weighed	O
daily	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
body	B-Organism_subdivision
weight	O
is	O
expressed	O
as	O
the	O
percentage	O
of	O
the	O
body	B-Organism_subdivision
weight	O
before	O
challenge	O
infection	O
(	O
A	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
survival	O
rates	O
of	O
mice	O
after	O
challenge	O
infection	O
with	O
WNV	O
-	O
NY99	O
are	O
depicted	O
as	O
Kaplan	O
-	O
Meier	O
survival	O
curves	O
(	O
B	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
difference	O
in	O
survival	O
rate	O
between	O
Flu	O
-	O
NA	O
-	O
DIII	O
and	O
Flu	O
-	O
NA	O
-	O
GFP	O
vaccinated	O
mice	O
was	O
statistically	O
significant	O
as	O
determined	O
by	O
the	O
logrank	O
test	O
.	O
</ALL>	O

<ALL>	O
The	O
symbols	O
for	O
the	O
respective	O
groups	O
are	O
the	O
same	O
as	O
in	O
panel	O
A	O
.	O
</ALL>	O

<ALL>	O
Representative	O
time	O
histories	O
of	O
the	O
estimated	O
SatO2	O
levels	O
of	O
normal	O
cortex	B-Multi-tissue_structure
(	O
black	O
)	O
and	O
tumor	B-Pathological_formation
(	O
grey	O
)	O
from	O
all	O
six	O
patients	O
.	O
</ALL>	O

<ALL>	O
Etymology	O
.	O
</ALL>	O

<ALL>	O
Professor	O
Stephen	O
Lane	O
Wood	O
worked	O
extensively	O
on	O
collections	O
of	O
Scolytinae	O
preserved	O
in	O
Indian	O
museums	O
,	O
and	O
described	O
a	O
number	O
of	O
new	O
Scolytinae	O
species	O
from	O
India	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
paper	O
we	O
describe	O
one	O
more	O
new	O
bark	O
-	O
beetle	O
species	O
from	O
India	O
kept	O
in	O
the	O
Natural	O
History	O
Museum	O
in	O
Vienna	O
(	O
NHMW	O
)	O
and	O
dedicate	O
this	O
species	O
to	O
the	O
late	O
Professor	O
Stephen	O
Lane	O
Wood	O
.	O
</ALL>	O

<ALL>	O
Statistics	O
</ALL>	O

<ALL>	O
The	O
survival	O
of	O
mice	O
was	O
analyzed	O
using	O
Kaplan	O
-	O
Meier	O
survival	O
analysis	O
.	O
</ALL>	O

<ALL>	O
All	O
other	O
data	O
were	O
analyzed	O
by	O
one	O
-	O
way	O
ANOVA	O
,	O
followed	O
by	O
the	O
Student	O
-	O
Newman	O
-	O
Keuls	O
test	O
for	O
all	O
pairwise	O
comparisons	O
.	O
</ALL>	O

<ALL>	O
Prior	O
to	O
ANOVA	O
,	O
Levene	O
'	O
s	O
Test	O
for	O
Equality	O
of	O
Variances	O
was	O
performed	O
.	O
</ALL>	O

<ALL>	O
All	O
statistical	O
analyses	O
were	O
performed	O
using	O
MedCalc	O
software	O
,	O
version	O
11	O
.	O
2	O
.	O
1	O
.	O
0	O
.	O
</ALL>	O

<ALL>	O
Acknowledgements	O
</ALL>	O

<ALL>	O
The	O
authors	O
gratefully	O
acknowledge	O
the	O
support	O
of	O
DRUID	O
study	O
participants	O
,	O
study	O
staff	O
,	O
members	O
of	O
the	O
Indigenous	O
Steering	O
Group	O
,	O
and	O
partner	O
organisations	O
.	O
</ALL>	O

<ALL>	O
The	O
DRUID	O
Study	O
was	O
funded	O
by	O
the	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
(	O
NHMRC	O
Project	O
Grant	O
#	O
236207	O
)	O
,	O
with	O
additional	O
support	O
from	O
the	O
Australian	O
Government	O
Department	O
of	O
Employment	O
and	O
Workplace	O
Relations	O
,	O
the	O
Clive	O
and	O
Vera	O
Ramaciotti	O
Foundation	O
,	O
the	O
Vincent	O
Fairfax	O
Family	O
Foundation	O
,	O
the	O
International	O
Diabetes	O
Institute	O
(	O
AusDiab	O
Partnership	O
)	O
,	O
and	O
Bayer	O
HealthCare	O
.	O
</ALL>	O

<ALL>	O
The	O
DRUID	O
Study	O
is	O
an	O
in	O
-	O
kind	O
project	O
of	O
the	O
Cooperative	O
Research	O
Centre	O
for	O
Aboriginal	O
Health	O
.	O
</ALL>	O

<ALL>	O
LMB	O
had	O
a	O
NHMRC	O
Scholarship	O
2003	O
-	O
5	O
and	O
is	O
supported	O
by	O
NHMRC	O
Training	O
Fellowship	O
(	O
#	O
605837	O
)	O
,	O
NHMRC	O
#	O
320860	O
and	O
the	O
Centre	O
of	O
Clinical	O
Research	O
Excellence	O
in	O
Clinical	O
Science	O
in	O
Diabetes	O
,	O
University	O
of	O
Melbourne	O
.	O
</ALL>	O

<ALL>	O
JC	O
was	O
supported	O
by	O
a	O
NHMRC	O
Career	O
Development	O
Award	O
(	O
#	O
283310	O
)	O
and	O
a	O
NHMRC	O
Research	O
Fellowship	O
(	O
#	O
545200	O
)	O
.	O
</ALL>	O

<ALL>	O
AH	O
is	O
supported	O
by	O
NHMRC	O
Fellowship	O
(	O
#	O
520316	O
)	O
.	O
</ALL>	O

<ALL>	O
Thank	O
you	O
to	O
Dr	O
Jaquelyne	O
Hughes	O
for	O
comments	O
on	O
the	O
manuscript	O
.	O
</ALL>	O

<ALL>	O
Funding	O
sources	O
played	O
no	O
role	O
in	O
the	O
study	O
design	O
,	O
in	O
the	O
collection	O
,	O
analysis	O
and	O
interpretation	O
of	O
the	O
data	O
,	O
in	O
the	O
writing	O
of	O
the	O
manuscript	O
,	O
or	O
in	O
the	O
decision	O
to	O
submit	O
the	O
manuscript	O
for	O
publication	O
.	O
</ALL>	O

<ALL>	O
Concurrent	O
disease	O
in	O
33	O
cows	O
with	O
LDA	O
.	O
</ALL>	O

<ALL>	O
Parkin	O
regulates	O
the	O
proteasomal	B-Cellular_component
degradation	O
of	O
PARIS	O
and	O
PGC	O
-	O
1alpha	O
-	O
dependent	O
mitochondrial	B-Cellular_component
biogenesis	O
.	O
</ALL>	O

<ALL>	O
(	O
A	O
)	O
Normal	O
physiological	O
conditions	O
that	O
maintain	O
mitochondrial	B-Cellular_component
homeostasis	O
:	O
PINK1	O
recruits	O
parkin	O
to	O
the	O
mitochondria	B-Cellular_component
,	O
where	O
these	O
two	O
proteins	O
interact	O
to	O
eliminate	O
abnormal	O
mitochondria	B-Cellular_component
through	O
mitophagy	O
.	O
</ALL>	O

<ALL>	O
Alterations	O
in	O
mitochondrial	B-Cellular_component
membrane	I-Cellular_component
potential	O
(	O
DeltaPsim	O
;	O
a	O
key	O
indicator	O
of	O
mitochondrial	B-Cellular_component
physiology	O
and	O
cell	B-Cell
viability	O
)	O
initiate	O
the	O
PINK1	O
-	O
parkin	O
cascade	O
of	O
events	O
that	O
lead	O
to	O
mitophagy	O
.	O
</ALL>	O

<ALL>	O
Furthermore	O
,	O
parkin	O
ubiquitylates	O
and	O
thereby	O
promotes	O
proteasomal	B-Cellular_component
degradation	O
of	O
PARIS	O
.	O
</ALL>	O

<ALL>	O
Because	O
PARIS	O
represses	O
the	O
expression	O
of	O
PGC	O
-	O
1alpha	O
,	O
degradation	O
of	O
PARIS	O
by	O
parkin	O
allows	O
PGC	O
-	O
1alpha	O
-	O
dependent	O
gene	O
expression	O
and	O
enables	O
mitochondrial	B-Cellular_component
biogenesis	O
.	O
</ALL>	O

<ALL>	O
Parkin	O
seems	O
to	O
be	O
an	O
integral	O
regulator	O
of	O
mitochondrial	B-Cellular_component
homeostasis	O
,	O
controlling	O
both	O
degradation	O
and	O
biogenesis	O
.	O
</ALL>	O

<ALL>	O
(	O
B	O
)	O
Loss	O
of	O
parkin	O
function	O
as	O
a	O
result	O
of	O
familial	O
mutations	O
(	O
in	O
the	O
case	O
of	O
AR	O
-	O
PD	O
)	O
or	O
aging	O
,	O
environmental	O
or	O
cellular	B-Cell
stress	O
(	O
in	O
the	O
case	O
of	O
sporadic	O
PD	O
)	O
leads	O
to	O
the	O
accumulation	O
of	O
abnormal	O
mitochondria	B-Cellular_component
,	O
owing	O
to	O
faulty	O
mitophagy	O
.	O
</ALL>	O

<ALL>	O
In	O
addition	O
,	O
PARIS	O
accumulates	O
and	O
represses	O
PGC	O
-	O
1alpha	O
,	O
preventing	O
mitochondrial	B-Cellular_component
biogenesis	O
.	O
</ALL>	O

<ALL>	O
Loss	O
of	O
parkin	O
function	O
does	O
not	O
tip	O
the	O
balance	O
between	O
mitochondrial	B-Cellular_component
biogenesis	O
and	O
degradation	O
to	O
either	O
side	O
,	O
but	O
leads	O
to	O
a	O
general	O
breakdown	O
of	O
mitochondrial	B-Cellular_component
homeostasis	O
that	O
can	O
ultimately	O
lead	O
to	O
PD	O
.	O
</ALL>	O

<ALL>	O
4	O
.	O
2	O
.	O
</ALL>	O

<ALL>	O
Histological	O
Findings	O
</ALL>	O

<ALL>	O
Microscopy	O
revealed	O
features	O
of	O
a	O
diffusely	O
growing	O
discohesive	B-Pathological_formation
carcinoma	I-Pathological_formation
,	O
exclusively	O
growing	O
in	O
the	O
alveolar	B-Multi-tissue_structure
interstitium	I-Multi-tissue_structure
,	O
thus	O
expanding	O
it	O
,	O
while	O
leaving	O
the	O
original	O
alveolar	B-Multi-tissue_structure
architecture	O
intact	O
(	O
Figure	O
2	O
)	O
.	O
</ALL>	O

<ALL>	O
There	O
was	O
local	O
ulceration	O
of	O
the	O
pleura	B-Multi-tissue_structure
,	O
while	O
,	O
beyond	O
this	O
ulcer	B-Pathological_formation
,	O
the	O
tumor	B-Pathological_formation
formed	O
a	O
thick	O
cake	O
of	O
discohesive	B-Cell
tumor	I-Cell
cells	I-Cell
lining	O
the	O
pleural	B-Multi-tissue_structure
membrane	I-Multi-tissue_structure
(	O
Figure	O
2	O
(	O
c	O
)	O
)	O
,	O
with	O
only	O
focal	O
,	O
microscopic	O
invasion	O
into	O
the	O
fatty	B-Tissue
tissue	I-Tissue
of	O
the	O
parietal	B-Multi-tissue_structure
pleura	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
The	O
tumor	B-Pathological_formation
consisted	O
of	O
atypical	O
,	O
moderately	O
polymorphous	O
,	O
and	O
irregularly	O
shaped	O
tumor	B-Cell
cells	I-Cell
with	O
marked	O
discohesiveness	O
.	O
</ALL>	O

<ALL>	O
They	O
featured	O
scant	O
eosinophilic	B-Organism_substance
cytoplasm	I-Organism_substance
and	O
irregularly	O
contoured	O
and	O
hyperchromatic	O
nuclei	B-Cellular_component
,	O
often	O
containing	O
one	O
or	O
more	O
prominent	O
nucleoli	B-Cellular_component
(	O
Figure	O
2	O
(	O
b	O
)	O
)	O
.	O
</ALL>	O

<ALL>	O
There	O
were	O
many	O
mitoses	O
and	O
apoptoses	O
present	O
,	O
but	O
necrosis	O
was	O
not	O
observed	O
.	O
</ALL>	O

<ALL>	O
No	O
squamous	B-Cell
or	O
glandular	B-Cell
differentiation	O
was	O
observed	O
,	O
and	O
mucin	O
stains	O
(	O
PAS	O
-	O
D	O
and	O
alcian	O
blue	O
)	O
were	O
negative	O
.	O
</ALL>	O

<ALL>	O
Within	O
the	O
tumor	B-Pathological_formation
,	O
there	O
were	O
multiple	O
small	O
blood	B-Organism_substance
-	O
filled	O
clefts	O
and	O
blood	B-Organism_substance
lakes	O
.	O
</ALL>	O

<ALL>	O
Angioinvasion	O
in	O
medium	O
-	O
sized	O
vessels	B-Multi-tissue_structure
,	O
including	O
an	O
artery	B-Multi-tissue_structure
,	O
was	O
demonstrated	O
(	O
Figure	O
2	O
(	O
d	O
)	O
)	O
.	O
</ALL>	O

<ALL>	O
Of	O
note	O
,	O
the	O
broadened	O
alveolar	B-Multi-tissue_structure
septa	I-Multi-tissue_structure
were	O
lined	O
by	O
markedly	O
atypical	O
epithelial	B-Cell
cells	I-Cell
,	O
yet	O
less	O
atypical	O
than	O
the	O
interstitial	B-Pathological_formation
carcinoma	I-Pathological_formation
(	O
Figures	O
2	O
(	O
a	O
)	O
and	O
2	O
(	O
b	O
)	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
atypia	O
of	O
the	O
lining	B-Cell
cells	I-Cell
extended	O
beyond	O
the	O
tumor	B-Pathological_formation
front	O
,	O
showing	O
a	O
sharp	O
demarcation	O
with	O
normal	O
type	B-Cell
I	I-Cell
pneumocytes	I-Cell
(	O
Figure	O
2	O
(	O
a	O
)	O
)	O
,	O
a	O
feature	O
characteristic	O
to	O
nonmucinous	B-Pathological_formation
adenocarcinoma	I-Pathological_formation
in	O
situ	O
with	O
lepidic	O
growth	O
pattern	O
(	O
former	O
bronchioloalveolar	B-Pathological_formation
carcinoma	I-Pathological_formation
,	O
BAC	B-Pathological_formation
)	O
[	O
3	O
]	O
.	O
</ALL>	O

<ALL>	O
Paederus	O
dermatitis	O
involving	O
the	O
neck	B-Organism_subdivision
</ALL>	O

<ALL>	O
Introduction	O
</ALL>	O

<ALL>	O
During	O
the	O
weaning	O
period	O
and	O
transition	O
to	O
solid	O
foods	O
in	O
the	O
first	O
year	O
of	O
life	O
,	O
infants	O
take	O
a	O
critical	O
step	O
in	O
their	O
eating	O
behavior	O
and	O
need	O
to	O
meet	O
high	O
nutrient	O
requirements	O
[	O
1	O
,	O
2	O
]	O
.	O
</ALL>	O

<ALL>	O
They	O
are	O
exposed	O
to	O
new	O
foods	O
and	O
food	O
combinations	O
,	O
which	O
should	O
ensure	O
a	O
smooth	O
transition	O
to	O
the	O
family	O
diet	O
later	O
in	O
life	O
.	O
</ALL>	O

<ALL>	O
At	O
this	O
stage	O
,	O
either	O
homemade	O
or	O
commercially	O
prepared	O
foods	O
may	O
be	O
fed	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
worth	O
noting	O
that	O
in	O
prosperous	O
countries	O
the	O
modern	O
diet	O
differs	O
considerably	O
from	O
that	O
of	O
previous	O
generations	O
,	O
now	O
dominated	O
by	O
products	O
that	O
have	O
been	O
processed	O
,	O
stored	O
,	O
and	O
transported	O
over	O
great	O
distances	O
.	O
</ALL>	O

<ALL>	O
Traditional	O
,	O
cold	O
-	O
pressed	O
vegetable	B-Organism_substance
oils	I-Organism_substance
of	O
the	O
highest	O
nutritional	O
quality	O
,	O
e	O
.	O
g	O
.	O
extra	O
virgin	O
olive	O
oil	B-Organism_substance
,	O
may	O
therefore	O
constitute	O
an	O
important	O
part	O
of	O
the	O
modern	O
diet	O
[	O
3	O
,	O
4	O
]	O
.	O
</ALL>	O

<ALL>	O
In	O
Poland	O
,	O
many	O
infants	O
do	O
not	O
receive	O
any	O
traditional	O
homemade	O
foods	O
and	O
even	O
fruits	B-Organism_subdivision
come	O
from	O
purchased	O
jars	O
.	O
</ALL>	O

<ALL>	O
Commercial	O
baby	O
foods	O
are	O
regarded	O
by	O
some	O
parents	O
and	O
medical	O
professionals	O
to	O
be	O
more	O
appropriate	O
for	O
several	O
reasons	O
:	O
they	O
undergo	O
intense	O
screening	O
for	O
contaminants	O
in	O
comparison	O
to	O
foods	O
sold	O
for	O
the	O
general	O
population	O
,	O
contain	O
no	O
additives	O
of	O
certain	O
types	O
,	O
and	O
are	O
thought	O
to	O
be	O
designed	O
to	O
help	O
infants	O
meet	O
nutrient	O
requirements	O
[	O
5	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
process	O
of	O
peeling	O
,	O
however	O
,	O
was	O
identified	O
as	O
the	O
most	O
effective	O
,	O
and	O
simple	O
,	O
procedure	O
in	O
reducing	O
residues	O
,	O
e	O
.	O
g	O
.	O
pesticides	O
,	O
in	O
fruits	B-Organism_subdivision
and	O
vegetables	B-Organism_subdivision
[	O
6	O
]	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
contrary	O
to	O
homemade	O
food	O
,	O
which	O
does	O
not	O
contain	O
furan	O
,	O
the	O
highest	O
average	O
content	O
of	O
this	O
chemical	O
was	O
found	O
in	O
ready	O
-	O
to	O
-	O
eat	O
baby	O
foods	O
with	O
pasta	O
meals	O
,	O
followed	O
by	O
vegetable	B-Organism_subdivision
meals	O
and	O
meals	O
with	O
meat	B-Organism_subdivision
[	O
7	O
]	O
.	O
</ALL>	O

<ALL>	O
Furan	O
is	O
considered	O
to	O
be	O
potentially	O
hazardous	O
chemical	O
and	O
is	O
classified	O
as	O
a	O
possible	O
carcinogen	O
.	O
</ALL>	O

<ALL>	O
The	O
problem	O
of	O
this	O
chemical	O
in	O
homemade	O
food	O
may	O
only	O
arise	O
if	O
meals	O
with	O
potatoes	O
are	O
stored	O
and	O
then	O
hardly	O
re	O
-	O
heated	O
[	O
7	O
]	O
.	O
</ALL>	O

<ALL>	O
There	O
is	O
a	O
growing	O
body	B-Organism_subdivision
of	O
evidence	O
that	O
flavor	O
experiences	O
and	O
dietary	O
patterns	O
in	O
childhood	O
influence	O
these	O
patterns	O
later	O
in	O
life	O
[	O
1	O
,	O
8	O
,	O
9	O
]	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
most	O
likely	O
early	O
in	O
life	O
that	O
culture	O
-	O
specific	O
flavor	O
preferences	O
are	O
initiated	O
[	O
10	O
,	O
11	O
]	O
.	O
</ALL>	O

<ALL>	O
Consequently	O
,	O
exposure	O
to	O
flavors	O
and	O
smells	O
of	O
transitory	O
foods	O
may	O
serve	O
to	O
heighten	O
preferences	O
for	O
"	O
known	O
tastes	O
"	O
in	O
the	O
family	O
diet	O
later	O
in	O
adulthood	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
adopting	O
elements	O
of	O
childhood	O
dinner	O
patterns	O
was	O
recognized	O
to	O
be	O
an	O
important	O
part	O
of	O
the	O
social	O
reproduction	O
of	O
family	O
identities	O
across	O
generations	O
[	O
12	O
]	O
.	O
</ALL>	O

<ALL>	O
Processing	O
industries	O
have	O
been	O
successful	O
in	O
manufacturing	O
and	O
marketing	O
jarred	O
baby	O
foods	O
on	O
a	O
commercial	O
scale	O
.	O
</ALL>	O

<ALL>	O
Available	O
products	O
contain	O
different	O
ingredients	O
and	O
depend	O
on	O
the	O
manufacturer	O
,	O
country	O
,	O
traditional	O
cuisine	O
,	O
income	O
rate	O
,	O
and	O
lastly	O
,	O
personal	O
beliefs	O
and	O
values	O
of	O
parents	O
[	O
9	O
,	O
11	O
]	O
.	O
</ALL>	O

<ALL>	O
Jarred	O
foods	O
with	O
vegetables	B-Organism_subdivision
,	O
meats	B-Organism_subdivision
,	O
and	O
desserts	O
may	O
contain	O
added	O
fat	O
from	O
a	O
variety	O
of	O
sources	O
:	O
vegetable	B-Organism_substance
oils	I-Organism_substance
,	O
cow	O
milk	B-Organism_substance
butter	O
,	O
or	O
cream	O
.	O
</ALL>	O

<ALL>	O
Manufacturer	O
advertising	O
makes	O
the	O
majority	O
of	O
consumers	O
feel	O
safe	O
,	O
causing	O
them	O
to	O
believe	O
that	O
they	O
are	O
doing	O
the	O
best	O
possible	O
in	O
buying	O
given	O
products	O
[	O
11	O
]	O
.	O
</ALL>	O

<ALL>	O
A	O
noteworthy	O
fact	O
is	O
that	O
many	O
types	O
of	O
baby	O
foods	O
produced	O
by	O
international	O
manufacturers	O
are	O
,	O
in	O
essence	O
,	O
the	O
same	O
mixtures	O
with	O
different	O
names	O
;	O
this	O
procedure	O
aims	O
to	O
exploit	O
the	O
specifics	O
of	O
local	O
markets	O
without	O
delivering	O
any	O
new	O
,	O
real	O
value	O
[	O
11	O
]	O
.	O
</ALL>	O

<ALL>	O
In	O
the	O
book	O
,	O
How	O
to	O
Eat	O
Well	O
and	O
Stay	O
Well	O
the	O
Mediterranean	O
Way	O
by	O
Keys	O
[	O
13	O
]	O
first	O
used	O
the	O
term	O
"	O
good	O
Mediterranean	O
diet	O
"	O
to	O
describe	O
the	O
eating	O
patterns	O
of	O
populations	O
dwelling	O
in	O
southern	O
Europe	O
,	O
where	O
the	O
olive	O
tree	O
(	O
Olea	O
europaea	O
)	O
is	O
an	O
emblematic	O
species	O
[	O
4	O
,	O
14	O
]	O
.	O
</ALL>	O

<ALL>	O
There	O
is	O
variation	O
between	O
the	O
exact	O
diet	O
in	O
different	O
parts	O
of	O
the	O
Mediterranean	O
region	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
generalized	O
and	O
distinctive	O
dietary	O
patterns	O
do	O
exist	O
,	O
including	O
olive	O
oil	B-Organism_substance
as	O
the	O
main	O
source	O
of	O
visible	O
fat	O
,	O
employed	O
both	O
in	O
cooking	O
and	O
as	O
a	O
dressing	O
,	O
moderate	O
fish	O
and	O
poultry	O
but	O
low	O
red	B-Organism_subdivision
meat	I-Organism_subdivision
consumption	O
,	O
high	O
intake	O
of	O
vegetables	B-Organism_subdivision
,	O
fruits	B-Organism_subdivision
,	O
legumes	O
,	O
nuts	B-Organism_subdivision
,	O
and	O
whole	O
-	O
grain	O
cereals	O
[	O
4	O
,	O
14	O
-	O
16	O
]	O
.	O
</ALL>	O

<ALL>	O
When	O
dietary	B-Organism_substance
fats	I-Organism_substance
are	O
added	O
,	O
in	O
accordance	O
with	O
the	O
traditional	O
Mediterranean	O
diet	O
,	O
olive	O
oil	B-Organism_substance
is	O
the	O
choice	O
for	O
children	O
[	O
17	O
]	O
.	O
</ALL>	O

<ALL>	O
It	O
has	O
been	O
repeatedly	O
observed	O
that	O
individuals	O
applying	O
the	O
Mediterranean	O
diet	O
have	O
reduced	O
risks	O
of	O
type	O
2	O
diabetes	O
and	O
other	O
diseases	O
associated	O
with	O
the	O
metabolic	O
syndrome	O
,	O
autoimmunological	O
diseases	O
,	O
and	O
certain	O
forms	O
of	O
cancer	B-Pathological_formation
[	O
18	O
]	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
considerable	O
evidence	O
exists	O
that	O
the	O
Mediterranean	O
diet	O
increases	O
quality	O
of	O
life	O
in	O
the	O
course	O
of	O
ageing	O
,	O
as	O
well	O
as	O
longevity	O
[	O
13	O
,	O
19	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
health	O
benefits	O
of	O
olive	O
oil	B-Organism_substance
have	O
been	O
attributed	O
to	O
two	O
main	O
constituents	O
:	O
a	O
high	O
oleic	O
acid	O
(	O
monounsaturated	O
fatty	O
acid	O
,	O
18	O
:	O
1n	O
-	O
9	O
)	O
content	O
(	O
70	O
-	O
85	O
%	O
)	O
and	O
a	O
large	O
amount	O
of	O
antioxidant	O
compounds	O
,	O
which	O
also	O
possess	O
antiviral	O
,	O
antibacterial	O
,	O
and	O
immunomodulating	O
effects	O
[	O
3	O
,	O
4	O
,	O
14	O
,	O
16	O
]	O
.	O
</ALL>	O

<ALL>	O
Polyphenols	O
found	O
in	O
virgin	O
olive	O
oil	B-Organism_substance
are	O
linked	O
to	O
both	O
its	O
flavor	O
and	O
its	O
remarkable	O
stability	O
[	O
3	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
introduction	O
of	O
solid	O
foods	O
in	O
infancy	O
is	O
one	O
of	O
the	O
primary	O
matters	O
often	O
discussed	O
by	O
parents	O
with	O
their	O
child	O
'	O
s	O
pediatrician	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
many	O
parents	O
do	O
not	O
feel	O
that	O
the	O
diet	O
of	O
their	O
child	O
may	O
be	O
linked	O
to	O
poor	O
health	O
outcomes	O
in	O
the	O
future	O
.	O
</ALL>	O

<ALL>	O
Parents	O
should	O
be	O
educated	O
about	O
the	O
interplay	O
of	O
environmental	O
and	O
genetic	O
influences	O
on	O
children	O
,	O
specifically	O
during	O
the	O
early	O
years	O
of	O
development	O
when	O
the	O
child	O
is	O
maturing	O
and	O
taking	O
control	O
of	O
its	O
own	O
diet	O
[	O
11	O
]	O
.	O
</ALL>	O

<ALL>	O
Nutrition	O
educators	O
should	O
increase	O
the	O
critical	O
awareness	O
of	O
parents	O
in	O
relation	O
to	O
their	O
child	O
'	O
s	O
solid	O
food	O
choices	O
.	O
</ALL>	O

<ALL>	O
It	O
is	O
important	O
to	O
emphasize	O
to	O
parents	O
the	O
fundamental	O
role	O
that	O
the	O
Mediterranean	O
diet	O
and	O
consumption	O
of	O
foods	O
with	O
olive	O
oil	B-Organism_substance
play	O
in	O
a	O
healthy	O
life	O
style	O
[	O
14	O
,	O
20	O
]	O
.	O
</ALL>	O

<ALL>	O
Parental	O
management	O
of	O
the	O
family	O
food	O
environment	O
may	O
be	O
complicated	O
by	O
numerous	O
mitigating	O
factors	O
,	O
e	O
.	O
g	O
.	O
health	O
literacy	O
,	O
time	O
availability	O
,	O
and	O
financial	O
resources	O
.	O
</ALL>	O

<ALL>	O
Considering	O
the	O
role	O
baby	O
food	O
manufacturers	O
play	O
in	O
the	O
infant	O
'	O
s	O
contextual	O
environment	O
,	O
their	O
products	O
,	O
as	O
well	O
as	O
the	O
manufacturers	O
themselves	O
,	O
should	O
also	O
be	O
viewed	O
as	O
key	O
players	O
and	O
central	O
agents	O
in	O
establishing	O
dietary	O
habits	O
.	O
</ALL>	O

<ALL>	O
Consequently	O
,	O
we	O
attempted	O
to	O
survey	O
manufacturer	O
claims	O
concerning	O
added	O
fat	O
in	O
jarred	O
infant	O
foods	O
supplied	O
to	O
the	O
Polish	O
market	O
.	O
</ALL>	O

<ALL>	O
2	O
.	O
1	O
.	O
3	O
</ALL>	O

<ALL>	O
Pixel	O
Classification	O
</ALL>	O

<ALL>	O
The	O
feature	O
vector	O
of	O
a	O
grid	O
,	O
which	O
consists	O
of	O
nine	O
features	O
,	O
is	O
normalized	O
to	O
[	O
0	O
,	O
1	O
]	O
,	O
and	O
the	O
position	O
features	O
are	O
scaled	O
by	O
the	O
weighting	O
coefficient	O
wpos	O
.	O
</ALL>	O

<ALL>	O
Then	O
,	O
taking	O
the	O
nine	O
dimensional	O
vector	O
of	O
each	O
grid	O
as	O
the	O
input	O
of	O
the	O
classifier	O
,	O
the	O
ROI	O
and	O
non	O
-	O
ROI	O
background	O
in	O
ultrasonic	O
breast	B-Pathological_formation
tumor	I-Pathological_formation
images	O
can	O
be	O
distinguished	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
section	O
,	O
the	O
self	O
-	O
organizing	O
feature	O
map	O
neural	O
network	O
(	O
SOMNN	O
)	O
[	O
25	O
]	O
,	O
proposed	O
by	O
Kohonen	O
according	O
to	O
characteristics	O
of	O
the	O
nervous	B-Anatomical_system
system	I-Anatomical_system
,	O
is	O
used	O
for	O
the	O
classification	O
of	O
these	O
grids	O
to	O
detect	O
the	O
ROI	O
automatically	O
.	O
</ALL>	O

<ALL>	O
The	O
SOM	O
is	O
trained	O
by	O
the	O
unsupervised	O
learning	O
to	O
produce	O
a	O
low	O
-	O
dimensional	O
discretized	O
representation	O
of	O
the	O
input	O
space	O
of	O
the	O
training	O
samples	O
,	O
and	O
it	O
uses	O
a	O
neighborhood	O
function	O
to	O
preserve	O
the	O
topological	O
properties	O
of	O
the	O
input	O
space	O
,	O
which	O
makes	O
it	O
different	O
from	O
other	O
artificial	O
neural	O
networks	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
way	O
,	O
the	O
SOM	O
is	O
able	O
to	O
classify	O
the	O
sub	O
-	O
blocks	O
into	O
n	O
clusters	O
only	O
by	O
the	O
unsupervised	O
learning	O
.	O
</ALL>	O

<ALL>	O
In	O
our	O
study	O
,	O
the	O
output	O
layer	O
number	O
n	O
is	O
set	O
to	O
2	O
(	O
ROI	O
and	O
non	O
-	O
ROI	O
output	O
)	O
and	O
the	O
feature	O
vector	O
extracted	O
from	O
each	O
grid	O
is	O
taken	O
as	O
the	O
input	O
.	O
</ALL>	O

<ALL>	O
To	O
map	O
the	O
sorted	O
sub	O
-	O
blocks	O
back	O
to	O
the	O
size	O
of	O
the	O
original	O
ultrasonic	O
images	O
,	O
the	O
initial	O
result	O
of	O
ROI	O
detection	O
can	O
be	O
represented	O
by	O
a	O
binary	O
image	O
as	O
shown	O
in	O
Fig	O
.	O
</ALL>	O

<ALL>	O
(	O
2d	O
)	O
,	O
where	O
white	O
areas	O
indicate	O
the	O
ROI	O
candidates	O
while	O
black	O
areas	O
the	O
non	O
-	O
ROIs	O
.	O
</ALL>	O

<ALL>	O
Materials	O
and	O
Methods	O
:	O
</ALL>	O

<ALL>	O
A	O
total	O
of	O
75	O
brain	B-Multi-tissue_structure
abscess	I-Multi-tissue_structure
pus	I-Multi-tissue_structure
specimens	I-Multi-tissue_structure
were	O
collected	O
during	O
neurosurgery	O
,	O
either	O
by	O
burr	O
hole	O
or	O
by	O
craniotomy	O
.	O
</ALL>	O

<ALL>	O
These	O
specimens	B-Multi-tissue_structure
were	O
further	O
subjected	O
to	O
Gram	O
stain	O
,	O
Ziehl	O
-	O
Neelsen	O
(	O
ZN	O
)	O
stain	O
,	O
and	O
conventional	O
microbiological	O
culture	O
.	O
</ALL>	O

<ALL>	O
Only	O
those	O
cases	O
which	O
showed	O
presence	O
of	O
AFB	O
on	O
ZN	O
stain	O
along	O
with	O
the	O
growth	O
of	O
Mycobacterium	O
tuberculosis	O
were	O
considered	O
as	O
TBAs	O
.	O
</ALL>	O

<ALL>	O
Such	O
TBA	O
cases	O
were	O
further	O
presented	O
along	O
with	O
their	O
In	O
vitro	O
Proton	O
Magnetic	O
Resonance	O
(	O
MR	O
)	O
Spectroscopic	O
findings	O
.	O
</ALL>	O

<ALL>	O
Challenges	O
to	O
creating	O
and	O
implementing	O
a	O
perioperative	O
glycemic	O
control	O
protocol	O
.	O
</ALL>	O

<ALL>	O
Parameters	O
derived	O
from	O
normalized	O
averaged	O
data	O
across	O
participants	O
</ALL>	O

<ALL>	O
Absolute	O
responder	O
rates	O
for	O
medical	O
management	O
recommendations	O
.	O
</ALL>	O

<ALL>	O
Conclusions	O
</ALL>	O

<ALL>	O
This	O
is	O
the	O
first	O
prospective	O
evaluation	O
of	O
parents	O
'	O
preferences	O
in	O
newly	O
diagnosed	O
juvenile	O
idiopathic	O
arthritis	O
patients	O
participating	O
in	O
the	O
BeSt	O
for	O
Kids	O
trial	O
.	O
</ALL>	O

<ALL>	O
Within	O
the	O
limitations	O
of	O
the	O
small	O
amounts	O
,	O
patients	O
clearly	O
preferred	O
initial	O
combination	O
therapy	O
with	O
etanercept	O
and	O
disliked	O
taking	O
prednisone	O
.	O
</ALL>	O

<ALL>	O
After	O
actual	O
exposure	O
and	O
follow	O
up	O
,	O
this	O
questionnaire	O
will	O
be	O
repeated	O
to	O
see	O
if	O
preferences	O
remain	O
the	O
same	O
.	O
</ALL>	O

<ALL>	O
Patients	O
and	O
Study	O
Design	O
</ALL>	O

<ALL>	O
A	O
prospective	O
evaluation	O
of	O
the	O
different	O
CMR	O
parameters	O
for	O
predicting	O
LV	B-Multi-tissue_structure
segmental	O
and	O
global	O
functional	O
recovery	O
was	O
performed	O
in	O
46	O
patients	O
(	O
63	O
+	O
/	O
-	O
10	O
years	O
old	O
,	O
3	O
with	O
previous	O
CABG	O
,	O
35	O
with	O
three	O
-	O
vessel	O
disease	O
,	O
3	O
with	O
one	O
-	O
vessel	O
disease	O
)	O
with	O
LV	B-Multi-tissue_structure
systolic	O
dysfunction	O
(	O
LVEF	O
35	O
+	O
/	O
-	O
8	O
%	O
)	O
before	O
they	O
underwent	O
surgical	O
(	O
n	O
=	O
34	O
)	O
or	O
percutaneous	O
(	O
n	O
=	O
12	O
)	O
revascularisation	O
.	O
</ALL>	O

<ALL>	O
Sixty	O
patients	O
without	O
contraindications	O
for	O
CMR	O
were	O
screened	O
for	O
the	O
following	O
inclusion	O
criteria	O
:	O
(	O
1	O
)	O
CAD	O
(	O
>	O
70	O
%	O
stenosis	O
in	O
one	O
or	O
more	O
major	O
epicardial	B-Multi-tissue_structure
vessels	I-Multi-tissue_structure
)	O
,	O
scheduled	O
for	O
a	O
revascularisation	O
procedure	O
;	O
(	O
2	O
)	O
LVEF	O
<	O
=	O
45	O
%	O
;	O
(	O
3	O
)	O
at	O
least	O
two	O
adjacent	O
segments	O
with	O
wall	B-Multi-tissue_structure
motion	O
abnormalities	O
at	O
rest	O
;	O
and	O
(	O
4	O
)	O
no	O
infarction	O
or	O
revascularisation	O
within	O
the	O
last	O
two	O
months	O
.	O
</ALL>	O

<ALL>	O
Patients	O
were	O
included	O
in	O
the	O
study	O
only	O
after	O
a	O
successful	O
and	O
complete	O
coronary	B-Multi-tissue_structure
revascularisation	O
.	O
</ALL>	O

<ALL>	O
Of	O
the	O
14	O
patients	O
who	O
did	O
not	O
complete	O
the	O
study	O
,	O
3	O
decided	O
not	O
to	O
undergo	O
the	O
repeated	O
CMR	O
scan	O
or	O
were	O
lost	O
during	O
follow	O
-	O
up	O
;	O
7	O
had	O
significant	O
periprocedural	O
injury	O
(	O
new	O
LGE	B-Pathological_formation
zones	O
on	O
repeated	O
CMR	O
scans	O
and	O
clinically	O
proven	O
periprocedural	O
myocardial	B-Multi-tissue_structure
infarction	O
(	O
MI	O
)	O
or	O
MI	O
between	O
both	O
scans	O
)	O
;	O
3	O
had	O
pacemakers	O
or	O
defibrillators	O
implanted	O
in	O
the	O
period	O
between	O
the	O
MR	O
scans	O
;	O
and	O
1	O
was	O
excluded	O
because	O
of	O
dilated	O
cardiomyopathy	O
with	O
secondary	O
CAD	O
.	O
</ALL>	O

<ALL>	O
None	O
of	O
the	O
patients	O
were	O
excluded	O
from	O
the	O
study	O
for	O
technical	O
reasons	O
or	O
image	O
quality	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
interval	O
between	O
CMR	O
and	O
revascularisation	O
was	O
12	O
+	O
/	O
-	O
13	O
days	O
,	O
and	O
none	O
of	O
the	O
patients	O
presented	O
clinical	O
evidence	O
of	O
infarction	O
during	O
this	O
period	O
.	O
</ALL>	O

<ALL>	O
The	O
mean	O
interval	O
between	O
MI	O
and	O
the	O
first	O
CMR	O
was	O
3	O
.	O
6	O
years	O
.	O
</ALL>	O

<ALL>	O
In	O
46	O
patients	O
,	O
the	O
extent	O
of	O
regional	O
contractility	O
and	O
LGE	B-Pathological_formation
were	O
determined	O
repeatedly	O
by	O
CMR	O
28	O
+	O
/	O
-	O
4	O
weeks	O
(	O
6	O
months	O
)	O
after	O
revascularisation	O
.	O
</ALL>	O

<ALL>	O
The	O
study	O
was	O
approved	O
by	O
the	O
Lithuanian	O
Bioethics	O
Committee	O
(	O
Nr	O
.	O
17	O
)	O
,	O
and	O
informed	O
written	O
consent	O
was	O
obtained	O
from	O
each	O
patient	O
prior	O
to	O
inclusion	O
in	O
the	O
study	O
.	O
</ALL>	O

<ALL>	O
Authors	O
'	O
contributions	O
</ALL>	O

<ALL>	O
EEKN	O
was	O
responsible	O
for	O
data	O
collection	O
,	O
statistical	O
analysis	O
and	O
drafting	O
the	O
manuscript	O
.	O
</ALL>	O

<ALL>	O
SAGN	O
and	O
YW	O
involved	O
in	O
data	O
collection	O
and	O
helped	O
with	O
the	O
data	O
analysis	O
.	O
</ALL>	O

<ALL>	O
AS	O
helped	O
in	O
data	O
analysis	O
.	O
</ALL>	O

<ALL>	O
EST	O
and	O
JL	O
directed	O
the	O
study	O
and	O
helped	O
in	O
revising	O
the	O
manuscript	O
.	O
</ALL>	O

<ALL>	O
RMVD	O
helped	O
in	O
data	O
analysis	O
,	O
interpretation	O
of	O
the	O
results	O
and	O
led	O
writing	O
of	O
the	O
manuscript	O
.	O
</ALL>	O

<ALL>	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
</ALL>	O

<ALL>	O
Figures	O
</ALL>	O

<ALL>	O
Fig	O
.	O
</ALL>	O

<ALL>	O
1	O
.	O
</ALL>	O

<ALL>	O
A	O
view	O
of	O
(	O
I	O
)	O
with	O
displacement	O
ellipsoids	O
drawn	O
at	O
the	O
30	O
%	O
probability	O
level	O
.	O
</ALL>	O

<ALL>	O
Fig	O
.	O
</ALL>	O

<ALL>	O
2	O
.	O
</ALL>	O

<ALL>	O
Stereoview	O
of	O
the	O
sheet	O
formed	O
by	O
C	O
-	O
-	O
H	O
.	O
.	O
.	O
pi	O
interactions	O
.	O
</ALL>	O

<ALL>	O
Hydrogen	O
atoms	O
not	O
involved	O
in	O
the	O
motifs	O
are	O
not	O
included	O
.	O
</ALL>	O

<ALL>	O
The	O
growth	O
in	O
the	O
number	O
of	O
database	O
publications	O
per	O
year	O
.	O
</ALL>	O

<ALL>	O
Each	O
bar	O
shows	O
the	O
number	O
of	O
research	O
articles	O
with	O
the	O
keyword	O
'	O
database	O
'	O
appearing	O
in	O
the	O
article	O
title	O
in	O
the	O
given	O
year	O
.	O
</ALL>	O

<ALL>	O
The	O
count	O
only	O
covers	O
articles	O
indexed	O
in	O
PubMed	O
.	O
</ALL>	O

<ALL>	O
The	O
increase	O
shows	O
an	O
exponential	O
trend	O
that	O
will	O
produce	O
nearly	O
2000	O
database	O
publications	O
per	O
year	O
by	O
2015	O
.	O
</ALL>	O

<ALL>	O
Cation	O
binding	O
to	O
yolk	B-Cell
platelet	I-Cell
phosvitin	O
</ALL>	O

<ALL>	O
In	O
addition	O
to	O
non	O
-	O
heme	O
iron	O
[	O
23	O
]	O
,	O
yolk	B-Developing_anatomical_structure
phosvitin	O
also	O
contains	O
Ca2	O
+	O
,	O
Mg2	O
+	O
,	O
Na	O
+	O
and	O
K	O
+	O
[	O
11	O
]	O
.	O
</ALL>	O

<ALL>	O
Partially	O
relaxed	O
23Na	O
Fourier	O
transform	O
NMR	O
spectra	O
revealed	O
the	O
existence	O
of	O
at	O
least	O
two	O
major	O
intracellular	B-Cellular_component
compartments	I-Cellular_component
of	O
NMR	O
-	O
visible	O
Na	O
+	O
[	O
35	O
]	O
.	O
</ALL>	O

<ALL>	O
A	O
large	O
fraction	O
of	O
the	O
Rana	O
oocyte	B-Cell
Na	O
+	O
was	O
NMR	O
-	O
invisible	O
and	O
could	O
be	O
recovered	O
in	O
the	O
yolk	B-Cell
platelets	I-Cell
[	O
35	O
]	O
.	O
</ALL>	O

<ALL>	O
During	O
the	O
first	O
meiotic	O
division	O
there	O
is	O
a	O
net	O
increase	O
in	O
NMR	O
-	O
visible	O
Na	O
+	O
;	O
by	O
completion	O
of	O
the	O
second	O
meiotic	O
division	O
(	O
following	O
fertilization	O
)	O
,	O
about	O
70	O
%	O
of	O
the	O
total	O
Na	O
+	O
becomes	O
NMR	O
-	O
visible	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
phosvitin	O
not	O
only	O
serves	O
as	O
a	O
site	O
for	O
energy	O
storage	O
,	O
but	O
also	O
as	O
a	O
storage	O
site	O
for	O
iron	O
and	O
other	O
ions	O
essential	O
for	O
embryonic	B-Developing_anatomical_structure
development	O
in	O
ponds	O
and	O
streams	O
that	O
contain	O
little	O
dissolved	O
salts	O
and	O
minerals	O
.	O
</ALL>	O

<ALL>	O
Predicted	O
methylation	O
level	O
of	O
C	O
.	O
gigas	O
genes	O
categorized	O
by	O
biological	O
processes	O
compared	O
to	O
measured	O
level	O
of	O
DNA	O
methylation	O
.	O
</ALL>	O

<ALL>	O
Mean	O
CpG	O
O	O
/	O
E	O
for	O
10	O
,	O
699	O
C	O
.	O
gigas	O
genes	O
categorized	O
according	O
to	O
Biological	O
Process	O
Gene	O
Ontology	O
(	O
GO	O
)	O
Slim	O
terms	O
are	O
plotted	O
on	O
the	O
x	O
-	O
axis	O
(	O
modified	O
from	O
Gavery	O
and	O
Roberts	O
,	O
2010	O
)	O
.	O
</ALL>	O

<ALL>	O
DNA	O
methylation	O
was	O
empirically	O
measured	O
by	O
performing	O
MBD	O
-	O
seq	O
on	O
the	O
SOLiD	O
4	O
platform	O
(	O
Applied	O
Biosystems	O
)	O
.	O
</ALL>	O

<ALL>	O
Genes	O
identified	O
in	O
the	O
MBD	O
-	O
library	O
were	O
associated	O
with	O
respective	O
GO	O
terms	O
and	O
enrichment	O
analysis	O
was	O
performed	O
based	O
on	O
the	O
entire	O
transcriptome	O
(	O
Fleury	O
et	O
al	O
.	O
,	O
2009	O
)	O
using	O
DAVID	O
(	O
Huang	O
et	O
al	O
.	O
,	O
2009a	O
,	O
b	O
)	O
.	O
</ALL>	O

<ALL>	O
Results	O
indicate	O
the	O
most	O
underrepresented	O
genes	O
in	O
the	O
library	O
are	O
involved	O
in	O
cell	B-Cell
adhesion	O
and	O
genes	O
involved	O
in	O
DNA	O
and	O
protein	O
metabolism	O
were	O
most	O
prevalent	O
in	O
the	O
MBD	O
-	O
library	O
.	O
</ALL>	O

<ALL>	O
Discussion	O
</ALL>	O

<ALL>	O
We	O
estimated	O
the	O
future	O
acceptability	O
of	O
PrEP	O
,	O
examining	O
the	O
attitudes	O
and	O
preferences	O
of	O
potential	O
user	O
groups	O
from	O
different	O
countries	O
towards	O
hypothetical	O
and	O
known	O
PrEP	O
attributes	O
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
show	O
that	O
participants	O
were	O
generally	O
willing	O
to	O
accept	O
PrEP	O
and	O
adopt	O
it	O
as	O
soon	O
as	O
it	O
becomes	O
available	O
.	O
</ALL>	O

<ALL>	O
Surprisingly	O
,	O
participants	O
were	O
also	O
willing	O
to	O
take	O
PrEP	O
even	O
when	O
reminded	O
of	O
potential	O
side	O
effects	O
,	O
cost	O
,	O
condom	O
use	O
,	O
and	O
frequent	O
HIV	O
testing	O
.	O
</ALL>	O

<ALL>	O
These	O
findings	O
indicate	O
participants	O
'	O
motivation	O
to	O
overcome	O
barriers	O
which	O
can	O
have	O
a	O
considerable	O
impact	O
on	O
uptake	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
participants	O
mentioned	O
that	O
the	O
thought	O
of	O
taking	O
PrEP	O
made	O
them	O
feel	O
anxious	O
,	O
although	O
they	O
also	O
indicated	O
that	O
taking	O
PrEP	O
would	O
not	O
be	O
embarrassing	O
and	O
they	O
would	O
want	O
their	O
partner	O
or	O
partners	O
to	O
know	O
.	O
</ALL>	O

<ALL>	O
Participants	O
'	O
anxiety	O
may	O
be	O
explained	O
by	O
the	O
hypothetical	O
nature	O
of	O
most	O
of	O
the	O
presented	O
PrEP	O
characteristics	O
,	O
the	O
stigma	O
associated	O
with	O
HIV	O
[	O
34	O
]	O
,	O
and	O
in	O
some	O
settings	O
,	O
the	O
criminalization	O
of	O
sex	O
work	O
,	O
injected	O
drug	O
use	O
and	O
homosexuality	O
[	O
35	O
]	O
.	O
</ALL>	O

<ALL>	O
Most	O
participants	O
,	O
nonetheless	O
,	O
subsequently	O
indicated	O
that	O
PrEP	O
would	O
give	O
them	O
hope	O
,	O
which	O
suggests	O
that	O
their	O
initial	O
willingness	O
to	O
take	O
it	O
remained	O
largely	O
unscathed	O
.	O
</ALL>	O

<ALL>	O
Female	O
participants	O
indicated	O
a	O
higher	O
level	O
of	O
willingness	O
to	O
take	O
PrEP	O
than	O
male	O
participants	O
,	O
which	O
may	O
be	O
explained	O
by	O
women	O
'	O
s	O
difficulty	O
negotiating	O
the	O
use	O
of	O
condoms	O
and	O
awareness	O
of	O
their	O
and	O
/	O
or	O
their	O
partners	O
'	O
risk	O
of	O
becoming	O
infected	O
with	O
HIV	O
[	O
36	O
]	O
.	O
</ALL>	O

<ALL>	O
We	O
also	O
found	O
that	O
younger	O
participants	O
and	O
those	O
with	O
fewer	O
children	O
,	O
those	O
who	O
reported	O
adherence	O
to	O
past	O
medication	O
,	O
more	O
frequent	O
condom	O
usage	O
,	O
having	O
been	O
tested	O
for	O
HIV	O
in	O
the	O
past	O
and	O
never	O
injecting	O
drugs	O
,	O
reported	O
greater	O
willingness	O
to	O
take	O
PrEP	O
.	O
</ALL>	O

<ALL>	O
These	O
promising	O
findings	O
suggest	O
that	O
those	O
who	O
are	O
currently	O
bearing	O
the	O
brunt	O
of	O
HIV	O
[	O
1	O
]	O
,	O
have	O
higher	O
perceived	O
risk	O
,	O
and	O
are	O
most	O
likely	O
to	O
adhere	O
to	O
a	O
comprehensive	O
PrEP	O
program	O
,	O
are	O
also	O
the	O
most	O
motivated	O
to	O
enroll	O
.	O
</ALL>	O

<ALL>	O
Yet	O
,	O
while	O
participants	O
stated	O
not	O
being	O
interested	O
in	O
selling	O
PrEP	O
,	O
the	O
majority	O
reported	O
intentions	O
to	O
share	O
it	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
information	O
and	O
counseling	O
about	O
the	O
risks	O
of	O
sharing	O
PrEP	O
should	O
be	O
readily	O
available	O
as	O
part	O
of	O
any	O
implementation	O
program	O
.	O
</ALL>	O

<ALL>	O
Results	O
from	O
the	O
conjoint	O
analysis	O
reveal	O
trends	O
in	O
participants	O
'	O
preferences	O
which	O
deserve	O
consideration	O
.	O
</ALL>	O

<ALL>	O
PrEP	O
route	O
of	O
administration	O
was	O
the	O
most	O
important	O
attribute	O
,	O
and	O
bi	O
-	O
monthly	O
and	O
monthly	O
injections	O
were	O
the	O
preferred	O
alternatives	O
.	O
</ALL>	O

<ALL>	O
This	O
finding	O
is	O
encouraging	O
from	O
a	O
policy	O
perspective	O
if	O
such	O
modalities	O
become	O
available	O
;	O
since	O
it	O
may	O
reduce	O
users	O
'	O
likelihood	O
of	O
sharing	O
,	O
selling	O
or	O
forgetting	O
to	O
take	O
PrEP	O
,	O
but	O
it	O
also	O
raises	O
questions	O
regarding	O
participants	O
'	O
willingness	O
to	O
take	O
oral	O
PrEP	O
.	O
</ALL>	O

<ALL>	O
HIV	O
testing	O
was	O
the	O
second	O
most	O
important	O
attribute	O
,	O
and	O
a	O
test	O
every	O
six	O
months	O
was	O
,	O
as	O
expected	O
,	O
the	O
preferred	O
alternative	O
.	O
</ALL>	O

<ALL>	O
Interestingly	O
,	O
dispensing	O
sites	O
were	O
more	O
important	O
than	O
any	O
other	O
attribute	O
for	O
some	O
groups	O
,	O
particularly	O
in	O
Africa	O
.	O
</ALL>	O

<ALL>	O
This	O
may	O
indicate	O
concerns	O
about	O
social	O
stigma	O
and	O
access	O
[	O
37	O
]	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
it	O
is	O
encouraging	O
that	O
most	O
participants	O
were	O
willing	O
to	O
receive	O
PrEP	O
at	O
a	O
healthcare	O
facility	O
,	O
which	O
can	O
facilitate	O
synergies	O
between	O
PrEP	O
and	O
other	O
existing	O
prevention	O
services	O
.	O
</ALL>	O

<ALL>	O
Time	O
spent	O
obtaining	O
PrEP	O
and	O
frequency	O
of	O
pick	O
up	O
,	O
which	O
we	O
used	O
as	O
a	O
proxy	O
measure	O
for	O
cost	O
-	O
opportunity	O
,	O
were	O
generally	O
less	O
important	O
,	O
consistent	O
with	O
participants	O
'	O
willingness	O
to	O
pay	O
for	O
PrEP	O
.	O
</ALL>	O

<ALL>	O
Our	O
findings	O
are	O
broadly	O
consistent	O
with	O
the	O
work	O
of	O
Guest	O
et	O
al	O
.	O
and	O
Galea	O
et	O
al	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
specific	O
comparisons	O
are	O
not	O
advisable	O
as	O
the	O
composition	O
and	O
size	O
of	O
the	O
samples	O
,	O
recruitment	O
methods	O
,	O
measures	O
and	O
statistical	O
analyses	O
differ	O
greatly	O
.	O
</ALL>	O

<ALL>	O
Previous	O
work	O
on	O
PrEP	O
implementation	O
suggests	O
that	O
delivery	O
programs	O
will	O
need	O
to	O
meet	O
a	O
number	O
of	O
requirements	O
in	O
order	O
to	O
be	O
effective	O
,	O
including	O
:	O
prioritization	O
of	O
groups	O
at	O
higher	O
risk	O
of	O
infection	O
;	O
delivery	O
of	O
PrEP	O
in	O
combination	O
with	O
other	O
prevention	O
services	O
,	O
including	O
risk	O
reduction	O
and	O
medication	O
adherence	O
counseling	O
,	O
condoms	O
provision	O
,	O
diagnosis	O
and	O
treatment	O
of	O
other	O
sexually	O
transmitted	O
infections	O
,	O
and	O
frequent	O
HIV	O
testing	O
;	O
and	O
monitoring	O
of	O
side	O
effects	O
,	O
adherence	O
and	O
risk	O
behaviors	O
[	O
8	O
]	O
,	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
,	O
[	O
40	O
]	O
,	O
[	O
41	O
]	O
,	O
[	O
42	O
]	O
.	O
</ALL>	O

<ALL>	O
Our	O
results	O
provide	O
valuable	O
clues	O
that	O
can	O
help	O
countries	O
to	O
deliver	O
PrEP	O
more	O
effectively	O
,	O
should	O
they	O
decide	O
to	O
implement	O
it	O
,	O
by	O
focusing	O
their	O
efforts	O
on	O
the	O
aspects	O
that	O
need	O
more	O
attention	O
.	O
</ALL>	O

<ALL>	O
This	O
is	O
the	O
first	O
multinational	O
study	O
,	O
to	O
our	O
knowledge	O
,	O
that	O
integrates	O
different	O
disciplines	O
to	O
shed	O
light	O
on	O
a	O
question	O
that	O
we	O
believe	O
is	O
of	O
global	O
importance	O
.	O
</ALL>	O

<ALL>	O
Our	O
study	O
complements	O
previous	O
work	O
on	O
PrEP	O
by	O
examining	O
potential	O
users	O
'	O
perspective	O
and	O
offering	O
insights	O
into	O
their	O
attitudes	O
and	O
preferences	O
.	O
</ALL>	O

<ALL>	O
We	O
note	O
that	O
it	O
may	O
not	O
be	O
possible	O
to	O
generalize	O
the	O
observed	O
PrEP	O
acceptability	O
to	O
other	O
settings	O
and	O
our	O
results	O
should	O
be	O
considered	O
within	O
the	O
context	O
of	O
this	O
study	O
'	O
s	O
limitations	O
.	O
</ALL>	O

<ALL>	O
Given	O
the	O
sensitive	O
nature	O
of	O
the	O
addressed	O
questions	O
,	O
and	O
despite	O
all	O
our	O
efforts	O
to	O
reduce	O
social	O
desirability	O
bias	O
,	O
there	O
is	O
an	O
unavoidable	O
risk	O
that	O
participants	O
may	O
have	O
felt	O
at	O
times	O
compelled	O
to	O
provide	O
what	O
they	O
felt	O
was	O
the	O
"	O
right	O
"	O
answer	O
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
our	O
data	O
collection	O
took	O
place	O
in	O
urban	O
areas	O
,	O
where	O
HIV	O
incidence	O
is	O
normally	O
higher	O
,	O
thus	O
current	O
findings	O
may	O
not	O
be	O
generalizable	O
to	O
rural	O
settings	O
.	O
</ALL>	O

<ALL>	O
Finally	O
,	O
examining	O
acceptability	O
among	O
users	O
enrolled	O
in	O
pilot	O
programs	O
is	O
much	O
deserving	O
,	O
as	O
actual	O
acceptability	O
may	O
differ	O
from	O
potential	O
willingness	O
to	O
take	O
PrEP	O
,	O
especially	O
if	O
relevant	O
attributes	O
of	O
a	O
product	O
or	O
program	O
are	O
modified	O
,	O
as	O
observed	O
in	O
other	O
comparable	O
interventions	O
[	O
43	O
]	O
.	O
</ALL>	O

<ALL>	O
Origins	O
of	O
Acquired	O
Antibiotic	O
Resistance	O
Mechanisms	O
</ALL>	O

<ALL>	O
Recently	O
,	O
D	O
'	O
Costa	O
et	O
al	O
.	O
</ALL>	O

<ALL>	O
(	O
2011	O
)	O
have	O
reported	O
a	O
metagenomic	O
analysis	O
of	O
the	O
Beringian	O
permafrost	O
,	O
which	O
is	O
30	O
,	O
000	O
years	O
old	O
.	O
</ALL>	O

<ALL>	O
They	O
showed	O
molecular	O
evidences	O
of	O
the	O
ancient	O
origins	O
of	O
antibiotic	O
resistances	O
,	O
detecting	O
beta	O
-	O
lactamases	O
genes	O
,	O
vanX	O
-	O
like	O
,	O
component	O
of	O
the	O
vancomycin	O
resistance	O
operon	O
,	O
and	O
tetM	O
,	O
coding	O
for	O
a	O
protein	O
protecting	O
the	O
ribosomal	B-Cellular_component
target	O
from	O
tetracycline	O
.	O
</ALL>	O

<ALL>	O
Sequence	O
analysis	O
revealed	O
that	O
the	O
beta	O
-	O
lactamases	O
genes	O
recovered	O
from	O
the	O
permafrost	O
demonstrated	O
an	O
amino	O
-	O
acid	O
homology	O
(	O
53	O
-	O
84	O
%	O
)	O
to	O
known	O
beta	O
-	O
lactamases	O
from	O
beta	O
-	O
lactams	O
producing	O
Streptomyces	O
.	O
</ALL>	O

<ALL>	O
The	O
tetM	O
sequences	O
revealed	O
a	O
high	O
similarity	O
to	O
the	O
genes	O
coding	O
for	O
the	O
ribosomal	B-Cellular_component
protection	O
protein	O
of	O
actinomycetes	O
.	O
</ALL>	O

<ALL>	O
The	O
vanX	O
sequence	O
showed	O
a	O
similarity	O
to	O
the	O
vanX	O
gene	O
recovered	O
in	O
pathogenic	O
vancomycin	O
resistant	O
enterococci	O
(	O
VRE	O
)	O
and	O
to	O
the	O
vanX	O
gene	O
from	O
Amycolatopsis	O
orientalis	O
.	O
</ALL>	O

<ALL>	O
This	O
environmental	O
species	O
,	O
belonging	O
to	O
the	O
actinobacteria	O
phylum	O
,	O
is	O
a	O
natural	O
producer	O
of	O
vancomycin	O
,	O
and	O
very	O
likely	O
the	O
progenitor	O
of	O
the	O
van	O
genes	O
operons	O
,	O
responsible	O
for	O
resistance	O
to	O
vancomycin	O
.	O
</ALL>	O

<ALL>	O
The	O
integration	O
of	O
the	O
van	O
operons	O
on	O
transposons	O
and	O
on	O
conjugative	B-Cellular_component
plasmids	I-Cellular_component
has	O
enhanced	O
their	O
spread	O
(	O
Courvalin	O
,	O
2006	O
)	O
.	O
</ALL>	O

<ALL>	O
Reports	O
of	O
VRE	O
in	O
freshwater	O
have	O
been	O
provided	O
by	O
several	O
authors	O
(	O
Talebi	O
et	O
al	O
.	O
,	O
2008	O
;	O
Lata	O
et	O
al	O
.	O
,	O
2009	O
;	O
Luczkiewicz	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O
</ALL>	O

<ALL>	O
Interestingly	O
,	O
Schwartz	O
et	O
al	O
.	O
</ALL>	O

<ALL>	O
(	O
2003	O
)	O
detected	O
vanA	O
genes	O
in	O
the	O
biofilm	B-Cell
of	O
drinking	O
water	O
supplies	O
,	O
in	O
the	O
absence	O
of	O
enterococci	O
,	O
demonstrating	O
the	O
lateral	O
transfer	O
of	O
this	O
gene	O
.	O
</ALL>	O

<ALL>	O
Notably	O
,	O
the	O
progenitors	O
of	O
these	O
resistance	O
genes	O
are	O
soil	O
bacteria	O
thus	O
most	O
likely	O
,	O
a	O
shuttle	O
has	O
been	O
responsible	O
for	O
the	O
introduction	O
of	O
these	O
genes	O
into	O
the	O
commensal	O
bacterial	O
community	O
and	O
afterward	O
into	O
the	O
pathogenic	O
species	O
.	O
</ALL>	O

<ALL>	O
Results	O
</ALL>	O

<ALL>	O
Supplementary	O
Material	O
</ALL>	O

<ALL>	O
Crystal	O
structure	O
:	O
contains	O
datablock	O
(	O
s	O
)	O
global	O
,	O
I	O
.	O
</ALL>	O

<ALL>	O
DOI	O
:	O
10	O
.	O
1107	O
/	O
S1600536812002796	O
/	O
hg5166sup1	O
.	O
cif	O
</ALL>	O

<ALL>	O
Structure	O
factors	O
:	O
contains	O
datablock	O
(	O
s	O
)	O
I	O
.	O
</ALL>	O

<ALL>	O
DOI	O
:	O
10	O
.	O
1107	O
/	O
S1600536812002796	O
/	O
hg5166Isup2	O
.	O
hkl	O
</ALL>	O

<ALL>	O
Additional	O
supplementary	O
materials	O
:	O
crystallographic	O
information	O
;	O
3D	O
view	O
;	O
checkCIF	O
report	O
</ALL>	O

<ALL>	O
Results	O
</ALL>	O

<ALL>	O
Images	O
</ALL>	O

<ALL>	O
Figure	O
1	O
</ALL>	O

<ALL>	O
Figure	O
2	O
</ALL>	O

<ALL>	O
Figure	O
3	O
</ALL>	O

<ALL>	O
Figure	O
4	O
</ALL>	O

<ALL>	O
Results	O
</ALL>	O

<ALL>	O
Images	O
</ALL>	O

<ALL>	O
FIGURE	O
2	O
.	O
</ALL>	O

<ALL>	O
Nf	O
and	O
GA	O
-	O
1	O
DNA	O
polymerases	O
couple	O
polymerization	O
to	O
strand	O
displacement	O
processively	O
</ALL>	O

<ALL>	O
The	O
results	O
presented	O
in	O
this	O
paper	O
clearly	O
indicate	O
that	O
Nf	O
and	O
GA	O
-	O
1	O
DNA	O
polymerases	O
can	O
account	O
for	O
their	O
genome	O
replication	O
without	O
the	O
assistance	O
of	O
unwinding	O
and	O
processivity	O
factors	O
,	O
in	O
contrast	O
to	O
most	O
replicative	O
DNA	O
polymerases	O
which	O
require	O
their	O
physical	O
association	O
to	O
processivity	O
factors	O
and	O
DNA	O
unwinding	O
proteins	O
(	O
1	O
,	O
70	O
)	O
.	O
</ALL>	O

<ALL>	O
Strand	O
displacement	O
capacity	O
has	O
also	O
been	O
shown	O
for	O
other	O
protein	O
-	O
primed	O
DNA	O
polymerases	O
as	O
those	O
of	O
bacteriophages	O
phi29	O
(	O
10	O
)	O
,	O
Cp	O
-	O
1	O
(	O
71	O
)	O
and	O
PRD1	O
(	O
72	O
,	O
73	O
)	O
.	O
</ALL>	O

<ALL>	O
On	O
the	O
contrary	O
,	O
adenovirus	O
DNA	O
polymerase	O
,	O
although	O
processive	O
,	O
cannot	O
couple	O
polymerization	O
to	O
strand	O
displacement	O
,	O
requiring	O
the	O
DNA	O
unwinding	O
activity	O
of	O
the	O
adenovirus	O
DBP	O
to	O
perform	O
strand	O
displacement	O
(	O
74	O
,	O
75	O
)	O
.	O
</ALL>	O

<ALL>	O
Whereas	O
it	O
was	O
possible	O
to	O
obtain	O
GA	O
-	O
1	O
DNA	O
replication	O
by	O
using	O
exclusively	O
the	O
GA	O
-	O
1	O
TP	O
and	O
DNA	O
polymerase	O
,	O
Nf	O
DNA	O
polymerase	O
,	O
although	O
provided	O
with	O
competent	O
strand	O
displacement	O
and	O
processivity	O
features	O
,	O
required	O
the	O
presence	O
of	O
Nf	O
DBP	O
for	O
an	O
effective	O
in	O
vitro	O
replication	O
of	O
Nf	O
TP	O
-	O
DNA	O
.	O
</ALL>	O

<ALL>	O
Results	O
presented	O
here	O
show	O
that	O
Nf	O
DBP	O
strongly	O
stimulates	O
the	O
formation	O
of	O
the	O
TP	O
-	O
dAMP	O
initiation	O
complex	O
by	O
decreasing	O
the	O
Km	O
for	O
dATP	O
and	O
facilitates	O
the	O
transition	O
from	O
initiation	O
to	O
elongation	O
,	O
as	O
it	O
occurs	O
in	O
phi29	O
(	O
76	O
)	O
.	O
</ALL>	O

<ALL>	O
These	O
results	O
point	O
to	O
either	O
a	O
specific	O
and	O
direct	O
contact	O
between	O
DBP	O
and	O
DNA	O
polymerase	O
that	O
promotes	O
conformational	O
changes	O
at	O
the	O
polymerization	O
active	O
site	O
or	O
to	O
an	O
effect	O
of	O
DBP	O
in	O
conferring	O
the	O
optimal	O
template	O
structure	O
to	O
direct	O
initiating	O
nucleotide	O
insertion	O
.	O
</ALL>	O

<ALL>	O
A	O
similar	O
role	O
has	O
been	O
proposed	O
for	O
adenovirus	O
DBP	O
,	O
a	O
DNA	O
unwinding	O
protein	O
(	O
77	O
)	O
.	O
</ALL>	O

<ALL>	O
As	O
in	O
the	O
case	O
of	O
phi29	O
and	O
Nf	O
DBP	O
,	O
this	O
protein	O
stimulates	O
the	O
rate	O
of	O
initiation	O
also	O
by	O
decreasing	O
the	O
Km	O
for	O
the	O
initiating	O
nucleotide	O
(	O
74	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
fact	O
that	O
an	O
adenovirus	O
DBP	O
mutant	O
defective	O
in	O
unwinding	O
can	O
still	O
stimulate	O
initiation	O
precludes	O
the	O
unwinding	O
role	O
as	O
the	O
one	O
responsible	O
for	O
such	O
an	O
activation	O
(	O
77	O
,	O
78	O
)	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
case	O
,	O
contacts	O
between	O
DBP	O
and	O
pTP	O
/	O
DNA	O
polymerase	O
complex	O
have	O
been	O
reported	O
(	O
77	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
effect	O
of	O
Nf	O
DBP	O
in	O
promoting	O
elongation	O
of	O
the	O
initiation	O
products	O
could	O
be	O
due	O
to	O
a	O
decrease	O
of	O
the	O
Km	O
also	O
for	O
the	O
incorporation	O
of	O
the	O
dNMPs	O
during	O
the	O
transition	O
stage	O
from	O
initiation	O
to	O
elongation	O
,	O
to	O
a	O
different	O
type	O
of	O
contact	O
with	O
the	O
DNA	O
polymerase	O
that	O
helps	O
transition	O
to	O
elongation	O
,	O
or	O
both	O
.	O
</ALL>	O

<ALL>	O
The	O
similarity	O
in	O
replication	O
rates	O
when	O
comparing	O
M13	O
DNA	O
replication	O
,	O
performed	O
in	O
the	O
absence	O
of	O
DBP	O
(	O
2400	O
nt	O
/	O
min	O
)	O
,	O
with	O
Nf	O
TP	O
-	O
DNA	O
replication	O
in	O
the	O
presence	O
of	O
DBP	O
(	O
2260	O
nt	O
/	O
min	O
)	O
,	O
suggests	O
that	O
the	O
DBP	O
stimulatory	O
role	O
is	O
restricted	O
to	O
the	O
first	O
phases	O
of	O
Nf	O
TP	O
-	O
DNA	O
replication	O
.	O
</ALL>	O

<ALL>	O
2	O
-	O
Theory	O
</ALL>	O

<ALL>	O
Scanning	O
holography	O
is	O
a	O
two	O
-	O
pupil	O
interaction	O
method	O
[	O
8	O
]	O
by	O
which	O
incoherent	O
imaging	O
with	O
complex	O
point	O
-	O
spread	O
-	O
functions	O
(	O
PSF	O
)	O
is	O
possible	O
.	O
</ALL>	O

<ALL>	O
The	O
method	O
has	O
recently	O
been	O
applied	O
to	O
the	O
recording	O
of	O
high	O
resolution	O
holographic	O
images	O
of	O
incoherent	O
objects	O
and	O
fluorescent	O
biological	O
specimens	O
[	O
6	O
,	O
7	O
]	O
.	O
</ALL>	O

<ALL>	O
A	O
single	O
-	O
sideband	O
in	O
-	O
line	O
Fresnel	O
hologram	O
is	O
obtained	O
by	O
a	O
2D	O
raster	O
scan	O
of	O
the	O
object	O
with	O
the	O
superposed	O
3D	O
diffraction	O
distributions	O
of	O
two	O
pupils	O
,	O
as	O
sketched	O
in	O
fig	O
.	O
</ALL>	O

<ALL>	O
1	O
.	O
</ALL>	O

<ALL>	O
The	O
two	O
pupil	O
distributions	O
P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa	O
@	O
3295	O
@	O
and	O
P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa	O
@	O
3297	O
@	O
from	O
the	O
same	O
source	O
(	O
for	O
example	O
,	O
but	O
not	O
necessarily	O
,	O
a	O
laser	O
)	O
are	O
combined	O
by	O
a	O
beam	O
splitter	O
in	O
the	O
pupil	O
plane	O
of	O
the	O
objective	O
where	O
they	O
interfere	O
,	O
forming	O
a	O
Fresnel	O
pattern	O
with	O
a	O
depth	O
-	O
dependent	O
Fresnel	O
number	O
.	O
</ALL>	O

<ALL>	O
To	O
obtain	O
the	O
conventional	O
point	O
-	O
spread	O
function	O
of	O
wide	O
field	O
imaging	O
,	O
P1	O
is	O
chosen	O
as	O
a	O
point	O
source	O
,	O
and	O
P2	O
as	O
a	O
spherical	O
wave	O
with	O
appropriate	O
curvature	O
.	O
</ALL>	O

<ALL>	O
The	O
3D	O
specimen	O
is	O
placed	O
in	O
the	O
focal	O
region	O
of	O
the	O
objective	O
,	O
and	O
scattered	O
lights	O
(	O
transmitted	O
,	O
reflected	O
,	O
and	O
fluorescent	O
)	O
are	O
collected	O
by	O
non	O
-	O
imaging	O
detectors	O
.	O
</ALL>	O

<ALL>	O
The	O
hologram	O
data	O
can	O
be	O
obtained	O
by	O
heterodyne	O
detection	O
with	O
one	O
of	O
the	O
pupils	O
shifted	O
in	O
frequency	O
(	O
as	O
done	O
in	O
this	O
work	O
)	O
,	O
or	O
by	O
a	O
homodyne	O
method	O
requiring	O
the	O
capture	O
of	O
at	O
least	O
three	O
frames	O
with	O
different	O
relative	O
phases	O
between	O
the	O
two	O
pupils	O
[	O
9	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
amplitude	O
distribution	O
of	O
the	O
illuminating	O
beam	O
,	O
in	O
a	O
transverse	O
plane	O
at	O
an	O
axial	O
distance	O
z	O
from	O
the	O
focal	O
plane	O
of	O
the	O
objective	O
,	O
is	O
the	O
Fourier	O
transform	O
of	O
the	O
combined	O
pupil	O
distributions	O
[	O
10	O
]	O
.	O
</ALL>	O

<ALL>	O
Namely	O
:	O
</ALL>	O

<ALL>	O
Figure	O
1	O
</ALL>	O

<ALL>	O
Experimental	O
set	O
up	O
of	O
a	O
scanning	O
holographic	O
microscope	O
.	O
</ALL>	O

<ALL>	O
Sketch	O
of	O
the	O
experimental	O
setup	O
.	O
</ALL>	O

<ALL>	O
M	O
'	O
s	O
are	O
mirrors	O
,	O
BS	O
'	O
s	O
are	O
beam	O
splitters	O
,	O
EO	O
is	O
an	O
electro	O
-	O
optic	O
phase	O
modulator	O
.	O
</ALL>	O

<ALL>	O
Lens	O
L1	O
(	O
achromat	O
doublet	O
16	O
cm	O
focal	O
length	O
)	O
produces	O
the	O
desired	O
Fresnel	O
pattern	O
in	O
the	O
focal	O
plane	O
of	O
L2	O
(	O
achromat	O
doublet	O
16	O
cm	O
focal	O
length	O
)	O
.	O
</ALL>	O

<ALL>	O
L2	O
and	O
the	O
objective	O
form	O
a	O
4	O
-	O
f	O
system	O
projecting	O
a	O
reduced	O
image	O
of	O
the	O
Fresnel	O
pattern	O
onto	O
the	O
specimen	O
.	O
</ALL>	O

<ALL>	O
L3	O
(	O
achromat	O
doublet	O
12	O
cm	O
focal	O
length	O
)	O
projects	O
the	O
images	O
of	O
the	O
pupils	O
on	O
the	O
pinhole	O
detector	O
.	O
</ALL>	O

<ALL>	O
(	O
Not	O
shown	O
are	O
the	O
beam	O
expanders	O
used	O
to	O
illuminate	O
the	O
pupils	O
)	O
.	O
</ALL>	O

<ALL>	O
S	O
(	O
r	O
-	O
-	O
>	O
,	O
z	O
)	O
=	O
F	O
-	O
1	O
{	O
[	O
P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
+	O
P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
exp	O
(	O
-	O
iOmegat	O
]	O
}	O
,	O
(	O
1a	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
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	O
@	O
5D95	O
@	O
</ALL>	O

<ALL>	O
where	O
</ALL>	O

<ALL>	O
P	O
~	O
1	O
,	O
2	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
=	O
P	O
~	O
1	O
,	O
2	O
(	O
rho	O
-	O
-	O
>	O
)	O
exp	O
(	O
ipilambdazrho2	O
)	O
(	O
1b	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmcqGGSaalcqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcqGH9aqpcuWGqbaugaacamaaBaaaleaacqaIXaqmcqGGSaalcqaIYaGmaeqaaOGaeiikaGIaf8xWdiNbaSaacqGGPaqkcyGGLbqzcqGG4baEcqGGWbaCcqGGOaakcqWGPbqAcqWFapaCcqWF7oaBcqWG6bGEcqWFbpGCdaahaaWcbeqaaiabikdaYaaakiabcMcaPiaaxMaacaWLjaWaaeWaaeaacqaIXaqmcqqGIbGyaiaawIcacaGLPaaaaaa	O
@	O
53A8	O
@	O
</ALL>	O

<ALL>	O
are	O
the	O
generalized	O
defocused	O
pupils	O
[	O
11	O
]	O
.	O
</ALL>	O

<ALL>	O
F	O
-	O
1	O
stands	O
for	O
inverse	O
Fourier	O
transform	O
,	O
and	O
Omega	O
is	O
the	O
frequency	O
shift	O
of	O
one	O
of	O
the	O
pupils	O
.	O
</ALL>	O

<ALL>	O
The	O
transverse	O
spatial	O
frequency	O
vector	O
rho	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFbpGCgaWcaaaa	O
@	O
2E85	O
@	O
=	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
P	O
/	O
lambdaf0	O
is	O
proportional	O
to	O
the	O
real	O
space	O
coordinate	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
P	O
in	O
the	O
pupil	O
plane	O
[	O
10	O
]	O
.	O
lambda	O
is	O
the	O
wavelength	O
of	O
the	O
illumination	O
,	O
and	O
f0	O
is	O
the	O
focal	O
length	O
of	O
the	O
objective	O
.	O
</ALL>	O

<ALL>	O
The	O
two	O
pupils	O
used	O
to	O
obtain	O
an	O
in	O
-	O
line	O
Fresnel	O
hologram	O
are	O
,	O
respectively	O
,	O
a	O
spherical	O
wave	O
filling	O
the	O
pupil	O
of	O
the	O
objective	O
,	O
and	O
a	O
point	O
at	O
the	O
center	O
of	O
that	O
pupil	O
:	O
</ALL>	O

<ALL>	O
P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa	O
@	O
3295	O
@	O
=	O
exp	O
(	O
ipilambdaz0rho2	O
)	O
circ	O
(	O
rho	O
/	O
rhoMAX	O
)	O
</ALL>	O

<ALL>	O
P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
delta	O
(	O
rho	O
-	O
-	O
>	O
)	O
.	O
</ALL>	O

<ALL>	O
(	O
2	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpcqWF0oazcqGGOaakcuWFbpGCgaWcaiabcMcaPiabc6caUiaaxMaacaWLjaWaaeWaaeaacqaIYaGmaiaawIcacaGLPaaaaaa	O
@	O
3D5F	O
@	O
</ALL>	O

<ALL>	O
circ	O
(	O
x	O
)	O
is	O
a	O
disc	O
function	O
of	O
unit	O
radius	O
.	O
</ALL>	O

<ALL>	O
rhoMAX	O
=	O
sinalpha	O
/	O
lambda	O
is	O
the	O
cutoff	O
frequency	O
of	O
the	O
objective	O
,	O
where	O
sinalpha	O
=	O
NA	O
is	O
its	O
numerical	O
aperture	O
.	O
</ALL>	O

<ALL>	O
The	O
Fresnel	O
pattern	O
projected	O
on	O
the	O
object	O
is	O
the	O
interference	O
of	O
the	O
Fourier	O
transforms	O
of	O
the	O
two	O
pupils	O
,	O
namely	O
a	O
spherical	O
wave	O
and	O
a	O
plane	O
wave	O
in	O
the	O
paraxial	O
approximation	O
.	O
</ALL>	O

<ALL>	O
The	O
Fresnel	O
number	O
of	O
this	O
pattern	O
is	O
determined	O
by	O
the	O
free	O
parameter	O
z0	O
,	O
which	O
is	O
the	O
distance	O
from	O
the	O
objective	O
'	O
s	O
focal	O
plane	O
to	O
the	O
point	O
where	O
the	O
spherical	O
wave	O
comes	O
to	O
a	O
focus	O
.	O
</ALL>	O

<ALL>	O
There	O
are	O
two	O
possible	O
modes	O
of	O
operation	O
,	O
depending	O
on	O
the	O
detector	O
geometry	O
[	O
5	O
]	O
.	O
</ALL>	O

<ALL>	O
With	O
a	O
spatially	O
integrating	O
detector	O
,	O
the	O
resulting	O
data	O
is	O
a	O
convolution	O
of	O
the	O
object	O
'	O
s	O
intensity	O
distribution	O
with	O
the	O
desired	O
complex	O
PSF	O
(	O
namely	O
,	O
a	O
spherical	O
wave	O
with	O
a	O
radius	O
of	O
curvature	O
z0	O
+	O
z	O
,	O
and	O
a	O
radius	O
a	O
=	O
z0sinalpha	O
,	O
in	O
this	O
case	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
detection	O
mode	O
leads	O
to	O
a	O
hologram	O
from	O
which	O
the	O
three	O
-	O
dimensional	O
distribution	O
of	O
scattering	O
intensity	O
,	O
absorption	O
,	O
and	O
fluorescence	O
intensity	O
can	O
be	O
reconstructed	O
.	O
</ALL>	O

<ALL>	O
With	O
a	O
point	O
detector	O
at	O
the	O
center	O
of	O
a	O
conjugate	O
pupil	O
plane	O
,	O
the	O
resulting	O
data	O
is	O
a	O
convolution	O
of	O
the	O
object	O
'	O
s	O
complex	O
amplitude	O
distribution	O
with	O
the	O
same	O
complex	O
PSF	O
.	O
</ALL>	O

<ALL>	O
The	O
reconstruction	O
of	O
this	O
hologram	O
gives	O
the	O
three	O
-	O
dimensional	O
distribution	O
of	O
the	O
specimen	O
'	O
s	O
complex	O
amplitude	O
transmittance	O
.	O
</ALL>	O

<ALL>	O
In	O
particular	O
,	O
assuming	O
that	O
multiple	O
scattering	O
can	O
be	O
ignored	O
,	O
the	O
phase	O
of	O
the	O
reconstruction	O
is	O
a	O
quantitative	O
measure	O
of	O
the	O
integrated	O
optical	O
path	O
length	O
through	O
the	O
specimen	O
.	O
</ALL>	O

<ALL>	O
These	O
two	O
modes	O
of	O
operation	O
are	O
similar	O
to	O
the	O
usual	O
coherent	O
/	O
incoherent	O
imaging	O
modes	O
of	O
a	O
conventional	O
system	O
,	O
which	O
are	O
obtained	O
by	O
using	O
,	O
respectively	O
,	O
a	O
point	O
source	O
,	O
or	O
a	O
large	O
spatially	O
incoherent	O
source	O
.	O
</ALL>	O

<ALL>	O
In	O
scanning	O
holography	O
,	O
the	O
detector	O
size	O
plays	O
a	O
similar	O
role	O
to	O
that	O
of	O
the	O
source	O
size	O
in	O
conventional	O
imaging	O
.	O
</ALL>	O

<ALL>	O
For	O
simplicity	O
,	O
let	O
'	O
s	O
assume	O
an	O
object	O
with	O
an	O
amplitude	O
transmittance	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
.	O
</ALL>	O

<ALL>	O
Note	O
that	O
for	O
an	O
incoherent	O
or	O
fluorescent	O
object	O
,	O
the	O
phase	O
of	O
the	O
transmitted	O
field	O
is	O
a	O
random	O
variable	O
,	O
and	O
only	O
the	O
intensity	O
I	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
=	O
|	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
|	O
2	O
is	O
measurable	O
.	O
</ALL>	O

<ALL>	O
For	O
a	O
quasi	O
transparent	O
object	O
,	O
the	O
phase	O
is	O
equal	O
to	O
the	O
integrated	O
optical	O
thickness	O
of	O
the	O
object	O
:	O
Phi	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
)	O
=	O
(	O
2pi	O
/	O
lambda	O
)	O
integraldzn	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
,	O
where	O
n	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
is	O
the	O
3D	O
distribution	O
of	O
refractive	O
index	O
.	O
</ALL>	O

<ALL>	O
The	O
amplitude	O
distribution	O
after	O
the	O
object	O
is	O
written	O
as	O
</ALL>	O

<ALL>	O
A	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
t	O
)	O
=	O
integraldzS	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
T	O
[	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
-	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
S	O
(	O
t	O
)	O
,	O
z	O
]	O
,	O
(	O
3	O
)	O
</ALL>	O

<ALL>	O
where	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
S	O
(	O
t	O
)	O
is	O
the	O
instantaneous	O
position	O
of	O
the	O
2D	O
raster	O
scan	O
.	O
</ALL>	O

<ALL>	O
The	O
incoherent	O
imaging	O
mode	O
is	O
obtained	O
with	O
a	O
spatially	O
integrating	O
detector	O
,	O
leading	O
to	O
a	O
temporal	O
signal	O
proportional	O
to	O
the	O
integrated	O
intensity	O
,	O
integrald2r	O
|	O
A	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
t	O
)	O
|	O
2	O
,	O
which	O
is	O
stored	O
in	O
the	O
computer	O
.	O
</ALL>	O

<ALL>	O
The	O
data	O
corresponding	O
to	O
each	O
hologram	O
line	O
is	O
cut	O
from	O
the	O
signal	O
,	O
and	O
band	O
pass	O
filtered	O
to	O
extract	O
the	O
term	O
oscillating	O
at	O
Omega	O
.	O
</ALL>	O

<ALL>	O
The	O
lines	O
are	O
then	O
rearranged	O
in	O
a	O
2D	O
format	O
.	O
</ALL>	O

<ALL>	O
The	O
resulting	O
hologram	O
amplitude	O
is	O
found	O
to	O
be	O
</ALL>	O

<ALL>	O
HI	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
)	O
=	O
integraldzI	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
(	O
+	O
)	O
[	O
p1	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
p	O
*	O
2	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
]	O
,	O
(	O
4	O
)	O
</ALL>	O

<ALL>	O
where	O
(	O
+	O
)	O
symbolizes	O
a	O
convolution	O
integral	O
,	O
I	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
=	O
|	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
|	O
2	O
,	O
and	O
p1	O
,	O
2	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
are	O
the	O
inverse	O
Fourier	O
transforms	O
of	O
the	O
defocused	O
pupil	O
distributions	O
(	O
eq	O
.	O
1b	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
superscript	O
*	O
stands	O
for	O
complex	O
conjugate	O
.	O
</ALL>	O

<ALL>	O
The	O
hologram	O
is	O
thus	O
the	O
convolution	O
of	O
the	O
object	O
intensity	O
with	O
a	O
spherical	O
wave	O
,	O
i	O
.	O
e	O
.	O
an	O
in	O
-	O
line	O
single	O
-	O
sideband	O
Gabor	O
hologram	O
.	O
</ALL>	O

<ALL>	O
In	O
Fourier	O
space	O
,	O
the	O
hologram	O
can	O
be	O
written	O
as	O
</ALL>	O

<ALL>	O
H	O
~	O
I	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
integraldzI	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
[	O
P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
(	O
*	O
)	O
P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
]	O
,	O
(	O
5	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGjbqsaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdMeajzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkdaWadaqaaiqbdcfaqzaaiaWaaSbaaSqaaiabigdaXaqabaGccqGGOaakcuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPiabgEPielqbdcfaqzaaiaWaaSbaaSqaaiabikdaYaqabaGccqGGOaakcuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPaGaay5waiaaw2faaiabcYcaSiaaxMaacaWLjaWaaeWaaeaacqaI1aqnaiaawIcacaGLPaaaaaa	O
@	O
58FF	O
@	O
</ALL>	O

<ALL>	O
where	O
(	O
+	O
)	O
symbolizes	O
a	O
correlation	O
integral	O
.	O
</ALL>	O

<ALL>	O
With	O
the	O
pupils	O
of	O
eq	O
.	O
2	O
,	O
we	O
find	O
,	O
in	O
the	O
paraxial	O
approximation	O
,	O
</ALL>	O

<ALL>	O
H	O
~	O
I	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
integraldzI	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
exp	O
[	O
ipilambda	O
(	O
z0	O
+	O
z	O
)	O
rho2	O
]	O
circ	O
(	O
rho	O
/	O
rhoMAX	O
)	O
,	O
(	O
6	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGjbqsaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdMeajzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcyGGLbqzcqGG4baEcqGGWbaCdaWadaqaaiabdMgaPjab	O
=	O
b8aWjab	O
=	O
T7aSjabcIcaOiabdQha6naaBaaaleaacqaIWaamaeqaaOGaey4kaSIaemOEaONaeiykaKIae8xWdi3aaWbaaSqabeaacqaIYaGmaaaakiaawUfacaGLDbaacqWGJbWycqWGPbqAcqWGYbGCcqWGJbWycqGGOaakcqWFbpGCcqGGVaWlcqWFbpGCdaWgaaWcbaGaemyta0KaemyqaeKaemiwaGfabeaakiabcMcaPiabcYcaSiaaxMaacaWLjaWaaeWaaeaacqaI2aGnaiaawIcacaGLPaaaaaa	O
@	O
67E3	O
@	O
</ALL>	O

<ALL>	O
which	O
is	O
the	O
Fourier	O
transform	O
of	O
the	O
Fresnel	O
hologram	O
of	O
the	O
object	O
'	O
s	O
intensity	O
distribution	O
.	O
</ALL>	O

<ALL>	O
The	O
coherent	O
imaging	O
mode	O
is	O
obtained	O
by	O
using	O
a	O
pinhole	O
or	O
a	O
point	O
detector	O
at	O
the	O
center	O
of	O
a	O
conjugate	O
plane	O
of	O
the	O
pupil	O
of	O
the	O
objective	O
.	O
</ALL>	O

<ALL>	O
This	O
leads	O
to	O
the	O
hologram	O
amplitude	O
</ALL>	O

<ALL>	O
HC	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
)	O
=	O
integraldz	O
[	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
(	O
+	O
)	O
p1	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
]	O
[	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
(	O
+	O
)	O
p2	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
]	O
*	O
.	O
</ALL>	O

<ALL>	O
(	O
7	O
)	O
</ALL>	O

<ALL>	O
Where	O
again	O
,	O
(	O
+	O
)	O
symbolizes	O
a	O
convolution	O
product	O
,	O
and	O
the	O
superscript	O
*	O
stands	O
for	O
complex	O
conjugate	O
.	O
</ALL>	O

<ALL>	O
In	O
Fourier	O
space	O
,	O
</ALL>	O

<ALL>	O
H	O
~	O
C	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
integraldzT	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
(	O
*	O
)	O
T	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
.	O
</ALL>	O

<ALL>	O
(	O
8	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGdbWqaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdsfauzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcqGHxkcXcuWGubavgaacaiabcIcaOiqb	O
=	O
f8aYzaalaGaei4oaSJaemOEaONaeiykaKIafmiuaaLbaGaadaWgaaWcbaGaeGOmaidabeaakiabcIcaOiqb	O
=	O
f8aYzaalaGaei4oaSJaemOEaONaeiykaKIaeiOla4IaaCzcaiaaxMaadaqadaqaaiabiIda4aGaayjkaiaawMcaaaaa	O
@	O
5E5B	O
@	O
</ALL>	O

<ALL>	O
With	O
the	O
pupils	O
of	O
eq	O
.	O
2	O
,	O
we	O
find	O
</ALL>	O

<ALL>	O
H	O
~	O
C	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
integraldzT	O
~	O
*	O
(	O
0	O
;	O
z	O
)	O
T	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
exp	O
[	O
ipilambda	O
(	O
z0	O
+	O
z	O
)	O
rho2	O
]	O
circ	O
(	O
rho	O
/	O
rhoMAX	O
)	O
.	O
</ALL>	O

<ALL>	O
(	O
9	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
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	O
=	O
f8aYjabc	O
+	O
caViab	O
=	O
f8aYnaaBaaaleaacqWGnbqtcqWGbbqqcqWGybawaeqaaOGaeiykaKIaeiOla4IaaCzcaiaaxMaadaqadaqaaiabiMda5aGaayjkaiaawMcaaaaa	O
@	O
6F41	O
@	O
</ALL>	O

<ALL>	O
Aside	O
from	O
an	O
inconsequential	O
complex	O
constant	O
(	O
the	O
first	O
term	O
under	O
the	O
integral	O
)	O
,	O
eq	O
.	O
9	O
is	O
the	O
Fourier	O
transform	O
of	O
the	O
Fresnel	O
hologram	O
of	O
the	O
object	O
'	O
s	O
complex	O
amplitude	O
distribution	O
.	O
</ALL>	O

<ALL>	O
Thus	O
,	O
the	O
reconstruction	O
of	O
the	O
hologram	O
recorded	O
in	O
the	O
coherent	O
mode	O
carries	O
a	O
quantitative	O
measure	O
of	O
the	O
object	O
'	O
s	O
phase	O
distribution	O
.	O
</ALL>	O

<ALL>	O
Results	O
</ALL>	O

<ALL>	O
Here	O
we	O
include	O
data	O
obtained	O
from	O
active	O
,	O
oscillatory	O
brain	B-Multi-tissue_structure
slices	I-Multi-tissue_structure
as	O
well	O
as	O
from	O
recordings	O
during	O
cortical	B-Multi-tissue_structure
slow	O
oscillations	O
in	O
anesthetized	O
animals	O
.	O
</ALL>	O

<ALL>	O
All	O
recordings	O
included	O
in	O
this	O
study	O
were	O
obtained	O
from	O
the	O
visual	B-Multi-tissue_structure
cortex	I-Multi-tissue_structure
of	O
the	O
ferret	O
(	O
in	O
vitro	O
)	O
,	O
cat	O
(	O
in	O
vivo	O
)	O
and	O
from	O
barrel	B-Multi-tissue_structure
cortex	I-Multi-tissue_structure
of	O
the	O
rat	O
(	O
in	O
vivo	O
)	O
.	O
</ALL>	O

<ALL>	O
Twenty	O
-	O
nine	O
neurons	B-Cell
recorded	O
from	O
ferret	O
cortical	B-Multi-tissue_structure
slices	I-Multi-tissue_structure
are	O
included	O
in	O
this	O
study	O
(	O
22	O
regular	O
spiking	O
(	O
RS	O
)	O
;	O
5	O
chattering	O
(	O
CH	O
)	O
and	O
2	O
intrinsic	O
bursting	O
(	O
IB	O
)	O
)	O
,	O
27	O
neurons	B-Cell
from	O
cat	O
visual	B-Multi-tissue_structure
cortex	I-Multi-tissue_structure
in	O
vivo	O
(	O
14	O
RS	O
;	O
5	O
CH	O
;	O
2	O
IB	O
;	O
3	O
fast	O
spiking	O
(	O
FS	O
)	O
;	O
plus	O
3	O
non	O
classified	O
)	O
and	O
14	O
neurons	B-Cell
from	O
rat	O
barrel	B-Multi-tissue_structure
cortex	I-Multi-tissue_structure
in	O
vivo	O
(	O
12	O
RS	O
;	O
1	O
CH	O
;	O
1	O
IB	O
)	O
.	O
</ALL>	O

<ALL>	O
Synaptic	B-Cellular_component
potentials	O
were	O
evoked	O
by	O
electric	O
shocks	O
(	O
intracortical	O
or	O
thalamocortical	O
connections	O
)	O
or	O
by	O
means	O
of	O
sensory	O
(	O
visual	O
or	O
whisker	O
)	O
stimulation	O
.	O
</ALL>	O

<ALL>	O
The	O
main	O
results	O
are	O
:	O
1	O
)	O
Synaptic	B-Cellular_component
potentials	O
show	O
more	O
paired	O
pulsed	O
facilitation	O
and	O
synaptic	B-Cellular_component
augmentation	O
in	O
active	O
than	O
in	O
silent	O
cortical	B-Multi-tissue_structure
networks	O
and	O
2	O
)	O
Synaptic	B-Cellular_component
potentials	O
occurring	O
during	O
up	O
or	O
activated	O
states	O
of	O
the	O
cortex	B-Multi-tissue_structure
increased	O
their	O
amplitude	O
with	O
respect	O
to	O
those	O
occurring	O
during	O
down	O
states	O
.	O
</ALL>	O

<ALL>	O
Ca2	O
+	O
Dependence	O
of	O
Slob57	O
Modulation	O
of	O
the	O
Voltage	O
Dependence	O
of	O
Activation	O
of	O
dSlo	O
</ALL>	O

<ALL>	O
Ca2	O
+	O
plays	O
a	O
fundamental	O
role	O
in	O
regulating	O
the	O
dSlo	O
response	O
to	O
membrane	B-Cellular_component
depolarization	O
.	O
</ALL>	O

<ALL>	O
One	O
of	O
the	O
three	O
known	O
Ca2	O
+	O
binding	O
sites	O
(	O
Xia	O
et	O
al	O
.	O
,	O
2002	O
;	O
Bao	O
et	O
al	O
.	O
,	O
2002	O
;	O
Zeng	O
et	O
al	O
.	O
,	O
2005b	O
)	O
,	O
known	O
as	O
the	O
calcium	O
bowl	O
(	O
Schreiber	O
and	O
Salkoff	O
,	O
1997	O
)	O
,	O
contributes	O
to	O
the	O
high	O
-	O
affinity	O
Ca2	O
+	O
sensitivity	O
of	O
the	O
channel	O
(	O
Schreiber	O
and	O
Salkoff	O
,	O
1997	O
;	O
Schreiber	O
et	O
al	O
.	O
,	O
1999	O
;	O
Braun	O
and	O
Sy	O
,	O
2001	O
;	O
Bao	O
et	O
al	O
.	O
,	O
2002	O
;	O
Niu	O
and	O
Magleby	O
,	O
2002	O
;	O
Xia	O
et	O
al	O
.	O
,	O
2002	O
;	O
Bao	O
et	O
al	O
.	O
,	O
2004	O
;	O
Zeng	O
et	O
al	O
.	O
,	O
2005b	O
)	O
.	O
</ALL>	O

<ALL>	O
We	O
used	O
a	O
mutated	O
dSlo	O
channel	O
with	O
substitution	O
of	O
Asp966	O
-	O
Asp970	O
by	O
Asn966	O
-	O
Asn970	O
within	O
its	O
calcium	O
bowl	O
,	O
which	O
greatly	O
reduces	O
the	O
channel	O
'	O
s	O
calcium	O
sensitivity	O
(	O
Bian	O
et	O
al	O
.	O
,	O
2001	O
)	O
,	O
to	O
determine	O
whether	O
Ca2	O
+	O
participates	O
in	O
Slob57	O
modulation	O
of	O
dSlo	O
.	O
</ALL>	O

<ALL>	O
This	O
mutated	O
channel	O
,	O
dSloD5N5	O
,	O
still	O
binds	O
to	O
full	O
-	O
length	O
and	O
truncated	O
Slobs	O
(	O
Fig	O
.	O
1	O
B	O
,	O
lanes	O
4	O
-	O
6	O
)	O
.	O
</ALL>	O

<ALL>	O
During	O
a	O
350	O
-	O
ms	O
test	O
pulse	O
(	O
Fig	O
.	O
7	O
E	O
)	O
,	O
Slob57	O
causes	O
dSloD5N5	O
inactivation	O
(	O
Fig	O
.	O
7	O
B	O
)	O
,	O
consistent	O
with	O
our	O
previous	O
finding	O
that	O
the	O
inactivation	O
caused	O
by	O
Slob57	O
is	O
Ca2	O
+	O
independent	O
(	O
Zeng	O
et	O
al	O
.	O
,	O
2005a	O
)	O
.	O
</ALL>	O

<ALL>	O
After	O
deletion	O
of	O
the	O
amino	O
-	O
terminal	O
residues	O
2	O
-	O
6	O
of	O
Slob57	O
,	O
the	O
inactivation	O
of	O
dSloD5N5	O
is	O
eliminated	O
(	O
Fig	O
.	O
7	O
C	O
)	O
,	O
and	O
further	O
truncation	O
of	O
Slob57	O
to	O
Arg16	O
also	O
eliminates	O
the	O
inactivation	O
(	O
Fig	O
.	O
7	O
D	O
)	O
,	O
just	O
as	O
observed	O
with	O
wild	O
-	O
type	O
dSlo	O
(	O
Fig	O
.	O
2	O
,	O
C	O
and	O
D	O
)	O
.	O
</ALL>	O

<ALL>	O
Figure	O
7	O
.	O
</ALL>	O

<ALL>	O
Slob57	O
causes	O
inactivation	O
of	O
dSloD5N5	O
.	O
</ALL>	O

<ALL>	O
Same	O
as	O
Fig	O
.	O
</ALL>	O

<ALL>	O
2	O
,	O
except	O
that	O
the	O
mutated	O
channel	O
dSloD5N5	O
was	O
used	O
instead	O
of	O
wild	O
-	O
type	O
dSlo	O
.	O
</ALL>	O

<ALL>	O
(	O
A	O
)	O
dSloD5N5	O
alone	O
,	O
(	O
B	O
)	O
dSloD5N5	O
together	O
with	O
Slob57	O
,	O
(	O
C	O
)	O
dSloD5N5	O
together	O
with	O
Slob57DeltaN5	O
,	O
(	O
D	O
)	O
dSloD5N5	O
together	O
with	O
Slob57DeltaN15	O
,	O
(	O
E	O
)	O
pulse	O
protocol	O
.	O
</ALL>	O

<ALL>	O
We	O
next	O
used	O
a	O
100	O
-	O
ms	O
test	O
pulse	O
(	O
during	O
which	O
no	O
inactivation	O
occurs	O
)	O
to	O
measure	O
the	O
voltage	O
dependence	O
of	O
activation	O
of	O
dSloD5N5	O
in	O
the	O
presence	O
of	O
110	O
muM	O
free	O
Ca2	O
+	O
,	O
as	O
only	O
at	O
high	O
concentrations	O
of	O
free	O
Ca2	O
+	O
can	O
tail	O
current	O
saturation	O
be	O
achieved	O
with	O
the	O
mutant	O
channel	O
(	O
Fig	O
.	O
8	O
)	O
.	O
</ALL>	O

<ALL>	O
As	O
shown	O
in	O
Fig	O
.	O
</ALL>	O

<ALL>	O
8	O
,	O
Slob57	O
does	O
not	O
rightward	O
shift	O
the	O
conductance	O
-	O
voltage	O
relationship	O
of	O
dSloD5N5	O
.	O
</ALL>	O

<ALL>	O
Because	O
dSloD5N5	O
can	O
still	O
respond	O
to	O
an	O
increment	O
of	O
free	O
Ca2	O
+	O
at	O
high	O
concentration	O
(	O
Bian	O
et	O
al	O
.	O
,	O
2001	O
)	O
,	O
we	O
then	O
increased	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
to	O
300	O
muM	O
.	O
</ALL>	O

<ALL>	O
As	O
shown	O
in	O
Fig	O
.	O
</ALL>	O

<ALL>	O
8	O
,	O
the	O
conductance	O
-	O
voltage	O
relationship	O
of	O
dSloD5N5	O
shifts	O
to	O
less	O
depolarized	O
voltages	O
when	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
is	O
increased	O
from	O
110	O
to	O
300	O
muM	O
,	O
but	O
again	O
the	O
V1	O
/	O
2	O
is	O
not	O
modulated	O
by	O
Slob57	O
.	O
</ALL>	O

<ALL>	O
Figure	O
8	O
.	O
</ALL>	O

<ALL>	O
Conductance	O
-	O
voltage	O
relationships	O
for	O
dSloD5N5	O
.	O
</ALL>	O

<ALL>	O
Same	O
protocol	O
as	O
Fig	O
.	O
</ALL>	O

<ALL>	O
6	O
,	O
except	O
that	O
the	O
mutated	O
channel	O
dSloD5N5	O
was	O
used	O
in	O
the	O
presence	O
(	O
circles	O
)	O
or	O
absence	O
(	O
squares	O
)	O
of	O
Slob57	O
,	O
and	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
was	O
either	O
110	O
muM	O
(	O
filled	O
symbols	O
)	O
or	O
300	O
muM	O
(	O
open	O
symbols	O
)	O
.	O
</ALL>	O

<ALL>	O
We	O
next	O
measured	O
the	O
voltage	O
dependence	O
of	O
activation	O
of	O
wild	O
-	O
type	O
dSlo	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
Slob57	O
,	O
at	O
free	O
Ca2	O
+	O
concentrations	O
ranging	O
from	O
20	O
to	O
300	O
muM	O
.	O
</ALL>	O

<ALL>	O
As	O
shown	O
in	O
Fig	O
.	O
</ALL>	O

<ALL>	O
9	O
A	O
(	O
and	O
by	O
many	O
previous	O
investigators	O
)	O
,	O
in	O
the	O
absence	O
of	O
Slob57	O
,	O
the	O
voltage	O
-	O
conductance	O
relationship	O
of	O
dSlo	O
shifts	O
to	O
less	O
depolarized	O
voltages	O
as	O
the	O
free	O
Ca2	O
+	O
concentration	O
is	O
increased	O
in	O
this	O
range	O
.	O
</ALL>	O

<ALL>	O
The	O
V1	O
/	O
2	O
decreases	O
from	O
85	O
to	O
-	O
22	O
mV	O
,	O
a	O
change	O
of	O
107	O
mV	O
,	O
when	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
is	O
increased	O
from	O
20	O
to	O
300	O
muM	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
when	O
dSlo	O
is	O
coexpressed	O
with	O
Slob57	O
,	O
this	O
increment	O
of	O
free	O
Ca2	O
+	O
concentration	O
shifts	O
the	O
V1	O
/	O
2	O
to	O
a	O
much	O
lesser	O
extent	O
(	O
Fig	O
.	O
9	O
B	O
and	O
Fig	O
.	O
10	O
A	O
)	O
.	O
</ALL>	O

<ALL>	O
Note	O
also	O
that	O
the	O
effect	O
of	O
Slob57	O
on	O
the	O
V1	O
/	O
2	O
is	O
more	O
apparent	O
at	O
higher	O
free	O
Ca2	O
+	O
concentrations	O
(	O
Fig	O
.	O
10	O
A	O
)	O
.	O
</ALL>	O

<ALL>	O
To	O
illustrate	O
this	O
better	O
,	O
we	O
plotted	O
the	O
V1	O
/	O
2	O
change	O
evoked	O
by	O
Slob57	O
(	O
DeltaV1	O
/	O
2	O
)	O
as	O
a	O
function	O
of	O
the	O
free	O
Ca2	O
+	O
concentration	O
(	O
Fig	O
.	O
10	O
B	O
)	O
to	O
demonstrate	O
that	O
the	O
magnitude	O
of	O
the	O
modulatory	O
shift	O
in	O
V1	O
/	O
2	O
evoked	O
by	O
Slob57	O
itself	O
is	O
calcium	O
dependent	O
.	O
</ALL>	O

<ALL>	O
Figure	O
9	O
.	O
</ALL>	O

<ALL>	O
Effect	O
of	O
calcium	O
on	O
dSlo	O
voltage	O
dependence	O
of	O
activation	O
in	O
the	O
absence	O
or	O
presence	O
of	O
Slob57	O
.	O
</ALL>	O

<ALL>	O
Same	O
as	O
Fig	O
.	O
</ALL>	O

<ALL>	O
6	O
,	O
except	O
that	O
the	O
measurements	O
of	O
dSlo	O
expressed	O
alone	O
(	O
A	O
)	O
or	O
together	O
with	O
Slob57	O
(	O
B	O
)	O
were	O
performed	O
in	O
the	O
presence	O
of	O
different	O
concentrations	O
of	O
free	O
Ca2	O
+	O
:	O
20	O
muM	O
(	O
diamonds	O
)	O
,	O
40	O
muM	O
(	O
inverted	O
triangles	O
)	O
,	O
80	O
muM	O
(	O
triangles	O
)	O
,	O
110	O
muM	O
(	O
squares	O
)	O
,	O
and	O
300	O
muM	O
(	O
circles	O
)	O
.	O
</ALL>	O

<ALL>	O
Figure	O
10	O
.	O
</ALL>	O

<ALL>	O
Interaction	O
between	O
Slob57	O
and	O
calcium	O
.	O
</ALL>	O

<ALL>	O
The	O
V1	O
/	O
2	O
(	O
A	O
)	O
of	O
the	O
conductance	O
-	O
voltage	O
relationship	O
for	O
dSlo	O
expressed	O
alone	O
(	O
O	O
)	O
or	O
together	O
with	O
Slob57	O
(	O
*	O
)	O
,	O
taken	O
from	O
Fig	O
.	O
</ALL>	O

<ALL>	O
9	O
,	O
and	O
the	O
difference	O
in	O
V1	O
/	O
2	O
(	O
DeltaV1	O
/	O
2	O
)	O
evoked	O
by	O
Slob57	O
(	O
B	O
)	O
are	O
plotted	O
as	O
a	O
function	O
of	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
.	O
</ALL>	O

<ALL>	O
Authors	O
'	O
contributions	O
</ALL>	O

<ALL>	O
OK	O
and	O
MG	O
analyzed	O
and	O
interpreted	O
the	O
patient	O
data	O
regarding	O
his	O
hospitalization	O
.	O
</ALL>	O

<ALL>	O
SP	O
and	O
PK	O
performed	O
the	O
coronary	B-Multi-tissue_structure
angiography	O
,	O
and	O
were	O
the	O
major	O
contributors	O
in	O
writing	O
the	O
manuscript	O
.	O
</ALL>	O

<ALL>	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
</ALL>	O

<ALL>	O
Authors	O
'	O
contributions	O
</ALL>	O

<ALL>	O
CM	O
,	O
JRH	O
,	O
HJP	O
,	O
and	O
JH	O
carried	O
animal	O
studies	O
.	O
</ALL>	O

<ALL>	O
CM	O
performed	O
the	O
statistical	O
analysis	O
.	O
</ALL>	O

<ALL>	O
JLK	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
drafted	O
and	O
edited	O
the	O
manuscript	O
.	O
</ALL>	O

<ALL>	O
All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O
</ALL>	O

<ALL>	O
Disk	O
preparation	O
phase	O
</ALL>	O

<ALL>	O
o	O
Adoption	O
of	O
a	O
two	O
-	O
stage	O
sampling	O
scheme	O
.	O
</ALL>	O

<ALL>	O
o	O
Careful	O
planning	O
and	O
choice	O
of	O
representative	O
sampling	O
groups	O
and	O
sites	O
according	O
to	O
the	O
adopted	O
network	O
sampling	O
technique	O
,	O
and	O
determining	O
certain	O
criteria	O
such	O
as	O
control	O
sites	O
where	O
major	O
sampling	O
groups	O
exist	O
(	O
i	O
.	O
e	O
.	O
surface	O
water	O
points	O
,	O
valleys	O
,	O
and	O
wells	O
)	O
,	O
impact	O
sites	O
where	O
contamination	O
is	O
expected	O
,	O
such	O
as	O
polygons	O
,	O
and	O
outlets	O
(	O
e	O
.	O
g	O
.	O
treated	O
water	O
discharges	O
site	O
)	O
to	O
maximise	O
understanding	O
the	O
quality	O
of	O
urban	O
water	O
sources	O
,	O
and	O
with	O
the	O
least	O
risk	O
of	O
missing	O
the	O
correct	O
representative	O
sampling	O
groups	O
and	O
sites	O
.	O
</ALL>	O

<ALL>	O
o	O
Attention	O
paid	O
to	O
ensure	O
inclusion	O
in	O
the	O
sampling	O
frame	O
of	O
all	O
groups	O
and	O
locations	O
(	O
sites	O
,	O
roads	O
,	O
venues	O
,	O
and	O
so	O
on	O
)	O
via	O
screening	O
,	O
browsing	O
,	O
and	O
delineation	O
from	O
a	O
satellite	O
digital	O
map	O
of	O
the	O
Khamis	O
Mushait	O
Governorate	O
zone	O
,	O
because	O
local	O
pre	O
-	O
knowledge	O
was	O
preferred	O
with	O
regard	O
to	O
accessibility	O
,	O
safety	O
,	O
and	O
permission	O
.	O
</ALL>	O

<ALL>	O
o	O
Approximation	O
of	O
the	O
number	O
of	O
the	O
target	O
study	O
population	O
in	O
each	O
group	O
and	O
sampling	O
location	O
.	O
</ALL>	O

<ALL>	O
o	O
Determination	O
of	O
the	O
proportional	O
allocation	O
of	O
samples	O
between	O
different	O
groups	O
and	O
locations	O
.	O
</ALL>	O

<ALL>	O
o	O
Training	O
of	O
interviewers	O
\	O
sample	O
collectors	O
to	O
follow	O
and	O
to	O
use	O
the	O
sampling	O
strategy	O
and	O
procedures	O
.	O
</ALL>	O

<ALL>	O
o	O
Implementation	O
of	O
ways	O
to	O
boost	O
participation	O
rates	O
in	O
the	O
screening	O
and	O
core	O
interviews	O
and	O
sample	O
collection	O
.	O
</ALL>	O

<ALL>	O
o	O
Planning	O
of	O
logistic	O
needs	O
of	O
timing	O
,	O
gathering	O
,	O
handling	O
samples	O
,	O
and	O
laboratory	O
.	O
</ALL>	O

<ALL>	O
o	O
Producing	O
sampling	O
cards	O
to	O
be	O
completed	O
to	O
record	O
observations	O
at	O
scene	O
(	O
sample	O
ID	O
and	O
data	O
/	O
information	O
:	O
date	O
,	O
time	O
,	O
temperature	O
,	O
group	O
,	O
locality	O
,	O
problems	O
in	O
the	O
area	O
,	O
sketch	O
map	O
)	O
.	O
</ALL>	O

<ALL>	O
o	O
Selection	O
of	O
an	O
appropriate	O
major	O
sampling	O
method	O
[	O
52	O
]	O
(	O
i	O
.	O
e	O
.	O
simple	O
random	O
sample	O
;	O
network	O
sampling	O
)	O
.	O
</ALL>	O

<ALL>	O
o	O
Planning	O
of	O
pilot	O
visits	O
to	O
samples	O
of	O
each	O
group	O
in	O
the	O
field	O
to	O
review	O
strategy	O
.	O
</ALL>	O

<ALL>	O
Results	O
</ALL>	O

<ALL>	O
In	O
the	O
established	O
adult	O
rat	O
NSC	B-Cell
culture	O
,	O
FGF	O
-	O
2	O
promotes	O
self	O
-	O
renewal	O
by	O
increasing	O
proliferation	O
and	O
inhibiting	O
spontaneous	O
differentiation	O
of	O
adult	O
NSCs	B-Cell
,	O
accompanied	O
with	O
activation	O
of	O
MAPK	O
and	O
PLC	O
pathways	O
.	O
</ALL>	O

<ALL>	O
Using	O
a	O
molecular	O
genetic	O
approach	O
,	O
we	O
demonstrate	O
that	O
activation	O
of	O
FGF	O
receptor	O
1	O
(	O
FGFR1	O
)	O
,	O
largely	O
through	O
two	O
key	O
cytoplasmic	B-Organism_substance
amino	O
acid	O
residues	O
that	O
are	O
linked	O
to	O
MAPK	O
and	O
PLC	O
activation	O
,	O
suffices	O
to	O
promote	O
adult	O
NSC	B-Cell
self	O
-	O
renewal	O
.	O
</ALL>	O

<ALL>	O
The	O
canonical	O
MAPK	O
,	O
Erk1	O
/	O
2	O
activation	O
,	O
is	O
both	O
required	O
and	O
sufficient	O
for	O
the	O
NSC	B-Cell
expansion	O
and	O
anti	O
-	O
differentiation	O
effects	O
of	O
FGF	O
-	O
2	O
.	O
</ALL>	O

<ALL>	O
In	O
contrast	O
,	O
PLC	O
activation	O
is	O
integral	O
to	O
the	O
maintenance	O
of	O
adult	O
NSC	B-Cell
characteristics	O
,	O
including	O
the	O
full	O
capacity	O
for	O
neuronal	B-Cell
and	O
oligodendroglial	B-Cell
differentiation	O
.	O
</ALL>	O

<ALL>	O
Stochastic	O
models	O
</ALL>	O

<ALL>	O
Stochasticity	O
inevitably	O
emerges	O
when	O
molecular	O
components	O
are	O
present	O
at	O
low	O
cellular	B-Cell
concentrations	O
(	O
McAdams	O
&	O
Arkin	O
,	O
1997	O
;	O
Kierzek	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
physical	O
phenomenon	O
generates	O
noise	O
in	O
synthetic	O
and	O
natural	O
circuits	O
(	O
Paulsson	O
,	O
2004	O
;	O
Mettetal	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
and	O
its	O
consequences	O
over	O
the	O
phenotype	O
are	O
starting	O
to	O
be	O
explored	O
(	O
Suel	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O
</ALL>	O

<ALL>	O
For	O
example	O
,	O
noise	O
constitutes	O
the	O
driving	O
force	O
behind	O
differentiation	O
in	O
isogenetic	O
colonies	O
(	O
Colman	O
-	O
Lerner	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O
</ALL>	O

<ALL>	O
Biological	O
and	O
theoretical	O
studies	O
have	O
aided	O
to	O
delineate	O
the	O
regulatory	O
mechanism	O
by	O
which	O
the	O
cell	B-Cell
handles	O
noise	O
efficiently	O
and	O
effectively	O
to	O
carry	O
out	O
its	O
biological	O
functions	O
(	O
Gardner	O
&	O
Collins	O
,	O
2000	O
;	O
Orrell	O
&	O
Bolouri	O
,	O
2004	O
;	O
Raser	O
&	O
O	O
'	O
Shea	O
,	O
2005	O
)	O
.	O
</ALL>	O

<ALL>	O
From	O
a	O
theoretical	O
point	O
of	O
view	O
,	O
stochastic	O
models	O
are	O
the	O
most	O
challenging	O
but	O
also	O
the	O
most	O
realistic	O
ones	O
:	O
there	O
is	O
a	O
precise	O
counting	O
of	O
how	O
,	O
through	O
individual	O
chemical	O
reactions	O
,	O
the	O
populations	O
of	O
every	O
chemical	O
species	O
change	O
.	O
</ALL>	O

<ALL>	O
The	O
milestone	O
to	O
simulate	O
stochastic	O
processes	O
is	O
the	O
Gillespie	O
algorithm	O
(	O
Gillespie	O
,	O
1992	O
)	O
.	O
</ALL>	O

<ALL>	O
Because	O
of	O
their	O
analytical	O
and	O
computational	O
complexity	O
,	O
the	O
present	O
models	O
do	O
not	O
surpass	O
a	O
handful	O
of	O
chemical	O
species	O
.	O
</ALL>	O

<ALL>	O
Two	O
immediate	O
problems	O
must	O
be	O
solved	O
to	O
model	O
systems	O
with	O
several	O
dozens	O
of	O
genetic	O
components	O
:	O
the	O
systematic	O
determination	O
of	O
kinetic	O
constants	O
and	O
the	O
efficient	O
computation	O
of	O
thousands	O
of	O
chemical	O
stochastic	O
equations	O
(	O
Kuwahara	O
et	O
al	O
.	O
,	O
2006	O
;	O
Sanchez	O
&	O
Kondev	O
,	O
2008	O
)	O
.	O
</ALL>	O

<ALL>	O
Model	O
of	O
how	O
estrogen	O
induces	O
DNA	O
damage	O
.	O
</ALL>	O

<ALL>	O
Estrogen	O
enters	O
the	O
cell	B-Cell
and	O
is	O
bound	O
by	O
the	O
ER	O
.	O
</ALL>	O

<ALL>	O
The	O
dimeric	O
ER	O
-	O
estrogen	O
complex	O
enters	O
the	O
nucleus	B-Cellular_component
and	O
induces	O
AID	O
expression	O
.	O
</ALL>	O

<ALL>	O
This	O
leads	O
to	O
an	O
increase	O
in	O
mutations	O
and	O
translocations	O
,	O
and	O
potentially	O
cancer	B-Pathological_formation
</ALL>	O

<ALL>	O
Results	O
:	O
</ALL>	O

<ALL>	O
In	O
the	O
total	O
population	O
(	O
N	O
=	O
95	O
)	O
,	O
median	O
OS	O
was	O
significantly	O
longer	O
in	O
patients	O
with	O
baseline	O
CA	O
19	O
-	O
9	O
values	O
at	O
or	O
below	O
the	O
median	O
than	O
in	O
those	O
with	O
values	O
above	O
it	O
(	O
12	O
.	O
2	O
months	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
8	O
.	O
6	O
-	O
16	O
.	O
6	O
%	O
]	O
vs	O
5	O
.	O
0	O
months	O
[	O
95	O
%	O
CI	O
,	O
3	O
.	O
9	O
-	O
5	O
.	O
7	O
%	O
]	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
also	O
reached	O
significance	O
in	O
the	O
Gem	O
+	O
A	O
arm	O
(	O
median	O
OS	O
,	O
12	O
.	O
5	O
months	O
[	O
95	O
%	O
CI	O
,	O
8	O
.	O
6	O
-	O
16	O
.	O
6	O
%	O
]	O
vs	O
4	O
.	O
9	O
months	O
[	O
95	O
%	O
CI	O
,	O
3	O
.	O
6	O
-	O
5	O
.	O
6	O
%	O
]	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O
</ALL>	O

<ALL>	O
Patients	O
with	O
any	O
dBP	O
>	O
90	O
mmHg	O
had	O
significantly	O
longer	O
OS	O
than	O
those	O
who	O
did	O
not	O
.	O
</ALL>	O

<ALL>	O
However	O
,	O
there	O
was	O
no	O
predictive	O
significance	O
of	O
CA	O
19	O
-	O
9	O
.	O
</ALL>	O

<ALL>	O
Percentage	O
reported	O
purchasing	O
intentions	O
,	O
comparing	O
ITN	O
-	O
owning	O
to	O
non	O
-	O
owning	O
households	O
</ALL>	O

<ALL>	O
School	O
environment	O
</ALL>	O

<ALL>	O
At	O
the	O
majority	O
of	O
the	O
schools	O
a	O
soft	O
drink	O
vending	O
machine	O
(	O
91	O
%	O
,	O
n	O
=	O
446	O
)	O
and	O
/	O
or	O
a	O
vending	O
machine	O
containing	O
sweets	O
and	O
candy	O
bars	O
(	O
81	O
%	O
,	O
n	O
=	O
413	O
)	O
is	O
present	O
(	O
Table	O
2	O
)	O
.	O
</ALL>	O

<ALL>	O
At	O
78	O
%	O
(	O
n	O
=	O
393	O
)	O
of	O
the	O
schools	O
there	O
is	O
a	O
supermarket	O
,	O
gas	O
station	O
or	O
a	O
fast	O
food	O
restaurant	O
in	O
the	O
neighbourhood	O
(	O
within	O
1	O
km	O
of	O
the	O
school	O
)	O
.	O
</ALL>	O

<ALL>	O
At	O
68	O
%	O
(	O
n	O
=	O
345	O
)	O
of	O
the	O
schools	O
there	O
are	O
facilities	O
at	O
or	O
around	O
the	O
school	O
property	O
where	O
the	O
students	O
can	O
be	O
physically	O
active	O
,	O
for	O
example	O
a	O
soccer	O
field	O
or	O
a	O
basketball	O
field	O
.	O
</ALL>	O

<ALL>	O
Table	O
2	O
</ALL>	O

<ALL>	O
The	O
school	O
environment	O
</ALL>	O

<ALL>	O
Total	O
School	O
level	O
</ALL>	O

<ALL>	O
Vocational	O
education	O
schools	O
Mixed	O
schools	O
Higher	O
education	O
schools	O
Vocational	O
education	O
schools	O
versus	O
higher	O
education	O
schools	O
#	O
Mixed	O
schools	O
versus	O
higher	O
education	O
schools	O
#	O
</ALL>	O

<ALL>	O
n	O
=	O
515	O
n	O
=	O
216	O
n	O
=	O
232	O
n	O
=	O
67	O
</ALL>	O

<ALL>	O
%	O
(	O
n	O
)	O
%	O
(	O
n	O
)	O
%	O
(	O
n	O
)	O
%	O
(	O
n	O
)	O
OR	O
(	O
95	O
%	O
CI	O
)	O
OR	O
(	O
95	O
%	O
CI	O
)	O
</ALL>	O

<ALL>	O
Soft	O
drink	O
vending	O
machine	O
present	O
at	O
school	O
91	O
.	O
4	O
(	O
466	O
)	O
90	O
.	O
2	O
(	O
194	O
)	O
91	O
.	O
3	O
(	O
209	O
)	O
95	O
.	O
5	O
(	O
63	O
)	O
1	O
.	O
0	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
1	O
)	O
1	O
.	O
0	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
0	O
)	O
</ALL>	O

<ALL>	O
Percentage	O
of	O
soft	O
drink	O
vending	O
machines	O
present	O
at	O
school	O
that	O
contain	O
light	O
soft	O
drinks	O
79	O
.	O
8	O
(	O
372	O
)	O
75	O
.	O
4	O
(	O
147	O
)	O
82	O
.	O
2	O
(	O
171	O
)	O
85	O
.	O
7	O
(	O
54	O
)	O
0	O
.	O
9	O
(	O
0	O
.	O
8	O
;	O
1	O
.	O
0	O
)	O
1	O
.	O
0	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
1	O
)	O
</ALL>	O

<ALL>	O
Soft	O
drink	O
vending	O
machines	O
contain	O
more	O
unhealthy	O
drinks	O
than	O
healthy	O
drinks	O
57	O
.	O
9	O
(	O
268	O
)	O
61	O
.	O
9	O
(	O
120	O
)	O
58	O
.	O
5	O
(	O
121	O
)	O
43	O
.	O
6	O
(	O
27	O
)	O
1	O
.	O
4	O
(	O
1	O
.	O
0	O
;	O
1	O
.	O
9	O
)	O
1	O
.	O
4	O
(	O
1	O
.	O
0	O
;	O
1	O
.	O
9	O
)	O
*	O
</ALL>	O

<ALL>	O
Vending	O
machine	O
present	O
at	O
school	O
that	O
contains	O
sweets	O
/	O
candy	O
bars	O
80	O
.	O
7	O
(	O
413	O
)	O
75	O
.	O
6	O
(	O
161	O
)	O
84	O
.	O
9	O
(	O
197	O
)	O
82	O
.	O
1	O
(	O
55	O
)	O
1	O
.	O
1	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
2	O
)	O
1	O
.	O
1	O
(	O
1	O
.	O
0	O
;	O
1	O
.	O
2	O
)	O
</ALL>	O

<ALL>	O
Sweets	O
/	O
candy	O
bars	O
vending	O
machines	O
contain	O
more	O
unhealthy	O
than	O
healthy	O
foods	O
63	O
.	O
7	O
(	O
260	O
)	O
70	O
.	O
6	O
(	O
113	O
)	O
64	O
.	O
4	O
(	O
125	O
)	O
40	O
.	O
7	O
(	O
22	O
)	O
1	O
.	O
7	O
(	O
1	O
.	O
2	O
;	O
2	O
.	O
4	O
)	O
*	O
1	O
.	O
6	O
(	O
1	O
.	O
1	O
;	O
2	O
.	O
3	O
)	O
*	O
</ALL>	O

<ALL>	O
There	O
is	O
a	O
supermarket	O
,	O
gas	O
station	O
,	O
or	O
fast	O
food	O
restaurant	O
in	O
the	O
neighbourhood	O
of	O
the	O
school	O
78	O
.	O
3	O
(	O
393	O
)	O
76	O
.	O
7	O
(	O
161	O
)	O
79	O
.	O
7	O
(	O
181	O
)	O
78	O
.	O
5	O
(	O
51	O
)	O
1	O
.	O
1	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
2	O
)	O
1	O
.	O
1	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
2	O
)	O
</ALL>	O

<ALL>	O
The	O
students	O
are	O
allowed	O
to	O
leave	O
the	O
school	O
property	O
during	O
school	O
hours	O
57	O
.	O
4	O
(	O
295	O
)	O
42	O
.	O
6	O
(	O
92	O
)	O
65	O
.	O
8	O
(	O
152	O
)	O
76	O
.	O
1	O
(	O
51	O
)	O
0	O
.	O
6	O
(	O
0	O
.	O
5	O
;	O
0	O
.	O
8	O
)	O
*	O
0	O
.	O
9	O
(	O
0	O
.	O
8	O
;	O
1	O
.	O
0	O
)	O
</ALL>	O

<ALL>	O
There	O
are	O
facilities	O
at	O
and	O
around	O
the	O
school	O
property	O
where	O
the	O
students	O
can	O
be	O
physically	O
active	O
68	O
.	O
1	O
(	O
345	O
)	O
63	O
.	O
1	O
(	O
135	O
)	O
70	O
.	O
3	O
(	O
161	O
)	O
76	O
.	O
6	O
(	O
49	O
)	O
0	O
.	O
8	O
(	O
0	O
.	O
7	O
;	O
1	O
.	O
0	O
)	O
0	O
.	O
9	O
(	O
0	O
.	O
8	O
;	O
1	O
.	O
1	O
)	O
</ALL>	O

<ALL>	O
#	O
Associations	O
are	O
adjusted	O
for	O
school	O
size	O
</ALL>	O

<ALL>	O
*	O
p	O
<	O
0	O
.	O
05	O
</ALL>	O

<ALL>	O
The	O
vocational	O
education	O
schools	O
did	O
not	O
differ	O
from	O
the	O
higher	O
education	O
schools	O
with	O
regard	O
to	O
the	O
presence	O
of	O
vending	O
machines	O
and	O
a	O
canteen	O
,	O
but	O
the	O
vending	O
machines	O
and	O
the	O
canteen	O
contained	O
a	O
less	O
favourable	O
selection	O
of	O
foods	O
and	O
drinks	O
.	O
</ALL>	O

<ALL>	O
The	O
vocational	O
education	O
schools	O
indicated	O
more	O
often	O
that	O
the	O
vending	O
machines	O
and	O
the	O
canteen	O
contained	O
more	O
unhealthy	O
foods	O
and	O
drinks	O
than	O
healthy	O
foods	O
and	O
drinks	O
.	O
</ALL>	O

<ALL>	O
Vocational	O
education	O
schools	O
had	O
fewer	O
facilities	O
at	O
and	O
around	O
the	O
school	O
property	O
to	O
be	O
physical	O
than	O
the	O
higher	O
education	O
schools	O
.	O
</ALL>	O

<ALL>	O
Most	O
associations	O
were	O
attenuated	O
after	O
adjustment	O
for	O
school	O
size	O
.	O
</ALL>	O

<ALL>	O
For	O
example	O
,	O
the	O
association	O
between	O
school	O
level	O
and	O
content	O
of	O
the	O
soft	O
drink	O
vending	O
machines	O
was	O
OR	O
=	O
1	O
.	O
42	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
05	O
-	O
1	O
.	O
93	O
in	O
the	O
crude	O
analysis	O
and	O
OR	O
=	O
1	O
.	O
35	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
99	O
-	O
1	O
.	O
85	O
in	O
the	O
adjusted	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Background	O
</ALL>	O

<ALL>	O
Over	O
the	O
past	O
decades	O
,	O
extensive	O
comparative	O
mapping	O
research	O
has	O
been	O
performed	O
in	O
the	O
plant	O
family	O
Solanaceae	O
.	O
</ALL>	O

<ALL>	O
The	O
recent	O
identification	O
of	O
a	O
large	O
set	O
of	O
single	O
-	O
copy	O
conserved	O
orthologous	O
(	O
COSII	O
)	O
markers	O
has	O
greatly	O
accelerated	O
comparative	O
mapping	O
studies	O
among	O
major	O
solanaceous	O
species	O
including	O
tomato	O
,	O
potato	O
,	O
eggplant	O
,	O
pepper	O
and	O
diploid	O
Nicotiana	O
species	O
(	O
as	O
well	O
as	O
tetraploid	O
tobacco	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
large	O
amount	O
of	O
comparative	O
data	O
now	O
available	O
for	O
these	O
species	O
provides	O
the	O
opportunity	O
to	O
describe	O
the	O
overall	O
patterns	O
of	O
chromosomal	B-Cellular_component
evolution	O
in	O
this	O
important	O
plant	O
family	O
.	O
</ALL>	O

<ALL>	O
The	O
results	O
of	O
this	O
investigation	O
are	O
described	O
herein	O
.	O
</ALL>	O

<ALL>	O
Introduction	O
</ALL>	O

<ALL>	O
Tea	O
(	O
Camellia	O
sinensis	O
L	O
.	O
)	O
is	O
one	O
of	O
the	O
most	O
widely	O
consumed	O
beverages	O
in	O
the	O
world	O
.	O
</ALL>	O

<ALL>	O
(	O
-	O
)	O
-	O
Epigallocatechin	O
-	O
3	O
-	O
O	O
-	O
gallate	O
(	O
EGCG	O
)	O
,	O
which	O
is	O
the	O
major	O
green	O
tea	O
catechin	O
present	O
in	O
the	O
leaves	B-Organ
,	O
is	O
believed	O
to	O
the	O
compound	O
most	O
responsible	O
for	O
the	O
health	O
benefits	O
attributed	O
to	O
tea	O
.	O
</ALL>	O

<ALL>	O
EGCG	O
was	O
reported	O
to	O
have	O
antioxidative	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
,	O
antimutagenic	O
[	O
3	O
]	O
,	O
anti	O
-	O
inflammatory	O
[	O
4	O
]	O
,	O
and	O
anticarcinogenic	O
activities	O
[	O
5	O
]	O
.	O
</ALL>	O

<ALL>	O
Although	O
the	O
EGCG	O
concentrations	O
required	O
to	O
elicit	O
the	O
anticancer	B-Pathological_formation
activity	O
have	O
been	O
shown	O
to	O
be	O
more	O
than	O
1	O
microM	O
,	O
the	O
blood	B-Organism_substance
level	O
of	O
EGCG	O
after	O
consuming	O
the	O
equivalent	O
of	O
2	O
-	O
3	O
cups	O
of	O
green	O
tea	O
was	O
0	O
.	O
1	O
-	O
0	O
.	O
6	O
microM	O
and	O
for	O
an	O
equivalent	O
of	O
7	O
-	O
9	O
cups	O
was	O
still	O
lower	O
than	O
1	O
microM	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
.	O
</ALL>	O

<ALL>	O
In	O
a	O
cohort	O
study	O
,	O
daily	O
consumption	O
of	O
ten	O
cups	O
of	O
green	O
tea	O
was	O
required	O
for	O
the	O
cancer	B-Pathological_formation
preventive	O
effect	O
[	O
8	O
]	O
.	O
</ALL>	O

<ALL>	O
Moreover	O
,	O
adverse	O
effects	O
of	O
green	O
tea	O
,	O
mainly	O
hepatitis	O
,	O
by	O
consumption	O
of	O
high	O
doses	O
of	O
green	O
tea	O
have	O
been	O
reported	O
[	O
9	O
]	O
.	O
</ALL>	O

<ALL>	O
Therefore	O
,	O
it	O
is	O
important	O
to	O
enhance	O
the	O
pharmacologic	O
effect	O
of	O
EGCG	O
to	O
obtain	O
the	O
health	O
benefit	O
in	O
reasonable	O
concentration	O
in	O
daily	O
life	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
reported	O
that	O
the	O
cell	B-Cellular_component
-	I-Cellular_component
surface	I-Cellular_component
binding	O
of	O
EGCG	O
and	O
its	O
derivatives	O
is	O
involved	O
in	O
their	O
biological	O
activities	O
[	O
10	O
]	O
-	O
[	O
15	O
]	O
.	O
</ALL>	O

<ALL>	O
We	O
have	O
identified	O
the	O
67	O
-	O
kDa	O
laminin	O
receptor	O
(	O
67LR	O
)	O
as	O
a	O
cell	B-Cellular_component
surface	I-Cellular_component
receptor	O
for	O
EGCG	O
that	O
mediates	O
the	O
anticancer	O
activity	O
of	O
EGCG	O
[	O
16	O
]	O
.	O
</ALL>	O

<ALL>	O
67LR	O
has	O
been	O
shown	O
to	O
be	O
overexpressed	O
on	O
the	O
cell	B-Cellular_component
surface	I-Cellular_component
of	O
various	O
tumor	B-Cell
cells	I-Cell
[	O
17	O
]	O
.	O
</ALL>	O

<ALL>	O
It	O
was	O
postulated	O
that	O
67LR	O
plays	O
a	O
significant	O
role	O
in	O
the	O
tumor	B-Pathological_formation
progression	O
and	O
speculated	O
that	O
studies	O
conducted	O
to	O
define	O
the	O
function	O
of	O
67LR	O
could	O
provide	O
a	O
new	O
approach	O
to	O
cancer	B-Pathological_formation
prevention	O
.	O
</ALL>	O

<ALL>	O
Indeed	O
,	O
expression	O
of	O
67	O
LR	O
confers	O
EGCG	O
responsiveness	O
to	O
tumor	B-Cell
cells	I-Cell
in	O
vivo	O
[	O
18	O
]	O
.	O
</ALL>	O

<ALL>	O
Vitamin	O
A	O
,	O
also	O
known	O
as	O
retinol	O
,	O
participates	O
in	O
physiological	O
activities	O
related	O
to	O
the	O
immune	O
system	O
,	O
maintenance	O
of	O
epithelial	B-Tissue
and	O
mucosa	B-Tissue
tissues	I-Tissue
,	O
growth	O
,	O
reproduction	O
,	O
and	O
bone	B-Organ
development	O
.	O
</ALL>	O

<ALL>	O
It	O
comes	O
from	O
animal	O
sources	O
,	O
such	O
as	O
eggs	B-Organism_substance
,	O
meat	B-Organism_subdivision
,	O
milk	B-Organism_substance
,	O
cheese	O
,	O
cream	O
,	O
liver	B-Organ
,	O
kidney	B-Organ
,	O
cod	O
and	O
halibut	O
fish	O
oil	B-Organism_substance
.	O
</ALL>	O

<ALL>	O
In	O
vitro	O
and	O
in	O
animal	O
models	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
vitamin	O
A	O
is	O
involved	O
in	O
the	O
regulation	O
and	O
promotion	O
of	O
growth	O
and	O
differentiation	O
of	O
many	O
cells	B-Cell
[	O
19	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
visual	O
function	O
of	O
vitamin	O
A	O
depends	O
on	O
its	O
natural	O
and	O
synthetic	O
derivatives	O
,	O
retinoids	O
[	O
20	O
]	O
.	O
</ALL>	O

<ALL>	O
All	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
the	O
active	O
derivative	O
of	O
vitamin	O
A	O
,	O
has	O
been	O
well	O
documented	O
as	O
a	O
growth	O
and	O
differentiation	O
factor	O
in	O
many	O
tissues	B-Tissue
and	O
cells	B-Cell
,	O
and	O
proved	O
to	O
be	O
an	O
effective	O
treatment	O
to	O
many	O
diseases	O
including	O
cancers	B-Pathological_formation
[	O
21	O
]	O
,	O
[	O
22	O
]	O
.	O
</ALL>	O

<ALL>	O
Retinoids	O
exert	O
their	O
physiological	O
activities	O
through	O
retinoid	O
receptor	O
nuclear	B-Cellular_component
proteins	O
that	O
belong	O
to	O
the	O
superfamily	O
of	O
steroid	O
/	O
thyroid	O
hormone	O
receptors	O
,	O
of	O
which	O
there	O
are	O
two	O
classes	O
,	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
and	O
the	O
retinoic	O
-	O
X	O
receptors	O
(	O
RXRs	O
)	O
,	O
each	O
of	O
which	O
has	O
three	O
subtypes	O
,	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
natural	O
ligands	O
for	O
the	O
RARs	O
are	O
ATRA	O
and	O
its	O
stereoisomers	O
9	O
-	O
cis	O
-	O
RA	O
and	O
13	O
-	O
cis	O
-	O
RA	O
,	O
whereas	O
RXRs	O
are	O
activated	O
by	O
9	O
-	O
cis	O
-	O
RA	O
only	O
.	O
</ALL>	O

<ALL>	O
ATRA	O
acts	O
through	O
RAR	O
to	O
transcriptionally	O
activate	O
target	O
genes	O
,	O
such	O
as	O
cytochrome	O
P450	O
and	O
CRABI	O
[	O
24	O
]	O
.	O
</ALL>	O

<ALL>	O
This	O
study	O
was	O
designed	O
to	O
identify	O
a	O
food	O
component	O
that	O
could	O
be	O
effectively	O
used	O
in	O
combination	O
with	O
EGCG	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
action	O
of	O
this	O
combination	O
.	O
</ALL>	O

<ALL>	O
By	O
using	O
in	O
vitro	O
and	O
in	O
vivo	O
systems	O
involving	O
a	O
highly	O
metastatic	O
mouse	O
B16	B-Cell
melanoma	I-Cell
cell	I-Cell
line	I-Cell
[	O
25	O
]	O
,	O
we	O
found	O
that	O
ATRA	O
enhances	O
the	O
antitumor	B-Pathological_formation
activity	O
of	O
EGCG	O
by	O
upregulating	O
the	O
67	O
LR	O
expression	O
through	O
RAR	O
.	O
</ALL>	O

<ALL>	O
Titration	O
of	O
Ab	O
-	O
01	O
inhibition	O
of	O
ex	O
vivo	O
response	O
to	O
rhIL21	O
</ALL>	O

<ALL>	O
Samples	O
from	O
4	O
individual	O
healthy	O
human	O
donors	O
were	O
pre	O
-	O
incubated	O
for	O
2	O
hours	O
at	O
the	O
indicated	O
concentration	O
of	O
Ab	O
-	O
01	O
or	O
the	O
control	O
IgG1TM	O
prior	O
to	O
addition	O
of	O
10	O
ng	O
/	O
mL	O
rhIL21	O
and	O
2	O
hr	O
incubation	O
,	O
and	O
the	O
effect	O
on	O
the	O
6	O
biomarkers	O
was	O
then	O
assessed	O
(	O
Figures	O
4	O
and	O
5	O
)	O
.	O
</ALL>	O

<ALL>	O
For	O
the	O
first	O
2	O
donors	O
tested	O
,	O
even	O
the	O
lowest	O
concentration	O
of	O
Ab	O
-	O
01	O
(	O
0	O
.	O
1	O
mug	O
/	O
mL	O
,	O
0	O
.	O
66	O
nM	O
)	O
resulted	O
in	O
complete	O
inhibition	O
of	O
the	O
rhIL21	O
response	O
,	O
therefore	O
the	O
two	O
subsequent	O
donors	O
were	O
tested	O
at	O
increasing	O
concentrations	O
of	O
Ab	O
-	O
01	O
starting	O
at	O
0	O
.	O
003	O
mug	O
/	O
mL	O
.	O
</ALL>	O

<ALL>	O
Ab	O
-	O
01	O
inhibited	O
the	O
response	O
of	O
all	O
6	O
genes	O
in	O
all	O
4	O
donors	O
.	O
</ALL>	O

<ALL>	O
IC50	O
values	O
ranged	O
between	O
0	O
.	O
003	O
and	O
0	O
.	O
015	O
mug	O
/	O
mL	O
Ab	O
-	O
01	O
(	O
Figure	O
5	O
)	O
.	O
</ALL>	O

<ALL>	O
Control	O
IgG1TM	O
had	O
no	O
significant	O
effect	O
on	O
rhIL21	O
response	O
(	O
Figure4B	O
)	O
.	O
</ALL>	O

<ALL>	O
Figure	O
4	O
</ALL>	O

<ALL>	O
Average	O
percent	O
inhibition	O
of	O
the	O
expression	O
level	O
of	O
6	O
IL21	O
-	O
responsive	O
genes	O
.	O
</ALL>	O

<ALL>	O
Percent	O
inhibition	O
values	O
were	O
calculated	O
based	O
on	O
RQ	O
(	O
relative	O
quantification	O
)	O
values	O
of	O
untreated	O
control	O
and	O
rhIL21	O
-	O
treated	O
samples	O
for	O
each	O
of	O
the	O
4	O
donors	O
,	O
and	O
subsequently	O
the	O
mean	O
and	O
standard	O
deviation	O
were	O
determined	O
for	O
each	O
gene	O
shown	O
.	O
</ALL>	O

<ALL>	O
A	O
:	O
Percent	O
inhibition	O
in	O
presence	O
of	O
Ab	O
-	O
01	O
.	O
</ALL>	O

<ALL>	O
B	O
:	O
Percent	O
inhibition	O
in	O
presence	O
of	O
control	O
IgG1TM	O
.	O
</ALL>	O

<ALL>	O
Data	O
for	O
the	O
0	O
.	O
1	O
mug	O
/	O
mL	O
,	O
0	O
.	O
3	O
mug	O
/	O
mL	O
and	O
1	O
mug	O
/	O
mL	O
concentrations	O
were	O
generated	O
using	O
4	O
donors	O
.	O
</ALL>	O

<ALL>	O
Data	O
for	O
the	O
higher	O
and	O
the	O
lower	O
concentrations	O
were	O
generated	O
using	O
2	O
donors	O
.	O
</ALL>	O

<ALL>	O
Figure	O
5	O
</ALL>	O

<ALL>	O
Inhibition	O
by	O
Ab	O
-	O
01	O
at	O
the	O
indicated	O
concentration	O
is	O
shown	O
for	O
6	O
IL21	O
-	O
responsive	O
genes	O
.	O
</ALL>	O

<ALL>	O
IC50	O
values	O
of	O
inhibition	O
curves	O
shown	O
in	O
Figure	O
4A	O
were	O
calculated	O
using	O
curve	O
fit	O
(	O
XLfit	O
)	O
program	O
for	O
each	O
of	O
the	O
referred	O
biomarker	O
genes	O
.	O
</ALL>	O

<ALL>	O
Values	O
for	O
the	O
0	O
.	O
1	O
mug	O
/	O
mL	O
,	O
0	O
.	O
3	O
mug	O
/	O
mL	O
and	O
1	O
mug	O
/	O
mL	O
concentrations	O
were	O
generated	O
using	O
4	O
donors	O
.	O
</ALL>	O

<ALL>	O
Data	O
for	O
the	O
higher	O
and	O
the	O
lower	O
concentrations	O
were	O
generated	O
using	O
2	O
donors	O
each	O
.	O
</ALL>	O

<ALL>	O
INTRODUCTION	O
</ALL>	O

<ALL>	O
For	O
several	O
years	O
now	O
,	O
virtual	O
microscopy	O
has	O
been	O
utilized	O
in	O
medical	O
teaching	O
,	O
research	O
,	O
proficiency	O
testing	O
,	O
American	O
Board	O
of	O
Pathology	O
examinations	O
,	O
pathology	O
meetings	O
and	O
conferences	O
,	O
and	O
quality	O
assurance	O
programs	O
.	O
</ALL>	O

<ALL>	O
In	O
diagnostic	O
practice	O
,	O
it	O
is	O
most	O
widely	O
and	O
routinely	O
used	O
in	O
image	O
analysis	O
.	O
</ALL>	O

<ALL>	O
Some	O
practices	O
are	O
beginning	O
to	O
use	O
it	O
internally	O
(	O
within	O
their	O
group	O
)	O
for	O
frozen	O
section	O
intraoperative	O
consultations	O
and	O
subspecialty	O
consultations	O
due	O
to	O
geographic	O
and	O
time	O
constrains	O
.	O
</ALL>	O

<ALL>	O
Although	O
diagnostic	O
consultation	O
for	O
expert	O
second	O
opinion	O
is	O
a	O
well	O
-	O
established	O
practice	O
in	O
pathology	O
for	O
glass	O
slides	O
,	O
similar	O
consultation	O
via	O
virtual	O
microscopy	O
poses	O
multiple	O
controversial	O
issues	O
such	O
as	O
licensing	O
,	O
liability	O
,	O
security	O
,	O
reimbursement	O
,	O
and	O
scanning	O
quality	O
and	O
its	O
validation	O
.	O
</ALL>	O

<ALL>	O
Regulations	O
and	O
standardization	O
are	O
not	O
yet	O
in	O
place	O
that	O
pathologists	O
can	O
use	O
to	O
allay	O
these	O
fears	O
.	O
</ALL>	O

<ALL>	O
Nevertheless	O
,	O
if	O
the	O
virtual	O
microscopy	O
scans	O
are	O
of	O
optimal	O
quality	O
,	O
these	O
can	O
be	O
simply	O
substituted	O
for	O
glass	O
slides	O
and	O
a	O
microscope	O
while	O
maintaining	O
all	O
other	O
practice	O
guidelines	O
for	O
second	O
opinion	O
consultation	O
.	O
</ALL>	O

<ALL>	O
Additionally	O
,	O
the	O
cost	O
and	O
maintenance	O
of	O
scanning	O
equipment	O
is	O
not	O
currently	O
affordable	O
to	O
most	O
practitioners	O
and	O
consultants	O
.	O
</ALL>	O

<ALL>	O
A	O
practice	O
model	O
that	O
offers	O
tertiary	O
consultation	O
in	O
gastrointestinal	B-Organism_subdivision
(	O
GI	B-Organism_subdivision
)	O
and	O
liver	B-Organ
pathology	O
is	O
presented	O
that	O
eliminates	O
the	O
cost	O
and	O
maintenance	O
of	O
scanners	O
by	O
the	O
consultants	O
and	O
clients	O
,	O
minimizes	O
the	O
need	O
for	O
review	O
of	O
glass	O
slides	O
,	O
facilitates	O
clinicopathological	O
and	O
radiological	O
correlation	O
and	O
serves	O
the	O
need	O
of	O
clients	O
who	O
need	O
timely	O
help	O
with	O
challenging	O
liver	B-Organ
and	O
GI	B-Organism_subdivision
cases	O
and	O
to	O
obtain	O
expert	O
opinion	O
for	O
dysplasia	O
in	O
Barrett	O
'	O
s	O
and	O
ulcerative	O
colitis	O
surveillance	O
biopsies	O
required	O
by	O
the	O
American	O
Gastroenterology	O
Association	O
(	O
AGA	O
)	O
.	O
</ALL>	O

<ALL>	O
This	O
model	O
has	O
been	O
practiced	O
for	O
3	O
years	O
and	O
applied	O
to	O
over	O
2000	O
cases	O
by	O
small	O
pathology	O
practices	O
in	O
the	O
50	O
United	O
States	O
and	O
a	O
single	O
consultant	O
GI	B-Organism_subdivision
and	O
liver	B-Organ
pathologist	O
.	O
</ALL>	O

<ALL>	O
Click	O
here	O
for	O
file	O
</ALL>	O

<ALL>	O
The	O
right	O
eye	B-Organ
of	O
a	O
50	O
-	O
year	O
-	O
old	O
patient	O
with	O
severe	O
hypertension	O
at	O
the	O
first	O
visit	O
.	O
</ALL>	O

<ALL>	O
(	O
a	O
)	O
Fundus	O
photograph	O
shows	O
serous	O
retinal	B-Multi-tissue_structure
detachment	O
.	O
</ALL>	O

<ALL>	O
The	O
optic	O
disc	O
is	O
pale	O
at	O
the	O
temporal	O
side	O
.	O
</ALL>	O

<ALL>	O
(	O
b	O
)	O
Optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
shows	O
retinal	B-Multi-tissue_structure
detachment	O
involving	O
the	O
fovea	O
and	O
cystic	O
change	O
of	O
inner	B-Multi-tissue_structure
retina	I-Multi-tissue_structure
.	O
</ALL>	O

<ALL>	O
(	O
c	O
)	O
Early	O
phase	O
images	O
of	O
fluorescein	O
angiography	O
(	O
FA	O
)	O
(	O
left	O
)	O
and	O
indocyanine	O
green	O
angiography	O
(	O
IA	O
)	O
(	O
right	O
)	O
.	O
</ALL>	O

<ALL>	O
(	O
d	O
)	O
Late	O
phase	O
images	O
of	O
FA	O
(	O
left	O
)	O
and	O
IA	O
(	O
right	O
)	O
.	O
</ALL>	O

<ALL>	O
FA	O
shows	O
window	O
defect	O
associated	O
with	O
macular	B-Tissue
cystic	O
change	O
.	O
</ALL>	O

<ALL>	O
Note	O
that	O
no	O
active	O
leakage	O
is	O
observed	O
in	O
the	O
area	O
with	O
serous	O
retinal	B-Multi-tissue_structure
detachment	O
or	O
cystoid	B-Pathological_formation
edema	I-Pathological_formation
.	O
</ALL>	O

<ALL>	O
IA	O
shows	O
decreased	O
perfusion	O
of	O
the	O
choroid	O
at	O
the	O
macula	B-Tissue
and	O
window	O
defect	O
with	O
the	O
damaged	O
RPE	O
.	O
</ALL>	O

<ALL>	O
Hypofluorescence	O
(	O
arrow	O
)	O
along	O
the	O
retinal	B-Tissue
artery	I-Tissue
are	O
observed	O
.	O
</ALL>	O

<ALL>	O
These	O
are	O
unique	O
findings	O
.	O
</ALL>	O

<ALL>	O
5	O
.	O
</ALL>	O

<ALL>	O
Conclusion	O
</ALL>	O

<ALL>	O
RLs	O
are	O
new	O
actors	O
in	O
animal	O
and	O
plant	O
defense	O
and	O
their	O
low	O
toxicity	O
and	O
biodegradability	O
make	O
them	O
promising	O
molecules	O
to	O
be	O
used	O
against	O
pathogens	O
.	O
</ALL>	O

<ALL>	O
In	O
this	O
respect	O
,	O
there	O
are	O
some	O
clues	O
now	O
available	O
for	O
the	O
success	O
of	O
RL	O
applications	O
in	O
greenhouses	O
to	O
fight	O
phytopathogens	O
.	O
</ALL>	O

<ALL>	O
A	O
better	O
understanding	O
of	O
RL	O
mode	O
of	O
action	O
,	O
especially	O
their	O
perception	O
and	O
the	O
signaling	O
pathways	O
activated	O
,	O
will	O
be	O
very	O
important	O
to	O
potentiate	O
their	O
beneficial	O
effects	O
in	O
plants	O
.	O
</ALL>	O

<ALL>	O
RLs	O
have	O
a	O
dual	O
mode	O
of	O
action	O
:	O
they	O
are	O
antimicrobial	O
and	O
also	O
stimulate	O
plant	O
defense	O
responses	O
.	O
</ALL>	O

<ALL>	O
This	O
dual	O
property	O
is	O
probably	O
very	O
important	O
for	O
the	O
efficiency	O
of	O
new	O
biopesticides	O
.	O
</ALL>	O

<ALL>	O
In	O
animals	O
,	O
the	O
use	O
of	O
RLs	O
is	O
also	O
at	O
an	O
advanced	O
stage	O
.	O
</ALL>	O

<ALL>	O
RLs	O
are	O
successfully	O
used	O
as	O
antimicrobial	O
agents	O
,	O
especially	O
for	O
skin	B-Organ
disease	O
treatment	O
.	O
</ALL>	O

<ALL>	O
Deep	O
insight	O
into	O
the	O
physiochemical	O
effects	O
of	O
RLs	O
and	O
their	O
biological	O
importance	O
would	O
reveal	O
new	O
dimensions	O
in	O
the	O
fields	O
of	O
research	O
like	O
agriculture	O
and	O
medicine	O
,	O
precisely	O
in	O
plant	O
defense	O
,	O
disease	O
control	O
and	O
pathogenesis	O
.	O
</ALL>	O

<ALL>	O
An	O
understanding	O
of	O
bacterial	O
genera	O
producing	O
RLs	O
that	O
are	O
not	O
yet	O
well	O
studied	O
would	O
provide	O
light	O
on	O
these	O
fascinating	O
aspects	O
.	O
</ALL>	O

<ALL>	O
Objectives	O
</ALL>	O

<ALL>	O
Evaluate	O
relationships	O
between	O
MRI	O
and	O
clinical	O
/	O
laboratory	O
/	O
radiographic	O
findings	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O
</ALL>	O

<ALL>	O
Assessment	O
instruments	O
</ALL>	O

<ALL>	O
The	O
SCID	O
-	O
I	O
/	O
P	O
was	O
administered	O
by	O
psychiatrists	O
trained	O
and	O
certified	O
in	O
the	O
use	O
of	O
all	O
instruments	O
in	O
this	O
study	O
.	O
</ALL>	O

<ALL>	O
The	O
ICG	O
is	O
a	O
self	O
-	O
report	O
instrument	O
that	O
can	O
be	O
used	O
to	O
identify	O
CG	O
when	O
the	O
total	O
score	O
is	O
>	O
25	O
,	O
that	O
demonstrated	O
high	O
internal	O
consistency	O
(	O
Cronbach	O
'	O
s	O
alpha	O
=	O
0	O
.	O
94	O
)	O
,	O
and	O
convergent	O
and	O
criterion	O
validity	O
[	O
27	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
ICG	O
total	O
score	O
also	O
showed	O
a	O
fairly	O
high	O
association	O
with	O
the	O
Beck	O
Depression	O
Inventory	O
(	O
BDI	O
)	O
[	O
32	O
]	O
total	O
score	O
(	O
r	O
=	O
0	O
.	O
67	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
the	O
Texas	O
Revised	O
Inventory	O
of	O
Grief	O
(	O
TRIG	O
)	O
[	O
33	O
]	O
score	O
(	O
r	O
=	O
0	O
.	O
87	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
the	O
Grief	O
Measurement	O
Scale	O
(	O
GMS	O
)	O
[	O
34	O
]	O
score	O
(	O
r	O
=	O
0	O
.	O
70	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
ASA	O
-	O
27	O
is	O
a	O
self	O
-	O
report	O
measure	O
developed	O
to	O
rate	O
separation	O
anxiety	O
symptoms	O
in	O
adult	O
life	O
(	O
from	O
18	O
years	O
of	O
age	O
)	O
.	O
</ALL>	O

<ALL>	O
Principal	O
components	O
analysis	O
revealed	O
a	O
coherent	O
construct	O
of	O
adult	O
separation	O
anxiety	O
with	O
high	O
internal	O
consistency	O
(	O
Cronbach	O
'	O
s	O
alpha	O
=	O
0	O
.	O
95	O
)	O
and	O
sound	O
test	O
-	O
retest	O
reliability	O
(	O
r	O
=	O
0	O
.	O
86	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O
</ALL>	O

<ALL>	O
Further	O
,	O
a	O
receiver	O
operation	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
against	O
the	O
semistructured	O
interview	O
yielded	O
a	O
high	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
index	O
of	O
0	O
.	O
9	O
,	O
suggesting	O
that	O
the	O
questionnaire	O
is	O
an	O
adequate	O
alternative	O
measure	O
of	O
adult	O
separation	O
anxiety	O
[	O
29	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
WSAS	O
is	O
a	O
self	O
-	O
report	O
scale	O
of	O
functional	O
impairment	O
that	O
includes	O
five	O
questions	O
rating	O
interference	O
of	O
psychiatric	O
symptoms	O
in	O
work	O
,	O
home	O
management	O
,	O
social	O
or	O
private	O
leisure	O
activities	O
,	O
and	O
ability	O
to	O
form	O
and	O
maintain	O
close	O
relationships	O
with	O
others	O
.	O
</ALL>	O

<ALL>	O
Each	O
question	O
is	O
rated	O
on	O
a	O
0	O
to	O
8	O
scale	O
with	O
0	O
indicating	O
no	O
impairment	O
at	O
all	O
and	O
8	O
indicating	O
very	O
severe	O
impairment	O
.	O
</ALL>	O

<ALL>	O
The	O
Cronbach	O
'	O
s	O
alpha	O
measure	O
of	O
internal	O
scale	O
consistency	O
ranged	O
from	O
0	O
.	O
70	O
to	O
0	O
.	O
94	O
,	O
the	O
test	O
-	O
retest	O
correlation	O
was	O
0	O
.	O
73	O
,	O
and	O
the	O
WSAS	O
interactive	O
voice	O
response	O
administrations	O
gave	O
correlations	O
of	O
0	O
.	O
81	O
and	O
0	O
.	O
86	O
with	O
clinician	O
interviews	O
[	O
30	O
]	O
.	O
</ALL>	O

<ALL>	O
Correlations	O
of	O
WSAS	O
with	O
severity	O
of	O
depression	O
and	O
obsessive	O
-	O
compulsive	O
disorder	O
symptoms	O
were	O
0	O
.	O
76	O
and	O
0	O
.	O
61	O
,	O
respectively	O
,	O
and	O
the	O
scores	O
were	O
sensitive	O
to	O
patient	O
differences	O
in	O
disorder	O
severity	O
and	O
treatment	O
-	O
related	O
change	O
[	O
30	O
]	O
.	O
</ALL>	O

<ALL>	O
The	O
MOODS	O
-	O
SR	O
is	O
an	O
instrument	O
developed	O
and	O
validated	O
to	O
assess	O
lifetime	O
mood	O
spectrum	O
symptoms	O
[	O
35	O
]	O
,	O
including	O
manic	O
and	O
depressive	O
features	O
,	O
rhythmicity	O
and	O
vegetative	O
functions	O
.	O
</ALL>	O

<ALL>	O
The	O
manic	O
and	O
depressive	O
components	O
are	O
subtyped	O
into	O
mood	O
,	O
energy	O
and	O
cognition	O
domains	O
,	O
focusing	O
on	O
manic	O
or	O
depressive	O
symptoms	O
,	O
respectively	O
.	O
</ALL>	O

<ALL>	O
The	O
rhythmicity	O
and	O
vegetative	O
functions	O
domain	O
include	O
changes	O
in	O
energy	O
,	O
physical	O
wellbeing	O
,	O
mental	O
and	O
physical	O
efficiency	O
,	O
related	O
to	O
the	O
weather	O
and	O
season	O
,	O
and	O
changes	O
in	O
appetite	O
,	O
sleep	O
and	O
sexual	O
activities	O
.	O
</ALL>	O

<ALL>	O
The	O
sum	O
of	O
the	O
scores	O
on	O
the	O
3	O
manic	O
domains	O
(	O
mood	O
,	O
energy	O
,	O
cognition	O
)	O
constitutes	O
the	O
'	O
manic	O
component	O
'	O
(	O
62	O
items	O
)	O
and	O
that	O
of	O
the	O
3	O
depressive	O
domains	O
the	O
'	O
depressive	O
component	O
'	O
(	O
63	O
items	O
)	O
.	O
</ALL>	O

<ALL>	O
The	O
rhythmicity	O
and	O
vegetative	O
functions	O
domain	O
includes	O
29	O
items	O
.	O
</ALL>	O

<ALL>	O
The	O
instrument	O
can	O
be	O
downloaded	O
from	O
http	O
:	O
/	O
/	O
www	O
.	O
spectrum	O
-	O
project	O
.	O
org	O
.	O
</ALL>	O

